PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Andersson, OK; Almgren, T; Persson, B; Samuelsson, O; Hedner, T; Wilhelmsen, L				Andersson, OK; Almgren, T; Persson, B; Samuelsson, O; Hedner, T; Wilhelmsen, L			Survival in treated hypertension: follow up study after two decades	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; PREVENTION; GOTEBORG; SWEDEN; LIPIDS; DEATH; TRIAL; MEN	Objective: To compare survival and cause specific mortality in hypertensive men with non-hypertensive men derived from the same random population, and to study mortality aid morbidity from cardiovascular diseases in the hypertensive men in relation to effects on cardiovascular risk factors during 22-23 years of follow up. Design: Prospective, population based observational study. Subjects and methods: 686 hypertensive men aged 47-55 at screening compared with 6810 non-hypertensive men. The hypertensive men were having stepped care treatment with either beta adrenergic blocking drugs, thiazide diuretics, or combination treatment. Mortality, morbidity and adverse effects were registered at yearly examinations and from death certificates. Main outcome measures: All cause mortality and cause specific mortality. Results: Treated hypertensive men had significantly impaired probability of total survival as well as survival from coronary heart disease and stroke. All cause mortality as well as coronary heart disease and stroke mortality were very similar in hypertensive men and normotensive men during the first decade, but increased steadily thereafter despite continuous good blood pressure control. Smoking, signs of target organ damage, and high serum cholesterol levels, but not blood pressure at screening, were significantly related to the incidence of coronary heart disease during follow up. In time dependent Cox's regression analysis, the incidence of coronary heart disease was significantly related only to serum cholesterol concentrations in the study. Cancer mortality was almost similar in treated hypertensive men (61/686, 8.9%) and non-hypertensive men (732/6810, 10.8%). Conclusion: Treated hypertensive men had impaired survival and increased mortality from cardiovascular disease compared with non-hypertensive men of similar age. These differences were observed during the second decade of follow up. During an observation period of 22-23 years-about 15 000 patient years-hypertensive men receiving diuretics and beta blockers had no increased risk of cancer or non-cardiovascular disease.	Sahlgrens Univ Hosp, Dept Med, Nephrol Sect, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Clin Pharmacol, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Inst Heart & Lung Dis, Sect Prevent Cardiol, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital	Andersson, OK (corresponding author), Sahlgrens Univ Hosp, Dept Med, Nephrol Sect, S-41345 Gothenburg, Sweden.							ALTMAN DG, 1994, STAT MED, V13, P301, DOI 10.1002/sim.4780130402; ANDERSSON O, 1978, ACTA MED SCAND, V203, P391; BERGLUND G, 1976, ACTA MED SCAND, V200, P163; BULPITT CJ, 1986, J HYPERTENS, V4, P93, DOI 10.1097/00004872-198602000-00015; BULPITT CJ, 1979, LANCET, V2, P134; Chobanian AV, 1996, CIRCULATION, V93, P638, DOI 10.1161/01.CIR.93.4.638; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COX DR, 1972, J R STAT SOC B, V34, P187; DAY JL, 1982, BRIT MED J, V284, P1145, DOI 10.1136/bmj.284.6323.1145; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; ELMFELDT D, 1975, J CHRON DIS, V28, P173, DOI 10.1016/0021-9681(75)90005-3; ERIKSSON H, 1992, J INTERN MED, V232, P389, DOI 10.1111/j.1365-2796.1992.tb00604.x; GRIMM RH, 1981, ANN INTERN MED, V94, P7, DOI 10.7326/0003-4819-94-1-7; HARMSEN P, 1972, ACTA MED SCAND, V191, P463; LEREN P, 1980, LANCET, V2, P4; PEDERSEN TR, 1994, LANCET, V344, P1383; RAY AA, 1982, SAS USERS GUIDE BASI; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Rose GA, 1968, WHO MONOGRAPHY SERIE, V56, P98; Samuelsson O, 1996, BMJ-BRIT MED J, V313, P660; *SAS I, 1991, SAS STAT SOFTWARE PH; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMIRK FH, 1972, AM HEART J, V83, P825, DOI 10.1016/0002-8703(72)90216-5; SOKOLOW M, 1961, CIRCULATION, V23, P697, DOI 10.1161/01.CIR.23.5.697; Sytkowski PA, 1996, CIRCULATION, V93, P697, DOI 10.1161/01.CIR.93.4.697; WILHELMSEN L, 1986, EUR HEART J, V7, P279, DOI 10.1093/oxfordjournals.eurheartj.a062065	26	163	167	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 18	1998	317	7152					167	171		10.1136/bmj.317.7152.167	http://dx.doi.org/10.1136/bmj.317.7152.167			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665894	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000075047800018
J	Meerding, WJ; Bonneux, L; Polder, JJ; Koopmanschap, MA; van der Maas, PJ				Meerding, WJ; Bonneux, L; Polder, JJ; Koopmanschap, MA; van der Maas, PJ			Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study	BRITISH MEDICAL JOURNAL			English	Article								Objectives:To determine the demands on healthcare resources caused by different types of illnesses and variation with age and sex. Design: Information on healthcare use was obtained from all 22 healthcare sectors in the Netherlands. Most important sectors (hospitals, nursing homes, inpatient psychiatric care, institutions for mentally disabled people) have national registries. Total expenditures for each sector were subdivided into 21 age groups, sex, and 34 diagnostic groups. Setting: Netherlands, 1994. Main outcome measures: Proportion of healthcare budget spent on each category of disease and cost of health care per person at various ages. Results: After the first year of life, costs per person for children were lowest Costs rose slowly throughout adult life and increased exponentially from age 50 onwards till the oldest age group (greater than or equal to 95). The top five areas of healthcare costs were mental retardation, musculoskeletal disease (predominantly joint disease and dorsopathy), dementia, a heterogeneous group of other mental disorders, and ill defined conditions. Stroke, all cancers combined, and coronary heart disease ranked 7, 8, and 10, respectively Conclusions: The main determinants of healthcare use in the Netherlands are old age and disabling conditions, particularly mental disability. A large share of the healthcare budget is spent on long term nursing care, and this cost will inevitably increase further in an ageing population, Non-specific cost containment measures may endanger the quality of care for old and mentally disabled people.	Erasmus Univ, Fac Med & Hlth Sci, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Inst Med Technol Assessment, Dept Hlth Policy & Management, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam	Meerding, WJ (corresponding author), Erasmus Univ, Fac Med & Hlth Sci, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands.	meerding@mgz.fgg.eur.nl						AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; *AUSTR I HLTH WELF, 1996, AUSTR HLTH 1996; *EX NHS, 1996, BURD DIS DISC DOC; GROENENBOOPM GKC, 1995, ELDERLY CARE EC PERS; Koopmanschap M, 1994, EUR J PUB HLTH, V4, P258, DOI [10.1093/eurpub/4.4.258, DOI 10.1093/EURPUB/4.4.258]; KOOPMANSCHAP MA, 1991, COSTS DIS NETHERLAND; LINDGREN B, 1990, KLIN PHARM, V4, P12; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; *MIN HLTH, 1996, ANN OV HLTH CAR 1997; MOORE R, 1997, EC BURDEN ILLNESS CA; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray CJL., 1996, GLOBAL BURDEN DIS, P201; Polder JJ, 1997, COSTS DIS NETHERLAND; World Health Organization, 1977, INT CLASS DIS	14	213	218	0	21	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					111	+		10.1136/bmj.317.7151.111	http://dx.doi.org/10.1136/bmj.317.7151.111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657785	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000075081700020
J	Zhang, GY; Darst, SA				Zhang, GY; Darst, SA			Structure of the Escherichia coli RNA polymerase alpha subunit amino-terminal domain	SCIENCE			English	Article							PROTEIN SECONDARY STRUCTURE; FUNCTIONAL MAP; ASSEMBLY DOMAIN; TRANSCRIPTION ACTIVATION; ASSOCIATION; PREDICTION; PROMOTERS; ERRORS; GENE	The 2.5 angstrom resolution x-ray crystal structure of the Escherichia coli RNA polymerase (RNAP) alpha subunit amino-terminal domain (alpha NTD), which is necessary and sufficient to dimerize and assemble the other RNAP subunits into a transcriptionally active enzyme and contains all of the sequence elements conserved among eukaryotic alpha homologs, has been determined. The alpha NTD monomer comprises two distinct, flexibly linked domains, only one of which participates in the dimer interface. In the alpha NTD dimer, a pair of helices from one monomer interact with the cognate helices of the other to form an extensive hydrophobic core. ALL of the determinants for interactions with the other RNAP subunits lie on one face of the aNTD dimer. Sequence alignments, combined with secondary-structure predictions, support proposals that a heterodimer of the eukaryotic RNAP subunits related to Saccharomyces cerevisiae Rpb3 and Rpb11 plays the role of the alpha NTD dimer in prokaryotic RNAP.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Darst, SA (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	darst@rockvax.rockefeller.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053759] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19441-01, GM53759] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; AZUMA Y, 1993, NUCLEIC ACIDS RES, V21, P3749, DOI 10.1093/nar/21.16.3749; Brunger AT, 1992, XPLOR VERSION 3 1 MA; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; HAYWARD RS, 1991, J MOL BIOL, V221, P23, DOI 10.1016/0022-2836(91)80197-3; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; IGARASHI K, 1990, NUCLEIC ACIDS RES, V18, P5945, DOI 10.1093/nar/18.20.5945; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; Ishihama A, 1981, Adv Biophys, V14, P1; JEON YH, 1995, SCIENCE, V270, P1495, DOI 10.1126/science.270.5241.1495; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMURA M, 1995, J MOL BIOL, V248, P756, DOI 10.1006/jmbi.1995.0258; KIMURA M, 1994, J MOL BIOL, V242, P107, DOI 10.1006/jmbi.1994.1562; KIMURA M, 1995, J MOL BIOL, V254, P342, DOI 10.1006/jmbi.1995.0621; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; PATI UK, 1994, GENE, V145, P289, DOI 10.1016/0378-1119(94)90022-1; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM, P23; Svetlov V, 1998, J BIOL CHEM, V273, P10827, DOI 10.1074/jbc.273.18.10827; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P34; Ulmasov T, 1996, J BIOL CHEM, V271, P5085, DOI 10.1074/jbc.271.9.5085; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; ZILLIG W, 1976, RNA POLYMERASE, P101	34	91	95	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1998	281	5374					262	266		10.1126/science.281.5374.262	http://dx.doi.org/10.1126/science.281.5374.262			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657722				2022-12-28	WOS:000074714200051
J	Garside, P; Ingulli, E; Merica, RR; Johnson, JG; Noelle, RJ; Jenkins, MK				Garside, P; Ingulli, E; Merica, RR; Johnson, JG; Noelle, RJ; Jenkins, MK			Visualization of specific B and T lymphocyte interactions in the lymph node	SCIENCE			English	Article							PRIMARY IMMUNE-RESPONSE; GERMINAL-CENTERS; CELLS; ANTIGEN; (4-HYDROXY-3-NITROPHENYL)ACETYL; IMMUNOGLOBULIN; TOLERANCE; INDUCTION; FOLLICLES; INSITU	Early events in the humoral immune response were visualized in Lymph nodes by simultaneous tracking of antigen-specific CD4 T and B cells after immunization. The T cells were initially activated in the T cell areas when the B cells were still randomly dispersed in the B cell-rich follicles. Both populations then migrated to the edges of the follicles and interacted there, resulting in CD154-dependent B cell proliferation and germinal center formation. These results provide visual documentation of cognate T-B cell interactions and Localize them to the follicular border.	Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Glasgow, Western Infirm, Dept Immunol, Glasgow G11 6NT, Lanark, Scotland; Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Ctr Immunol, Minneapolis, MN 55455 USA; Dartmouth Med Coll, Dept Microbiol, Lebanon, NH USA	University of Minnesota System; University of Minnesota Twin Cities; University of Glasgow; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Dartmouth College	Jenkins, MK (corresponding author), Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA.		Garside, Paul/A-4227-2009; Jenkins, Marc K/G-1063-2012	Jenkins, Marc K/0000-0001-8009-7655	NIAID NIH HHS [AI27998, AI39614, AI35296] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027998, R01AI027998, P01AI035296, R01AI039614] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRAUN J, 1982, J IMMUNOL, V128, P1198; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Cyster JG, 1995, IMMUNITY, V3, P691, DOI 10.1016/1074-7613(95)90059-4; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; FULLER KA, 1993, J IMMUNOL, V151, P4505; GARSIDE P, UNPUB; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GulbransonJudge A, 1996, EUR J IMMUNOL, V26, P1830, DOI 10.1002/eji.1830260825; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; Liu CP, 1996, J EXP MED, V184, P1619, DOI 10.1084/jem.184.5.1619; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; Luther SA, 1997, J EXP MED, V185, P551, DOI 10.1084/jem.185.3.551; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Raff M C, 1970, Nature, V226, P1257, DOI 10.1038/2261257a0; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; VITETTA ES, 1989, ADV IMMUNOL, V45, P1, DOI 10.1016/S0065-2776(08)60692-6; Vora KA, 1998, J IMMUNOL, V160, P728; ZHDNG B, 1996, J EXP MED, V1874, P1083	29	591	610	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1998	281	5373					96	99		10.1126/science.281.5373.96	http://dx.doi.org/10.1126/science.281.5373.96			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651253				2022-12-28	WOS:000074685800045
J	Seto, TB; Mittleman, MA; Davis, RB; Taira, DA; Kawachi, I				Seto, TB; Mittleman, MA; Davis, RB; Taira, DA; Kawachi, I			Seasonal variation in coronary artery disease mortality in Hawaii: observational study	BRITISH MEDICAL JOURNAL			English	Article									Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Harvard Univ, Sch Med, New England Med Ctr, Hlth Inst, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tufts Medical Center; Harvard University; Harvard T.H. Chan School of Public Health	Seto, TB (corresponding author), Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA.	tseto@bidmc.harvard.edu		Mittleman, Murray/0000-0001-9788-7274				DEPASQUALE N, 1961, AM J MED SCI, V242, P468, DOI 10.1097/00000441-196110000-00012; DOUGLAS AS, 1990, AUST NZ J MED, V20, P669, DOI 10.1111/j.1445-5994.1990.tb00397.x; DOUGLAS AS, 1991, SCOT MED J, V36, P76, DOI 10.1177/003693309103600304; FAMIGHETTI R, 1993, WORLD ALMANAC BOOK F, P407; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2	5	33	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1946	1947		10.1136/bmj.316.7149.1946	http://dx.doi.org/10.1136/bmj.316.7149.1946			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641932	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000074636700027
J	Schaffer, R; Ramsay, N; Samach, A; Corden, S; Putterill, J; Carre, IA; Coupland, G				Schaffer, R; Ramsay, N; Samach, A; Corden, S; Putterill, J; Carre, IA; Coupland, G			The late elongated hypocotyl mutation of Arabidopsis disrupts circadian rhythms and the photoperiodic control of flowering	CELL			English	Article							DNA-BINDING DOMAIN; PROTEIN; PERIOD; CLOCK; EXPRESSION; TIMELESS; MYB; AUTOREGULATION; INSERTION; MUTANT	The dominant late elongated hypocotyl (lhy) mutation of Arabidopsis disrupted circadian clock regulation of gene expression and leaf movements and caused flowering to occur independently of photoperiod. LHY was shown to encode a MYB DNA-binding protein. In wild-type plants, the LHY mRNA showed a circadian pattern of expression with a peak around dawn but in the mutant was expressed constantly at high levels. Increased LHY expression from a transgene caused the endogenous gene to be expressed at a constant level, suggesting that LHY was part of a feedback circuit that regulated its own expression. Thus, constant expression of LHY disrupts several distinct circadian rhythms in Arabidopsis, and LHY may be closely associated with the central oscillator of the circadian clock.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Warwick	Coupland, G (corresponding author), John Innes Ctr Plant Sci Res, Colney Lane, Norwich NR4 7UH, Norfolk, England.		Schaffer, Robert J/D-1018-2011; CARRE, Isabelle A/D-8802-2011; Coupland, George/AAP-8609-2020	CARRE, Isabelle A/0000-0002-0548-7378; Coupland, George/0000-0001-6988-4172; Schaffer, Robert/0000-0003-1272-667X				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BARANOWSKIJ N, 1994, EMBO J, V13, P5383, DOI 10.1002/j.1460-2075.1994.tb06873.x; CARPENTER CD, 1994, PLANT PHYSIOL, V104, P1015, DOI 10.1104/pp.104.3.1015; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Edmunds LN, 1988, CELLULAR MOL BASES B; ENGELMANN W, 1992, Z NATURFORSCH C, V47, P925; Feldbrugge M, 1997, PLANT J, V11, P1079, DOI 10.1046/j.1365-313X.1997.11051079.x; Finlayson SA, 1998, PLANT PHYSIOL, V116, P17, DOI 10.1104/pp.116.1.17; FOLLET BK, 1985, REPROD MAMMALS; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; HALL JC, 1995, TRENDS NEUROSCI, V18, P218; HARDIN P, 1995, SEMIN NEUROSCI, V7, P15, DOI 10.1016/1044-5765(95)90013-6; Heintzen C, 1997, P NATL ACAD SCI USA, V94, P8515, DOI 10.1073/pnas.94.16.8515; Hicks KA, 1996, SCIENCE, V274, P790, DOI 10.1126/science.274.5288.790; KAY SA, 1995, CELL, V83, P361, DOI 10.1016/0092-8674(95)90113-2; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; Kreps JA, 1997, PLANT CELL, V9, P1235, DOI 10.1105/tpc.9.7.1235; Kreps JA, 1997, PLANT CELL, V9, P297, DOI 10.1105/tpc.9.3.297; LOGEMANN J, 1987, ANAL BIOCHEM, V141, P329; LONG D, 1993, P NATL ACAD SCI USA, V90, P10370, DOI 10.1073/pnas.90.21.10370; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; Millar AJ, 1996, P NATL ACAD SCI USA, V93, P15491, DOI 10.1073/pnas.93.26.15491; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; RIKIN A, 1984, PLANT PHYSIOL, V75, P493, DOI 10.1104/pp.75.2.493; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SCHAFFER R, 1997, THESIS U E ANGLIA NO; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Sweeney BM., 1987, RHYTHMIC PHENOMENA P; Thomas B., 1997, PHOTOPERIODISM PLANT; Wang ZY, 1997, PLANT CELL, V9, P491, DOI 10.1105/tpc.9.4.491; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; Wilson K, 1996, PLANT CELL, V8, P659, DOI 10.1105/tpc.8.4.659	39	677	739	8	91	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1219	1229		10.1016/S0092-8674(00)81465-8	http://dx.doi.org/10.1016/S0092-8674(00)81465-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657154	Bronze			2022-12-28	WOS:000074491100016
J	Yang, N; Higuchi, O; Ohashi, K; Nagata, K; Wada, A; Kangawa, K; Nishida, E; Mizuno, K				Yang, N; Higuchi, O; Ohashi, K; Nagata, K; Wada, A; Kangawa, K; Nishida, E; Mizuno, K			Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization	NATURE			English	Article							PROTEIN-KINASE; STRESS FIBERS; ZINC-FINGER; IDENTIFICATION; RHO; GTPASES; FAMILY; CDC42; MOTIF	Rac is a small GTPase of the Rho family that mediates stimulus-induced actin cytoskeletal reorganization to generate lamellipodia(1-5). Little is known about the signalling pathways that link pac activation to changes in actin filament dynamics. Cofilin is known to be a potent regulator of actin filament dynamics(6-10), and its ability to bind and depolymerize actin is abolished by phosphorylation of serine residue at 3 (refs 11, 12); however, the kinases responsible for this phosphorylation have not been identified. Here we show that LIM-kinase 1 (LIMK-1), a serine/threonine kinase containing LIM and PDZ domains(13-16), phosphorylates cofilin at Ser3, both in vitro and in vivo. When expressed in cultured cells, LIMK-1 induces actin reorganization and reverses cofilin-induced actin depolymerization. Expression of an inactive form of LIMK-1 suppresses lamellipodium formation induced by pac or insulin. Furthermore, insulin and an active form of Rac increase the activity of LIMK-1. Taken together, our results indicate that LIMK-1 participates in,Rac-mediated actin cytoskeletal reorganization, probably by phosphorylating cofilin.	Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan; Japan Sci & Technol Corp, PRESTO, Kyoto 6190237, Japan	Kyushu University; Kyoto University; National Cerebral & Cardiovascular Center - Japan; Japan Science & Technology Agency (JST)	Mizuno, K (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan.		Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019	Ohashi, Kazumasa/0000-0001-7617-403X				AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hiraoka J, 1996, FEBS LETT, V399, P117, DOI 10.1016/S0014-5793(96)01303-8; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUNOUE K, 1995, ONCOGENE, V11, P701; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roof DJ, 1997, J CELL BIOL, V138, P575, DOI 10.1083/jcb.138.3.575; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Theriot JA, 1997, J CELL BIOL, V136, P1165, DOI 10.1083/jcb.136.6.1165; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4	21	1026	1050	2	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1998	393	6687					809	812		10.1038/31735	http://dx.doi.org/10.1038/31735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655398				2022-12-28	WOS:000074433100055
J	Ridgway, GL; Hodges, CJS; Kreuzer, MH				Ridgway, GL; Hodges, CJS; Kreuzer, MH			Implications of European directive on medical devices	LANCET			English	Editorial Material									UCL Hosp, Dept Microbiol, London WC1E 6DB, England; Assoc British Hlth Care Ind, London, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Ridgway, GL (corresponding author), UCL Hosp, Dept Microbiol, London WC1E 6DB, England.							Allen KW, 1997, PUBLIC HEALTH, V111, P115, DOI 10.1016/S0033-3506(97)90012-3; *HOSP INF WORK GRO, 1995, HOSP INF CONTR GUID; *MED DEV AG, 1996, COMM GUID B A, V18; *MED DEV AG, 1995, DEV B DB, V951	4	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1831	1832		10.1016/S0140-6736(05)78802-4	http://dx.doi.org/10.1016/S0140-6736(05)78802-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652664				2022-12-28	WOS:000074347100007
J	Farthing, MJG				Farthing, MJG			An editor's response to fraudsters	BRITISH MEDICAL JOURNAL			English	Article							MISCONDUCT		St Bartholomews & Royal London Sch Med & Dent, Digest Dis Res Ctr, London E1 2AD, England	University of London; Queen Mary University London	Farthing, MJG (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Digest Dis Res Ctr, London E1 2AD, England.							Doherty M, 1996, ANN RHEUM DIS, V55, P783, DOI 10.1136/ard.55.11.783; Farthing MJG, 1997, GUT, V41, P1; Jacobsen G, 1997, J ROY COLL PHYS LOND, V31, P8; JAMES P, 1997, FOOD STANDARDS AGENC; Kohn A., 1986, FALSE PROPHETS; LOCK S, 1988, BRIT MED J, V297, P1531, DOI 10.1136/bmj.297.6662.1531; LOCK S, 1996, FRAUD MISCONDUCT MED; *ROYAL COLL PHYS, 1994, FRAUD MISC MED RES; Smith R, 1997, BRIT MED J, V315, P201, DOI 10.1136/bmj.315.7102.201	9	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1729	1731						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9652922				2022-12-28	WOS:000074129500031
J	Calarota, S; Bratt, G; Nordlund, S; Hinkula, J; Leandersson, AC; Sandstrom, E; Wahren, B				Calarota, S; Bratt, G; Nordlund, S; Hinkula, J; Leandersson, AC; Sandstrom, E; Wahren, B			Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; EPSTEIN-BARR-VIRUS; QUANTITATIVE-ANALYSIS; IMMUNE-RESPONSES; HIGH-FREQUENCY; LYMPHOCYTES-T; HIV-1; INDIVIDUALS; INFECTION; EXPANSION	Background DNA vaccination is known to generate immune responses against HIV-1 in animal models. We aimed to assess the efficacy of DNA vaccination in induction of immune responses in HIV-1-infected human beings. Methods Nine symptom-free HIV-1-infected patients were immunised with DNA constructs encoding the nef, rev, or tat regulatory genes of HIV-1. The patients were selected for having no or low antibody reactivities to these antigens. HIV-1-specific cytotoxic T-lymphocytes (CTLs), precursor frequencies, and antigen-specific proliferative responses were measured before, during, and after three immunisations over 6 months. Findings Cellular immune reactivities against the HIV-1 regulatory proteins were absent or low before DNA immunisation. DNA vaccination induced detectable memory cells in all patients and specific cytotoxicity in eight patients. CTLs were MHC-class-I restricted and mainly of CD8+ origin. In three patients the cellular activity was transient, decreasing after an initial response. Interpretation DNA immunisation with HIV-1 genes can induce specific cellular responses in human beings with no apparent side-effects. It is theoretically possible that HIV-1-specific cytotoxic responses to regulatory proteins could lead to infected cells being eliminated before they have released new viral particles. However, it is possible that the patients we selected responded less than would nonselected or non-infected individuals. The small number of patients presented here does not allow generalisation of our findings.	Karolinska Inst, Swedish Inst Infect Dis Control, Ctr Microbiol & Tumor Biol, S-10521 Stockholm, Sweden; South Hosp, Dept Dermatovenereol, Stockholm, Sweden	Karolinska Institutet; Swedish Institute for Infectious Disease Control	Wahren, B (corresponding author), Karolinska Inst, Swedish Inst Infect Dis Control, Ctr Microbiol & Tumor Biol, S-10521 Stockholm, Sweden.		Hinkula, Jorma/P-6849-2018	Hinkula, Jorma/0000-0003-1908-5609				Asakura Y, 1996, AM J HEMATOL, V53, P116, DOI 10.1002/(SICI)1096-8652(199610)53:2&lt;116::AID-AJH9&gt;3.0.CO;2-2; BOYER JD, 1997, NAT MED, V3, P525; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CEASE KB, 1994, ANNU REV IMMUNOL, V12, P923, DOI 10.1146/annurev.iy.12.040194.004423; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; Geretti AM, 1996, J INFECT DIS, V174, P34, DOI 10.1093/infdis/174.1.34; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Hinkula J, 1997, VACCINE, V15, P874, DOI 10.1016/S0264-410X(96)00257-5; Hinkula J, 1997, J VIROL, V71, P5528, DOI 10.1128/JVI.71.7.5528-5539.1997; HYDENBURGFULLER D, 1994, AIDS RES HUM RETROV, V10, P1433; Johnson R P, 1994, Curr Top Microbiol Immunol, V189, P35; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; LAMHAMEDICHERRADI S, 1995, AIDS, V9, P421, DOI 10.1097/00002030-199509050-00002; LAMHAMEDICHERRADI S, 1992, AIDS, V6, P1249, DOI 10.1097/00002030-199211000-00002; LEANDERSSON AC, IN PRESS AIDS; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LUBAKI MN, 1994, AIDS RES HUM RETROV, V10, P1427, DOI 10.1089/aid.1994.10.1427; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; Ratto S, 1996, J ACQ IMMUN DEF SYND, V11, P128, DOI 10.1097/00042560-199602010-00003; Riviere Y, 1994, Curr Top Microbiol Immunol, V189, P65; ROBERTGUROFF M, 1990, J VIROL, V64, P3391, DOI 10.1128/JVI.64.7.3391-3398.1990; Rowland-Jones S, 1997, ADV IMMUNOL, V65, P277, DOI 10.1016/S0065-2776(08)60745-2; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; SPECTOR DH, 1990, J VIROL, V64, P2298, DOI 10.1128/JVI.64.5.2298-2308.1990; STRIJBOSCH LWG, 1988, INT J BIOMED COMPUT, V23, P279, DOI 10.1016/0020-7101(88)90020-7; vanBaalen CA, 1997, J GEN VIROL, V78, P1913, DOI 10.1099/0022-1317-78-8-1913; VANBAALEN CA, 1993, AIDS, V7, P781, DOI 10.1097/00002030-199306000-00004; WAHREN B, 1994, J ACQ IMMUN DEF SYND, V7, P220; Wahren B, 1995, ANN NY ACAD SCI, V772, P278, DOI 10.1111/j.1749-6632.1995.tb44759.x; WANG B, 1993, DNA CELL BIOL, V12, P799, DOI 10.1089/dna.1993.12.799; Woods TC, 1997, BLOOD, V89, P1635, DOI 10.1182/blood.V89.5.1635.1635_1635_1641; Yasutomi Y, 1996, J VIROL, V70, P678, DOI 10.1128/JVI.70.1.678-681.1996; Zhong Q, 1997, VACCINE, V15, P497, DOI 10.1016/S0264-410X(97)00223-5	35	336	358	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1320	1325		10.1016/S0140-6736(97)09440-3	http://dx.doi.org/10.1016/S0140-6736(97)09440-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643795				2022-12-28	WOS:000073439400010
J	Glanville, J; Haines, M; Auston, I				Glanville, J; Haines, M; Auston, I			Getting research findings into practice - Finding information on clinical effectiveness	BRITISH MEDICAL JOURNAL			English	Article							PRACTICE GUIDELINES; SYSTEMATIC REVIEWS; MEDICAL LITERATURE; USERS GUIDES; RECOMMENDATIONS; LIBRARY		Univ York, NHS Ctr Reviews & Disseminat, York YO1 5DD, N Yorkshire, England; Lib & Informat Commiss, London W1V 4BH, England; Natl Lib Med, Natl Informat Ctr Hlth Serv Res & Hlth Care Techn, Bethesda, MD 20894 USA	University of York - UK; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Glanville, J (corresponding author), Univ York, NHS Ctr Reviews & Disseminat, York YO1 5DD, N Yorkshire, England.		Glanville, Julie May/C-2358-2008	Glanville, Julie May/0000-0002-1253-8524				CIMPL K, 1985, B MED LIBR ASSOC, V73, P21; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DEYKIN D, 1996, SCI BASIS HLTH SERVI; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; FULLER AB, 1993, B MED LIBR ASSOC, V81, P38; GLASZIOU PP, 1995, MED J AUSTRALIA, V162, P33, DOI 10.5694/j.1326-5377.1995.tb138409.x; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; HILLEY CM, 1994, BRIT MED J, V309, P703; KLEIN MS, 1994, ACAD MED, V69, P489, DOI 10.1097/00001888-199406000-00017; MARSHALL JG, 1992, B MED LIBR ASSOC, V80, P169; MCKIBBON KA, 1996, EVIDENCE BASED MED, V1, P70; *NHS EX, 1996, PRIOR PLANN GUID NHS; *NHS EX, 1996, IMPR OUTC BREAST CAN; OLIVER S, 1996, PILOT STUDY INFORMED; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648, DOI 10.1136/bmj.309.6955.648; PALMER J, 1995, LIB ASS REC, V97, P153; Rowlands JL, 1996, B MED LIBR ASSOC, V84, P116; SCHATZ CA, 1995, B MED LIBR ASSOC, V83, P469; Scottish Intercollegiate Guidelines Network, 1995, CLIN GUID CRIT APPR; SPIERS PS, 1994, ARCH PEDIAT ADOL MED, V148, P141, DOI 10.1001/archpedi.1994.02170020027004; STERN K, 1995, CLIN EFFECTIVENESS G; URQUHART CJ, 1995, 6205 BRIT LIB RES DE; Wallingford K T, 1996, Bull Med Libr Assoc, V84, P1; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630; 1995, ECONOMICST      0819, P23	25	42	42	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					200	203		10.1136/bmj.317.7152.200	http://dx.doi.org/10.1136/bmj.317.7152.200			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	103FZ	9665910	Green Published			2022-12-28	WOS:000075047800038
J	Jaffuel, D; Lebel, B; Hillaire-Buys, D; Pene, J; Godard, P; Michel, FB; Blayac, JP; Bousquet, J; Demoly, P				Jaffuel, D; Lebel, B; Hillaire-Buys, D; Pene, J; Godard, P; Michel, FB; Blayac, JP; Bousquet, J; Demoly, P			Drug points - Eosinophilic pneumonia induced by dapsone	BRITISH MEDICAL JOURNAL			English	Letter							PULMONARY						Demoly, Pascal/Y-9938-2019	Demoly, Pascal/0000-0001-7827-7964				DAVIDSON AC, 1988, BRIT MED J, V297, P1240, DOI 10.1136/bmj.297.6658.1240; Graham W R Jr, 1975, Int J Dermatol, V14, P494, DOI 10.1111/j.1365-4362.1975.tb04283.x; JANIER M, 1994, LANCET, V343, P860, DOI 10.1016/S0140-6736(94)92066-4; PANG JA, 1989, RESP MED, V83, P247, DOI 10.1016/S0954-6111(89)80041-1	4	12	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					181	181		10.1136/bmj.317.7152.181	http://dx.doi.org/10.1136/bmj.317.7152.181			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665900	Green Published			2022-12-28	WOS:000075047800026
J	Leff, JA; Busse, WW; Pearlman, D; Bronsky, EA; Kemp, JA; Hendeles, L; Dockhorn, R; Kundu, S; Zhang, J; Seidenberg, BC; Reiss, TF				Leff, JA; Busse, WW; Pearlman, D; Bronsky, EA; Kemp, JA; Hendeles, L; Dockhorn, R; Kundu, S; Zhang, J; Seidenberg, BC; Reiss, TF			Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHIBITION; SALMETEROL; CHILDREN; POTENT	Background Patients with mild asthma frequently have only exercise-induced bronchoconstriction, a symptom of inadequate control of asthma. We evaluated the ability of montelukast, a leukotriene-receptor antagonist, to protect such patients against exercise-induced bronchoconstriction. Methods We randomly assigned 110 patients (age, 15 to 45 years) with mild asthma and a decrease in the forced expiratory volume in one second (FEV1) of at least 20 percent after exercise on two occasions during a placebo run-in period to receive 10 mg of montelukast (54 patients) or placebo (56 patients) once daily at bedtime for 12 weeks in a double-blind study. Treatment was followed by a two-week, single-blind washout period during which all patients received placebo. Exercise challenges were performed at base line; 20 to 24 hours after dosing at weeks 4, 8, and 12; and at the end of the washout period. The primary end point was the area under the curve for FEV1 (expressed as the percent change from base-line values) in the first 60 minutes after exercise. This measure summarized the extent and duration of bronchoconstriction after exercise. Results At 12 weeks, montelukast therapy offered significantly greater protection against exercise-induced bronchoconstriction than placebo therapy (expressed as the percentage of inhibition of the end points), as evidenced by the improvement in the area under the FEV1 curve (degree of inhibition, 47.4 per cent; P = 0.002). Montelukast therapy was also associated with a significant improvement in the maximal decrease in FEV1 after exercise (P = 0.003) and the time from the maximal decrease in FEV1 to the return of lung function to within 5 percent of pre-exercise values (P = 0.04). The differences between groups in the various measures of lung function were similar at 4, 8, and 12 weeks; there was no evidence of rebound worsening of lung function in the montelukast group after the washout period. After 12 weeks of treatment, patients in the montelukast group were more likely to rate their asthma control as better and less likely to require rescue therapy with a beta-agonist during or after exercise challenge. The rates of adverse events were similar in the two groups. Conclusions As compared with placebo, once-daily treatment with montelukast provided significant protection against exercise-induced asthma over a 12-week period. Tolerance to the medication and rebound worsening of lung function after discontinuation of treatment were not seen. (N Engl J Med 1998;339:147-52.) (C)1998, Massachusetts Medical Society.	Merck Res Labs, Dept Pulm Immunol, Rahway, NJ USA; Merck Res Labs, Dept Biostat, Rahway, NJ USA; Univ Wisconsin, Madison, WI USA; Colorado Allergy & Asthma Clin, Aurora, CO USA; AAAA Med Res Grp, Salt Lake City, UT USA; Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; Univ Florida, Sch Pharm, Gainesville, FL USA; Int Med Technical Consultants, Kansas City, MO USA	Merck & Company; Merck & Company; University of Wisconsin System; University of Wisconsin Madison; State University System of Florida; University of Florida	Reiss, TF (corresponding author), Merck & Co Inc, POB 2000, Rahway, NJ 07065 USA.							Adelroth E, 1997, J ALLERGY CLIN IMMUN, V99, P210, DOI 10.1016/S0091-6749(97)70098-8; ALTMAN LC, IN PRESS J ALLERGY C; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Bhagat, 1996, CHEST, V109, P592; BHAGAT R, 1995, CHEST, V108, P1235, DOI 10.1378/chest.108.5.1235; Bronsky EA, 1997, CLIN PHARMACOL THER, V62, P556, DOI 10.1016/S0009-9236(97)90051-5; DeLepeleire I, 1997, CLIN PHARMACOL THER, V61, P83, DOI 10.1016/S0009-9236(97)90184-3; FREEZER NJ, 1995, EUR RESPIR J, V8, P1488; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65, DOI 10.1164/ajrccm.153.1.8542164; JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P191, DOI 10.1139/y95-028; JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P747, DOI 10.1139/y95-098; Kemp J. P., 1997, Journal of Allergy and Clinical Immunology, V99, pS321; KIKAWA Y, 1992, J ALLERGY CLIN IMMUN, V89, P1111, DOI 10.1016/0091-6749(92)90294-C; KNORR B, IN PRESS EUR RESP J; MAKKER HK, 1993, AM REV RESPIR DIS, V147, P1413, DOI 10.1164/ajrccm/147.6_Pt_1.1413; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931, DOI 10.1164/ajrccm.153.3.8630575; NOONAN MJ, IN PRESS EUR RESP J; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; Reiss TF, 1997, THORAX, V52, P1030, DOI 10.1136/thx.52.12.1030; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; SNEDECOR GW, 1989, STAT METHODS, P299; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; WILLIAMS J, 1996, AM J RESP CRIT CAR S, V153, pA803	27	407	423	1	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					147	152		10.1056/NEJM199807163390302	http://dx.doi.org/10.1056/NEJM199807163390302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ922	9664090				2022-12-28	WOS:000074782900002
J	Poon, B; Grovit-Ferbas, K; Stewart, SA; Chen, ISY				Poon, B; Grovit-Ferbas, K; Stewart, SA; Chen, ISY			Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; OPEN READING FRAME; PRODUCTIVE INFECTION; MUTATIONAL ANALYSIS; RHESUS-MONKEYS; TYPE-1; GENE; PROTEIN; MACROPHAGES; LYMPHOCYTES	Expression of human immunodeficiency virus-type 1 (HIV-1) Vpr after productive infection of T cells induces cell cycle arrest in the G(2) phase of the cell cycle. In the absence of de novo expression, HIV-1 Vpr packaged into virions still induced cell cycle arrest. Naturally noninfectious virus or virus rendered defective for infection by reverse transcriptase or protease inhibitors were capable of inducing Vpr-mediated cell cycle arrest. These results suggest a model whereby both infectious and noninfectious virions in vivo, such as those surrounding follicular dendritic cells, participate in immune suppression.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol & Med, AIDS Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, AIDS Inst, Los Angeles, CA 90095 USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Chen, ISY (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol & Med, AIDS Inst, Los Angeles, CA 90095 USA.		Stewart, Sheila A/C-5213-2012		NATIONAL CANCER INSTITUTE [R01CA070018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER; NCI NIH HHS [CA70018] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline; PHS HHS [T32/A107388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; BALLIET JW, 1994, VIROLOGY, V200, P623, DOI 10.1006/viro.1994.1225; BALOTTO CP, 1993, J EXP MED, V176, P1099; CAMERINI D, 1994, SCIENCE, V264, P1160, DOI 10.1126/science.7909961; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; HATTORI N, 1990, P NATL ACAD SCI USA, V87, P8080, DOI 10.1073/pnas.87.20.8080; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HOCH J, 1995, J VIROL, V69, P4807, DOI 10.1128/JVI.69.8.4807-4813.1995; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; NALDINI L, 1996, P NATL ACAD SCI USA, V93, P11383; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Planelles V, 1996, J VIROL, V70, P2516, DOI 10.1128/JVI.70.4.2516-2524.1996; Poon B, 1997, J VIROL, V71, P3961, DOI 10.1128/JVI.71.5.3961-3971.1997; POON B, UNPUB; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Sambrook J., 1989, MOL CLONING; SHEARER GM, 1986, J IMMUNOL, V137, P2515; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Subbramanian RA, 1998, J EXP MED, V187, P1103, DOI 10.1084/jem.187.7.1103; TENNERRACZ K, 1989, PROGR AIDS PATHOLOGY, P29; WAHREN B, 1987, J VIROL, V61, P2017, DOI 10.1128/JVI.61.6.2017-2023.1987; WESTERVELT P, 1992, J VIROL, V66, P3925, DOI 10.1128/JVI.66.6.3925-3931.1992; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; YU XF, 1990, J VIROL, V64, P5688, DOI 10.1128/JVI.64.11.5688-5693.1990; YU XF, 1988, NATURE, V335, P262, DOI 10.1038/335262a0; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265	50	165	166	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					266	269		10.1126/science.281.5374.266	http://dx.doi.org/10.1126/science.281.5374.266			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657723				2022-12-28	WOS:000074714200052
J	Wong, SS; Joselevich, E; Woolley, AT; Cheung, CL; Lieber, CM				Wong, SS; Joselevich, E; Woolley, AT; Cheung, CL; Lieber, CM			Covalently functionalized nanotubes as nanometre-sized probes in chemistry and biology	NATURE			English	Article							FORCE MICROSCOPY; CARBON NANOTUBES	Carbon nanotubes combine a range of properties that make them well suited for use as probe tips in applications such as atomic force microscopy (AFM)(1-3), Their high aspect ratio, for example, opens up the possibility of probing the deep crevices(4) that occur in microelectronic circuits, and the small effective radius of nanotube tips significantly improves the lateral resolution beyond what can be achieved using commercial silicon tips(5). Another characteristic feature of nanotubes is their ability to buckle elastically(4,6), which makes them very robust while limiting the maximum force that is applied to delicate organic and biological samples, Earlier investigations into the performance of nanotubes as scanning probe microscopy tips have focused on topographical imaging, but a potentially more significant issue is the question of whether nanotubes can be modified to create probes that can sense and manipulate matter at the molecular level(7), Here we demonstrate that nanotube tips with the capability of chemical and biological discrimination can be created with acidic functionality and by coupling basic or hydrophobic functionalities or biomolecular probes to the carboxyl groups that are present at the open tip ends. We have used these modified nanotubes as AFM tips to titrate the acid and base groups, to image patterned samples based on molecular interactions, and to measure the binding force between single protein-ligand pairs. As carboxyl groups are readily derivatized by a variety of reactions(8), the preparation of a wide range of functionalized nanotube tips should be possible, thus creating molecular probes with potential applications in many areas of chemistry and biology.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.		Cheung, Chin Li/B-8270-2013	Cheung, Chin Li/0000-0001-8210-2833; Joselevich, Ernesto/0000-0002-9919-0734				BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Bodanszky M., 1994, PRACTICE PEPTIDE SYN; Bustamante C, 1997, CURR OPIN STRUC BIOL, V7, P709, DOI 10.1016/S0959-440X(97)80082-6; Dai HJ, 1996, NATURE, V384, P147, DOI 10.1038/384147a0; EVANS JF, 1977, J ELECTROANAL CHEM, V80, P409, DOI 10.1016/S0022-0728(77)80064-8; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRISBIE CD, 1994, SCIENCE, V265, P2071, DOI 10.1126/science.265.5181.2071; GILES MA, 1990, ANAL BIOCHEM, V184, P244; HIURA H, 1995, ADV MATER, V7, P275, DOI 10.1002/adma.19950070304; Keller D, 1996, NATURE, V384, P111, DOI 10.1038/384111a0; KUMARAMANICKAVEL G, 1994, NAT GENET, V8, P10, DOI 10.1038/ng0994-10; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; March J., 1992, ADV ORG CHEM, V4th; Marti A, 1995, LANGMUIR, V11, P4632, DOI 10.1021/la00012a009; McKendry R, 1998, NATURE, V391, P566, DOI 10.1038/35339; Noy A, 1998, LANGMUIR, V14, P1508, DOI 10.1021/la970948f; Noy A, 1997, ANNU REV MATER SCI, V27, P381, DOI 10.1146/annurev.matsci.27.1.381; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Vezenov DV, 1997, J AM CHEM SOC, V119, P2006, DOI 10.1021/ja963375m; WANDASS JH, 1987, J ELECTROCHEM SOC, V134, P2734, DOI 10.1149/1.2100278; Wong EW, 1997, SCIENCE, V277, P1971, DOI 10.1126/science.277.5334.1971; Wong SS, 1998, J AM CHEM SOC, V120, P603, DOI 10.1021/ja9737735; WONG SS, UNPUB J AM CHEM SOC	24	1343	1419	4	342	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					52	55		10.1038/27873	http://dx.doi.org/10.1038/27873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665127	Green Published			2022-12-28	WOS:000074579600044
J	Greenway, BA				Greenway, BA			Effect of flutamide on survival in patients with pancreatic cancer: results of a prospective, randomised, double blind, placebo controlled trial	BRITISH MEDICAL JOURNAL			English	Article							CYPROTERONE-ACETATE; CARCINOMA; ADENOCARCINOMA; RECEPTOR; THERAPY; TISSUE; FETAL	Objectives: To assess whether flutamide (Drogenil), a pure androgen receptor blocking agent, improves survival in patients with pancreatic carcinoma and thus whether testosterone is a major growth factor for this tumour. Design: A prospective, randomised, double blind placebo controlled trial. Subjects: 49 patients with a clinical diagnosis of pancreatic carcinoma. Interventions: 24 patients received flutamide and 25 received placebo. Main outcome measures: Death of the patient. Results: Analysis of all patients at 6 months and 1 year showed 14 and eight patients alive, respectively: in the flutamide group compared with 10 and one in the placebo group. After exclusion of those patients in both groups who received less than 6 weeks' treatment because of advanced disease and early death the comparable results were 14 (88%) and eight (50%) alive in the flutamide group compared with 10 (50%)and one (5%) in the placebo group. Median survival for all patients was 8 months in the flutamide group compared with 4 months in the placebo group. With the 6 week exclusions median survival was 12 months compared with 5 months, respectively. Conclusions: This study supports the concept that testosterone is a growth factor for pancreatic carcinoma and that blockade of androgen receptors offers an appropriate new approach to treatment.	Hinchingbrooke Hosp, Dept Surg, Cambridge PE18 8NT, England		Greenway, BA (corresponding author), Hinchingbrooke Hosp, Dept Surg, Cambridge PE18 8NT, England.							CORBISHLEY TP, 1986, CANCER, V57, P1992, DOI 10.1002/1097-0142(19860515)57:10<1992::AID-CNCR2820571019>3.0.CO;2-0; FREENY PC, 1989, RADIOL CLIN N AM, V27, P121; Freeny PC, 1982, RADIOLOGY PANCREAS; GONZALEZBARCENA D, 1989, BIOMED PHARMACOTHER, V43, P313, DOI 10.1016/0753-3322(89)90014-0; GREENWAY B, 1983, BRIT MED J, V286, P93, DOI 10.1136/bmj.286.6359.93; GREENWAY B, 1982, BRIT J SURG, V69, P595, DOI 10.1002/bjs.1800691013; GREENWAY B, 1981, BRIT MED J, V283, P751, DOI 10.1136/bmj.283.6294.751; GREENWAY BA, 1987, BRIT J SURG, V74, P441, DOI 10.1002/bjs.1800740602; IQBAL MJ, 1983, CLIN SCI, V65, P71, DOI 10.1042/cs0650071; ISAACS JT, 1981, CANCER RES, V41, P5070; KAUFMAN AR, 1988, GASTROINTEST ENDOSC, V34, P47, DOI 10.1016/S0016-5107(88)71230-4; KEATING JJ, 1989, BRIT J CANCER, V60, P789, DOI 10.1038/bjc.1989.361; POYET P, 1985, MOL CELL ENDOCRINOL, V42, P283, DOI 10.1016/0303-7207(85)90059-0; REDDING TW, 1984, P NATL ACAD SCI-BIOL, V81, P248, DOI 10.1073/pnas.81.1.248; ROSEWICZ S, 1997, LANCET, V349, P185; SHEARER MG, 1984, DIGESTION, pA78; TAYLOR OM, 1993, BRIT J SURG, V80, P1083; TONNESEN K, 1986, EUR J SURG ONCOL, V12, P69	18	31	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1935	1938		10.1136/bmj.316.7149.1935	http://dx.doi.org/10.1136/bmj.316.7149.1935			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641928	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000074636700023
J	Miller, C				Miller, C			Glutamate receptor activation: A four-step program	SCIENCE			English	Article									Brandeis Univ, Dept Biochem, Waltham, MA 02254 USA	Brandeis University	Miller, C (corresponding author), Brandeis Univ, Dept Biochem, Waltham, MA 02254 USA.	cmiller@brandeis.edu						Mano I, 1998, NEUROREPORT, V9, P327, DOI 10.1097/00001756-199801260-00027; Premkumar LS, 1997, J GEN PHYSIOL, V110, P485, DOI 10.1085/jgp.110.5.485; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596	3	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1998	280	5369					1547	1548		10.1126/science.280.5369.1547	http://dx.doi.org/10.1126/science.280.5369.1547			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9644020				2022-12-28	WOS:000074061200026
J	Henry, PD; Pacifico, A				Henry, PD; Pacifico, A			Altering molecular mechanisms to prevent sudden arrhythmic death	LANCET			English	Article							PLATELET-ACTIVATING-FACTOR; LEFT-VENTRICULAR DYSFUNCTION; ISCHEMIC-HEART-DISEASE; MYOCARDIAL REPERFUSION; ALPHA; ATHEROSCLEROSIS; INFLAMMATION; INFARCTION; RECEPTOR; BLOOD	Trials of drug treatment for prevention of sudden arrhythmic death have been disappointing, perhaps because suppressive therapy with arrhythmic agents fails to address the mechanisms leading; to electrophysiological failure. We propose that preventive treatment should pay more attention to molecular mechanisms responsible for the progression of cardiac disease to electrophysiological failure. Most sudden cardiac deaths occur in people with atherogenic dyslipidaemias. Our hypothesis is that the pathogenic molecular mechanisms of dyslipidaemias contribute directly to arrhythmogenesis. Proinflammatory-prothrombotic lipid-derived mediators that may play a part in arrhythmogenesis include phospholipids and leucotrienes acting through the platelet-activating-factor and peroxisome proliferator-activated-receptor pathways. There are drugs available to test the hypothesis of dyslipidaemias-specific prevention of electrophysiological failure.	Texas Arrhythmia Inst, Houston, TX 77030 USA		Henry, PD (corresponding author), Texas Arrhythmia Inst, Houston, TX 77030 USA.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; ASAI K, 1993, ARTERIOSCLER THROMB, V13, P892, DOI 10.1161/01.ATV.13.6.892; Becker L, 1996, CARDIAC ARREST SCI P, P28; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; FORNES P, 1994, ARCH MAL COEUR VAISS, V87, P319; Galea J, 1996, ARTERIOSCL THROM VAS, V16, P1000, DOI 10.1161/01.ATV.16.8.1000; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; HERTUALLA SYY, 1993, P NATL ACAD SCI USA, V88, P5252; Hoffman BF, 1996, J CARDIOVASC ELECTR, V7, P120, DOI 10.1111/j.1540-8167.1996.tb00507.x; Jacobsen AN, 1996, CIRCULATION, V93, P23, DOI 10.1161/01.CIR.93.1.23; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; JuhanVague I, 1996, CIRCULATION, V94, P2057, DOI 10.1161/01.CIR.94.9.2057; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; Kang JX, 1996, CIRCULATION, V94, P1774, DOI 10.1161/01.CIR.94.7.1774; KLUFT C, 1988, THROMB HAEMOSTASIS, V59, P329; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; Matsumori A, 1997, CIRCULATION, V96, P1386, DOI 10.1161/01.CIR.96.5.1386; Ogita T, 1997, AM J PHYSIOL-HEART C, V272, pH17, DOI 10.1152/ajpheart.1997.272.1.H17; PEDERSEN TR, 1994, LANCET, V344, P1383; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; Prescott SM, 1996, JPN CIRC J, V60, P137, DOI 10.1253/jcj.60.137; RIALS SJ, 1995, CIRCULATION, V91, P426, DOI 10.1161/01.CIR.91.2.426; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Sakai A, 1997, ARTERIOSCL THROM VAS, V17, P310, DOI 10.1161/01.ATV.17.2.310; Schoonjans K, 1996, J LIPID RES, V37, P907; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; TAMURA K, 1994, CORONARY ARTERY DIS, V5, P267; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; WEIDTMANN A, 1995, ARTERIOSCL THROM VAS, V15, P1131, DOI 10.1161/01.ATV.15.8.1131; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; YOUNG MRI, 1995, CHRONOBIOL INT, V12, P19, DOI 10.3109/07420529509064496; ZOLBE RG, 1997, CIRCADIAN RHYTHMS CA, P1	35	10	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 25	1998	351	9111					1276	1278		10.1016/S0140-6736(97)10049-6	http://dx.doi.org/10.1016/S0140-6736(97)10049-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643764				2022-12-28	WOS:000073283600043
J	Whitehead, M; Scott-Samuel, A; Dahlgren, G				Whitehead, M; Scott-Samuel, A; Dahlgren, G			Setting targets to address inequalities in health	LANCET			English	Editorial Material									Kings Fund, London W1M OAN, England; Karolinska Inst, Stockholm, Sweden; Univ Liverpool, Dept Publ Hlth, Equity Hlth Res & Dev Unit, Liverpool L69 3BX, Merseyside, England; Swedish Natl Inst Publ Hlth, Stockholm, Sweden	Karolinska Institutet; University of Liverpool	Whitehead, M (corresponding author), Kings Fund, 11-13 Cavendish Sq, London W1M OAN, England.							Benzeval M, 1995, TACKLING INEQUALITIE; *GLASG CIT COUNC, 1995, WORK TOG GLASG HLTH; GRIFFITHS J, 1991, HLTH SERVICE J  0820; *HLTH PROM AUTH WA, 1990, HLTH ALL WAL B; Horton R, 1998, LANCET, V351, P463, DOI 10.1016/S0140-6736(05)78677-3; *IR GOV, 1997, NAT ANT POV STAT; *NHS, 1998, NEW NHS MOD DEP NAT; *NHS, 1997, CM3807; Nutbeam D., 1993, GOALS TARGETS AUSTRA; PLATT MJ, 1991, OBSERVATORY REPORT S, V1; *SCOTT OFF DEP HLT, 1998, CM3854; SCOTT-SAMUEL A, 1989, Nutrition and Health (Bicester), V6, P129; SCOTTSAMUEL A, 1987, LANCET, V1, P1084; *STAT OFF, 1998, CM3852; *SWED MIN HL SOC A, 1995, TERMS REF PARL COMM; *US DEP HHS, 1989, PROM HLTH PREV DIS Y; *WELSH HL PLANN FO, 1991, PROT INV HLTH GAIN M; Whitehead M, 1997, BRIT MED J, V315, P1006, DOI 10.1136/bmj.315.7114.1006; Whitehead M., 1992, INEQUALITIES HLTH BL; WHITEHEAD M, 1997, OFFICE NAT STAT SERI, V15; *WHO, 1991, STRAT HLTH ALL REV T; *WHO, 1995, REN HLTH ALL STRAT E; *WHO, 1985, TARG HLTH ALL TARG S; World Health Organization, 1997, EUR SUST DEV HLTH SE, V2; 1994, LANCET, V343, P429	25	28	30	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1279	1282		10.1016/S0140-6736(98)03302-9	http://dx.doi.org/10.1016/S0140-6736(98)03302-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643765				2022-12-28	WOS:000073283600044
J	Kaplan, EH				Kaplan, EH			Israel's ban on use of Ethiopians' blood: how many infectious donations were prevented?	LANCET			English	Editorial Material									Yale Univ, Sch Management, New Haven, CT 06520 USA	Yale University	Kaplan, EH (corresponding author), Yale Univ, Sch Management, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH056826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009531] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA09531] Funding Source: Medline; NIMH NIH HHS [P01-MH/DA-56826] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*CENT BUR STAT, 1995, STAT ABSTR ISR; Kaplan E H, 1995, Public Health Rev, V23, P215; KAPLAN EH, 1998, IN PRESS J ACQ IMM D; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; Litvak E, 1997, MED DECIS MAKING, V17, P455, DOI 10.1177/0272989X9701700411; NAVON Y, 1996, SUMMONING CLARIFY BL; POLLACK S, 1993, ISRAEL J MED SCI, V29, P19; Satten GA, 1997, MATH BIOSCI, V141, P101, DOI 10.1016/S0025-5564(96)00185-X; SCHMEMANN S, 1996, NY TIMES        0129; SIEGEL J, 1996, JERUSALEM POST  0318; Siegel Judy, 1996, JERUSALEM POST  0206, P12; SLATER PE, 1993, ISRAEL J MED SCI, V29, P2; Vikhanski L, 1996, NAT MED, V2, P260, DOI 10.1038/nm0396-260; 1996, JERUSALEM POST  0129	14	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1127	1128		10.1016/S0140-6736(97)10356-7	http://dx.doi.org/10.1016/S0140-6736(97)10356-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660600				2022-12-28	WOS:000073090200047
J	Weiden, PL; Bauermeister, DE; Fatta, EA				Weiden, PL; Bauermeister, DE; Fatta, EA			An Asian man with enlarged glands	LANCET			English	Article									Virginia Mason Med Ctr, Dept Med, Seattle, WA 98101 USA; Virginia Mason Med Ctr, Dept Pathol, Seattle, WA 98101 USA; Boeing Co, Natl & Int Hlth Serv, Seattle, WA 98124 USA	Virginia Mason Medical Center; Virginia Mason Medical Center; Boeing	Weiden, PL (corresponding author), Virginia Mason Med Ctr, Dept Med, Seattle, WA 98101 USA.							HUI PK, 1989, AM J SURG PATHOL, V13, P177, DOI 10.1097/00000478-198903000-00001; KIM BH, 1975, ARCH SURG-CHICAGO, V110, P1246; Kim HT., 1937, CHIN MED J, V23, P699; Kimura T., 1948, T SOC PATH JAP, V37, P179; Takagi K, 1993, Nihon Rinsho, V51, P785	5	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1098	1098		10.1016/S0140-6736(97)10481-0	http://dx.doi.org/10.1016/S0140-6736(97)10481-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660580				2022-12-28	WOS:000073090200012
J	Neelon, FA				Neelon, FA			Osler and Ernulf's curse	LANCET			English	Editorial Material											Neelon, FA (corresponding author), UNIV DURHAM,MED CTR,BOX 3021,DURHAM,NC 27710, USA.							BAMFORD C, 1981, CELTIC CONSCIOUSNESS; Cushing H., 1925, LIFE W OSLER; DROGIN M, 1983, ANATHEMAL MEDIEVAL S; ELTON IE, 1983, GREAT BOOK COLLECTOR; Francis W W, 1937, Bull Med Libr Assoc, V26, P1; HUNTER R J, 1951, Bull Hist Med, V25, P554; JACKSON H, 1931, ANATOMY BIBLIOMANIA, V2; OSLER W, 1913, CAN MED ASSOC J, V3, P612; OSLER W, 1961, SELECTED WRITINGS WO; RAABE T, 1991, BIBLIOHOLISM; SHERRINGTON CS, 1949, N CAROL MED J, V10, P377; STERNE L, 1819, WORKS L STERNE; Whitelock D., 1961, ANGLOSAXON CHRONICLE	13	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1245	1246		10.1016/S0140-6736(97)05143-X	http://dx.doi.org/10.1016/S0140-6736(97)05143-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652582				2022-12-28	WOS:A1997YD23800043
J	Nurden, AT				Nurden, AT			Platelet glycoprotein IIIa polymorphism and coronary thrombosis	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION				Nurden, AT (corresponding author), HOP CARDIOL,CNRS,UMR 5533,F-33604 PESSAC,FRANCE.							Carter AM, 1997, CIRCULATION, V96, P1424, DOI 10.1161/01.CIR.96.5.1424; COLLER BS, 1995, CIRCULATION, V92, P2373, DOI 10.1161/01.CIR.92.9.2373; Herrmann SM, 1997, THROMB HAEMOSTASIS, V77, P1179; Humbert M, 1996, ARTERIOSCL THROM VAS, V16, P1532, DOI 10.1161/01.ATV.16.12.1532; KUNICKI TJ, 1993, BLOOD, V82, P2693; KUNICKI TJ, 1992, BLOOD, V80, P1396; Marian AJ, 1996, NEW ENGL J MED, V335, P1071; NURDEN AT, 1995, THROMB HAEMOSTASIS, V74, P345; Nurden AT, 1994, HAEMOSTASIS THROMBOS, P115; Osborn SV, 1996, LANCET, V348, P1309, DOI 10.1016/S0140-6736(05)65785-6; Ridker PM, 1997, LANCET, V349, P385, DOI 10.1016/S0140-6736(97)80010-4; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703	12	30	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1189	1191		10.1016/S0140-6736(05)63447-2	http://dx.doi.org/10.1016/S0140-6736(05)63447-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652554				2022-12-28	WOS:A1997YD23800003
J	Rees, K; Wright, A; Keeling, JW; Douglas, NJ				Rees, K; Wright, A; Keeling, JW; Douglas, NJ			Facial structure in the sudden infant death syndrome: case-control study	BRITISH MEDICAL JOURNAL			English	Article							SLEEP-APNEA		Univ Edinburgh, Royal Infirm, Dept Med, Resp Med Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Edinburgh, Dept Med, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Edinburgh, Dept Paediat Pathol, Edinburgh EH8 9YL, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh	Douglas, NJ (corresponding author), Univ Edinburgh, Royal Infirm, Dept Med, Resp Med Unit, Edinburgh EH3 9YW, Midlothian, Scotland.	n.j.douglas@ed.ac.uk	Douglas, Neil/B-1491-2013	Rees, Karen/0000-0003-1832-3679				KAHN A, 1992, SLEEP, V15, P287, DOI 10.1093/sleep/15.4.287; MATHUR R, 1995, ANN INTERN MED, V122, P174, DOI 10.7326/0003-4819-122-3-199502010-00003; MATHUR R, 1994, LANCET, V344, P819, DOI 10.1016/S0140-6736(94)92375-2; SKATVEDT O, 1994, ARCH DIS CHILD, V71, P133; Tishler PV, 1996, AM J RESP CRIT CARE, V153, P1857, DOI 10.1164/ajrccm.153.6.8665046	5	20	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					179	180		10.1136/bmj.317.7152.179	http://dx.doi.org/10.1136/bmj.317.7152.179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665897	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000075047800024
J	McConkey, B				McConkey, B			Ceremonial haemoglobinuria	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					153	153		10.1136/bmj.317.7151.153	http://dx.doi.org/10.1136/bmj.317.7151.153			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657816	Green Published			2022-12-28	WOS:000075081700067
J	Lim, JME				Lim, JME			The importance of social context	BRITISH MEDICAL JOURNAL			English	Article									Econ Dev Board, Singapore 179101, Singapore		Lim, JME (corresponding author), Econ Dev Board, 250 N Bridge Rd 24-00,Raffles City Tower, Singapore 179101, Singapore.							Department of Health, 1997, NEW NHS; HAM C, 1996, LANCET, V3147, P951; HONG PK, 1991, 5 IPS; Light DW, 1997, BRIT MED J, V315, P112, DOI 10.1136/bmj.315.7100.112; Ministerial Committee on Health Policy Singapore, 1993, AFF HLTH CAR WHIT PA; Powell M., 1997, EVALUATING NATL HLTH	6	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					51	52		10.1136/bmj.317.7150.51	http://dx.doi.org/10.1136/bmj.317.7150.51			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651274	Green Published			2022-12-28	WOS:000075081600029
J	Gulick, RM; Mellors, JW; Havlir, D; Eron, JJ; Gonzalez, C; McMahon, D; Jonas, L; Meibohm, A; Holder, D; Schleif, WA; Condra, JH; Emini, EA; Isaacs, R; Chodakewitz, JA; Richman, DD				Gulick, RM; Mellors, JW; Havlir, D; Eron, JJ; Gonzalez, C; McMahon, D; Jonas, L; Meibohm, A; Holder, D; Schleif, WA; Condra, JH; Emini, EA; Isaacs, R; Chodakewitz, JA; Richman, DD			Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection - 100-week follow-up	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	37th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 28-OCT 03, 1997	TORONTO, CANADA				HIGH-LEVEL RESISTANCE; REVERSE-TRANSCRIPTASE; INHIBITOR; PROTEASE; RITONAVIR; MUTATION; AZT; 3TC	Context.-Combination antiretroviral therapy can markedly suppress human immunodeficiency virus (HIV) replication but the duration of HIV suppression varies among patients. Objective.-To compare the antiretroviral effect of a 3-drug regimen started simultaneously or sequentially in patients with HIV infection, Design.-A multicenter, randomized, double-blind study, modified after at least 24 weeks of blinded therapy to provide open-label 3-drug therapy with follow-up through 100 weeks. Setting.-Four clinical research units Patients.-Ninety-seven patients with HIV infection who had taken zidovudine for at least 6 months with serum HIV RNA level of at least 20 000 copies/mL and CD4 cell count of 0.05 to 0.40 x 10(9)/L, Interventions.-Patients were initially randomized to receive 1 of 3 antiretroviral regimens: indinavir, 800 mg every 8 hours; zidovudine, 200 mg every 8 hours and lamivudine, 150 mg every 12 hours; or all 3 drugs. After at least 24 weeks of blinded therapy, all patients received open-label 3-drug therapy. Main Outcome Measures.-Anti retroviral activity was assessed by changes in HIV RNA level and CD4 cell count from baseline. Data through 100 weeks were summarized. Results.-Simultaneous initiation of indinavir, zidovudine, and lamivudine suppressed HIV RNA in 78% (25/32) of contributing patients to less than 500 copies/ mi and increased CD4 cell count to a median of 0.209 x 10(9)/L above baseline at 100 weeks. When these 3 drugs were initiated sequentially, only 30% to 45% of contributing patients (10 of 33 in the zidovudine-lamivudine group and 13 of 29 in the indinavir group, respectively) had a sustained reduction in H(V RNA to less than 500 copies/mL, and median CD4 cell count increased to 0.101 to 0.163 x 10(9)/L above baseline at 100 weeks. Conclusions.-A 3-drug combination of indinavir, zidovudine, and lamivudine, started simultaneously has durable antiretroviral activity for at least 2 years. Sequential initiation of the same 3 drugs is much less effective.	NYU, Sch Med, Dept Med, New York, NY USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA; Vet Adm Med Ctr, Pittsburgh, PA USA; Univ Calif San Diego, Dept Pathol, San Diego, CA USA; Univ Calif San Diego, Dept Med, San Diego, CA USA; Vet Adm Med Ctr, San Diego, CA 92161 USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA; Merck Res Labs, W Point, PA USA	New York University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of North Carolina; University of North Carolina Chapel Hill; Merck & Company	Gulick, RM (corresponding author), Cornell Clin Trials Unit, Ground Floor,119 W 24th St, New York, NY 10011 USA.				NIAID NIH HHS [U01-AI-27665, P30-AI-27742, N01-AI-27670] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742, U01AI027670, U01AI027665] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BUCKTON KE, 1967, NATURE, V214, P470, DOI 10.1038/214470a0; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONNICK E, 1998, 5 C RETR OPP INF FEB; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; Deeks S., 1997, 37 INT C ANT AG CHEM; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P1390, DOI 10.1128/AAC.37.6.1390; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gunthard HF, 1998, J VIROL, V72, P2422; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HAUBRICH R, 1997, 37 INT C ANT AG CHEM; HIRSCH MS, 1998, 5 C RETR OPP INF FEB; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; Kuritzkes DR, 1996, AIDS, V10, P975, DOI 10.1097/00002030-199610090-00007; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Mackall CL, 1997, BLOOD, V89, P3700, DOI 10.1182/blood.V89.10.3700.3700_3700_3707; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; ROZENBAUM W, 1998, 5 C RETR OPP INF FEB; SALIT IE, 1997, 37 INT C ANT AG CHEM; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; *US DEP HHS, 1998, MMWR-MORBID MORTAL W, V47, P43; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	30	203	204	2	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					35	41		10.1001/jama.280.1.35	http://dx.doi.org/10.1001/jama.280.1.35			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660361	Bronze			2022-12-28	WOS:000074379400021
J	Kirkwood, JM				Kirkwood, JM			Adjuvant IFN alpha 2 therapy of melanoma	LANCET			English	Editorial Material							RESECTED CUTANEOUS MELANOMA; COOPERATIVE-ONCOLOGY-GROUP; INTERFERON ALFA-2A; SURVIVAL; TRIAL; LIFE		Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 17213 USA; Univ Pittsburgh, Inst Canc, Melanoma Ctr, Pittsburgh, PA 17213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kirkwood, JM (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 17213 USA.							Balch Charles M., 1997, P1947; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; CASCINELLI N, 1995, P ASCO, V14, pA129; Cole BF, 1996, J CLIN ONCOL, V14, P2666, DOI 10.1200/JCO.1996.14.10.2666; CREAGAN ET, 1995, J CLIN ONCOL, V13, P2776, DOI 10.1200/JCO.1995.13.11.2776; EZEKOWITZ RAB, 1992, NEW ENGL J MED, V326, P1456, DOI 10.1056/NEJM199205283262203; Hillner BE, 1997, J CLIN ONCOL, V15, P2351, DOI 10.1200/JCO.1997.15.6.2351; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; MORTON DL, 1992, ANN SURG, V216, P463, DOI 10.1097/00000658-199210000-00010; Pehamberger H, 1998, J CLIN ONCOL, V16, P1425, DOI 10.1200/JCO.1998.16.4.1425; REINTGEN D, 1997, ANN SURG, V1, P1	11	26	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1901	1903		10.1016/S0140-6736(05)78608-6	http://dx.doi.org/10.1016/S0140-6736(05)78608-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654253				2022-12-28	WOS:000074464700003
J	Little, P; Griffin, S; Kelly, J; Dickson, N; Sadler, C				Little, P; Griffin, S; Kelly, J; Dickson, N; Sadler, C			Effect of educational leaflets and questions on knowledge of contraception in women taking the combined contraceptive pill: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective: To assess whether provision of educational leaflets or questions on contraception improves knowledge of contraception in women taking the combined contraceptive pill. Design: Randomisation of women into three groups according to type of educational leaflet on contraceptive information. These groups were subdivided into two on the basis of questions on contraception asked by the doctor or practice nurse. The women were followed up by postal questionnaire 3 months later. Setting: 15 general practices in South and West region. Subjects: 636 women attending check up appointment for repeat prescription of the combined contraceptive pill. Main outcome measures: Knowledge of: factors causing pill failure, subsequent action, emergency contraception, and all the rules (pill rules) that apply to the contraceptive pill. Results: 523 women returned completed questionnaires (response rate 82%). Knowledge of contraception with no intervention was low with only 10 (12%) women knowing all the pill rules. Educational intervention had a highly significant effect on knowledge of factors causing pill failure (likelihood ratio chi(2) = 22); subsequent action (21); emergency contraception (24); and all the pill rules (22) (P < 0.01 in all cases).Improvement in knowledge of all the pill rules occurred with provision of the summary leaflet (28% knew all the rules, adjusted odds ratio 4.04, 95% confidence interval 1.68 to 9.75), the Family Planning Association's leaflet (27%, 3.43, 1.45 to 8.09), and asking questions (26%, 3.03, 1.30 to 7.00). Asking questions in addition to provision of leaflets improved knowledge of contraception further for the summary leaflet (39%, 6.81, 2.85 to 16.27) but not for the Family Planning Association leaflet (21%, 2.58, 1.07 to 6.18). Conclusion: Women attending check ups for repeat prescriptions of the contraceptive pill should be provided with educational leaflets on contraception or asked relevant questions to help improve their knowledge of contraception. Asking questions in addition to providing a summary leaflet is time consuming, but results in the most knowledge gained.	Aldermoor Hlth Ctr, Fac Hlth Med & Biol Sci, Southampton SO16 5ST, Hants, England; Park Surg, Chandlers Ford SO5 2ZH, Hants, England		Little, P (corresponding author), Aldermoor Hlth Ctr, Fac Hlth Med & Biol Sci, Southampton SO16 5ST, Hants, England.	pmc1@soton.ac.uk	Potter, Joseph E/A-3122-2008; Griffin, Simon J/K-3106-2013	Griffin, Simon J/0000-0002-2157-4797; Little, Paul/0000-0003-3664-1873	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROMHAM DR, 1993, BRIT MED J, V306, P556, DOI 10.1136/bmj.306.6877.556; BROOK SJ, 1991, BR J FAMILY PLANNING, V17, P18; DAY SJ, 1989, BMJ-BRIT MED J, V299, P663, DOI 10.1136/bmj.299.6700.663; DUNCAN G, 1990, BRIT J FAM PLANN, V15, P112; FINLAY IG, 1986, BRIT MED J, V293, P601, DOI 10.1136/bmj.293.6547.601; International Working Group on Enhancing Patient Compliance and Oral Contraceptive Efficacy, 1993, BR J FAM PLANN, V18, P126; LITTLE PS, IN PRESS BR J FAM PL; METSON D, 1992, BR J FAM PLANN, V17, P21; SMITH LFP, 1995, BRIT J GEN PRACT, V45, P409; WILSON S, 1992, BR J FAM PLANN, V18, P3; 1996, MED RESOURCE CTR B, V7, P33	11	90	92	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 27	1998	316	7149					1948	1952		10.1136/bmj.316.7149.1948	http://dx.doi.org/10.1136/bmj.316.7149.1948			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641933	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000074636700029
J	Boeke, JD; Devine, SE				Boeke, JD; Devine, SE			Yeast retrotransposons: Finding a nice quiet neighborhood	CELL			English	Review							RNA-POLYMERASE-III; INTEGRATION; CHROMATIN; REGIONS; GENES		Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Johns Hopkins University	Boeke, JD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.							Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; Curcio MJ, 1996, TRENDS GENET, V12, P436; Devine SE, 1996, GENE DEV, V10, P620, DOI 10.1101/gad.10.5.620; Gai XW, 1998, MOL CELL, V1, P1051, DOI 10.1016/S1097-2765(00)80105-7; HULL MW, 1994, MOL CELL BIOL, V14, P1266, DOI 10.1128/MCB.14.2.1266; Kenna MA, 1998, MOL CELL BIOL, V18, P1115, DOI 10.1128/MCB.18.2.1115; Kim JM, 1998, GENOME RES, V8, P464, DOI 10.1101/gr.8.5.464; KIRCHNER J, 1995, SCIENCE, V267, P1488, DOI 10.1126/science.7878467; Lewin B, 1998, CELL, V93, P301, DOI 10.1016/S0092-8674(00)81154-X; MARSOLIER MC, 1996, GENE DEV, V15, P410; Moore SP, 1998, MOL CELL BIOL, V18, P1105, DOI 10.1128/MCB.18.2.1105; MORSE RH, 1992, MOL CELL BIOL, V12, P4015, DOI 10.1128/MCB.12.9.4015; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; WEINSTOCK KG, 1990, MOL CELL BIOL, V10, P2882, DOI 10.1128/MCB.10.6.2882; Zou S, 1996, GENE DEV, V10, P634, DOI 10.1101/gad.10.5.634	18	105	105	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1087	1089		10.1016/S0092-8674(00)81450-6	http://dx.doi.org/10.1016/S0092-8674(00)81450-6			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657139	hybrid			2022-12-28	WOS:000074491100001
J	Lutz, C; Ledermann, B; Kosco-Vilbois, MH; Ochsenbein, AF; Zinkernagel, RM; Kohler, G; Brombacher, F				Lutz, C; Ledermann, B; Kosco-Vilbois, MH; Ochsenbein, AF; Zinkernagel, RM; Kohler, G; Brombacher, F			IgD can largely substitute for loss of IgM function in B cells	NATURE			English	Article							IMMUNOGLOBULIN MU-CHAIN; DEFICIENT MICE; GENE; ANTIGEN; TERMINATION; LYMPHOCYTES; EXPRESSION; DISRUPTION; DIFFERENTIATION; RECOMBINATION	The mu and delta heavy chains of IgM and IgD, the first antibody isotypes expressed during bone-marrow B-cell development, are encoded by a common transcription unit. Expression of the mu chain on the surface of late pre-B cells allows their further development to immature B cells. Coexpression of the delta chain and emigration of the immature B cells to the periphery eventually leads to the development of naive mature IgM/IgD double-positive cells. Although IgM is important in driving B-cell development(1), the contribution of IgD is not clear. Here we investigate the function of IgD. We generated mice deficient in IgM (IgM(-/-) mice) by deleting the mu. region in embryonic stem cells. IgM-/- mice showed normal B-cell development and maturation, with IgD replacing membrane-bound and secretory IgM. Moreover, specific B-cell responses and isotype class switches occurred during immunization or infection. In contrast to mice deficient in B cells, IgM(-/-) mice survived infection with vesicular stomatitis virus by developing neutralizing immunoglobulins, but they were more susceptible than wild-type controls with delayed specific immunoglobulin responses. These data lead us to conclude that IgD is largely able to substitute for IgM functions.	Max Planck Inst Immunobiol, D-7800 Freiburg, Germany; Novartis Pharma Inc Res, Basel, Switzerland; Glaxo Wellcome Res & Dev Ltd, Geneva Biomed Res Inst, Plan Les Ouates, Switzerland; Univ Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Univ Cape Town, Groote Schuur Hosp, Dept Immunol, ZA-7925 Cape Town, South Africa	Max Planck Society; Novartis; GlaxoSmithKline; University of Zurich; University of Cape Town	Brombacher, F (corresponding author), Max Planck Inst Immunobiol, Stubeweg 51, D-7800 Freiburg, Germany.	fbrombac@uctgshl.uct.ac.za		Ochsenbein, Adrian/0000-0003-1773-5436				Achatz G, 1997, SCIENCE, V276, P409, DOI 10.1126/science.276.5311.409; Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; Bachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024; BROMBACHER F, 1991, J EXP MED, V174, P1335, DOI 10.1084/jem.174.6.1335; Brundler MA, 1996, EUR J IMMUNOL, V26, P2257, DOI 10.1002/eji.1830260943; COICO RF, 1983, J IMMUNOL, V131, P2254; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FREER G, 1994, J VIROL, V68, P3650, DOI 10.1128/JVI.68.6.3650-3655.1994; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P450, DOI 10.1002/eji.1830160423; HAYAKAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P2494, DOI 10.1073/pnas.81.8.2494; IGLESIAS A, 1993, EUR J IMMUNOL, V23, P2622, DOI 10.1002/eji.1830231036; IGLESIAS A, 1987, NATURE, V330, P482, DOI 10.1038/330482a0; Kalinke U, 1996, EUR J IMMUNOL, V26, P2801, DOI 10.1002/eji.1830261202; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LEIST TP, 1987, J IMMUNOL, V138, P2278; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MUMMERY CL, 1990, CELL DIFFER DEV, V30, P195, DOI 10.1016/0922-3371(90)90139-N; NITSCHKE L, 1993, P NATL ACAD SCI USA, V90, P1887, DOI 10.1073/pnas.90.5.1887; NITSCHKE L, 1993, BIOTECHNIQUES, V14, P914; NobenTrauth N, 1996, TRANSGENIC RES, V5, P487, DOI 10.1007/BF01980214; RANDALL TD, 1990, EUR J IMMUNOL, V20, P1971, DOI 10.1002/eji.1830200915; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; SAUER B, 1993, METHOD ENZYMOL, V225, P890; WEISS EA, 1991, MOL IMMUNOL, V28, P687, DOI 10.1016/0161-5890(91)90110-6; Yuan D, 1996, J IMMUNOL, V157, P2073	30	113	120	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 25	1998	393	6687					797	801		10.1038/31716	http://dx.doi.org/10.1038/31716			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655395				2022-12-28	WOS:000074433100052
J	Borgstein, J				Borgstein, J			The poetry of genetics: or reading a genetic sequence - a literary model for cellular mechanisms	LANCET			English	Article											Borgstein, J (corresponding author), Hercules 9,Col Credito Constructor, Mexico City 03940, DF, Mexico.							Blake William, 1968, AUGURIES INNOCENCE; KIPLING R, 1987, JUST SO STORIES ELEP	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1353	1354		10.1016/S0140-6736(97)12036-0	http://dx.doi.org/10.1016/S0140-6736(97)12036-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643814				2022-12-28	WOS:000073439400043
J	Liu, B; Anderson, G; Mittmann, N; To, T; Axcell, T; Shear, N				Liu, B; Anderson, G; Mittmann, N; To, T; Axcell, T; Shear, N			Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people	LANCET			English	Article							MEDICATION USE; NURSING-HOME; FALLS; WOMEN; EPIDEMIOLOGY; OSTEOPOROSIS; METAANALYSIS; DEPRESSION; THERAPY	Background Tricyclic antidepressants (TCAs) are associated with an increased risk of falls and hip fractures in elderly people. Selective serotonin-reuptake inhibitors (SSRIs) are reported to be better tolerated than TCAs. We investigated the risk of hip fractures associated with SSRIs and TCAs. Methods This case-control study used administrative healthcare data from the province of Ontario, Canada. 8239 cases-patients aged 66 years or older, treated in hospital between April, 1994, and March, 1995, for hip fracture-were each matched for age and sex to five controls. Logistic regression was used to calculate the odds ratio for hip fracture with adjustment for potential confounding effects produced by concomitant drug use and comorbidity. Findings With participants who had no exposure to antidepressants as the reference category, the adjusted odds ratio for hip fracture was 2.4 (95% CI 2.0-2.7) for exposure to SSRIs, 2.2 (1.8-2.8) for exposure to secondary-amine TCAs, and 1.5 (1.3-1.7) for exposure to tertiary-amine TCAs, For all types of antidepressants, current use was associated with a higher risk of hip fracture than former use, The odds ratios for hip fracture were higher for new current users than for continuous current users in all three drug classes. The proportion of current use in the low-dose range was 22% for SSRIs, 50% for secondary-amine TCAs, and 58% for tertiary-amine TCAs. Interpretation Exposure to any of the three classes of antidepressants is associated with a significant increase in the risk of hip fracture. Despite differences in dose distribution, this analysis suggests that SSRIs do not offer an advantage over TCAs in terms of risk of hip fracture.	Sunnybrook Hlth Sci Ctr, Baycrest Ctr Geriatr Care, Kunin Lunenfeld Clin Res Unit, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Div Geriatr Med, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Dept Med, Div Clin Pharmacol, Toronto, ON, Canada; Univ Toronto, Fac Med, Inst Clin & Evaluat Sci Ontario, Toronto, ON, Canada; Univ Toronto, Fac Med, Dept Hlth Adm, Toronto, ON, Canada; Univ Toronto, Fac Med, Dept Pharmacol & Drug Safety Res, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Baycrest; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto	Liu, B (corresponding author), 2075 Bayview Ave,Room E240, Toronto, ON M4N 3M5, Canada.							ANDERSON G, 1996, PATTERNS HLTH CARE O, P323; ANDERSON IM, 1995, BMJ-BRIT MED J, V310, P1433, DOI 10.1136/bmj.310.6992.1433; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; CAMPBELL A J, 1991, Drugs and Aging, V1, P289, DOI 10.2165/00002512-199101040-00005; CLAYER MT, 1989, J TRAUMA, V29, P1673, DOI 10.1097/00005373-198912000-00016; *COMM PROF HOSP AC, 1978, INT CLASS DIS; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; de Jonghe F, 1992, Drugs, V43 Suppl 2, P40; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; GALES BJ, 1995, ANN PHARMACOTHER, V29, P354, DOI 10.1177/106002809502900402; GREENDALE GA, 1995, J AM GERIATR SOC, V43, P955, DOI 10.1111/j.1532-5415.1995.tb05557.x; HERINGS RMC, 1995, ARCH INTERN MED, V155, P1801, DOI 10.1001/archinte.155.16.1801; LEONARD BE, 1993, J CLIN PSYCHIAT, V54, P3; LEVINSON ML, 1991, DICP ANN PHARMAC, V25, P657; LIU BA, 1995, J AM GERIATR SOC, V43, P1141, DOI 10.1111/j.1532-5415.1995.tb07016.x; LORD SR, 1995, BRIT J CLIN PHARMACO, V39, P227, DOI 10.1111/j.1365-2125.1995.tb04441.x; Macdonald J B, 1985, Clin Geriatr Med, V1, P621; Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602; Mittmann N, 1997, J AFFECT DISORDERS, V46, P191, DOI 10.1016/S0165-0327(97)00107-9; NEVITT MC, 1994, RHEUM DIS CLIN N AM, V20, P535; PRESKORN SH, 1993, AM J MED, V94, pS2; PRESKORN SH, 1995, INT CLIN PSYCHOPHARM, V10, P129, DOI 10.1097/00004850-199510030-00001; RAY WA, 1990, AM J EPIDEMIOL, V131, P502, DOI 10.1093/oxfordjournals.aje.a115524; RAY WA, 1991, ARCH INTERN MED, V151, P754, DOI 10.1001/archinte.151.4.754; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RUBENSTEIN LZ, 1994, ANN INTERN MED, V121, P442, DOI 10.7326/0003-4819-121-6-199409150-00009; RUTHAZER R, 1993, AM J PUBLIC HEALTH, V83, P746, DOI 10.2105/AJPH.83.5.746; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; SULSER F, 1983, J CLIN PSYCHIAT, V44, P14; THRONGREN KG, 1993, CLIN ORTHOP RELAT R, V287, P76; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TINETTI ME, 1988, JAMA-J AM MED ASSOC, V259, P1190, DOI 10.1001/jama.259.8.1190; *WHO COLL CTR DRUG, 1991, ATC IND; Williams J. I., 1996, PATTERNS HLTH CARE O, P339	34	286	291	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1303	1307		10.1016/S0140-6736(97)09528-7	http://dx.doi.org/10.1016/S0140-6736(97)09528-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643791				2022-12-28	WOS:000073439400006
J	Rubin, CM; Lindvall, SC; Rockwell, TK				Rubin, CM; Lindvall, SC; Rockwell, TK			Evidence for large earthquakes in metropolitan Los Angeles	SCIENCE			English	Article							WHITTIER-NARROWS EARTHQUAKE; SOUTHERN-CALIFORNIA; MAGNITUDE; REGION; FAULTS; AREA	The Sierra Madre fault, along the southern flank of the San Gabriel Mountains in the Los Angeles region, has failed in magnitude 7.2 to 7.6 events at Least twice in the past 15,000 years. Restoration of slip on the fault indicated a minimum of about 4.0 meters of slip from the most recent earthquake and suggests a total cumulative slip of about 10.5 meters for the past two prehistoric earthquakes. Large surface displacements and strong ground motions resulting from greater than magnitude 7 earthquakes within the Los Angeles region are not yet considered in most seismic hazard and risk assessments.	Cent Washington Univ, Dept Geol, Ellensburg, WA 98926 USA; William Lettis & Associates, Valencia, CA 91355 USA; San Diego State Univ, Dept Geol Sci, San Diego, CA 92182 USA	Central Washington University; California State University System; San Diego State University	Rubin, CM (corresponding author), Cent Washington Univ, Dept Geol, Ellensburg, WA 98926 USA.			Rockwell, Thomas/0000-0001-5319-6447				CLARK MM, 1972, US GEOL SURV PROFESS, V787, P190; CROOK R, 1987, US GEOL SURV PROF PA, V1339, P27; DAVIS J, 1988, 88398 US GEOL SURV; DAVIS J, 1982, CALIF DIV MINES GEOL, V60; DAVIS TL, 1989, J GEOPHYS RES-SOLID, V94, P9644, DOI 10.1029/JB094iB07p09644; DOLAN JF, 1995, SCIENCE, V267, P199, DOI 10.1126/science.267.5195.199; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; FLEIGEL K, 1993, J GEOPHYS RES, V98, P21677; GATH E, 1992, GEOL SOC AM ABSTR, V24, P26; HANKS TC, 1979, J GEOPHYS RES, V84, P2348, DOI 10.1029/JB084iB05p02348; HANKS TC, 1979, B SEISMOL SOC AM, V69, P451; HARDEN JW, 1982, GEODERMA, V28, P1, DOI 10.1016/0016-7061(82)90037-4; HAUKSSON E, 1995, J GEOPHYS RES-SOL EA, V100, P12335, DOI 10.1029/95JB00865; HAUKSSON E, 1994, B SEISMOL SOC AM, V84, P1058; HAUKSSON E, 1989, J GEOPHYS RES-SOLID, V94, P9569, DOI 10.1029/JB094iB07p09569; HAUKSSON E, 1991, J GEOPHYS RES-SOLID, V96, P8143, DOI 10.1029/91JB00481; HEATON TH, 1995, SCIENCE, V267, P206, DOI 10.1126/science.267.5195.206; HOUGH SE, 1995, SCIENCE, V267, P211, DOI 10.1126/science.267.5195.211; HUDNUT K, 1994, SEISMOL RES LETT, V65, P59; JACKSON DD, 1995, B SEISMOL SOC AM, V85, P379; JACKSON DD, 1996, SEISMOL RES LETT, V67, P3, DOI DOI 10.1785/GSSRL.67.1.3; KACHADOORIAN R, 1987, US GEOL SURV PROF PA, V1339, P5; Kamb B., 1971, US GEOL SURV PROFESS, V733, P41; Morton D. M., 1987, RECENT REVERSE FAULT, P179; ROCKWELL T, 1990, J GEOPHYS RES-SOLID, V95, P8593, DOI 10.1029/JB095iB06p08593; ROCKWELL T, 1988, GEOL SOC AM ABSTR, V20, P224; Rubin CM, 1996, GEOLOGY, V24, P989, DOI 10.1130/0091-7613(1996)024<0989:SUOEMF>2.3.CO;2; Shaw JH, 1996, J GEOPHYS RES-SOL EA, V101, P8623, DOI 10.1029/95JB03453; SHAW JH, 1994, GEOL SOC AM BULL, V106, P607, DOI 10.1130/0016-7606(1994)106<0607:AFAGFI>2.3.CO;2; SHAW JH, 1993, THESIS PRINCETON U P; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; STUIVER M, 1983, RADIOCARBON, V25, P219, DOI 10.1017/S0033822200005518; TOPPOZADA T, 1993, CALIF DIV MINES GEOL, V102; WELLS DL, 1994, B SEISMOL SOC AM, V84, P974; WESNOUSKY SG, 1986, J GEOPHYS RES-SOLID, V91, P2587, DOI 10.1029/JB091iB12p12587	35	35	35	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 17	1998	281	5375					398	402		10.1126/science.281.5375.398	http://dx.doi.org/10.1126/science.281.5375.398			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665880				2022-12-28	WOS:000074918800043
J	McGowan, JA; Cayan, DR; Dorman, LM				McGowan, JA; Cayan, DR; Dorman, LM			Climate-ocean variability and ecosystem response in the northeast Pacific	SCIENCE			English	Review							LONG-TERM TRENDS; CALIFORNIA CURRENT; DISTURBANCE; ANOMALIES; COMMUNITY; DYNAMICS; AMERICA; COAST	The role of climatic variation in regulating marine populations and communities is not well understood. To improve our knowledge, the sign, amplitude, and frequency of climatic and biotic variations should be compared as a necessary first step. it is shown that there have been large interannual and interdecadal sea-surface temperature changes off the West Coast of North America during the past 80 years. Interannual anomalies appear and disappear rather suddenly and synchronously along the entire coastline. The frequency of warm events has increased since 1977. Although extensive, serial, biological observations are often incomplete, it is clear that climate-ocean variations have disturbed and changed our coastal ecosystems.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Univ Calif San Diego, US Geol Survey, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; United States Department of the Interior; United States Geological Survey; University of California System; University of California San Diego	McGowan, JA (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.							AEBISCHER NJ, 1990, NATURE, V347, P753, DOI 10.1038/347753a0; ARTHUR RS, 1954, DEEP-SEA RES, V2, P107; BARLOW J, 1998, PINNIPEDS EL NINO RE, P1; BARRY JP, 1995, SCIENCE, V267, P672, DOI 10.1126/science.267.5198.672; BEAMISH RJ, 1995, FISH OCEANOGR, V4, P243, DOI 10.1111/j.1365-2419.1995.tb00148.x; Botsford LW, 1997, SCIENCE, V277, P509, DOI 10.1126/science.277.5325.509; Brodeur R.D., 1992, Fisheries Oceanography, V1, P32, DOI 10.1111/j.1365-2419.1992.tb00023.x; Brodeur RD, 1996, CAL COOP OCEAN FISH, V37, P80; Cayan D. R., 1995, NATURAL CLIMATE VARI, P133; CHELTON DB, 1982, J PHYS OCEANOGR, V12, P757, DOI 10.1175/1520-0485(1982)012<0757:MMSLVA>2.0.CO;2; CHELTON DB, 1982, J MAR RES, V40, P1095; DAYTON PK, 1992, ECOL MONOGR, V62, P421, DOI 10.2307/2937118; DUARTE CM, 1992, NATURE, V356, P190, DOI 10.1038/356190a0; EBBESMEYER CC, 1990, P 7 ANN PAC CLIM PAC, P115; ENFIELD DB, 1980, J PHYS OCEANOGR, V10, P557, DOI 10.1175/1520-0485(1980)010<0557:OTSADO>2.0.CO;2; FRANCIS RC, IN PRESS FISH OCEANO; Francis Robert C., 1994, Fisheries Oceanography, V3, P279, DOI 10.1111/j.1365-2419.1994.tb00105.x; FROST BW, 1983, YEAR YEAR INTERANNUA, P146; Glynn P.W, 1990, GLOBAL ECOLOGICAL CO, P433; Hayward TL, 1997, TRENDS ECOL EVOL, V12, P150, DOI 10.1016/S0169-5347(97)01002-1; Hayward TL, 1996, CAL COOP OCEAN FISH, V37, P22; Hollowed Anne Babcock, 1995, Canadian Special Publication of Fisheries and Aquatic Sciences, V121, P373; Hubbs C.L., 1929, CALIF FISH GAME, V1, P234; Isaacs J. D., 1969, CALCOFI Atlas, VNo. 10, P1; ISAACS JD, 1974, CALIFORNIA COOPERATI, V21, P1; LEBRASSEUR R, 1965, MANUSCRIPT REPORT SE, V201, P1; LIST EJ, 1976, J GEOPHYS RES-OC ATM, V81, P1971, DOI 10.1029/JC081i012p01971; McGowan JA, 1996, CAL COOP OCEAN FISH, V37, P45; MCGOWAN JA, 1995, NATURAL CLIMATE VARI, P55; Miller AJ, 1996, CAL COOP OCEAN FISH, V37, P69; MILLER AJ, 1994, CLIM DYNAM, V9, P287, DOI 10.1007/BF00204744; MUCK P, 1989, ICLARM C P, V18; MYSAK LA, 1995, CAN SPEC PUBL FISH A, V121, P464; NAMIAS J, 1974, J GEOPHYS RES, V79, P797, DOI 10.1029/JC079i006p00797; PAINE RT, 1981, ECOL MONOGR, V51, P145, DOI 10.2307/2937261; PARKER DE, 1995, 63 HADL CTR MET OFF; Polovina JJ, 1995, DEEP-SEA RES PT I, V42, P1701, DOI 10.1016/0967-0637(95)00075-H; Radovich J., 1981, RESOURCE MANAGEMENT, P107; RADOVICH JOHN, 1960, CALIFORNIA COOP OCEANIC FISH INVEST REPTS, V7, P163; REID JOSEPH L., 1960, CALIFORNIA COOP OCEANIC FISH INVEST REPTS, V7, P77; RODEN GUNNAR I., 1961, CALIFORNIA COOP OCEANIC FISH INVEST REPTS, V8, P95; ROEMMICH D, 1995, SCIENCE, V267, P1324, DOI 10.1126/science.267.5202.1324; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P2161, DOI 10.1175/1520-0493(1987)115<2161:AEOTTS>2.0.CO;2; SETTE OE, 1960, CAL COOP OCEAN FISH, V7, P14; STAMATOPOULOS C, 1993, FAO FISH CIRC, V855, P3; TEGNER MJ, 1991, MAR ECOL PROG SER, V77, P49, DOI 10.3354/meps077049; Tegner MJ, 1997, MAR ECOL PROG SER, V146, P117, DOI 10.3354/meps146117; Tegner MJ, 1996, CAL COOP OCEAN FISH, V37, P111; Thomson D. J, 1991, ADV SPECTRUM ANAL AR, VI, P58; *U CA, 1916, SURF WAT TEMP SAL DE; Veit RR, 1996, MAR ECOL PROG SER, V139, P11, DOI 10.3354/meps139011; Veit RR, 1997, GLOB CHANGE BIOL, V3, P23, DOI 10.1046/j.1365-2486.1997.d01-130.x; VENRICK EL, 1987, SCIENCE, V238, P70, DOI 10.1126/science.238.4823.70; WILLIAMSON M. H., 1961, BULL MAR ECOL, V5, P207; WOOSTER WS, 1985, EL NINO N EFFECTS E; WOOSTER WS, 1983, YEAR YEAR, P1	56	505	522	2	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					210	217		10.1126/science.281.5374.210	http://dx.doi.org/10.1126/science.281.5374.210			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9660743				2022-12-28	WOS:000074714200037
J	Baumbach, A; Erley, CM				Baumbach, A; Erley, CM			Floating right atrial thrombus and massive pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Tubingen, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Baumbach, A (corresponding author), Univ Tubingen, D-72076 Tubingen, Germany.			Baumbach, Andreas/0000-0001-7707-2254					0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1998	339	2					86	86		10.1056/NEJM199807093390205	http://dx.doi.org/10.1056/NEJM199807093390205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY828	9654539				2022-12-28	WOS:000074665300005
J	Bloom, SL; McIntire, DD; Kelly, MA; Beimer, HL; Burpo, RH; Garcia, MA; Leveno, KJ				Bloom, SL; McIntire, DD; Kelly, MA; Beimer, HL; Burpo, RH; Garcia, MA; Leveno, KJ			Lack of effect of walking on labor and delivery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UPRIGHT POSTURE; AMBULATION	Background and Methods Walking during labor may reduce patients' discomfort and improve outcomes, We conducted a randomized trial of walking during active labor to determine whether it altered the duration of labor or other maternal or fetal outcomes. Women with uncomplicated pregnancies between 36 and 41 weeks' gestation and in active labor were randomly assigned either to walking or to no walking (usual care). Pedometers were used to quantify walking, and the time spent walking was recorded. Results Of the 536 women assigned to the walking group, 380 actually walked. Their mean (+/-SD) walking time was 56+/-46 minutes. There were no significant differences between the women assigned to the walking group and the 531 women assigned to the usual-care group in the duration of the first stage of labor (6.1 hours in both groups, P=0.83), the need for labor augmentation with oxytocin (23 percent vs. 26 percent, P=0.25), and the use of analgesia (84 percent vs, 86 percent, P=0.59). Similarly, the percentages of women requiring delivery by forceps (4 percent vs. 3 percent, P=0,35) and cesarean section (4 percent vs. 6 percent, P=0.25) were not significantly different. These labor and delivery outcomes were unrelated to walking in both nulliparous and parous women. The infants' outcomes were also similar in the two study groups. Conclusions Walking neither enhanced nor impaired active labor and was not harmful to the mothers or their infants. (N Engl J Med 1998;339:76-9.) (C)1998, Massachusetts Medical Society.	Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bloom, SL (corresponding author), Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							FLYNN AM, 1978, BRIT MED J, V2, P591, DOI 10.1136/bmj.2.6137.591; HAUTH JC, 1991, OBSTET GYNECOL, V78, P344; HEMMINKI E, 1983, EUR J OBSTET GYN R B, V15, P129, DOI 10.1016/0028-2243(83)90128-4; LUPE PJ, 1986, OBSTET GYNECOL, V67, P727, DOI 10.1097/00006250-198605000-00023; MCMANUS TJ, 1978, LANCET, V1, P72; READ JA, 1981, AM J OBSTET GYNECOL, V139, P669, DOI 10.1016/0002-9378(81)90482-8; ROBERTS J, 1991, EFFECTIVE CARE PREGN, V2, P883; SATIN AJ, 1992, OBSTET GYNECOL, V80, P111; WILLIAMS JW, 1903, OBSTET TXB USE STUDE, P282	9	85	88	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1998	339	2					76	79		10.1056/NEJM199807093390203	http://dx.doi.org/10.1056/NEJM199807093390203			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY828	9654537				2022-12-28	WOS:000074665300003
J	Hirsch, MS; Conway, B; D'Aquila, RT; Johnson, VA; Brun-Vezinet, F; Clotet, B; Demeter, LM; Hammer, SM; Jacobsen, DM; Kuritzkes, DR; Loveday, C; Mellors, JW; Vella, S; Richman, DD				Hirsch, MS; Conway, B; D'Aquila, RT; Johnson, VA; Brun-Vezinet, F; Clotet, B; Demeter, LM; Hammer, SM; Jacobsen, DM; Kuritzkes, DR; Loveday, C; Mellors, JW; Vella, S; Richman, DD		Int AIDS Society USA Panel	Antiretroviral drug resistance testing in adults with HIV infection - Implications for clinical management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 REVERSE-TRANSCRIPTASE; ZIDOVUDINE RESISTANCE; COMBINATION THERAPY; IN-VIVO; PROTEASE INHIBITORS; CONFERS RESISTANCE; CELL-CULTURE; MUTATIONS; SENSITIVITY	Objectives.-To review current knowledge of the biology and clinical implications of human immunodeficiency virus (HIV) resistance to antiretroviral drugs, describe assays for measuring resistance, and assess their use in clinical practice. Participants.-The international AIDS Society-USA assembled a panel of 13 physicians with expertise in basic science, clinical research, and patient care relevant to HIV resistance to antiretroviral drugs. Evidence.-We reviewed available data from published reports and presented at national and international research conferences. Basic science research, clinical trial results, and expert opinions were used to form the basis of this report, Data on methods for and characteristics of specific genotypic and phenotypic assays were obtained from manufacturers and service providers. Consensus Process.-The panel met regularly between October 1997 and April 1998, Panel subgroups developed and discussed different sections of the report before discussing them with the entire panel. Conclusions and suggested approaches to the use of resistance testing were determined by group consensus. Conclusions.-Plasma HIV RNA level and CD4(+) cell count are the primary values that should be used to guide the initiation of antiretroviral therapy and subsequent changes in therapy. Possible causes of treatment failure other than development of drug resistance that should be considered are adherence, drug potency, and pharmacokinetic issues, Genotypic and phenotypic testing for HIV resistance to antiretroviral drugs may prove useful for individual patient management. Assays under development need validation, standardization, and a clearer definition of their clinical roles, Possible current roles of resistance testing for choosing an initial regimen or changing antiretroviral therapy, as well as possible implications of the presence or absence of phenotypic resistance and genotypic changes, are discussed.	Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Infectious Dis Unit, Boston, MA 02114 USA; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; Vet Affairs Med Ctr, Birmingham, AL USA; Hop Bichat Claude Bernard, F-75877 Paris 18, France; Hosp Badalona Germans Trias & Pujol, Fdn Irsa Caixa, Barcelona, Spain; Hosp Badalona Germans Trias & Pujol, HIV Unit, Barcelona, Spain; Univ Rochester, Rochester, NY 14627 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Royal Free Hosp, Sch Med, London, England; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; Ist Super Sanita, I-00161 Rome, Italy; Univ Calif San Diego, San Diego, CA 92103 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA; Int AIDS Soc USA, San Francisco, CA 94129 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; St. Paul's Hospital; University of Saskatchewan; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Hospital Germans Trias i Pujol; Hospital Germans Trias i Pujol; University of Rochester; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Istituto Superiore di Sanita (ISS); University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Hirsch, MS (corresponding author), Int AIDS Soc USA, 1001-B Oreilly Ave,Box 29916, San Francisco, CA 94129 USA.	hirsch.martin@mgh.harvard.edu	Johnson, Victoria/GVU-7127-2022; VELLA, STEFANO/ABI-3368-2020; VELLA, STEFANO/V-8440-2019; Vella, Stefano/GZM-0519-2022	VELLA, STEFANO/0000-0003-2347-5984; 				[Anonymous], 1998, MMWR Recomm Rep, V47, P1; BLOOR S, 1997, ANTIVIRAL THER S5, V2; BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P1525, DOI 10.1128/AAC.37.7.1525; Brown AJL, 1997, NAT MED, V3, P268, DOI 10.1038/nm0397-268; Caliendo AM, 1996, J VIROL, V70, P2146, DOI 10.1128/JVI.70.4.2146-2153.1996; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; CARPENTER CJ, IN PRESS JAMA; CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDA JH, 1997, ANTIVIRAL THER S5, V2; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONWAY B, 1997, ANTIVIRAL THER S5, V2; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; DAQUILA RT, 1997, ANTIVIRAL THER S5, V2; DEJONG MD, 1996, ANTIVIR THER, V1, P34; DEMETER L, 1998, 5 C RETR OPP INF FEB; DRAKE JW, 1993, P NATL ACAD SCI USA, V90, P4171, DOI 10.1073/pnas.90.9.4171; DUEWEKE TJ, 1993, P NATL ACAD SCI USA, V90, P4713, DOI 10.1073/pnas.90.10.4713; EIGEN M, 1993, SCI AM, V269, P42, DOI 10.1038/scientificamerican0793-42; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gunthard HF, 1998, J VIROL, V72, P2422; GUNTHARD HF, IN PRESS AIDS RES HU; HARRIS M, 1997, 37 INT C ANT AG CHEM; HARRIS M, IN PRESS J INFECT DI; HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; HAVLIR DV, 1998, 5 C RETR OPP INF FEB; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; JAPOUR AJ, 1995, J INFECT DIS, V171, P1172, DOI 10.1093/infdis/171.5.1172; JOHNSON VA, 1995, J INFECT DIS, V171, pS140, DOI 10.1093/infdis/171.Supplement_2.S140; JOHNSON VA, 1991, J INFECT DIS, V164, P646, DOI 10.1093/infdis/164.4.646; JOHNSON VA, 1997, ANTIVIRAL THER S5, V2; KELLAM P, 1994, ANTIMICROB AGENTS CH, V38, P23, DOI 10.1128/AAC.38.1.23; Kemp SD, 1998, J VIROL, V72, P5093, DOI 10.1128/JVI.72.6.5093-5098.1998; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; KLEIM JP, 1994, VIROLOGY, V200, P696, DOI 10.1006/viro.1994.1233; KOZAL MJ, 1994, ANN INTERN MED, V121, P263, DOI 10.7326/0003-4819-121-4-199408150-00005; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; LACEY SF, 1994, ANTIMICROB AGENTS CH, V38, P1428, DOI 10.1128/AAC.38.6.1428; LANIER ER, 1998, 5 C RETR OPP INF FEB; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1993, NATURE, V365, P451, DOI 10.1038/365451a0; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LIN PF, 1994, J INFECT DIS, V170, P1157, DOI 10.1093/infdis/170.5.1157; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MAYERS DL, 1992, J ACQ IMMUN DEF SYND, V5, P749; MAYERS DL, 1997, ANTIVIRAL THER S5, V2; MELLORS JW, 1998, 5 C RETR OPP INF FEB; Merry C, 1997, AIDS, V11, pF29, DOI 10.1097/00002030-199704000-00001; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MONTANER JSG, 1993, AIDS, V7, P189, DOI 10.1097/00002030-199302000-00006; NAJERA I, 1994, AIDS RES HUM RETROV, V10, P1479, DOI 10.1089/aid.1994.10.1479; NAJERA I, 1995, J VIROL, V69, P23; Nijhuis M, 1997, J INFECT DIS, V176, P398, DOI 10.1086/514056; OGINO MT, 1993, J PEDIATR-US, V123, P1, DOI 10.1016/S0022-3476(05)81529-X; Overbaugh J, 1996, AIDS RES HUM RETROV, V12, P107, DOI 10.1089/aid.1996.12.107; PARKIN N, 1997, 37 INT C ANT AG CHEM; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PERELSON AS, 1997, AIDS SA, V11, P517; PIZZO PA, 1994, CLIN INFECT DIS, V19, P177, DOI 10.1093/clinids/19.1.177; Rey D, 1998, J ACQ IMMUN DEF SYND, V17, P203, DOI 10.1097/00042560-199803010-00003; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; RICHMAN DD, 1993, CURRENT PROTOCOLS IM; RUBIO A, 1998, 5 C RETR OPP INF FEB; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; Schinazi R. F., 1997, International Antiviral News, V5, P129; Schock HB, 1996, J BIOL CHEM, V271, P31957, DOI 10.1074/jbc.271.50.31957; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; SOMMADOSSI JP, 1998, 5 C RETR OPP INF FEB; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; Stuyver L, 1997, ANTIMICROB AGENTS CH, V41, P284, DOI 10.1128/AAC.41.2.284; Tachedjian G, 1996, J VIROL, V70, P7171, DOI 10.1128/JVI.70.10.7171-7181.1996; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; UENO T, 1995, J BIOL CHEM, V270, P23605, DOI 10.1074/jbc.270.40.23605; *US DEP HHS, 1998, MMWR-MORBID MORTAL W, V47, P43; VANLEEUWEN R, 1995, J INFECT DIS, V171, P1166, DOI 10.1093/infdis/171.5.1166; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, J VIROL, V71, P2059, DOI 10.1128/JVI.71.3.2059-2071.1997; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yerly S, 1996, SCHWEIZ MED WSCHR, V126, P1845; YOUNG B, 1997, ANTIVIRAL THER S5, V2; ZHANG LQ, 1991, AIDS, V5, P675, DOI 10.1097/00002030-199106000-00006	90	493	519	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1984	1991		10.1001/jama.279.24.1984	http://dx.doi.org/10.1001/jama.279.24.1984			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU945	9643863				2022-12-28	WOS:000074252100036
J	Lamarche, B; Tchernof, A; Mauriege, P; Cantin, B; Dagenais, GR; Lupien, PJ; Despres, JP				Lamarche, B; Tchernof, A; Mauriege, P; Cantin, B; Dagenais, GR; Lupien, PJ; Despres, JP			Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; PLASMA TRIGLYCERIDE CONCENTRATION; MYOCARDIAL-INFARCTION; LDL CHOLESTEROL; HDL-CHOLESTEROL; A-I; MEN; ASSOCIATION; HYPERINSULINEMIA; SUBFRACTION	Context.-Epidemiological studies have established a relationship between cholesterol and low-density lipoprotein cholesterol (LDL-C) concentrations and the risk of ischemic heart disease (IHD), but up to half of patients with IHD may have cholesterol levels in the normal range. Objective.-To assess the ability to predict the risk of IHD using a cluster of nontraditional metabolic risk factors that includes elevated fasting insulin and apolipoprotein B levels as well as small, dense LDL particles. Design.-Nested case-control study. Setting.-Cases and controls were identified from the population-based cohort of the Quebec Cardiovascular Study, a prospective study conducted in men free of IHD in 1985 and followed up for 5 years. Participants.-Incident IHD cases were matched with controls selected from among the sample of men who remained IHD free during follow-up. Matching variables were age, smoking habits, body mass index, and alcohol consumption. The sample included 85 complete pairs of nondiabetic IHD cases and controls, Main Outcome Measures.-Ability of fasting insulin level, apolipoprotein B level, and LDL particle diameter to predict IHD events, defined as angina, coronary insufficiency, nonfatal myocardial infarction, anti coronary death. Results.-The risk of IHD was significantly increased in men who had elevated fasting plasma insulin and apolipoprotein B levels and small, dense LDL particles, compared with men who had normal levels for 2 of these 3 risk factors (odds ratio [OR], 5.9; 95% confidence interval [CI], 2.3-15.4). Multivariate adjustment for LDL-C, triglycerides, and high-density lipoprotein cholesterol (HDL-C) did not attenuate the relationship between the cluster of nontraditional risk factors and IHD (OR, 5.2; 95% CI, 1.7-15.7). On the other hand, the risk of IHD in men having a combination of elevated LDL-C and triglyceride levels and reduced HDL-C levels was no longer significant (OR, 1.4, 95% CI, 0.5-3.5) after multivariate adjustment for fasting plasma insulin level, apolipoprotein B level, and LDL particle size. Conclusion.-Results from this prospective study suggest that the measurement of fasting plasma insulin level, apolipoprotein B level, and LDL particle size may provide further information on the risk of IHD compared with the information provided by conventional lipid variables.	Laval Univ Hosp, Res Ctr, Lipid Res Ctr, St Foy, PQ, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Laval University; Universite de Montreal	Despres, JP (corresponding author), CHUL, Res Ctr, Lipid Res Ctr, 2705 Laurier Blvd,TR-93, St Foy, PQ G1V 4G2, Canada.		应, 宁宁/G-9472-2011; Lamarche, Benoit/ABA-4785-2021	Lamarche, Benoit/0000-0002-4443-5378; Tchernof, Andre/0000-0002-2587-1000				ALBERS JJ, 1978, CLIN CHEM, V24, P323; ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; ASSMANN G, 1994, ATHEROSCLEROSIS, V110, pS11, DOI 10.1016/0021-9150(94)05386-W; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P187, DOI 10.1161/01.ATV.12.2.187; CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; CORESH J, 1993, J LIPID RES, V34, P1687; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P274; Davignon J, 1996, ATHEROSCLEROSIS, V124, pS57, DOI 10.1016/0021-9150(96)05858-3; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; Despres Jean-Pierre, 1993, Nutrition Research Reviews, V6, P137, DOI 10.1079/NRR19930010; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FRIEDEWALD WT, 1972, SCAND J CLIN LAB INV, V124, P23; Gardner CD, 1996, JAMA-J AM MED ASSOC, V276, P875, DOI 10.1001/jama.276.11.875; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GINSBURG GS, 1991, AM J CARDIOL, V68, P187, DOI 10.1016/0002-9149(91)90742-4; Guerin M, 1996, ARTERIOSCL THROM VAS, V16, P763, DOI 10.1161/01.ATV.16.6.763; HAFFNER SM, 1993, DIABETES, V42, P1297, DOI 10.2337/diabetes.42.9.1297; HODIS HN, 1994, CIRCULATION, V90, P42, DOI 10.1161/01.CIR.90.1.42; JUHANVAGUE I, 1991, DIABETOLOGIA, V34, P457, DOI 10.1007/BF00403280; KRAUSS RM, 1982, J LIPID RES, V23, P97; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; Lamarche B, 1996, CIRCULATION, V94, P273, DOI 10.1161/01.CIR.94.3.273; LAMARCHE B, 1995, AM J CARDIOL, V75, P1189, DOI 10.1016/S0002-9149(99)80760-7; Lamarche B, 1996, ATHEROSCLEROSIS, V119, P235, DOI 10.1016/0021-9150(95)05653-X; Lamarche B, 1997, ARTERIOSCL THROM VAS, V17, P1098, DOI 10.1161/01.ATV.17.6.1098; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; MCNAMARA JR, 1992, ARTERIOSCLER THROMB, V12, P1284, DOI 10.1161/01.ATV.12.11.1284; MCNAMARA JR, 1987, ARTERIOSCLEROSIS, V7, P483, DOI 10.1161/01.ATV.7.5.483; MOORJANI S, 1987, METABOLISM, V36, P244, DOI 10.1016/0026-0495(87)90183-1; NIGON F, 1991, J LIPID RES, V32, P1741; Perry IJ, 1996, AM J EPIDEMIOL, V144, P224, DOI 10.1093/oxfordjournals.aje.a008917; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; REAVEN GM, 1988, DIABETES, V37, P1495; Sniderman AD, 1996, CLIN CHEM, V42, P489; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; Superko HR, 1996, CIRCULATION, V94, P2351, DOI 10.1161/01.CIR.94.10.2351; Tchernof A, 1996, DIABETES CARE, V19, P629, DOI 10.2337/diacare.19.6.629; WILLIAMS PT, 1990, CIRCULATION, V81, P1293, DOI 10.1161/01.CIR.81.4.1293; YARNELL JWG, 1994, BRIT HEART J, V71, P293; YUAN JN, 1994, ATHEROSCLEROSIS, V110, P1, DOI 10.1016/0021-9150(94)90062-0	44	303	325	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1955	1961		10.1001/jama.279.24.1955	http://dx.doi.org/10.1001/jama.279.24.1955			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU945	9643858	Bronze			2022-12-28	WOS:000074252100031
J	Coni, N				Coni, N			Providing letters to patients - Summary letters may be especially appropriate after emergency admissions	BRITISH MEDICAL JOURNAL			English	Letter									Addenbrookes Hosp, Dept Med Elderly, Cambridge CB2 2QQ, England	Addenbrooke's Hospital; University of Cambridge	Coni, N (corresponding author), Addenbrookes Hosp, Dept Med Elderly, Hills Rd, Cambridge CB2 2QQ, England.							Essex C, 1998, BRIT MED J, V316, P706, DOI 10.1136/bmj.316.7132.706	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1831	1831						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9652951				2022-12-28	WOS:000074286300062
J	Evans, I				Evans, I			Conduct unbecoming - the MRC's approach	BRITISH MEDICAL JOURNAL			English	Article									MRC, London W1N 4AL, England		Evans, I (corresponding author), MRC, London W1N 4AL, England.							*MRC, 1997, MRC ETH SER	1	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1728	1729						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9652921				2022-12-28	WOS:000074129500030
J	Galloway, DA				Galloway, DA			Is vaccination against human papillomavirus a possibility?	LANCET			English	Article							VIRUS-LIKE PARTICLES; CERVICAL CARCINOMAS; L1 PROTEIN; TUMOR; IMMUNIZATION; EXPRESSION; INFECTION; TYPE-16; INVIVO; CANCER		Fred Hutchinson Canc Res Ctr, Program Canc Biol, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Galloway, DA (corresponding author), Fred Hutchinson Canc Res Ctr, Program Canc Biol, 1100 Fairview Ave N C1-105,POB 19024, Seattle, WA 98109 USA.	dgallowa@fhcrc.org						BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; Borysiewicz LK, 1996, LANCET, V347, P1523, DOI 10.1016/S0140-6736(96)90674-1; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BREITBURD F, 1995, J VIROL, V69, P3959, DOI 10.1128/JVI.69.6.3959-3963.1995; CAMPO MS, 1993, J GEN VIROL, V74, P945, DOI 10.1099/0022-1317-74-6-945; CHEN L, 1992, J IMMUNOL, V148, P2617; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; CHRISTENSEN ND, 1990, J VIROL, V64, P3151, DOI 10.1128/JVI.64.7.3151-3156.1990; CHRISTENSEN ND, 1992, J GEN VIROL, V73, P1261, DOI 10.1099/0022-1317-73-5-1261; CONNOR ME, 1990, INT J CANCER, V46, P1029, DOI 10.1002/ijc.2910460614; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; Dupuy C, 1997, MICROB PATHOGENESIS, V22, P219, DOI 10.1006/mpat.1996.0113; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; Greenstone HL, 1998, P NATL ACAD SCI USA, V95, P1800, DOI 10.1073/pnas.95.4.1800; HAGENSEE ME, 1993, J VIROL, V67, P315, DOI 10.1128/JVI.67.1.315-322.1993; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Jensen ER, 1997, J VIROL, V71, P8467, DOI 10.1128/JVI.71.11.8467-8474.1997; KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; KREIDER JW, 1985, NATURE, V317, P639, DOI 10.1038/317639a0; McNeil C, 1997, J NATL CANCER I, V89, P280, DOI 10.1093/jnci/89.4.280; NardelliHaefliger D, 1997, INFECT IMMUN, V65, P3328, DOI 10.1128/IAI.65.8.3328-3336.1997; OSSEVOORT MA, 1995, J IMMUNOTHER, V18, P86, DOI 10.1097/00002371-199508000-00002; Peng SW, 1998, VIROLOGY, V240, P147, DOI 10.1006/viro.1997.8912; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; SELVAKUMAR R, 1995, J VIROL, V69, P602, DOI 10.1128/JVI.69.1.602-605.1995; SUZICH JA, 1995, P NATL ACAD SCI USA, V92, P11553, DOI 10.1073/pnas.92.25.11553; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; vanDriel WJ, 1996, ANN MED, V28, P471, DOI 10.3109/07853899608999110	29	32	34	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN	1998	351			3			22	24						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV844	9652717				2022-12-28	WOS:000074347300008
J	Hawkey, PM				Hawkey, PM			Action against antibiotic resistance: no time to lose	LANCET			English	Editorial Material									Univ Leeds, Antimicrobial Res Ctr, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Dept Microbiol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Hawkey, PM (corresponding author), Univ Leeds, Antimicrobial Res Ctr, Leeds LS2 9JT, W Yorkshire, England.							Bjorkman J, 1998, P NATL ACAD SCI USA, V95, P3949, DOI 10.1073/pnas.95.7.3949; Chiew YF, 1998, J ANTIMICROB CHEMOTH, V41, P247, DOI 10.1093/jac/41.2.247; HALL A, 1976, NATURE, V264, P803, DOI 10.1038/264803a0; *HOUS LORDS SEL CO, 1998, 7 HOUS LORDS SEL CO, P1; *JOINT COMM US ANT, 1969, REP JOINT COMM US AN; LACEY RW, 1984, LANCET, V2, P1022; M'Zali FH, 1997, J ANTIMICROB CHEMOTH, V40, P823, DOI 10.1093/jac/40.6.823; Munro S, 1998, AM J CLIN PATHOL, V109, P144; Piddock LJV, 1997, J ANTIMICROB CHEMOTH, V39, P177, DOI 10.1093/jac/39.2.177; Piddock LJV, 1996, J ANTIMICROB CHEMOTH, V38, P1, DOI 10.1093/jac/38.1.1; Woodford N, 1998, ANTIMICROB AGENTS CH, V42, P502, DOI 10.1128/AAC.42.3.502	11	41	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1298	1299		10.1016/S0140-6736(98)22018-6	http://dx.doi.org/10.1016/S0140-6736(98)22018-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643787				2022-12-28	WOS:000073439400002
J	Holgate, ST				Holgate, ST			Biomarkers of asthma	LANCET			English	Editorial Material									Univ Southampton, Dept Resp Med, Southampton SO16 6YD, Hants, England	University of Southampton	Holgate, ST (corresponding author), Univ Southampton, Dept Resp Med, Southampton SO16 6YD, Hants, England.							Crowther SD, 1997, CLIN EXP ALLERGY, V27, P606; Dahlen SE, 1998, CLIN EXP ALLERGY, V28, P129; Holz O, 1998, THORAX, V53, P83, DOI 10.1136/thx.53.2.83; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; JOSEPHS LK, 1990, EUR RESPIR J, V3, P220; Kips JC, 1998, CLIN EXP ALLERGY, V28, P1; Nijkamp FP, 1997, CLIN EXP ALLERGY, V27, P347; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Polosa R, 1997, THORAX, V52, P919, DOI 10.1136/thx.52.10.919; Ricciardolo FLM, 1997, LANCET, V350, P1297, DOI 10.1016/S0140-6736(05)62474-9; Spanevello A, 1997, CLIN EXP ALLERGY, V27, P1138	11	11	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1300	1301		10.1016/S0140-6736(05)79051-6	http://dx.doi.org/10.1016/S0140-6736(05)79051-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643789				2022-12-28	WOS:000073439400004
J	Sone, S; Takashima, S; Li, F; Yang, ZG; Honda, T; Maruyama, Y; Hasegawa, M; Yamanda, T; Kubo, K; Hanamura, K; Asakura, K				Sone, S; Takashima, S; Li, F; Yang, ZG; Honda, T; Maruyama, Y; Hasegawa, M; Yamanda, T; Kubo, K; Hanamura, K; Asakura, K			Mass screening for lung cancer with mobile spiral computed tomography scanner	LANCET			English	Article							DETECTION PROGRAM; NEW-YORK; PREVALENCE; SURVIVAL	Background The incidence of and mortality from lung cancer have increased steadily. Most lung cancers are not localised when first detected, but early detection is mandatory to improve prognosis. Since curable early cases are hard to visualise with conventional chest radiography, a new diagnostic means must be found. We assessed whether population-based mass screening with a spiral computed tomography scanner could contribute substantially to detection of smaller cancers, and decrease mortality. Methods In 1996, we screened in a mobile unit 5483 individuals from the general population of Matsumoto, Japan, aged between 40 years and 74 years who had undergone annual chest radiography (miniature fluorophotography) and cytological assessment of sputum. All participants had a low-dose X-ray spiral computed tomography (CT) scan of the thorax; 3967 also underwent miniature fluorophotography. We compared smokers and non-smokers. Further assessments were done for probably benign but suspicious lesions; suspicion of cancer; and indeterminate small nodules by chest radiography and conventional CT, with additional transbronchial biopsy when possible. Thoracotomy was recommended when it was strongly suspected that the patients had lung cancer. Findings 19 patients were diagnosed as having lung cancer--14 with suspicion of lung cancer, three with benign but suspicious lesions, and two with indeterminate small nodules. 18 cases were surgically confirmed, and one was clinically diagnosed. The mean size of lesions was 17 mm (range 6-47). In four of 19 patients, lung abnormality was seen on CT and miniature fluorophotography, The lung-cancer detection rate with CT was 0 4846, significantly higher than the 0 03-0 05% for standard mass assessments done previously in the same area. CT missed one case that was found solely on a sputum cytology examination. Interpretation Our results show that miniature fluorophotography or conventional chest radiography, which have been the main diagnostic techniques for lung cancer, showed few small cancers. CT was more accurate in mass screening for lung cancer and led to early detection and an accurate diagnosis of lung cancer, and should be considered in future health plans.	Shinshu Univ, Sch Med, Dept Radiol, Matsumoto, Nagano 390862, Japan; Shinshu Univ, Sch Med, Dept Lab Med, Matsumoto, Nagano 390862, Japan; Shinshu Univ, Sch Med, Dept Surg, Matsumoto, Nagano 390862, Japan; Shinshu Univ, Sch Med, Dept Internal Med, Matsumoto, Nagano 390862, Japan; Japan Matsumoto Res Ctr, Telecommun Advancement Org, Matsumoto, Nagano, Japan	Shinshu University; Shinshu University; Shinshu University; Shinshu University; National Institute of Information & Communications Technology (NICT) - Japan	Sone, S (corresponding author), Shinshu Univ, Sch Med, Dept Radiol, 3-1-1 Asahi, Matsumoto, Nagano 390862, Japan.							BERLIN NI, 1984, AM REV RESPIR DIS, V130, P545; EBELING K, 1987, INT J CANCER, V40, P141, DOI 10.1002/ijc.2910400202; FLEHINGER BJ, 1992, CHEST, V101, P1013, DOI 10.1378/chest.101.4.1013; FONTANA RS, 1991, CANCER-AM CANCER SOC, V67, P1155, DOI 10.1002/1097-0142(19910215)67:4+<1155::AID-CNCR2820671509>3.0.CO;2-0; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; Hillerdal G, 1996, LUNG CANCER-J IASLC, V15, P21, DOI 10.1016/0169-5002(96)00567-3; Kaneko M, 1996, RADIOLOGY, V201, P798, DOI 10.1148/radiology.201.3.8939234; KUBIK A, 1990, INT J CANCER, V45, P26, DOI 10.1002/ijc.2910450107; MELAMED M, 1977, CANCER, V39, P369, DOI 10.1002/1097-0142(197702)39:2<369::AID-CNCR2820390202>3.0.CO;2-I; MELAMED MR, 1984, CHEST, V86, P44, DOI 10.1378/chest.86.1.44; SOBUE T, 1992, INT J CANCER, V50, P230, DOI 10.1002/ijc.2910500212	12	689	727	0	65	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1242	1245		10.1016/S0140-6736(97)08229-9	http://dx.doi.org/10.1016/S0140-6736(97)08229-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643744				2022-12-28	WOS:000073283600010
J	Tomaszunas, S				Tomaszunas, S			Health care for seafarers	LANCET			English	Editorial Material									Inst Maritaime & Trop Med, PL-81519 Gdynia, Poland; WHO, Collaborating Ctr, PL-81519 Gdynia, Poland	World Health Organization	Tomaszunas, S (corresponding author), Inst Maritaime & Trop Med, PL-81519 Gdynia, Poland.							[Anonymous], [No title captured]; *INT LAB OFF, 1990, MAR LAB CONV RECO; TOMASZUNAS S, 1994, TRAVEL MED INT, V12, P220	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1148	1148		10.1016/S0140-6736(05)79117-0	http://dx.doi.org/10.1016/S0140-6736(05)79117-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643683				2022-12-28	WOS:000073220200005
J	Pisarska, MD; Carson, SA; Buster, JE				Pisarska, MD; Carson, SA; Buster, JE			Ectopic pregnancy	LANCET			English	Article							EMBRYO-TRANSFER TECHNIQUE; IN-VITRO FERTILIZATION; RISK-FACTORS; TUBAL PREGNANCY; INVITRO FERTILIZATION; CHORIONIC-GONADOTROPIN; SPONTANEOUS RESOLUTION; HETEROTOPIC PREGNANCY; EXPECTANT MANAGEMENT; SERUM PROGESTERONE		Baylor Coll Med, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Houston, TX 77030 USA	Baylor College of Medicine	Pisarska, MD (corresponding author), Baylor Coll Med, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Smith Tower,Suite 801,6550 Fannin, Houston, TX 77030 USA.							Alexander JM, 1996, OBSTET GYNECOL, V88, P123, DOI 10.1016/0029-7844(96)00086-5; *AM FERT SOC SOC A, 1996, FERTIL STERIL, V66, P697; Ankum WM, 1996, FERTIL STERIL, V65, P1093, DOI 10.1016/S0015-0282(16)58320-4; Ankum WM, 1996, J REPROD MED, V41, P724; Ankum WM, 1996, HUM REPROD, V11, P238, DOI 10.1093/HUMREP/11.2.238; ANKUM WM, 1993, HUM REPROD, V8, P1301, DOI 10.1093/oxfordjournals.humrep.a138246; [Anonymous], 1994, FERTIL STERIL, V62, P1121; [Anonymous], 1995, JAMA, V273, P533; BALASCH J, 1994, HUM REPROD, V9, P547, DOI 10.1093/oxfordjournals.humrep.a138543; BARNHART K, 1994, OBSTET GYNECOL, V84, P1010; BATEMAN BG, 1990, OBSTET GYNECOL, V75, P421; BRAFFMAN BH, 1994, RADIOLOGY, V190, P797, DOI 10.1148/radiology.190.3.7509494; BRENNER PF, 1977, OBSTET GYNECOL, V49, P323; BRUMSTEAD JB, 1996, CONT OBSTET GYNE MAR, P43; BRUNHAM RC, 1986, OBSTET GYNECOL, V67, P722, DOI 10.1097/00006250-198605000-00022; BRZEZINSKI A, 1994, EUR J OBSTET GYN R B, V54, P43, DOI 10.1016/0028-2243(94)90080-9; BUSTER JE, 1995, CURR OPIN OBSTET GYN, V7, P168, DOI 10.1097/00001703-199506000-00003; CACCIATORE B, 1990, BRIT J OBSTET GYNAEC, V97, P904, DOI 10.1111/j.1471-0528.1990.tb02445.x; CACCIATORE B, 1994, LANCET, V343, P517, DOI 10.1016/S0140-6736(94)91464-8; CARSON SA, 1993, NEW ENGL J MED, V329, P1174; CARSON SA, 1991, FERTIL STERIL, V55, P629; CHARD T, 1992, HUM REPROD, V7, P701, DOI 10.1093/oxfordjournals.humrep.a137722; Chew S, 1996, J Obstet Gynaecol Res, V22, P455; CHEZ RA, 1963, SURG GYNECOL OBSTET, V117, P589; CHOW WH, 1987, EPIDEMIOL REV, V9, P70, DOI 10.1093/oxfordjournals.epirev.a036309; CHU E, 1990, J BIOL CHEM, V265, P8470; Clausen I, 1996, ACTA OBSTET GYN SCAN, V75, P8, DOI 10.3109/00016349609033276; Coste J, 1996, CONTRACEPT FERTIL S, V24, P135; Dimitry ES, 1996, BRIT J CLIN PRACT, V50, P376; DUBUISSON JB, 1991, FERTIL STERIL, V56, P686; FEICHTINGER W, 1989, ARCH GYNECOL OBSTET, V246, P85, DOI 10.1007/BF00934124; FERNANDEZ H, 1991, OBSTET GYNECOL, V78, P656; FRATES MC, 1995, AM J ROENTGENOL, V165, P251, DOI 10.2214/ajr.165.2.7618535; Goldner T E, 1993, MMWR CDC Surveill Summ, V42, P73; GOLDSTEIN DP, 1986, 34 ANN M AM COLL OBS; Graczykowski JW, 1997, OBSTET GYNECOL, V89, P118, DOI 10.1016/S0029-7844(96)00370-5; HAGSTROM HG, 1994, OBSTET GYNECOL, V84, P798; Hajenius PJ, 1997, LANCET, V350, P774, DOI 10.1016/S0140-6736(97)05487-1; HERMAN A, 1990, FERTIL STERIL, V54, P864; Hidlebaugh D, 1997, J AM ASSOC GYN LAP, V4, P207, DOI 10.1016/S1074-3804(97)80011-4; HOPPE DE, 1994, OBSTET GYNECOL, V83, P51; Horrigan TJ, 1997, AM J OBSTET GYNECOL, V176, P714, DOI 10.1016/S0002-9378(97)70578-7; Isaacs JD, 1996, OBSTET GYNECOL, V88, P694, DOI 10.1016/0029-7844(96)00252-9; Jehle Dietrich, 1994, Emergency Medicine Clinics of North America, V12, P55; KIM DS, 1987, OBSTET GYNECOL, V70, P547; Kooi S, 1992, Obstet Gynecol Surv, V47, P739, DOI 10.1097/00006254-199211000-00001; KRANTZ SG, 1990, FERTIL STERIL, V54, P42; LENTON EA, 1982, FERTIL STERIL, V37, P773; MARCUS SF, 1995, HUM REPROD, V10, P199, DOI 10.1093/humrep/10.1.199; MARURI F, 1993, FERTIL STERIL, V59, P487; MAYMON R, 1995, EUR J OBSTET GYN R B, V62, P61, DOI 10.1016/0301-2115(95)02165-4; MCBAIN JC, 1980, BRIT J OBSTET GYNAEC, V87, P5, DOI 10.1111/j.1471-0528.1980.tb04417.x; MCCAUSLAND A, 1982, AM J OBSTET GYNECOL, V143, P12, DOI 10.1016/0002-9378(82)90677-9; MCCAUSLAND A, 1980, AM J OBSTET GYNECOL, V136, P97, DOI 10.1016/0002-9378(80)90573-6; Mol BWJ, 1997, OBSTET GYNECOL, V89, P704, DOI 10.1016/S0029-7844(97)00101-4; Mol BWJ, 1997, BRIT J OBSTET GYNAEC, V104, P834, DOI 10.1111/j.1471-0528.1997.tb12029.x; Mol BWJ, 1995, CONTRACEPTION, V52, P337, DOI 10.1016/0010-7824(95)00221-9; MOL BWJ, 1997, ACTA OBSTET GYNECOL, V76, P1; NAZARI A, 1993, FERTIL STERIL, V60, P919; ORY HW, 1981, OBSTET GYNECOL, V57, P137; PITTAWAY DE, 1987, CLIN OBSTET GYNECOL, V30, P129, DOI 10.1097/00003081-198703000-00019; Qasim SM, 1996, FERTIL STERIL, V65, P443, DOI 10.1016/S0015-0282(16)58114-X; Rojansky N, 1996, J ASSIST REPROD GEN, V13, P594, DOI 10.1007/BF02066615; RUSSELL JB, 1987, CLIN OBSTET GYNECOL, V30, P181, DOI 10.1097/00003081-198703000-00025; SCHOENFELD A, 1992, OBSTET GYNECOL, V80, P520; Seifer DB, 1997, FERTIL STERIL, V68, P402, DOI 10.1016/S0015-0282(97)00271-9; Shalev E, 1998, FERTIL STERIL, V69, P62, DOI 10.1016/S0015-0282(97)00425-1; SHALEV E, 1995, FERTIL STERIL, V63, P15, DOI 10.1016/S0015-0282(16)57289-6; Skejeldestad FE, 1998, OBSTET GYNECOL, V91, P129; Soriano D, 1997, J AM ASSOC GYN LAP, V4, P363, DOI 10.1016/S1074-3804(05)80229-4; Storeide O, 1997, ACTA OBSTET GYN SCAN, V76, P345, DOI 10.1111/j.1600-0412.1997.tb07990.x; STOVALL TG, 1992, FERTIL STERIL, V57, P456; STOVALL TG, 1991, OBSTET GYN CLIN N AM, V18, P135; STOVALL TG, 1989, FERTIL STERIL, V51, P435; STOVALL TG, 1989, AM J OBSTET GYNECOL, V160, P1425, DOI 10.1016/0002-9378(89)90866-1; STOVALL TG, 1990, FERTIL STERIL, V54, P537; Tal J, 1996, FERTIL STERIL, V66, P1; Thorburn J, 1995, Lakartidningen, V92, P4701; TRIO D, 1995, FERTIL STERIL, V63, P469, DOI 10.1016/S0015-0282(16)57410-X; VERHULST G, 1993, HUM REPROD, V8, P1284, DOI 10.1093/oxfordjournals.humrep.a138242; VESSEY M, 1979, BRIT J OBSTET GYNAEC, V86, P548, DOI 10.1111/j.1471-0528.1979.tb10808.x; WALDEN PAM, 1976, AM J OBSTET GYNECOL, V125, P1108, DOI 10.1016/0002-9378(76)90816-4; WASHINGTON AE, 1993, OBSTET GYNECOL, V81, P287; WECKSTEIN LN, 1985, OBSTET GYNECOL, V65, P393; WHO, 1985, CLIN REPROD FERTIL, V3, P131; Yao M, 1996, HUM REPROD, V11, P2762; Yao ML, 1997, FERTIL STERIL, V67, P421, DOI 10.1016/S0015-0282(97)80064-7; YOVICH JL, 1985, FERTIL STERIL, V44, P318; Zullo F, 1996, EUR J OBSTET GYN R B, V70, P213, DOI 10.1016/S0301-2115(95)02573-1	89	144	160	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 11	1998	351	9109					1115	1120		10.1016/S0140-6736(97)11476-3	http://dx.doi.org/10.1016/S0140-6736(97)11476-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660597				2022-12-28	WOS:000073090200044
J	Wennerholm, UB; Albertsson-Wikland, K; Bergh, C; Hamberger, L; Niklasson, A; Nilsson, L; Thiringer, K; Wennergren, M; Wikland, M; Borres, MP				Wennerholm, UB; Albertsson-Wikland, K; Bergh, C; Hamberger, L; Niklasson, A; Nilsson, L; Thiringer, K; Wennergren, M; Wikland, M; Borres, MP			Postnatal growth and health in children born after cryopreservation as embryos	LANCET			English	Article							IN-VITRO FERTILIZATION; CONGENITAL-MALFORMATIONS; ASSISTED REPRODUCTION; INVITRO FERTILIZATION; CHRONIC ILLNESS; BIRTH; PREGNANCIES; PREVALENCE; WEIGHT	Background There is uncertainty about the health of children born from in-vitro fertilisation (IVF) with cryopreserved embryos. We investigated the postnatal growth and health (up to 18 months) of these children compared with those born after standard IVF with fresh embryos and those from spontaneous pregnancies. Methods 255 children from cryopreserved embryos were matched by maternal age, parity, single or twin pregnancy, and date of delivery with 255 children born after IVF with fresh embryos, and 252 children from spontaneous pregnancies. The main endpoint was growth; secondary endpoints were the prevalence of chronic illness, major malformations, cumulative incidence of common diseases, and development during the first 18 months. Growth was assessed by comparison with standard Swedish growth charts and by standard deviation scores. Findings Growth features were similar for both singletons and twins in the three groups, There were 6 (2.4%) of 255, 9 (3.5%) of 255, and 8 (3.2%) of 252 major malformations in the cryopreserved group, standard IVF, and spontaneous groups, respectively (p=0.6 between the cryopreserved and standard IVF group). The prevalence of chronic diseases did not differ between the three groups, with 18.0%, 15.3%, and 16.7% of children with a chronic illness in the cryopreserved group, standard IVF, and spontaneous groups, respectively. Interpretation The cryopreservation process does not adversely affect the growth and health of children during infancy and early childhood. Minor handicaps, behavioural disturbances, learning difficulties, and dysfunction of attention and perception cannot be ruled out at this age.	Sahlgrens Univ Hosp, Dept Obstet & Gynaecol, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Paediat, S-41345 Gothenburg, Sweden; Univ Goteborg, Carlanderska Hosp, Fertil Ctr Scandinavla, Gothenburg, Sweden	Sahlgrenska University Hospital; Sahlgrenska University Hospital; University of Gothenburg	Wennerholm, UB (corresponding author), Sahlgrens Univ Hosp, Dept Obstet & Gynaecol, S-41345 Gothenburg, Sweden.		Albertsson-Wikland, Kerstin/D-3843-2012					BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BRANDES JM, 1992, PEDIATRICS, V90, P424; BYLUND B, IN PRESS ACTA SCAND; CADMAN D, 1987, PEDIATRICS, V79, P805; Cederblad M, 1996, HUM REPROD, V11, P2052; DARIN N, IN PRESS DEV MED CHI; DEMOUZON J, 1997, J ASSIST REPROD GEN, V14, pS251; DULIOUST E, 1995, P NATL ACAD SCI USA, V92, P589, DOI 10.1073/pnas.92.2.589; FOYLE LW, 1995, ARCH DIS CHILD, V73, pF143; GISSLER M, 1995, HUM REPROD, V10, P1856, DOI 10.1093/oxfordjournals.humrep.a136191; Golombok S, 1996, HUM REPROD, V11, P2324; Hagberg B, 1996, ACTA PAEDIATR, V85, P954, DOI 10.1111/j.1651-2227.1996.tb14193.x; HAGELIN E, 1991, J ADV NURS, V16, P15, DOI 10.1111/j.1365-2648.1991.tb01492.x; KARLBERG J, 1987, ACTA PAEDIATR SCAND, V76, P478, DOI 10.1111/j.1651-2227.1987.tb10503.x; KARLBERG J, 1995, PEDIATR RES, V38, P733, DOI 10.1203/00006450-199511000-00017; KARLBERG P, 1976, ACTA PAEDIATR SC   S, V258, P1; Kohler L, 1991, CHILDRENS HLTH SWEDE; KOHLER L, 1987, CLIN DEV MED, V98, P36; LASSALLE B, 1985, FERTIL STERIL, V44, P645; MORIN NC, 1989, J PEDIATR-US, V115, P222, DOI 10.1016/S0022-3476(89)80069-1; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; NIKLASSON A, 1991, ACTA PAEDIATR SCAND, V80, P756, DOI 10.1111/j.1651-2227.1991.tb11945.x; Olivennes F, 1996, HUM REPROD, V11, P1565; RAOULDUVAL A, 1994, HUM REPROD, V9, P1097, DOI 10.1093/oxfordjournals.humrep.a138639; Saunders K, 1996, PEDIATRICS, V97, P688; SCHEFFZEK A, 1989, MONATSSCHR KINDERH, V137, P42; Sutcliffe AG, 1995, HUM REPROD, V10, P3332, DOI 10.1093/oxfordjournals.humrep.a135915; SUTCLIFFE AG, 1995, ARCH DIS CHILD, V72, P290, DOI 10.1136/adc.72.4.290; TANBO T, 1995, OBSTET GYNECOL, V86, P188, DOI 10.1016/0029-7844(95)00159-O; Wennerholm UB, 1997, HUM REPROD, V12, P1819, DOI 10.1093/humrep/12.8.1819; WESTBOM L, 1987, SCAND J SOC MED, V15, P87, DOI 10.1177/140349488701500206; WIDLUND G, 1986, SCAND J SOC MED, V14, P97, DOI 10.1177/140349488601400210; WIKLAND M, 1994, HUM REPROD, V9, P1430, DOI 10.1093/oxfordjournals.humrep.a138724	33	88	95	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1085	1090		10.1016/S0140-6736(97)08247-0	http://dx.doi.org/10.1016/S0140-6736(97)08247-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660577				2022-12-28	WOS:000073090200009
J	Verne, JECW; Aubrey, R; Love, SB; Talbot, IC; Northover, JMA				Verne, JECW; Aubrey, R; Love, SB; Talbot, IC; Northover, JMA			Population based randomised study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing	BRITISH MEDICAL JOURNAL			English	Article							COLORECTAL-CANCER; ADENOMAS; PREVENTION; NEOPLASIA; RECTUM; POLYPS; RISK	Objectives: To compare the feasibility of mass screening by flexible sigmoidoscopy with screening by faecal occult blood testing (Haemoccult) and both tests combined. Design: Patients were randomised to screening by flexible sigmoidoscopy, faecal blood testing, or both tests. The flexible sigmoidoscopy examinations were performed by a general practitioner. Setting: General practice. Subjects: 3744 patients aged 50-75 years. Main outcome measures: Uptake, positive results, detection of neoplasia, complications, and recall for diagnostic colonoscopy. Results: Uptake was significantly higher in the flexible sigmoidoscopy group (46.6%) than in the faecal blood test group (31.6%; P < 0.001) or than in the group having both tests (30.1%; P < 0.001). Telephone reminders increased uptake of sigmoidoscopy to 61.8%. In total, 1116 sigmoidoscopy examinations were performed without major complication. Polyps were found in 19.3% (95% confidence interval 17.0% to 21.6%) but only 6.8% (5.3% to 8.3%) had adenomas and 2.4% (1.5% to 3.3%) "high risk" adenomas. Cancer was detected in four subjects. The faecal blood test yielded positive results In 0.8% (0.2% to 1.4%) but missed at least one cancer and 30 cases of adenoma which were found by sigmoidoscopy in the combined group. Use of histological criteria-shown elsewhere to correlate with future risk of colorectal cancer-to select "positive" patients could reduce recall for diagnostic colonoscopy from about 20% to less than 5%. Conclusions: Some of the predicted obstacles to screening with flexible sigmoidoscopy are surmountable. Clear evidence relating to efficacy will be obtained only from a randomised controlled trial.	St Marks Hosp, ICRF, Colorectal Canc Unit, Northwick Pk HA1 3UJ, Middx, England; Bridge Cottage Surg, Welwyn AL6 9EF, Herts, England; Inst Hlth Sci, Ctr Stat Med, ICRF, Med Stat Grp, Oxford OX3 7LF, England; St Marks Hosp, Dept Histopathol, London, England	University of Oxford; Imperial College London	Verne, JECW (corresponding author), N Thames Reg Off, London W2 3QR, England.							ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; BLALOCK SJ, 1987, PREV MED, V16, P9, DOI 10.1016/0091-7435(87)90002-8; BOX V, 1984, PUBLIC HEALTH, V98, P16, DOI 10.1016/S0033-3506(84)80055-4; *END SECT COMM BRI, 1987, GUT, V28, P772; FOLEY DP, GUT, V28, P10; FRAME PM, 1988, J FAM PRACTICE, V26, P614; GILBERTSEN VA, 1978, CANCER, V41, P1137, DOI 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G; HOFF G, 1987, SCAND J GASTROENTERO, V22, P769, DOI 10.3109/00365528708991912; HOFF G, 1985, SCAND J GASTROENTERO, V20, P351, DOI 10.3109/00365528509091663; Machin D., 1987, STAT TABLES DESIGN C; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MARTEAU TM, 1989, BRIT MED J, V299, P527, DOI 10.1136/bmj.299.6698.527; MORSON BC, 1985, BRIT J SURG, V72, pS23, DOI 10.1002/bjs.1800721315; MOSS SM, 1991, INT J EPIDEMIOL, V20, P1, DOI 10.1093/ije/20.1.1; MULLER AD, 1995, ARCH INTERN MED, V155, P1711; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; NEWCOMB PA, 1989, AM J EPIDEMIOL, V30, P827; *OFF POP CENS SURV, 1981, KEY STAT URB AR SE C; *OFF POP CENS SURV, 1991, MORT STAT CAUS 1989; Robinson WF, 1993, PATHOLOGY DOMESTIC A, V3, P1; ROZEN P, 1987, CANCER-AM CANCER SOC, V60, P2553, DOI 10.1002/1097-0142(19871115)60:10<2553::AID-CNCR2820601034>3.0.CO;2-S; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; TRIPP MR, 1987, CANCER, V60, P1599, DOI 10.1002/1097-0142(19871001)60:7<1599::AID-CNCR2820600730>3.0.CO;2-I; UJSZASZY L, 1985, ENDOSCOPY, V17, P109, DOI 10.1055/s-2007-1018473; *UKCCCR, 1989, REP UK COORD COMM CA; WELDON MJ, 1992, GUT, V33, pS52; WILSON JMG, 1968, 24 WHO PUBL HLTH PAP; ZARCHY TM, 1994, GASTROENTEROLOGY, V106, P1501, DOI 10.1016/0016-5085(94)90403-0; [No title captured]	29	66	68	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					182	185		10.1136/bmj.317.7152.182	http://dx.doi.org/10.1136/bmj.317.7152.182			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665902	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000075047800027
J	Beecham, L				Beecham, L			National home health guide launched	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					151	151						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657813				2022-12-28	WOS:000075081700061
J	Warren, WS; Ahn, S; Mescher, M; Garwood, M; Ugurbil, K; Richter, W; Rizi, RR; Hopkins, J; Leigh, JS				Warren, WS; Ahn, S; Mescher, M; Garwood, M; Ugurbil, K; Richter, W; Rizi, RR; Hopkins, J; Leigh, JS			MR imaging contrast enhancement based on intermolecular zero quantum coherences	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; MULTIPLE SPIN ECHOES; SOLUTION NMR; DIPOLAR-FIELD; LIQUIDS	A new method for magnetic resonance imaging (MRI) based on the detection of relatively strong signal from intermolecular zero-quantum coherences (iZQCs) is reported. Such a signal would not be observable in the conventional framework of magnetic resonance; it originates in Long-range dipolar couplings (10 micrometers to 1 millimeter) that are traditionally ignored. Unlike conventional MRI, where image contrast is based on variations in spin density and relaxation times (often with injected contrast agents), contrast with iZQC images comes from variations in the susceptibility over a distance dictated by gradient strength. phantom and in vivo (rat brain) data confirm that iZQC images give contrast enhancement. This contrast might be useful in the detection of small tumors, in that susceptibility correlates with oxygen concentration and in functional MRI.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Univ Minnesota, Ctr Magnet Resonance Res, Minneapolis, MN 55455 USA; Natl Res Council Canada, Inst Biodiagnost, Winnipeg, MB R3B 1Y6, Canada; Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA	Princeton University; University of Minnesota System; University of Minnesota Twin Cities; National Research Council Canada; University of Pennsylvania	Warren, WS (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.	wwarren@princeton.edu	Ahn, Sangdoo/A-4615-2009; Ugurbil, Kamil/AAD-6058-2022	Garwood, Michael/0000-0003-1578-9166	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035253] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08079, RR02305] Funding Source: Medline; NIGMS NIH HHS [GM35253] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDFORD AS, 1991, J MAGN RESON, V93, P516, DOI 10.1016/0022-2364(91)90080-D; BHUJWALLA ZM, 1994, NMR PHYSL BIOMEDICIN, P311; BLOEMBERGEN N, 1948, PHYS REV, V73, P679, DOI 10.1103/PhysRev.73.679; BOWTELL R, 1990, J MAGN RESON, V88, P643, DOI 10.1016/0022-2364(90)90297-M; Broekaert P, 1996, J MAGN RESON SER A, V120, P97, DOI 10.1006/jmra.1996.0103; Cremillieux Y, 1998, MAGN RESON MED, V39, P285, DOI 10.1002/mrm.1910390216; DEVILLE G, 1979, PHYS REV B, V19, P5666, DOI 10.1103/PhysRevB.19.5666; DURNEY CH, 1989, J MAGN RESON, V85, P554, DOI 10.1016/0022-2364(89)90245-X; EINZEL D, 1984, PHYS REV LETT, V53, P2312, DOI 10.1103/PhysRevLett.53.2312; FRAHM J, 1986, MAGNET RESON MED, V3, P321, DOI 10.1002/mrm.1910030217; HE QH, 1993, J CHEM PHYS, V98, P6779, DOI 10.1063/1.464770; JEENER J, 1995, J CHEM PHYS, V103, P1309, DOI 10.1063/1.469808; KORBER H, 1991, J MAGN RESON, V93, P589, DOI 10.1016/0022-2364(91)90085-8; Lee S, 1996, J CHEM PHYS, V105, P874, DOI 10.1063/1.471968; Levitt MH, 1996, CONCEPT MAGNETIC RES, V8, P77, DOI 10.1002/(SICI)1099-0534(1996)8:2<77::AID-CMR1>3.0.CO;2-L; McKinstry RC, 1998, SCIENCE, V279, P1965, DOI 10.1126/science.279.5358.1965; Mori S, 1997, MAGNET RESON MED, V37, P336, DOI 10.1002/mrm.1910370305; RICHTER W, 1995, SCIENCE, V267, P654, DOI 10.1126/science.7839140; Robyr P, 1996, J MAGN RESON SER A, V121, P206, DOI 10.1006/jmra.1996.0162; SCHUPP DG, 1993, MAGNET RESON MED, V30, P18, DOI 10.1002/mrm.1910300105; Springer CS, 1994, NMR PHYSL BIOMEDICIN, P75; Vathyam S, 1996, SCIENCE, V272, P92, DOI 10.1126/science.272.5258.92; Warren WS, 1995, CHEM PHYS LETT, V247, P207, DOI 10.1016/0009-2614(95)01184-5; WARREN WS, 1993, SCIENCE, V262, P2005, DOI 10.1126/science.8266096; ZHOU X, 1991, P SOC MAGN RESON MED, P345	25	167	178	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					247	251		10.1126/science.281.5374.247	http://dx.doi.org/10.1126/science.281.5374.247			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657717				2022-12-28	WOS:000074714200046
J	Purdie, A				Purdie, A			A memorable patient - It pays to be a native	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					27	27		10.1136/bmj.317.7150.27	http://dx.doi.org/10.1136/bmj.317.7150.27			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651265				2022-12-28	WOS:000075081600020
J	Chistoserdova, L; Vorholt, JA; Thauer, RK; Lidstrom, ME				Chistoserdova, L; Vorholt, JA; Thauer, RK; Lidstrom, ME			C-1 transfer enzymes and coenzymes linking methylotrophic bacteria and methanogenic Archaea	SCIENCE			English	Article							METHYLOBACTERIUM-EXTORQUENS AM1; TETRAHYDROMETHANOPTERIN FORMYLTRANSFERASE; FORMYLMETHANOFURAN; METHANOBACTERIUM; CYCLOHYDROLASE; DEHYDROGENASE; MECHANISM; SEQUENCE; GENE	Methanogenic and sulfate-reducing Archaea are considered to have an energy metabolism involving C-1 transfer coenzymes and enzymes unique for this group of strictly anaerobic microorganisms. An aerobic methylotrophic bacterium, Methylobacterium extorquens AM1, was found to contain a cluster of genes that are predicted to encode some of these enzymes and was shown to contain two of the enzyme activities and one of the methanogenic coenzymes. Insertion mutants were all unable to grow on C-1 compounds, suggesting that the archaeal enzymes function in aerobic C-1 metabolism. Thus, methylotrophy and methanogenesis involve common genes that cross the bacterial/archaeal boundaries.	Univ Washington, Dept Microbiol, Dept Chem Engn, Seattle, WA 98195 USA; Max Planck Inst Terr Microbiol, Dept Biochem, D-35043 Marburg, Germany	University of Washington; University of Washington Seattle; Max Planck Society	Lidstrom, ME (corresponding author), Univ Washington, Dept Microbiol, Dept Chem Engn, Seattle, WA 98195 USA.		Chistoserdova, Ludmila/K-2364-2017; Vorholt, Julia/K-3514-2016	Chistoserdova, Ludmila/0000-0002-5777-0263; Vorholt, Julia/0000-0002-6011-4910	NIGMS NIH HHS [GM36296] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036296] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREITUNG J, 1992, EUR J BIOCHEM, V210, P971, DOI 10.1111/j.1432-1033.1992.tb17502.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHISTOSERDOV AY, 1994, J BACTERIOL, V176, P4052, DOI 10.1128/JB.176.13.4052-4065.1994; Chistoserdova L, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P16; CHISTOSERDOVA L, UNPUB; CHISTOSERDOVA LV, 1994, J BACTERIOL, V176, P1957, DOI 10.1128/jb.176.7.1957-1968.1994; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; DONNELLY MI, 1985, ARCH BIOCHEM BIOPHYS, V242, P430, DOI 10.1016/0003-9861(85)90227-9; GORRIS LGM, 1994, BIOFACTORS, V4, P139; KLENK HP, 1997, ATURE, V390, P364; Lidstrom ME, 1991, PROKARYOTES, P431; MARISON IW, 1982, J GEN MICROBIOL, V128, P1441; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; POMPER B, UNPUB; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWORER B, 1993, ARCH MICROBIOL, V159, P225, DOI 10.1007/BF00248476; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Thauer RK, 1996, CHEM REV, V96, P3031, DOI 10.1021/cr9500601; Vaupel M, 1996, EUR J BIOCHEM, V236, P294, DOI 10.1111/j.1432-1033.1996.00294.x; VORHOLT J, 1995, ARCH MICROBIOL, V163, P112, DOI 10.1007/s002030050179; Vorholt JA, 1997, MOL MICROBIOL, V23, P1033, DOI 10.1046/j.1365-2958.1997.2931653.x; Vorholt JA, 1997, ARCH MICROBIOL, V167, P19, DOI 10.1007/s002030050411; White RH, 1998, BBA-GEN SUBJECTS, V1380, P257, DOI 10.1016/S0304-4165(97)00148-7; WOLFE RS, 1991, ANNU REV MICROBIOL, V45, P1, DOI 10.1146/annurev.mi.45.100191.000245	24	218	231	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					99	102		10.1126/science.281.5373.99	http://dx.doi.org/10.1126/science.281.5373.99			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651254				2022-12-28	WOS:000074685800046
J	Janssen, RS; Satten, GA; Stramer, SL; Rawal, BD; O'Brien, TR; Weiblen, BJ; Hecht, FM; Jack, N; Cleghorn, FR; Kahn, JO; Chesney, MA; Busch, MP				Janssen, RS; Satten, GA; Stramer, SL; Rawal, BD; O'Brien, TR; Weiblen, BJ; Hecht, FM; Jack, N; Cleghorn, FR; Kahn, JO; Chesney, MA; Busch, MP			New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FRANCISCO MENS HEALTH; HOMOSEXUAL BISEXUAL MEN; EARLY DIAGNOSTIC-TESTS; AIDS EPIDEMIC; TYPE-1 SEROCONVERSION; ANTIBODY-RESPONSE; INCIDENCE RATES; UNITED-STATES; PLASMA	Context.-Differentiating individuals with early human immunodeficiency virus 1 (HIV-1) infection from those infected for longer periods is difficult but important for estimating HIV incidence and for purposes of clinical care and prevention. Objective.-To develop and validate a serologic testing algorithm in which HIV-1-positive persons with reactive test results on a sensitive HIV-1 enzyme immunoassay (EIA) but nonreactive results on a less sensitive (LS) EIA are identified as having early infection. Design.-Diagnostic test and testing strategy development, validation, and application. Specimens were tested with both a sensitive HIV-1 EIA (3A11 assay) and a less sensitive modification of the same EIA (3A11-LS assay). Settings and Participants.-For assay development: 104 persons seroconverting to HIV-1 comprising 38 plasma donors, 18 patients of a sexually transmitted disease clinic in Trinidad, and 48 participants in the San Francisco Men's Health Study (SFMHS); 268 men without the acquired immunodeficiency syndrome (AIDS) in the SFMHS who had been infected for at least 2.5 years; and 207 persons with clinical AIDS; for testing strategy validation: 488 men in the SFMHS from 1985 through 1990 and 1 275 449 repeat blood donors at 3 American Red Cross blood centers from 1993 through 1995; and for HIV-1 incidence estimates: 2 717 910 first-time blood donors. We retrospectively identified persons eligible for a study of early infection. Main Outcome Measure.-Ability to identify early HIV infection. Results.-Estimated mean time to being 3A11 reactive/3A11-LS nonreactive was 129 days (95% confidence interval [CI], 109-149 days). Our testing strategy accurately diagnosed 95% of persons with early infection; however, 0.4% (1/268) of men with established infection and 2% (5/207) of persons with late-stage AIDS were misdiagnosed as having early HIV-1 infection. Average yearly incidence estimates in SFMHS subjects were 1.5% per year vs observed average incidence of 1.4 per 100 person-years. Incidence in repeat blood donors using the sensitive/less sensitive assay testing strategy was 2.95 per 100 000 per year (95% CI, 1.14-6.53/ 100 000) vs observed incidence of 2.60 per 100 000 person-years (95% CI, 1.49-4.21/100 000). Overall incidence in first-time blood donors was 7.18 per 100 000 per year (95% CI, 4.51-11.20/100 000) and did not change statistically significantly between 1993 and 1996. Use of the sensitive/less sensitive testing strategy alone would have identified all 17 persons with antibodies to HIV-1 eligible for a study of early HIV-1 infection and would have increased enrollment. Conclusions.-The sensitive/less sensitive testing strategy provides accurate diagnosis of early HIV-1 infection, provides accurate estimates of HIV-1 incidence, can facilitate clinical studies of early HIV-1 infection, and provides information on HIV-1 infection duration for care planning.	Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Off Commun, Atlanta, GA 30333 USA; Amer Red Cross, Natl Reference Lab Infect Dis, Rockville, MD USA; Blood Ctr Pacific, Irwin Ctr, San Francisco, CA USA; NCI, Viral Epidemiol Branch, Rockville, MD USA; Boston Biomed Inc, W Bridgewater, MA USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, AIDS Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Aids Prevent Studies, San Francisco, CA 94143 USA; Med Res Ctr, Port Spain, Trinidad Tobago; Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA	Centers for Disease Control & Prevention - USA; American Red Cross; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System of Maryland; University of Maryland Baltimore	Janssen, RS (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Off Commun, Mailstop E-06,1600 Clifton Rd, Atlanta, GA 30333 USA.	RXJ1@cdc.gov		Satten, Glen/0000-0001-7275-5371; Hecht, Frederick/0000-0002-5782-1171				*ABB LAB, 1994, ENZ IMM DET ANT HUM; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BACCHETTI P, 1993, STAT SCI, V8, P82, DOI 10.1214/ss/1177010994; Beyrer C, 1996, J ACQ IMMUN DEF SYND, V12, P495, DOI 10.1097/00042560-199608150-00009; BROOKMEYER R, 1995, AM J EPIDEMIOL, V141, P166, DOI 10.1093/oxfordjournals.aje.a117404; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BROOKMEYER R, 1995, AM J EPIDEMIOL, V142, P709, DOI 10.1093/oxfordjournals.aje.a117700; BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDCP, 1994, NAT HIV SER SUMM RES, V3, P1; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Chambers J. M., 1983, GRAPHICAL METHODS DA, DOI DOI 10.1201/9781351072304; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Cleghorn Farley R., 1996, P147; CLEGHORN FR, 1995, 2 NAT C HUM RETR REL, P57; Cochran W.G., 1967, STAT METHODS; CONWAY B, 1998, 5 C RETR OPP INF CHI, P189; COOPER DA, 1987, J INFECT DIS, V155, P1113, DOI 10.1093/infdis/155.6.1113; *DCDP, 1997, HIV AIDS SURV REP, V9, P5; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Efron B., 1994, MONOGRAPHS STAT APPL; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; KAHN JO, IN PRESS N ENGL J ME; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; LANGE JMA, 1988, AIDS, V2, P31, DOI 10.1097/00002030-198802000-00005; Lilienfeld AM, 1976, FDN EPIDEMIOLOGY; LOES SKD, 1993, CLIN INFECT DIS, V17, P59, DOI 10.1093/clinids/17.1.59; MCDOUGAL JS, 1987, J CLIN INVEST, V80, P316, DOI 10.1172/JCI113075; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; NIU MT, 1993, J INFECT DIS, V168, P1490, DOI 10.1093/infdis/168.6.1490; OBRIEN TR, 1994, J ACQ IMMUN DEF SYND, V7, P705; Pantaleo G, 1998, NAT MED, V4, P341, DOI 10.1038/nm0398-341; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Quinn TC, 1997, JAMA-J AM MED ASSOC, V278, P58, DOI 10.1001/jama.278.1.58; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; Rothenberg ML, 1996, SEMIN ONCOL, V23, P21; SAGET B, 1998, 5 C RETR OPP INF CHI, P189; Satten GA, 1997, MATH BIOSCI, V141, P101, DOI 10.1016/S0025-5564(96)00185-X; Sayre KR, 1996, TRANSFUSION, V36, P45, DOI 10.1046/j.1537-2995.1996.36196190514.x; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SILVERMAN BW, 1990, J ROY STAT SOC B MET, V52, P271; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; TORIAN LV, 1997, 4 C RETR OPP INF WAS, P97; TURNBULL BW, 1976, J R STAT SOC B, V38, P290; *UN AIDS WHO WORK, 1997, REP GLOB HIV AIDS EP, P1; Weinstock Hillard S., 1996, P336; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; Zuck TF, 1995, TRANSFUSION, V35, P944, DOI 10.1046/j.1537-2995.1995.351196110900.x; [No title captured]	56	552	572	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					42	48		10.1001/jama.280.1.42	http://dx.doi.org/10.1001/jama.280.1.42			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660362				2022-12-28	WOS:000074379400022
J	Reginster, JY; Meurmans, L; Zegels, B; Rovati, LC; Minne, HW; Giacovelli, G; Taquet, AN; Setnikar, I; Collette, J; Gosset, C				Reginster, JY; Meurmans, L; Zegels, B; Rovati, LC; Minne, HW; Giacovelli, G; Taquet, AN; Setnikar, I; Collette, J; Gosset, C			The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						osteoporosis, postmenopausal; fractures; fluorides; bone density; calcium	BONE-MINERAL DENSITY; FLUORIDE TREATMENT; SPINE	Background: Fluoride is effective in increasing trabecular bone mineral density (BMD) in the spine, but its efficacy in reducing vertebral fracture rates and its effect on BMD at cortical sites are controversial. Objective: To study the effect of low-dose fluoride (sodium monofluorophosphate [MFP]) plus a calcium supplement over 4 years on vertebral fractures and BMD at the lumbar spine and total hip in postmenopausal women with moderately low BMD of the spine. Design: Randomized, double-blind, controlled clinical trial. Setting: Outpatient clinic for osteoporosis at a university medical center. Patients: 200 postmenopausal women with osteoporosis (according to the World Health Organization definition) and a T-score less than -2.5 for BMD of the spine. Intervention: Women were randomly assigned (100 patients per group) to continuous daily treatment for 4 years with 1) oral MFP (20 mg of equivalent fluoride) plus 1000 mg of calcium las calcium carbonate) or 2) calcium only. Measurements: Lateral spine radiographs were taken at enrollment and at each year of follow-up for detection of new vertebral fractures (defined as a reduction greater than or equal to 20% and greater than or equal to 4 mm from baseline in any of the heights of a vertebral body). Nonvertebral fractures were also recorded. All analyses were done with the intention-to-treat approach. Results: Radiologic follow-up was possible for 164 of 200 patients (82%). The rate of new vertebral fractures during the 4 years of the study was lower in the MFP-plus-calcium group (2 of 84 patients; 2.4% [95% Cl, 0.3% to 8.3%]) than in the calcium-only group (8 of 80 patients; 10% [Cl, 4.4% to 18.8%]). The difference between the groups was 7.6 percentage points (Cl, 0.3 to 15 percentage points) (P = 0.05). A moderate but progressive increase in BMD of the spine (10.0% +/- 1.5% at 4 years) was found for MFP plus calcium compared with calcium only (P < 0.001), whereas the more modest increase in BMD of the total hip seen with MFP plus calcium (1.8% +/- 0.6%) did not differ from the increase seen with calcium only. Conclusions: Low-dose fluoride (20 mg/d) given continuously with calcium for prolonged periods can decrease vertebral fracture rates compared with calcium alone in patients with mild to moderate osteoporosis.	Klin Furstenhof, Ctr Endocrinol, D-31812 Bad Pyrmont, Germany; Rotta Res Lab SpA, I-20052 Monza, Italy; Univ Liege, Liege, Belgium; Georgetown Univ, Med Ctr, Washington, DC 20007 USA	University of Liege; Georgetown University	Reginster, JY (corresponding author), CHU Ctr Ville, Quai Godefroid Kurth 45,Batiment K1, B-4020 Liege, Belgium.			Rovati, Lucio/0000-0002-3425-1583				COMPSTON JE, 1995, CALCIFIED TISSUE INT, V57, P247, DOI 10.1007/BF00298877; DELMAS PD, 1990, J BONE MINER RES  S1, V5, P143; DureSmith BA, 1996, J CLIN ENDOCR METAB, V81, P269, DOI 10.1210/jc.81.1.269; ERICSSON Y, 1983, CARIES RES, V17, P46, DOI 10.1159/000260728; FARLEY JR, 1983, SCIENCE, V222, P330; HEANEY RP, 1989, ANN INTERN MED, V111, P678, DOI 10.7326/0003-4819-111-8-678; KANIS JA, 1993, AM J MED, V95, pS53, DOI 10.1016/0002-9343(93)90384-2; Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446; MAMELLE N, 1988, LANCET, V2, P361, DOI 10.1016/S0140-6736(88)92834-6; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; Meunier PJ, 1998, OSTEOPOROSIS INT, V8, P4, DOI 10.1007/s001980050041; MINNE HW, 1988, BONE MINER, V3, P335; MULLER P, 1992, Z GASTROENTEROL, V30, P252; PAK CYC, 1995, ANN INTERN MED, V123, P401, DOI 10.7326/0003-4819-123-6-199509150-00001; Parfitt A.M., 1988, OSTEOPOROSIS ETIOLOG, P45; REED BY, 1993, J BONE MINER RES, V8, P19; REGINSTER JY, 1995, CLIN RHEUMATOL, V14, P68, DOI 10.1007/BF02208087; REGINSTER JY, 1993, OSTEOPOROSE POSTMENO; RIGGS BL, 1981, J CLIN INVEST, V67, P328, DOI 10.1172/JCI110039; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1992, BONE MINER, V17, P574; STEIN JA, 1987, RADIOLOGY, V165, P313; WARNEKE G, 1993, ARZNEIMITTEL-FORSCH, V43-1, P590; WHO Study Group, 1994, ASS FRACT RISK ITS A	24	76	76	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					1	+		10.7326/0003-4819-129-1-199807010-00001	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9652994				2022-12-28	WOS:000074513300001
J	Goss, BM				Goss, BM			Primary care: core values - Contracting for general practice: another turn of the wheel of history	BRITISH MEDICAL JOURNAL			English	Article																		BEECHAM L, 1995, BRIT MED J, V311, P1170; BEVERIDGE WH, 1940, SOCIAL INSURANCE ALL; *GEN MED SERV COMM, 1995, ANN REP 1995; *GEN MED SERV COMM, 1996, COR SERV TAK IN; Hart, 1988, NEW KIND DOCTOR; MANN E, 1996, ENGLISHMAN HOME ABRO, P160; MANN E, 1988, ENGLISHMAN HOME ABRO, P217; 1890, RAYNERS BUNGAY ALMAN; 1908, KELLYS DIRECTORY SUF; 1875, KELLYS DIRECTORY SUF	10	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1953	1955		10.1136/bmj.316.7149.1953	http://dx.doi.org/10.1136/bmj.316.7149.1953			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641934	Green Published			2022-12-28	WOS:000074636700031
J	Crawford, SE; Stellmach, V; Murphy-Ullrich, JE; Ribeiro, SMF; Lawler, J; Hynes, RO; Boivin, GP; Bouck, N				Crawford, SE; Stellmach, V; Murphy-Ullrich, JE; Ribeiro, SMF; Lawler, J; Hynes, RO; Boivin, GP; Bouck, N			Thrombospondin-1 is a major activator of TGF-beta 1 in vivo	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; HAMSTER OVARY CELLS; FACTOR-BETA; TGF-BETA; ENDOTHELIAL-CELLS; FACTOR-BETA-1-DEFICIENT MICE; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; TRANSGENIC MICE; LATENT FORMS	The activity of TGF-beta 1 is regulated primarily extracellularly where the secreted latent form must be modified to expose the active molecule. Here we show that thrombospondin-1 is responsible for a significant proportion of the activation of TGF-beta 1 in vivo. Histological abnormalities in young TGF-beta 1 null and thrombospondin-1 null mice were strikingly similar in nine organ systems. Lung and pancreas pathologies similar to those observed in TGF-beta 1 null animals could be induced in wild-type pups by systemic treatment with a peptide that blocked the activation of TGF-beta 1 by thrombospondin-1. Although these organs produced little active TGF-beta 1 in thrombospondin null mice, when pups were treated with a peptide derived from thrombospondin-l that could activate TGF-beta 1, active cytokine was detected in situ, and the lung and pancreatic abnormalities reverted toward wild type.	Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Chicago, IL 60614 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Harvard Univ, Sch Med, Beth Israel Deaconness Med Ctr, Dept Pathol, Boston, MA 02215 USA; MIT, Dept Biol, Ctr Canc Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Univ Cincinnati, Dept Pathol, Cincinnati, OH 45267 USA	Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Alabama System; University of Alabama Birmingham; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University System of Ohio; University of Cincinnati	Crawford, SE (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA.		Lawler, Jack/AAJ-1379-2020		NCI NIH HHS [CA52750, CA64239] Funding Source: Medline; NHLBI NIH HHS [HL28749, R01 HL050061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028749, R01HL050061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Abe M, 1998, J CELL PHYSIOL, V174, P186, DOI 10.1002/(SICI)1097-4652(199802)174:2<186::AID-JCP6>3.0.CO;2-K; BarcellosHoff MH, 1996, MOL ENDOCRINOL, V10, P1077, DOI 10.1210/me.10.9.1077; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092; BOIVIN GP, 1995, AM J PATHOL, V146, P276; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; Caver TE, 1996, J CLIN INVEST, V98, P2496, DOI 10.1172/JCI119068; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DAWSON DW, 1998, ANGIOGENIC AGENTS; DeBleser PJ, 1996, HEPATOLOGY, V23, P1530; Diebold RJ, 1995, P NATL ACAD SCI USA, V92, P12215, DOI 10.1073/pnas.92.26.12215; Ehrhart EJ, 1997, FASEB J, V11, P991, DOI 10.1096/fasebj.11.12.9337152; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; JETTEN AM, 1986, EXP CELL RES, V167, P539, DOI 10.1016/0014-4827(86)90193-X; JIRTLE RL, 1991, J BIOL CHEM, V266, P22444; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KOJIMA S, 1993, J CELL PHYSIOL, V155, P323, DOI 10.1002/jcp.1041550213; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; Letterio JJ, 1996, J LEUKOCYTE BIOL, V59, P769, DOI 10.1002/jlb.59.6.769; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LIOUBIN MN, 1991, J CELL BIOCHEM, V45, P112, DOI 10.1002/jcb.240450118; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; McMahon GA, 1996, BIOCHEM J, V313, P343, DOI 10.1042/bj3130343; MERWIN JR, 1991, AM J PATHOL, V138, P37; MIYAZONO K, 1991, CIBA F SYMP, V157, P81; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; MOSES HL, 1981, CANCER RES, V41, P2842; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; RAYCHAUDHURY A, 1994, J CELL SCI, V107, P39; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SANVITO F, 1994, DEVELOPMENT, V120, P3451; SAPERSTEIN LA, 1994, HEPATOLOGY, V19, P412; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SCHULZ E, 1994, ACROS CHIMICA ACTA, V1, P1; Serra R, 1996, NAT MED, V2, P390, DOI 10.1038/nm0496-390; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SJOHOLM A, 1991, AM J PHYSIOL, V260, pC1046, DOI 10.1152/ajpcell.1991.260.5.C1046; SOUCHELNITSKIY S, 1995, ENDOCRINOLOGY, V136, P5118, DOI 10.1210/en.136.11.5118; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; YAMANAKA Y, 1993, DIABETES, V42, P746, DOI 10.2337/diabetes.42.5.746; Yang YB, 1997, BIOCHEMISTRY-US, V36, P11923, DOI 10.1021/bi9710479; Yaswen L, 1996, BLOOD, V87, P1439, DOI 10.1182/blood.V87.4.1439.bloodjournal8741439; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; Zhou L, 1996, DEV BIOL, V175, P227, DOI 10.1006/dbio.1996.0110	72	924	978	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1998	93	7					1159	1170		10.1016/S0092-8674(00)81460-9	http://dx.doi.org/10.1016/S0092-8674(00)81460-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657149	Bronze			2022-12-28	WOS:000074491100011
J	Mohri, M; Koyanagi, M; Egashira, K; Tagawa, H; Ichiki, T; Shimokawa, H; Takeshita, A				Mohri, M; Koyanagi, M; Egashira, K; Tagawa, H; Ichiki, T; Shimokawa, H; Takeshita, A			Angina pectoris caused by coronary microvascular spasm	LANCET			English	Article							INDUCED MYOCARDIAL-ISCHEMIA; ARTERY SPASM; SYNDROME-X; VARIANT ANGINA; NITRIC-OXIDE; ACETYLCHOLINE; ARTERIOGRAMS; VASODILATION; SITE; RESISTANCE	Background Microvascular angina can occur during exercise and at rest. Reduced vasodilator capacity of the coronary microvessels is implicated as a cause of angina during exercise, but the mechanism of angina at rest is not known. Our aim was to test the hypothesis that primary hyperconstriction (spasm) of microvessels causes myocardial ischaemia at rest. Methods Acetylcholine induces coronary artery spasm in patients with variant angina. We tested the effects of intracoronary acetylcholine at graded doses in 117 consecutive patients with chest pain (at rest, during exertion, or both) and no flow-limiting (>50%) organic stenosis in the large epicardial coronary arteries. We also assessed the metabolism of myocardial lactate during acetylcholine administration in 36 of the patients by measurement of lactate in paired blood samples from the coronary artery and coronary sinus vein. Findings Of the 117 patients, 63 (54%) had large-artery spasm, 29 (25%) had microvascular spasm, and 25 (21%) had atypical chest pain. The 29 patients with microvascular spasm developed angina-like chest pain, ischaemic electrocardiogram (ECG) changes, or both spontaneously (two patients) or after administration of acetylcholine (27 patients) without spasm of the large epicardial coronary arteries. Testing of paired samples of arterial and coronary sinus venous blood showed that lactate was produced during angina attack in nine of 11 patients with microvascular spasm. There was more women (p<0.01) and fewer coronary risk factors (p<0.01) in patients with microvascular spasm than in those with large-artery spasm. Interpretation Coronary microvascular spasm and resultant myocardial ischaemia may be the cause of chest pain in a subgroup of patients with microvascular angina.	Kyushu Univ, Fac Med, Angiocardiol Res Inst, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Cardiovasc Clin, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Mohri, M (corresponding author), Kyushu Univ, Fac Med, Angiocardiol Res Inst, Higashi Ku, 3-1-1 maidashi, Fukuoka 8128582, Japan.	mmohri@med.kyushu-u.ac.jp						BORTONE AS, 1989, CIRCULATION, V79, P516, DOI 10.1161/01.CIR.79.3.516; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; CANNON RO, 1983, J AM COLL CARDIOL, V1, P359; Egashira K, 1996, J AM COLL CARDIOL, V27, P1444, DOI 10.1016/0735-1097(96)00021-6; Egashira K, 1996, CIRCULATION, V94, P130, DOI 10.1161/01.CIR.94.2.130; EGASHIRA K, 1993, NEW ENGL J MED, V328, P1659, DOI 10.1056/NEJM199306103282302; EPSTEIN SE, 1986, J AM COLL CARDIOL, V8, P459, DOI 10.1016/S0735-1097(86)80067-5; EPSTEIN SE, 1991, CIRCULATION, V83, P73; ITO A, 1995, CIRCULATION, V92, P2636, DOI 10.1161/01.CIR.92.9.2636; KASKI JC, 1995, J AM COLL CARDIOL, V25, P807, DOI 10.1016/0735-1097(94)00507-M; Kemp H G, 1967, Trans Assoc Am Physicians, V80, P59; KEMP HG, 1991, J AM COLL CARDIOL, V17, P507, DOI 10.1016/S0735-1097(10)80123-8; KUGA T, 1995, CIRCULATION, V92, P183, DOI 10.1161/01.CIR.92.2.183; LIKOFF W, 1967, NEW ENGL J MED, V276, P1063, DOI 10.1056/NEJM196705112761904; MASERI A, 1991, J AM COLL CARDIOL, V17, P499, DOI 10.1016/S0735-1097(10)80122-6; MOSSERI M, 1986, CIRCULATION, V74, P964, DOI 10.1161/01.CIR.74.5.964; MOTZ W, 1991, AM J CARDIOL, V68, P996, DOI 10.1016/0002-9149(91)90485-4; NAGAI H, 1994, ANGIOLOGY, V45, P391, DOI 10.1177/000331979404500509; OKUMURA K, 1988, J AM COLL CARDIOL, V12, P883, DOI 10.1016/0735-1097(88)90449-4; OPHERK D, 1981, CIRCULATION, V63, P817, DOI 10.1161/01.CIR.63.4.817; QUYYUMI AA, 1992, CIRCULATION, V86, P1864, DOI 10.1161/01.CIR.86.6.1864; SEKIYA M, 1993, ANGIOLOGY, V44, P811, DOI 10.1177/000331979304401008; SEROTA H, 1991, AM HEART J, V121, P1807, DOI 10.1016/0002-8703(91)90031-C; SUGIISHI M, 1993, CIRCULATION, V87, P76, DOI 10.1161/01.CIR.87.1.76; SUZUKI H, 1994, INT J CARDIOL, V43, P139, DOI 10.1016/0167-5273(94)90003-5; VRINTS CJM, 1992, J AM COLL CARDIOL, V19, P21, DOI 10.1016/0735-1097(92)90046-P; Yamagishi H, 1997, JPN CIRC J, V61, P87, DOI 10.1253/jcj.61.87; YASUE H, 1986, CIRCULATION, V74, P955, DOI 10.1161/01.CIR.74.5.955	28	220	225	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1165	1169		10.1016/S0140-6736(97)07329-7	http://dx.doi.org/10.1016/S0140-6736(97)07329-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643687				2022-12-28	WOS:000073220200009
J	Peverill, RE; Harper, RW; Smolich, JJ				Peverill, RE; Harper, RW; Smolich, JJ			Interpretation of thrombosis prevention trial	LANCET			English	Letter									Monash Med Ctr, Ctr Heart & Chest Res, Clayton, Vic 3168, Australia; Monash Univ, Clayton, Vic 3168, Australia	Monash University; Monash University	Peverill, RE (corresponding author), Monash Med Ctr, Ctr Heart & Chest Res, Clayton, Vic 3168, Australia.			Peverill, Roger/0000-0002-3319-5356				Feinberg WM, 1997, STROKE, V28, P1101, DOI 10.1161/01.STR.28.6.1101; Fuster V, 1997, LANCET, V350, P389; Meade TW, 1998, LANCET, V351, P233; Peverill RE, 1997, LANCET, V350, P1177, DOI 10.1016/S0140-6736(05)63824-X	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 18	1998	351	9110					1206	1206		10.1016/S0140-6736(05)79154-6	http://dx.doi.org/10.1016/S0140-6736(05)79154-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643717				2022-12-28	WOS:000073220200055
J	Clements, JL; Yang, B; Ross-Barta, SE; Eliason, SL; Hrstka, RF; Williamson, RA; Koretzky, GA				Clements, JL; Yang, B; Ross-Barta, SE; Eliason, SL; Hrstka, RF; Williamson, RA; Koretzky, GA			Requirement for the leukocyte-specific adapter protein SLP-76 for normal T-cell development	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR; ALPHA-BETA; GENE; KINASE; INHIBITION; ACTIVATION; P56(LCK); MICE	The Leukocyte-specific adapter molecule SLP-76 (Src homology 2 domain-containing Leukocyte protein of 76 kilodaltons) is rapidly phosphorylated on tyrosine residues after receptor Ligation in several hematopoietically derived cell types. Mice made deficient for SLP-76 expression contained no peripheral T cells as a result of an early block in thymopoiesis. Macrophage and natural killer cell compartments were intact in SLP-76-deficient mice, despite SLP-76 expression in these lineages in wild-type mice. Thus, the SLP-76 adapter protein is required for normal-thymocyte development and plays a crucial role in translating signals mediated by pre-T cell receptors into distal biochemical events.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Obstet & Gynecol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Koretzky, GA (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA.		Koretzky, Gary/AAU-5381-2021		NIGMS NIH HHS [GM53256] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053256, R01GM053256] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON SJ, 1993, NATURE, V365, P552, DOI 10.1038/365552a0; BALDARI CT, 1995, ONCOGENE, V10, P1141; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; CHU KT, 1994, J BIOL CHEM, V269, P24095; CLEMENTS JA, UNPUB; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Hoffman ES, 1996, GENE DEV, V10, P948, DOI 10.1101/gad.10.8.948; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; VANOERS NSC, 1995, J EXP MED, V182, P1585, DOI 10.1084/jem.182.5.1585; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	25	357	363	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					416	419		10.1126/science.281.5375.416	http://dx.doi.org/10.1126/science.281.5375.416			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665885				2022-12-28	WOS:000074918800048
J	Krause, PJ; Spielman, A; Telford, SR; Sikand, VK; McKay, K; Christianson, D; Pollack, RJ; Brassard, P; Magera, J; Ryan, R; Persing, DH				Krause, PJ; Spielman, A; Telford, SR; Sikand, VK; McKay, K; Christianson, D; Pollack, RJ; Brassard, P; Magera, J; Ryan, R; Persing, DH			Persistent parasitemia after acute babesiosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; BORRELIA-BURGDORFERI DNA; LYME-DISEASE; ANTIBIOTIC-TREATMENT; RAPID DIAGNOSIS; TRANSFUSION; MICROTI; INFECTIONS; STATE; FLUID	Background Babesiosis, a zoonosis caused by the protozoan Babesia microti, is usually nor treated when the symptoms are mild, because the parasitemia appears to be transient. However, the microscopical methods used to diagnose this infection are insensitive, and few infected people have been followed longitudinally. We compared the duration of parasitemia in people who had received specific antibabesial therapy with that in silently infected people who had not received specific therapy. Methods Forty-six babesia-infected subjects were identified from 1991 through 1996 in a prospective, community-based study designed to detect episodes of illness and of seroconversion among the residents of southeastern Connecticut and Block Island, Rhode island. Subjects with acute babesial illness were monitored every 3 months for up to 27 months by means of thin blood smears, Bab. microti polymerase-chain-reaction assays, serologic tests, and questionnaires. Results Babesial DNA persisted in the blood for a mean of 82 days in 24 infected subjects without specific symptoms who received no specific therapy. Babesial DNA persisted for 16 days in 22 acutely ill subjects who received clindamycin and quinine therapy (P = 0.03), of whom 9 had side effects from the treatment. Among the subjects who did not receive specific therapy, symptoms of babesiosis persisted for a mean of 114 days in five subjects with babesial DNA present for 3 or more months and for only 15 days in seven others in whom the DNA was detectable for less than 3 months (P<0.05); one subject had recrudescent disease after two years. Conclusions When left untreated, silent babesial infection may persist For months or even years. Although treatment with clindamycin and quinine reduces the duration of parasitemia, infection may still persist and recrudesce and side effects are common. Improved treatments are needed. (N Engl J Med 1998;339:160-5.) (C)1998, Massachusetts Medical Society.	Connecticut Childrens Med Ctr, Dept Pediat, Div Pediat Infect Dis, Hartford, CT 06106 USA; Univ Connecticut, Sch Med, Hartford, CT 06106 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA USA; Brown Univ, Sch Med, Dept Med, Providence, RI USA; Mayo Clin & Mayo Fdn, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Clin Microbiol, Mol Microbiol Lab, Rochester, MN 55905 USA	Connecticut Children's Medical Center; University of Connecticut; Harvard University; Harvard T.H. Chan School of Public Health; Tufts University; Brown University; Mayo Clinic; Mayo Clinic	Krause, PJ (corresponding author), Connecticut Childrens Med Ctr, Dept Pediat, Div Pediat Infect Dis, Hartford, CT 06106 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032403, R01AI042402] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 42402, AI 41157, AI 32403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BISHOP R, 1992, PARASITOLOGY, V104, P215, DOI 10.1017/S0031182000061655; CONRAD P, 1991, J AM VET MED ASSOC, V199, P601; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; Falagas ME, 1996, CLIN INFECT DIS, V22, P809, DOI 10.1093/clinids/22.5.809; FIGUEROA JV, 1992, J CLIN MICROBIOL, V30, P2576, DOI 10.1128/JCM.30.10.2576-2582.1992; GELFAND JA, 1995, MANDELL DOUGLAS BENN, V2, P2497; GERBER MA, 1994, J INFECT DIS, V170, P231, DOI 10.1093/infdis/170.1.231; Herwaldt BL, 1997, J INFECT DIS, V175, P1259, DOI 10.1086/593812; KAIN KC, 1993, AM J TROP MED HYG, V49, P478, DOI 10.4269/ajtmh.1993.49.478; KRAUSE PJ, 1994, J INFECT DIS, V169, P923, DOI 10.1093/infdis/169.4.923; Krause PJ, 1996, JAMA-J AM MED ASSOC, V275, P1657, DOI 10.1001/jama.275.21.1657; Krause PJ, 1996, J CLIN MICROBIOL, V34, P2014, DOI 10.1128/JCM.34.8.2014-2016.1996; Krause PJ, 1996, J CLIN MICROBIOL, V34, P2791, DOI 10.1128/JCM.34.11.2791-2794.1996; KRAUSE PJ, 1991, J CLIN MICROBIOL, V29, P1; KRAUSE PJ, 1997, 46 ANN M AM SOC TROP, P247; KROGSTAD DJ, 1995, MANDELL DOUGLAS BENN, V2, P2415; MALAWISTA SE, 1994, J INFECT DIS, V170, P1312, DOI 10.1093/infdis/170.5.1312; MELDRUM SC, 1992, CLIN INFECT DIS, V15, P1019, DOI 10.1093/clind/15.6.1019; MINTZ ED, 1991, TRANSFUSION, V31, P365, DOI 10.1046/j.1537-2995.1991.31491213305.x; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; ONG KR, 1990, LANCET, V336, P112, DOI 10.1016/0140-6736(90)91624-J; PERSING DH, 1992, J CLIN MICROBIOL, V30, P2097, DOI 10.1128/JCM.30.8.2097-2103.1992; RUEBUSH TK, 1977, NEW ENGL J MED, V297, P825, DOI 10.1056/NEJM197710132971511; SMITH RP, 1986, JAMA-J AM MED ASSOC, V256, P2726, DOI 10.1001/jama.256.19.2726; SPIELMAN A, 1985, ANNU REV ENTOMOL, V30, P439, DOI 10.1146/annurev.en.30.010185.002255; STAMM WE, 1988, ANN INTERN MED, V108, P710, DOI 10.7326/0003-4819-108-5-710; Telford S. R. III, 1993, PARASIT PROTOZOA, V5, P1; TEUTSCH SM, 1980, AM J TROP MED HYG, V29, P738, DOI 10.4269/ajtmh.1980.29.738; Wittner M, 1996, AM J TROP MED HYG, V55, P219, DOI 10.4269/ajtmh.1996.55.219; WITTNER M, 1982, ANN INTERN MED, V96, P601, DOI 10.7326/0003-4819-96-5-601; 1990, MMWR MORB MORTAL WKL, V39, P19	32	208	210	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					160	165		10.1056/NEJM199807163390304	http://dx.doi.org/10.1056/NEJM199807163390304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ922	9664092	Bronze			2022-12-28	WOS:000074782900004
J	Nagel, RL				Nagel, RL			A knockout of a transgenic mouse - Animal models of sickle cell anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MICE		Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Nagel, RL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12150, DOI 10.1073/pnas.89.24.12150; Kaul DK, 1995, J CLIN INVEST, V96, P2845, DOI 10.1172/JCI118355; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; Ryan TM, 1997, SCIENCE, V278, P873, DOI 10.1126/science.278.5339.873; TRUDEL M, 1994, BLOOD, V84, P3189	5	24	36	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					194	195		10.1056/NEJM199807163390310	http://dx.doi.org/10.1056/NEJM199807163390310			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ922	9664098				2022-12-28	WOS:000074782900010
J	Beecham, L				Beecham, L			DGHs should remain backbone of secondary care	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					151	151						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657813				2022-12-28	WOS:000075081700064
J	Edwards, N; Hensher, M				Edwards, N; Hensher, M			Managing demand - Managing demand for secondary care services: the changing context	BRITISH MEDICAL JOURNAL			English	Article							STAY		Univ London London Sch Hyg & Trop Med, London Hlth Econ Consortium, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Edwards, N (corresponding author), Univ London London Sch Hyg & Trop Med, London Hlth Econ Consortium, Keppel St, London WC1E 7HT, England.		Hensher, Martin C/N-4635-2017	Hensher, Martin C/0000-0001-6444-6827				*AUD COMM, 1992, LYING WAIT US MED BE; Clarke A, 1996, QUAL HEALTH CARE, V5, P172, DOI 10.1136/qshc.5.3.172; COAST J, 1995, J EPIDEMIOL COMMUN H, V49, P194, DOI 10.1136/jech.49.2.194; *DEP HLTH, 1997, STAT B, V20; FRANKEL S, 1993, RATIONING RATIONALIT, P115; GASPOZ JM, 1994, J AM COLL CARDIOL, V24, P1249, DOI 10.1016/0735-1097(94)90106-6; MARBER M, 1991, BRIT MED J, V302, P1189, DOI 10.1136/bmj.302.6786.1189; Naylor C D, 1994, Qual Health Care, V3, P221, DOI 10.1136/qshc.3.4.221; *NHS, 1997, TACKL EM ADM POL PRA; POOLE P, 1996, PHYSIOTHERAPY, V82, P28; *SECR STAT HLTH, 1997, NEW NHS; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005; Smith P., 1994, FORMULA DISTRIBUTING; VANDOORSLAER EKA, 1989, SOC SCI MED, V28, P155, DOI 10.1016/0277-9536(89)90143-3	14	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					135	138		10.1136/bmj.317.7151.135	http://dx.doi.org/10.1136/bmj.317.7151.135			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657796	Green Published			2022-12-28	WOS:000075081700030
J	Hutchinson, G				Hutchinson, G			Words to the wise - Words that count	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					121	121		10.1136/bmj.317.7151.121	http://dx.doi.org/10.1136/bmj.317.7151.121			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657790	Green Published			2022-12-28	WOS:000075081700024
J	Mossad, SB				Mossad, SB			Fortnightly review - Treatment of the common cold	BMJ-BRITISH MEDICAL JOURNAL			English	Review							EXPERIMENTAL RHINOVIRUS COLDS; RESPIRATORY-TRACT INFECTIONS; RANDOMIZED CONTROLLED TRIAL; DOUBLE-BLIND; IPRATROPIUM BROMIDE; HUMAN VOLUNTEERS; ZINC GLUCONATE; DOSE-RESPONSE; NASAL SPRAY; VITAMIN-C		Cleveland Clin Fdn, Dept Infect Dis, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Mossad, SB (corresponding author), Cleveland Clin Fdn, Dept Infect Dis, 9500 Euclid Ave, Cleveland, OH 44195 USA.							ABerg N, 1996, CLIN EXP ALLERGY, V26, P1045, DOI 10.1111/j.1365-2222.1996.tb00642.x; AKERLUND A, 1989, J LARYNGOL OTOL, V103, P743, DOI 10.1017/S0022215100109958; ALNAKIB W, 1989, ANTIMICROB AGENTS CH, V33, P522, DOI 10.1128/AAC.33.4.522; BARROW GI, 1990, CLIN EXP ALLERGY, V20, P45, DOI 10.1111/j.1365-2222.1990.tb02774.x; BORUM P, 1981, AM REV RESPIR DIS, V123, P418; CHALMERS TC, 1975, AM J MED, V58, P532, DOI 10.1016/0002-9343(75)90127-8; Clemens CJ, 1997, J PEDIATR-US, V130, P463, DOI 10.1016/S0022-3476(97)70211-7; DIAMOND L, 1995, J ALLERGY CLIN IMMUN, V95, P1139, DOI 10.1016/S0091-6749(95)70219-9; DOLOVICH MB, 1992, CHEST, V102, P284, DOI 10.1378/chest.102.1.284; DOYLE WJ, 1993, ANN OTO RHINOL LARYN, V102, P521, DOI 10.1177/000348949310200706; Eccles R, 1995, J PHARM PHARMACOL, V47, P990, DOI 10.1111/j.2042-7158.1995.tb03283.x; English J A, 1997, Fam Med, V29, P38; FARR BM, 1987, J CHRON DIS, V40, P875, DOI 10.1016/0021-9681(87)90187-1; FARR BM, 1984, ANTIMICROB AGENTS CH, V26, P31, DOI 10.1128/AAC.26.1.31; FARR BM, 1990, J INFECT DIS, V162, P1173, DOI 10.1093/infdis/162.5.1173; FORSTALL GJ, 1994, JAMA-J AM MED ASSOC, V271, P1109, DOI 10.1001/jama.271.14.1109; GAFFEY MJ, 1988, PEDIATR INFECT DIS J, V7, P223, DOI 10.1097/00006454-198803000-00032; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; GRAHAM NMH, 1990, J INFECT DIS, V162, P1277, DOI 10.1093/infdis/162.6.1277; Gustafson LM, 1996, J ALLERGY CLIN IMMUN, V97, P1009, DOI 10.1016/S0091-6749(96)80077-7; Gwaltney JM, 1996, ANTIVIR RES, V29, P287, DOI 10.1016/0166-3542(95)00935-3; Gwaltney JM, 1996, CLIN INFECT DIS, V22, P656, DOI 10.1093/clinids/22.4.656; GWALTNEY JM, 1980, J INFECT DIS, V142, P811, DOI 10.1093/infdis/142.6.811; Hayden FG, 1996, ANN INTERN MED, V125, P89, DOI 10.7326/0003-4819-125-2-199607150-00002; HAYDEN FG, 1995, ANTIMICROB AGENTS CH, V39, P290, DOI 10.1128/AAC.39.2.290; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; HEMILA H, 1994, SCAND J INFECT DIS, V26, P1, DOI 10.3109/00365549409008582; HEMILA H, 1995, J AM COLL NUTR, V14, P116; HENDLEY JO, 1994, JAMA-J AM MED ASSOC, V271, P1112, DOI 10.1001/jama.271.14.1112; HOWARD JC, 1979, JAMA-J AM MED ASSOC, V242, P2414, DOI 10.1001/jama.242.22.2414; Kaiser L, 1996, LANCET, V347, P1507, DOI 10.1016/S0140-6736(96)90670-4; Kirkpatrick GL, 1996, PRIMARY CARE, V23, P657, DOI 10.1016/S0095-4543(05)70355-9; KUHN JJ, 1982, CHEST, V82, P713, DOI 10.1378/chest.82.6.713; Litovitz TL, 1997, AM J EMERG MED, V15, P447, DOI 10.1016/S0735-6757(97)90193-5; Lowenstein S R, 1987, Adv Intern Med, V32, P207; MAIMAN LA, 1982, PUBLIC HEALTH REP, V97, P140; Mainous AG, 1996, J FAM PRACTICE, V42, P357; MCKINLAY MA, 1992, ANNU REV MICROBIOL, V46, P635, DOI 10.1146/annurev.micro.46.1.635; Mossad SB, 1996, ANN INTERN MED, V125, P81, DOI 10.7326/0003-4819-125-2-199607150-00001; Novick SG, 1996, MED HYPOTHESES, V46, P295, DOI 10.1016/S0306-9877(96)90259-5; OPHIR D, 1987, AM J OTOLARYNG, V8, P149, DOI 10.1016/S0196-0709(87)80037-6; POTTER YJ, 1993, ANN PHARMACOTHER, V27, P589; ROBERTS CR, 1983, JAMA-J AM MED ASSOC, V250, P1986, DOI 10.1001/jama.250.15.1986; SAMO TC, 1983, J INFECT DIS, V148, P535; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; SPERBER SJ, 1992, ANN INTERN MED, V117, P37, DOI 10.7326/0003-4819-117-1-37; SPERBER SJ, 1989, B NEW YORK ACAD MED, V65, P145; STANLEY ED, 1975, JAMA-J AM MED ASSOC, V231, P1248, DOI 10.1001/jama.231.12.1248; TYRRELL D, 1989, BRIT MED J, V298, P1280, DOI 10.1136/bmj.298.6683.1280	49	33	34	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 4	1998	317	7150					33	36		10.1136/bmj.317.7150.33	http://dx.doi.org/10.1136/bmj.317.7150.33			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651268	Green Published			2022-12-28	WOS:000075081600023
J	Aldrich, PR; Hamrick, JL				Aldrich, PR; Hamrick, JL			Reproductive dominance of pasture trees in a fragmented tropical forest mosaic	SCIENCE			English	Article							RAIN-FOREST; PATTERN; LIGHT	Tropical forest fragmentation threatens biodiversity, yet basic information on population responses for major groups such as plants is lacking. Hypervariable genetic markers were used to reconstruct a population-level pedigree in fragmented tropical forest for the tree Symphonia globulifera. Though seedlings occurred only in remnant forest, the pedigree showed that most seedlings had been produced by sequentially fewer adults in pasture, creating a genetic bottleneck. The pedigree also implicated shifts in the foraging of animals that disperse pollen and seed in a secondary constriction of the bottleneck. These results suggest that tropical conservation strategies should anticipate complex, cryptic responses to fragmentation.	Univ Georgia, Dept Bot, Athens, GA 30602 USA; Univ Georgia, Dept Genet, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Aldrich, PR (corresponding author), Smithsonian Inst, Natl Museum Nat Hist, Dept Bot, MRC-166, Washington, DC 20560 USA.	aldrich.preston@nmnh.si.edu						ALDRICH PR, IN PRESS MOL ECOL; Bittrich V, 1996, PLANT SYST EVOL, V200, P101, DOI 10.1007/BF00984751; BORGELLA R, 1995, THESIS CORNELL U ITH; BULLOCK SH, 1981, ECOLOGY, V62, P1494, DOI 10.2307/1941506; Chase MR, 1996, NATURE, V383, P398, DOI 10.1038/383398a0; Croat T.B., 1978, FLORA BARRO COLORADO; DAILY GC, 1995, BIODIVERS CONSERV, V4, P35, DOI 10.1007/BF00115313; DUCREY M, 1992, ANN SCI FOREST, V49, P553, DOI 10.1051/forest:19920601; FEINSINGER P, 1988, AM NAT, V131, P33, DOI 10.1086/284772; FLEMING TH, 1987, ANNU REV ECOL SYST, V18, P91, DOI 10.1146/annurev.ecolsys.18.1.91; GAVIN T, UNPUB; Gill GE, 1998, BIOTROPICA, V30, P139, DOI 10.1111/j.1744-7429.1998.tb00378.x; HEYWOOD JS, 1986, AM NAT, V127, P851, DOI 10.1086/284529; LAURANCE WF, 1997, SCIENCE, V278, P117; Levey Douglas J., 1994, P282; LEVIN DA, 1995, AM NAT, V145, P109, DOI 10.1086/285730; MEAGHER TR, 1987, ECOLOGY, V68, P803, DOI 10.2307/1938351; Mulkey SS, 1996, TRENDS ECOL EVOL, V11, P408, DOI 10.1016/0169-5347(96)10043-4; PULLIAM HR, 1988, AM NAT, V132, P652, DOI 10.1086/284880; Stiles F.G., 1989, GUIDE BIRDS COSTA RI; WRIGHT SJ, 1994, AM NAT, V143, P192, DOI 10.1086/285600	21	230	249	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1998	281	5373					103	105		10.1126/science.281.5373.103	http://dx.doi.org/10.1126/science.281.5373.103			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651242				2022-12-28	WOS:000074685800047
J	Burman, WJ; Reves, RR; Cohn, DL				Burman, WJ; Reves, RR; Cohn, DL			The case for conservative management of early HIV disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Denver Publ Hlth, Infect Dis AIDS Clin, Denver, CO 80204 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Infect Dis, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Burman, WJ (corresponding author), Denver Publ Hlth, Infect Dis AIDS Clin, 605 Bannock St, Denver, CO 80204 USA.	bburman@dhha.org						Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; CARR A, 1998, 5 C RETR OPP INF FEB; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P889; Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONDRA JH, 1996, 11 INT C AIDS JUL 7; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; FREIMAN JP, 1993, AIDS, V7, P379, DOI 10.1097/00002030-199303000-00012; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; GEISELER PJ, 1987, AM REV RESPIR DIS, V135, P3; GOUJARD C, 1998, 5 C RETR OPP INF FEB; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Henry K, 1998, LANCET, V351, P1328, DOI 10.1016/S0140-6736(05)79053-X; Lennox J. L., 1997, Clinical Infectious Diseases, V25, P397; MIEDEMA F, 1998, 5 C RETR OPP INF FEB; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *PAN CLIN PRACT TR, 1997, GUID US ANT AG HIV I; PULLAR T, 1988, CLIN PHARMACOL THER, V44, P540, DOI 10.1038/clpt.1988.191; ROTH HP, 1978, CLIN PHARMACOL THER, V23, P361; RUBIO A, 1996, 3 INT C DRUG THER HI; Steger K. A., 1997, Clinical Infectious Diseases, V25, P444; Tural C, 1998, J INFECT DIS, V177, P1080, DOI 10.1086/517399; WANG SA, 1998, CLIN INFECT DIS, V25, P444	26	24	24	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					93	95		10.1001/jama.280.1.93	http://dx.doi.org/10.1001/jama.280.1.93			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660372				2022-12-28	WOS:000074379400032
J	Holmboe, ES; Hawkins, RE				Holmboe, ES; Hawkins, RE			Methods for evaluating the clinical competence of residents in internal medicine: A review	ANNALS OF INTERNAL MEDICINE			English	Article							IN-TRAINING EXAMINATION; ABIM CERTIFYING EXAMINATION; STANDARDIZED PATIENTS; EVALUATION EXERCISE; AMERICAN-BOARD; PHYSICIAN PERFORMANCE; FACULTY EVALUATIONS; SIMULATED PATIENTS; EVALUATION FORM; SKILLS	This paper reviews methods commonly used to assess the clinical competence of residents in internal medicine, including the In-Training Examination, medical record audits, rating scales, clinical evaluation exercises, and the use of standardized patients. Studies were identified through a MEDLINE search (1966 to present) and from the bibliographies of relevant articles and were selected for inclusion according to consensus between the authors. Whenever possible, original studies were chosen over reviews and editorials. No single assessment method can successfully evaluate the clinical competence of residents in internal medicine, and educators need to be cognizant of the most appropriate applications and the advantages and disadvantages of the available evaluation tools. A combination of assessment tools provides the best opportunity to evaluate and educate physicians-in-training.	Uniformed Serv Univ Hlth Sci, Dept Med, EDP, Bethesda, MD 20814 USA; Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA	Uniformed Services University of the Health Sciences - USA; Yale University	Holmboe, ES (corresponding author), Natl Naval Med Ctr, Div Gen Med, Bethesda, MD 20814 USA.							AINSWORTH MA, 1991, JAMA-J AM MED ASSOC, V266, P1390, DOI 10.1001/jama.266.10.1390; *AM BOARD INT MED, 1992, GUID EV RES INT MED; *AM BOARD INT MED, 1994, PROJ PROF; *AM MED ASS, 1990, DIR GRAD MED ED PROG; ANDERSON MB, 1994, TEACH LEARN MED, V6, P15, DOI DOI 10.1080/10401339409539637; ASHTON CM, 1993, ACAD MED, V68, P823, DOI 10.1097/00001888-199311000-00003; BARROWS HS, 1993, ACAD MED, V68, P443, DOI 10.1097/00001888-199306000-00002; BLANK LL, 1984, J MED EDUC, V59, P401; BORMAN WC, 1975, J APPL PSYCHOL, V60, P556, DOI 10.1037/0021-9010.60.5.556; BOUDREAU D, 1994, AM J RESP CRIT CARE, V150, P1298, DOI 10.1164/ajrccm.150.5.7952556; BRAILOVSKY CA, 1995, ACAD MED, V70, P410, DOI 10.1097/00001888-199505000-00018; BROOK RH, 1987, JAMA-J AM MED ASSOC, V258, P3138, DOI 10.1001/jama.258.21.3138; Burdick WP, 1996, ACAD EMERG MED, V3, P1119, DOI 10.1111/j.1553-2712.1996.tb03371.x; Chalabian J, 1996, AM SURGEON, V62, P840; Cohen R, 1996, ACAD MED, V71, pS22, DOI 10.1097/00001888-199601000-00032; COLLIVER JA, 1993, ACAD MED, V68, P454, DOI 10.1097/00001888-199306000-00003; DAY RP, 1993, J GEN INTERN MED, V8, P193, DOI 10.1007/BF02599266; DAY SC, 1990, J GEN INTERN MED, V5, P421, DOI 10.1007/BF02599432; DUPRAS DM, 1995, ACAD MED, V70, P1029, DOI 10.1097/00001888-199511000-00022; Eggly S, 1997, ACAD MED, V72, P397, DOI 10.1097/00001888-199705000-00023; EISENBERG JM, 1989, J GEN INTERN MED, V4, P139, DOI 10.1007/BF02602356; ENGEBRETSEN B, 1977, NEW ENGL J MED, V296, P1230, DOI 10.1056/NEJM197705262962112; FLETCHER SW, 1985, JAMA-J AM MED ASSOC, V253, P2224, DOI 10.1001/jama.253.15.2224; GARIBALDI RA, 1994, ANN INTERN MED, V121, P117, DOI 10.7326/0003-4819-121-2-199407150-00008; GENNIS VM, 1994, J GEN INTERN MED, V9, P116; Gray JD, 1996, ACAD MED, V71, pS55, DOI 10.1097/00001888-199601000-00043; GROSSMAN RS, 1992, J GEN INTERN MED, V7, P63, DOI 10.1007/BF02599105; HABER RJ, 1994, J GEN INTERN MED, V9, P140, DOI 10.1007/BF02600028; HERBERS JE, 1989, J GEN INTERN MED, V4, P202, DOI 10.1007/BF02599524; Holmboe E, 1996, ACAD MED, V71, P1139, DOI 10.1097/00001888-199611000-00008; HULL AL, 1995, ACAD MED, V70, P517, DOI 10.1097/00001888-199506000-00013; Joorabchi B, 1996, PEDIATRICS, V97, P179; KERN DE, 1990, J GEN INTERN MED, V5, P218, DOI 10.1007/BF02600538; KLESSIG J, 1989, J GEN INTERN MED, V4, P514, DOI 10.1007/BF02599551; KOKOTAILO PK, 1995, PEDIATRICS, V96, P99; KROBOTH FJ, 1985, ARCH INTERN MED, V145, P1121, DOI 10.1001/archinte.145.6.1121; KROBOTH FJ, 1992, J GEN INTERN MED, V7, P174, DOI 10.1007/BF02598008; LEAF DA, 1995, J GEN INTERN MED, V10, P194, DOI 10.1007/BF02600254; Mangione S, 1997, JAMA-J AM MED ASSOC, V278, P717, DOI 10.1001/jama.278.9.717; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; Martin JA, 1996, ACAD MED, V71, P170, DOI 10.1097/00001888-199602000-00025; MATTHEWS DA, 1989, J GEN INTERN MED, V4, P14, DOI 10.1007/BF02596484; MILLER GE, 1990, ACAD MED, V65, pS63, DOI 10.1097/00001888-199009000-00045; Neufeld VR, 1985, ASSESSING CLIN COMPE; NOEL GL, 1992, ANN INTERN MED, V117, P757, DOI 10.7326/0003-4819-117-9-757; NORCINI JJ, 1987, J GEN INTERN MED, V2, P330, DOI 10.1007/BF02596169; NORCINI JJ, 1995, ANN INTERN MED, V123, P795, DOI 10.7326/0003-4819-123-10-199511150-00008; NORMAN GR, 1982, J MED EDUC, V57, P708; NORMAN GR, 1985, J MED EDUC, V60, P925; ODELL JR, 1995, ANN INTERN MED, V122, P73, DOI 10.7326/0003-4819-122-1-199501010-00033; OGNIBENE AJ, 1994, ACAD MED, V69, P583, DOI 10.1097/00001888-199407000-00016; Opila DA, 1997, J GEN INTERN MED, V12, P352, DOI 10.1007/s11606-006-5083-8; PETRUSA ER, 1990, ARCH INTERN MED, V150, P573, DOI 10.1001/archinte.150.3.573; Pololi LH, 1996, J GEN INTERN MED, V11, P545, DOI 10.1007/BF02599603; RAMSDELL JW, 1983, MED CARE, V21, P1144, DOI 10.1097/00005650-198312000-00002; Reznick RK, 1996, ACAD MED, V71, pS19, DOI 10.1097/00001888-199601000-00031; Rosebraugh CJ, 1996, ACAD MED, V71, pS102, DOI 10.1097/00001888-199601000-00057; Rothman AI, 1996, ACAD MED, V71, pS110, DOI 10.1097/00001888-199601000-00060; SCHWARTZ RW, 1995, AM J SURG, V169, P414, DOI 10.1016/S0002-9610(99)80187-1; SCRANTON R, 1998, IN PRESS ACAD MED; SHATZER JH, 1994, TEACH LEARN MED, V6, P54; SINGER PA, 1993, J GEN INTERN MED, V8, P23, DOI 10.1007/BF02600289; Sloan PA, 1996, PAIN, V67, P475, DOI 10.1016/0304-3959(96)03152-1; SOLOMON DJ, 1994, ACAD MED, V69, P754, DOI 10.1097/00001888-199409000-00022; STILLMAN P, 1991, ANN INTERN MED, V114, P393, DOI 10.7326/0003-4819-114-5-393; STILLMAN PL, 1986, ANN INTERN MED, V105, P762, DOI 10.7326/0003-4819-105-5-762; STILLMAN PL, 1992, ACAD MED S, V76, pS57; STREINER DL, 1985, ASSESSING CLIN COMPE, P119; SUTNICK AI, 1994, ACAD MED, V69, P65, DOI 10.1097/00001888-199401000-00019; TAMBLYN R, 1994, J GEN INTERN MED, V9, P146, DOI 10.1007/BF02600030; THOMPSON WG, 1990, J GEN INTERN MED, V5, P214, DOI 10.1007/BF02600537; Tugwell P, 1985, ASSESSING CLIN COMPE, P142; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; VANROSENDAAL GMA, 1994, ACAD MED, V69, P299, DOI 10.1097/00001888-199404000-00014; WAXMAN H, 1994, J GEN INTERN MED, V9, P692, DOI 10.1007/BF02599012; WAYLAND MT, 1987, J MED EDUC, V62, P519; WINICKOFF RN, 1984, MED CARE, V22, P527, DOI 10.1097/00005650-198406000-00003; WOLFSTHAL SD, 1995, ANN INTERN MED, V122, P73, DOI 10.7326/0003-4819-122-1-199501010-00031; WOOLLISCROFT JO, 1984, J MED EDUC, V59, P799; WRAY NP, 1983, JAMA-J AM MED ASSOC, V249, P1035, DOI 10.1001/jama.249.8.1035; YINDRA KJ, 1988, J MED EDUC, V63, P356	81	127	130	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					42	48		10.7326/0003-4819-129-1-199807010-00011	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9652999				2022-12-28	WOS:000074513300007
J	Schacker, T; Ryncarz, AJ; Goddard, J; Diem, K; Shaughnessy, M; Corey, L				Schacker, T; Ryncarz, AJ; Goddard, J; Diem, K; Shaughnessy, M; Corey, L			Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HETERODUPLEX MOBILITY ASSAY; VIRAL EXPRESSION; PERIPHERAL-BLOOD; TYPE-1; TRANSMISSION; INFECTIONS; SEROCONVERSION; REPLICATION; ACTIVATION	Context.-Genital ulcer disease has been epidemiologically linked as a risk factor in the transmission of the human immunodeficiency virus 1 (HIV-1). While herpes simplex virus 2 (HSV-2) is the most common cause of genital ulcers, no study has systematically evaluated the frequency or titer of HIV-1 virus in HSV-2 lesions. Objective.-To compare lesional HIV-1 RNA levels during and after genital HSV-2 reactivation and to evaluate the frequency, titer, and duration of HIV-1 RNA shedding in lesions due to HSV-2. Design.-Convenience sample. Setting.-Sexually transmitted disease research clinic at the University of Washington, Seattle. Patients.-Twelve HIV-infected men with a history of symptomatic HSV-2 infection who underwent daily sampling of genital lesions for HIV-1 RNA by polymerase chain reaction assay and HSV-2 by culture. Main Outcome Measure.-Detection of lesional HIV RNA and HSV-2. Results.-HIV-1 RNA was detected from lesional swabs in 25 of 26 consecutively studied HSV-2 episodes and on 67% of days in which genital lesions were noted. The HIV-1 RNA titers in lesional swabs exceeded 10 000 copies/mL of swab sample in 75% of samples (range, 2.2-3.2 x 10(5) copies/mL of swab sample). HIV-1 RNA in genital lesion swabs was seen in persons with high and low titers of plasma HIV-1 RNA and was not associated with plasma HIV-1 RNA levels. Conclusions.-HIV-1 virions can consistently be detected in genital ulcers caused by HSV-2, which suggests that genital herpes infection likely increases the efficiency of the sexual transmission of HIV-1.	Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Lab Med, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Corey, L (corresponding author), Fred Hutchinson Canc Res Ctr, Program Infect Dis M115, POB 19024,1100 Fairview Ave N D3-100, Seattle, WA 98109 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001228] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-01228, U01 AI-35498, AI-30371] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRECHT MA, 1989, J VIROL, V63, P1861, DOI 10.1128/JVI.63.5.1861-1868.1989; AUGENBRAUN M, 1995, ANN INTERN MED, V123, P845, DOI 10.7326/0003-4819-123-11-199512010-00006; AUGENBRAUN MH, 1994, INFECT DIS CLIN N AM, V8, P439; Brichacek B, 1996, J INFECT DIS, V174, P1191, DOI 10.1093/infdis/174.6.1191; CAMERON DW, 1989, LANCET, V2, P403; CASTRO KG, 1988, SCIENCE, V239, P193, DOI 10.1126/science.3336781; CLUMECK N, 1989, NEW ENGL J MED, V321, P1460, DOI 10.1056/NEJM198911233212107; CONE RW, 1991, J INFECT DIS, V164, P757, DOI 10.1093/infdis/164.4.757; COREY L, 1983, ANN INTERN MED, V98, P973, DOI 10.7326/0003-4819-98-6-973; CUNNINGHAM AL, 1985, J CLIN INVEST, V75, P226, DOI 10.1172/JCI111678; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DELWART EL, 1995, AIDS RES HUM RETROV, V11, P1081, DOI 10.1089/aid.1995.11.1081; DELWART EL, 1995, PCR METH APPL, V4, pS202; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; DEVINCENZI I, 1989, BRIT MED J, V298, P411; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GOLDEN MP, 1992, J INFECT DIS, V166, P494, DOI 10.1093/infdis/166.3.494; HENG MCY, 1994, LANCET, V343, P255, DOI 10.1016/S0140-6736(94)91110-X; KOELLE DM, 1994, J INFECT DIS, V169, P956, DOI 10.1093/infdis/169.5.956; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; KUCERA LS, 1990, AIDS RES HUM RETROV, V6, P641, DOI 10.1089/aid.1990.6.641; LANGENBERG A, 1988, J CLIN MICROBIOL, V26, P1772, DOI 10.1128/JCM.26.9.1772-1774.1988; LATIF AS, 1989, AIDS, V3, P519, DOI 10.1097/00002030-198908000-00006; MARGOLIS DM, 1992, VIROLOGY, V186, P788, DOI 10.1016/0042-6822(92)90048-T; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MOSCA JD, 1987, P NATL ACAD SCI USA, V84, P7408, DOI 10.1073/pnas.84.21.7408; OBRIEN WA, 1995, BLOOD, V86, P1082; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OFARRELL N, 1994, INT J STD AIDS, V5, P415, DOI 10.1177/095646249400500607; OSTROVE JM, 1987, J VIROL, V61, P3726, DOI 10.1128/JVI.61.12.3726-3732.1987; OTTEN MW, 1994, AIDS, V8, P549, DOI 10.1097/00002030-199404000-00020; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PIATAK M, 1993, LANCET, V341, P1099, DOI 10.1016/0140-6736(93)92463-4; Piot P, 1989, SEXUALLY TRANSMITTED, P711; RIOS Z, 1995, CELL MOL BIOL, V41, pS93; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; Schacker T, 1998, ANN INTERN MED, V128, P21, DOI 10.7326/0003-4819-128-1-199801010-00004; Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; WALD A, 1994, ANTIMICROB AGENTS CH, V38, P174, DOI 10.1128/AAC.38.2.174	42	240	244	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					61	66		10.1001/jama.280.1.61	http://dx.doi.org/10.1001/jama.280.1.61			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660365	Bronze			2022-12-28	WOS:000074379400025
J	Davies, M; Batten, J				Davies, M; Batten, J			John Parker - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1987	1987		10.1136/bmj.316.7149.1987	http://dx.doi.org/10.1136/bmj.316.7149.1987			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641961	Green Published			2022-12-28	WOS:000074636700075
J	Grob, JJ; Dreno, B; de la Salmoniere, P; Delaunay, M; Cupissol, D; Guillot, B; Souteyrand, P; Sassolas, B; Cesarini, JP; Lionnet, S; Lok, C; Chastang, C; Bonerandi, JJ				Grob, JJ; Dreno, B; de la Salmoniere, P; Delaunay, M; Cupissol, D; Guillot, B; Souteyrand, P; Sassolas, B; Cesarini, JP; Lionnet, S; Lok, C; Chastang, C; Bonerandi, JJ		French Cooperative Grp Melanoma	Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1 center dot 5 mm without clinically detectable node metastases	LANCET			English	Article							RISK	Background Owing to the limited efficacy of therapy on melanoma at the stage of distant metastases, a well-tolerated adjuvant therapy is needed for patients with high-risk primary melanoma, Our hypothesis was that an adjuvant treatment with low doses of interferon a could be effective in patients with localised melanoma. Methods After resection of a primary cutaneous melanoma thicker than 1.5 mm, patients without clinically detectable node metastases were randomly assigned to receive either 3x10(6) IU interferon alpha-2a, three-times weekly for 18 months, or no treatment. The primary endpoint was the relapse-free interval. Findings 499 patients were enrolled, of whom 489 were eligible. When used as part of a sequential procedure, interferon a-2a was of significant benefit for relapse-free interval (p=0.038). A long-term analysis, after a median follow-up of 5 years, showed a significant extension of relapse-free interval (p=0.035) and a clear trend towards an increase in overall survival (p=0.059) in interferon alpha-2a-treated patients compared with controls. There were 100 relapses and 59 deaths among the 244 interferon alpha-2a-treated patients compared with 119 relapses and 76 deaths among the 245 controls. The estimated 3-year-relapse rates were 32% in the interferon alpha-2a group and 44% in controls; the 3-year death rates were 15% and 21%, respectively. Only 10% of patients experienced WHO grade 3 or 4 adverse events. Treatment was compatible with normal daily life. Interpretation Adjuvant therapy of high-risk melanoma with low doses of interferon a-2a for 18 months is safe and is beneficial when started before clinically detectable node metastases develop.	CHR St Marguerite, Marseille, France; CHR Hotel Dieu, Nantes, France; CHR Hop St Louis, Dept Biostat & Informat Med, Paris, France; Hop Pellegrin, F-33076 Bordeaux, France; Ctr Val Aurelle, Montpellier, France; CHR Caremeau, Nimes, France; CHR Hotel Dieu, Clermont Ferrand, France; CHR Augustin Morvan, Brest, France; Fdn Rothschild, Paris, France; CHR Hop Edouard Herriot, Lyon, France; CHR Hop Sud, Amiens, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; CHU Bordeaux; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; CHU de Nimes; CHU Clermont Ferrand; CHU Lyon	Grob, JJ (corresponding author), Hop St Marguerite, Dermatol Serv, 270 Bd St Marguerite,BP 29, F-13277 Marseille 9, France.			Grob, Jean-Jacques/0000-0002-0667-153X				[Anonymous], 1992, DESIGN ANAL SEQUENTI; Balch CM, 1996, J CLIN ONCOL, V14, P1; BALCH CM, 1992, CUTANEOUS MELANOMA, P165; BALCH CM, 1992, CUTANEOUS MELANOMA, P188; BARTH A, 1995, CANCER, V75, P726, DOI 10.1002/1097-0142(19950115)75:2+<726::AID-CNCR2820751417>3.0.CO;2-R; CASCINELLI N, 1994, LANCET, V343, P913, DOI 10.1016/S0140-6736(94)90030-2; CASCINELLI N, 1995, P AN M AM SOC CLIN, V14, P410; COX DR, 1972, J R STAT SOC B, V34, P187; CREAGAN ET, 1995, J CLIN ONCOL, V13, P2776, DOI 10.1200/JCO.1995.13.11.2776; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; KIRKWOOD JM, 1991, SEMIN ONCOL, V18, P83; SLINGLUFF CL, 1992, CANCER-AM CANCER SOC, V70, P1917, DOI 10.1002/1097-0142(19921001)70:7<1917::AID-CNCR2820700719>3.0.CO;2-5	13	330	335	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1905	1910		10.1016/S0140-6736(97)12445-X	http://dx.doi.org/10.1016/S0140-6736(97)12445-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654256				2022-12-28	WOS:000074464700006
J	Routledge, P				Routledge, P			150 years of pharmacovigilance	LANCET			English	Article									Univ Wales Coll Med, Dept Pharmacol Therapeut & Toxicol, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Routledge, P (corresponding author), Univ Wales Coll Med, Dept Pharmacol Therapeut & Toxicol, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.							Commission on Anaesthetics, 1893, LANCET, V1, P629; Geiling EMK., 1938, J AM MED ASS, V111, P919, DOI [10.1001/jama.1938.72790360005007, DOI 10.1001/JAMA.1938.72790360005007]; GOLDBERG A, 1987, ADVERSE DRUG REACT, P1; MANN RD, 1907, ADVERSE DRUG REACT, P5; MCBRIDE WG, 1961, LANCET, V2, P1358; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; McNamee D, 1997, LANCET, V350, P1646, DOI 10.1016/S0140-6736(05)64272-9; RAWLINS MD, 1995, J ROY COLL PHYS LOND, V29, P41; SKEGG DCG, 1977, LANCET, V2, P475; SKEGG DCG, 1977, BRIT MED J, V2, P1523, DOI 10.1136/bmj.2.6101.1523; TAUSSIG HB, 1962, JAMA-J AM MED ASSOC, V180, P1106, DOI 10.1001/jama.1962.03050260028005; WALKER RS, 1959, BRIT MED J, V2, P1005, DOI 10.1136/bmj.2.5158.1005	12	43	49	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1200	1201		10.1016/S0140-6736(98)03148-1	http://dx.doi.org/10.1016/S0140-6736(98)03148-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643710				2022-12-28	WOS:000073220200048
J	Tetteroo, E; van der Graaf, Y; Bosch, JL; van Engelen, AD; Hunink, MGM; Eikelboom, BC; Mali, WPTM				Tetteroo, E; van der Graaf, Y; Bosch, JL; van Engelen, AD; Hunink, MGM; Eikelboom, BC; Mali, WPTM		Dutch Iliac Stent Trial Study Grp	Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease	LANCET			English	Article							BALLOON ANGIOPLASTY; PALMAZ STENT; ENDOVASCULAR PROCEDURES; PRESSURE MEASUREMENTS; MULTICENTER TRIAL; FEMORAL ARTERIES; STENOSIS; ANGIOGRAPHY	Background Percutaneous transluminal angioplasty (PTA) is a safe, simple, and successful treatment for intermittent claudication caused by iliac-artery occlusive disease. Primary stent placement has been proposed as more effective than PTA. We compared the technical results and clinical outcomes of two treatment strategies-primary placement of a stent across the stenotic segment of the iliac artery, or primary PTA followed by selective stent placement when haemodynamic results were inadequate. Methods We randomly assigned 279 patients with intermittent claudication, recruited from departments of vascular surgery, either to direct stent placement (group I, n=143) or primary angioplasty (group II, n=136), with subsequent stent placement in case of a residual mean pressure gradient greater than 10 mm Hg across the treated site. The main inclusion criterion was intermittent claudication on the basis of iliac-artery stenosis of more than 50%, proven by angiography. All patients had a clinical assessment before intervention and at 3, 12, and 24 months. Clinical success was defined as improvement of at least one clinical category. Secondary endpoints were initial technical results, procedural complications, cumulative patency as assessed by duplex ultrasonography, and quality of life. Findings In group II, selective stent placement was done in 59 (43%) of the 136 patients. The mean follow-up was 9.3 months (range 3-24). Initial haemodynamic success and complication rates were 119 (81%) of 149 limbs and 6 (4%) of 143 limbs (group I) versus 103 (82%) of 126 limbs and 10 (7%) of 136 limbs (group II), respectively. Clinical success rates at 2 years were 29 (78%) of 37 patients and 26 (77%) of 34 patients in groups I and II, respectively (p=0.6); however, 43% and 35% of the patients, respectively, still had symptoms. Quality of life improved significantly after intervention (p<0.05) but we found no difference between the groups during follow-up. 2-year cumulative patency rates were similar at 71% versus 70% (p=0.2), respectively, as were reintervention rates at 7% versus 4%, respectively (95% CI -2% to 9%). Interpretation There were no substantial differences in technical results and clinical outcomes of the two treatment strategies both at short-term and long-term follow-up. Since angioplasty followed by selective stent placement is less expensive than direct placement of a stent, the former seems to be the treatment of choice for lifestyle-limiting intermittent claudication caused by iliac artery occlusive disease.	Univ Utrecht Hosp, Dept Radiol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht Hosp, Dept Clin Epidemiol, NL-3584 CX Utrecht, Netherlands; Univ Groningen, Dept Hlth Sci, Groningen, Netherlands; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Univ Utrecht Hosp, Dept Surg, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Groningen; Harvard University; Harvard T.H. Chan School of Public Health; Utrecht University; Utrecht University Medical Center	Mali, WPTM (corresponding author), Univ Utrecht Hosp, Dept Radiol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.		Mali, Willem PThM/I-1123-2014	Mali, Willem PThM/0000-0003-4391-0904				AHN SS, 1993, J VASC SURG, V17, P1103, DOI 10.1016/0741-5214(93)90682-C; ARCHIE JP, 1981, SURGERY, V90, P876; Bosch JL, 1997, RADIOLOGY, V204, P87, DOI 10.1148/radiology.204.1.9205227; BRESLAU PJ, 1985, ARCH SURG-CHICAGO, V120, P1050; CHALMERS TC, 1977, NEW ENGL J MED, V297, P1091, DOI 10.1056/NEJM197711172972004; COLLEDGE J, 1997, LANCET, V350, P1459; GALLINO A, 1984, CIRCULATION, V70, P619, DOI 10.1161/01.CIR.70.4.619; GUNN IG, 1981, BRIT J SURG, V68, P858, DOI 10.1002/bjs.1800681209; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; HENRY M, 1995, RADIOLOGY, V197, P167, DOI 10.1148/radiology.197.1.7568818; JOHNSTON KW, 1993, RADIOLOGY, V186, P207, DOI 10.1148/radiology.186.1.8416566; KADIR S, 1983, SURGERY, V94, P10; Kinney TB, 1996, AM J ROENTGENOL, V166, P277, DOI 10.2214/ajr.166.2.8553930; Martin EC, 1995, J VASC INTERV RADIOL, V6, P843, DOI 10.1016/S1051-0443(95)71198-8; MEWISSEN MW, 1992, J VASC SURG, V15, P860, DOI 10.1016/0741-5214(92)90721-J; MILLER BV, 1991, ARCH SURG-CHICAGO, V126, P867; MOORE WS, 1971, ARCH SURG-CHICAGO, V103, P633; MURPHY KD, 1995, J VASC INTERV RADIOL, V6, P321, DOI 10.1016/S1051-0443(95)72815-9; PALMAZ JC, 1992, CARDIOVASC INTER RAD, V15, P291, DOI 10.1007/BF02733953; PALMAZ JC, 1993, AM J ROENTGENOL, V160, P613, DOI 10.2214/ajr.160.3.8430566; RICHTER GM, 1991, RADIOLOGY, V181, P161; Sapoval MR, 1996, AM J ROENTGENOL, V166, P1173, DOI 10.2214/ajr.166.5.8615265; SCHWARTEN DE, 1992, INTERVENTIONAL RADIO, P378; SPENCE RK, 1981, ARCH SURG-CHICAGO, V116, P1377; Spijkerboer AM, 1996, J VASC SURG, V23, P691, DOI 10.1016/S0741-5214(96)80051-6; Tetteroo E, 1996, RADIOLOGY, V201, P155, DOI 10.1148/radiology.201.1.8816537; Tetteroo E, 1996, CARDIOVASC INTER RAD, V19, P411, DOI 10.1007/BF02577629; THIELE BL, 1983, PROG CARDIOVASC DIS, V26, P223, DOI 10.1016/0033-0620(83)90007-5; UDOFF EJ, 1979, RADIOLOGY, V132, P289, DOI 10.1148/132.2.289; Vorwerk D, 1996, RADIOLOGY, V198, P45, DOI 10.1148/radiology.198.1.8539403; VORWERK D, 1995, RADIOLOGY, V194, P745, DOI 10.1148/radiology.194.3.7862973	31	232	238	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1153	1159		10.1016/S0140-6736(97)09508-1	http://dx.doi.org/10.1016/S0140-6736(97)09508-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643685	Green Submitted			2022-12-28	WOS:000073220200007
J	Watson, P; Marcus, JN; Lynch, HT				Watson, P; Marcus, JN; Lynch, HT			Prognosis of BRCA1 hereditary breast cancer	LANCET			English	Editorial Material							CARCINOMA; MUTATION		Creighton Univ, Sch Med, Dept Prevent Med, Omaha, NE 68178 USA; St Lukes Hosp, Dept Pathol, Chesterfield, MO 63017 USA	Creighton University; Saint Luke's Hospital - Missouri	Watson, P (corresponding author), Creighton Univ, Sch Med, Dept Prevent Med, Omaha, NE 68178 USA.							Eisinger F, 1996, CANCER RES, V56, P471; GAMEL JW, 1995, CANCER, V76, P1009; Johannsson OT, 1998, J CLIN ONCOL, V16, P397, DOI 10.1200/JCO.1998.16.2.397; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Lakhani SR, 1997, LANCET, V349, P1505; Marcus JN, 1997, CANCER-AM CANCER SOC, V80, P543, DOI 10.1002/(SICI)1097-0142(19970801)80:3+<543::AID-CNCR4>3.3.CO;2-R; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; RIDOLFI RL, 1977, CANCER, V40, P1365, DOI 10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845	11	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					304	305		10.1016/S0140-6736(98)22005-8	http://dx.doi.org/10.1016/S0140-6736(98)22005-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652604				2022-12-28	WOS:000071864000002
J	Stanley, AJ; Hayes, PC				Stanley, AJ; Hayes, PC			Portal hypertension and variceal haemorrhage	LANCET			English	Article							BLEEDING ESOPHAGEAL-VARICES; TERM FOLLOW-UP; HYPERDYNAMIC CIRCULATION; NATURAL-HISTORY; NITRIC-OXIDE; INJECTION SCLEROTHERAPY; CIRRHOSIS; HEMORRHAGE; MANAGEMENT; PREVENTION		ROYAL INFIRM,DEPT MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh				Stanley, Adrian/0000-0002-9761-9795				ABELMANN WH, 1994, HEPATOLOGY, V20, P1356; ANGELICO M, 1993, GASTROENTEROLOGY, V104, P1460, DOI 10.1016/0016-5085(93)90356-H; BENOIT JN, 1986, SEMIN LIVER DIS, V6, P287, DOI 10.1055/s-2008-1040611; BINMOELLER KF, 1995, ENDOSCOPY, V27, P392, DOI 10.1055/s-2007-1005720; BOMZON A, 1994, HEPATOLOGY, V20, P1343, DOI 10.1002/hep.1840200535; BONMAN PC, 1994, LANCET, V343, P1079; BURROUGHS AK, 1989, HEPATOLOGY, V9, P801, DOI 10.1002/hep.1840090602; BURROUGHS AK, 1993, J HEPATOL, V17, pS10, DOI 10.1016/S0168-8278(05)80448-9; CHRISTENSEN E, 1981, GASTROENTEROLOGY, V81, P944; DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1002/hep.1840220145; deFranchis R, 1996, J HEPATOL, V25, P390, DOI 10.1016/S0168-8278(96)80127-9; FEU F, 1995, LANCET, V346, P1056, DOI 10.1016/S0140-6736(95)91740-3; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GarciaPagan JC, 1996, GASTROENTEROLOGY, V111, P1300, DOI 10.1053/gast.1996.v111.pm8898644; GARCIATSAO G, 1985, HEPATOLOGY, V5, P419, DOI 10.1002/hep.1840050313; GENECIN P, 1993, DISEASES LIVER, V2, P935; GOUSTOUT CJ, 1993, AM J GASTROENTEROL, V88, P2030; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; GROSZMANN RJ, 1994, HEPATOLOGY, V20, P1359, DOI 10.1016/0270-9139(94)90780-3; Hayes PC, 1996, BRIT MED J, V312, P1111; HAYES PC, 1990, LANCET, V336, P153, DOI 10.1016/0140-6736(90)91668-Z; HEATON ND, 1993, GUT, V34, P7, DOI 10.1136/gut.34.1.7; IMPERIALE TF, 1995, GASTROENTEROLOGY, V109, P1289, DOI 10.1016/0016-5085(95)90590-1; LAINE L, 1995, ANN INTERN MED, V123, P180; Lebrec D, 1997, J GASTROEN HEPATOL, V12, P159, DOI 10.1111/j.1440-1746.1997.tb00400.x; LEVACHER S, 1995, LANCET, V346, P865, DOI 10.1016/S0140-6736(95)92708-5; MAROTO A, 1993, HEPATOLOGY, V17, P788, DOI 10.1016/0270-9139(93)90153-E; MEHTA R, 1990, HEPATOLOGY, V12, P1152, DOI 10.1002/hep.1840120513; Merkel C, 1996, LANCET, V348, P1677, DOI 10.1016/S0140-6736(96)05406-2; MILLIKAN WJ, 1990, AM J SURG, V160, P117, DOI 10.1016/S0002-9610(05)80880-3; *N IT END CLUB STU, 1988, NEW ENGL J MED, V319, P983; PAGLIARO L, 1995, J HEPATOL, V23, P36; PAGLIARO L, 1994, PORTAL HYPERTENSION, V5, P72; PAGLIARO L, 1997, ANN INTERN MED, V17, P59; POYNARD T, 1991, NEW ENGL J MED, V324, P1532, DOI 10.1056/NEJM199105303242202; *PROVA STUD GROUP, 1991, HEPATOLOGY, V14, P1016; RING EJ, 1992, ANN INTERN MED, V116, P304, DOI 10.7326/0003-4819-116-4-304; Rocky D, 1997, HEPATOLOGY, V25, P2, DOI 10.1002/hep.510250102; Rosemurgy AS, 1996, ANN SURG, V224, P378, DOI 10.1097/00000658-199609000-00014; SARIN SK, 1992, HEPATOLOGY, V16, P1343, DOI 10.1002/hep.1840160607; SODERLUND C, 1990, SCAND J GASTROENTERO, V25, P622, DOI 10.3109/00365529009095539; Stanley AJ, 1996, GUT, V39, P479, DOI 10.1136/gut.39.3.479; Stanley AJ, 1997, ALIMENT PHARM THERAP, V11, P261, DOI 10.1046/j.1365-2036.1997.156331000.x; Sung JJY, 1995, LANCET, V346, P1666, DOI 10.1016/S0140-6736(95)92840-5; Teran JC, 1997, GASTROENTEROLOGY, V112, P473, DOI 10.1053/gast.1997.v112.pm9024301; TERBLANCHE J, 1989, NEW ENGL J MED, V320, P1393, DOI 10.1056/NEJM198905253202107; VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7; *VET AFF COOP VAR, 1991, NEW ENGL J MED, V324, P1779; VILLANUEVA C, 1996, NEW ENGL J MED, V334, P1642; VLAVIANOS P, 1989, BRIT MED J, V298, P1158, DOI 10.1136/bmj.298.6681.1158; VORBIOFF J, 1996, GASTROENTEROLOGY, V111, P701; WHITTLE BJR, 1992, HEPATOLOGY, V16, P1089, DOI 10.1002/hep.1840160437; WILLIAMS SGJ, 1995, GUT, V36, P647, DOI 10.1136/gut.36.5.647	53	32	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1235	1239		10.1016/S0140-6736(97)06283-1	http://dx.doi.org/10.1016/S0140-6736(97)06283-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652580				2022-12-28	WOS:A1997YD23800041
J	Drife, JO				Drife, JO			A very British Congress	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					220	220		10.1136/bmj.317.7152.220	http://dx.doi.org/10.1136/bmj.317.7152.220			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665933	Green Published			2022-12-28	WOS:000075047800075
J	Beecham, L				Beecham, L			Shadow health team calls for GP ballot	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					151	151						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657813				2022-12-28	WOS:000075081700060
J	Dixon, J; Holland, P; Mays, N				Dixon, J; Holland, P; Mays, N			Primary care, core values - Developing primary care: gatekeeping, commissioning, and managed care	BRITISH MEDICAL JOURNAL			English	Article									Kings Fund, London W1M 0AN, England; Lambeth Southwark & Lewisham Hlth Author, London SE1 7NT, England		Dixon, J (corresponding author), Kings Fund, London W1M 0AN, England.	j.dixon@kehf.org.uk						[Anonymous], 1993, WORLD DEV REP 1993; APPLEBY J, 1996, MEASURE EFFICTIVENES; *AUD COMM, 1996, WHAT DOCT ORD STUD G; BLACK DG, 1994, BRIT MED J, V309, P930, DOI 10.1136/bmj.309.6959.930; Coulter A, 1997, BRIT MED J, V314, P510; COULTER A, 1995, EUR J PUBLIC HEALTH, V5, P223; Dale J, 1996, BRIT MED J, V312, P1340, DOI 10.1136/bmj.312.7042.1340; DIXON J, 1995, BRIT MED J, V311, P727, DOI 10.1136/bmj.311.7007.727; DIXON J, 1994, BRIT MED J, V309, P30, DOI 10.1136/bmj.309.6946.30; Dixon J, 1997, BMJ-BRIT MED J, V314, P216, DOI 10.1136/bmj.314.7075.216a; English T, 1997, BRIT MED J, V314, P661, DOI 10.1136/bmj.314.7081.661; Fairfield G, 1997, BRIT MED J, V314, P1823, DOI 10.1136/bmj.314.7097.1823; Ginzberg E, 1997, NEW ENGL J MED, V336, P1018, DOI 10.1056/NEJM199704033361411; Groves T, 1997, BRIT MED J, V314, P436, DOI 10.1136/bmj.314.7078.436; *GUYS ST THOM HOSP, 1997, CONT CAR STRAT IMPR; Hine CE, 1997, BRIT MED J, V314, P1246, DOI 10.1136/bmj.314.7089.1246; HSAIO WC, 1993, NEW ENGL J MED, V328, P928; HSIAO WC, 1988, NEW ENGL J MED, V319, P881, DOI 10.1056/NEJM198809293191330; Hunter DJ, 1997, BRIT MED J, V315, P50, DOI 10.1136/bmj.315.7099.50; Josefson D, 1997, BRIT MED J, V314, P625; Kendrick T, 1997, BRIT MED J, V314, P672, DOI 10.1136/bmj.314.7081.672; KONGSTVEDT PR, 1995, ESSENTIALS MANAGED H; MACLEOD GK, 1995, ESSENTIALS MANAGED H; MAYS N, 1997, TOTAL PURCHASING PRO; MAYS N, 1996, PURCHASER PLURALITY; Oxley C, 1997, Health Serv J, V107, P34; Pedersen LL, 1997, BMJ-BRIT MED J, V314, P1337, DOI 10.1136/bmj.314.7090.1337; PETCHEY R, 1995, LANCET, V346, P1139, DOI 10.1016/S0140-6736(95)91805-1; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; *SECR STAT SCOTL, 1997, DES CAR; SMITH J, 1997, HLTH SERV       0106, P26; *STAT HLTH ENGL, 1996, PRIM CAR DEL FUT; *STET HLTH ENGL, 1996, CHOC APP PRIM CAR FU; *WHO, 1995, BRIDG GAPS REP DIR G; [No title captured]	35	21	21	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					125	128		10.1136/bmj.317.7151.125	http://dx.doi.org/10.1136/bmj.317.7151.125			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657792	Green Published			2022-12-28	WOS:000075081700026
J	Li, YD; Qian, YT; Liao, HW; Ding, Y; Yang, L; Xu, CY; Li, FQ; Zhou, G				Li, YD; Qian, YT; Liao, HW; Ding, Y; Yang, L; Xu, CY; Li, FQ; Zhou, G			A reduction-pyrolysis-catalysis synthesis of diamond	SCIENCE			English	Article							THIN-FILMS; METHYL RADICALS; GROWTH; DEPOSITION; CARBON; PLASMA; HYDROGEN; SYSTEM	Diamond powder was synthesized through a metallic reduction-pyrolysis-catalysis route with the reaction of carbon tetrachloride and sodium at 700 degrees C, in which the sodium was used as reductant and flux. This temperature is much lower than that of traditional methods. The x-ray powder diffraction patterns showed three strong peaks of diamond. The Raman spectrum showed a sharp peak at 1332 inverse centimeters, which is characteristic of diamond. Although the yield was only 2 percent, this method is a simple means of forming diamond.	Univ Sci & Technol China, Struct Res Lab, Hefei 230026, Anhui, Peoples R China; Univ Sci & Technol China, Dept Chem, Hefei 230026, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Li, YD (corresponding author), Univ Sci & Technol China, Struct Res Lab, Hefei 230026, Anhui, Peoples R China.		Liao, Hongwei/C-8652-2011; Qian, Yitai/F-9692-2010; DING, YI/F-6990-2013	DING, YI/0000-0002-1347-2811				AISENBERG S, 1971, J APPL PHYS, V42, P2953, DOI 10.1063/1.1660654; ANGUS JC, 1968, J APPL PHYS, V39, P2915, DOI 10.1063/1.1656693; BUNDY FP, 1955, NATURE, V176, P51, DOI 10.1038/176051a0; EVERSOLE WG, 1958, Patent No. 3030188; Eversole WG, 1958, US Patents NN, Patent No. 3030187; FINAR IL, 1973, ORGANIC CHEM, V1, P76; Gneiner N.R., 1988, NATURE, V333, P440; GRAEBNER JE, 1992, NATURE, V359, P401, DOI 10.1038/359401a0; HARRIS SJ, 1990, APPL PHYS LETT, V56, P2298, DOI 10.1063/1.102946; HOLLAND L, 1976, THIN SOLID FILMS, V38, pL17, DOI 10.1016/0040-6090(76)90214-5; *JOINT COMM POWD D, 60675 JCPDS; Lee J, 1997, APPL PHYS LETT, V70, P1527, DOI 10.1063/1.118607; LEE SS, 1994, SCIENCE, V263, P1596, DOI 10.1126/science.263.5153.1596; MASTUMOTO S, 1982, JPN J APPL PHYS, V21, P1183; MURANAKA Y, 1990, J APPL PHYS, V67, P6247, DOI 10.1063/1.345191; Novikov VP, 1997, APPL PHYS LETT, V70, P200, DOI 10.1063/1.118355; Roy R, 1996, J MATER RES, V11, P1164, DOI 10.1557/JMR.1996.0150; SOKOLOWSKI M, 1979, J CRYST GROWTH, V47, P421, DOI 10.1016/0022-0248(79)90208-2; SOLIN SA, 1970, PHYS REV B, V1, P1678; SPITSYN BV, 1981, J CRYST GROWTH, V52, P219, DOI 10.1016/0022-0248(81)90197-4; SUZUKI K, 1987, APPL PHYS LETT, V50, P728, DOI 10.1063/1.98080; Thiel M V, 1987, J APPL PHYS, V62, P1761; VORA H, 1981, J APPL PHYS, V52, P6151, DOI 10.1063/1.328514; WHITMELL DS, 1976, THIN SOLID FILMS, V35, P255, DOI 10.1016/0040-6090(76)90263-7; Wu JJ, 1997, APPL PHYS LETT, V70, P185, DOI 10.1063/1.118352; Zhao XZ, 1997, NATURE, V385, P513, DOI 10.1038/385513a0	26	120	138	12	273	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					246	247		10.1126/science.281.5374.246	http://dx.doi.org/10.1126/science.281.5374.246			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657716				2022-12-28	WOS:000074714200045
J	McCarthy, MD; Hedges, JI; Benner, R				McCarthy, MD; Hedges, JI; Benner, R			Major bacterial contribution to marine dissolved organic nitrogen	SCIENCE			English	Article							NORTH PACIFIC-OCEAN; AMINO-ACIDS; SARGASSO SEA; CARBON; MATTER; RACEMIZATION; SEAWATER	Next to N(2) gas, the Largest pool of reduced nitrogen in the ocean resides in the enormous reservoir of dissolved organic nitrogen (DON). The chemical identity of most of this material, and the mechanisms by which it is cycled, remain fundamental questions in contemporary oceanography. Amino acid enantiomeric ratios in the high molecular weight fraction of DON from surface and deep water in three ocean basins show substantial enrichment in D enantiomers of four amino acids. The magnitude and pattern of these D/L enrichments indicate that peptidoglycan remnants derived from bacterial cell walls constitute a major source of DON throughout the sea. These observations suggest that structural properties of specific bacterial biopolymers, and the mechanisms for their accumulation, are among the central controls on hong-term cycling of dissolved organic nitrogen in the sea.	Univ Washington, Sch Oceanog, Seattle, WA 98195 USA; Univ Texas, Inst Marine Sci, Port Aransas, TX 78373 USA	University of Washington; University of Washington Seattle; University of Texas System	McCarthy, MD (corresponding author), Univ Washington, Sch Oceanog, Box 357940, Seattle, WA 98195 USA.		Benner, Ronald/M-4412-2015	Benner, Ronald/0000-0002-1238-2777				BADA JL, 1980, EARTH-SCI REV, V16, P21, DOI 10.1016/0012-8252(80)90003-3; BADA JL, 1979, NATURE, V282, P822, DOI 10.1038/282822a0; BADA JL, 1971, KINETICS NONBIOLOGIC, P308; BADA JL, 1985, CHEM BIOCH AMINO ACI, P684; Benner R, 1997, MAR CHEM, V57, P243, DOI 10.1016/S0304-4203(97)00013-3; BENNER R, 1992, SCIENCE, V255, P1561, DOI 10.1126/science.255.5051.1561; BIERSMITH A, IN PRESS MAR CHEM; BOON JJ, IN PRESS ORG GEOCHEM; CAMPBELL L, 1994, LIMNOL OCEANOGR, V39, P954, DOI 10.4319/lo.1994.39.4.0954; CARLSON CA, 1994, NATURE, V371, P405, DOI 10.1038/371405a0; COWIE GL, 1992, MAR CHEM, V37, P223, DOI 10.1016/0304-4203(92)90079-P; COWIE GL, 1992, LIMNOL OCEANOGR, V37, P703, DOI 10.4319/lo.1992.37.4.0703; De Leeuw J.W., 1993, ORG GEOCHEM, V11, P23, DOI [10.1007/978-1-4615-2890-6_2, DOI 10.1007/978-1-4615-2890-6]; ENGEL MH, 1985, CHEM BIOCH AMINO ACI, P461; FITZNAR HP, COMMUNICATION; FUHRMAN J, 1992, ENVIR SCI R, V43, P361; Fuhrman JA, 1995, LIMNOL OCEANOGR, V40, P1236, DOI 10.4319/lo.1995.40.7.1236; FUHRMAN JA, 1993, OCEANOGRAPHY, V6, P51; GHUYSEN JM, 1973, BACTERIAL MEMBRANES, V1; GOODFRIEND GA, 1992, NATURE, V357, P399, DOI 10.1038/357399a0; JACKSON GA, 1985, DEEP-SEA RES, V32, P223, DOI 10.1016/0198-0149(85)90030-5; KILLOPS SD, 1993, LONGMAN GEOCHEMISTRY; KIMBER RWL, 1992, GEOCHIM COSMOCHIM AC, V56, P739, DOI 10.1016/0016-7037(92)90094-Y; KVENVOLDEN KA, 1975, ANNU REV EARTH PL SC, V3, P183, DOI 10.1146/annurev.ea.03.050175.001151; LEE C, 1977, LIMNOL OCEANOGR, V22, P502, DOI 10.4319/lo.1977.22.3.0502; McCarthy M, 1997, NATURE, V390, P150, DOI 10.1038/36535; McCarthy M, 1996, MAR CHEM, V55, P281, DOI 10.1016/S0304-4203(96)00041-2; MICHAELS AF, 1994, NATURE, V372, P537, DOI 10.1038/372537a0; Mitterer R.M., 1984, ORG GEOCHEM, V7, P91; MORIARTY DJW, 1977, OECOLOGIA, V26, P317, DOI 10.1007/BF00345531; Nagata T, 1997, ADV MICROB ECOL, V15, P81; ROGERS HJ, 1974, ANN NY ACAD SCI, V235, P29, DOI 10.1111/j.1749-6632.1974.tb43255.x; ROGERS HJ, 1983, ASPECTS MICROBIOLOGY, V7, P6; SANTSCHI PH, 1995, GEOCHIM COSMOCHIM AC, V59, P625, DOI 10.1016/0016-7037(94)00378-Y; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Tanoue E, 1995, MAR CHEM, V51, P239, DOI 10.1016/0304-4203(95)00061-5; VANHEEMST JDH, 1993, ORGANIC GEOCHEMISTRY, P694; WILLIAMS PJL, 1995, MAR CHEM, V51, P17, DOI 10.1016/0304-4203(95)00046-T; WILLIAMS PM, 1987, NATURE, V330, P246, DOI 10.1038/330246a0	39	286	290	4	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					231	234		10.1126/science.281.5374.231	http://dx.doi.org/10.1126/science.281.5374.231			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657711				2022-12-28	WOS:000074714200040
J	Koltover, I; Salditt, T; Radler, JO; Safinya, CR				Koltover, I; Salditt, T; Radler, JO; Safinya, CR			An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery	SCIENCE			English	Article							GENE-TRANSFER; EXPRESSION; MEMBRANES; SERIES	A two-dimensional columnar phase in mixtures of DNA complexed with cationic liposomes has been found in the Lipid composition regime known to be significantly more efficient at transfecting mammalian cells in culture compared to the lamellar (L-alpha(subset of)) structure of cationic liposome-DNA complexes. The structure, derived from synchrotron x-ray diffraction, consists of DNA coated by cationic lipid monolayers and arranged on a two-dimensional hexagonal lattice (H-parallel to(subset of)). Two membrane-altering pathways induce the L-alpha(subset of) --> H-parallel to(subset of) transition: one where the spontaneous curvature of the Lipid monolayer is driven negative, and another where the membrane bending rigidity is lowered with a new class of helper-lipids. Optical microscopy revealed that the L-alpha(subset of) complexes bind stably to anionic vesicles (models of cellular membranes), whereas the more transfectant H-parallel to(subset of) complexes are unstable and rapidly fuse and release DNA upon adhering to anionic vesicles.	Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Biochem & Mol Biol Program, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Safinya, CR (corresponding author), Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA.		Rädler, Joachim/AAD-8747-2019	Rädler, Joachim/0000-0002-5846-1489				BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; Dan N, 1998, BBA-BIOMEMBRANES, V1369, P34, DOI 10.1016/S0005-2736(97)00171-5; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0; Felgner PL, 1997, SCI AM, V276, P102, DOI 10.1038/scientificamerican0697-102; Friedmann T, 1997, SCI AM, V276, P96; GRUNER SM, 1989, J PHYS CHEM-US, V93, P7562, DOI 10.1021/j100359a011; GUTTMAN GD, 1993, J PHYS II, V3, P1411, DOI 10.1051/jp2:1993210; HARRINGTON JJ, 1997, NAT GENET, V15, P21994; Hui SW, 1996, BIOPHYS J, V71, P590, DOI 10.1016/S0006-3495(96)79309-8; KOLTOVER I, UNPUB; LAPPALAINEN K, 1994, BBA-BIOMEMBRANES, V1196, P201, DOI 10.1016/0005-2736(94)00224-X; LEGENDRE JY, 1992, PHARMACEUT RES, V9, P1235, DOI 10.1023/A:1015836829670; LIN AL, UNPUB; May S, 1997, BIOPHYS J, V73, P2427, DOI 10.1016/S0006-3495(97)78271-7; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; REMY JS, 1994, BIOCONJUGATE CHEM, V5, P647, DOI 10.1021/bc00030a021; Roush W, 1997, SCIENCE, V276, P38, DOI 10.1126/science.276.5309.38; SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134; Salditt T, 1997, PHYS REV LETT, V79, P2582, DOI 10.1103/PhysRevLett.79.2582; SEDDON JM, 1989, BIOCHIM BIOPHYS ACTA, V1031, P1; SZLEIFER I, 1988, PHYS REV LETT, V60, P1966, DOI 10.1103/PhysRevLett.60.1966; WROBEL I, 1995, BBA-BIOMEMBRANES, V1235, P296, DOI 10.1016/0005-2736(95)80017-A; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	27	1118	1154	9	239	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					78	81		10.1126/science.281.5373.78	http://dx.doi.org/10.1126/science.281.5373.78			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651248				2022-12-28	WOS:000074685800040
J	Glasier, A; Baird, D				Glasier, A; Baird, D			The effects of self-administering emergency contraception	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Emergency postcoital contraception prevents pregnancy, but it must be prescribed by a doctor and taken within 72 hours of intercourse. It has been proposed that emergency contraception be made available without a prescription. We undertook a study to learn how women might behave if given a supply of emergency contraceptive pills to keep at home. Methods We assigned 553 women to be given a replaceable supply of hormonal emergency contraceptive pills to take home (the treatment group) and 530 women to use emergency contraception obtained by visiting a doctor (the control group). The frequency of use of emergency contraception, the use of other contraceptives, and the incidence of unwanted pregnancy were determined in both groups of women one year later. Results The results for 549 women in the treatment group and 522 women in the control group were available for analysis. Three hundred seventy-nine of the women in the treatment group (69 percent) and 326 of the women in the control group (62 percent) contributed detailed information at followup. One hundred eighty of the women in the treatment group (47 percent) used emergency contraception at least once. Among those who returned the study questionnaire, 98 percent used emergency contraception correctly. There were no serious adverse effects. Eighty-seven women in the control group (27 percent) used emergency contraception at least once (P<0.001 for the comparison with the treatment group). The women in the treatment group were not more likely to use emergency contraception repeatedly. Their use of other methods of contraception was no different from that of the women in the control group. There were 18 unintended pregnancies in the treatment group and 25 in the control group (relative risk, 0.7; 95 percent confidence interval, 0.4 to 1.2), Conclusions Making emergency contraception more easily obtainable does no harm and may reduce the rate of unwanted pregnancies. [N Engl J Med 1998;339:1-4.) (C) 1998, Massachusetts Medical Society.	Univ Edinburgh, Dept Obstet & Gynaecol, Edinburgh EH4 1NL, Midlothian, Scotland; Edinburgh Healthcare Natl Hlth Serv Trust, Edinburgh, Midlothian, Scotland	University of Edinburgh	Glasier, A (corresponding author), Univ Edinburgh, Dept Obstet & Gynaecol, 18 Dean Terr, Edinburgh EH4 1NL, Midlothian, Scotland.							*DEP HLTH HUM SERV, 1997, FED REGISTER, V62, P8610; Glasier A, 1997, NEW ENGL J MED, V337, P1058, DOI 10.1056/NEJM199710093371507; GLASIER A, 1995, PROVISION EMERGENCY, P16; Graham A, 1996, BRIT MED J, V312, P1567, DOI 10.1136/bmj.312.7046.1567; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P269, DOI 10.2307/2135857; Williams C, 1996, BRIT MED J, V312, P463, DOI 10.1136/bmj.312.7029.463a; Wright DW, 1986, BR J FAM PLANN, V12, P88; 1992, PHARM J, V249, P530	8	237	240	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					1	4		10.1056/NEJM199807023390101	http://dx.doi.org/10.1056/NEJM199807023390101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647872				2022-12-28	WOS:000074500000001
J	Gitlin, N; Julie, NL; Spurr, CL; Lim, KN; Juarbe, HM				Gitlin, N; Julie, NL; Spurr, CL; Lim, KN; Juarbe, HM			Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone	ANNALS OF INTERNAL MEDICINE			English	Article							INSULIN		Emory Univ, Sch Med, Div Digest Dis, Atlanta, GA 30322 USA; Shady Grove Adventist Hosp, Atlanta, GA USA	Emory University	Gitlin, N (corresponding author), Emory Univ, Sch Med, Div Digest Dis, WMB 2101,Pierce Dr, Atlanta, GA 30322 USA.							Farrell GC, 1994, DRUG INDUCED LIVER D, P247; Kumar S, 1996, DIABETOLOGIA, V39, P701; LEE WM, 1993, ALIMENT PHARM THERAP, V7, P477; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803	4	191	192	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					36	38		10.7326/0003-4819-129-1-199807010-00008	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9652997				2022-12-28	WOS:000074513300005
J	Venn, A; Lewis, S; Cooper, M; Hill, J; Britton, J				Venn, A; Lewis, S; Cooper, M; Hill, J; Britton, J			Questionnaire study of effect of sex and age on the prevalence of wheeze and asthma in adolescence	BRITISH MEDICAL JOURNAL			English	Article									City Hosp, Div Resp Med, Nottingham NG5 1PB, England	University of Nottingham	Venn, A (corresponding author), City Hosp, Div Resp Med, Nottingham NG5 1PB, England.		Britton, John R/G-9705-2011					ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; LUYT DK, 1993, BMJ-BRIT MED J, V306, P1386, DOI 10.1136/bmj.306.6889.1386; SCHACHTER J, 1976, J ALLERGY CLIN IMMUN, V57, P342, DOI 10.1016/0091-6749(76)90091-9; TEPPER RS, 1986, AM REV RESPIR DIS, V134, P513; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368	5	78	80	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1945	1946		10.1136/bmj.316.7149.1945	http://dx.doi.org/10.1136/bmj.316.7149.1945			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641931	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000074636700026
J	Neufeld, TP; de la Cruz, AFA; Johnston, LA; Edgar, BA				Neufeld, TP; de la Cruz, AFA; Johnston, LA; Edgar, BA			Coordination of growth and cell division in the Drosophila wing	CELL			English	Article							GENETIC-CONTROL; CYCLIN-E; S-PHASE; TRANSLATION INITIATION; RETINOBLASTOMA PROTEIN; DEVELOPMENTAL CONTROL; EXPRESSION; PROLIFERATION; YEAST; G(1)	In most tissues, cell division is coordinated with increases in mass (i.e., growth). To understand this coordination, we altered rates of division in cell clones or compartments of the Drosophila wing and measured the effects on growth. Constitutive overproduction of the transcriptional regulator dE2F increased expression of the S- and M-phase initiators Cyclin E and String (Cdc25), thereby accelerating cell proliferation. Loss of dE2F or overproduction of its corepressor, RBF, retarded cell proliferation. These manipulations altered cell numbers over a 4- to 5-fold range but had little effect on clone or compartment sizes. Instead, changes in cell division rates were offset by changes in cell size. We infer that dE2F and RBF function specifically in cell cycle control, and that cell cycle acceleration is insufficient to stimulate growth. Variations in dE2F activity could be used to coordinate cell division with growth.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Edgar, BA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Johnston, Laura A/ABC-1945-2021	Neufeld, Thomas/0000-0001-5659-4811; JOHNSTON, LAURA A/0000-0001-9477-7897	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051186, GM17373, GM51186, F32 GM017373, F32 GM017373-03, F32 GM017373-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ANDERSSON S, 1994, GENETICS, V137, P513; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook A, 1996, EMBO J, V15, P3676, DOI 10.1002/j.1460-2075.1996.tb00737.x; Bryant PJ, 1996, BIOESSAYS, V18, P781, DOI 10.1002/bies.950181003; Burke R, 1996, DEVELOPMENT, V122, P2261; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Finley RL, 1996, P NATL ACAD SCI USA, V93, P3011, DOI 10.1073/pnas.93.7.3011; FRANCH HA, 1995, J CELL BIOL, V129, P245, DOI 10.1083/jcb.129.1.245; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GONZALEZGAITAN M, 1994, MECH DEVELOP, V46, P183, DOI 10.1016/0925-4773(94)90070-1; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; HARTWELL LH, 1971, J MOL BIOL, V59, P183, DOI 10.1016/0022-2836(71)90420-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HEMERLY A, 1995, EMBO J, V14, P3925, DOI 10.1002/j.1460-2075.1995.tb00064.x; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; JOHNSTON LA, 1998, IN PRESS NATURE; Karim FD, 1998, DEVELOPMENT, V125, P1; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; Milan M, 1996, P NATL ACAD SCI USA, V93, P640, DOI 10.1073/pnas.93.2.640; Milan M, 1996, P NATL ACAD SCI USA, V93, P11687, DOI 10.1073/pnas.93.21.11687; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; MITCHISON JM, 1971, BIOL CELL CYCLE; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pignoni F, 1997, DEVELOPMENT, V124, P271; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; Serrano N, 1997, CURR BIOL, V7, pR186, DOI 10.1016/S0960-9822(97)70085-X; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIMPSON P, 1979, DEV BIOL, V69, P182, DOI 10.1016/0012-1606(79)90284-7; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WATSON KL, 1994, J CELL SCI, P19; Weigmann K, 1997, DEVELOPMENT, V124, P3555; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	69	620	624	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1998	93	7					1183	1193		10.1016/S0092-8674(00)81462-2	http://dx.doi.org/10.1016/S0092-8674(00)81462-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657151	Bronze			2022-12-28	WOS:000074491100013
J	Serghiou, G; Zerr, A; Boehler, R				Serghiou, G; Zerr, A; Boehler, R			(Mg,Fe)SiO3-perovskite stability under lower mantle conditions	SCIENCE			English	Article							HIGH-PRESSURE; PEROVSKITE; TEMPERATURE; PHASE; MGSIO3	In three different experiments up to 100 gigapascals and 3000 kelvin, (Mg,Fe)SiO3-perovskite, the major component of the lower mantle, remained stable and did not decompose to its component oxides (Mg,Fe)O and SiO2. Perovskite was formed from these oxides when heated in a diamond anvil cell at pressures up to 100 gigapascals. Both MgSiO3 crystals and glasses heated to 3000 kelvin at 75 gigapascals also formed perovskite as a single phase, as evident from Raman spectre. Moreover, fluorescence measurements on chromium-doped samples synthesized at these conditions gave no indication of the presence of MgO.	Max Planck Inst Chem, D-55020 Mainz, Germany	Max Planck Society	Serghiou, G (corresponding author), Max Planck Inst Chem, Postfach 3060, D-55020 Mainz, Germany.		Boehler, Reinhard/L-3971-2016; Zerr, Andreas/AFV-5252-2022	Boehler, Reinhard/0000-0003-0222-6997; Zerr, Andreas/0000-0002-4744-3074				BOEHLER R, 1994, SCIENCE, V264, P280, DOI 10.1126/science.264.5156.280; Boehler R., 1992, HIGH PRESSURE RES AP, P55; CAMPBELL AJ, 1992, GEOPHYS RES LETT, V19, P1061, DOI 10.1029/92GL00972; Chopelas A, 1996, PHYS EARTH PLANET IN, V98, P3, DOI 10.1016/S0031-9201(96)03175-5; Chopelas A, 1992, HIGH PRESSURE RES AP, P101; Chopelas A., 1996, SPECIAL PUBLICATION, V5, P229; Dubrovinsky LS, 1997, NATURE, V388, P362, DOI 10.1038/41066; Fei YW, 1996, J GEOPHYS RES-SOL EA, V101, P11525, DOI 10.1029/96JB00408; FUNAMORI N, 1993, GEOPHYS RES LETT, V20, P387, DOI 10.1029/92GL02960; GLASS AM, 1967, J CHEM PHYS, V46, P2080, DOI 10.1063/1.1841004; HEINZ DL, 1987, J GEOPHYS RES-SOLID, V92, P11437, DOI 10.1029/JB092iB11p11437; KINGMA KJ, 1995, NATURE, V374, P243, DOI 10.1038/374243a0; KNITTLE E, 1987, SCIENCE, V235, P668, DOI 10.1126/science.235.4789.668; Mao HK, 1997, SCIENCE, V278, P2098, DOI 10.1126/science.278.5346.2098; MEADE C, 1995, SCIENCE, V268, P1743, DOI 10.1126/science.268.5218.1743; Saxena SK, 1996, SCIENCE, V274, P1357, DOI 10.1126/science.274.5291.1357; Serghiou G, 1998, PHYS CHEM MINER, V25, P193, DOI 10.1007/s002690050102; SLACK GA, 1985, J PHYS C SOLID STATE, V18, P3957, DOI 10.1088/0022-3719/18/20/021	18	75	82	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2093	2095		10.1126/science.280.5372.2093	http://dx.doi.org/10.1126/science.280.5372.2093			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641909				2022-12-28	WOS:000074435900037
J	Wang, ZY; Tobin, EM				Wang, ZY; Tobin, EM			Constitutive expression of the CIRCADIAN CLOCK ASSOCIATED 1 (CCA1) gene disrupts circadian rhythms and suppresses its own expression	CELL			English	Article							ARABIDOPSIS; PLANTS; PHYTOCHROME; FREQUENCY; PROTEINS; PROMOTER; INCREASE; WHEAT	The CIRCADIAN CLOCK ASSOCIATED 1 (CCA1) gene encodes a MYB-related transcription factor involved in the phytochrome induction of a light-harvesting chlorophyll alb-protein (Lhcb) gene. Expression of the CCA1 gene is transiently induced by phytochrome and oscillates with a circadian rhythm. Constitutive expression of CCA1 protein in transgenic plants abolished the circadian rhythm of several genes with dramatically different phases. These plants also had longer hypocotyls and delayed flowering, developmental processes regulated by light and the circadian clock. Furthermore, the expression of both endogenous CCA1 and the related LHY gene was suppressed. Our results suggest that CCA1 is a part of a feedback loop that is closely associated with the circadian clock in Arabidopsis.	Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Tobin, EM (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.		Rosa, Bruce/F-6393-2010; Wang, Zhi-Yong/E-3810-2012	Wang, Zhi-Yong/0000-0003-4602-3390	NIGMS NIH HHS [GM-23167] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023167] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson S, 1996, TRENDS PLANT SCI, V1, P51, DOI 10.1016/S1360-1385(96)80029-X; Anderson SL, 1997, PLANT CELL, V9, P1727, DOI 10.1105/tpc.9.10.1727; ANDERSON SL, 1995, P NATL ACAD SCI USA, V92, P1500, DOI 10.1073/pnas.92.5.1500; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Bunning E., 1936, BER DEUT BOT GES, V54, P590, DOI DOI 10.1038/424033A; CARPENTER CD, 1994, PLANT PHYSIOL, V104, P1015, DOI 10.1104/pp.104.3.1015; Carre IA, 1995, PLANT CELL, V7, P2039, DOI 10.2307/3870149; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DAMERVAL C, 1986, ELECTROPHORESIS, V7, P52, DOI 10.1002/elps.1150070108; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Harlow E., 1988, ANTIBODIES LAB MANUA; Heintzen C, 1997, P NATL ACAD SCI USA, V94, P8515, DOI 10.1073/pnas.94.16.8515; Hicks KA, 1996, SCIENCE, V274, P790, DOI 10.1126/science.274.5288.790; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; Johnson Carl Hirschie, 1994, Seminars in Cell Biology, V5, P355, DOI 10.1006/scel.1994.1042; KAY SA, 1995, CELL, V83, P361, DOI 10.1016/0092-8674(95)90113-2; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KENIGSBUCH D, 1995, PLANT PHYSIOL, V108, P1023, DOI 10.1104/pp.108.3.1023; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kolar C, 1998, PLANT J, V13, P563, DOI 10.1046/j.1365-313X.1998.00048.x; Kreps JA, 1997, PLANT CELL, V9, P1235, DOI 10.1105/tpc.9.7.1235; LECHARNY A, 1984, PHYSIOL PLANTARUM, V60, P437, DOI 10.1111/j.1399-3054.1984.tb06089.x; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; MCCLUNG CR, 1994, ARABIDOPSIS THALIANA, P615; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; Millar AJ, 1996, P NATL ACAD SCI USA, V93, P15491, DOI 10.1073/pnas.93.26.15491; Millar AJ, 1997, BIOESSAYS, V19, P209, DOI 10.1002/bies.950190306; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; NAGY F, 1993, P NATL ACAD SCI USA, V90, P6290, DOI 10.1073/pnas.90.13.6290; PIECHULLA B, 1993, PLANT MOL BIOL, V22, P533, DOI 10.1007/BF00015982; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; Somers DE, 1998, DEVELOPMENT, V125, P485; Stirland JA, 1996, P ROY SOC B-BIOL SCI, V263, P345, DOI 10.1098/rspb.1996.0053; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thomas B., 1997, PHOTOPERIODISM PLANT; Wang ZY, 1997, PLANT CELL, V9, P491, DOI 10.1105/tpc.9.4.491; Zagotta MT, 1996, PLANT J, V10, P691, DOI 10.1046/j.1365-313X.1996.10040691.x; ZENG H, 1997, NATURE, V380, P129; Zhong HH, 1997, PLANT CELL, V9, P947, DOI 10.1105/tpc.9.6.947; Zhong HH, 1996, MOL GEN GENET, V251, P196	45	739	794	4	124	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1207	1217		10.1016/S0092-8674(00)81464-6	http://dx.doi.org/10.1016/S0092-8674(00)81464-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657153	Bronze			2022-12-28	WOS:000074491100015
J	Brown, SK; Shalita, AR				Brown, SK; Shalita, AR			Acne vulgaris	LANCET			English	Article							INFLAMMATORY ACNE; BENZOYL PEROXIDE; RESISTANT PROPIONIBACTERIA; PHARMACOLOGICAL PROPERTIES; ISOTRETINOIN TREATMENT; THERAPEUTIC EFFICACY; TOPICAL ERYTHROMYCIN; SKIN DISORDERS; MULTICENTER; MINOCYCLINE		SUNY Hlth Sci Ctr, Dept Dermatol, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Shalita, AR (corresponding author), SUNY Hlth Sci Ctr, Dept Dermatol, 450 Clarkson Ave,Box 46, Brooklyn, NY 11203 USA.							BLAIR C, 1970, BRIT J DERMATOL, V82, P572, DOI 10.1111/j.1365-2133.1970.tb06098.x; BNALEY DJ, 1976, ARCH DERMATOL, V112, P971; BULENGORANSBY SM, 1993, NEW ENGL J MED, V328, P1438, DOI 10.1056/NEJM199305203282002; BURKE B, 1983, BRIT J DERMATOL, V108, P199, DOI 10.1111/j.1365-2133.1983.tb00063.x; CHALKER DK, 1987, J AM ACAD DERMATOL, V17, P251, DOI 10.1016/S0190-9622(87)70200-X; CHALKER DK, 1983, J AM ACAD DERMATOL, V9, P933, DOI 10.1016/S0190-9622(83)70211-2; COLVER GB, 1988, BRIT J DERMATOL, V118, P95, DOI 10.1111/j.1365-2133.1988.tb01756.x; Cunliffe W J, 1989, Acta Derm Venereol Suppl (Stockh), V143, P31, DOI 10.2340/000155551433134; CUNLIFFE WJ, 1981, ACTA DERM-VENEREOL, V61, P267; CUNLIFFE WJ, 1979, BRIT MED J, V1, P1109, DOI 10.1136/bmj.1.6171.1109; CUNLIFFE WJ, 1987, J AM ACAD DERMATOL, V16, P591, DOI 10.1016/S0190-9622(87)70079-6; DRAKE LY, 1990, J AM ACAD DERMATOL, V22, P676, DOI 10.1016/S0190-9622(08)81045-6; EADY EA, 1989, BRIT J DERMATOL, V121, P51, DOI 10.1111/j.1365-2133.1989.tb01399.x; EADY EA, 1993, BRIT MED J, V306, P555, DOI 10.1136/bmj.306.6877.555; EADY EA, 1988, BRIT J DERMATOL, V118, P415, DOI 10.1111/j.1365-2133.1988.tb02437.x; FITTON A, 1991, DRUGS, V41, P780, DOI 10.2165/00003495-199141050-00007; FREEMAN K, 1989, BRIT J CLIN PRACT, V43, P112; GAMMON WR, 1986, J AM ACAD DERMATOL, V14, P183, DOI 10.1016/S0190-9622(86)70019-4; GOODFELLOW A, 1984, BRIT J DERMATOL, V111, P209, DOI 10.1111/j.1365-2133.1984.tb04045.x; Gough A, 1996, BRIT MED J, V312, P169; GOULDEN V, 1994, BRIT J DERMATOL, V131, P360, DOI 10.1111/j.1365-2133.1994.tb08524.x; HABIF T, 1996, ACNE ROSACEA RELATED, P162; HANSTED B, 1982, DERMATOLOGICA, V164, P117, DOI 10.1159/000250077; HARMS M, 1986, DERMATOLOGICA, V172, P148, DOI 10.1159/000249320; HEALY E, 1994, BRIT MED J, V308, P831, DOI 10.1136/bmj.308.6932.831; HERSLE K, 1972, DERMATOLOGICA, V145, P187, DOI 10.1159/000252042; HUBBELL CG, 1982, ARCH DERMATOL, V118, P989, DOI 10.1001/archderm.118.12.989; HUGHES BR, 1989, BRIT J DERMATOL, V121, P623, DOI 10.1111/j.1365-2133.1989.tb08194.x; Jansen T, 1997, Eur J Med Res, V2, P321; KARMINER MS, 1995, J AM ACAD DERMATOL, V32, pS6; KNUTSON DD, 1974, J INVEST DERMATOL, V62, P288, DOI 10.1111/1523-1747.ep12676804; KOO J, 1995, J AM ACAD DERMATOL, V32, pS26, DOI 10.1016/0190-9622(95)90417-4; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LEVER L, 1990, DRUGS, V39, P681, DOI 10.2165/00003495-199039050-00005; LEVINE RM, 1983, ARCH DERMATOL, V119, P480, DOI 10.1001/archderm.119.6.480; LEYDEN JJ, 1975, J INVEST DERMATOL, V65, P382, DOI 10.1111/1523-1747.ep12607634; LEYDEN JJ, 1995, J AM ACAD DERMATOL, V32, pS15, DOI 10.1016/0190-9622(95)90416-6; Leyden JJ, 1997, NEW ENGL J MED, V336, P1156, DOI 10.1056/NEJM199704173361607; LEYDEN JJ, 1982, ARCH DERMATOL, V118, P19, DOI 10.1001/archderm.118.1.19; LEYDEN JJ, 1980, ACTA DERM-VENEREOL, P75; LEYDEN JJ, 1988, J AM ACAD DERMATOL, V19, P164, DOI 10.1016/S0190-9622(88)70160-7; LEYDEN JJ, 1986, J AM ACAD DERMATOL, V15, P907, DOI 10.1016/S0190-9622(86)70250-8; LUCKY AW, 1995, AM J MED, V98, pS89, DOI 10.1016/S0002-9343(99)80064-3; LUCKY AW, 1983, J INVEST DERMATOL, V81, P70, DOI 10.1111/1523-1747.ep12539043; MAIBACH H, 1991, CUTIS, V48, P411; MILLS OH, 1986, INT J DERMATOL, V25, P664, DOI 10.1111/j.1365-4362.1986.tb04534.x; MORELLO AM, 1976, J INVEST DERMATOL, V66, P319, DOI 10.1111/1523-1747.ep12482300; NGUYEN QH, 1994, AM FAM PHYSICIAN, V50, P89; POCHI PE, 1964, J INVEST DERMATOL, V43, P383, DOI 10.1038/jid.1964.169; POCHI PE, 1965, J CLIN ENDOCR METAB, V51, P287; POULOS ET, 1976, ARCH DERMATOL, V112, P974, DOI 10.1001/archderm.112.7.974; PUHVEL SM, 1978, J INVEST DERMATOL, V71, P324, DOI 10.1111/1523-1747.ep12529815; Redmond GP, 1997, OBSTET GYNECOL, V89, P615, DOI 10.1016/S0029-7844(97)00059-8; REISNER RM, 1983, DERMATOL CLIN, V1, P385, DOI 10.1016/S0733-8635(18)31026-X; Rothman K F, 1993, Adv Dermatol, V8, P347; ROTHMAN KF, 1988, J AM ACAD DERMATOL, V19, P431, DOI 10.1016/S0190-9622(88)70195-4; Shalita A, 1996, J AM ACAD DERMATOL, V34, P482, DOI 10.1016/S0190-9622(96)90443-0; SHALITA A R, 1987, Dermatologica (Basel), V175, P151; SHALITA AR, 1995, INT J DERMATOL, V34, P434, DOI 10.1111/j.1365-4362.1995.tb04449.x; SHALITA AR, 1984, ARCH DERMATOL, V120, P351, DOI 10.1001/archderm.1984.01650390073015; SHALITA AR, 1983, DERMATOL CLIN, V1, P399, DOI 10.1016/S0733-8635(18)31027-1; SHALITA AR, 1983, J AM ACAD DERMATOL, V9, P629, DOI 10.1016/S0190-9622(83)70176-3; SHALITA AR, 1981, CUTIS, V28, P556; SHALITA AR, 1983, DERMATOL CLIN, V1, P361, DOI 10.1016/S0733-8635(18)31022-2; Shaw JC, 1996, DERMATOL CLIN, V14, P803, DOI 10.1016/S0733-8635(05)70405-8; SHAW JC, 1991, J AM ACAD DERMATOL, V24, P236, DOI 10.1016/0190-9622(91)70034-Y; SMIT F, 1978, DERMATOLOGICA, V157, P186, DOI 10.1159/000250830; STERN RS, 1984, J AM ACAD DERMATOL, V10, P851, DOI 10.1016/S0190-9622(84)80142-5; STRAUSS JS, 1984, J AM ACAD DERMATOL, V10, P490, DOI 10.1016/S0190-9622(84)80100-0; Thiboutot DM, 1997, DERMATOL CLIN, V15, P97, DOI 10.1016/S0733-8635(05)70418-6; TUCKER SB, 1984, BRIT J DERMATOL, V110, P487, DOI 10.1111/j.1365-2133.1984.tb04664.x; VOWELS BR, 1995, INFECT IMMUN, V63, P3158, DOI 10.1128/IAI.63.8.3158-3165.1995; WARD A, 1984, DRUGS, V28, P6, DOI 10.2165/00003495-198428010-00002; Webster G.F., 1996, CURR PROBL DERMATOL, V8, P237; Weiss JS, 1997, PEDIATR DERMATOL, V14, P480, DOI 10.1111/j.1525-1470.1997.tb00696.x; YONKOSKY DM, 1986, DERMATOL CLIN, V4, P127, DOI 10.1016/S0733-8635(18)30851-9	76	92	100	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 20	1998	351	9119					1871	1876		10.1016/S0140-6736(98)01046-0	http://dx.doi.org/10.1016/S0140-6736(98)01046-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652685				2022-12-28	WOS:000074347100042
J	Goedert, JJ; Cote, TR; Virgo, P; Scoppa, SM; Kingma, DW; Gail, MH; Jaffe, ES; Biggar, RJ				Goedert, JJ; Cote, TR; Virgo, P; Scoppa, SM; Kingma, DW; Gail, MH; Jaffe, ES; Biggar, RJ		AIDS-Canc Match Study Grp	Spectrum of AIDS-associated malignant disorders	LANCET			English	Article							EPSTEIN-BARR-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; TESTICULAR CANCER; HODGKINS-DISEASE; LYMPHOMAS; INFECTION; TUMOR; RISK	Background To clarify which types of cancer result from AIDS, we compared the cancer experiences of people with AIDS with those of the general population by matching population-based cancer and AIDS registries in the USA and Puerto Rico. Methods We used a probabilistic matching algorithm to compare names, birth dates, and, where available, social-security numbers of 98 336 people with AIDS and 1 125 098 people with cancer aged less than 70 years. We defined AIDS-related cancers as those with both significantly raised incidence post-AIDS and increasing prevalence from 5 years pre-AIDS to 2 years post-AIDS. Findings Among people with AIDS, we found 7028 cases of Kaposi's sarcoma (KS), 1793 of non-Hodgkin lymphoma (NHL), and 712 other cases of histologically defined cancer. Incidence rates among people with AIDS were increased 310-fold for KS, 113-fold for NHL, and l.9-fold (95% CI 1.5-2.3) for other cancers. Of 38 malignant disorders other than KS and NHL, only angiosarcoma (36.7-fold), Hodgkin's disease (7.6-fold), multiple myeloma (4.5-fold), brain cancer (3.5-fold), and seminoma (2.9-fold) were raised and increasing significantly (p<0.02) from the pre-AIDS to the post-AIDS period. Interpretation Interpretation is complicated by screening and shared risk factors, such as sexual behaviour and cigarette smoking. However, our data indicate that AIDS leads to a significantly increased risk of Hodgkin's disease, multiple myeloma, brain cancer, and seminoma. Immunological failure to control herpes or other viral infections may contribute to these malignant diseases.	NCI, Viral Epidemiol Branch, Rockville, MD USA; NCI, Pathol Lab, Bethesda, MD 20892 USA; Comp Sci Corp, Rockville, MD USA; Informat Management Serv Inc, Silver Spring, MD USA; NCI, Biostat Branch, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Information Management Services, Inc.; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Goedert, JJ (corresponding author), 6130 Execut Blvd,Suite 434, Rockville, MD 20852 USA.		Jaffe, Elaine/G-8981-2014		NCI NIH HHS [N01-CP-40514, YO1-CP-0003-01, N01-CP-40521] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMMANN AJ, 1993, J ACQ IMMUN DEF SYND, V6, P1224; [Anonymous], 1996, IARC MON EV CARC RIS; ARTHUR RR, 1994, J NEURO-ONCOL, V20, P55, DOI 10.1007/BF01057961; Bataille R, 1997, NEW ENGL J MED, V336, P1657, DOI 10.1056/NEJM199706053362307; BIGGAR RJ, 1994, AM J EPIDEMIOL, V139, P362, DOI 10.1093/oxfordjournals.aje.a117008; Biggar RJ, 1996, INT J CANCER, V68, P754; *CDCP, 1996, HIV AIDS SURV REP, V8, P18; COTE TR, 1995, PREV MED, V24, P375, DOI 10.1006/pmed.1995.1061; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; DAY NE, 1984, BIOMETRICS, V40, P1, DOI 10.2307/2530739; DICTOR M, 1988, INT J CANCER, V42, P346, DOI 10.1002/ijc.2910420307; Fizazi K, 1996, EUR J CANCER, V32A, P1812, DOI 10.1016/0959-8049(96)00167-0; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GOEDERT JJ, 1995, LANCET, V346, P257, DOI 10.1016/S0140-6736(95)91309-2; HEINZER H, 1993, EUR UROL, V24, P271; *IARC, 1998, IARC MON EV CARC RIS, V70; *IARC, 1995, IARC MON EV CARC RIS, V64; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kingma DW, 1996, AM J SURG PATHOL, V20, P1511, DOI 10.1097/00000478-199612000-00011; KINGMA DW, 1994, AM J SURG PATHOL, V18, P48, DOI 10.1097/00000478-199401000-00005; KINLEN LJ, 1996, CANC EPIDEMIOLOGY PR, P532; LONDON WT, 1996, CANC EPIDEMIOLOGY PR, P772; LYTER DW, 1995, J CLIN ONCOL, V13, P2540, DOI 10.1200/JCO.1995.13.10.2540; LYTER DW, 1996, P AM SOC CLIN ONCOL, V15, P852; MCCLAIN KL, 1995, NEW ENGL J MED, V332, P12, DOI 10.1056/NEJM199501053320103; MELBYE M, 1994, LANCET, V343, P636, DOI 10.1016/S0140-6736(94)92636-0; Melbye M, 1996, BRIT J CANCER, V73, P995, DOI 10.1038/bjc.1996.194; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; MUELLER N, 1988, INT J CANCER, V41, P399, DOI 10.1002/ijc.2910410314; Mueller NE, 1996, CANC EPIDEMIOLOGY PR, P893; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Parravicini C, 1997, SCIENCE, V278, P1969, DOI 10.1126/science.278.5345.1969; Percy C., 1990, INT CLASSIFICATION D; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; Ries L, 1994, NIH PUBLICATION, V94-2789; YU MC, 1996, CANC EPIDEMIOLOGY PR, P603	37	530	544	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1833	1839		10.1016/S0140-6736(97)09028-4	http://dx.doi.org/10.1016/S0140-6736(97)09028-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652666				2022-12-28	WOS:000074347100009
J	Ott, A; Slooter, AJC; Hofman, A; van Harskamp, F; Witteman, JCM; Van Broeckhoven, C; van Duijn, CM; Breteler, MMB				Ott, A; Slooter, AJC; Hofman, A; van Harskamp, F; Witteman, JCM; Van Broeckhoven, C; van Duijn, CM; Breteler, MMB			Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study	LANCET			English	Article							VASCULAR DEMENTIA; CIGARETTE-SMOKING; BLOOD-PRESSURE; MENTAL STATE; ASSOCIATION; DIAGNOSIS	Background Previous studies suggested a protective effect of smoking on Alzheimer's disease, but most were case-control studies based on prevalent cases. The findings of prospective studies on the association between smoking and the risk of dementia are inconclusive. Methods We did a population-based follow-up study of elderly people who were initially free of dementia. 6870 people aged 55 years and older agreed to take part. Smoking history was taken at baseline and participants were classified as never smokers, former smokers, and current smokers. During follow-up, we recorded all incident cases of dementia, We used never smokers as the reference category to calculate relative risks of dementia and Alzheimer's disease by Cox proportional hazards regression, after adjustment for age, sex, education, and alcohol intake. We also examined modification of risk by age, sex, and the apolipoprotein E (APOE) genotype. Findings During mean follow-up of 2.1 (range 1.5-3.4) years, 146 incident cases of dementia were detected, of which 105 were Alzheimer's disease. Compared with never smokers, smokers had an increased risk of dementia (relative risk 2.2 [95% CI 1.3-3.6]) and Alzheimer's disease (2.3 [1.3-4.1]). Smoking was a strong risk factor for Alzheimer's disease in individuals without the APOE epsilon 4 allele (4.6 [1.5-14.2]), but had no effect in participants with this allele (0.6 [0.1-4.8]). Interpretation Smoking was associated with a doubling of the risk of dementia and Alzheimer's disease. Our finding that carriers of the APOE epsilon 4 had no increased risk of dementia suggests an interaction between smoking and the APOE epsilon 4 genotype in the aetiology of Alzheimer's disease.	Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Sch Med, Dept Neurol, NL-3000 DR Rotterdam, Netherlands; Univ Antwerp VIB, Born Bunge Fdn,Dept Biochem, Neurogenet Lab, B-2020 Antwerp, Belgium	Erasmus University Rotterdam; Erasmus University Rotterdam; Flanders Institute for Biotechnology (VIB); University of Antwerp	Breteler, MMB (corresponding author), Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, POB 1738, NL-3000 DR Rotterdam, Netherlands.	breteler@epib.fgg.eur.nl	Breteler, Monique M.B./J-5058-2014; Van Broeckhoven, Christine/M-7853-2019; Van Broeckhoven, Christine/G-8362-2017	Breteler, Monique M.B./0000-0002-0626-9305; Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BARTECCHI CE, 1994, NEW ENGL J MED, V330, P907, DOI 10.1056/NEJM199403313301307; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; CRUICKSHANK JM, 1989, J HUM HYPERTENS, V3, P443; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Geleijnse JM, 1996, J HYPERTENS, V14, P737, DOI 10.1097/00004872-199606000-00009; GORELICK PB, 1993, ARCH NEUROL-CHICAGO, V50, P714, DOI 10.1001/archneur.1993.00540070034011; HACHINSKI V, 1992, LANCET, V340, P645; HEBERT LE, 1992, AM J EPIDEMIOL, V135, P347, DOI 10.1093/oxfordjournals.aje.a116296; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; LEE PN, 1994, NEUROEPIDEMIOLOGY, V13, P131, DOI 10.1159/000110372; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MEYER JS, 1988, J NEUROL NEUROSUR PS, V51, P1489, DOI 10.1136/jnnp.51.12.1489; Orgogozo JM, 1997, REV NEUROL-FRANCE, V153, P185; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; Ott A, 1998, AM J EPIDEMIOL, V147, P574; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; PRINCE M, 1994, NEUROLOGY, V44, P97; RIGGS JE, 1993, LANCET, V342, P793, DOI 10.1016/0140-6736(93)91547-Y; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; VANDUIJN CM, 1995, BMJ-BRIT MED J, V310, P627, DOI 10.1136/bmj.310.6980.627; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161	29	365	386	1	36	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1840	1843		10.1016/S0140-6736(97)07541-7	http://dx.doi.org/10.1016/S0140-6736(97)07541-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652667				2022-12-28	WOS:000074347100010
J	Schanen, A; Gallou, G; Hincky, JM; Saron, MF				Schanen, A; Gallou, G; Hincky, JM; Saron, MF			A rash, circulating anticoagulant, then meningitis	LANCET			English	Article							VIRUS		Inst Pasteur, Grp Virol Expt, F-75724 Paris 15, France; Ctr Hosp Gen Falalse, Med Serv, F-14700 Falalse, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Saron, MF (corresponding author), Inst Pasteur, Grp Virol Expt, F-75724 Paris 15, France.	mfsaron@pasteur.fr						LEFRERE JJ, 1988, ANN INTERN MED, V108, P771, DOI 10.7326/0003-4819-108-5-771_1; Park JY, 1997, J MED VIROL, V51, P107, DOI 10.1002/(SICI)1096-9071(199702)51:2&lt;107::AID-JMV4&gt;3.0.CO;2-B; Rousseau MC, 1997, EUR J EPIDEMIOL, V13, P817, DOI 10.1023/A:1007434521082; Violi F, 1997, HEPATOLOGY, V25, P782, DOI 10.1002/hep.510250354; YAMAZAKI M, 1991, BLOOD COAGUL FIBRIN, V2, P771, DOI 10.1097/00001721-199112000-00012	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1856	1856		10.1016/S0140-6736(98)02207-7	http://dx.doi.org/10.1016/S0140-6736(98)02207-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652671				2022-12-28	WOS:000074347100014
J	Gennis, RB				Gennis, RB			Protein structure - Cytochrome c oxidase: One enzyme, two mechanisms?	SCIENCE			English	Editorial Material							UBIQUINOL OXIDASE; ESCHERICHIA-COLI; PROTON-TRANSFER; 2.8 ANGSTROM; SUBUNIT-I; TRANSLOCATION; SUPERFAMILY; OXYGEN; MODEL; BO(3)		Univ Illinois, Sch Chem Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Gennis, RB (corresponding author), Univ Illinois, Sch Chem Sci, Urbana, IL 61801 USA.	Gennis@aries.scs.uiuc.edu						Adelroth P, 1997, BIOCHEMISTRY-US, V36, P13824, DOI 10.1021/bi9629079; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; CALHOUN MW, 1994, TRENDS BIOCHEM SCI, V19, P325, DOI 10.1016/0968-0004(94)90071-X; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; GARCIAHORSMAN JA, 1995, BIOCHEMISTRY-US, V34, P4428, DOI 10.1021/bi00013a035; Gutman M, 1997, ANNU REV PHYS CHEM, V48, P329, DOI 10.1146/annurev.physchem.48.1.329; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Moody AJ, 1996, BBA-BIOENERGETICS, V1276, P6; MORGAN JE, 1994, J BIOENERG BIOMEMBR, V26, P599, DOI 10.1007/BF00831534; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; PAPADOPOULOS PG, 1991, BIOCHEMISTRY-US, V30, P840, DOI 10.1021/bi00217a038; Pomes R, 1996, J PHYS CHEM-US, V100, P2519, DOI 10.1021/jp9525752; Riistama S, 1997, FEBS LETT, V414, P275, DOI 10.1016/S0014-5793(97)01003-X; SvenssonEk M, 1996, BIOCHEMISTRY-US, V35, P13673, DOI 10.1021/bi961466q; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Verkhovskaya ML, 1997, P NATL ACAD SCI USA, V94, P10128, DOI 10.1073/pnas.94.19.10128; Watmough NJ, 1997, BIOCHEMISTRY-US, V36, P13736, DOI 10.1021/bi971434i; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	22	37	37	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1712	1713		10.1126/science.280.5370.1712	http://dx.doi.org/10.1126/science.280.5370.1712			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9660711				2022-12-28	WOS:000074197800029
J	Hook, EW				Hook, EW			Is elimination of endemic syphilis transmission a realistic goal for the USA?	LANCET			English	Article							SEXUALLY-TRANSMITTED DISEASES; AZITHROMYCIN; POPULATIONS		Univ Alabama, Sch Med, Birmingham, AL 35294 USA; Univ Alabama, Sch Publ Hlth, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Hook, EW (corresponding author), Univ Alabama, Sch Med, 229 Tinsley Harrison Tower,1900 Univ Blvd, Birmingham, AL 35294 USA.							ANTAL G M, 1986, Southeast Asian Journal of Tropical Medicine and Public Health, V17, P1; Brandt Allan M, 1985, NO MAGIC BULLET SOCI; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P28; CUMBERLAND MARY C, 1949, AMER JOUR SYPHILIS GONORRHEA AND VENEREAL DIS, V33, P201; *DIV STD PREV, 1997, SEX TRANSM DIS SURV, P21; Eng TR, 1997, HIDDEN EPIDEMIC CONF, P28; Gunn RA, 1998, JAMA-J AM MED ASSOC, V279, P680, DOI 10.1001/jama.279.9.680; John St RK, 1984, HDB ENDEMIC TREPONEM; LUKEHART SA, 1990, J ANTIMICROB CHEMOTH, V25, P91, DOI 10.1093/jac/25.suppl_A.91; MORAN JS, 1989, PUBLIC HEALTH REP, V104, P560; PARRAN T, 1937, SHADOW LAND; PIOT P, 1994, SEX TRANSM DIS, V21, pS7; TOOMEY KE, 1993, INFECT DIS CLIN N AM, V7, P739; VERDON MS, 1994, CLIN INFECT DIS, V19, P486, DOI 10.1093/clinids/19.3.486	14	20	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN	1998	351			3			19	21						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV844	9652716				2022-12-28	WOS:000074347300007
J	Cooper, A; Spencer, C; Whitehead, MI; Ross, D; Barnard, GJR; Collins, WP				Cooper, A; Spencer, C; Whitehead, MI; Ross, D; Barnard, GJR; Collins, WP			Systemic absorption of progesterone from Progest cream in postmenopausal women	LANCET			English	Article							ORAL PROGESTERONE		Univ London Kings Coll Hosp, Menopause Clin, London SE5 8RX, England; Churchill Clin, Amarant Trust, London, England; Southampton Univ Hosp Trust, Dept Chem Pathol, Endocrine Unit, Southampton, Hants, England; Univ London Kings Coll, Sch Med & Dent, Acad Dept Obstet & Gynaecol, London, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of London; King's College London	Whitehead, MI (corresponding author), Univ London Kings Coll Hosp, Menopause Clin, Denmark Hill, London SE5 8RX, England.							KESNER JS, 1994, STEROIDS, V59, P205, DOI 10.1016/0039-128X(94)90029-9; LANE G, 1983, BRIT MED J, V287, P1241, DOI 10.1136/bmj.287.6401.1241; Lee J.R., 1990, INT CLIN NUTR REV, V10, P384; PADWICK ML, 1986, FERTIL STERIL, V46, P402	4	47	67	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1255	1256		10.1016/S0140-6736(05)79323-5	http://dx.doi.org/10.1016/S0140-6736(05)79323-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643756				2022-12-28	WOS:000073283600022
J	Saad, Z; Bramwell, VHC; Wilson, SM; O'Malley, FP; Jeacock, J; Chambers, AF				Saad, Z; Bramwell, VHC; Wilson, SM; O'Malley, FP; Jeacock, J; Chambers, AF			Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases	LANCET			English	Article							EXTRACELLULAR-MATRIX; PREMENOPAUSAL WOMEN; CATHEPSIN-L; CYCLE; SURGERY; CELLS; DEGRADATION; SURVIVAL; ACID	Background Retrospective studies show significant improvements in survival among women who had breast cancer resected during the luteal phase of their menstrual cycle compared with the follicular phase. We hypothesised that tumour tissue would show cyclical changes in expression of genes whose products might contribute to metastatic potential. Methods We studied 32 premenopausal women with operable breast cancer. We assayed hormones to define more accurately the menstrual phase during which surgery was done. We used northern blot analysis of RNA from fresh-frozen tumour specimens to study the patterns of expression of genes for proteolytic enzymes (cysteine proteinase cathepsin L and aspartyl proteinase cathepsin D; matrix metalloproteinases MMP-9 and MMP-2), tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2, and TP53. Results There was a significantly higher level of expression of RNA for cathepsin L, MMP-9, and TP53 (p=0.005, 0.03, 0.03, respectively) in tumours that were resected during the follicular and periovulatory phases of the menstrual cycle than at other times in the cycle. A similar but nonsignificant trend was seen for MMP-2 and cathepsin D. A non-significant trend in the opposite direction was seen for TIMP-1 and TIMP-2. Interpretation We found that tumour expression of genes that may contribute to proliferative capacity and metastatic potential can change in breast cancer during the course of the menstrual cycle. The finding could provide a molecular explanation for the reports of improved survival in some breast-cancer patients whose tumours were removed during the luteal phase of the menstrual cycle. Larger studies are required to extend our study, assess mechanisms of gene regulation, and verify any relevant influence in long-term survival.	London Reg Canc Ctr, London, ON N6A 4L6, Canada; London Hlth Sci Ctr, London, ON, Canada; Univ Manchester, Sch Nursing, Manchester, Lancs, England	Western University (University of Western Ontario); London Health Sciences Centre; University of Manchester	Saad, Z (corresponding author), Hope Hosp, Stott Lane, Salford M6 8HD, Lancs, England.		Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123; Winstanley, Julie/0000-0002-9353-6757				AUGEREAU P, 1988, MOL ENDOCRINOL, V2, P186, DOI 10.1210/mend-2-2-186; BADWE RA, 1991, LANCET, V337, P1261, DOI 10.1016/0140-6736(91)92927-T; BRIOZZO P, 1988, CANCER RES, V48, P3688; CHAMBERS AF, 1992, MOL CARCINOGEN, V5, P238, DOI 10.1002/mc.2940050311; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; FERGUSON JE, 1992, CELL TISSUE RES, V268, P167, DOI 10.1007/BF00338066; Hrushesky W., 1996, Breast Cancer Research and Treatment, V41, P272; HRUSHESKY WJM, 1989, LANCET, V2, P949; JARVIS PM, 1980, ANN NY ACAD SCI, V464, P152; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; LEIS HP, 1991, BREAST, P331; LEVINE M, 1996, P AN M AM SOC CLIN, V15, P99; MARBAIX E, 1992, P NATL ACAD SCI USA, V89, P11789, DOI 10.1073/pnas.89.24.11789; POWLES TJ, 1991, LANCET, V337, P1604; PRICE JE, 1990, CANCER RES, V50, P717; RADVIN PM, 1993, BREAST CANC RES TREA, V24, P219; RAGETH JC, 1991, ANN ONCOL, V2, P269, DOI 10.1093/oxfordjournals.annonc.a057935; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; SAAD Z, 1994, BRIT J SURG, V81, P217, DOI 10.1002/bjs.1800810219; SAINSBURY R, 1991, LANCET, V338, P391; SENIE RT, 1991, ANN INTERN MED, V115, P337, DOI 10.7326/0003-4819-115-5-337; SORSDAHL K, 1994, CANCER DETECT PREV, V18, P179; Thomssen C, 1995, CLIN CANCER RES, V1, P741; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; VERONESI U, 1994, LANCET, V343, P1544	27	38	41	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1170	1173		10.1016/S0140-6736(97)07498-9	http://dx.doi.org/10.1016/S0140-6736(97)07498-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643688				2022-12-28	WOS:000073220200010
J	Di Bisceglie, AM				Di Bisceglie, AM			Hepatitis C	LANCET			English	Article							NON-B-HEPATITIS; RECOMBINANT INTERFERON-ALFA; PLACEBO-CONTROLLED TRIAL; HUMAN ALPHA-INTERFERON; TERM FOLLOW-UP; CHRONIC NON-A; VIRUS-INFECTION; POSTTRANSFUSION HEPATITIS; LIVER-DISEASE; SUSTAINED RESPONSE		St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO 63104 USA	Saint Louis University	Di Bisceglie, AM (corresponding author), St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO 63104 USA.							ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; ALTER HJ, 1995, J VIRAL HEPATITIS, V2, P121, DOI 10.1111/j.1365-2893.1995.tb00017.x; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; [Anonymous], 1997, HEPATOLOGY, V26, pS2; Arthur RR, 1997, T ROY SOC TROP MED H, V91, P271, DOI 10.1016/S0035-9203(97)90070-5; Bennett WG, 1997, ANN INTERN MED, V127, P855, DOI 10.7326/0003-4819-127-10-199711150-00001; Bresee JS, 1996, JAMA-J AM MED ASSOC, V276, P1563, DOI 10.1001/jama.276.19.1563; BRESTERS D, 1993, LANCET, V342, P210, DOI 10.1016/0140-6736(93)92300-I; BRILLANTI S, 1994, GASTROENTEROLOGY, V107, P812, DOI 10.1016/0016-5085(94)90131-7; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; Chemello L, 1996, ANN INTERN MED, V124, P1058, DOI 10.7326/0003-4819-124-12-199606150-00005; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; DAVIDSON F, 1995, J GEN VIROL, V76, P1197, DOI 10.1099/0022-1317-76-5-1197; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DECASTRO M, 1993, HEPATOLOGY, V17, P551, DOI 10.1002/hep.1840170405; DEMEDINA M, 1995, SEMIN LIVER DIS, V15, P33, DOI 10.1055/s-2007-1007261; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DIBISCEGLIE AM, 1995, ANN INTERN MED, V123, P897, DOI 10.7326/0003-4819-123-12-199512150-00001; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DiBisceglie AM, 1997, HEPATOLOGY, V26, pS34, DOI 10.1002/hep.510260706; ESTEBAN JI, 1989, LANCET, V2, P294; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; FEINMAN SV, 1988, GASTROENTEROLOGY, V95, P464, DOI 10.1016/0016-5085(88)90505-7; FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1016/0270-9139(94)90748-X; GOODMAN ZD, 1995, SEMIN LIVER DIS, V15, P70, DOI 10.1055/s-2007-1007264; GRETCH DR, 1995, ANN INTERN MED, V123, P321, DOI 10.7326/0003-4819-123-5-199509010-00001; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; LAU JYN, 1993, LANCET, V342, P1208, DOI 10.1016/0140-6736(93)92187-X; LEE SR, 1995, TRANSFUSION, V35, P845, DOI 10.1046/j.1537-2995.1995.351096026366.x; LIN R, 1995, J HEPATOL, V23, P487, DOI 10.1016/0168-8278(95)80052-2; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; MAHANEY K, 1994, HEPATOLOGY, V20, P1405, DOI 10.1002/hep.1840200605; MARCELLIN P, 1991, HEPATOLOGY, V13, P393, DOI 10.1002/hep.1840130302; MARCELLIN P, 1994, LIVER, V14, P302; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; NOLTE FS, 1995, J CLIN MICROBIOL, V33, P1775, DOI 10.1128/JCM.33.7.1775-1778.1995; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; PEREIRA BJG, 1992, NEW ENGL J MED, V327, P910, DOI 10.1056/NEJM199209243271302; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; Poynard T, 1996, HEPATOLOGY, V24, P778; REICHARD O, 1994, HEPATOLOGY, V19, P280; Reichard O, 1998, LANCET, V351, P83, DOI 10.1016/S0140-6736(97)06088-1; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHAKIL AO, 1995, ANN INTERN MED, V123, P330, DOI 10.7326/0003-4819-123-5-199509010-00002; SHINDO M, 1992, J INFECT DIS, V166, P424, DOI 10.1093/infdis/166.2.424; SHINDO M, 1992, HEPATOLOGY, V15, P1013, DOI 10.1002/hep.1840150607; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; Silini E, 1996, GASTROENTEROLOGY, V111, P199, DOI 10.1053/gast.1996.v111.pm8698200; SILVA AE, 1994, AM J GASTROENTEROL, V89, P493; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; TSUBOTA A, 1994, HEPATOLOGY, V19, P1088, DOI 10.1016/0270-9139(94)90854-0; YAMADA G, 1995, HEPATOLOGY, V22, P1351, DOI 10.1002/hep.1840220502; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607	68	331	346	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	1998	351	9099					351	355		10.1016/S0140-6736(97)07361-3	http://dx.doi.org/10.1016/S0140-6736(97)07361-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652633				2022-12-28	WOS:000071864000043
J	Beecham, L				Beecham, L			Minimum wage will hit NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					151	151						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657813				2022-12-28	WOS:000075081700063
J	Zerr, A; Diegeler, A; Boehler, R				Zerr, A; Diegeler, A; Boehler, R			Solidus of Earth's deep mantle	SCIENCE			English	Article							MELTING TEMPERATURE; HIGH-PRESSURES; PERIDOTITE; CORE	The solidus of a pyrolite-like composition, approximating that of the lower mantle, was measured up to 59 gigapascals by using CO2 laser heating in a diamond anvil. cell. The solidus temperatures are at Least 700 kelvin below the melting temperatures of magnesiowustite, which in the deep mantle has the Lowest melting temperatures of the three major components-magnesiowustite, Mg-Si-perovskite, and Ca-Si-perovskite. The solidus in the deep mantle is more than 1500 kelvin above the average present-day geotherm, but at the core-mantle boundary it is near the core temperature. Thus, partial melting of the mantle is possible at the core-mantle boundary.	Max Planck Inst Chem, D-55020 Mainz, Germany; Univ Koln, Inst Mineral & Geochim, D-50674 Koln, Germany	Max Planck Society; University of Cologne	Zerr, A (corresponding author), Max Planck Inst Chem, Postfach 3060, D-55020 Mainz, Germany.		Boehler, Reinhard/L-3971-2016; Zerr, Andreas/AFV-5252-2022	Boehler, Reinhard/0000-0003-0222-6997; Zerr, Andreas/0000-0002-4744-3074				Boehler R, 1996, PHILOS T R SOC A, V354, P1265, DOI 10.1098/rsta.1996.0048; Boehler R, 1996, ANNU REV EARTH PL SC, V24, P15, DOI 10.1146/annurev.earth.24.1.15; BOEHLER R, 1991, GEOPHYS RES LETT, V18, P1147, DOI 10.1029/91GL01144; BROWN JM, 1981, GEOPHYS J ROY ASTR S, V66, P579, DOI 10.1111/j.1365-246X.1981.tb04891.x; Chopelas A, 1992, HIGH PRESSURE RES AP, P101; Holland KG, 1997, SCIENCE, V275, P1623, DOI 10.1126/science.275.5306.1623; ITO E, 1987, NATURE, V328, P514, DOI 10.1038/328514a0; Ito E., 1992, HIGH PRESSURE RES AP, P315; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; MCMILLAN P, 1989, PHYS CHEM MINER, V16, P428, DOI 10.1007/BF00197012; Ringwood A.E, 1975, COMPOSITION PETROLOG; SERGHIOU G, 1995, GEOPHYS RES LETT, V22, P441, DOI 10.1029/94GL02692; Serghiou G, 1998, PHYS CHEM MINER, V25, P193, DOI 10.1007/s002690050102; Serghiou G, 1998, SCIENCE, V280, P2093, DOI 10.1126/science.280.5372.2093; SHEN GY, 1995, J GEOPHYS RES-SOL EA, V100, P17699, DOI 10.1029/95JB01864; TAKAHASHI E, 1986, J GEOPHYS RES-SOLID, V91, P9367, DOI 10.1029/JB091iB09p09367; Wen LX, 1998, SCIENCE, V279, P1701, DOI 10.1126/science.279.5357.1701; WIESENDANGER R, 1996, SCANNING TUNNELING 3, V29; WIESENDANGER R, 1995, SCANNING TUNNELING 2, V28; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528; Zerr A, 1997, GEOPHYS RES LETT, V24, P909, DOI 10.1029/97GL00829; ZERR A, 1994, NATURE, V371, P506, DOI 10.1038/371506a0; ZERR A, 1993, SCIENCE, V262, P553, DOI 10.1126/science.262.5133.553; Zerr A., 1998, P 5 NIRIM INT S ADVA, P5; ZHA CS, 1986, J CHEM PHYS, V85, P1034, DOI 10.1063/1.451295; ZHANG JZ, 1994, J GEOPHYS RES-SOL EA, V99, P17729, DOI 10.1029/94JB01406	26	165	168	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					243	246		10.1126/science.281.5374.243	http://dx.doi.org/10.1126/science.281.5374.243			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657715				2022-12-28	WOS:000074714200044
J	Lerner, BH				Lerner, BH			Fighting the war on breast cancer: Debates over early detection, 1945 to the present	ANNALS OF INTERNAL MEDICINE			English	Review							LOBULAR CARCINOMA INSITU; IN-SITU; THERAPY; SURGERY		Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University	Lerner, BH (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, Box 11,630 W 168th St, New York, NY 10032 USA.							ALTMAN R, 1996, WAKING FIGHTING BACK, P169; *AM CANC SOC, 1952, P 2 NAT CANC C, V1, P114; ARONOWITZ R, 1995, J GEN INTERN MED, V10, P295, DOI 10.1007/BF02599892; Bailar JC, 1997, NEW ENGL J MED, V336, P1569, DOI 10.1056/NEJM199705293362206; Baum M, 1986, BREAST DIS, P95; BEGLEY S, 1997, NEWSWEEL        0421, P54; BENFIELD JR, 1969, ARCH SURG-CHICAGO, V99, P129; BLACK MEA, 1995, CANCER NURS, V18, P270; BLACK MM, 1953, NEW YORK STATE J MED, V53, P1560; BLACK MM, 1972, CANCER, V29, P338, DOI 10.1002/1097-0142(197202)29:2&lt;338::AID-CNCR2820290212&gt;3.0.CO;2-U; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; Boyd D P, 1969, Lahey Clin Found Bull, V18, P135; BRODERS AC, 1932, JAMA-J AM MED ASSOC, V99, P1671; BRODY JE, 1977, YOU CAN FIGHT CANC W, P136; BROWN J, 1992, DEFINITION PROFESSIO, P139; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Cady B, 1996, ARCH SURG-CHICAGO, V131, P301; CARSON W, 1994, ANN SURG ONCOL, V1, P141, DOI 10.1007/BF02303558; CHAMBLISS L, 1995, WORKING WOMAN    OCT, P74; CHEN E, 1980, LOS ANGELES TIM 1209, P1; CHEN E, 1980, LOS ANGELES TIM 1209, P17; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; COULTON A, 1997, AM BANKER       0818, P12; Crile G., 1955, CANC COMMON SENSE, P7; CRILE G, 1967, JAMA-J AM MED ASSOC, V199, P146; Eddy DM, 1997, ANN INTERN MED, V127, P1035, DOI 10.7326/0003-4819-127-11-199712010-00017; Ernster VL, 1997, AM J PUBLIC HEALTH, V87, P1103, DOI 10.2105/AJPH.87.7.1103; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; Farrow J H, 1970, Cancer, V25, P468, DOI 10.1002/1097-0142(197002)25:2<468::AID-CNCR2820250226>3.0.CO;2-0; FECHNER RE, 1993, AM J CLIN PATHOL, V100, P654, DOI 10.1093/ajcp/100.6.654; FISHER B, 1992, CANCER RES, V52, P2371; Fletcher SW, 1997, NEW ENGL J MED, V336, P1180, DOI 10.1056/NEJM199704173361612; FOX MS, 1979, JAMA-J AM MED ASSOC, V241, P489, DOI 10.1001/jama.241.5.489; Fredericks S, 1975, Clin Plast Surg, V2, P347; FUGHBERMAN A, 1992, NATION          1221, P757; FUGHBERMAN A, 1992, NATION          1221, P770; FUGHBERMAN A, 1992, NATION          1221, P772; GROOFF PN, 1993, HOSP PRACT, V28, P122, DOI 10.1080/21548331.1993.11442810; HAAGENSEN CD, 1978, CANCER, V42, P737, DOI 10.1002/1097-0142(197808)42:2<737::AID-CNCR2820420247>3.0.CO;2-T; HAAGENSEN CD, 1956, DIS BREAST, P522; Healy B, 1997, NEW ENGL J MED, V336, P1448, DOI 10.1056/NEJM199705153362009; Hellman S, 1997, NEW ENGL J MED, V337, P996, DOI 10.1056/NEJM199710023371408; HUBBARD TB, 1953, SURGERY, V34, P706; HUTTER RVP, 1969, CANCER, V24, P1081, DOI 10.1002/1097-0142(196911)24:5<1081::AID-CNCR2820240534>3.0.CO;2-D; Jonsen AR, 1996, NAT MED, V2, P622, DOI 10.1038/nm0696-622; Kilgore AR, 1921, J AMER MED ASSOC, V77, P454; KOLATA G, 1997, NY TIMES        0224, pA1; Kolata G, 1997, NY TIMES        0128, pC8; Kolata G., 1997, NY TIMES        0128, pC1; KOLATA G, 1997, NY TIMES        0124, pA15; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Kramer BS, 1997, NEW ENGL J MED, V337, P931, DOI 10.1056/NEJM199709253371312; KUSHNER R, 1984, CA-CANCER J CLIN, V34, P345, DOI 10.3322/canjclin.34.6.345; LEIS HP, 1965, NEW YORK STATE J MED, V65, P2460; LEWISON EF, 1964, MIL MED, V129, P115, DOI 10.1093/milmed/129.2.115; LOVE S, 1990, S LOVES BREAST BOOK; MACDONALD I, 1951, Surg Gynecol Obstet, V92, P443; MACDONALD I, 1958, SURG GYNECOL OBSTET, V106, P227; McDivitt R W, 1972, Proc Natl Cancer Conf, V7, P269; MCDIVITT RW, 1967, J AMER MED ASSOC, V201, P82, DOI 10.1001/jama.201.2.82; MCKINNON N E, 1955, Can Med Assoc J, V73, P614; Nattinger AB, 1996, NEW ENGL J MED, V335, P1035, DOI 10.1056/NEJM199610033351407; NEWMAN W, 1966, ANN SURG, V164, P305, DOI 10.1097/00000658-196608000-00018; NOTKIN L J, 1959, Can Med Assoc J, V81, P190; PARK WW, 1951, SURG GYNECOL OBSTET, V93, P129; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PATTERSON JT, 1987, DREAD DIS CANC MODER, P137; Perez F M, 1974, Med Times, V102, P147; PEREZ FM, 1974, MED TIMES, V102, P158; PEREZ FM, 1974, MED TIMES, V102, P160; PEREZ FM, 1974, MED TIMES, V102, P154; PEREZ FM, 1974, MED TIMES, V102, P152; PLOTKIN D, 1996, ATLANTIC MONTHLY JUN, P66; PLOTKIN D, 1996, ATLANTIC MONTHLY JUN, P60; PLOTKIN D, 1996, ATLANTIC MONTHLY JUN, P81; PLOTKIN D, 1996, ATLANTIC MONTHLY JUN, P72; PLOTKIN D, 1996, ATLANTIC MONTHLY JUN, P76; PLOTKIN D, 1996, ATLANTIC MONTHLY JUN, P58; PLOTKIN D, 1996, ATLANTIC MONTHLY JUN, P78; Plotkin D., ATLANTIC MONTHLY JUN, P53; PLOTKIN D, 1996, ATLANTIC MONTHLY JUN, P62; POWELL M, 1997, WASHINGTON POST 0608, P81; Proctor RN, 1995, CANC WARS POLITICS S; QUALHEIM RE, 1957, CANCER, V10, P460, DOI 10.1002/1097-0142(195705/06)10:3<460::AID-CNCR2820100307>3.0.CO;2-E; Ransohoff DF, 1997, ANN INTERN MED, V127, P1029, DOI 10.7326/0003-4819-127-11-199712010-00016; ROSEN M, 1997, GOOD HOUSEKEEPIN APR, P30; ROSEN PP, 1981, CANCER, V47, P813, DOI 10.1002/1097-0142(19810215)47:4<813::AID-CNCR2820470431>3.0.CO;2-J; ROSS WS, 1987, CRUSADE OFFICIAL HIS, P94; Sanders-Goebel P, 1991, Can Bull Med Hist, V8, P77; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; SHALALA D, 1995, CHICAGO TRIBUNE 0305, P6; SNYDER RE, 1966, SURG GYNECOL OBSTETR, V122, P255; Sontag S, 1978, ILLNESS METAPHOR, P66; STABINER K, 1997, DANCE DEVIL NEW WAR, P3; STRAX P, 1979, CONTROL BREAST CANC, P6; STRAX P, 1974, EARLY DETECTION BREA, P5; SUBALTSHARPE G, 1976, NY TIMES MAGAZI 1024, P42; URBAN JA, 1967, CANCER, V20, P1867, DOI 10.1002/1097-0142(196711)20:11<1867::AID-CNCR2820201111>3.0.CO;2-#; VENDANTAM S, 1996, HOUSTON CHRONIC 1102, pA6; WALDHOLZ M, 1997, WALL STREET J   1110, pB1; WALDHOLZ M, 1997, WALL STREET J   1110, pB13; WANEBO HJ, 1974, CANCER, V33, P349, DOI 10.1002/1097-0142(197402)33:2<349::AID-CNCR2820330208>3.0.CO;2-4; WARNER NE, 1969, CANCER, V23, P840, DOI 10.1002/1097-0142(196904)23:4<840::AID-CNCR2820230418>3.0.CO;2-1; Weber B, 1996, ANN INTERN MED, V124, P1088, DOI 10.7326/0003-4819-124-12-199606150-00012; WHEELER JE, 1974, CANCER-AM CANCER SOC, V34, P554, DOI 10.1002/1097-0142(197409)34:3<554::AID-CNCR2820340313>3.0.CO;2-7; *WOM FIELD ARM AM, 1945, THER SHALL BE LIGHT; Woolf SH, 1997, JAMA-J AM MED ASSOC, V278, P2105, DOI 10.1001/jama.278.23.2105; 1994, MACLEANS        0711, P42; 1955, LIFE            1031, P129	110	11	12	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					74	78		10.7326/0003-4819-129-1-199807010-00028	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00028			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9653011				2022-12-28	WOS:000074513300022
J	Shekelle, PG; Courter, I; Hurwitz, EL; Genovese, B; Adams, AH; Mior, SA; Brook, RH				Shekelle, PG; Courter, I; Hurwitz, EL; Genovese, B; Adams, AH; Mior, SA; Brook, RH			Congruence between decisions to initiate chiropractic spinal manipulation for low back pain and appropriateness criteria in North America	ANNALS OF INTERNAL MEDICINE			English	Article						low back pain; spine; chiropractic; manipulation, orthopedic; quality of health care	RANDOMIZED CLINICAL-TRIAL; NEW-YORK-STATE; BYPASS GRAFT-SURGERY; CORONARY-ANGIOGRAPHY; NECK COMPLAINTS; MANUAL THERAPY; CAROTID ENDARTERECTOMY; OUTCOME MEASURES; PERSISTENT BACK; FOLLOW-UP	Background: Recent U.S. practice guidelines recommend spinal manipulation for some patients with low back pain. If followed, these guidelines are likely to increase the number of persons referred for chiropractic care. Concerns have been raised about the appropriate use of chiropractic care, but systematic data are lacking. Objective: To determine the appropriateness of chiropractors' decisions to use spinal manipulation for patients with low back pain. Design: Retrospective review of chiropractic office records against preset criteria for appropriateness that were developed from a systematic review of the literature and a nine-member panel of chiropractic and medical specialists. Appropriateness criteria reflect the expected balance between risk and benefit. Setting: 131 of 185 (71%) chiropractic offices randomly sampled from sites in the United States and Canada. Patients: 10 randomly selected records of patients presenting with low back pain from each office (1310 patients total). Measurements: Sociodemographic data on patients and chiropractors; use of health care services by patients; assessment of the decision to initiate spinal manipulation as appropriate, uncertain, or inappropriate. Results: Of the 1310 patients who sought chiropractic care for low back pain, 1088 (83%) had spinal manipulation. For 859 of these patients (79%), records contained data sufficient to determine whether care was congruent with appropriateness criteria. Care was classified as appropriate in 46% of cases, uncertain in 25% of cases, and inappropriate in 29% of cases. Patients who did not undergo spinal manipulation were less likely to have a presentation judged appropriate and were more likely to have a presentation judged inappropriate than were patients who did undergo spinal manipulation (P = 0.01). Conclusions: The proportion of chiropractic spinal manipulation judged to be congruent with appropriateness criteria is similar to proportions previously described for medical procedures; thus, the findings provide some reassurance about the appropriate application of chiropractic care. However, more than one quarter of patients were treated for indications that were judged inappropriate. The number of inappropriate decisions to use chiropractic spinal manipulation should be decreased.	Rand Corp, Santa Monica, CA 90401 USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA; Los Angeles Coll Chiropract, Whittier, CA 90609 USA; Canadian Mem Chiropract Coll, Toronto, ON M4G 3E6, Canada	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Shekelle, PG (corresponding author), Rand Corp, 1700 Main St,POB 2138, Santa Monica, CA 90401 USA.		Mior, Silvano A/L-4786-2015	Mior, Silvano A/0000-0001-6575-2797				BALLANTINE HT, 1972, NEW ENGL J MED, V286, P237, DOI 10.1056/NEJM197202032860504; BENGTSON A, 1994, JAMA-J AM MED ASSOC, V271, P1260, DOI 10.1001/jama.271.16.1260; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BIGOS SJ, 1992, AHCPR PUBLICATION; BLOMBERG S, 1994, SPINE, V19, P569, DOI 10.1097/00007632-199403000-00013; BROOK RH, 1993, SCHWEIZ MED WSCHR, V123, P249; CHASSIN MR, 1993, MED CARE, V31, pYS37, DOI 10.1097/00005650-199305001-00006; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHASSIN MR, 1989, APPROPRIATENESS USE; CURTIS P, 1992, J FAM PRACTICE, V35, P551; DEYO RA, 1991, ANNU REV PUBL HEALTH, V12, P141, DOI 10.1146/annurev.pu.12.050191.001041; DEYO RA, 1993, SPINE, V18, P2153, DOI 10.1097/00007632-199311000-00002; ERHARD RE, 1994, PHYS THER, V74, P1093, DOI 10.1093/ptj/74.12.1093; FELLEGI IP, 1980, J AM STAT ASSOC, V75, P261, DOI 10.2307/2287444; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; HERZOG W, 1991, J MANIP PHYSIOL THER, V14, P104; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; HSIEH CYJ, 1992, J MANIP PHYSIOL THER, V15, P4; Hurwitz EL, 1998, AM J PUBLIC HEALTH, V88, P771, DOI 10.2105/AJPH.88.5.771; KAHAN JP, 1994, MED CARE, V32, P357, DOI 10.1097/00005650-199404000-00004; KAHN KL, 1988, J CLIN EPIDEMIOL, V41, P115, DOI 10.1016/0895-4356(88)90085-6; Kahn KL., 1992, EFFECTS DRG BASED PR, pxxiv 343; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KLEINMAN LC, 1994, JAMA-J AM MED ASSOC, V271, P1250, DOI 10.1001/jama.271.16.1250; KOES BW, 1992, J MANIP PHYSIOL THER, V15, P16; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; KOES BW, 1993, J MANIP PHYSIOL THER, V16, P211; KOSECOFF J, 1987, MED CARE, V25, P196, DOI 10.1097/00005650-198703000-00003; KRAVITZ RL, 1995, JAMA-J AM MED ASSOC, V274, P632, DOI 10.1001/jama.274.8.632; Leape LL, 1996, ANN INTERN MED, V125, P8, DOI 10.7326/0003-4819-125-1-199607010-00003; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MCGLYNN EA, 1994, JAMA-J AM MED ASSOC, V272, P934, DOI 10.1001/jama.272.12.934; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; MERRICK NJ, 1987, AM J PUBLIC HEALTH, V77, P187, DOI 10.2105/AJPH.77.2.187; POPE MH, 1994, SPINE, V19, P2571, DOI 10.1097/00007632-199411001-00013; *ROYAL COLL GEN PR, 1996, CLIN GUID MAN AC LOW; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SHEKELLE PG, 1995, J MANIP PHYSIOL THER, V18, P265; SHEKELLE PG, 1991, APPROPRIATE USE SPIN; SHEKELLE PG, 1994, USE COSTS CHIROPRACT; SHEKELLE PG, IN PRESS INT J TECH; THOMAS DR, 1987, J AM STAT ASSOC, V82, P630, DOI 10.2307/2289475; TRIANO JJ, 1995, SPINE, V20, P948, DOI 10.1097/00007632-199504150-00013; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V258, P2568, DOI 10.1001/jama.258.18.2568; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; Wreje Ullacarin, 1992, Scandinavian Journal of Primary Health Care, V10, P310, DOI 10.3109/02813439209014080	50	37	37	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					9	+		10.7326/0003-4819-129-1-199807010-00003	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9653012				2022-12-28	WOS:000074513300002
J	Horton, R				Horton, R			How should doctors respond to the GMC's judgments on Bristol?	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Horton, R (corresponding author), Lancet, London WC1B 3SL, England.							Dehlendorf CE, 1998, JAMA-J AM MED ASSOC, V279, P1883, DOI 10.1001/jama.279.23.1883; *GMC, 1998, GOOD MED PRACT; *GMC, 1998, MAINT GOOD MED PRACT; MACSWEEN R, 1998, HOSP DOCTOR     0611, P15; Morrison J, 1998, JAMA-J AM MED ASSOC, V279, P1889, DOI 10.1001/jama.279.23.1889	5	23	23	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1900	1901						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654252				2022-12-28	WOS:000074464700002
J	Tagliaro, F; De Battisti, Z; Smith, FP; Marigo, M				Tagliaro, F; De Battisti, Z; Smith, FP; Marigo, M			Death from heroin overdose: findings from hair analysis	LANCET			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; MORPHINE; BLOOD; COCAINE	Background Morphine analysis of hair is used in forensic toxicology to study the addiction history of heroin addicts. To clarify the features underlying fatal heroin intake, we measured hair morphine content in a group of deceased heroin addicts, to verify a possible correlation between fatal heroin overdoses and the addiction behaviour of these individuals before death. Methods 91 deaths were attributed to heroin overdose in Verona, Italy, in 1993-96. We analysed the hair of 37 of these individuals, and of 37 active heroin addicts, 37 former heroin users abstinent from the drug for several months, and 20 individuals with no evidence of exposure to opioids. From each individual, a hair sample of about 150 mg was analysed by RIA and high-performance liquid chromatography, to measure the morphine content. Findings The mean morphine content in the hair of the addicts who had died was 1.15 ng/mg (SD 2.35 ng/mg; range 0-12.25 ng/mg) compared with 6.07 ng/mg (4.29; 1.15-17.0) in the active heroin addicts, 0.74 ng/mg (0.93; 0.10-3.32) in the abstinent former addicts, and values below the detection limit in the non-exposed group. Hair morphine content among those who had died was significantly lower than that in active heroin consumers (p<0.0001), but not significantly different from that in the former addicts (p=0.978). Interpretation Although our findings may be subject to selection bias, since suitable hair samples were available for only 37 of the 91 addicts who had died, these findings support the theory of high susceptibility to opioid overdose after periods of intentional or unintentional abstinence, due to loss of tolerance. Medical staff running detoxification programmes should be aware of the risk inherent in relapse to heroin after a period of abstinence. Moreover, occasional heroin use without a build-up of tolerance could also give a high risk of overdose.	Univ Verona Policlin, Inst Forens Med, I-37134 Verona, Italy; Univ Alabama, Dept Justice Sci, Birmingham, AL USA	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Alabama System; University of Alabama Birmingham	Tagliaro, F (corresponding author), Univ Verona Policlin, Inst Forens Med, I-37134 Verona, Italy.		Tagliaro, Franco/AAB-8631-2022	Tagliaro, Franco/0000-0002-2187-9128				ADDINGTON WW, 1972, CHEST, V62, P199, DOI 10.1378/chest.62.2.199; Baselt R., 1995, DISPOSITION TOXIC DR; BRASHEAR RE, 1974, J LAB CLIN MED, V83, P451; CONE EJ, 1991, J ANAL TOXICOL, V15, P250, DOI 10.1093/jat/15.5.250; HARDINGPINK D, 1988, BRIT MED J, V297, P596, DOI 10.1136/bmj.297.6648.596; HENDERSON GL, 1993, FORENSIC SCI INT, V63, P19, DOI 10.1016/0379-0738(93)90256-A; *IT MIN INT AFF, 1996, DIR CENTR SERV ANT; KINTZ P, 1992, EUR J CLIN PHARMACOL, V42, P351; LEVINE B, 1995, J FORENSIC SCI, V40, P808; LORATAMAYO C, 1987, J CHROMATOGR-BIOMED, V422, P267, DOI 10.1016/0378-4347(87)80462-0; MARIGO M, 1986, J ANAL TOXICOL, V10, P158, DOI 10.1093/jat/10.4.158; MIYAZAWA N, 1991, FORENSIC SCI INT, V51, P65, DOI 10.1016/0379-0738(91)90206-X; PUSCHEL K, 1983, FORENSIC SCI INT, V21, P181, DOI 10.1016/0379-0738(83)90108-1; PUSCHEL K, 1993, FORENSIC SCI INT, V62, P129, DOI 10.1016/0379-0738(93)90057-H; QUESTEL F, 1996, ANN INTERN MED, V15, P616; Richards R G, 1976, J Forensic Sci, V21, P467; SACHS H, 1995, FORENSIC SCI INT, V70, P53, DOI 10.1016/0379-0738(94)01611-8; Skopp G, 1997, FORENSIC SCI INT, V84, P43, DOI 10.1016/S0379-0738(96)02047-6; Smith FP, 1996, FORENSIC SCI INT, V83, P179, DOI 10.1016/S0379-0738(96)02035-X; SPIEHLER V, 1987, J FORENSIC SCI, V32, P906; STAUB C, 1990, INT J LEGAL MED, V104, P39, DOI 10.1007/BF01816482; TAGLIARO D, 1997, FORENSIC SCI INT, V84, P129; TAGLIARO F, 1994, J CHROMATOGR A, V674, P207, DOI 10.1016/0021-9673(94)85225-1; TAGLIARO F, 1988, CHROMATOGRAPHIA, V26, P163, DOI 10.1007/BF02268144; UEMATSU T, 1989, EUR J CLIN PHARMACOL, V37, P239, DOI 10.1007/BF00679777; UGES DRA, 1996, TIAFT B, V26, P5; *US GEN ASS OFF, 1993, DRUG US MEAS STRENGT	27	89	91	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1923	1925		10.1016/S0140-6736(97)10101-5	http://dx.doi.org/10.1016/S0140-6736(97)10101-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654260				2022-12-28	WOS:000074464700010
J	Fleming, A; Copp, AJ				Fleming, A; Copp, AJ			Embryonic folate metabolism and mouse neural tube defects	SCIENCE			English	Article							MUTATED METHYLENETETRAHYDROFOLATE REDUCTASE; FOLIC-ACID; SPINA-BIFIDA; RAT EMBRYOS; MUTANT; PAX-3; PREVENTION; GENE; VITAMIN-B12; METHIONINE	Folic acid prevents 70 percent of human neural tube defects (NTDs) but its mode of action is unclear. The deoxyuridine suppression test detects disturbance of folate metabolism in homozygous splotch (Pax3) mouse embryos that are developing NTDs in vitro. Excessive incorporation of [(3)H]thymidine in splotch embryos indicates a metabolic deficiency in the supply of folate for the biosynthesis of pyrimidine. Exogenous folic acid and thymidine both correct the biosynthetic defect and prevent some NTDs in splotch homozygotes, whereas methionine has an exacerbating effect. These data support a direct normalization of neurulation by folic acid in humans and suggest a metabolic basis for folate action.	UCL, Inst Child Hlth, Neural Dev Unit, London WC1N 1EH, England	University of London; University College London	Copp, AJ (corresponding author), UCL, Inst Child Hlth, Neural Dev Unit, London WC1N 1EH, England.	a.copp@ich.ucl.ac.uk	Copp, Andrew/C-4174-2008	Copp, Andrew/0000-0002-2544-9117; Fleming, Angeleen/0000-0003-3721-7126	NICHD NIH HHS [HD 28882] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD028882] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BADEN JM, 1991, BRIT J ANAESTH, V66, P500, DOI 10.1093/bja/66.4.500; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; Chanarin I, 1990, MEGALOBLASTIC ANAEMI; CHATKUPT S, 1995, J MED GENET, V32, P200, DOI 10.1136/jmg.32.3.200; COCKROFT DL, 1991, HUM REPROD, V6, P148, DOI 10.1093/oxfordjournals.humrep.a137250; COPP AJ, 1985, J EMBRYOL EXP MORPH, V88, P39; COPP AJ, 1994, DEV BIOL, V165, P20, DOI 10.1006/dbio.1994.1230; Daston G, 1996, DEVELOPMENT, V122, P1017; deFranchis R, 1995, LANCET, V346, P1703, DOI 10.1016/S0140-6736(95)92865-0; EDELMAN GM, 1995, PHILOS T R SOC B, V349, P305, DOI 10.1098/rstb.1995.0118; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; ESSIEN FB, 1993, J NUTR, V123, P27, DOI 10.1093/jn/123.1.27; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Greene NDE, 1997, NAT MED, V3, P60, DOI 10.1038/nm0197-60; HELD MK, 1992, J NUTR, V122, P888; Henderson DJ, 1997, MECH DEVELOP, V69, P39, DOI 10.1016/S0925-4773(97)00151-2; Hook EB, 1997, LANCET, V350, P513, DOI 10.1016/S0140-6736(97)01342-1; KIRKE PN, 1993, Q J MED, V86, P703; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; Morrison K, 1997, J MED GENET, V34, P958, DOI 10.1136/jmg.34.11.958; Papapetrou C, 1996, LANCET, V348, P58, DOI 10.1016/S0140-6736(05)64382-6; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; SCOTT JM, 1994, CIBA F SYMP, V181, P180; SELLER MJ, 1994, CIBA F SYMP, V181, P161; SMITHELLS RW, 1981, ARCH DIS CHILD, V56, P911, DOI 10.1136/adc.56.12.911; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; VANAERTS LAGJM, 1994, TERATOLOGY, V50, P348, DOI 10.1002/tera.1420500506; VANALLEN MI, 1993, AM J MED GENET, V47, P723, DOI 10.1002/ajmg.1320470528; VANDERPUT NMJ, 1995, LANCET, V346, P1070, DOI 10.1016/S0140-6736(95)91743-8; WHITEHEAD AS, 1995, J MED, V88, P763; Wilcken DEL, 1996, LANCET, V347, P340, DOI 10.1016/S0140-6736(96)90526-7; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275	34	196	206	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2107	2109		10.1126/science.280.5372.2107	http://dx.doi.org/10.1126/science.280.5372.2107			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641914				2022-12-28	WOS:000074435900042
J	Po, ALW; Zhang, WY				Po, ALW; Zhang, WY			What lessons can be learnt from withdrawal of mibefradil from the market?	LANCET			English	Editorial Material									Univ Nottingham, Ctr Evidence Based Pharmacotherapy, Nottingham NG7 2RD, England	University of Nottingham	Po, ALW (corresponding author), Univ Nottingham, Ctr Evidence Based Pharmacotherapy, Nottingham NG7 2RD, England.		Zhang, Weiya/X-9481-2019	Zhang, Weiya/0000-0003-1142-1460				Alderman M, 1997, J HUM HYPERTENS, V11, P331; BENNETT N, 1998, SUNDAY TELEGRAP 0426, pB5; *BRIT MED ASS ROYA, 1998, BRIT NAT FORM, V35, P99; Dent THS, 1997, BMJ-BRIT MED J, V315, P1248, DOI 10.1136/bmj.315.7118.1248; DIMASI JA, 1991, J HEALTH ECON, V10, P107, DOI 10.1016/0167-6296(91)90001-4; HALL W, 1998, FINANCIAL TIMES 0609, P28; Stanton AV, 1998, BMJ-BRIT MED J, V316, P1471, DOI 10.1136/bmj.316.7143.1471; WECHSLER J, 1994, APPL CLIN TRIALS, V3, P18	8	67	69	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1829	1830		10.1016/S0140-6736(05)78800-0	http://dx.doi.org/10.1016/S0140-6736(05)78800-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652662				2022-12-28	WOS:000074347100005
J	Beasley, R; Keil, U; von Mutius, E; Pearce, N; Ait-Khaled, N; Anabwani, G; Anderson, HR; Asher, MI; Bjorkstein, B; Burr, ML; Clayton, TO; Crane, J; Ellwood, P; Lai, CKW; Mallol, J; Martinez, FD; Mitchell, EA; Montefort, S; Robertson, CF; Shah, JR; Sibbald, B; Stewart, AW; Strachan, DP; Weiland, SK; Williams, HC				Beasley, R; Keil, U; von Mutius, E; Pearce, N; Ait-Khaled, N; Anabwani, G; Anderson, HR; Asher, MI; Bjorkstein, B; Burr, ML; Clayton, TO; Crane, J; Ellwood, P; Lai, CKW; Mallol, J; Martinez, FD; Mitchell, EA; Montefort, S; Robertson, CF; Shah, JR; Sibbald, B; Stewart, AW; Strachan, DP; Weiland, SK; Williams, HC		Int Study Asthma Allergies Childhood	Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC	LANCET			English	Article							SELF-REPORTED PREVALENCE; OUTDOOR AIR-POLLUTION; QUESTIONNAIRE; DERMATITIS; CHILDREN; GERMANY	Background Systematic international comparisons of the prevalences of asthma and other allergic disorders in children are needed for better understanding of their global epidemiology, to generate new hypotheses, and to assess existing hypotheses of possible causes. We investigated worldwide prevalence of asthma, allergic rhinoconjunctivitis, and atopic eczema. Methods We studied 463 801 children aged 13-14 years in 155 collaborating centres in 56 countries. Children self-reported, through one-page questionnaires, symptoms of these three atopic disorders. In 99 centres in 42 countries, a video asthma questionnaire was also used for 304 796 children. Findings We found differences of between 20-fold and 60-fold between centres in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema, with four-fold to 12-fold variations between the 10th and 90th percentiles for the different disorders. For asthma symptoms, the highest 12-month prevalences were from centres in the UK, Australia, New Zealand, and Republic of Ireland, followed by most centres in North, Central, and South America; the lowest prevalences were from centres in several Eastern European countries, Indonesia, Greece, China, Taiwan, Uzbekistan, India, and Ethiopia. For allergic rhinoconjunctivitis, the centres with the highest prevalences were scattered across the world. The centres with the lowest prevalences were similar to those for asthma symptoms. For atopic eczema, the highest prevalences came from scattered centres, including some from Scandinavia and Africa that were not among centres with the highest asthma prevalences; the lowest prevalence rates of atopic eczema were similar in centres, as for asthma symptoms. Interpretation The variation in the prevalences of asthma, allergic rhinoconjunctivitis, and atopic-eczema symptoms is striking between different centres throughout the world. These findings will form the basis of further studies to investigate factors that potentially lead to these international patterns.	Wellington Sch Med, Dept Med, Wellington Asthma Res Grp, Wellington, New Zealand; Univ Munster, D-4400 Munster, Germany; Univ Munich, Kinderklin, D-80539 Munich, Germany; IUATLD, Paris, France; Princess Marina Hosp, Gaborone, Botswana; Univ London St Georges Hosp, Sch Med, London SW17 0RE, England; Univ Auckland, ISAAC, Steering Comm, Auckland 1, New Zealand; Univ Auckland, ISAAC, Int Data Ctr, Auckland 1, New Zealand; Linkoping Univ Hosp, S-58185 Linkoping, Sweden; Univ Wales Coll Med, Cardiff CF4 4XN, S Glam, Wales; Chinese Univ Hong Kong, Hong Kong, Hong Kong; Univ Santiago, Santiago, Chile; Univ Arizona, Tucson, AZ 85721 USA; Univ Malta, Sch Med, Gmangia, Malta; Royal Childrens Hosp, Parkville, Vic 3052, Australia; Jaslok Hosp & Res Ctr, Bombay, Maharashtra, India; Univ Manchester, Manchester M13 9PL, Lancs, England; Univ Nottingham Hosp, Nottingham NG7 2UH, England	University of Otago; University of Munster; University of Munich; St Georges University London; University of Auckland; University of Auckland; Linkoping University; Cardiff University; Chinese University of Hong Kong; Universidad de Santiago de Chile; University of Arizona; University of Malta; Royal Children's Hospital Melbourne; University of Manchester; University of Nottingham	Beasley, R (corresponding author), Wellington Sch Med, Dept Med, Wellington Asthma Res Grp, POB 7343, Wellington, New Zealand.		Asher, Innes/O-2604-2016; Clayton, Tadd O/B-7914-2009; Ellwood, Philippa/G-7555-2015	Asher, Innes/0000-0003-1768-3832; Ellwood, Philippa/0000-0002-1994-4023; Beasley, Richard/0000-0003-0337-406X; Pearce, Neil/0000-0002-9938-7852				[Anonymous], 1966, CANC INCIDENCE 5 CON, DOI DOI 10.1001/jamaoncol.2019.2996; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477, DOI 10.1164/ajrccm.153.2.8564086; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; BURR ML, 1994, INT J EPIDEMIOL, V23, P341, DOI 10.1093/ije/23.2.341; CRANE J, 1994, NEW ZEAL MED J, V107, P417; *DEP HLTH COMM MED, 1995, ASTHM OUTD AIR POLL; Lai CKW, 1997, CLIN EXP ALLERGY, V27, P540, DOI 10.1111/j.1365-2222.1997.tb00742.x; Larsen FS, 1996, J AM ACAD DERMATOL, V34, P760, DOI 10.1016/S0190-9622(96)90009-2; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; PEARCE N, 1993, EUR RESPIR J, V6, P1455; POPESCU CM, 1997, IN PRESS BR J DERMAT; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Rose G., 1992, STRATEGY PREVENTIVE; SHAW R, 1995, INT J EPIDEMIOL, V24, P597, DOI 10.1093/ije/24.3.597; SHAW RA, 1992, CLIN EXP ALLERGY, V22, P561, DOI 10.1111/j.1365-2222.1992.tb00166.x; WEILAND SK, 1993, MONATSSCHR KINDERH, V141, P878; Weiland SK, 1993, GUIDELINES TRANSLATI; Williams HC, 1996, BRIT J DERMATOL, V135, P12; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	24	2747	2890	2	356	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1225	1232		10.1016/S0140-6736(97)07302-9	http://dx.doi.org/10.1016/S0140-6736(97)07302-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643741				2022-12-28	WOS:000073283600007
J	Newburg, DS; Peterson, JA; Ruiz-Palacios, GM; Matson, DO; Morrow, AL; Shults, J; Guerrero, MD; Chaturvedi, P; Newburg, SO; Scallan, CD; Taylor, MR; Ceriani, RL; Pickering, LK				Newburg, DS; Peterson, JA; Ruiz-Palacios, GM; Matson, DO; Morrow, AL; Shults, J; Guerrero, MD; Chaturvedi, P; Newburg, SO; Scallan, CD; Taylor, MR; Ceriani, RL; Pickering, LK			Role of human-milk lactadherin in protection against symptomatic rotavirus infection	LANCET			English	Article							FAT-GLOBULE-MEMBRANE; ESCHERICHIA-COLI; MEXICAN CHILDREN; OLIGOSACCHARIDES; DIARRHEA; RECEPTOR; GASTROENTERITIS; INHIBITION; COHORT; MUCIN	Background Human milk contains a 46 kDa mucin-associated glycoprotein, lactadherin, which binds specifically to rotavirus and inhibits its replication. This study tested the hypothesis that lactadherin protects against symptoms of rotavirus infection. Methods 200 infants in Mexico City were recruited at birth and monitored by regular stool EIA for rotavirus, serology, and recording of feeding and stool patterns. Milk samples were obtained from the mothers weekly until 4 weeks post partum then monthly. The sample taken immediately before an infant's episode of rotavirus infection was assayed for lactadherin, butyrophilin, mucin, and secretory IgA. An infection was defined as symptomatic if diarrhoea occurred in the 5 days before or after detection of the virus. Findings 31 infants developed rotavirus infection; 15 were symptomatic and 16 had no symptoms. The median concentration of lactadherin in the milk samples (obtained 4-41 days [median 13] before the infection) was 484 (range 5.6-180) mu g/mL in the asymptomatic group and 29.2 (6.2-103.4) mu g/mL in the symptomatic group. Although these medians did not differ significantly, in logistic regression analysis adjusted for age at infection and secretory IgA concentration there was a significant difference between the groups (p=0.01). No association between symptom status and concentrations of butyrophilin, mucin, or secretory IgA was found. Interpretation Protection against rotavirus by human milk is associated with the glycoprotein lactadherin. This association is independent of products of the secretory immune system.	Shriver Ctr Mental Retardat, Waltham, MA 02254 USA; Harvard Univ, Sch Med, Boston, MA USA; Canc Res Inst Contra Costa, Walnut Creek, CA USA; Inst Nacl Nutr Salvador Zubiran, Mexico City 14000, DF, Mexico; Childrens Hosp Kings Daughters, Ctr Pediat Res, Norfolk, VA USA; Eastern Virginia Med Sch, Norfolk, VA 23501 USA	Harvard University; Harvard Medical School; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Eastern Virginia Medical School	Newburg, DS (corresponding author), Shriver Ctr Mental Retardat, 200 Trapelo Rd, Waltham, MA 02254 USA.		Morrow, Ardythe/GQO-8482-2022; Newburg, david/ABE-8139-2020; Ruiz-Palacios, Guillermo/GYQ-5462-2022; Taylor, Michael/K-1379-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD013021] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030444] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA039932] Funding Source: NIH RePORTER; NCI NIH HHS [CA39932] Funding Source: Medline; NICHD NIH HHS [HD30444, HD13021] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON B, 1986, J INFECT DIS, V153, P232, DOI 10.1093/infdis/153.2.232; Ashkenazi S, 1991, Adv Exp Med Biol, V310, P173; Buchheim W., 1988, Nestle Nutrition Workshop Series, V15, P27; CALVA JJ, 1988, LANCET, V1, P503; CERIANI RL, 1992, ANAL BIOCHEM, V201, P178, DOI 10.1016/0003-2697(92)90192-A; CERIANI RL, 1992, MONOCLONAL ANTIBODIE, P398; DUWE AK, 1989, BIOCHEM BIOPH RES CO, V165, P1305, DOI 10.1016/0006-291X(89)92745-9; Glass RI, 1996, J INFECT DIS, V174, pS5, DOI 10.1093/infdis/174.Supplement_1.S5; LOPEZVIDA Y, 1990, J INFECT DIS, V162, P442, DOI 10.1093/infdis/162.2.442; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Newburg DS, 1996, J MAMMARY GLAND BIOL, V1, P271, DOI 10.1007/BF02018080; NEWBURG DS, 1992, J INFECT DIS, V166, P832, DOI 10.1093/infdis/166.4.832; NEWBURG DS, 1992, PEDIATR RES, V31, P22, DOI 10.1203/00006450-199201000-00004; NEWBURG DS, 1990, J INFECT DIS, V162, P1075, DOI 10.1093/infdis/162.5.1075; NEWBURG DS, 1996, PEDIATR RES, V39, P229; NEWBURG DS, 1996, PEDIATR RES, V39, pA229; ORYAN ML, 1994, J INFECT DIS, V169, P504, DOI 10.1093/infdis/169.3.504; OTNAESS AB, 1980, ACTA PATH MICRO IM C, V88, P247; Peterson J. A., 1996, Pediatric Research, V39, p126A; PICKERING LK, 1988, J PEDIATR-US, V112, P361, DOI 10.1016/S0022-3476(88)80313-5; RUIZPALACIOS GM, 1992, CAMPLYLOBACTER JEJUNI, P176; SCHROTEN H, 1992, INFECT IMMUN, V60, P2893, DOI 10.1128/IAI.60.7.2893-2899.1992; SHIMIZU M, 1986, BIOCHEM J, V233, P725, DOI 10.1042/bj2330725; Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404; VELAZQUEZ FR, 1993, PEDIATR INFECT DIS J, V12, P54, DOI 10.1097/00006454-199301000-00013; VIVERGE D, 1985, ANN NUTR METAB, V29, P1, DOI 10.1159/000176947; WARREN C, 1997, GLYCOBIOLOGY, V6, P730; WEINBERG RJ, 1984, PEDIATRICS, V74, P250; YOLKEN RH, 1992, J CLIN INVEST, V90, P1984, DOI 10.1172/JCI116078; [No title captured]	30	226	253	0	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1160	1164		10.1016/S0140-6736(97)10322-1	http://dx.doi.org/10.1016/S0140-6736(97)10322-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643686				2022-12-28	WOS:000073220200008
J	del Rosario, MAF; Davis, MM; Chong, SKF				del Rosario, MAF; Davis, MM; Chong, SKF			Wobbly handwriting	LANCET			English	Article							WILSONS-DISEASE		Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Div Pediat Gastroenterol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Div Pediat Pathol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Chong, SKF (corresponding author), Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Div Pediat Gastroenterol, Indianapolis, IN 46202 USA.							PLESKOW RB, 1996, PEDIAT GASTROINTESTI, P1233; PRAYER L, 1990, NEURORADIOLOGY, V32, P211, DOI 10.1007/BF00589114; STAROSTARUBINSTEIN S, 1987, ARCH NEUROL-CHICAGO, V44, P365, DOI 10.1001/archneur.1987.00520160007005; Steindl P, 1997, GASTROENTEROLOGY, V113, P212, DOI 10.1016/S0016-5085(97)70097-0; WALSHE JM, 1992, J NEUROL NEUROSUR PS, V55, P692, DOI 10.1136/jnnp.55.8.692	5	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					336	336		10.1016/S0140-6736(97)10254-9	http://dx.doi.org/10.1016/S0140-6736(97)10254-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652615				2022-12-28	WOS:000071864000015
J	Werther, G				Werther, G			Measuring height: to stretch or not to stretch?	LANCET			English	Editorial Material							GROWTH		Royal Childrens Hosp, Ctr Hormone Res, Melbourne, Vic 3052, Australia	Royal Children's Hospital Melbourne	Werther, G (corresponding author), Royal Childrens Hosp, Ctr Hormone Res, Melbourne, Vic 3052, Australia.		Werther, George/B-3784-2012					AHMED ML, 1990, ARCH DIS CHILD, V65, P1345, DOI 10.1136/adc.65.12.1345; BUCKLER JMH, 1978, ARCH DIS CHILD, V53, P762, DOI 10.1136/adc.53.9.762; STRICKLAND AL, 1972, J PEDIATR-US, V80, P1023, DOI 10.1016/S0022-3476(72)80018-0; Voss LD, 1997, ARCH DIS CHILD, V77, P319, DOI 10.1136/adc.77.4.319; VOSS LD, 1990, ARCH DIS CHILD, V65, P1340, DOI 10.1136/adc.65.12.1340; WASSE J, 1726, PHILOS T ROY SOC LON, V33, P87; Werther GA, 1996, J PEDIATR-US, V128, pS47, DOI 10.1016/S0022-3476(96)70011-2; WHITEHOUSE RH, 1974, ANN HUM BIOL, V1, P103, DOI 10.1080/03014467400000101	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					309	310		10.1016/S0140-6736(05)78342-2	http://dx.doi.org/10.1016/S0140-6736(05)78342-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652608				2022-12-28	WOS:000071864000006
J	Sharp, D				Sharp, D			It's my book	LANCET			English	Editorial Material																		COMBE V, 1997, DAILY TELEGRAPH 1003, P4	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1192	1192		10.1016/S0140-6736(05)63450-2	http://dx.doi.org/10.1016/S0140-6736(05)63450-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652557				2022-12-28	WOS:A1997YD23800006
J	Walter, DH; Schachinger, V; Elsner, M; Dimmeler, S; Zeiher, AM				Walter, DH; Schachinger, V; Elsner, M; Dimmeler, S; Zeiher, AM			Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis	LANCET			English	Article							BALLOON ANGIOPLASTY; ARTERY DISEASE; PLACEMENT	Background Coronary stents are an effective treatment for selected coronary stenoses. However, thrombosis of the stented segment is a major adverse complication. Platelet aggregation has a key role in stent thrombosis. We investigated whether a polymorphism of platelet glycoprotein IIIa gene (PIA2) Is associated with an increased risk of coronary stent thrombosis. Methods 318 consecutive patients were followed up for 30 days after coronary stent insertion. The primary endpoints were death, myocardial infarction, stent-vessel occlusion, and coronary artery bypass surgery. Gel electrophoresis of PCR products was used to identify the PIA1 and PIA2 alleles. The relative risk of stent occlusion was calculated from the odds ratio on logistic regression analysis. Findings 63 (19.8%) of patients had the P1(A2) allele and 255 (80.2%) were homozygous for PIA1. Baseline clinical, angiographic, and procedural features did not differ between the groups with and without the PIA2 allele. Occlusion of the stent vessel occurred in five (1.9%) patients homozygous for PIA1 and six (9.5%) patients with PIA2 allele (odds ratio 5.26 [95% CI 1.55-17.85]). On multivariate regression analysis PIA1/A2 genotype was the only significant independent predictor of stent thrombosis. Interpretation Patients with the PIA2 allele have an increased risk of coronary stent thrombosis, which may warrant antiplatelet therapy with glycoprotein-IIb/IIIa inhibitors, although bleeding complications may also increase.	UNIV FRANKFURT, DEPT INTERNAL MED 4, DIV CARDIOL, D-60590 FRANKFURT, GERMANY	Goethe University Frankfurt				Dimmeler, Stefanie/0000-0002-1045-2436				Albiero R, 1997, CIRCULATION, V95, P1145; Baim DS, 1997, CIRCULATION, V95, P1098; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Carter AM, 1996, LANCET, V348, P485, DOI 10.1016/S0140-6736(05)64592-8; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; GEORGE BS, 1993, J AM COLL CARDIOL, V22, P135, DOI 10.1016/0735-1097(93)90827-N; Karrillon GJ, 1996, CIRCULATION, V94, P1519, DOI 10.1161/01.CIR.94.7.1519; Moussa I, 1997, J AM COLL CARDIOL, V29, P6, DOI 10.1016/S0735-1097(96)00452-4; Neumann FJ, 1996, J AM COLL CARDIOL, V27, P15, DOI 10.1016/0735-1097(95)00433-5; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; REIBER JHC, 1994, PROGR QUANTITATIVE C; Ridker PM, 1997, LANCET, V349, P385, DOI 10.1016/S0140-6736(97)80010-4; Samani NJ, 1997, CARDIOVASC RES, V33, P693, DOI 10.1016/S0008-6363(96)00222-2; SCHACHINGER V, 1994, CIRCULATION, V90, P2258, DOI 10.1161/01.CIR.90.5.2258; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Schuhlen H, 1997, CIRCULATION, V95, P2015, DOI 10.1161/01.CIR.95.8.2015; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703	23	159	164	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 25	1997	350	9086					1217	1219		10.1016/S0140-6736(97)05399-3	http://dx.doi.org/10.1016/S0140-6736(97)05399-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652563				2022-12-28	WOS:A1997YD23800012
J	Lee, WR				Lee, WR			Trevor Lloyd Davies - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item														Lee, W Robert/0000-0002-3545-0170					0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					150	150		10.1136/bmj.317.7151.150	http://dx.doi.org/10.1136/bmj.317.7151.150			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657812	Green Published			2022-12-28	WOS:000075081700054
J	Kortemme, T; Ramirez-Alvarado, M; Serrano, L				Kortemme, T; Ramirez-Alvarado, M; Serrano, L			Design of a 20-amino acid, three-stranded beta-sheet protein	SCIENCE			English	Article							SIDE-CHAIN INTERACTIONS; NMR-SPECTROSCOPY; HELICAL PROTEIN; AMINO-ACIDS; QUANTUM NMR; CONFORMATION; POLYPEPTIDE; SEQUENCE; PEPTIDE; VALUES	20-residue protein (named Betanova) forming a monomeric, three-stranded, antiparallel beta sheet was designed using a structural backbone template and an iterative hierarchical approach. Structural and physicochemical characterization show that the beta-sheet conformation is stabilized by specific tertiary interactions and that the protein exhibits a cooperative two-state folding-unfolding transition, which is a hallmark of natural proteins. The Betanova molecule constitutes a tractable model system to aid in the understanding of beta-sheet formation, including beta-sheet aggregation and amyloid fibril formation.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Kortemme, T (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	Kortemme@EMBL-Heidelberg.DE; Ramirez@EMBL-Heidelberg.DE	Serrano, Luis/B-3355-2013	Serrano, Luis/0000-0002-5276-1392; Ramirez-Alvarado, Marina/0000-0003-2325-6773; Kortemme, Tanja/0000-0002-8494-680X				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; Blanco F, 1998, CURR OPIN STRUC BIOL, V8, P107, DOI 10.1016/S0959-440X(98)80017-1; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; CHOTHIA C, 1973, J MOL BIOL, V75, P295, DOI 10.1016/0022-2836(73)90022-3; Dahiyat BI, 1997, J MOL BIOL, V273, P789, DOI 10.1006/jmbi.1997.1341; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; deAlba E, 1996, FOLD DES, V1, P133, DOI 10.1016/S1359-0278(96)00022-3; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; GORAJ K, 1990, PROTEIN ENG, V3, P259, DOI 10.1093/protein/3.4.259; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; Ilyina E, 1997, BIOCHEMISTRY-US, V36, P5245, DOI 10.1021/bi963064o; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jones DT, 1996, PROTEINS, V24, P502, DOI 10.1002/(SICI)1097-0134(199604)24:4<502::AID-PROT9>3.0.CO;2-F; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; KORTEMMA T, UNPUB; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MACIAS MJ, COMMUNICATION; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; PESSI A, 1993, NATURE, V362, P367, DOI 10.1038/362367a0; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Prieto J, 1997, J MOL BIOL, V268, P760, DOI 10.1006/jmbi.1997.0984; RamirezAlvarado M, 1997, J MOL BIOL, V273, P898, DOI 10.1006/jmbi.1997.1347; RamirezAlvarado M, 1996, NAT STRUCT BIOL, V3, P604, DOI 10.1038/nsb0796-604; RAMIREZALVARADO M, UNPUB; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; Schafmeister CE, 1997, NAT STRUCT BIOL, V4, P1039, DOI 10.1038/nsb1297-1039; Schenck HL, 1998, J AM CHEM SOC, V120, P4869, DOI 10.1021/ja973984+; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; STONEHOUSE J, 1995, J MAGN RESON SER A, V112, P43, DOI 10.1006/jmra.1995.1008; Struthers MD, 1996, SCIENCE, V271, P342, DOI 10.1126/science.271.5247.342; WOUTERS MA, 1995, PROTEINS, V22, P119, DOI 10.1002/prot.340220205; Wuthrich K, 1986, NMR PROTEINS NUCL AC	46	296	306	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1998	281	5374					253	256		10.1126/science.281.5374.253	http://dx.doi.org/10.1126/science.281.5374.253			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657719				2022-12-28	WOS:000074714200048
J	Sun, ZX; Hsiao, J; Fay, DS; Stern, DF				Sun, ZX; Hsiao, J; Fay, DS; Stern, DF			Rad53 FHA domain associated with phosphorylated Rad9 in the DNA damage checkpoint	SCIENCE			English	Article							CELL-CYCLE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; S-PHASE; PROTEIN-KINASE; BUDDING YEAST; REPLICATION; MITOSIS; GENE; TRANSCRIPTION; THREONINE	The Rad53 protein kinase of Saccharomyces cerevisiae is required for checkpoints that prevent cell division in cells with damaged or incompletely replicated DNA, The Rad9 protein was phosphorylated in response to DNA damage, and phosphorylated Rad9 interacted with the COOH-terminal forkhead homology-associated (FHA) domain of Rad53, Inactivation of this domain abolished DNA damage-dependent Rad53 phosphorylation, G(2)/M cell cycle phase arrest, and increase of RNR3 transcription but did not affect replication inhibition-dependent Rad53 phosphorylation, Thus, Rad53 integrates DNA damage signals by coupling with phosphorylated Rad9, The hitherto uncharacterized FHA domain appears to be a modular protein-binding domain.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Yale Univ, Dept Biol, New Haven, CT 06511 USA	Yale University; Yale University	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,Room BML 342, New Haven, CT 06520 USA.	Stern@biomed.med.yale.edu						ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; EMILI A, IN PRESS MOL CELL; Fay DS, 1997, CURR GENET, V31, P97, DOI 10.1007/s002940050181; GARDNER R, UNPUB; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Longhese MP, 1997, EMBO J, V16, P5216, DOI 10.1093/emboj/16.17.5216; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; REYNOLDS A, 1991, CURRENT PROTOCOLS MO, V2; RICE SA, 1994, J VIROL, V68, P988, DOI 10.1128/JVI.68.2.988-1001.1994; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SCHIESTL RH, 1989, MOL CELL BIOL, V9, P1882, DOI 10.1128/MCB.9.5.1882; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Sun Z., UNPUB; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	30	323	331	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					272	274		10.1126/science.281.5374.272	http://dx.doi.org/10.1126/science.281.5374.272			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657725				2022-12-28	WOS:000074714200054
J	Haines, A; Donald, A				Haines, A; Donald, A			Getting research findings into practice - Making better use of research findings	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE; PERFORMANCE		Royal Free Hosp, Sch Med, Dept Primary Care & Populat, London NW3 2PF, England; UCL, Sch Med, Dept Epidemiol & Publ Hlth, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School	Haines, A (corresponding author), Royal Free Hosp, Sch Med, Dept Primary Care & Populat, London NW3 2PF, England.	a.haines@ucl.ac.uk		Haines, Andy/0000-0002-8053-4605				*ADV GROUP NHS CEN, 1995, METH IMPL FIND RES P; BERO L, 1998, IN PRESS BMJ; BUXTON M, 1995, J HLTH SERV RES POLI, V1, P10; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1430, DOI 10.1136/bmj.316.7142.1430; CIMPL K, 1985, B MED LIBR ASSOC, V73, P21; Davis David A., 1995, JAMA (Journal of the American Medical Association), V274, P700, DOI 10.1001/jama.274.9.700; ENKIN M, 1996, EVIDENCE BASED MED, V1, P132; GOUWS D, 1994, CASE STUDIES VIEW IM; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; HAINES A, 1995, BRIT MED J, V310, P815, DOI 10.1136/bmj.310.6983.815; HAYNES B, 1998, IN PRESS BMJ; Hopkins A, 1996, BRIT MED J, V313, P477; Hyde CJ, 1996, INT J TECHNOL ASSESS, V12, P280, DOI 10.1017/S0266462300009636; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; JONES R, 1995, BRIT MED J, V311, P1076, DOI 10.1136/bmj.311.7012.1076; LIDSTONE J, 1987, MARKET PLANNING PHAR; Mittman B S, 1992, QRB Qual Rev Bull, V18, P413; MULROW CD, 1994, BRIT MED J, V309, P597, DOI 10.1136/bmj.309.6954.597; Murray TS, 1997, BRIT MED J, V315, P353; NHS Centre for Reviews and Dissemination, 1994, EFF HLTH CAR B; *NHS CTR REV DISS, 1995, EFF HLTH CAR B, V9; OXMAN A, IN PRESS EVIDENCE BA; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Prescott K, 1997, FAM PRACT, V14, P320, DOI 10.1093/fampra/14.4.320; Rogers EM., 1983, DIFFUSION INNOVATION; Sackett D. L., 1997, EVIDENCE BASED MED P; *SECR STAT HLTH, 1997, CMND3807; STOCKINB G, 1997, HLTH MANAGE, V1, P12; STOCKING B, 1993, MILBANK Q, V71, P497, DOI 10.2307/3350412; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529	32	120	120	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 4	1998	317	7150					72	75		10.1136/bmj.317.7150.72	http://dx.doi.org/10.1136/bmj.317.7150.72			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651281	Green Published			2022-12-28	WOS:000075081600037
J	Rajagopalan, M				Rajagopalan, M			The escape	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Ballarat Hlth Serv, Ballarat, Vic, Australia		Rajagopalan, M (corresponding author), Ballarat Hlth Serv, Box 577, Ballarat, Vic, Australia.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					67	68		10.7326/0003-4819-129-1-199807010-00015	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9653003				2022-12-28	WOS:000074513300011
J	Beecham, L				Beecham, L			Out of area treatments will replace ECRs	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1988	1988						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641962				2022-12-28	WOS:000074636700081
J	Ahmed, Y; Hayashi, S; Levine, A; Wieschaus, E				Ahmed, Y; Hayashi, S; Levine, A; Wieschaus, E			Regulation of armadillo by a Drosophila APC inhibits neuronal apoptosis during retinal development	CELL			English	Article							SEGMENT POLARITY GENE; FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; CELL-DEATH; PIGMENT EPITHELIUM; CONGENITAL HYPERTROPHY; MOLECULAR ANALYSIS; GARDNERS-SYNDROME; 4TH CHROMOSOME	We find that inactivation of a Drosophila homolog of the tumor suppressor APC (D-APC) causes retinal neuronal degeneration and pigment cell hypertrophy, a phenotype remarkably similar to that found in humans with germline APC mutations. Retinal degeneration in the D-APC mutant results from apoptotic cell death, which accompanies a defect in neuronal differentiation. Reduction in the Drosophila beta-catenin, Armadillo (Arm), rescues the differentiation defect and prevents apoptosis in the D-APC mutant, while Arm overexpression mimics D-APC inactivation. A mutation in dTCF, the DNA-binding protein required in Arm-mediated signal transduction, can eliminate the cell death without rescuing the differentiation defect in D-APC mutants. Uncoupling of these two Arm-induced processes suggests a novel role for the Arm/dTCF complex in the activation of apoptosis.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA	Princeton University; Howard Hughes Medical Institute; Princeton University	Wieschaus, E (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BLAIR NP, 1980, AM J OPHTHALMOL, V90, P661, DOI 10.1016/S0002-9394(14)75133-5; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; BROWNE SJ, 1994, INT J CANCER, V59, P56, DOI 10.1002/ijc.2910590113; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; BUETTNER H, 1975, AM J OPHTHALMOL, V79, P177, DOI 10.1016/0002-9394(75)90069-0; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLIFFORD RJ, 1989, GENETICS, V123, P771; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; HAY BA, 1994, DEVELOPMENT, V120, P2121; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LOCKE J, 1994, MOL GEN GENET, V243, P234, DOI 10.1007/BF00280321; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; ORENIC T, 1987, DEV BIOL, V124, P50, DOI 10.1016/0012-1606(87)90458-1; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Reddy GV, 1997, DEVELOPMENT, V124, P703; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; STEITZ MC, 1998, IN PRESS DEV BIOL, V197; STRATER J, 1995, GUT, V37, P819, DOI 10.1136/gut.37.6.819; SUGIYAMA H, 1994, J FOOD HYG SOC JPN, V35, P13, DOI 10.3358/shokueishi.35.13; TRABOULSI EI, 1990, ARCH OPHTHALMOL-CHIC, V108, P525, DOI 10.1001/archopht.1990.01070060073052; TRABOULSI EI, 1990, AM J OPHTHALMOL, V110, P550, DOI 10.1016/S0002-9394(14)77880-8; TZEPACZ C, 1997, J BIOL CHEM, V272, P21681; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; WOLFF T, 1991, DEVELOPMENT, V113, P825; WOLFF T, 1993, DEV DROSOPHILA MELAN, V2, P1277; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	58	193	196	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1171	1182		10.1016/S0092-8674(00)81461-0	http://dx.doi.org/10.1016/S0092-8674(00)81461-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657150	Bronze			2022-12-28	WOS:000074491100012
J	Chen, SW; Ingram, RS; Hostetler, MJ; Pietron, JJ; Murray, RW; Schaaff, TG; Khoury, JT; Alvarez, MM; Whetten, RL				Chen, SW; Ingram, RS; Hostetler, MJ; Pietron, JJ; Murray, RW; Schaaff, TG; Khoury, JT; Alvarez, MM; Whetten, RL			Gold nanoelectrodes of varied size: Transition to molecule-like charging	SCIENCE			English	Article							ELECTROCHEMICAL PROPERTIES; NANOPARTICLES; MONOLAYERS; CLUSTERS; SPECTRA	A transition from metal-like double-layer capacitive charging to redox-like charging was observed in electrochemical ensemble Coulomb staircase experiments on solutions of gold nanoparticles of varied core size. The monodisperse gold nanoparticles are stabilized by short-chain alkanethiolate monolayers and have 8 to 38 kilodaltons core mass (1.1 to 1.9 nanometers in diameter). Larger cores display Coulomb staircase responses consistent with double-layer charging of metal-electrolyte interfaces, whereas smaller core nanoparticles exhibit redox chemical character, including a large central gap. The change in behavior is consistent with new near-infrared spectroscopic data showing an emerging gap between the highest occupied and lowest unoccupied orbitals of 0.4 to 0.9 electron volt.	Univ N Carolina, Kenan Labs Chem, Dept Chem, Chapel Hill, NC 27599 USA; Georgia Inst Technol, Sch Chem, Atlanta, GA 30332 USA; Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA	University of North Carolina; University of North Carolina Chapel Hill; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	Murray, RW (corresponding author), Univ N Carolina, Kenan Labs Chem, Dept Chem, Chapel Hill, NC 27599 USA.	rwm@Qemail.unc.edu; robert.whetten@physics.gatech.edu	Chen, Shaowei/B-5171-2013	Pietron, Jeremy/0000-0001-7761-2812				Alvarez MM, 1997, J PHYS CHEM B, V101, P3706, DOI 10.1021/jp962922n; AMMAN M, 1991, PHYS REV B, V43, P1146, DOI 10.1103/PhysRevB.43.1146; Andres RP, 1996, SCIENCE, V272, P1323, DOI 10.1126/science.272.5266.1323; Badia A, 1996, CHEM-EUR J, V2, P359, DOI 10.1002/chem.19960020318; Bard A. J., 1980, ELECTROCHEMICAL METH; BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801; Collier CP, 1997, SCIENCE, V277, P1978, DOI 10.1126/science.277.5334.1978; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; Fan FRF, 1997, SCIENCE, V277, P1791, DOI 10.1126/science.277.5333.1791; Green SJ, 1997, J PHYS CHEM B, V101, P2663, DOI 10.1021/jp962664u; Guo LJ, 1997, SCIENCE, V275, P649, DOI 10.1126/science.275.5300.649; Hartmann E, 1996, APPL SURF SCI, V107, P197, DOI 10.1016/S0169-4332(96)00507-7; Hayat MA, 1991, COLLOIDAL GOLD PRINC; Hofstetter W, 1997, PHYS REV LETT, V78, P3737, DOI 10.1103/PhysRevLett.78.3737; Hostetler MJ, 1997, CURR OPIN COLLOID IN, V2, P42, DOI 10.1016/S1359-0294(97)80007-6; Ingram RS, 1997, J AM CHEM SOC, V119, P9279, DOI 10.1021/ja972319y; INGRAM RS, UNPUB; LI Q, 1992, J AM CHEM SOC, V114, P3994, DOI 10.1021/ja00036a068; PORTER MD, 1987, J AM CHEM SOC, V109, P3559, DOI 10.1021/ja00246a011; *RA WELCH FDN, 1996, P RA WELCH FDN 40 C; ROTH JD, 1992, J AM CHEM SOC, V114, P6159, DOI 10.1021/ja00041a038; Sato T, 1997, APPL PHYS LETT, V70, P2759, DOI 10.1063/1.118975; Schaaff TG, 1997, J PHYS CHEM B, V101, P7885, DOI 10.1021/jp971438x; Schmid G., 1994, CLUSTERS COLLOIDS; SUZUKI T, 1993, J AM CHEM SOC, V115, P11006, DOI 10.1021/ja00076a075; TAYLOR KJ, 1992, J CHEM PHYS, V96, P3319, DOI 10.1063/1.461927; UNDERWOOD S, 1994, LANGMUIR, V10, P3427, DOI 10.1021/la00022a011; WEAVER MJ, 1993, J PHYS CHEM-US, V97, P332, DOI 10.1021/j100104a012; Whetten RL, 1996, ADV MATER, V8, P428, DOI 10.1002/adma.19960080513	29	1037	1050	0	189	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2098	2101		10.1126/science.280.5372.2098	http://dx.doi.org/10.1126/science.280.5372.2098			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641911				2022-12-28	WOS:000074435900039
J	Jenkins, JS				Jenkins, JS			The voice of the castrato	LANCET			English	Article							CHROMOSOME				Jenkins, JS (corresponding author), 40 Hampstead Way, London NW11 7JL, England.							ANDERSON E, 1988, LETT MOZART HIS FAMI, P54; AUFDEMORTE TB, 1983, LARYNGOSCOPE, V93, P1607, DOI 10.1288/00005537-198312000-00013; BALLABIO A, 1989, P NATL ACAD SCI USA, V86, P10001, DOI 10.1073/pnas.86.24.10001; BARBIER P, 1996, WORLD CASTRATI, P93; BUHLER EM, 1980, HUM GENET, V55, P145, DOI 10.1007/BF00291764; BURNEY C, 1935, GEN HIST MUSIC EARLI, V2, P789; Burney Charles, 1959, BURNEYS MUSICAL TOUR, V1, P247; DEBROSSES C, 1999, LETT HIST CRITIQUES, V3, P246; DRYDEN J, 1958, POEMS J DRYDEN, V2, P708; Goldman J. L., 1942, ANN OTORHINOL LARYNG, V51, P961; HABOCK F, 1927, KASTRATEN IHRE GESAN, P238; HABOCK F, 1927, KASTRATEN IHRE GESAN, P207; HERIOT A, 1956, CASTRATI OPERA, P99; KAHANE JC, 1982, J SPEECH HEAR RES, V25, P446, DOI 10.1044/jshr.2503.446; LUSCHINGER R, 1965, VOICE SPEECH LANGUAG, P190; Milner Anthony, 1973, MUSIC TIMES, V114, P250; SMOLLETT T, 1988, H CLINKER 1771, P123; Tandler J, 1909, ARCH ENTWICKLUNG ORG, V27, P35, DOI 10.1007/BF02161788; TUOHIMAA PT, 1981, ACTA OTO-LARYNGOL, V91, P149, DOI 10.3109/00016488109138493; 1918, EUNUCHISM DISPLAYD	20	46	46	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1877	1880		10.1016/S0140-6736(97)10198-2	http://dx.doi.org/10.1016/S0140-6736(97)10198-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652686				2022-12-28	WOS:000074347100043
J	Kamwendo, F; Forslin, L; Bodin, L; Danielsson, D				Kamwendo, F; Forslin, L; Bodin, L; Danielsson, D			Programmes to reduce pelvic inflammatory disease - the Swedish experience	LANCET			English	Article							ACUTE SALPINGITIS; CHLAMYDIA-TRACHOMATIS; CENTRAL SWEDEN; URBAN AREA; WOMEN; INFECTION; GONORRHEA; ETIOLOGY; CONSEQUENCES; PREVENTION		Orebro Med Ctr Hosp, Dept Clin Microbiol & Immunol, S-70185 Orebro, Sweden; Orebro Med Ctr Hosp, Dept Obstet & Gynaecol, S-70185 Orebro, Sweden; Orebro Med Ctr Hosp, Dept Occupat & Environm Med, Biostat Sect, S-70185 Orebro, Sweden		Danielsson, D (corresponding author), Orebro Med Ctr Hosp, Dept Clin Microbiol & Immunol, S-70185 Orebro, Sweden.							ADLER MW, 1980, AM J OBSTET GYNECOL, V138, P901, DOI 10.1016/0002-9378(80)91079-0; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; Centers for Disease Control and Prevention, 1998, MMWR-MORBID MORTAL W, V47, P79; COUTINHO RA, 1992, GENITOURIN MED, V68, P353; CURRAN JW, 1980, AM J OBSTET GYNECOL, V138, P848, DOI 10.1016/0002-9378(80)91069-8; *DIV STD PREV, 1997, SEX TRANSM DIS SURV; EILARD T, 1976, SCAND J INFECT DIS, P82; ESCHENBACH DA, 1975, NEW ENGL J MED, V293, P166, DOI 10.1056/NEJM197507242930403; FALK V, 1965, ACTA OBSTET GYN SCAN, VS 44, P1, DOI 10.3109/00016346509158538; FORSLIN L, 1978, BRIT J VENER DIS, V54, P247; Hadgu A, 1997, STAT MED, V16, P2403; HADGU A, 1986, AM J OBSTET GYNECOL, V155, P954, DOI 10.1016/0002-9378(86)90324-8; HEMSELL DL, 1988, J REPROD MED, V33, P799; JACOBSON L, 1969, AM J OBSTET GYNECOL, V105, P1088, DOI 10.1016/0002-9378(69)90132-X; JOHANSSON E, 1987, 7 INT M INT SOC STD; KAHN JG, 1991, JAMA-J AM MED ASSOC, V266, P2594, DOI 10.1001/jama.266.18.2594; KAMWENDO F, 1990, GENITOURIN MED, V66, P324; Kamwendo F, 1996, SEX TRANSM DIS, V23, P384, DOI 10.1097/00007435-199609000-00007; KAMWENDO F, 1993, SEX TRANSM DIS, V20, P143, DOI 10.1097/00007435-199305000-00005; KIHLSTROM E, 1994, CURR OPIN INFECT DIS, V7, P25, DOI 10.1097/00001432-199402000-00005; LEE NC, 1988, OBSTET GYNECOL, V72, P1; MARDH PA, 1977, NEW ENGL J MED, V296, P1377, DOI 10.1056/NEJM197706162962403; OLNERHANSEN P, 1990, SEXUALLY TRANSMITTED, P615; RIPA T, 1990, SCAND J INFECT DIS, P157; RIPA T, 1982, CHLAMYDIAL INFECTION, P179; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; SELLORS J, 1991, AM J OBSTET GYNECOL, V164, P113, DOI 10.1016/0002-9378(91)90639-9; SELLORS J, 1987, 7 INT M INT SOC STD; SWEET RL, 1981, OBSTET GYNECOL, V58, P62; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2574, DOI 10.1001/jama.266.18.2574; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2565, DOI 10.1001/jama.266.18.2565; Washington E, 1996, J FAM PRACTICE, V43, P283; WESTROM L, 1988, GENITOURIN MED, V64, P59; WESTROM L, 1980, AM J OBSTET GYNECOL, V138, P880, DOI 10.1016/0002-9378(80)91077-7; WESTROM L, 1992, SEX TRANSM DIS, V19, P185, DOI 10.1097/00007435-199207000-00001; WESTROM L, 1982, SCAND J INFECT DIS, P157; WESTROM L, 1976, LANCET, V2, P221; WESTROM L, 1990, SEXUALLY TRANSMITTED, P593; WRIGHT NH, 1968, AM J OBSTET GYNECOL, V101, P979, DOI 10.1016/0002-9378(68)90285-8	39	52	54	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN	1998	351			3			25	28						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV844	9652718				2022-12-28	WOS:000074347300009
J	Nagaoka, T; Matsushita, S; Nagai, Y; Kobayashi, K				Nagaoka, T; Matsushita, S; Nagai, Y; Kobayashi, K			A woman who trembled, then had chorea	LANCET			English	Article									Kanazawa Univ, Sch Med, Dept Internal Med 1, Kanazawa, Ishikawa 9200934, Japan; Natl Yamanaka Hosp, Ishikawa, Japan	Kanazawa University	Nagaoka, T (corresponding author), Kanazawa Univ, Sch Med, Dept Internal Med 1, Kanazawa, Ishikawa 9200934, Japan.							Delong G. Robert, 1996, P645; Lucantoni C, 1994, Acta Neurol (Napoli), V16, P129; POZZAN GB, 1992, BRAIN DEV-JPN, V14, P126, DOI 10.1016/S0387-7604(12)80102-1; SHAHAR E, 1988, ISRAEL J MED SCI, V24, P264; Sutherland GA, 1903, BRAIN, V26, P210, DOI 10.1093/brain/26.2.210	5	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1326	1326		10.1016/S0140-6736(97)11126-6	http://dx.doi.org/10.1016/S0140-6736(97)11126-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643796				2022-12-28	WOS:000073439400011
J	Brown, P				Brown, P			BSE: the final resting place	LANCET			English	Editorial Material							SURVIVAL; VARIANT		NINDS, Cent Nervous Syst Studies Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Brown, P (corresponding author), NINDS, Cent Nervous Syst Studies Lab, Bethesda, MD 20892 USA.							BROWN P, 1990, J INFECT DIS, V161, P467, DOI 10.1093/infdis/161.3.467; BROWN P, 1991, LANCET, V337, P269, DOI 10.1016/0140-6736(91)90873-N; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Collee JG, 1997, LANCET, V349, P715, DOI 10.1016/S0140-6736(96)08496-6; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Palsson P. A., 1979, Slow transmissible diseases of the nervous system. Volume 1., P357; Scrimgeour EM, 1996, VET REC, V139, P219; Taylor David M., 1996, P105; Wells GAH, 1998, VET REC, V142, P103, DOI 10.1136/vr.142.5.103; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	10	19	19	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1146	1147		10.1016/S0140-6736(05)79115-7	http://dx.doi.org/10.1016/S0140-6736(05)79115-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643681				2022-12-28	WOS:000073220200003
J	Sharp, D				Sharp, D			A ghostly crew	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Sharp, D (corresponding author), The Lancet, London WC1B 3SL, England.							Calder I, 1997, BRIT MED J, V314, P2, DOI 10.1136/bmj.314.7073.2; Horton R, 1998, LANCET, V351, P688, DOI 10.1016/S0140-6736(98)22010-1; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; 1993, LANCET, V342, P1498	4	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1076	1076		10.1016/S0140-6736(05)79376-4	http://dx.doi.org/10.1016/S0140-6736(05)79376-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660573				2022-12-28	WOS:000073090200005
J	Abse, D				Abse, D			More than a green placebo	LANCET			English	Editorial Material									The Lancet, London, England		Abse, D (corresponding author), The Lancet, London, England.							AUDEN WH, 1950, COLLECTED SHORTER PO, P65; ECKERMANN JP, 1970, CONVERSATIONS GOETHE; LEVETOV D, 1981, LIGHT CAVE, P284; RILKE RM, 1948, POEMS BOOK HOURS; SHELLEY PB, DEFENCE OF POETRY; SMITH K, 1997, BEDLAM; Soderberg Hjalmar, 1905, DOCTOR GLAS; WILLIAMS WC, 1987, DOCTOR STORIES, P59; WILLIAMS WC, 1987, DOCTOR STORIES, P56; YOUNG I, 1991, PRIVATE LIFE ISLAM; 1972, LANCET, V2, P122	11	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					362	364		10.1016/S0140-6736(97)10380-4	http://dx.doi.org/10.1016/S0140-6736(97)10380-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652635				2022-12-28	WOS:000071864000045
J	Neumann, CJ; Cohen, SM				Neumann, CJ; Cohen, SM			Boundary formation in Drosophila wing: Notch activity attenuated by the POU protein Nubbin	SCIENCE			English	Article							DORSAL/VENTRAL COMPARTMENT BOUNDARY; DORSAL-VENTRAL BOUNDARY; SPLIT COMPLEX GENES; VESTIGIAL GENE; EXPRESSION; SUPPRESSOR; ACTIVATION; RECEPTOR; SERRATE; SIGNAL	Cell interactions mediated by Notch-family receptors have been implicated in the specification of tissue boundaries in vertebrate and insect development, Although Notch Ligands are often widely expressed, tightly Localized activation of Notch is critical for the formation of sharp boundaries. Evidence is presented here that the POU domain protein Nubbin contributes to the formation of a sharp dorsoventral boundary in the Drosophila wing. Nubbin represses Notch-dependent target genes and sets a threshold for Notch activity that defines the spatial domain of boundary-specific gene expression.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Cohen, SM (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163				Averof M, 1997, NATURE, V385, P627, DOI 10.1038/385627a0; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Cifuentes FJ, 1997, P NATL ACAD SCI USA, V94, P11405, DOI 10.1073/pnas.94.21.11405; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; deCelis JF, 1996, DEVELOPMENT, V122, P359; deCelis JF, 1997, DEVELOPMENT, V124, P3241; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jen WC, 1997, DEVELOPMENT, V124, P1169; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Neumann CJ, 1997, DEVELOPMENT, V124, P871; NG M, 1995, DEVELOPMENT, V121, P589; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; Pignoni F, 1997, DEVELOPMENT, V124, P271; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; RORTH P, 1992, GENE DEV, V6, P2299, DOI 10.1101/gad.6.12a.2299; Rulifson EJ, 1996, NATURE, V384, P72, DOI 10.1038/384072a0; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; Sidow A, 1997, NATURE, V389, P722, DOI 10.1038/39587; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	39	55	56	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					409	413		10.1126/science.281.5375.409	http://dx.doi.org/10.1126/science.281.5375.409			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665883				2022-12-28	WOS:000074918800046
J	Barnett, JL				Barnett, JL			Vascular ectasia of the gastric antrum	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Michigan Hosp, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Barnett, JL (corresponding author), Univ Michigan Hosp, Ann Arbor, MI 48109 USA.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					166	166		10.1056/NEJM199807163390305	http://dx.doi.org/10.1056/NEJM199807163390305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ922	9664093				2022-12-28	WOS:000074782900005
J	Perneger, TV; Giner, F; del Rio, M; Mino, A				Perneger, TV; Giner, F; del Rio, M; Mino, A			Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments	BMJ-BRITISH MEDICAL JOURNAL			English	Article							METHADONE	Objective: To evaluate an experimental heroin maintenance programme. Design: Randomised trial. Setting: Outpatient clinic in Geneva, Switzerland. Subjects: Heroin addicts recruited from the community who were socially marginalised and in poor health and had failed in at least two previous drug treatments. Intervention: Patients in the experimental programme (n = 27) received intravenous heroin and other health and psychosocial services. Control patients (n = 24) received any other conventional drug treatment (usually methadone maintenance). Main outcome measures: Self reported drug use, health status (SF-36), and social functioning. Results: 25 experimental patients completed 6 months in the programme, receiving a median of 480 mg of heroin daily. One experimental subject and 10 control subjects still used street heroin daily at follow up (difference 44%; 95% confidence interval 16% to 71%). Health status scores that improved significantly more in experimental subjects were mental health (0.58 SD; 0.07 to 1.10), role limitations due to emotional problems (0.95 SD; 0.11 to 1.79), and social functioning (0.65 SD; 0.03 to 1.26). Experimental subjects also significantly reduced their illegal income and drug expenses and committed fewer drug and property related offences. There were no benefits in terms of work, housing situation, somatic health status, and use of other drugs. Unexpectedly, only nine (38%) control subjects entered the heroin maintenance programme at follow UP Conclusions: A heroin maintenance programme is a feasible and clinically effective treatment for heroin users who fail in conventional drug treatment programmes. Even in this population, however another attempt at methadone maintenance may be successful and help the patient to stop using injectable opioids.	Univ Geneva, Sch Med, Inst Social & Prevent Med, CH-1211 Geneva 4, Switzerland; Univ Hosp Geneva, Dept Psychiat, Div Subst Abuse, CH-1211 Geneva 14, Switzerland	University of Geneva; University of Geneva	Perneger, TV (corresponding author), Univ Geneva, Sch Med, Inst Social & Prevent Med, CH-1211 Geneva 4, Switzerland.	perneger@cmu.unige.ch						Armitage P., 1987, STAT METHODS MED RES; Bammer G, 1996, MED J AUSTRALIA, V164, P690, DOI 10.5694/j.1326-5377.1996.tb122243.x; DOLE VP, 1972, J AMER MED ASSOC, V220, P1493, DOI 10.1001/jama.220.11.1493; DOLE VP, 1969, NEW ENGL J MED, V280, P1372, DOI 10.1056/NEJM196906192802502; DOLE VP, 1965, JAMA-J AM MED ASSOC, V193, P80; FARRELL M, 1994, BMJ-BRIT MED J, V309, P997, DOI 10.1136/bmj.309.6960.997; GHODSE AH, 1983, LANCET, V1, P636; GUNNE LM, 1981, DRUG ALCOHOL DEPEN, V7, P249, DOI 10.1016/0376-8716(81)90096-X; HARTNOLL RL, 1980, ARCH GEN PSYCHIAT, V37, P877; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; KORAN LM, 1973, NEW ENGL J MED, V288, P654, DOI 10.1056/NEJM197303292881305; LEWIS E, 1973, JAMA-J AM MED ASSOC, V223, P539, DOI 10.1001/jama.223.5.539; Mino A, 1990, SCI ANAL LIT CONTROL; NADELMANN EA, 1989, SCIENCE, V245, P939, DOI 10.1126/science.2772647; NEWMAN RG, 1979, LANCET, V2, P485; OSTINI R, 1993, J MED ETHICS, V19, P175, DOI 10.1136/jme.19.3.175; RIHSMIDDEL M, 1996, SWISS FEDERAL OFFICE; SHELDON T, 1995, BRIT MED J, V310, P1625, DOI 10.1136/bmj.310.6995.1625; Stimson G., 1982, HEROIN ADDICTION TRE; Strang J., 1994, HEROIN ADDICTION DRU; Uchtenhagen A, 1994, Schweiz Rundsch Med Prax, V83, P931	22	187	187	1	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 4	1998	317	7150					13	18		10.1136/bmj.317.7150.13	http://dx.doi.org/10.1136/bmj.317.7150.13			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651260	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000075081600016
J	Young, WA				Young, WA			Locking the door: US imprisonment of asylum seekers	LANCET			English	Editorial Material									Womens Commiss Regugee Women & Children, Washington, DC USA		Young, WA (corresponding author), Womens Commiss Regugee Women & Children, Washington, DC USA.							*WOM COMM REF WOM, 1996, LIB DEN REP COND DET	1	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1955	1956		10.1016/S0140-6736(05)78641-4	http://dx.doi.org/10.1016/S0140-6736(05)78641-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654282				2022-12-28	WOS:000074464700047
J	Marsh, JCW; Gordon-Smith, EC				Marsh, JCW; Gordon-Smith, EC			Treatment options in severe aplastic anaemia	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; ANEMIA; CYCLOPHOSPHAMIDE; GLOBULIN		Univ London St Georges Hosp, Sch Med, Dept Cellular & Mol Sci, Div Haematol, London SW17 0RE, England	St Georges University London	Marsh, JCW (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Cellular & Mol Sci, Div Haematol, London SW17 0RE, England.							BACIGALUPO A, 1995, BLOOD, V85, P1348, DOI 10.1182/blood.V85.5.1348.bloodjournal8551348; BACIGALUPO A, 1998, BONE MARROS TRANS S1, V21, pA177; Brodsky RA, 1996, BLOOD, V87, P491, DOI 10.1182/blood.V87.2.491.bloodjournal872491; HOWS JM, 1996, BONE MARROW TRANS S1, V17, pA269; Killick SB, 1997, BRIT J HAEMATOL, V97, P677, DOI 10.1046/j.1365-2141.1997.812721.x; Margolis D, 1996, BRIT J HAEMATOL, V94, P65, DOI 10.1046/j.1365-2141.1996.d01-1772.x; MARSH JCW, 1994, LANCET, V344, P172, DOI 10.1016/S0140-6736(94)92763-4; SCHREZENMEIER H, 1995, BONE MARROW TRANS S2, V15, pA65; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; Speiser DE, 1996, BRIT J HAEMATOL, V93, P935; STORB R, 1994, BLOOD, V84, P941, DOI 10.1182/blood.V84.3.941.941; Tichelli A, 1998, BRIT J HAEMATOL, V100, P393, DOI 10.1046/j.1365-2141.1998.00578.x; YOUNG NS, 1995, LANCET, V346, P228, DOI 10.1016/S0140-6736(95)91273-8; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906; YOUNG NS, 1995, BLOOD, V85, P3367, DOI 10.1182/blood.V85.12.3367.bloodjournal85123367	15	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1830	1831		10.1016/S0140-6736(05)78801-2	http://dx.doi.org/10.1016/S0140-6736(05)78801-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652663				2022-12-28	WOS:000074347100006
J	Irving, M				Irving, M			What should a junior doctor have done?	BRITISH MEDICAL JOURNAL			English	Article									Hope Hosp, Dept Surg, Salford M6 8HD, Lancs, England		Irving, M (corresponding author), Hope Hosp, Dept Surg, Clin Sci Bldg, Salford M6 8HD, Lancs, England.							deLeval MR, 1997, LANCET, V349, P723, DOI 10.1016/S0140-6736(96)11327-1; *DEP HLTH, 1990, HC909 DEP HLTH; *NHS EX, 1994, HSG9449 NHS EX	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1737	1738						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9652925				2022-12-28	WOS:000074129500037
J	Ison, CA; Dillon, JR; Tapsall, JW				Ison, CA; Dillon, JR; Tapsall, JW			The epidemiology of global antibiotic resistance among Neisseria gonorrhoeae and Haemophilus ducreyi	LANCET			English	Article							SEXUALLY-TRANSMITTED DISEASES; IMMUNODEFICIENCY-VIRUS INFECTION; HEMOPHILUS-DUCREYI; TRIMETHOPRIM-SULFAMETHOXAZOLE; PENICILLIN; SUSCEPTIBILITY; TETRACYCLINE; CEFTRIAXONE; FLEROXACIN; KENYA		Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis & Microbiol, London W2 1PG, England; Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; WHO PAHO Coordinating Ctr Genococcal Antimicrobia, Ottawa, ON, Canada; Prince Wales Hosp, Dept Microbiol, GASP WHO Collaborating Ctr WPR, Randwick, NSW 2031, Australia	Imperial College London	Ison, CA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis & Microbiol, St Marys Campus,Norfolk Pl, London W2 1PG, England.	c.ison@ic.ac.uk						ALBRITTON WL, 1982, ANTIMICROB AGENTS CH, V21, P159, DOI 10.1128/AAC.21.1.159; ASHFORD WA, 1976, LANCET, V2, P657; Ballard RC, 1996, INT J STD AIDS, V7, P9, DOI 10.1258/0956462961917230; BIRLEY H, 1994, GENITOURIN MED, V70, P292; BOGAERTS J, 1995, CLIN INFECT DIS, V20, P924, DOI 10.1093/clinids/20.4.924; BRUNTON JL, 1979, ANTIMICROB AGENTS CH, V15, P294, DOI 10.1128/AAC.15.2.294; Dillon J A, 1992, Can J Infect Dis, V3, P202; FARUKI H, 1985, NEW ENGL J MED, V313, P607, DOI 10.1056/NEJM198509053131004; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HAMMOND GW, 1978, ANTIMICROB AGENTS CH, V13, P608, DOI 10.1128/AAC.13.4.608; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; MACDONALD KS, 1989, ANTIMICROB AGENTS CH, V33, P612, DOI 10.1128/AAC.33.5.612; MANESS MJ, 1974, J BACTERIOL, V120, P1293, DOI 10.1128/JB.120.3.1293-1299.1974; *MEMB AUSTR GON SU, 1984, BR J VENER DIS, V60, P226; MORSE SA, 1989, CLIN MICROBIOL REV, V2, P137, DOI 10.1128/CMR.2.2.137-157.1989; MORSE SA, 1986, ANTIMICROB AGENTS CH, V30, P664, DOI 10.1128/AAC.30.5.664; PHILLIPS I, 1976, LANCET, V2, P656; PLOURDE PJ, 1992, J INFECT DIS, V165, P949, DOI 10.1093/infdis/165.5.949; ROBERTS MC, 1989, ANTIMICROB AGENTS CH, V33, P1611, DOI 10.1128/AAC.33.9.1611; SCHWARCZ SK, 1990, JAMA-J AM MED ASSOC, V264, P1413, DOI 10.1001/jama.264.11.1413; SCHWEBKE JR, 1995, ANTIMICROB AGENTS CH, V39, P917, DOI 10.1128/AAC.39.4.917; SPARLING PF, 1975, J BACTERIOL, V124, P740, DOI 10.1128/JB.124.2.740-749.1975; Tapsall J., 1997, Communicable Diseases Intelligence, V21, P349; Tapsall JW, 1996, SEX TRANSM DIS, V23, P425, DOI 10.1097/00007435-199609000-00014; TAPSALL JW, 1988, GENITOURIN MED, V64, P147; TYNDALL M, 1993, J INFECT DIS, V167, P469, DOI 10.1093/infdis/167.2.469; TYNDALL MW, 1993, AM J MED, V94, P85; van de Laar MJW, 1997, GENITOURIN MED, V73, P510; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; *WHO, 1990, WHOVDT90452	30	78	83	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN	1998	351			3			8	11						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV844	9652713				2022-12-28	WOS:000074347300004
J	Lewis, S				Lewis, S			ISAAC - a hypothesis generator for asthma?	LANCET			English	Editorial Material							COMMUNITY		Univ Nottingham, Div Resp Med, Nottingham NG5 1PB, England	University of Nottingham	Lewis, S (corresponding author), Univ Nottingham, Div Resp Med, Nottingham NG5 1PB, England.							Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Butland BK, 1997, BRIT MED J, V315, P717, DOI 10.1136/bmj.315.7110.717; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Lewis S, 1996, THORAX, V51, P670, DOI 10.1136/thx.51.7.670; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P10; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P296, DOI 10.1111/j.1365-2222.1995.tb01046.x; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P791, DOI 10.1111/j.1365-2222.1995.tb00019.x; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; 1997, LANCET, V350, P1113	10	29	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1220	1221		10.1016/S0140-6736(98)22017-4	http://dx.doi.org/10.1016/S0140-6736(98)22017-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643736				2022-12-28	WOS:000073283600002
J	Banks, JT				Banks, JT			Mrs Woolf in Harley Street	LANCET			English	Editorial Material									Penn State Univ, Milton S Hershey Med Ctr, Dept Humanities, Hershey, PA 17003 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Banks, JT (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Humanities, POB 850, Hershey, PA 17003 USA.							BANKS JT, 1994, CHARLESTON MAGAZ AUT, P29; BAYLY S, 1998, DALLOWAY; BELL Q, 1972, V WOOLF BIOGRAPHY, V2, P8; BELL Q, 1972, V WOOLF BIOGRAPHY, V1, P90; Caramagno T., 1992, FLIGHT MIND V WOOLFS; DeSalvo L., 1989, V WOOLF IMPACT CHILD; Jones AH, 1997, LANCET, V350, P359, DOI 10.1016/S0140-6736(97)07123-7; Laing R., 1965, DIVIDED SELF; LEE H, 1996, V WOOLF, P195; MARCUS J, 1987, V WOOLF LANGUAGES PA, P99; NICOLSON N, 1977, CHANGE PERSPECTIVE L, P221; NICOLSON N, 1976, QUESTION THINGS HAPP, P35; NICOLSON N, 1975, FLIGHT MIND LETT V W, P148; POIRIER S, 1985, LIT MED, V2, P23; Poole R., 1995, UNKNOWN V WOOLF; SHAW GB, 1965, DOCTORS DILEMMA 1913, P8; Spilka Mark, 1980, V WOOLFS QUARREL GRI; Trombley Stephen, 1981, V WOOLF HER DOCTORS; WEINTRAUB S, 1997, CHARLESTON MAGAZ AUT, P19; Woolf Virginia, 1996, DALLOWAY	20	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1124	1126		10.1016/S0140-6736(98)02502-1	http://dx.doi.org/10.1016/S0140-6736(98)02502-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660599				2022-12-28	WOS:000073090200046
J	Baron, JA; Gridley, G; Weiderpass, E; Nyren, O; Linet, M				Baron, JA; Gridley, G; Weiderpass, E; Nyren, O; Linet, M			Venous thromboembolism and cancer	LANCET			English	Article							PULMONARY-EMBOLISM; ORAL-CONTRACEPTIVES; OVARIAN-CANCER; THROMBOSIS; RISK; MALIGNANCY	Background Although cancer has been clearly associated with venous thromboembolism (VTE), many aspects of this relation are poorly understood, including the cancer sites most affected and the cancer risk during long-term follow-up. To clarify these relations, we carried out a large, population-based analysis of VTE and cancer risk. Methods Using the Swedish Inpatient Register and linkage to the nationwide Cancer Registry, we assessed cancer incidence during 1989 among 61 998 patients without a previous cancer diagnosis admitted to hospital between 1965 and 1983 for VTE. To measure possible increases in cancer risk, we computed standardised incidence ratios (SIRs) using Swedish national cancer rates for the period of the study. Findings At the time of thromboembolic admission or during the first year of follow-up, 2509 cancers were diagnosed (SIR 3.2, 95% CI 3.1-3.4). The SIR for polycythaemia vera was 12.9 (8.6-18.7), and the SIRs for cancers of the liver, pancreas, ovary, and brain, and for Hodgkin lymphoma also exceeded 5.0. Patients aged less than 65 years had higher SIRs than those who were older. In subsequent years, 6081 cancers were diagnosed (1.3, 1.3-1.3). Even 10 years or more after admission to hospital with VTE, cancer incidence had increased (1.3, 1.3-1.4). Interpretation At the time of VTE or in the first year afterwards, we found a large increase in the risk for diagnosis of virtually all cancers. In subsequent years, a persistent 30% increase in risk remains. Either premalignant change promotes thrombosis, or cancer and thrombosis share common risk factors.	Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA; Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden; NCI, Div Canc Etiol, Epidemiol & Biostat Program, Bethesda, MD 20892 USA	Dartmouth College; Dartmouth College; Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Baron, JA (corresponding author), DHMC, 7927 Rubin Bldg,1 Med Ctr Dr, Lebanon, NH 03756 USA.	John.Baron@Dartmouth.edu	Weiderpass, Elisabete/M-4029-2016; Couturaud, Francis/Q-1366-2019; Weiderpass, Elisabete/AAP-2747-2021; Okutan, Oguzhan/I-8809-2016	Weiderpass, Elisabete/0000-0003-2237-0128; Couturaud, Francis/0000-0002-1855-8032; Weiderpass, Elisabete/0000-0003-2237-0128; Okutan, Oguzhan/0000-0002-4660-1595	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP060538] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-60538] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adami HO, 1995, MUTAT RES-FUND MOL M, V333, P29, DOI 10.1016/0027-5107(95)00128-X; Baron JA, 1996, BRIT MED BULL, V52, P58, DOI 10.1093/oxfordjournals.bmb.a011533; BRESLOW NE, IARC SCI PUBLICATION, V82, P131; CARTER CJ, 1994, PROG CARDIOVASC DIS, V36, P423, DOI 10.1016/S0033-0620(94)80051-0; FEINLEIB M, 1972, MILBANK MEML FUND Q, V50, P123, DOI 10.2307/3349403; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; GOLDHABER SZ, 1983, AM J MED, V74, P1023, DOI 10.1016/0002-9343(83)90805-7; GORE JM, 1982, ANN INTERN MED, V96, P556, DOI 10.7326/0003-4819-96-5-556; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; HANKINSON SE, 1995, CANCER, V76, P284, DOI 10.1002/1097-0142(19950715)76:2<284::AID-CNCR2820760219>3.0.CO;2-5; MARNETT LJ, 1992, CANCER RES, V52, P5575; MATTSSON B, 1985, INT J EPIDEMIOL, V14, P64, DOI 10.1093/ije/14.1.64; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; Rothman K, 1986, MODERN EPIDEMIOLOGY; SAMKOFF JS, 1981, AM J EPIDEMIOL, V114, P488, DOI 10.1093/oxfordjournals.aje.a113214; SILVERSTEIN RL, 1992, NEW ENGL J MED, V327, P1163, DOI 10.1056/NEJM199210153271611; TOMATIS L, 1990, IARC SCI PUBL, V100, P169; TROUSSEAU A, 1872, LECT CLIN MED DEL HO, P282; TULINIUS H, 1991, AUTOPSY EPIDEMIOLOGY, P253; VESSEY MP, 1995, BRIT J CANCER, V71, P1340, DOI 10.1038/bjc.1995.260; WEISS N, 1995, LANCET, V346, P1570, DOI 10.1016/S0140-6736(95)91921-X; Willett WC, 1996, CANCER CAUSE CONTROL, V7, P178, DOI 10.1007/BF00115648; ZACHARSKI LR, 1992, SEMIN THROMB HEMOST, V18, P104, DOI 10.1055/s-2007-1002415; Zondervan KT, 1996, BRIT J CANCER, V73, P1291, DOI 10.1038/bjc.1996.247	27	375	398	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1077	1080		10.1016/S0140-6736(97)10018-6	http://dx.doi.org/10.1016/S0140-6736(97)10018-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660575	hybrid			2022-12-28	WOS:000073090200007
J	Northover, J				Northover, J			Realism or nihilism in bowel cancer follow-up?	LANCET			English	Editorial Material							COLORECTAL-CANCER; COLON-CANCER; CEA; COST		St Marks Hosp, Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England	Imperial College London	Northover, J (corresponding author), St Marks Hosp, Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England.							Audisio RA, 1996, ANN SURG ONCOL, V3, P349, DOI 10.1007/BF02305664; BRUINVELS DJ, 1995, EUR J SURG, V161, P827; COCHRANE JPS, 1980, BRIT MED J, V280, P593, DOI 10.1136/bmj.280.6214.593; FLETCHER RH, 1993, JAMA-J AM MED ASSOC, V270, P987, DOI 10.1001/jama.270.8.987; HAWARD R, 1997, IMPROVING OUTCOMES C; KIEVIT J, 1995, EUR J CANCER, V31A, P1222, DOI 10.1016/0959-8049(95)00155-C; MAKELA J, 1996, ARCH SURG-CHICAGO, V130, P1062; MARTIN EW, 1979, AM J SURG, V137, P167, DOI 10.1016/0002-9610(79)90137-5; MOERTEL C, 1978, JAMA-J AM MED ASSOC, V78, P1065; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; NORTHOVER J, 1994, JAMA-J AM MED ASSOC, V272, P31, DOI 10.1001/jama.1994.03520010041025; OHLSSON B, 1995, DIS COLON RECTUM, V38, P219; Schoemaker D, 1998, GASTROENTEROLOGY, V114, P7, DOI 10.1016/S0016-5085(98)70626-2; SUGARBAKER P, 1994, TUMORI, V31, P126; VIRGO KS, 1995, JAMA-J AM MED ASSOC, V273, P1837, DOI 10.1001/jama.273.23.1837	15	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1074	1076		10.1016/S0140-6736(05)79375-2	http://dx.doi.org/10.1016/S0140-6736(05)79375-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660572				2022-12-28	WOS:000073090200004
J	Nicholson, KG; Nguyen-Van-Tam, JS; Ahmed, AH; Wiselka, MJ; Leese, J; Ayres, J; Campbell, JH; Ebden, P; Eiser, NM; Hutchcroft, BJ; Pearson, JCG; Willey, RF; Wolstenholme, RJ; Woodhead, MA				Nicholson, KG; Nguyen-Van-Tam, JS; Ahmed, AH; Wiselka, MJ; Leese, J; Ayres, J; Campbell, JH; Ebden, P; Eiser, NM; Hutchcroft, BJ; Pearson, JCG; Willey, RF; Wolstenholme, RJ; Woodhead, MA			Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma	LANCET			English	Article							CHILDREN; EXACERBATIONS; ADULTS; INFECTIONS; VIRUS; PRECIPITANTS; IMMUNIZATION; REACTIVITY; COMMUNITY; SAFETY	Background Despite current recommendations, many people with asthma do not receive annual vaccination against influenza, partly because of concern that vaccine may trigger exacerbations. Colds can trigger exacerbations, which may be mistaken for vaccine-related adverse events. We undertook a double-blind placebo-controlled multicentre crossover study to assess the safety of influenza vaccine in patients with asthma, with allowance for the occurrence of colds. Methods We studied 262 patients, aged 18-75 years, who recorded daily peak expiratory flow (PEF), respiratory symptoms, medication, medical consultations, and hospital admissions for 2 weeks before the first injection and until 2 weeks after the second injection. Order of injection (vaccine and placebo) was assigned randomly. There was an interval of 2 weeks between injections. The main outcome measure was an exacerbation of asthma within 72 h of injection (defined as a fall in PEF of >20%). Findings Among 255 participants with paired data, 11 recorded a fall in PEF of more than 20% after vaccine compared with three after placebo (McNemar's test p=0.06); a fall of more than 30% was recorded by eight after vaccine compared with none after placebo (binomial test p=0.008). However, when participants with colds were excluded, there was no significant difference in the numbers with falls of more than 20% between vaccine and placebo (six vs three; binomial test p=0.51), although the difference for PEF decreases of more than 30% approached significance (five vs none; binomial test, p=0.06). This association was confined to first-time vaccinees. Interpretation Our findings indicate that pulmonary-function abnormalities may occur as a complication of influenza vaccination. However, the risk of pulmonary complications is very small and outweighted by the benefits of vaccination.	Leicester Royal Infirm, Dept Trop Med & Infect Dis, Leicester LE1 5WW, Leics, England; Queens Med Ctr, Dept Epidemiol & Publ Hlth Med, Nottingham NG7 2UH, England; Dept Hlth, London SE1 6TE, England; Birmingham Heartlands Hosp, Dept Med Res, Birmingham B9 5ST, W Midlands, England; Grantham & Dist Hosp, Grantham, Lincs, England; Prince Philip Hosp, Llanelli, Dyfed, Wales; Lewisham Hosp, London SE13 6LH, England; Sheffield Chest Clin, Sheffield, S Yorkshire, England; Royal Lancaster Infirmary, Lancaster, England; Royal Albert Edward Infirmary, Wigan, England; Manchester Royal Infirm, Manchester M13 9WL, Lancs, England	University of Leicester; University of Nottingham; Heart of England NHS Foundation Trust; University of Birmingham; University of Manchester	Nicholson, KG (corresponding author), Leicester Royal Infirm, Dept Trop Med & Infect Dis, Leicester LE1 5WW, Leics, England.		Nguyen-Van-Tam, Jonathan/I-2162-2019	Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655				ALBAZZAZ MK, 1987, BRIT MED J, V294, P1196, DOI 10.1136/bmj.294.6581.1196; ANAND SC, 1968, J ALLERGY, V42, P187, DOI 10.1016/S0021-8707(68)90115-9; BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679; BELL TD, 1977, J INFECT DIS, V136, pS612, DOI 10.1093/infdis/136.Supplement_3.S612; BELL TD, 1978, CHEST, V73, P140, DOI 10.1378/chest.73.2.140; CAMPBELL BG, 1984, MED J AUSTRALIA, V140, P773, DOI 10.5694/j.1326-5377.1984.tb132595.x; *COMM ISS PRIOR NE, 1992, NEW VACCINE DEV ESTA, P342; DAGGETT P, 1992, LANCET, V339, P367; GHIRGA G, 1991, VACCINE, V9, P913, DOI 10.1016/0264-410X(91)90022-X; HASSAN WU, 1992, LANCET, V339, P194, DOI 10.1016/0140-6736(92)90274-7; HOUSWORTH J, 1974, AM J EPIDEMIOL, V100, P40, DOI 10.1093/oxfordjournals.aje.a112007; *INT CONS REP DIAG, 1992, CLIN EXP ALLERGY, V22, pS1; JAMES JM, 1994, AM J RESP CRIT CARE, V149, P59, DOI 10.1164/ajrccm.149.1.8111598; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; KAVA T, 1987, RESPIRATION, V51, P98, DOI 10.1159/000195173; KAVA T, 1985, ALLERGY, V40, P42, DOI 10.1111/j.1398-9995.1985.tb04153.x; KONDO S, 1991, CHEST, V100, P1235, DOI 10.1378/chest.100.5.1235; MCINTOSH K, 1977, J INFECT DIS, V136, pS645, DOI 10.1093/infdis/136.Supplement_3.S645; MEIKLEJOHN G, 1978, J INFECT DIS, V138, P618, DOI 10.1093/infdis/138.5.618; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; MODLIN JF, 1977, J INFECT DIS, V136, pS626, DOI 10.1093/infdis/136.Supplement_3.S626; MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779; NGUYENVANTAM JS, 1993, EPIDEMIOL INFECT, V111, P347, DOI 10.1017/S0950268800057058; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; OUELLETTE JJ, 1965, J ALLERGY, V36, P558, DOI 10.1016/0021-8707(65)90193-0; STENIUSAARNIALA B, 1986, CHEST, V89, P786, DOI 10.1378/chest.89.6.786; SUGIURA A, 1970, J INFECT DIS, V122, P472, DOI 10.1093/infdis/122.6.472; VANUFFORD WJQ, 1959, INT ARCH ALLER A IMM, V15, P189	30	77	77	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					326	331		10.1016/S0140-6736(97)07468-0	http://dx.doi.org/10.1016/S0140-6736(97)07468-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652613				2022-12-28	WOS:000071864000012
J	Beddows, R				Beddows, R			Lifeline - Joseph B Kirsner	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1260	1260		10.1016/S0140-6736(05)63505-2	http://dx.doi.org/10.1016/S0140-6736(05)63505-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652602				2022-12-28	WOS:A1997YD23800067
J	Dennis, DT; Meltzer, MI				Dennis, DT; Meltzer, MI			Antibiotic prophylaxis after tick bites	LANCET			English	Editorial Material							LYME-DISEASE; MISDIAGNOSIS; PREVENTION		CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA	Centers for Disease Control & Prevention - USA	Dennis, DT (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,FT COLLINS,CO, USA.		Meltzer, Martin/AAT-3235-2021	Meltzer, Martin/0000-0002-7250-0472				Coyle BS, 1996, J INFECT DIS, V173, P1260, DOI 10.1093/infdis/173.5.1260; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; PIESMAN J, 1993, J INFECT DIS, V167, P1082, DOI 10.1093/infdis/167.5.1082; Seltzer EG, 1996, PEDIATR INFECT DIS J, V15, P762, DOI 10.1097/00006454-199609000-00003; Sigal LH, 1996, ARCH INTERN MED, V156, P1493, DOI 10.1001/archinte.156.14.1493; Sood SK, 1997, J INFECT DIS, V175, P996, DOI 10.1086/514009; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Strickland GT, 1997, J INFECT DIS, V176, P819, DOI 10.1086/517311; Warshafsky S, 1996, J GEN INTERN MED, V11, P329, DOI 10.1007/BF02600042	9	15	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1191	1192		10.1016/S0140-6736(05)63449-6	http://dx.doi.org/10.1016/S0140-6736(05)63449-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652556				2022-12-28	WOS:A1997YD23800005
J	Reaich, D				Reaich, D			Odour perception in chronic renal disease	LANCET			English	Editorial Material											Reaich, D (corresponding author), S CLEVELAND HOSP,DEPT NEPHROL,MIDDLESBROUGH TS4 3BW,CLEVELAND,ENGLAND.							Griep MI, 1997, NEPHROL DIAL TRANSPL, V12, P2093, DOI 10.1093/ndt/12.10.2093; KOPPLE JD, 1994, J AM SOC NEPHROL, V5, P335	2	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1191	1191		10.1016/S0140-6736(05)63448-4	http://dx.doi.org/10.1016/S0140-6736(05)63448-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652555				2022-12-28	WOS:A1997YD23800004
J	Butler, A				Butler, A			Acquisition and utilization of transition metal ions by marine organisms	SCIENCE			English	Review							HYDROXAMATE-SIDEROPHORE PRODUCTION; DIATOM THALASSIOSIRA-WEISSFLOGII; EQUATORIAL PACIFIC-OCEAN; NORTH PACIFIC; IRON FERTILIZATION; OZONE DESTRUCTION; ARCTIC ATMOSPHERE; PHYTOPLANKTON; IRON(III); VANADIUM	Recent research has revealed that trace metals, particularly transition metals, play important roles in marine productivity. Most of the work has been on iron, which shows a nutrient-depleted profile in the upper ocean. Marine organisms have a variety of means for acquiring iron and other transition metal ions that differ from those of terrestrial organisms.	Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Butler, A (corresponding author), Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA.		Butler, Alison/D-5094-2015	Butler, Alison/0000-0002-3525-7864	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038130, R29GM038130, R55GM038130] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38130] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRIE LA, 1988, NATURE, V334, P138, DOI 10.1038/334138a0; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BREWER PG, 1972, EARTH PLANET SC LETT, V16, P111, DOI 10.1016/0012-821X(72)90243-9; BRULAND KW, 1991, LIMNOL OCEANOGR, V36, P1555, DOI 10.4319/lo.1991.36.8.1555; BRULAND KW, 1980, EARTH PLANET SC LETT, V47, P176, DOI 10.1016/0012-821X(80)90035-7; Butler A, 1998, CURR OPIN CHEM BIOL, V2, P279, DOI 10.1016/S1367-5931(98)80070-7; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; COLLIER RW, 1984, NATURE, V309, P441, DOI 10.1038/309441a0; Cooper DJ, 1996, NATURE, V383, P511, DOI 10.1038/383511a0; COYNE ER, 1974, LIMNOL OCEANOGR, V19, P840; Donat John R., 1995, P247; Doucette GJ, 1996, MAR ECOL PROG SER, V130, P269, DOI 10.3354/meps130269; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; GLEDHILL M, 1994, MAR CHEM, V47, P41, DOI 10.1016/0304-4203(94)90012-4; GSCHWEND PM, 1985, SCIENCE, V227, P1033, DOI 10.1126/science.227.4690.1033; HAYGOOD MG, 1993, LIMNOL OCEANOGR, V38, P1091, DOI 10.4319/lo.1993.38.5.1091; Johnson MK, 1996, CHEM REV, V96, P2817, DOI 10.1021/cr950063d; LANDING WM, 1980, EARTH PLANET SC LETT, V49, P45, DOI 10.1016/0012-821X(80)90149-1; Lankford C., 1973, CRC CRIT R MICROBIOL, V2, P273, DOI DOI 10.3109/10408417309108388; LaRoche J, 1996, NATURE, V382, P802; LEE JG, 1995, LIMNOL OCEANOGR, V40, P1056, DOI 10.4319/lo.1995.40.6.1056; LEWIS BL, 1995, MAR CHEM, V50, P179, DOI 10.1016/0304-4203(95)00034-O; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; MARTIN JH, 1989, DEEP-SEA RES, V36, P649, DOI 10.1016/0198-0149(89)90144-1; MARTIN JH, 1991, LIMNOL OCEANOGR, V36, P1793, DOI 10.4319/lo.1991.36.8.1793; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; MATZANKE CB, 1989, IRON CARRIERS IRON P, P1; Messerschmidt A, 1997, BIOL CHEM, V378, P309, DOI 10.1515/bchm.1997.378.3-4.309; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; MOREL FMM, 1995, NATURE, V373, P28, DOI 10.1038/373028c0; MOREL FMM, 1994, NATURE, V369, P740, DOI 10.1038/369740a0; NAKAYAMA E, 1981, NATURE, V290, P768, DOI 10.1038/290768a0; Nozaki Y., 1997, EOS T AM GEOPHYS UN, V78, P221, DOI DOI 10.1029/97E000148; ORIANS KJ, 1990, NATURE, V348, P322, DOI 10.1038/348322a0; Pakulski JD, 1996, NATURE, V383, P133, DOI 10.1038/383133b0; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; PRICE NM, 1994, LIMNOL OCEANOGR, V39, P520, DOI 10.4319/lo.1994.39.3.0520; REID RT, 1993, NATURE, V366, P455, DOI 10.1038/366455a0; RICH HW, 1990, LIMNOL OCEANOGR, V35, P652, DOI 10.4319/lo.1990.35.3.0652; Roberts SB, 1997, J PHYCOL, V33, P845, DOI 10.1111/j.0022-3646.1997.00845.x; RUE EL, 1995, MAR CHEM, V50, P117, DOI 10.1016/0304-4203(95)00031-L; Rue EL, 1997, LIMNOL OCEANOGR, V42, P901, DOI 10.4319/lo.1997.42.5.0901; SAAGER PM, 1989, GEOCHIM COSMOCHIM AC, V53, P2259, DOI 10.1016/0016-7037(89)90348-7; SMITH MJ, 1995, MET IONS BIOL SYST, V31, P423; SORIADENGG S, 1995, MAR ECOL PROG SER, V127, P269, DOI 10.3354/meps127269; Tortell PD, 1996, NATURE, V383, P330, DOI 10.1038/383330a0; TRICK CG, 1983, MAR BIOL, V75, P9, DOI 10.1007/BF00392625; TRICK CG, 1989, CURR MICROBIOL, V18, P375, DOI 10.1007/BF01571131; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; WELLS ML, 1995, MAR CHEM, V48, P157, DOI 10.1016/0304-4203(94)00055-I; WEVER R, 1988, NATURE, V335, P501, DOI 10.1038/335501b0; Wu JF, 1996, GEOCHIM COSMOCHIM AC, V60, P2729, DOI 10.1016/0016-7037(96)00135-4; WU JF, 1995, MAR CHEM, V50, P159, DOI 10.1016/0304-4203(95)00033-N; YEE D, 1996, OCEANOGR, V41, P573; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	56	217	233	3	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1998	281	5374					207	210		10.1126/science.281.5374.207	http://dx.doi.org/10.1126/science.281.5374.207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9660742				2022-12-28	WOS:000074714200036
J	Nightingale, SL				Nightingale, SL			Proposal published on dissemination of information on unapproved uses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					12	12		10.1001/jama.280.1.12	http://dx.doi.org/10.1001/jama.280.1.12			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660348				2022-12-28	WOS:000074379400005
J	Kozasa, T; Jiang, XJ; Hart, MJ; Sternweis, PM; Singer, WD; Gilman, AG; Bollag, G; Sternweis, PC				Kozasa, T; Jiang, XJ; Hart, MJ; Sternweis, PM; Singer, WD; Gilman, AG; Bollag, G; Sternweis, PC			p115 RhoGEF, a GTPase activating protein for G alpha(12) and G alpha(13)	SCIENCE			English	Article							ALPHA-SUBUNITS; DBL FAMILY; PURIFICATION; INHIBITION; CLONING; CELLS; RGS4	Members of the regulators of G protein signaling (RGS) family stimulate the intrinsic guanosine triphosphatase (GTPase) activity of the alpha subunits of certain heterotrimeric guanine nucleotide-binding proteins (G proteins). The guanine nucleotide exchange factor (GEF) for Rho, p115 RhoGEF, has an amino-terminal region with similarity to RGS proteins. Recombinant p115 RhoGEF and a fusion protein containing the amino terminus of p115 had specific activity as GTPase activating proteins toward the alpha subunits of the G proteins G(12) and G(13), but not toward members of the G(s), G(i), or G(q) subfamilies of G alpha proteins. This GEF may act as an intermediary in the regulation of Rho proteins by G(13) and G(12).	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kozasa, T (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.	tohru.kozasa@email.swmed.edu; bollag@onyx-pharm.com; slernwei@utsw.swmed.edu		Hart, Matthew/0000-0002-2683-480X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497, R01GM031954] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31954, GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; INGI T, IN PRESS J NEUROSCI; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KOZASA T, UNPUB; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	35	710	718	3	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2109	2111		10.1126/science.280.5372.2109	http://dx.doi.org/10.1126/science.280.5372.2109			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641915				2022-12-28	WOS:000074435900043
J	Yamaoka, S; Courtois, G; Bessia, C; Whiteside, ST; Weil, R; Agou, F; Kirk, HE; Kay, RJ; Israel, A				Yamaoka, S; Courtois, G; Bessia, C; Whiteside, ST; Weil, R; Agou, F; Kirk, HE; Kay, RJ; Israel, A			Complementation cloning of NEMO, a component of the I kappa B kinase complex essential for NF-kappa B activation	CELL			English	Article							VIRUS TYPE-I; RAT FIBROBLASTS; TAX PROTEIN; EXPRESSION; PATHWAY	We have characterized a flat cellular variant of HTLV-1 Tax-transformed rat fibroblasts, 5R, which is unresponsive to all tested NF-kappa B activating stimuli, and we report here its genetic complementation. The recovered full-length cDNA encodes a 48 kDa protein, NEMO (NF-kappa B Essential MOdulator), which contains a putative leucine zipper motif. This protein is absent from 5R cells, is part of the high molecular weight I kappa B kinase complex, and is required for its formation. In vitro, NEMO can homodimerize and directly interacts with IKK-2. The NEMO cDNA was also able to complement another NF-kappa B-unresponsive cell line, 1.3E2, in which the protein is also absent, allowing us to demonstrate that this factor is required not only for Tax but also for LPS, PMA, and IL-1 stimulation of NF-kappa B activity.	Inst Pasteur, Unite Biol Mol Express Gen, CNRS, URA 1773, F-75724 Paris 15, France; Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, CNRS, URA 1773, F-75724 Paris, France; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 606, Japan	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; British Columbia Cancer Agency; Kyoto University	Yamaoka, S (corresponding author), Inst Pasteur, Unite Biol Mol Express Gen, CNRS, URA 1773, 25 Rue Dr Roux, F-75724 Paris 15, France.		, AGOU/GXA-2760-2022	COURTOIS, Gilles/0000-0003-3117-9595; Weil, Robert/0000-0001-5235-0932				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORI K, 1987, J GEN VIROL, V68, P499, DOI 10.1099/0022-1317-68-2-499; PYSZNIAK AM, 1994, J IMMUNOL, V152, P5241; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	28	917	965	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1231	1240		10.1016/S0092-8674(00)81466-X	http://dx.doi.org/10.1016/S0092-8674(00)81466-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657155	Bronze			2022-12-28	WOS:000074491100017
J	Wainberg, MA; Friedland, G				Wainberg, MA; Friedland, G			Public health implications of antiretroviral therapy and HIV drug resistance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; ZIDOVUDINE-RESISTANCE; HETEROSEXUAL TRANSMISSION; TYPE-1 RNA; IN-VIVO; SEROPOSITIVE INDIVIDUALS; GENITAL SECRETIONS; SEMINAL PLASMA; INFECTION	Widespread use of antiretroviral agents and increasing occurrence of human immunodeficiency virus (HIV) strains resistant to these drugs have given rise to a number of important issues. Some of these concerns are distinct from the obvious question of the relationship between drug resistance and treatment failure and have potentially widespread public health implications. The relevant issues include but are not limited to the following. (1) frequency with which drug-resistant virus may be transmitted via sexual, intravenous, or mother-to-child routes; (2) ability of drug-resistant variants to be transmitted, a question that relates, in part, to the relative fitness of such strains; (3) effectiveness of antiviral therapy in diminishing viral burden in both blood and genital secretions, and whether this may be compromised in persons harboring resistant virus; and (4) importance of patient adherence to antiviral therapy and its relationship to sustained reduction in viral load to minimize the appearance in and transmission of drug-resistant virus from both blood and genital secretions. Thus, prevention of both development of HIV drug resistance as well as transmission of drug-resistant variants is a central issue of public: health importance. Unless this topic is appropriately addressed, the likelihood is that drug-resistant variants of HIV, if able to successfully replicate, will sustain the epidemic and limit the effectiveness of antiviral therapy.	McGill Univ, Jewish Gen Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada; Yale Univ, Sch Med, AIDS Program, New Haven, CT USA	McGill University; Yale University	Wainberg, MA (corresponding author), McGill Univ, Jewish Gen Hosp, AIDS Ctr, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	mdwa@musica.mcgill.ca						Albrecht H, 1998, AIDS, V12, P333; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Bayer R, 1997, IMPLICATIONS OF ANTIRETROVIRAL TREATMENTS, P95; BROERS B, 1994, ARCH INTERN MED, V154, P1121, DOI 10.1001/archinte.154.10.1121; Byrn RA, 1997, LANCET, V350, P1141, DOI 10.1016/S0140-6736(97)24042-0; *CDC, 1996, MMWR-MORBID MORTAL W, V45, P468; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; COLGROVE R, 1998, 5 C RETR OPP INF CHI; CONLON CP, 1994, J INFECT DIS, V169, P411, DOI 10.1093/infdis/169.2.411; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CONWAY B, 1997, INT WORKSH HIV DRUG; CONWAY B, 1996, 3 INT C DRUG THER HI; Coombs RW, 1998, J INFECT DIS, V177, P320, DOI 10.1086/514213; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; CORELLI RL, 1991, DICP ANN PHARMAC, V25, P1374; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; DEEKS S, 1998, 5 C RETR OPP INF CHI; Delwart EL, 1998, J VIROL, V72, P617, DOI 10.1128/JVI.72.1.617-623.1998; DEOLIVEIRA CF, 1998, 5 C RETR OPP INF CHI; deRonde A, 1996, AIDS, V10, P231, DOI 10.1097/00002030-199602000-00017; Doyon L, 1996, J VIROL, V70, P3763, DOI 10.1128/JVI.70.6.3763-3769.1996; Dyer JR, 1996, J VIROL METHODS, V60, P161, DOI 10.1016/0166-0934(96)02063-0; Eastman PS, 1998, J INFECT DIS, V177, P557, DOI 10.1086/514228; EPSTEIN LH, 1984, HEALTH PSYCHOL, V3, P385, DOI 10.1037/0278-6133.3.4.385; ERAKER SA, 1984, ANN INTERN MED, V100, P258, DOI 10.7326/0003-4819-100-2-258; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; ERON J, 1998, 5 C RETR OPP INF CHI; EVANS JS, 1998, 5 C RETR OPP INF CHI; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FITZGIBBON JE, 1993, NEW ENGL J MED, V329, P1835, DOI 10.1056/NEJM199312163292502; FRENKEL LM, 1995, CLIN INFECT DIS, V20, P1321, DOI 10.1093/clinids/20.5.1321; FROST SDW, 1994, AIDS, V8, P323, DOI 10.1097/00002030-199403000-00005; Ghys PD, 1997, AIDS, V11, pF85, DOI 10.1097/00002030-199712000-00001; Goudsmit J, 1996, J VIROL, V70, P5662, DOI 10.1128/JVI.70.8.5662-5664.1996; GRIFFITH S, 1990, BRIT J GEN PRACT, V40, P114; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HART C, 1998, 5 C RETR OPP INF CHI; Haynes R. B., 1979, COMPLIANCE HLTH CARE; Haynes RB, 1996, LANCET, V348, P383; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOESLEY C, 1998, 5 C RETR OPP INF CHI; HOLODNIY M, 1991, J CLIN INVEST, V88, P1755, DOI 10.1172/JCI115494; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; Ickovics JR, 1997, J CLIN EPIDEMIOL, V50, P385, DOI 10.1016/S0895-4356(97)00041-3; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; JAPOUR AJ, 1995, J INFECT DIS, V171, P1172, DOI 10.1093/infdis/171.5.1172; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; KATZENSTEIN DA, 1992, J ACQ IMMUN DEF SYND, V5, P107; Kotler DP, 1998, AIDS, V12, P597, DOI 10.1097/00002030-199806000-00008; KRAVCIK S, 1998, 5 C RETR OPP INF CHI; KROODSMA KL, 1994, J INFECT DIS, V170, P1292, DOI 10.1093/infdis/170.5.1292; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Lee TH, 1996, J ACQ IMMUN DEF SYND, V12, P427, DOI 10.1097/00042560-199608010-00015; LENNOX J, 1997, 4 C RETR OPP INF WAS; Liuzzi G, 1996, AIDS, V10, pF51, DOI 10.1097/00002030-199612000-00001; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MAYERS D, 1997, INT WORKSH HIV DRUG; MAYERS DL, 1995, AIDS RES HUM RETROV, V11, pS162; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MONTANER JSG, 1995, ANN INTERN MED, V123, P561, DOI 10.7326/0003-4819-123-8-199510150-00001; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; MOORE RD, 1997, 37 INT C ANT AG CHEM; Mostad SB, 1997, LANCET, V350, P922, DOI 10.1016/S0140-6736(97)04240-2; MUMA RD, 1995, AIDS CARE, V7, P439, DOI 10.1080/09540129550126399; MUSICCO M, 1994, ARCH INTERN MED, V154, P1971, DOI 10.1001/archinte.154.17.1971; NIJHUIS M, 1997, INT WORKSH HIV DRUG; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; O'Brien M K, 1992, Med Care Rev, V49, P435, DOI 10.1177/002570879204900403; Operskalski EA, 1997, AM J EPIDEMIOL, V146, P655, DOI 10.1093/oxfordjournals.aje.a009331; Overbaugh J, 1996, AIDS RES HUM RETROV, V12, P107, DOI 10.1089/aid.1996.12.107; POMERANTZ R, 1998, 5 C RETR OPP INF CHI; POSS M, 1995, J VIROL, V69, P8118, DOI 10.1128/JVI.69.12.8118-8122.1995; Quayle AJ, 1997, J INFECT DIS, V176, P960, DOI 10.1086/516541; Quigg M, 1997, AIDS, V11, P835; Ragni MV, 1998, J ACQ IMMUN DEF SYND, V17, P42, DOI 10.1097/00042560-199801010-00006; RASHEED S, 1995, J REPROD MED, V40, P747; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Rubio A, 1997, AIDS, V11, P1184, DOI 10.1097/00002030-199709000-00016; Sackett DL, 1979, COMPLIANCE HLTH CARE; SALOMON H, 1995, ANTIVIR CHEM CHEMOTH, V6, P222, DOI 10.1177/095632029500600404; SAMET JH, 1992, AM J MED, V92, P495, DOI 10.1016/0002-9343(92)90746-X; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; UVIN CU, 1998, 5 C RETR OPP INF CHI; VERNAZZA L, 1998, 5 C RETR OPP INF CHI; Vernazza PL, 1996, J VIROL METHODS, V56, P33, DOI 10.1016/0166-0934(95)01899-9; Vernazza PL, 1997, AIDS, V11, P1249, DOI 10.1097/00002030-199710000-00008; VERNAZZA PL, 1994, AIDS, V8, P1325, DOI 10.1097/00002030-199409000-00017; Vernazza PL, 1997, AIDS, V11, P987, DOI 10.1097/00002030-199708000-00006; VUTHIPONGSE P, 1998, MMWR-MORBID MORTAL W, V47, P151; WAHLBERG J, 1994, J INFECT DIS, V169, P611, DOI 10.1093/infdis/169.3.611; WAINBERG M, 1996, 3 INT C DRUG THER HI; WALL TL, 1995, DRUG ALCOHOL DEPEN, V37, P261, DOI 10.1016/0376-8716(94)01080-5; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Williams A, 1997, AIDS Clin Care, V9, P51; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Xu C, 1997, J INFECT DIS, V176, P941, DOI 10.1086/516539; Yerly S, 1996, SCHWEIZ MED WSCHR, V126, P1845; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	110	375	388	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1977	1983		10.1001/jama.279.24.1977	http://dx.doi.org/10.1001/jama.279.24.1977			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU945	9643862				2022-12-28	WOS:000074252100035
J	Hanratty, CG; McAuley, DF; McGurk, C; Young, IS; Johnston, GD				Hanratty, CG; McAuley, DF; McGurk, C; Young, IS; Johnston, GD			Homocysteine and endothelial vascular function	LANCET			English	Letter							HYPERHOMOCYST(E)INEMIA		Queens Univ Belfast, Dept Therapeut & Pharmacol, Belfast BT9 7BL, Antrim, North Ireland; Royal Victoria Hosp, Inst Clin Sci, Dept Clin Biochem, Belfast BT12 6BA, Antrim, North Ireland	Queens University Belfast	Hanratty, CG (corresponding author), Queens Univ Belfast, Dept Therapeut & Pharmacol, Belfast BT9 7BL, Antrim, North Ireland.			McAuley, Daniel/0000-0002-3283-1947; Young, Ian/0000-0003-3890-3152				Chambers JC, 1998, LANCET, V351, P36, DOI 10.1016/S0140-6736(05)78090-9; Lentz SR, 1996, J CLIN INVEST, V98, P24, DOI 10.1172/JCI118771; Loscalzo J, 1996, J CLIN INVEST, V98, P5, DOI 10.1172/JCI118776; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877	4	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1288	1289		10.1016/S0140-6736(05)79355-7	http://dx.doi.org/10.1016/S0140-6736(05)79355-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643777	Bronze			2022-12-28	WOS:000073283600057
J	Beecham, L				Beecham, L			Help planned for carers	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					151	151						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657813				2022-12-28	WOS:000075081700062
J	Adams, RJ; McKie, VC; Hsu, L; Files, B; Vichinsky, E; Pegelow, C; Abboud, M; Gallagher, D; Kutlar, A; Nichols, FT; Bonds, DR; Brambilla, D; Woods, G; Olivieri, N; Driscoll, C; Miller, S; Wang, W; Hurlett, A; Scher, C; Berman, B; Carl, E; Jones, AM; Roach, ES; Wright, E; Zimmerman, RA; Waclawiw, M; Pearson, H; Powars, D; Younkin, D; El-Gammal, T; Seibert, J; Moye, L; Espeland, M; Murray, R; McKinley, R; McKinley, S; Hagner, S; Weiner, S; Estow, S; Yelle, M; Brock, K; Carter, E; Chiarucci, K; Debarr, M; Feron, P; Harris, S; Hoey, L; Jacques, K; Kuisel, L; Lewis, N; Lindsey, R; Martin, B; McMeechan, C; Muracca, M; Rey, K; Roath, G; Hackney-Stephens, E; Sumter, L; Talbot, A; Taplin, G; Whittle, C; Woods, P; Harbin, J; Holley, L; Jackson, B; Kutlar, F; Miller, B; Odo, N; Sahm, M; Schweitzer, J; Winstead, A; Swift, T; Allen, F; Allen, K; Beasley, M; Ejantkar, A; Houston, E; Hunter, D; Luden, J; Ottenlips, J; Trocio, S; Hernandez, C; McKie, K; McMorrow-Touhy, AM; Perry, R; Bello, J; Luban, N; Moser, F; Caplan, L; DeWitt, D; Riela, A; Babyn, P; Cure, J; Davis, P; Fiqueroa, R; Gaensler, E; Hotson, W; Kodroff, M; Langston, J; Lewin, J; Rho, T; Seidel, G; Sutton, C; Vezina, G; Whitman, M; Al-Mateen, M; Barfield, J; Caragan, A; Curless, R; Facchini, S; Flemming, F; Holden, K; MacGregor, D; Murphy, J; Packer, R; Park, Y; Rose, A; Sutton, C; Wiznitzer, M				Adams, RJ; McKie, VC; Hsu, L; Files, B; Vichinsky, E; Pegelow, C; Abboud, M; Gallagher, D; Kutlar, A; Nichols, FT; Bonds, DR; Brambilla, D; Woods, G; Olivieri, N; Driscoll, C; Miller, S; Wang, W; Hurlett, A; Scher, C; Berman, B; Carl, E; Jones, AM; Roach, ES; Wright, E; Zimmerman, RA; Waclawiw, M; Pearson, H; Powars, D; Younkin, D; El-Gammal, T; Seibert, J; Moye, L; Espeland, M; Murray, R; McKinley, R; McKinley, S; Hagner, S; Weiner, S; Estow, S; Yelle, M; Brock, K; Carter, E; Chiarucci, K; Debarr, M; Feron, P; Harris, S; Hoey, L; Jacques, K; Kuisel, L; Lewis, N; Lindsey, R; Martin, B; McMeechan, C; Muracca, M; Rey, K; Roath, G; Hackney-Stephens, E; Sumter, L; Talbot, A; Taplin, G; Whittle, C; Woods, P; Harbin, J; Holley, L; Jackson, B; Kutlar, F; Miller, B; Odo, N; Sahm, M; Schweitzer, J; Winstead, A; Swift, T; Allen, F; Allen, K; Beasley, M; Ejantkar, A; Houston, E; Hunter, D; Luden, J; Ottenlips, J; Trocio, S; Hernandez, C; McKie, K; McMorrow-Touhy, AM; Perry, R; Bello, J; Luban, N; Moser, F; Caplan, L; DeWitt, D; Riela, A; Babyn, P; Cure, J; Davis, P; Fiqueroa, R; Gaensler, E; Hotson, W; Kodroff, M; Langston, J; Lewin, J; Rho, T; Seidel, G; Sutton, C; Vezina, G; Whitman, M; Al-Mateen, M; Barfield, J; Caragan, A; Curless, R; Facchini, S; Flemming, F; Holden, K; MacGregor, D; Murphy, J; Packer, R; Park, Y; Rose, A; Sutton, C; Wiznitzer, M			Prevention of a first stroke by transfusions in children with sickle, cell anemia and abnormal results on transcranial Doppler ultrasonography	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE; ANGIOGRAPHY; THERAPY	Background Blood transfusions prevent recurrent stroke in children with sickle cell anemia, but the value of transfusions in preventing a first stroke is unknown. We used transcranial Doppler ultrasonography to identify children with sickle cell anemia who were at high risk for stroke and then randomly assigned them to receive standard care or transfusions to prevent a first stroke. Methods To enter the study, children with sickle cell anemia and no history of stroke had to have undergone two transcranial Doppler studies that showed that the time-averaged mean blood-flow velocity in the internal carotid or middle cerebral artery was 200 cm per second or higher. The patients were randomly assigned to receive standard care or transfusions to reduce the hemoglobin S concentration to less than 30 percent of the total hemoglobin concentration. The incidence of stroke (cerebral infarction or intracranial hemorrhage) was compared between the two groups. Results A total of 130 children (mean [+/- SD] age, 8.3 +/- 3.3 years) were enrolled; 63 were randomly assigned to receive transfusions, and 67 to receive standard care. At base line, the transfusion group had a slightly lower mean hemoglobin concentration (7.2 vs. 7.6 g per deciliter, P = 0.001) and hematocrit (20.4 vs. 21.7 percent, P = 0.002). Ten patients dropped out of the transfusion group, and two patients crossed over from the standard-care group to the transfusion group. There were 10 cerebral infarctions and ? intracerebral hematoma in the standard-care group, as compared with 1 infarction in the transfusion group - a 92 percent difference in the risk of stroke (P<0.001). This result led to the early termination of the trial. Conclusions Transfusion greatly reduces the risk of a first stroke in children with sickle cell anemia who have abnormal results on transcranial Doppler ultrasonography. (N Engl J Med 1998;339:5-11.) (C) 1998. Massachusetts Medical Society.	Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat Hematol & Oncol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Med, Augusta, GA 30912 USA; Emory Univ, Sch Med, Sickle Cell Ctr, Atlanta, GA USA; E Carolina Univ, Sch Med, Dept Pediat Hematol & Oncol, Greenville, NC USA; Childrens Hosp Oakland, Dept Hematol & Oncol, Oakland, CA 94609 USA; Univ Miami, Sch Med, Sickle Cell Ctr, Miami, FL USA; Med Univ S Carolina, Pediat Sickle Cell Program, Charleston, SC 29425 USA; New England Res Inst, Watertown, MA 02172 USA; NHLBI, Bethesda, MD 20892 USA; Childrens Mercy Hosp, Dept Hematol & Oncol, Kansas City, MO 64108 USA; Hosp Sick Children, Dept Hematol & Oncol, Toronto, ON M5G 1X8, Canada; Childrens Natl Med Ctr, Dept Hematol & Oncol, Washington, DC 20010 USA; SUNY Hlth Sci Ctr, Pediat Sickle Cell Program, Brooklyn, NY 11203 USA; St Jude Childrens Res Hosp, Dept Hematol & Oncol, Memphis, TN 38105 USA; Columbia Presbyterian Med Ctr, Dept Pediat Hematol, New York, NY 10032 USA; Tulane Univ, Sch Med, Dept Pediat Hematol & Oncol, New Orleans, LA 70112 USA; Rainbow Babies & Childrens Hosp, Dept Pediat Hematol & Oncol, Cleveland, OH 44106 USA; Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA; Univ Texas, SW Med Ctr, Dept Pediat Neurol, Dallas, TX USA; New England Res Inst, Watertown, MA 02172 USA; Childrens Hosp Philadelphia, Dept Neuroradiol, Philadelphia, PA 19104 USA; NHLBI, Bethesda, MD 20892 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Emory University; University of North Carolina; East Carolina University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of Miami; Medical University of South Carolina; HealthCore, Inc; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Children's Mercy Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Children's National Health System; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; St Jude Children's Research Hospital; Columbia University; NewYork-Presbyterian Hospital; Tulane University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University System of Georgia; Augusta University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; HealthCore, Inc; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Adams, RJ (corresponding author), Med Coll Georgia, Dept Neurol, 1467 Harper St,HB-2060, Augusta, GA 30912 USA.		Vichinsky, Elliott P/F-8541-2011; Hsu, Lewis/A-3360-2008; Olivieri, Nancy/AAI-2250-2020; Adams, Robert/GPW-8528-2022; Roach, Ewell/E-3958-2011; Hsu, Lewis L/H-8001-2019	Vichinsky, Elliott P/0000-0002-0500-9579; Hsu, Lewis L/0000-0002-3156-2378; Brambilla, Donald/0000-0002-7276-4689	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL052193, U10HL052016] Funding Source: NIH RePORTER; NHLBI NIH HHS [U10 HL 52016, U10 HL 52193] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaslid R., 1992, TRANSCRANIAL DOPPLER, V1, P1; ADAMS R, 1992, NEW ENGL J MED, V326, P605, DOI 10.1056/NEJM199202273260905; Adams RJ, 1997, ANN NEUROL, V42, P699, DOI 10.1002/ana.410420505; ADAMS RJ, 1992, STROKE, V23, P1073, DOI 10.1161/01.STR.23.8.1073; Adams RJ, 1998, CONTROL CLIN TRIALS, V19, P110, DOI 10.1016/S0197-2456(97)00099-8; Adams RJ, 1993, TRANSCRANIAL DOPPLER, P160; Adams Robert J., 1994, P599; ALBERTS MJ, 1992, STROKE, V23, P663, DOI 10.1161/01.STR.23.5.663; BISSE E, 1988, J CHROMATOGR-BIOMED, V434, P95, DOI 10.1016/0378-4347(88)80065-3; BRASS LM, 1988, STROKE, V19, P1466, DOI 10.1161/01.STR.19.12.1466; Bunn HF, 1997, NEW ENGL J MED, V337, P762, DOI 10.1056/NEJM199709113371107; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; COHEN AR, 1992, BLOOD, V79, P1657; Cox D. R., 1984, ANAL SURVIVAL DATA; MAEDA H, 1990, ULTRASOUND MED BIOL, V16, P9, DOI 10.1016/0301-5629(90)90080-V; MILLER ST, 1992, J PEDIATR-US, V120, P54, DOI 10.1016/S0022-3476(05)80597-9; Moser FG, 1996, AM J NEURORADIOL, V17, P965; Ohene-Frempong K, 1998, BLOOD, V91, P288; OHENEFREMPONG K, 1991, SEMIN HEMATOL, V28, P213; PEGELOW CH, 1995, J PEDIATR-US, V126, P896, DOI 10.1016/S0022-3476(95)70204-0; POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6; RANKIN J, 1957, Scott Med J, V2, P200; ROSSE WF, 1990, BLOOD, V76, P1431; ROTHMAN SM, 1986, ANN NEUROL, V20, P684, DOI 10.1002/ana.410200606; RUSSELL MO, 1984, BLOOD, V63, P162; SEIBERT JJ, 1993, RADIOLOGY, V189, P457, DOI 10.1148/radiology.189.2.8105505; STOCKMAN JA, 1972, NEW ENGL J MED, V287, P846, DOI 10.1056/NEJM197210262871703; VERIHAC S, 1995, PEDIAT RADIOL S1, V25, pS14; Walters MC, 1996, NEW ENGL J MED, V335, P369, DOI 10.1056/NEJM199608083350601; WAYNE AS, 1993, BLOOD, V81, P1109	30	1093	1107	1	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					5	11		10.1056/NEJM199807023390102	http://dx.doi.org/10.1056/NEJM199807023390102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647873				2022-12-28	WOS:000074500000002
J	Kahn, J				Kahn, J			Success and sadness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					89	89		10.1001/jama.280.1.89	http://dx.doi.org/10.1001/jama.280.1.89			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660370				2022-12-28	WOS:000074379400030
J	Langford, CA; Klippel, JH; Balow, JE; James, SP; Sneller, MC				Langford, CA; Klippel, JH; Balow, JE; James, SP; Sneller, MC			Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease - Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CHURG-STRAUSS-SYNDROME; PULSE CYCLOPHOSPHAMIDE THERAPY; ACTIVE CROHNS-DISEASE; TERM FOLLOW-UP; RHEUMATOID-ARTHRITIS; WEGENERS GRANULOMATOSIS; POLYARTERITIS-NODOSA; ULCERATIVE-COLITIS; RANDOMIZED TRIAL; NECROTIZING VASCULITIS	When cytotoxic agents were introduced, their ability to disrupt nucleic acid and protein synthesis led to their effective use for the treatment of neoplastic disease. During the course of this use, however, it became apparent that these agents also suppress the immune system. This usually unwelcome effect was subsequently studied and beneficially directed toward the treatment of non-neoplastic diseases in which autoimmune mechanisms were considered important to pathogenesis. As a result of these investigations, cytotoxic agents and, more recently, cyclosporine have emerged to become an important part of the therapeutic regimen for many autoimmune diseases. Nonetheless, these medications may still cause treatment-induced illness or even death. It is therefore particularly important to weigh the benefits and risks of cytotoxic therapy when treating a non-neoplastic disease. This two-part Clinical Staff Conference reviews data on the efficacy and toxicity of cytotoxic drugs and cyclosporine in selected autoimmune diseases. In part 2, we focus on the role of these agents in treating inflammatory bowel disease and systemic vasculitis and review the toxic effects of these agents.	NIAID, NIH, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Div Gastroenterol, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University System of Maryland; University of Maryland Baltimore	Langford, CA (corresponding author), NIAID, NIH, Bldg 10,Room 11B-13, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047708] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47708] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERK PD, 1981, NEW ENGL J MED, V304, P441, DOI 10.1056/NEJM198102193040801; Bouhnik Y, 1996, LANCET, V347, P215, DOI 10.1016/S0140-6736(96)90402-X; BOUMPAS DT, 1993, ANN INTERN MED, V119, P366, DOI 10.7326/0003-4819-119-5-199309010-00003; BRYNSKOV J, 1989, NEW ENGL J MED, V321, P845, DOI 10.1056/NEJM198909283211301; CALABRESE LH, 1995, RHEUM DIS CLIN N AM, V21, P41; CANNON GW, 1985, SEMIN ARTHRITIS RHEU, V15, P106, DOI 10.1016/0049-0172(85)90028-9; COHEN RD, 1980, MAYO CLIN PROC, V55, P146; CONNELL WR, 1994, LANCET, V343, P1249, DOI 10.1016/S0140-6736(94)92150-4; CONNELL WR, 1993, GUT, V34, P1081, DOI 10.1136/gut.34.8.1081; DALE DC, 1974, NEW ENGL J MED, V291, P1154, DOI 10.1056/NEJM197411282912203; deGroot K, 1996, ARTHRITIS RHEUM, V39, P2052, DOI 10.1002/art.1780391215; FAUCI AS, 1973, MEDICINE, V52, P535, DOI 10.1097/00005792-197311000-00002; FAUCI AS, 1979, NEW ENGL J MED, V301, P235, DOI 10.1056/NEJM197908023010503; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; FEAGAN BG, 1994, NEW ENGL J MED, V330, P1846, DOI 10.1056/NEJM199406303302602; FEAGAN BG, 1995, NEW ENGL J MED, V332, P292, DOI 10.1056/NEJM199502023320503; FEUTREN G, 1992, NEW ENGL J MED, V326, P1654, DOI 10.1056/NEJM199206183262502; FORTIN PR, 1995, J RHEUMATOL, V22, P78; FRAISER LH, 1991, DRUGS, V42, P781, DOI 10.2165/00003495-199142050-00005; FROHNERT PP, 1967, AM J MED, V43, P8, DOI 10.1016/0002-9343(67)90144-1; George J, 1996, AM J GASTROENTEROL, V91, P1711; GOODMAN TA, 1994, RHEUM DIS CLIN N AM, V20, P513; GREENSTEIN AJ, 1992, CANCER-AM CANCER SOC, V69, P1119; GUILLEVIN L, 1995, ARTHRITIS RHEUM, V38, P1638, DOI 10.1002/art.1780381116; GUILLEVIN L, 1992, ARTHRITIS RHEUM, V35, P208, DOI 10.1002/art.1780350214; Guillevin L, 1996, MEDICINE, V75, P17, DOI 10.1097/00005792-199601000-00003; GUILLEVIN L, 1991, J RHEUMATOL, V18, P567; Guillevin L, 1997, ARTHRITIS RHEUM, V40, P2187, DOI 10.1002/art.1780401213; Guillevin Loic, 1995, Current Opinion in Rheumatology, V7, P20; Hoffman GS, 1997, ARTHRITIS RHEUM, V40, P2099, DOI 10.1002/art.1780401202; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; HOFFMAN GS, 1990, AM J MED, V89, P403, DOI 10.1016/0002-9343(90)90367-M; HOFFMAN GS, 1994, ADV INTERNAL MED, V39, P277; HOLLANDER D, 1967, ANN INTERN MED, V67, P393, DOI 10.7326/0003-4819-67-2-393; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; JEWELL DP, 1994, EUR J GASTROEN HEPAT, V6, P499, DOI 10.1097/00042737-199406000-00009; KNOWLES SR, 1995, CLIN EXP DERMATOL, V20, P353, DOI 10.1111/j.1365-2230.1995.tb01343.x; KREMER JM, 1994, ARTHRITIS RHEUM-US, V37, P316, DOI 10.1002/art.1780370304; Langford CA, 1996, ARTHRITIS RHEUM, V39, P1754, DOI 10.1002/art.1780391020; Langford CA, 1996, ARTHRITIS RHEUM, V39, P1102; LEIB ES, 1979, AM J MED, V67, P941, DOI 10.1016/0002-9343(79)90634-X; LICHTIGER S, 1994, NEW ENGL J MED, V330, P1841, DOI 10.1056/NEJM199406303302601; Lynch JP, 1997, AM J RESP CRIT CARE, V155, P395, DOI 10.1164/ajrccm.155.2.9032171; Masala A, 1997, ANN INTERN MED, V126, P292, DOI 10.7326/0003-4819-126-4-199702150-00005; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; MORGAN SL, 1994, ANN INTERN MED, V121, P833, DOI 10.7326/0003-4819-121-11-199412010-00002; Nachman PH, 1996, J AM SOC NEPHROL, V7, P33; OGNIBENE FP, 1995, AM J RESP CRIT CARE, V151, P795; Oren R, 1996, GASTROENTEROLOGY, V110, P1416, DOI 10.1053/gast.1996.v110.pm8613046; PANAYI GS, 1994, BRIT J RHEUMATOL, V33, P967; PATAPANIAN H, 1988, BRIT J RHEUMATOL, V27, P44; PEARSON DC, 1995, ANN INTERN MED, V123, P132, DOI 10.7326/0003-4819-123-2-199507150-00009; PORTER GA, 1990, ARCH INTERN MED, V150, P280; PRESENT DH, 1994, DIGEST DIS SCI, V39, P374, DOI 10.1007/BF02090211; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; RADIS CD, 1995, ARTHRITIS RHEUM, V38, P1120, DOI 10.1002/art.1780380815; RamseyGoldman R, 1997, RHEUM DIS CLIN N AM, V23, P149, DOI 10.1016/S0889-857X(05)70320-3; REINHOLDKELLER E, 1994, ARTHRITIS RHEUM, V37, P919, DOI 10.1002/art.1780370622; ROENIGK HH, 1988, J AM ACAD DERMATOL, V19, P145, DOI 10.1016/S0190-9622(88)80237-8; RUDD P, 1975, J RHEUMATOL, V2, P421; Sandborn WJ, 1996, AM J GASTROENTEROL, V91, P423; SANDBORN WJ, 1995, GASTROENTEROLOGY, V109, P1808, DOI 10.1016/0016-5085(95)90747-5; SANTOS J, 1995, J CLIN GASTROENTEROL, V20, P285, DOI 10.1097/00004836-199506000-00005; SEARLES G, 1987, J RHEUMATOL, V14, P1164; Segal BH, 1997, RHEUM DIS CLIN N AM, V23, P219, DOI 10.1016/S0889-857X(05)70327-6; SINGH G, 1989, ARTHRITIS RHEUM, V32, P837; SNELLER MC, 1995, ARTHRITIS RHEUM, V38, P608, DOI 10.1002/art.1780380505; SNELLER MC, 1995, JAMA-J AM MED ASSOC, V273, P1288; Sneller MC, 1997, MED CLIN N AM, V81, P221, DOI 10.1016/S0025-7125(05)70512-5; STANGE EF, 1995, GASTROENTEROLOGY, V109, P774, DOI 10.1016/0016-5085(95)90384-4; TalarWilliams C, 1996, ANN INTERN MED, V124, P477, DOI 10.7326/0003-4819-124-5-199603010-00003; vandeRijn M, 1996, ARTHRITIS RHEUM, V39, P638, DOI 10.1002/art.1780390415; WALKER AM, 1993, ARTHRITIS RHEUM, V36, P329, DOI 10.1002/art.1780360307; WALTON EW, 1958, BRIT MED J, V2, P265, DOI 10.1136/bmj.2.5091.265	75	57	57	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					49	58		10.7326/0003-4819-129-1-199807010-00012	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9653000				2022-12-28	WOS:000074513300008
J	Powderly, WG; Landay, A; Lederman, MM				Powderly, WG; Landay, A; Lederman, MM			Recovery of the immune system with antiretroviral therapy - The end of opportunism?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; HELPER CELL DYSFUNCTION; HIV-INFECTED PATIENTS; CD8(+) T-CELLS; ACQUIRED IMMUNODEFICIENCY; MUCOSAL CANDIDIASIS; HOMOSEXUAL MEN; AIDS; INDIVIDUALS	Objective.-Clinical care of people infected with human immunodeficiency virus (HIV) has been substantially affected by the introduction of potent antiretroviral therapy. Changes in the immune system after such therapy and the clinical consequences are important issues for clinicians treating patients with HIV, Data Sources.-A systematic review of MEDLINE, 1993 to January 1998, of peer-reviewed publications, abstracts from national and international conferences, and product registration information through January 1998, Study Selection and Data Extraction-Criteria used to select studies include relevance to immune reconstitution with potent antiretroviral therapy and having been published in the English language, Assessment of data quality and validity included consideration of venue of the publication and relevance to practice. Data Synthesis.-Suppression of viral replication after administration of potent antiretroviral therapy that includes inhibitors of the HIV-l protease is associated with quantitative and qualitative changes in the immune system, in patients with relatively advanced disease, there is a first-phase rise (during the initial 3 months) in both naive and memory CD4(+) and CD8(+) T lymphocytes and B lymphocytes. This is followed by a slower second-phase increase (after 3 months) in cells primarily of the naive CD4(+) and CD8(+) phenotypes. These quantitative changes are associated with qualitative improvements in host immune responses, best characterized by dramatically reduced risk of opportunistic infection, Restoration of the immune system during the first year of potent antiretroviral therapy is partial at best. Conclusions.-Potent antiretroviral therapy has become the standard of care for people with HIV infection, and its use has led to significant reductions in the incidence of the acquired immunodeficiency syndrome (AIDS) and in mortality from HIV infection. Although incomplete, considerable immune recovery occurs, sufficient, in most cases, to provide adequate protection against most AIDS-associated opportunistic infections.	Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA; Rus Med Sch, Dept Immunol Microbiol, Chicago, IL USA; Case Western Reserve Univ, Sch Med, Div Infect Dis, Cleveland, OH 44106 USA	Washington University (WUSTL); Case Western Reserve University	Powderly, WG (corresponding author), Washington Univ, Sch Med, Div Infect Dis, Campus Box 8051,660 S Euclid Ave, St Louis, MO 63110 USA.			Powderly, William/0000-0001-7808-3086	NIAID NIH HHS [AI 25903, AI 25879, AI 36219] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036219, U01AI025903, U01AI025879] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABERG JA, 1998, 5 C RETR OPP INF CHI; ANDERSSON J, 1998, 5 C RETR OPP INF CHI; Angel JB, 1998, J INFECT DIS, V177, P898, DOI 10.1086/515244; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BIRX DL, 1993, J ACQ IMMUN DEF SYND, V6, P1248; BUCY RP, 1998, 5 C RETR OPP INF CHI; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carr A, 1996, J ACQ IMMUN DEF SYND, V13, P320, DOI 10.1097/00042560-199612010-00004; Carr A, 1998, LANCET, V351, P256, DOI 10.1016/S0140-6736(97)07529-6; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P861; CESAR D, 1998, 5 C RETR OPP INF CHI; CHOU CC, 1994, J ACQ IMMUN DEF SYND, V7, P665; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNICK E, 1998, 5 C RETR OPP INF CHI; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; DEEKS S, 1998, 5 C RETR OPP INF CHI; Dezube BJ, 1997, J INFECT DIS, V176, P807, DOI 10.1086/517308; DOCKRELL D, 1998, 5 C RETR OPP INF CHI; DOLAN MJ, 1995, J INFECT DIS, V172, P79, DOI 10.1093/infdis/172.1.79; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRENCH MAH, 1992, AIDS, V6, P1293, DOI 10.1097/00002030-199211000-00009; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; GOETZ MB, 1997, INF DIS SOC AM 35 AN; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; GRAY CM, 1998, 5 C RETR OPP INF CHI; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HOFFMANN C, 1997, INF DIS SOC AM 35 AN; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KESTENS L, 1994, CLIN EXP IMMUNOL, V95, P436, DOI 10.1111/j.1365-2249.1994.tb07015.x; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LANDAY A, 1990, AIDS, V4, P479, DOI 10.1097/00002030-199006000-00001; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LEDERMAN MM, IN PRESS J INFECT DI; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; LIEBMANN J, 1998, 5 C RETR OPP INF CHI; Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003; Macdonald JC, 1998, J INFECT DIS, V177, P1182, DOI 10.1086/515281; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MICHAELS S, 1998, 5 C RETR OPP INF CHI; MILDVAN D, 1982, ANN INTERN MED, V96, P700, DOI 10.7326/0003-4819-96-6-700; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; MOORE RD, 1998, 5 C RETR OPP INF CHI; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Pantaleo G, 1997, P NATL ACAD SCI USA, V94, P254, DOI 10.1073/pnas.94.1.254; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Powderly WG, 1996, ANN INTERN MED, V124, P342, DOI 10.7326/0003-4819-124-3-199602010-00012; Race EM, 1998, LANCET, V351, P252, DOI 10.1016/S0140-6736(97)04352-3; RINALDO C, 1991, J INFECT DIS, V164, P638, DOI 10.1093/infdis/164.4.638; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; Roglic M, 1997, CLIN EXP IMMUNOL, V107, P21, DOI 10.1046/j.1365-2249.1997.d01-886.x; Roos MTL, 1996, CLIN EXP IMMUNOL, V105, P409, DOI 10.1046/j.1365-2249.1996.d01-794.x; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SHEARER GM, 1991, AIDS, V5, P245, DOI 10.1097/00002030-199103000-00001; SIEGAL FP, 1981, NEW ENGL J MED, V305, P1439, DOI 10.1056/NEJM198112103052403; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; Torres RA, 1997, NEW ENGL J MED, V336, P1531, DOI 10.1056/NEJM199705223362118; *US DEP HHS, 1998, MMWR-MORBID MORTAL W, V47, P43; VALDEZ H, 1998, AIDS, V12, P14; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; Whitcup SM, 1997, JAMA-J AM MED ASSOC, V277, P1519, DOI 10.1001/jama.277.19.1519; *WORK GROUP ANT TH, 1998, MMWR-MORBID MORTAL W, V47, P1; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154; Zingman BS, 1996, NEW ENGL J MED, V334, P1674, DOI 10.1056/NEJM199606203342516; ZINKERNAGEL RM, 1994, IMMUNOL TODAY, V15, P262, DOI 10.1016/0167-5699(94)90005-1	76	179	188	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					72	77		10.1001/jama.280.1.72	http://dx.doi.org/10.1001/jama.280.1.72			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660367				2022-12-28	WOS:000074379400027
J	Siriwasin, W; Shaffer, N; Roongpisuthipong, A; Bhiraleus, P; Chinayon, P; Wasi, C; Singhanati, S; Chotpitayasunondh, T; Chearskul, S; Pokapanichwong, W; Mock, P; Weniger, BG; Mastro, TD				Siriwasin, W; Shaffer, N; Roongpisuthipong, A; Bhiraleus, P; Chinayon, P; Wasi, C; Singhanati, S; Chotpitayasunondh, T; Chearskul, S; Pokapanichwong, W; Mock, P; Weniger, BG; Mastro, TD		Bangkok Collaborative Perinatal HIV Transmissi	HIV prevalence, risk, and partner serodiscordance among pregnant women in Bangkok	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	10th International Conference on AIDS	AUG 07-12, 1994	YOKOHAMA, JAPAN				HUMAN-IMMUNODEFICIENCY-VIRUS; TO-MALE TRANSMISSION; YOUNG MEN; NORTHERN THAILAND; INFECTION; FEMALE	Context.-Most prior studies of the human immunodeficiency virus (H[V) epidemic in Thailand have focused on commercial sex encounters; however, because the epidemic increasingly concerns stable heterosexual relationships, determining risk factors for this form of transmission is warranted. Objectives.-To determine temporal trends in HIV prevalence, risk factors for H[V seropositivity, and rates of partner serodiscordance for pregnant women in Bangkok, Thailand. Design.-Retrospective review of hospital antenatal clinic HIV test results from 1991 through 1996. Baseline demographic and behavioral risk factors for HIV were assessed for subjects enrolled from November 1992 through March 1994. Setting.-Two Bangkok hospitals with routine antenatal clinic HIV counseling and testing. Participants.-The HIV-positive pregnant women enrolled in a perinatal HIV transmission study and their partners and HIV-negative pregnant controls. Results.-From 1991 through 1996, antenatal clinic HIV seroprevalence increased from 1.0% to 2.3%. On multivariate analysis of data from 342 HIV-positive and 344 HIV-negative pregnant women, more than 1 lifetime sex partner, history of a sexually transmitted disease, and a high-risk sex partner were the most important factors for seropositivity tall P<.001). Twenty-six percent of partners of HIV-positive women were HIV negative. Women reporting more than 1 lifetime sex partner were more likely to have an HIV-negative partner than women reporting only 1 (45% vs 8%; relative risk, 5.5; 95% confidence interval, 3.2-9.5; P<.001); women reporting no high-risk behaviors were less likely to have an H[V-negative partner (10% vs 44%; relative risk, 0.2; 95% confidence interval, 0.1-0.4; P<.001). Conclusions.-Prevalence of HIV in pregnant women has increased steadily in Bangkok from 1991 through 1996, Sex with current partners was the only identified risk exposure for about half (52%) of the HIV-positive women. Although few HIV-positive pregnant women reported high-risk behaviors, more than 1 lifetime partner and a partner with high-risk behavior were strong risk factors for seropositivity. Together with the unexpected finding that one fourth of partners of seropositive pregnant women were seronegative, these data emphasize that women in the general population are at risk for HIV because of the risk behavior of both current and previous partners.	Minist Publ Hlth, HIV AIDS Collaborat, Nonthaburi 11000, Thailand; Minist Publ Hlth, Rajavithi Hosp, Bangkok, Thailand; Ctr Dis Control & Prevent, Atlanta, GA USA; Mahidol Univ, Siriraj Hosp, Fac Med, Bangkok, Thailand; Minist Publ Hlth, Childrens Hosp, Dept Med Serv, Bangkok, Thailand	Ministry of Public Health - Thailand; Ministry of Public Health - Thailand; Rajavithi Hospital; Centers for Disease Control & Prevention - USA; Mahidol University; Ministry of Public Health - Thailand	Shaffer, N (corresponding author), Minist Publ Hlth, HIV AIDS Collaborat, DMS 6 Bldg,Tivanon Rd, Nonthaburi 11000, Thailand.	nas4@cdc.gov		Weniger, Bruce/0000-0002-5450-5464				ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; dCruzGrote D, 1996, LANCET, V348, P1071, DOI 10.1016/S0140-6736(95)11031-3; DEVINCENZI I, 1992, BRIT MED J, V304, P809; ELLERBROCK TV, 1992, NEW ENGL J MED, V327, P1704, DOI 10.1056/NEJM199212103272402; JOHNSON AM, 1989, AIDS, V3, P367, DOI 10.1097/00002030-198906000-00005; LESTER P, 1995, J ACQ IMMUN DEF SYND, V10, P341; Manopaiboon C, 1998, J ACQ IMMUN DEF SYND, V18, P54, DOI 10.1097/00042560-199805010-00009; MASON CJ, 1995, AIDS, V9, P1061, DOI 10.1097/00002030-199509000-00012; Mastro T D, 1996, AIDS, V10 Suppl A, pS75, DOI 10.1097/00002030-199601001-00011; MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3; MASTRO TD, 1995, AIDS, V9, P523; Mertens T E, 1995, AIDS, V9 Suppl A, pS259; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NICOLOSI A, 1994, EPIDEMIOLOGY, V5, P570, DOI 10.1097/00001648-199411000-00003; NOPKESORN T, 1993, AIDS, V7, P1233, DOI 10.1097/00002030-199309000-00013; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; SHAFFER N, 1996, 11 INT C AIDS JUL 7; Sirisopana N, 1996, J ACQ IMMUN DEF SYND, V11, P492, DOI 10.1097/00042560-199604150-00010; SITTITRAI W, 1994, AIDS, V8, pS143; SITTITRAI W, 1992, REPORT 1990 SURVEY P, P33; *THAIL MIN PUBL HL, 1996, RESULTS 14 ROUND HIV; UNGCHUSAK K, 1997, WKLY EPIDEMIOL SURVE, V28, P225; UNGCHUSAK K, 1997, WKLY EPIDEMIOL SURVE, V28, P237; UNGEHUSAK K, 1995, THAI AIDS J, V7, P177; UNGEHUSAK K, 1996, J ACQ IMMUN DEF SYND, V12, P500; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011	29	58	62	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					49	54		10.1001/jama.280.1.49	http://dx.doi.org/10.1001/jama.280.1.49			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZW145	9660363	Bronze			2022-12-28	WOS:000074379400023
J	Walker, BD; Basgoz, N				Walker, BD; Basgoz, N			Treat HIV-1 infection like other infections - Treat it	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-LYMPHOCYTES; IN-VIVO		Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Div Infect Dis, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Walker, BD (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, 149 13th St, Charlestown, MA 02129 USA.	bwalker@helix.mgh.harvard.edu						Angel JB, 1998, J INFECT DIS, V177, P898, DOI 10.1086/515244; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; CURRIER JS, 1998, 5 C RETR OPP INF FEB; DEEKS S, 1998, JAMA-J AM MED ASSOC, V27, P1343; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; Harrer T, 1996, J IMMUNOL, V156, P2616; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; Ho DD, 1997, J CLIN INVEST, V99, P2565, DOI 10.1172/JCI119443; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; MILLER K, IN PRESS CLIN INFECT; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Pantaleo G, 1996, ANNU REV MICROBIOL, V50, P825, DOI 10.1146/annurev.micro.50.1.825; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Spruance SL, 1997, ANN INTERN MED, V126, P355, DOI 10.7326/0003-4819-126-5-199703010-00003; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	21	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					91	93		10.1001/jama.280.1.91	http://dx.doi.org/10.1001/jama.280.1.91			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660371				2022-12-28	WOS:000074379400031
J	Ban, N; Freeborn, B; Nissen, P; Penczek, P; Grassucci, RA; Sweet, R; Frank, J; Moore, PB; Steitz, TA				Ban, N; Freeborn, B; Nissen, P; Penczek, P; Grassucci, RA; Sweet, R; Frank, J; Moore, PB; Steitz, TA			A 9 angstrom resolution x-ray crystallographic map of the large ribosomal subunit	CELL			English	Article							ESCHERICHIA-COLI RIBOSOME; 3-DIMENSIONAL RECONSTRUCTION; CRYOELECTRON MICROSCOPY; ELECTRON-MICROSCOPY; PROTEIN; CRYSTALLIZATION; REFINEMENT; EXTENSION; PARTICLES; SYMMETRY	The 50S subunit of the ribosome catalyzes the peptidyl-transferase reaction of protein synthesis. We have generated X-ray crystallographic electron density maps of the large ribosomal subunit from Haloarcula marismortui at various resolutions up to 9 Angstrom using data from crystals that diffract to 3 Angstrom. Positioning a 20 Angstrom resolution EM image of these particles in the crystal lattice produced phases accurate enough to locate the bound heavy atoms in three derivatives using difference Fourier maps, thus demonstrating the correctness of the EM model and its placement in the unit cell. At 20 Angstrom resolution, the X-ray map is similar to the EM map; however, at 9 Angstrom it reveals long, continuous, but branched features whose shape, diameter, and right-handed twist are consistent with segments of double-helical RNA that crisscross the subunit.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; United States Department of Energy (DOE); Brookhaven National Laboratory	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009; Nissen, Poul/D-5774-2014	Nissen, Poul/0000-0003-0948-6628	NIGMS NIH HHS [GM-22778, GM-29169, GM-54216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029169, R37GM029169] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BECKMANN R, 1997, BOTT, V278, P2123; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1997, METHOD ENZYMOL, V276, P558, DOI 10.1016/S0076-6879(97)76078-6; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1998, IN PRESS ACTA CRYSTA; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CARSON M, 1991, J APPL CRYSTALLOGR, V13, P458; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; Dube P, 1998, STRUCTURE, V6, P389, DOI 10.1016/S0969-2126(98)00040-9; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EISENSTEIN M, 1994, BIOPHYSICAL METHODS, P213; FRANCESCHI F, 1993, TRANSLATIONAL APPARATUS, P397; Frank J, 1995, BIOCHEM CELL BIOL, V73, P757, DOI 10.1139/o95-084; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; HUBER R, 1985, MOL REPLACEMENT, P58; JACK A, 1975, J MOL BIOL, V97, P163, DOI 10.1016/S0022-2836(75)80032-5; KNALEIN J, 1997, J MOL BIOL, V270, P1; LADENSTEIN R, 1987, J MOL BIOL, V195, P751, DOI 10.1016/0022-2836(87)90196-3; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; LEONARD KR, 1979, J MOL BIOL, V128, P155; MALHOTRA A, 1994, J MOL BIOL, V240, P308, DOI 10.1006/jmbi.1994.1448; MALHOTRA A, 1998, IN PRESS J MOL BIOL; MAY RP, 1992, EMBO J, V11, P373, DOI 10.1002/j.1460-2075.1992.tb05060.x; MILLIGAN RA, 1986, NATURE, V319, P693, DOI 10.1038/319693a0; Mueller F, 1997, J MOL BIOL, V271, P566, DOI 10.1006/jmbi.1997.1212; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Mueller F, 1997, J MOL BIOL, V271, P545, DOI 10.1006/jmbi.1997.1211; Neuefeind T, 1997, BIOL CHEM, V378, P219; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OHALLORAN TV, 1987, J MOL BIOL, V194, P705, DOI 10.1016/0022-2836(87)90248-8; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; Podjarny AD, 1997, METHOD ENZYMOL, V276, P641, DOI 10.1016/S0076-6879(97)76084-1; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; ROSSMANN MG, 1995, CURR OPIN STRUC BIOL, V5, P650, DOI 10.1016/0959-440X(95)80058-1; Schlunzen F, 1995, BIOCHEM CELL BIOL, V73, P739, DOI 10.1139/o95-082; SHEVACK A, 1985, FEBS LETT, V184, P68, DOI 10.1016/0014-5793(85)80655-4; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STOEFFLER G, 1986, STRUCTURE FUNCTION G, P28; Thygesen J, 1996, STRUCTURE, V4, P513, DOI 10.1016/S0969-2126(96)00057-3; VANBOHLEN K, 1991, J MOL BIOL, V222, P11; Verschoor A, 1998, NUCLEIC ACIDS RES, V26, P655, DOI 10.1093/nar/26.2.655; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1; Wittmann-Liebold Brigitte, 1986, STRUCTURE FUNCTION G, P326; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; WOESE CR, 1996, RIBOSOMAL RNA STRUCT, P23; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; YONATH AE, 1980, BIOCHEM INT, V1, P428; Zhu J, 1997, J STRUCT BIOL, V118, P197, DOI 10.1006/jsbi.1997.3845	56	211	222	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1105	1115		10.1016/S0092-8674(00)81455-5	http://dx.doi.org/10.1016/S0092-8674(00)81455-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657144	hybrid			2022-12-28	WOS:000074491100006
J	Bignall, J				Bignall, J			"Let no man name death to me"	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1296	1296		10.1016/S0140-6736(05)79373-9	http://dx.doi.org/10.1016/S0140-6736(05)79373-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643785				2022-12-28	WOS:000073283600071
J	Dally, A				Dally, A			Thalidomide: was the tragedy preventable?	LANCET			English	Article									Wellcome Inst Hist Med, London NW1 2BE, England	University of London; University College London	Dally, A (corresponding author), Wellcome Inst Hist Med, 183 Euston Rd, London NW1 2BE, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1935, GENESIS DEV SCI FACT; ASHLEY J, 1997, INDEPENDENT     0826, P12; BAKER JBE, 1960, PHARMACOL REV, V12, P37; BALLANTYNE A, 1990, SUNDAY TIMES    0204, pA12; BALLANTYNE JW, 1904, ESSENTIALS OBSTET, P101; BROWNE EJ, 1981, DICT HIST SCI, P278; BROWNE FJ, 1937, ANTENATAL POSTNATAL, P498; BUTLER NR, 1963, 1 NAT BIRTH TRUST FU; GILLIATT W, 1954, HIST REV BRIT OBSTET, P285; Goldstein L, 1929, AM J ROENTGENOL RADI, V22, P322; Gregg NM, 1941, T OPHTHALMOL SOC AUS, V3, P35; Haggard H.W., 1942, ALCOHOL EXPLORED; JONES KL, 1975, TERATOLOGY, V12, P1, DOI 10.1002/tera.1420120102; LESLIE FA, 1960, BRIT MED J, V2, P1954; MCBRIDE WG, 1961, LANCET, V2, P1358; MORLEY J, 1829, ESSAY SYMPTONS PREGN; Moscucci Ornella, 1990, SCI WOMAN GYNAECOLOG; MUNRO I, 1979, BRIT MED J, V2, P1625; Nunn JF, 1996, ANCIENT EGYPTIAN MED; PERSAUD TVN, 1977, PROBLEMS BIRTH DEFEC; PORTER D, 1989, PATIENTS PROGR DOCTO, P183; Rosenberg C, 1967, Bull Hist Med, V41, P223; SMITH JB, 1986, PHARM HIST, V16, P6; SULLIVAN WC, 1900, MED TEMP REV, V1, P72; *SUND TIM INS TEAM, 1979, SUFF CHILDR STOR THA, P91; Warkany J, 1944, J PEDIATR-US, V25, P476, DOI 10.1016/S0022-3476(44)80170-6; WARKANY J, 1947, AM J ROENTGENOL, V57, P455; Warkany J, 1942, AM J DIS CHILD, V64, P860, DOI 10.1001/archpedi.1942.02010110092009; Warkany J., 1965, TERATOLOGY, P1; WILSON PK, 1992, ANN SCI, V49, P63, DOI 10.1080/00033799200200141	30	58	62	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1197	1199		10.1016/S0140-6736(97)09038-7	http://dx.doi.org/10.1016/S0140-6736(97)09038-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643709				2022-12-28	WOS:000073220200047
J	Fraser, CM; Norris, SJ; Weinstock, CM; White, O; Sutton, GG; Dodson, R; Gwinn, M; Hickey, EK; Clayton, R; Ketchum, KA; Sodergren, E; Hardham, JM; McLeod, MP; Salzberg, S; Peterson, J; Khalak, H; Richardson, D; Howell, JK; Chidambaram, M; Utterback, T; McDonald, L; Artiach, P; Bowman, C; Cotton, MD; Fujii, C; Garland, S; Hatch, B; Horst, K; Roberts, K; Sandusky, M; Weidman, J; Smith, HO; Venter, JC				Fraser, CM; Norris, SJ; Weinstock, CM; White, O; Sutton, GG; Dodson, R; Gwinn, M; Hickey, EK; Clayton, R; Ketchum, KA; Sodergren, E; Hardham, JM; McLeod, MP; Salzberg, S; Peterson, J; Khalak, H; Richardson, D; Howell, JK; Chidambaram, M; Utterback, T; McDonald, L; Artiach, P; Bowman, C; Cotton, MD; Fujii, C; Garland, S; Hatch, B; Horst, K; Roberts, K; Sandusky, M; Weidman, J; Smith, HO; Venter, JC			Complete genome sequence of Treponema pallidum, the syphilis spirochete	SCIENCE			English	Article							PYROPHOSPHATE-DEPENDENT PHOSPHOFRUCTOKINASE; OUTER-MEMBRANE ULTRASTRUCTURE; ENDOFLAGELLAR SHEATH PROTEIN; ESCHERICHIA-COLI; SUBSP PALLIDUM; PHOSPHOTRANSFERASE SYSTEM; ENTAMOEBA-HISTOLYTICA; ENTEROCOCCUS-HIRAE; MOLECULAR-CLONING; PORIN ACTIVITY	The complete genome sequence of Treponema pallidum was determined and shown to be 1,138,006 base pairs containing 1041 predicted coding sequences (open reading frames). Systems for DNA replication, transcription, translation, and repair are intact, but catabolic and biosynthetic activities are minimized. The number of identifiable transporters is small, and no phoiphoenolpyruvate: phosphotransferase carbohydrate transporters were found. Potential virulence factors include a family of 12 potential membrane proteins and several putative hemolysins. Comparison of the T. pallidum genome sequence with that of another pathogenic spirochete, Borrelia burgdorferi, the agent of Lyme disease, identified unique and common genes and substantiates the considerable diversity observed among pathogenic spirochetes.	Inst Genom Res, Rockville, MD 20850 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Ctr Study Emerging & Reemerging Pathogens, Houston, TX 77225 USA	J. Craig Venter Institute; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Fraser, CM (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	tpdb@tigr.org	Salzberg, Steven/Q-6514-2019; Norris, Steven James/K-6586-2019; Salzberg, Steven L/F-6162-2011; Weinstock, George/C-6314-2013	Salzberg, Steven/0000-0002-8859-7432; Norris, Steven James/0000-0002-2501-8034; Salzberg, Steven L/0000-0002-8859-7432; Weinstock, George/0000-0002-2997-4592; Fraser, Claire/0000-0003-1462-2428	NIAID NIH HHS [AI31068] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031068] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akins DR, 1997, J BACTERIOL, V179, P5076, DOI 10.1128/jb.179.16.5076-5086.1997; BARBIERI JT, 1981, INFECT IMMUN, V31, P1071, DOI 10.1128/IAI.31.3.1071-1077.1981; BARONDES SH, 1993, MOL MENTAL ILLNESS; Blanco DR, 1997, EMERG INFECT DIS, V3, P11, DOI 10.3201/eid0301.970102; Blanco DR, 1996, J BACTERIOL, V178, P6685, DOI 10.1128/jb.178.23.6685-6692.1996; BLANCO DR, 1995, J BACTERIOL, V177, P3556, DOI 10.1128/jb.177.12.3556-3562.1995; Bruchhaus I, 1996, BIOCHEM J, V316, P57, DOI 10.1042/bj3160057; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cartwright Frederick Fox, 1972, DIS HIST; Champion CI, 1997, J BACTERIOL, V179, P1230, DOI 10.1128/jb.179.4.1230-1238.1997; CHAMPION CI, 1990, INFECT IMMUN, V58, P1697, DOI 10.1128/IAI.58.6.1697-1704.1990; CHARON NW, 1992, RES MICROBIOL, V143, P597, DOI 10.1016/0923-2508(92)90117-7; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; COMMANS S, 1995, J MOL BIOL, V253, P100, DOI 10.1006/jmbi.1995.0539; COX CD, 1983, PATHOGENESIS IMMUNOL, P57; COX DL, 1990, APPL ENVIRON MICROB, V56, P3063, DOI 10.1128/AEM.56.10.3063-3072.1990; COX DL, 1992, INFECT IMMUN, V60, P1076, DOI 10.1128/IAI.60.3.1076-1083.1992; DEATH A, 1993, RES MICROBIOL, V144, P529, DOI 10.1016/0923-2508(93)90002-J; DEUTSCHER J, 1983, P NATL ACAD SCI-BIOL, V80, P6790, DOI 10.1073/pnas.80.22.6790; Fenno JC, 1996, J BACTERIOL, V178, P2489, DOI 10.1128/jb.178.9.2489-2497.1996; Fenno JC, 1997, J BACTERIOL, V179, P1082, DOI 10.1128/jb.179.4.1082-1089.1997; FIELDSTEEL AH, 1981, INFECT IMMUN, V32, P908, DOI 10.1128/IAI.32.2.908-915.1981; FITZGERALD TJ, 1982, BRIT J VENER DIS, V58, P1; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Freist W, 1997, BIOL CHEM, V378, P1103; Greene SR, 1997, DNA SEQUENCE, V7, P267, DOI 10.3109/10425179709034046; Guina T, 1997, MOL MICROBIOL, V24, P1201, DOI 10.1046/j.1365-2958.1997.4291786.x; Hagman KE, 1997, INFECT IMMUN, V65, P1701, DOI 10.1128/IAI.65.5.1701-1709.1997; Hardham JM, 1997, GENE, V197, P47, DOI 10.1016/S0378-1119(97)00234-5; Ibba M, 1997, P NATL ACAD SCI USA, V94, P14383, DOI 10.1073/pnas.94.26.14383; Ibba M, 1997, SCIENCE, V278, P1119, DOI 10.1126/science.278.5340.1119; ISAACS RD, 1990, INFECT IMMUN, V58, P2025, DOI 10.1128/IAI.58.7.2025-2034.1990; ISAACS RD, 1989, INFECT IMMUN, V57, P3403, DOI 10.1128/IAI.57.11.3403-3411.1989; JOHNSON RC, 1981, PROCARYOTES, P582; Jones BE, 1997, J BIOL CHEM, V272, P26530, DOI 10.1074/jbc.272.42.26530; KAISER GE, 1975, NATURE, V255, P656, DOI 10.1038/255656a0; KEMP RG, 1993, J BACTERIOL, V175, P5723, DOI 10.1128/JB.175.17.5723-5724.1993; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; Limberger RJ, 1996, J BACTERIOL, V178, P4628, DOI 10.1128/jb.178.15.4628-4634.1996; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; LYSKO PG, 1977, INFECT IMMUN, V16, P885, DOI 10.1128/IAI.16.3.885-890.1977; LYSKO PG, 1978, INFECT IMMUN, V21, P462, DOI 10.1128/IAI.21.2.462-473.1978; Mathers DA, 1996, INFECT IMMUN, V64, P2904, DOI 10.1128/IAI.64.8.2904-2910.1996; MATSUURA A, 1972, J VITAMINOL, V18, P29, DOI 10.5925/jnsv1954.18.29; NEILSEN H, 1997, PROTEIN ENG, V10, P1; Nichols HJ, 1913, J AMER MED ASSOC, V60, P108, DOI 10.1001/jama.1913.04340020016005; NORRIS SJ, 1993, MICROBIOL REV, V57, P750, DOI 10.1128/MMBR.57.3.750-779.1993; NORRIS SJ, 1988, J BACTERIOL, V170, P4072, DOI 10.1128/jb.170.9.4072-4082.1988; NORRIS SJ, UNPUB; OAKES SG, 1982, BRIT J VENER DIS, V58, P220; OBRIEN WE, 1975, J BIOL CHEM, V250, P8690; OJAIMI C, 1994, MICROBIOL-SGM, V140, P2931, DOI 10.1099/13500872-140-11-2931; PALLESEN L, 1989, INFECT IMMUN, V57, P2166, DOI 10.1128/IAI.57.7.2166-2172.1989; PASTER BJ, 1991, J BACTERIOL, V173, P6101, DOI 10.1128/JB.173.19.6101-6109.1991; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Porcella SF, 1996, GENE, V177, P115, DOI 10.1016/0378-1119(96)00286-7; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; RADOLF JD, 1989, P NATL ACAD SCI USA, V86, P2051, DOI 10.1073/pnas.86.6.2051; RADOLF JD, 1995, MOL MICROBIOL, V16, P1067, DOI 10.1111/j.1365-2958.1995.tb02332.x; REEVES RE, 1976, J BIOL CHEM, V251, P2958; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1992, PROTEIN SCI, V1, P722, DOI 10.1002/pro.5560010604; Reizer J, 1998, MOL MICROBIOL, V27, P1157, DOI 10.1046/j.1365-2958.1998.00747.x; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; ROBINSON EN, 1993, SYPHILIS DIS HIST ME, P334; SAIER MH, 1994, MOL MICROBIOL, V13, P755; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; SCHILLER NL, 1977, INFECT IMMUN, V16, P60, DOI 10.1128/IAI.16.1.60-68.1977; SCHWARZ E, 1988, J BIOL CHEM, V263, P9640; SELL S, 1983, INT REV EXP PATHOL, V24, P204; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SHIBATA C, 1992, J BACTERIOL, V174, P6117, DOI 10.1128/JB.174.19.6117-6124.1992; SONHAMMER EL, 1997, PROTEINS, V28, P405; Stamm LV, 1997, FEMS MICROBIOL LETT, V155, P115, DOI 10.1016/S0378-1097(97)00375-3; STAMM LV, 1991, INFECT IMMUN, V59, P1572, DOI 10.1128/IAI.59.4.1572-1575.1991; Stamm LV, 1996, DNA SEQUENCE, V6, P293, DOI 10.3109/10425179609020876; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VANHORN KG, 1983, CAN J MICROBIOL, V29, P1141, DOI 10.1139/m83-175; WALKER EM, 1991, J BACTERIOL, V173, P5585, DOI 10.1128/jb.173.17.5585-5588.1991; WALKER EM, 1995, J BACTERIOL, V177, P1797, DOI 10.1128/jb.177.7.1797-1804.1995; WONG GHW, 1983, INFECT IMMUN, V41, P636, DOI 10.1128/IAI.41.2.636-643.1983	86	785	1483	0	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 17	1998	281	5375					375	388		10.1126/science.281.5375.375	http://dx.doi.org/10.1126/science.281.5375.375			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665876				2022-12-28	WOS:000074918800039
J	Richet, P; Polian, A				Richet, P; Polian, A			Water as a dense icelike component in silicate glasses	SCIENCE			English	Article							VISCOSITY; MELTS; H2O	Density and Brillouin-scattering measurements of hydrous andesite glasses.at ambient conditions showed that dissolved water has a concentration-independent partial molar volume of 12 +/- 0.5 cubic centimeters per mole and a bulk modulus of 18 +/- 3 gigapascals. Dissolved as hydroxyl ions or as molecular water, water has volume properties similar to those of ice VII, the densest form of ice. These properties point to hydrogen bonding as an important factor in water dissolution, and they indicate that changes of water speciation are driven by the entropy and not by the volume of the system. Water in a concentration greater than 1 percent by weight also causes a marked decrease of the shear modulus df the glass.	Inst Phys Globe, CNRS, Unite Rech Associee 734, Lab Phys Geomat, F-75252 Paris 05, France; Univ Paris 06, CNRS, Unite Rech Associee 782, Lab Phys Milieux Condenses, F-75252 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD)	Richet, P (corresponding author), Inst Phys Globe, CNRS, Unite Rech Associee 734, Lab Phys Geomat, 4 Pl Jussieu, F-75252 Paris 05, France.		Polian, Alain/E-1555-2017; Polian, Alain/B-8166-2019; Polian, Alain/AAA-6504-2021	Polian, Alain/0000-0003-2261-9114; Polian, Alain/0000-0003-2261-9114; 				ADAM G, 1965, J CHEM PHYS, V43, P139, DOI 10.1063/1.1696442; BASSI GS, 1995, NAT STRUCT BIOL, V2, P45, DOI 10.1038/nsb0195-45; Dingwell DB, 1996, CONTRIB MINERAL PETR, V124, P19, DOI 10.1007/s004100050170; Doweidar H, 1996, J NON-CRYST SOLIDS, V194, P155, DOI 10.1016/0022-3093(95)00489-0; ECKERT H, 1988, J PHYS CHEM-US, V92, P2055, DOI 10.1021/j100318a070; HEMLEY RJ, 1987, NATURE, V330, P737, DOI 10.1038/330737a0; KEPPLER H, 1993, AM MINERAL, V78, P1324; LANGE RA, 1994, REV MINERAL, V30, P331; RICHET P, 1980, GEOCHIM COSMOCHIM AC, V44, P1535, DOI 10.1016/0016-7037(80)90117-9; Richet P, 1995, REV MINERAL, V32, P67; RICHET P, 1996, CHEM GEOL, V128, P195; RICHET P, 1996, EOS S, V77, P799; Sandercock J. R., 1982, LIGHT SCATTERING SOL, VIII, P173, DOI DOI 10.1007/3-540-11513-7; Schroeder J., 1974, THESIS CATHOLIC U AM; SILVER LA, 1990, CONTRIB MINERAL PETR, V104, P142, DOI 10.1007/BF00306439; STOLPER E, 1982, CONTRIB MINERAL PETR, V81, P1, DOI 10.1007/BF00371154; TAKATA M, 1981, J AM CERAM SOC, V64, P719, DOI 10.1111/j.1151-2916.1981.tb15894.x; Tammann G, 1929, Z ANORG ALLG CHEM, V184, P416, DOI 10.1002/zaac.19291840134; Villemant B, 1996, EARTH PLANET SC LETT, V140, P259, DOI 10.1016/0012-821X(96)00035-0	19	52	52	2	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					396	398		10.1126/science.281.5375.396	http://dx.doi.org/10.1126/science.281.5375.396			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665879				2022-12-28	WOS:000074918800042
J	Weich, S; Lewis, G				Weich, S; Lewis, G			Poverty, unemployment, and common mental disorders: population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-DISORDER; GENERAL-POPULATION; DEPRESSION; SAMPLE	Objective: To determine whether poverty and unemployment increase the likelihood of or delay recovery from common mental disorders, and whether these associations could be explained by subjective financial strain. Design: Prospective cohort study. Setting: England, Wales, and Scotland. Subjects: 7726 adults aged 16-75 living in private households. Main outcome measures: Common mental disorders were assessed using the general health questionnaire, a self assessed measure of psychiatric morbidity. Results: Poverty and unemployment (odds ratio 1.86, 95% confidence interval 1.18 to 2.94) were associated with the maintenance but not onset of episodes of common mental disorders. Associations between poverty and employment and maintenance of common mental disorders, however, were much smaller than those of cross sectional studies. Financial strain at baseline was independently associated with both onset (1.57, 1.19 to 2.07) and maintenance (1,86, 1.36 to 2.53) even after adjusting for objective indices of standard of living. Conclusions: Poverty and unemployment increased the duration of episodes of common mental disorders but not the likelihood of their onset Financial strain was a better predictor of future psychiatric morbidity than either of these more objective risk factors though the nature of this risk factor and its relation with poverty and unemployment remain unclear.	Univ London, Royal Free Hosp, Dept Psychiat, London NW3 2PG, England; Cardiff Univ, Div Psychol Med, Cardiff CF4 4XN, S Glam, Wales	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Cardiff University	Weich, S (corresponding author), Univ London, Royal Free Hosp, Dept Psychiat, London NW3 2PG, England.	scott@rfhsm.ac.uk	Lewis, Glyn/E-9944-2012	Lewis, Glyn/0000-0001-5205-8245; Weich, Scott/0000-0002-7552-7697	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Blaxter M., 1990, HLTH LIFESTYLES; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; BRUCE ML, 1991, ARCH GEN PSYCHIAT, V48, P470; Fergusson DM, 1997, PSYCHOL MED, V27, P371, DOI 10.1017/S0033291796004412; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; Goldberg DP., 1992, COMMON MENTAL DISORD; Huber P. H., 1981, ROBUST STAT; JENKINS R, 1985, BRIT J IND MED, V42, P147; Lloyd KR, 1996, BRIT MED J, V313, P26, DOI 10.1136/bmj.313.7048.26; Meltzer H., 1995, 1 OPCS; MURPHY JM, 1991, ARCH GEN PSYCHIAT, V48, P223; MURPHY JM, 1987, ARCH GEN PSYCHIAT, V44, P473; RODGERS B, 1991, SOC PSYCH PSYCH EPID, V26, P104, DOI 10.1007/BF00782949; ROMANS SE, 1993, BRIT J PSYCHIAT, V163, P739, DOI 10.1192/bjp.163.6.739; STANSFELD SA, 1992, PSYCHOL MED, V22, P739, DOI 10.1017/S0033291700038186; TURNER JB, 1995, J HEALTH SOC BEHAV, V36, P213, DOI 10.2307/2137339; Warr P., 1987, WORK UNEMPLOYMENT ME; Weich S, 1997, PSYCHOL MED, V27, P73, DOI 10.1017/S0033291796004023; Weich S, 1998, J EPIDEMIOL COMMUN H, V52, P8, DOI 10.1136/jech.52.1.8; Weich S, 1997, PSYCHOL MED, V27, P757, DOI 10.1017/S0033291797005394; WELLS KB, 1988, AM J PSYCHIAT, V145, P712; WILLIAMS P, 1986, PSYCHOL MED, P1; [No title captured]	23	313	322	16	82	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 11	1998	317	7151					115	119		10.1136/bmj.317.7151.115	http://dx.doi.org/10.1136/bmj.317.7151.115			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105PE	9657786	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000075081700021
J	Costanza, R; Andrade, F; Antunes, P; van den Belt, M; Boersma, D; Boesch, DF; Catarino, F; Hanna, S; Limburg, K; Low, B; Molitor, M; Pereira, JG; Rayner, S; Santos, R; Wilson, J; Young, M				Costanza, R; Andrade, F; Antunes, P; van den Belt, M; Boersma, D; Boesch, DF; Catarino, F; Hanna, S; Limburg, K; Low, B; Molitor, M; Pereira, JG; Rayner, S; Santos, R; Wilson, J; Young, M			Principles for sustainable governance of the oceans	SCIENCE			English	Editorial Material								Pressures being exerted on the ocean ecosystems through overfishing, pollution, and environmental and climate change are increasing. Six core principles are proposed to guide governance and use of ocean resources and to promote sustainability. Examples of governance structures that embody these principles are given.	Univ Maryland, Ctr Environm Sci, Dept Biol, Solomons, MD 20688 USA; Univ Maryland, Ctr Environm Sci, Inst Ecol Econ, Solomons, MD 20688 USA; Univ Lisbon, Fac Sci, Marine Lab Guia, P-2750 Cascais, Portugal; Univ Nova Lisboa, Dept Environm Sci & Engn, Ecoman Ctr, P-2825 Monte De Caparica, Portugal; Ecol Econ Res & Applicat Inc, Solomons, MD 20688 USA; Univ Washington, Dept Zool, Seattle, WA 98195 USA; Univ Maryland, Ctr Environm Sci, Cambridge, MD 21613 USA; Oregon State Univ, Dept Agr & Resource Econ, Corvallis, OR 97331 USA; Univ Lisbon, Fac Sci, P-1250 Lisbon, Portugal; Univ Stockholm, Dept Syst Ecol, S-10691 Stockholm, Sweden; Univ Michigan, Sch Nat Resources, Ann Arbor, MI 48109 USA; Univ Azores, Dept Oceanog & Fisheries, Azores, Portugal; Columbia Univ, Dept Earth & Environm Sci, Oracle, AZ 85623 USA; Battelle Mem Inst, Washington, DC 20024 USA; Univ Maine, Sch Marine Sci, Orono, ME 04469 USA; CSIRO, Glen Osmond, SA 5064, Australia	University System of Maryland; University of Maryland Center for Environmental Science; University System of Maryland; University of Maryland Center for Environmental Science; Universidade de Lisboa; Universidade Nova de Lisboa; University of Washington; University of Washington Seattle; University System of Maryland; University of Maryland Center for Environmental Science; Oregon State University; Universidade de Lisboa; Stockholm University; University of Michigan System; University of Michigan; Universidade dos Acores; Columbia University; Battelle Memorial Institute; University of Maine System; University of Maine Orono; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Costanza, R (corresponding author), Univ Maryland, Ctr Environm Sci, Dept Biol, POB 38, Solomons, MD 20688 USA.		Antunes, Paula/O-9608-2019; Costanza, Robert/A-4912-2008; Costanza, Robert/AAJ-3546-2021; Limburg, Karin E/M-8380-2013; Santos, Rui F/Q-6837-2016; Antunes, Paula/F-9145-2011; Andrade, Francisco/J-4585-2012	Antunes, Paula/0000-0002-9461-2328; Costanza, Robert/0000-0001-6348-8734; Santos, Rui F/0000-0003-2829-6475; Antunes, Paula/0000-0002-9461-2328; Pereira, Joao/0000-0002-6651-0017; Young, Michael/0000-0001-8205-689X; rayner, steve/0000-0001-6779-9345; Andrade, Francisco/0000-0001-6257-1712				BOCKSTAEL N, 1995, ECOL ECON, V14, P143, DOI 10.1016/0921-8009(95)00026-6; Botsford LW, 1997, SCIENCE, V277, P509, DOI 10.1126/science.277.5325.509; COSTANZA R, 1998, ECOLOGICAL EC SUSTAI; Folke C, 1997, AMBIO, V26, P167; Gunderson L.H., 1995, BARRIERS BRIDGES REN; Heathcote I.W, 1998, INTEGRATED WATERSHED; Holling C.S., 1978, ADAPTIVE ENV ASSESSM; *IND WORLD COMM OC, 1997, WORK HELD 7 9 JUL SP; JONES PJS, 1994, OCEAN COAST MANAGE, V24, P149, DOI 10.1016/0964-5691(94)90036-1; LEE KN, 1993, COMPASS GYROSCOPE; LUDWIG D, 1993, SCIENCE, V260, P17, DOI 10.1126/science.260.5104.17; NAIMAN RJ, 1994, WATERSHED MANAGEMENT; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; Pelley J, 1997, ENVIRON SCI TECHNOL, V31, pA322, DOI 10.1021/es972368a; Rees W.E., 1994, INVESTING NATURAL CA; Walters C., 1986, ADAPTIVE MANAGEMENT; WILSON J, 1997, SOCIAL IMPLICATIONS; YOUNG MD, 1998, OCEAN COAST MANAGE, V28, P45	18	211	220	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					198	199		10.1126/science.281.5374.198	http://dx.doi.org/10.1126/science.281.5374.198			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9660740				2022-12-28	WOS:000074714200034
J	Field, CB; Behrenfeld, MJ; Randerson, JT; Falkowski, P				Field, CB; Behrenfeld, MJ; Randerson, JT; Falkowski, P			Primary production of the biosphere: Integrating terrestrial and oceanic components	SCIENCE			English	Article							NET PRIMARY PRODUCTION; GLOBAL-SCALE; CARBON SINK; SATELLITE; MODEL; PHOTOSYNTHESIS; LIGHT; ECOSYSTEMS; CO2	Integrating conceptually similar models of the growth of marine and terrestrial primary producers yielded an estimated global net primary production (NPP) of 104.9 petagrams of carbon per year, with roughly equal contributions from Land and oceans. Approaches based on satellite indices of absorbed solar radiation indicate marked heterogeneity in NPP for both Land and oceans, reflecting the influence of physical and ecological processes. The spatial and temporal distributions of ocean NPP are consistent with primary I.imitation by Light, nutrients, and temperature. On Land, water limitation imposes additional constraints. On Land and ocean, progressive changes in NPP can result in altered carbon storage, although contrasts in mechanisms of carbon storage and rates of organic matter turnover result in a range of relations between carbon storage and changes in NPP.	Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA; Rutgers State Univ, Inst Marine & Coastal Sci, New Brunswick, NJ 08901 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Carnegie Institution for Science; Rutgers State University New Brunswick; Stanford University	Field, CB (corresponding author), Carnegie Inst Washington, Dept Plant Biol, 290 Panama St, Stanford, CA 94305 USA.		Randerson, James/Y-2550-2019	Randerson, James/0000-0001-6559-7387				[Anonymous], 1986, 87802 NASA; Antoine D, 1996, GLOBAL BIOGEOCHEM CY, V10, P57, DOI 10.1029/95GB02832; BAKER CB, 1995, 9 C APPL CLIM AM MET; BALCH W, 1992, J GEOPHYS RES-OCEANS, V97, P2279, DOI 10.1029/91JC02843; BALCH WM, 1994, J GEOPHYS RES-OCEANS, V99, P7555, DOI 10.1029/93JC03091; Behrenfeld MJ, 1997, LIMNOL OCEANOGR, V42, P1, DOI 10.4319/lo.1997.42.1.0001; Behrenfeld MJ, 1997, LIMNOL OCEANOGR, V42, P1479, DOI 10.4319/lo.1997.42.7.1479; BERTHON JF, 1992, LIMNOL OCEANOGR, V37, P781, DOI 10.4319/lo.1992.37.4.0781; BIDIGARE RR, 1992, ENVIR SCI R, V43, P175; BISHOP JKB, 1991, J GEOPHYS RES-OCEANS, V96, P16839, DOI 10.1029/91JC01754; BRASWELL RH, 1997, SCIENCE, V278, P870; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; DEFRIES RS, 1994, INT J REMOTE SENS, V15, P3567, DOI 10.1080/01431169408954345; Falkowski P.G., 2013, AQUATIC PHOTOSYNTHES; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; Feldman G., 1989, EOS T AM GEOPHYS UN, V70, P634, DOI [10.1029/89EO00184, DOI 10.1029/89EO00184]; FIELD CB, 1995, REMOTE SENS ENVIRON, V51, P74, DOI 10.1016/0034-4257(94)00066-V; GRUBER N, 1996, GLOBAL BIOGEOCHEM CY, V10, P797; HANSEN J, 1987, J GEOPHYS RES-ATMOS, V92, P13345, DOI 10.1029/JD092iD11p13345; Joel G, 1997, REMOTE SENS ENVIRON, V62, P176, DOI 10.1016/S0034-4257(97)00093-X; KEELING RF, 1992, NATURE, V358, P723, DOI 10.1038/358723a0; KNORR W, 1995, TELLUS B, V47, P471, DOI 10.1034/j.1600-0889.47.issue4.7.x; Koblentz-Mishke OJ, 1970, SCI EXPLORATION S PA, P183; Lindeman RL, 1942, ECOLOGY, V23, P399, DOI 10.2307/1930126; Los S.O., 1998, THESIS VRIJE U AMSTE; Malmstrom CM, 1997, GLOBAL BIOGEOCHEM CY, V11, P367, DOI 10.1029/97GB01419; MARTIN JH, 1991, LIMNOL OCEANOGR, V36, P1793, DOI 10.4319/lo.1991.36.8.1793; Martin JH, 1990, GLOBAL BIOGEOCHEM CY, V4, P5, DOI 10.1029/GB004i001p00005; MCNAUGHTON SJ, 1990, NATURE, V345, P613, DOI 10.1038/345613a0; MONTEITH JL, 1972, J APPL ECOL, V9, P747, DOI 10.2307/2401901; MOREL A, 1991, PROG OCEANOGR, V26, P263, DOI 10.1016/0079-6611(91)90004-6; Myneni RB, 1997, NATURE, V386, P698, DOI 10.1038/386698a0; Osmond C.B., 1989, PHOTOSYNTHESIS PHOTOSYNTHESIS, P5; PICKARD GL, 1982, DESCRIPTIVE PHYSICAL; POTTER CS, 1993, GLOBAL BIOGEOCHEM CY, V7, P811, DOI 10.1029/93GB02725; Randerson JT, 1997, GLOBAL BIOGEOCHEM CY, V11, P535, DOI 10.1029/97GB02268; Ruimy A, 1994, J GEOPHYS RES-ATMOS, V99, P5263, DOI 10.1029/93JD03221; RUNYON J, 1994, ECOL APPL, V4, P226, DOI 10.2307/1941929; Russell G., 1989, Plant canopies: their growth, form and function., P21, DOI 10.1017/CBO9780511752308.003; Schimel DS, 1996, GLOBAL BIOGEOCHEM CY, V10, P677, DOI 10.1029/96GB01524; SCHIMEL DS, 1994, GLOBAL BIOGEOCHEM CY, V8, P279, DOI 10.1029/94GB00993; Schlesinger WH., 1998, BIOGEOCHEMISTRY ANAL, V73, P353, DOI 10.1016/0016-7037(92)90106-s; SELLERS PJ, 1987, REMOTE SENS ENVIRON, V21, P143, DOI 10.1016/0034-4257(87)90051-4; SHAVER GR, 1992, BIOSCIENCE, V42, P433, DOI 10.2307/1311862; SHEA DJ, 1986, TN269 NAT CTR ATM RE; SMITH SV, 1981, SCIENCE, V211, P838, DOI 10.1126/science.211.4484.838; TARPLEY JD, 1984, J CLIM APPL METEOROL, V23, P491, DOI 10.1175/1520-0450(1984)023<0491:GVIFTN>2.0.CO;2; Thompson MV, 1996, GLOBAL BIOGEOCHEM CY, V10, P711, DOI 10.1029/96GB01667; THOMPSON MV, IN PRESS GLOBAL CHAN; Tynan CT, 1998, NATURE, V392, P708, DOI 10.1038/33675; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; WOODWELL GM, 1978, SCIENCE, V199, P141, DOI 10.1126/science.199.4325.141	52	3416	3812	99	1546	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					237	240		10.1126/science.281.5374.237	http://dx.doi.org/10.1126/science.281.5374.237			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657713	Green Submitted			2022-12-28	WOS:000074714200042
J	Guilderson, TP; Schrag, DP				Guilderson, TP; Schrag, DP			Abrupt shift in subsurface temperatures in the Tropical Pacific associated with changes in El Nino	SCIENCE			English	Article							EQUATORIAL PACIFIC; NORTH PACIFIC; SOUTHERN OSCILLATION; SURFACE-TEMPERATURE; OCEAN; CHLOROFLUOROCARBONS; RADIOCARBON; CIRCULATION; TRITIUM; TRENDS	Radiocarbon (C-14) content of surface waters inferred from a coral record from the Galapagos Islands increased abruptly during the upwelling season (July through September) after the El Nino event of 1976. Sea-surface temperatures (SSTs) associated with the upwelling season also shifted after 1976. The synchroneity of the shift in both C-14 and SST implies that the vertical thermal structure of the eastern tropical Pacific changed in 1976. This change may be responsible for the increase in frequency and intensity of El Nino events since 1976.	Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Univ Calif Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94550 USA	Harvard University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Guilderson, TP (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.							BARNETT TP, 1984, MON WEATHER REV, V112, P303, DOI 10.1175/1520-0493(1984)112<0303:LTTIST>2.0.CO;2; Bottomley M, 1990, GLOBAL OCEAN SURFACE; Clarke AJ, 1996, J CLIMATE, V9, P1020, DOI 10.1175/1520-0442(1996)009<1020:LTCITE>2.0.CO;2; Clarke AJ, 1997, J CLIMATE, V10, P1722, DOI 10.1175/1520-0442(1997)010<1722:IADCIE>2.0.CO;2; DAVIS JC, 1990, NUCL INSTRUM METH B, V52, P269, DOI 10.1016/0168-583X(90)90419-U; Deser C, 1996, J CLIMATE, V9, P1840, DOI 10.1175/1520-0442(1996)009<1840:UOTVIT>2.0.CO;2; DRUFFEL EM, 1981, GEOPHYS RES LETT, V8, P59, DOI 10.1029/GL008i001p00059; DRUFFEL ERM, 1987, J MAR RES, V45, P667, DOI 10.1357/002224087788326876; FINE RA, 1994, J GEOPHYS RES-OCEANS, V99, P25063, DOI 10.1029/94JC02277; FINE RA, 1981, J PHYS OCEANOGR, V11, P3, DOI 10.1175/1520-0485(1981)011<0003:COTITP>2.0.CO;2; GOURIOU Y, 1993, J GEOPHYS RES-OCEANS, V98, P22495, DOI 10.1029/93JC02513; GRAHAM NE, 1988, SCIENCE, V240, P1293, DOI 10.1126/science.240.4857.1293; Gu DF, 1997, SCIENCE, V275, P805, DOI 10.1126/science.275.5301.805; Key RM, 1996, RADIOCARBON, V38, P425, DOI 10.1017/S0033822200030071; KUMAR A, 1994, SCIENCE, V266, P632, DOI 10.1126/science.266.5185.632; LUTHER DS, 1984, MON WEATHER REV, V112, P285, DOI 10.1175/1520-0493(1984)112<0285:OLPFOS>2.0.CO;2; MCPHADEN MJ, 1988, J PHYS OCEANOGR, V18, P1454, DOI 10.1175/1520-0485(1988)018<1454:ADIOTT>2.0.CO;2; *NAT OC SCI ACC MA, 1994, 94109 NOSAMS; QUAY PD, 1983, J MAR RES, V41, P769, DOI 10.1357/002224083788520423; Rajagopalan B, 1997, J CLIMATE, V10, P2351, DOI 10.1175/1520-0442(1997)010<2351:AEOAAV>2.0.CO;2; REYNOLDS RW, 1994, J CLIMATE, V7, P929, DOI 10.1175/1520-0442(1994)007<0929:IGSSTA>2.0.CO;2; STULVER M, 1977, RADIOCARBON, V19, P355; TOGGWEILER JR, 1991, J GEOPHYS RES, V96, P50; Trenberth KE, 1996, GEOPHYS RES LETT, V23, P57, DOI 10.1029/95GL03602; TRENBERTH KE, 1994, CLIM DYNAM, V9, P303, DOI 10.1007/BF00204745; TSUCHIYA M, 1989, PROG OCEANOGR, V23, P101, DOI 10.1016/0079-6611(89)90012-8; VOGEL JS, 1987, NUCL INSTRUM METH B, V29, P50, DOI 10.1016/0168-583X(87)90202-3; Wallace JM, 1996, J CLIMATE, V9, P249, DOI 10.1175/1520-0442(1996)009<0249:IOITIN>2.0.CO;2; Warner MJ, 1996, J GEOPHYS RES-OCEANS, V101, P20525, DOI 10.1029/96JC01849; WATANABE YW, 1994, J GEOPHYS RES-OCEANS, V99, P25195, DOI 10.1029/94JC01884; WOODRUFF SD, 1987, B AM METEOROL SOC, V68, P521; WYRTKI K, 1984, J PHYS OCEANOGR, V14, P42; ZEBIAK SE, 1987, MON WEATHER REV, V115, P2262, DOI 10.1175/1520-0493(1987)115<2262:AMENO>2.0.CO;2; Zhang RH, 1998, NATURE, V391, P879, DOI 10.1038/36081; Zhang Y, 1997, J CLIMATE, V10, P1004, DOI 10.1175/1520-0442(1997)010<1004:ELIV>2.0.CO;2	35	201	209	3	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					240	243		10.1126/science.281.5374.240	http://dx.doi.org/10.1126/science.281.5374.240			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657714				2022-12-28	WOS:000074714200043
J	Gulbrandsen, P; Fugelli, P; Sandvik, L; Hjortdahl, P				Gulbrandsen, P; Fugelli, P; Sandvik, L; Hjortdahl, P			Influence of social problems on management in general practice: multipractice questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							KNOWLEDGE; CARE	Objectives: To find how often social problems influence clinical management in general practice, hew management is changed, and how the characteristics of patients, doctors, and the doctor-patient relationship influence this management influence this management. Design: Multipractice sun ey of patients consulting general practitioners. Doctors completed a questionnaire for each patient Setting General practices in Buskerud county Norway. Subjects: 1401 consecutive adult patients attending 89 general practitioners. Main outcome measures: How often management of patients was influenced by different types of social problem and main reasons for consultation; frequency and intercorrelation of different types of management applied; odds ratios for social problems' influence on management, controlled for by characteristics of doctors, patients, and their relationship. Results: In 17% of all consultations the doctors' knowledge of patients' social problems influenced their management, stressful working conditions being the most frequent influencing type of problem. Knowledge of social problems influenced management more often when the doctor knew a patient well, but less often the longer a doctor had worked in a practice. When social problems influenced management, the commonest types of management offered were extra time for consultation (51%), advice (42%), authorisation of sick leave (28%), and prescription of a psychotropic drug (20%), while referral to community services was used in 2.6% of these consultations. Prescription of a psychotropic drug was positively correlated with use of extra time, and was made more often by female doctors. Conclusions: Patients' social problems influenced choice of management in at least a sixth of consultations. Prior knowledge of the patient, the doctor's time in present practice, age and sex of the patient, and sex of the doctor significantly influenced management of patients.	Univ Oslo, Inst Gen Practice & Community Med, N-0317 Oslo, Norway	University of Oslo	Gulbrandsen, P (corresponding author), Univ Oslo, Inst Gen Practice & Community Med, POB 1130 Blindern, N-0317 Oslo, Norway.							Andersson S O, 1993, Scand J Prim Health Care, V11, P61, DOI 10.3109/02813439308994904; Britt H, 1996, MED CARE, V34, P403, DOI 10.1097/00005650-199605000-00003; BROOKE JB, 1985, DECISION MAKING GENE, P95; BROWN JB, 1995, PATIENT CTR MED TRAN, P44; ESSEX BJ, 1985, DECISION MAKING GEN, P183; *FYLK BUSK, 1996, ANN REP MED SOC AFF; GROPPER M, 1987, SOC WORK HEALTH CARE, V13, P75; Gulbrandsen P, 1997, BRIT MED J, V314, P1014, DOI 10.1136/bmj.314.7086.1014; GULBRANDSEN P, IN PRESS SCAND J PRI; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HJORTDAHL P, 1992, THESIS U OSLO OSLO; HOOKEY P, 1980, PRIMARY CARE, P176; HOWIE JG, 1997, MEASURING QUALITY GE, P75; Lamberts H., 1987, ICPC INT CLASSIFICAT; Larsen Bernt Arne, 1994, Tidsskrift for den Norske Laegeforening, V114, P1442; MARTIN FJ, 1989, FAM PRACT, V6, P254, DOI 10.1093/fampra/6.4.254; MCWHINNEY IR, 1997, TXB FAMILY MED, P129; MORABIA A, 1992, J CLIN EPIDEMIOL, V45, P111, DOI 10.1016/0895-4356(92)90003-6; MORRELL D, 1987, PRACTICE CLIN MANAGE, P75; QUERIDO A, 1963, EFFICIENCY MED CARE, P46; *RIKSTR, 1997, STAT YB NORW NAT INS, P12; ROSENBERG EE, 1985, FAM PRACT, V2, P23, DOI 10.1093/fampra/2.1.23; RUTLE O, 1983, ANAL ENCOUNTERS GEN, V1, P178; *STAT NORW, 1997, SOC STAT 1995; STEWART MA, 1977, MED CARE, V15, P578, DOI 10.1097/00005650-197707000-00005; TELLNES G, 1990, THESIS U OSLO OSLO; VERHAAK PFM, 1990, INT J PSYCHIAT MED, V20, P151, DOI 10.2190/WHGG-2KQG-65GN-57YJ; YAFFE MJ, 1985, MED CARE, V23, P1276, DOI 10.1097/00005650-198511000-00006	28	27	27	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					28	32		10.1136/bmj.317.7150.28	http://dx.doi.org/10.1136/bmj.317.7150.28			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651266	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000075081600021
J	Kubo, T; Ohtani, E; Kato, T; Shinmei, T; Fujino, K				Kubo, T; Ohtani, E; Kato, T; Shinmei, T; Fujino, K			Effects of water on the alpha-beta transformation kinetics in San Carlos Olivine	SCIENCE			English	Article							MODIFIED SPINEL; MG2SIO4	In experiments at 13.5 gigapascals and 1030 degrees C, the growth rate of wadsleyite, which forms from transformation of olivine, was substantially enhanced by the presence of water. Wadsleyite had a low dislocation density and subgrain boundaries in wet runs. Water enhanced the dislocation recovery in wadsleyite and therefore caused inelastic relaxation of the localized pressure drop associated with the transformation, resulting in an increase of the growth rate in wet runs. These results imply that even a smalt amount of water of 0.05 weight percent can weaken wadsleyite in the mantle.	Tohoku Univ, Fac Sci, Inst Mineral Petrol & Econ Geol, Sendai, Miyagi 9808578, Japan; Univ Tsukuba, Inst Geosci, Tsukuba, Ibaraki 3050006, Japan; Hokkaido Univ, Grad Sch Sci, Div Earth & Planetary Sci, Sapporo, Hokkaido 0600810, Japan	Tohoku University; University of Tsukuba; Hokkaido University	Kubo, T (corresponding author), Tohoku Univ, Fac Sci, Inst Mineral Petrol & Econ Geol, Sendai, Miyagi 9808578, Japan.		Shinmei, Toru/AAE-4932-2021; Ohtani, Eiji/AAD-8011-2019	Ohtani, Eiji/0000-0001-8631-0736				AKAOGI M, 1989, J GEOPHYS RES-SOLID, V94, P15671, DOI 10.1029/JB094iB11p15671; BREARLEY AJ, 1992, PHYS CHEM MINER, V18, P343; Chen JH, 1998, GEOPHYS RES LETT, V25, P575, DOI 10.1029/98GL00043; GRIGGS DT, 1965, SCIENCE, V147, P292, DOI 10.1126/science.147.3655.292; GUYOT F, 1991, GEOPHYS RES LETT, V18, P89, DOI 10.1029/90GL02719; INOUE T, 1995, GEOPHYS RES LETT, V22, P117, DOI 10.1029/94GL02965; INOUE T, 1997, SPEC ISS REV HIGH PR, V6, P489; KARATO SI, 1986, J GEOPHYS RES-SOLID, V91, P8151, DOI 10.1029/JB091iB08p08151; LIU M, 1996, EOS S, V77, P716; Manghani, 1992, HIGH PRESSURE RES AP, V67, P237; MORRIS S, 1992, P ROY SOC LOND A MAT, V436, P203, DOI 10.1098/rspa.1992.0015; PATERSON MS, 1982, B MINERAL, V105, P20; RUBIE DC, 1985, ADV PHYSICAL GEOCHEM, V4, P27	13	92	97	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					85	87		10.1126/science.281.5373.85	http://dx.doi.org/10.1126/science.281.5373.85			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651250				2022-12-28	WOS:000074685800042
J	Willenberg, HS; Stratakis, CA; Marx, C; Ehrhart-Bornstein, M; Chrousos, GP; Bornstein, SR				Willenberg, HS; Stratakis, CA; Marx, C; Ehrhart-Bornstein, M; Chrousos, GP; Bornstein, SR			Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; CELLS; STEROIDOGENESIS; GLAND		NICHHD, NIH, Ctr Clin, Bethesda, MD 20892 USA; Univ Leipzig, Dept Internal Med 3, D-7010 Leipzig, Germany; NIMH, NIH, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Leipzig University; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Mental Health (NIMH)	Bornstein, SR (corresponding author), NICHHD, NIH, Ctr Clin, Bldg 10,Rm 10N262, Bethesda, MD 20892 USA.		Stratakis, Constantine/AAP-4745-2020					ALLEN RC, 1992, AM J HUM GENET, V51, P1229; ANDRADA JA, 1979, ARCH PATHOL LAB MED, V103, P244; BEUSCHLEIN F, 1994, CANCER RES, V54, P4927; BORNSTEIN SR, 1994, J CLIN ENDOCR METAB, V78, P225, DOI 10.1210/jcem.78.1.7507122; Ehrhart-Bornstein M, 1998, ENDOCR REV, V19, P101, DOI 10.1210/er.19.2.101; GICQUEL C, 1994, CLIN ENDOCRINOL, V40, P465, DOI 10.1111/j.1365-2265.1994.tb02485.x; Glasow A, 1996, J CLIN ENDOCR METAB, V81, P3103, DOI 10.1210/jc.81.8.3103; HANLEY N, 1992, J MOL ENDOCRINOL, V8, P131, DOI 10.1677/jme.0.0080131; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; Lacroix A, 1997, J CLIN ENDOCR METAB, V82, P2414, DOI 10.1210/jc.82.8.2414; Lacroix A, 1997, NEW ENGL J MED, V337, P1429, DOI 10.1056/NEJM199711133372004; Path G, 1997, J CLIN ENDOCR METAB, V82, P2343, DOI 10.1210/jc.82.7.2343; Reincke M, 1997, J CLIN ENDOCR METAB, V82, P3054, DOI 10.1210/jc.82.9.3054; REZNIK Y, 1992, NEW ENGL J MED, V327, P981, DOI 10.1056/NEJM199210013271403; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1994, CLIN IMMUNOL IMMUNOP, V72, P9, DOI 10.1006/clin.1994.1100; Stratakis CA, 1996, J CLIN ENDOCR METAB, V81, P3607, DOI 10.1210/jc.81.10.3607; TADA M, 1994, J NEUROIMMUNOL, V50, P187, DOI 10.1016/0165-5728(94)90045-0; WEGIENKA LC, 1966, LANCET, V1, P741; Zieleniewski W, 1995, EXP CLIN ENDOCR DIAB, V103, P373, DOI 10.1055/s-0029-1211381	20	88	88	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					27	31		10.1056/NEJM199807023390105	http://dx.doi.org/10.1056/NEJM199807023390105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647876	Bronze			2022-12-28	WOS:000074500000005
J	ter Borg, F; ten Kate, FJW; Cuypers, HTM; Leentvaar-Kuijpers, A; Oosting, J; Wertheim-van Dillen, PME; Honkoop, P; Rasch, MC; de Man, RA; van Hattum, J; Chamuleau, RAFM; Reesink, HW; Jones, EA				ter Borg, F; ten Kate, FJW; Cuypers, HTM; Leentvaar-Kuijpers, A; Oosting, J; Wertheim-van Dillen, PME; Honkoop, P; Rasch, MC; de Man, RA; van Hattum, J; Chamuleau, RAFM; Reesink, HW; Jones, EA			Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen	LANCET			English	Article							ALANINE AMINOTRANSFERASE; HBV-DNA; CIRRHOSIS; CARRIERS	Background Hepatitis B surface antigen (HBsAg) and antibodies to hepatitis B e antigen (anti-HBe) commonly coexist, and laboratory tests are often requested to assess histological hepatitis activity. An optimum panel of tests has not been found and the usefulness of hepatitis B virus (HBV) DNA assays in this context has not been established. We assessed various blood tests to find which best predicted hepatitis activity. Methods Routine plasma biochemical liver tests and serum HBV DNA (hybridisation and PCR assays) were assessed prospectively in 123 patients positive for HBsAg and anti-HBe. We scored histological hepatitis activity (hepatitis activity index) and determined whether chronic active hepatitis (chronic hepatitis with portal and periportal lesions) was present. We analysed the relation between laboratory data and the hepatitis activity index or risk of chronic active hepatitis by multiple regression and multiple logistic regression, respectively. Findings The analyses provided models for predicting either the hepatitis activity index or the risk of chronic active hepatitis. Aspartate aminotransferase was the most important test in the two models. The contribution of HBV DNA and other assays, especially alanine-aminotransferase activity, were of no practical importance. Interpretation Because screening by aspartate-aminotransferase activity could not be improved by the addition of other assays or HBV DNA, patients positive for HBsAg and anti-HBe could be screened for chronic active hepatitis with a single assay and counselling of patients can be improved if proper reference values are used.	Univ Amsterdam, Acad Med Ctr, Dept Gastrointestinal & Liver Dis C2 117, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Virol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, NL-1100 DE Amsterdam, Netherlands; Municipal Publ Hlth Serv, Dept Infect Dis Control, Amsterdam, Netherlands; Dutch Red Cross Blood Transfus Serv, Cent Lab, Dept Viral Serol, Amsterdam, Netherlands; Erasmus Univ Hosp Rotterdam, Dept Hepatogastroenterol, Rotterdam, Netherlands; Univ Hosp, Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Public Health Service Amsterdam; Erasmus University Rotterdam; Erasmus MC	ter Borg, F (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Gastrointestinal & Liver Dis C2 117, POB 22700, NL-1100 DE Amsterdam, Netherlands.							ALBERTI A, 1994, ANTIVIR RES, V24, P145, DOI 10.1016/0166-3542(94)90063-9; BERGMEYER HU, 1986, J CLIN CHEM CLIN BIO, V24, P481; CARLONI G, 1987, J MED VIROL, V21, P15, DOI 10.1002/jmv.1890210104; Colloredo G, 1996, J HEPATOL, V25, P644, DOI 10.1016/S0168-8278(96)80233-9; DEFRANCHIS R, 1993, ANN INTERN MED, V118, P191, DOI 10.7326/0003-4819-118-3-199302010-00006; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DRAGOSICS B, 1987, HEPATOLOGY, V7, P302, DOI 10.1002/hep.1840070215; FATTOVICH G, 1986, HEPATOLOGY, V6, P167, DOI 10.1002/hep.1840060203; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; Mangia A, 1996, DIGEST DIS SCI, V41, P2447, DOI 10.1007/BF02100141; MCCULLOUGH AJ, 1987, HEPATOLOGY, V7, P49, DOI 10.1002/hep.1840070112; NIITSUMA H, 1997, GASTROENTEROLOGY, V92, P119; PAZ MOA, 1986, J HEPATOL, V3, P371, DOI 10.1016/S0168-8278(86)80491-3; RAPICETTA M, 1990, EPIDEMIOL INFECT, V104, P511, DOI 10.1017/S0950268800047518; SCHEUER PJ, 1994, LIVER BIOPSY INTERPR, P117; VILLENEUVE JP, 1994, GASTROENTEROLOGY, V106, P1000, DOI 10.1016/0016-5085(94)90760-9; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; *WHO, 1993, GLOB HLTH SIT PROJ E; WILLIAMS ALB, 1988, GASTROENTEROLOGY, V95, P734, DOI 10.1016/S0016-5085(88)80022-2; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; YANG PM, 1987, HEPATO-GASTROENTEROL, V34, P251; ZAAIJER HL, 1994, J CLIN MICROBIOL, V32, P2088, DOI 10.1128/JCM.32.9.2088-2091.1994; Zavaglia C, 1997, LIVER, V17, P83	24	51	51	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1914	1918		10.1016/S0140-6736(97)09391-4	http://dx.doi.org/10.1016/S0140-6736(97)09391-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654258				2022-12-28	WOS:000074464700008
J	Kentros, C; Hargreaves, E; Hawkins, RD; Kandel, ER; Shapiro, M; Muller, RV				Kentros, C; Hargreaves, E; Hawkins, RD; Kandel, ER; Shapiro, M; Muller, RV			Abolition of long-term stability of new hippocampal place cell maps by NMDA receptor blockade	SCIENCE			English	Article							COMPLEX-SPIKE CELLS; SPATIAL MEMORY; ANTAGONIST MK-801; UNIT-ACTIVITY; POTENTIATION; ENVIRONMENT; RAT; CPP; ASPARTATE; PERFORMANCE	Hippocampal pyramidal cells are called place cells because Each cell tends to fire only when the animal is in a particular part of the environment-the cell's firing field. Acute pharmacological blockade, of N-methyl-D-aspartate (NMDA) glutamate receptors was used to investigate how NMDA-based synaptic plasticity participates in the formation and maintenance of the firing fields. The results suggest that the formation and short-term stability of firing fields in a new environment involve plasticity that is independent of NMDA receptor activation. By contrast, the long-term stabilization of newly established firing fields required normal NMDA receptor function and, therefore, may be related to other NMDA-dependent processes such as long-term potentiation and spatial teaming.	McGill Univ, Dept Psychol, Montreal, PQ H3A 1B1, Canada; New York State Psychiat Inst, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Ctr Neurobiol & Behav, Howard Hughes Med Inst, New York, NY 10032 USA; SUNY Hlth Sci Ctr, Dept Physiol, Brooklyn, NY 11203 USA	McGill University; New York State Psychiatry Institute; Columbia University; Howard Hughes Medical Institute; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Muller, RV (corresponding author), SUNY Hlth Sci Ctr, Dept Physiol, 450 Clarkson Ave, Brooklyn, NY 11203 USA.		Hargreaves, Eric/H-4891-2011	Hargreaves, Eric/0000-0001-5311-9804; Kentros, Clifford/0000-0003-3850-3829	NATIONAL INSTITUTE ON AGING [T32AG000189] Funding Source: NIH RePORTER; NIA NIH HHS [T32 AGO 00189] Funding Source: Medline; PHS HHS [R01 45923, R01 20686] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAM WC, 1988, BRAIN RES, V462, P40, DOI 10.1016/0006-8993(88)90582-3; AUSTIN K B, 1990, Society for Neuroscience Abstracts, V16, P263; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; Bostock E, 1991, Hippocampus, V1, P193, DOI 10.1002/hipo.450010207; Bures J, 1997, P NATL ACAD SCI USA, V94, P343, DOI 10.1073/pnas.94.1.343; Cain DP, 1997, CURR OPIN NEUROBIOL, V7, P235, DOI 10.1016/S0959-4388(97)80012-8; CARAMANOS Z, 1994, BEHAV NEUROSCI, V108, P30, DOI 10.1037/0735-7044.108.1.30; Chen C, 1997, ANNU REV NEUROSCI, V20, P157, DOI 10.1146/annurev.neuro.20.1.157; Cho YH, 1998, SCIENCE, V279, P867, DOI 10.1126/science.279.5352.867; COLE BJ, 1993, PSYCHOPHARMACOLOGY, V111, P465, DOI 10.1007/BF02253537; CURRAN HV, 1986, BIOL PSYCHOL, V23, P179, DOI 10.1016/0301-0511(86)90081-5; Davis S, 1997, J NEUROSCI METH, V75, P75, DOI 10.1016/S0165-0270(97)00053-8; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; HERNANDEZ RV, 1994, BRAIN RES, V656, P215, DOI 10.1016/0006-8993(94)91388-9; HETHERINGTON PA, 1993, BEHAV NEUROSCI, V107, P434, DOI 10.1037/0735-7044.107.3.434; HILL AJ, 1978, EXP NEUROL, V62, P282, DOI 10.1016/0014-4886(78)90058-4; Isaac JTR, 1996, J PHYSIOLOGY-PARIS, V90, P299, DOI 10.1016/S0928-4257(97)87901-6; JARBE TU, 1986, ACTA NEUROL SCAND  S, V109, P37; KENTROS C, UNPUB; Kubie J. L., 1983, NEUROBIOLOGY HIPPOCA, P433; LARSON J, 1988, BRAIN RES, V441, P111, DOI 10.1016/0006-8993(88)91388-1; McHugh TJ, 1996, CELL, V87, P1339, DOI 10.1016/S0092-8674(00)81828-0; MORRIS RG, 1997, T R SOC LONDON B, V352, P1489; Muller R, 1996, NEURON, V17, P813, DOI 10.1016/S0896-6273(00)80214-7; Muller R U, 1991, Hippocampus, V1, P243, DOI 10.1002/hipo.450010306; Muller RU, 1996, J GEN PHYSIOL, V107, P663, DOI 10.1085/jgp.107.6.663; MULLER RU, 1987, J NEUROSCI, V7, P1951; MULLER RU, 1987, J NEUROSCI, V7, P1935; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1987, EXP BRAIN RES, V68, P1; PELLICANO MP, 1993, PHYSIOL BEHAV, V54, P563, DOI 10.1016/0031-9384(93)90250-J; Rotenberg A, 1996, CELL, V87, P1351, DOI 10.1016/S0092-8674(00)81829-2; Rotenberg A., 1997, Society for Neuroscience Abstracts, V23, P501; RUDY JW, 1987, BEHAV NEUROSCI, V101, P62, DOI 10.1037/0735-7044.101.1.62; SAUCIER D, 1995, NATURE, V378, P186, DOI 10.1038/378186a0; SHAPIRO ML, 1992, BEHAV NEUROSCI, V106, P604, DOI 10.1037/0735-7044.106.4.604; THOMPSON LT, 1990, BRAIN RES, V509, P189; UNGERER A, 1991, BRAIN RES, V549, P59, DOI 10.1016/0006-8993(91)90599-Q; WARD L, 1990, PHARMACOL BIOCHEM BE, V35, P785, DOI 10.1016/0091-3057(90)90359-P; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	42	371	376	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2121	2126		10.1126/science.280.5372.2121	http://dx.doi.org/10.1126/science.280.5372.2121			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641919				2022-12-28	WOS:000074435900047
J	Aron, DC; Harper, DL; Shepardson, LB; Rosenthal, GE				Aron, DC; Harper, DL; Shepardson, LB; Rosenthal, GE			Impact of risk-adjusting cesarean delivery rates when reporting hospital performance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SECTION RATES; MATERNAL AGE; BIRTH-WEIGHT; MORTALITY; CARE; SEVERITY; ILLNESS; HEALTH; LENGTH; WOMEN	Context.-Hospitals and health plans are often ranked on rates of cesarean delivery, under the assumption that lower rates reflect more appropriate, more efficient care. However, most rankings do not account for patient factors that affect the likelihood of cesarean delivery. Objective.-To compare hospital cesarean delivery rates before and after adjusting for clinical risk factors that increase the likelihood of cesarean delivery. Design.-Retrospective cohort study, Setting.-Twenty-one hospitals in northeast Ohio. Patients.-A total of 26 127 women without prior cesarean deliveries admitted for labor and delivery from January 1993 through June 1995. Main Outcome Measures.-Hospital rankings based on observed and risk-adjusted cesarean delivery rates. Results.-The overall cesarean delivery rate was 15.9% and varied (P<.001) from 6.3% to 26.5% in individual hospitals. Adjusted rates varied from 8.4% to 22.0%. The correlation between unadjusted and adjusted hospital rankings (ie, 1-21) was only modest (R=0.35, P=.12). Whereas 7 hospitals were classified as outliers tie, had rates higher or lower [P<.05] than overall rate) on the basis of both unadjusted and adjusted rates, outlier status changed for 5 hospitals (24%), including 2 that changed from outliers to nonoutliers, 2 that changed from nonoutliers to outliers, and 1 that changed from a high outlier to a low outlier. Conclusions.-Cesarean delivery rates varied across hospitals in a single metropolitan region. However, rankings that fail to account for clinical factors that increase the risk of cesarean delivery may be methodologically biased and misleading to the public.	Case Western Reserve Univ, Cleveland Vet Affairs Med Ctr, Inst Hlth Care Res, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Div Clin & Mol Endocrinol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Div Gen Internal Med, Cleveland, OH 44106 USA; Qual Informet Management Program, Cleveland, OH USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Aron, DC (corresponding author), Case Western Reserve Univ, Sch Med, Inst Hlth Care Res Endocrinol, WG 37,10900 Euclid Ave, Cleveland, OH 44106 USA.	dca2@po.cwru.edu						ASH AS, 1994, ADJUSTMENT MEASURING, P313; BRAVEMAN P, 1995, AM J PUBLIC HEALTH, V85, P625, DOI 10.2105/AJPH.85.5.625; BURNS LR, 1995, MED CARE, V33, P365, DOI 10.1097/00005650-199504000-00004; Centers for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P303; CURTIN SC, 1997, MONTHLY VITAL STA S3, V45, P1; DEREGT RH, 1986, NEW ENGL J MED, V315, P619, DOI 10.1056/NEJM198609043151005; DESHARNAIS SI, 1990, MED CARE, V28, P1127, DOI 10.1097/00005650-199012000-00002; FINE MJ, 1993, MED CARE, V31, P371, DOI 10.1097/00005650-199304000-00008; FINKLER MD, 1991, MED CARE, V29, P951, DOI 10.1097/00005650-199110000-00002; GABAY M, 1994, UNNECESSARY CESAREAN, P1; GIFFORD DS, 1995, OBSTET GYNECOL, V85, P930, DOI 10.1016/0029-7844(95)00044-R; GOULD JB, 1989, NEW ENGL J MED, V321, P233, DOI 10.1056/NEJM198907273210406; GOYERT GL, 1989, NEW ENGL J MED, V320, P706, DOI 10.1056/NEJM198903163201106; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; HAAS JS, 1993, JAMA-J AM MED ASSOC, V270, P61, DOI 10.1001/jama.270.1.61; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HARLOW BL, 1995, AM J OBSTET GYNECOL, V172, P156, DOI 10.1016/0002-9378(95)90106-X; HUESTON WJ, 1994, OBSTET GYNECOL, V84, P965; IEZZONI LI, 1994, RISK ADJUSTMENT MEAS, P1; Irwin DE, 1996, OBSTET GYNECOL, V88, P530, DOI 10.1016/0029-7844(96)00263-3; Keeler EB, 1997, HEALTH SERV RES, V32, P511; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; KNOX AJ, 1993, OBSTET GYNECOL, V81, P195; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; MCCLOSKEY L, 1992, MED CARE, V30, P126, DOI 10.1097/00005650-199202000-00004; MCKENZIE L, 1993, AM J PUBLIC HEALTH, V83, P1109, DOI 10.2105/AJPH.83.8.1109; MORYOSEF S, 1990, OBSTET GYNECOL, V75, P944; *NEW ENGL HEDIS CO, 1994, NEW ENGL HEDIS COAL, pV12; OLESKE DM, 1991, HEALTH SERV RES, V26, P325; PARRISH KM, 1994, JAMA-J AM MED ASSOC, V271, P443, DOI 10.1001/jama.271.6.443; PAUL RH, 1995, AM J OBSTET GYNECOL, V172, P1903, DOI 10.1016/0002-9378(95)91430-7; PEIPERT JF, 1993, OBSTET GYNECOL, V81, P200; PETITTI DB, 1985, CLIN OBSTET GYNECOL, V28, P763, DOI 10.1097/00003081-198528040-00009; READ AW, 1994, AM J PUBLIC HEALTH, V84, P37, DOI 10.2105/AJPH.84.1.37; ROSENTHAL GE, 1994, JOINT COMM J QUAL IM, V20, P425, DOI 10.1016/S1070-3241(16)30088-8; Rosenthal GE, 1997, JAMA-J AM MED ASSOC, V278, P485, DOI 10.1001/jama.278.6.485; SHEARER EL, 1993, SOC SCI MED, V37, P1223, DOI 10.1016/0277-9536(93)90334-Z; Signorelli C, 1991, Ann Ostet Ginecol Med Perinat, V112, P15; STAFFORD RS, 1990, JAMA-J AM MED ASSOC, V263, P683, DOI 10.1001/jama.263.5.683; THOMAS JW, 1991, INQUIRY-J HEALTH CAR, V28, P39; Turcot L, 1997, AM J OBSTET GYNECOL, V176, P395, DOI 10.1016/S0002-9378(97)70505-2; TUSSING AD, 1992, MED CARE, V30, P529, DOI 10.1097/00005650-199206000-00006; U.S. Department of Health and Human Services, 1991, DHHS PUBL; WITTER FR, 1995, OBSTET GYNECOL, V85, P947, DOI 10.1016/0029-7844(95)00082-3	44	61	64	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1968	1972		10.1001/jama.279.24.1968	http://dx.doi.org/10.1001/jama.279.24.1968			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZU945	9643860				2022-12-28	WOS:000074252100033
J	Everett, SM; Axon, ATR				Everett, SM; Axon, ATR			Early gastric cancer: disease or pseudo-disease?	LANCET			English	Editorial Material									Gen Infirm, Ctr Digest Dis, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary; University of Leeds	Everett, SM (corresponding author), Gen Infirm, Ctr Digest Dis, Great George St, Leeds LS1 3EX, W Yorkshire, England.							ANDERSON GH, 1988, BMJ-BRIT MED J, V296, P975, DOI 10.1136/bmj.296.6627.975; COLEMAN MP, 1993, IARC SCI PUBL, V121, P193; CORREA P, 1994, CANCER SURV, V20, P55; *DEP HLTH SOC SEC, 1986, BREAST CANC SCREEN R; ECKARDT VF, 1990, GASTROENTEROLOGY, V98, P708, DOI 10.1016/0016-5085(90)90292-9; FONSECA L, 1994, ONCOLOGY, V51, P485; FUJII T, 1994, JPN J CLIN ONCOL, V24, P128; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; HAMPSON LG, 1990, CAN J SURG, V33, P349; HISAMICHI S, 1989, WORLD J SURG, V13, P31, DOI 10.1007/BF01671151; IKEDA Y, 1994, SEMIN SURG ONCOL, V10, P150, DOI 10.1002/ssu.2980100218; KOHLI Y, 1981, J CLIN GASTROENTEROL, V3, P129, DOI 10.1097/00004836-198106000-00005; KURIHARA M, CANC MORTALITY STAT, P63; ROKKAS T, 1991, GUT, V32, P1110, DOI 10.1136/gut.32.10.1110; Schlemper RJ, 1997, LANCET, V349, P1725, DOI 10.1016/S0140-6736(96)12249-2; SUELING HM, 1992, GUT, V33, P1318, DOI 10.1136/gut.33.10.1318; TSUKUMA H, 1983, INT J CANCER, V31, P421, DOI 10.1002/ijc.2910310405; VONHOLSTEIN CS, 1991, SCAND J GASTROENTERO, V26, P1020, DOI 10.3109/00365529109003951; YAMAZAKI H, 1989, CANCER-AM CANCER SOC, V63, P613, DOI 10.1002/1097-0142(19890215)63:4<613::AID-CNCR2820630402>3.0.CO;2-0; YOSHIDA S, 1993, GASTRIC CANCER, P246	20	44	46	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 2	1998	351	9112					1350	1352		10.1016/S0140-6736(98)04365-7	http://dx.doi.org/10.1016/S0140-6736(98)04365-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643813				2022-12-28	WOS:000073439400042
J	Clark, S				Clark, S			Training in orthopaedic spinal surgery	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Clark, S (corresponding author), Lancet, London WC1B 3SL, England.								0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1224	1224		10.1016/S0140-6736(05)79314-4	http://dx.doi.org/10.1016/S0140-6736(05)79314-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643740				2022-12-28	WOS:000073283600006
J	Nutt, JG				Nutt, JG			Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease	LANCET			English	Editorial Material							LEVODOPA		Oregon Hlth Sci Univ, Sch Med, Dept Neurol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Sch Med, Dept Physiol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Sch Med, Dept Pharmacol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Nutt, JG (corresponding author), Oregon Hlth Sci Univ, Sch Med, Dept Neurol, Portland, OR 97201 USA.							Agid Y, 1997, LANCET, V350, P712, DOI 10.1016/S0140-6736(05)63511-8; Baas H, 1997, J NEUROL NEUROSUR PS, V63, P421, DOI 10.1136/jnnp.63.4.421; HAUSER RA, IN PRESS MOV DISORD; Jorga KM, 1997, CLIN PHARMACOL THER, V62, P300, DOI 10.1016/S0009-9236(97)90033-3; Kieburtz K, 1997, ANN NEUROL, V42, P747; Kurth MC, 1997, NEUROLOGY, V48, P81, DOI 10.1212/WNL.48.1.81; Mannisto P T, 1992, Prog Drug Res, V39, P291; NUTT JG, 1987, ANN NEUROL, V21, P584, DOI 10.1002/ana.410210610; NUTT JG, 1994, NEUROLOGY, V44, P913, DOI 10.1212/WNL.44.5.913; Rajput AH, 1997, NEUROLOGY, V49, P1066, DOI 10.1212/WNL.49.4.1066; ROBERTS JW, 1993, NEUROLOGY, V43, P2685, DOI 10.1212/WNL.43.12.2685; Ruottinen HM, 1996, J NEUROL NEUROSUR PS, V60, P36, DOI 10.1136/jnnp.60.1.36; Waters CH, 1997, NEUROLOGY, V49, P665, DOI 10.1212/WNL.49.3.665	13	32	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1221	1222		10.1016/S0140-6736(05)79311-9	http://dx.doi.org/10.1016/S0140-6736(05)79311-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643737				2022-12-28	WOS:000073283600003
J	Koeck, CM				Koeck, CM			As others see us: views from abroad - A rational bureaucracy in a civilised society	BRITISH MEDICAL JOURNAL			English	Article									Koeck Ebner & Partners, A-1010 Vienna, Austria		Koeck, CM (corresponding author), Koeck Ebner & Partners, Parkring 12A-4, A-1010 Vienna, Austria.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					48	49		10.1136/bmj.317.7150.48	http://dx.doi.org/10.1136/bmj.317.7150.48			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651272	Green Published			2022-12-28	WOS:000075081600027
J	Mays, N; Keen, J				Mays, N; Keen, J			Will the fudge on equity sustain the NHS into the next millennium?	BRITISH MEDICAL JOURNAL			English	Article							HEALTH		Kings Fund, Hlth Syst Programme, London W1M 0AN, England; Brunel Univ, Dept Govt, Uxbridge UB8 3PH, Middx, England	Brunel University	Mays, N (corresponding author), Kings Fund, Hlth Syst Programme, London W1M 0AN, England.							*ASS BRIT INS, 1997, PRIV MED INS MARKE; BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; Evans RG, 1997, J PUBLIC HEALTH MED, V19, P45, DOI 10.1093/oxfordjournals.pubmed.a024586; Hills J., 1997, FUTURE WELFARE GUIDE; HOFFMEYER UK, 1995, FINANCING HLTH CARE; Judge K, 1997, BRIT SOCIAL ATTITUDE, P49; LAING W, 1997, LAINGS REV PRIVATE H; MCGUIGAN S, 1997, OFFICE HLTH EC COMPE; MILBURN A, 1998, HLTH SERV J, V108, P20; *ORG EC COOP DEV, 1996, HLTH CAR REF WILL CH; Pollock A, 1998, Health Serv J, V108, P28; PROPPER C, 1998, HLTH EC SERIES, V5; Reinhardt UE, 1996, HEALTH ECON, V5, P479, DOI 10.1002/(SICI)1099-1050(199611)5:6<479::AID-HEC228>3.0.CO;2-N; Rivett Geoffrey, 1998, CRADLE GRAVE 50 YEAR; *SECR STAT, 1989, CMND555; *SECR STAT HLTH, 1997, CMND3807; Treasure T, 1998, BMJ-BRIT MED J, V316, P1685, DOI 10.1136/bmj.316.7146.1685; WAGSTAFF A, 1992, J HEALTH ECON, V11, P361, DOI 10.1016/0167-6296(92)90012-P	18	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					66	69		10.1136/bmj.317.7150.66	http://dx.doi.org/10.1136/bmj.317.7150.66			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105PD	9651279	Green Published			2022-12-28	WOS:000075081600035
J	Amitay, Z; Baer, A; Dahan, M; Knoll, L; Lange, M; Levin, J; Schneider, IF; Schwalm, D; Suzor-Weiner, A; Vager, Z; Wester, R; Wolf, A; Zajfman, D				Amitay, Z; Baer, A; Dahan, M; Knoll, L; Lange, M; Levin, J; Schneider, IF; Schwalm, D; Suzor-Weiner, A; Vager, Z; Wester, R; Wolf, A; Zajfman, D			Dissociative recombination of HD+ in selected vibrational quantum states	SCIENCE			English	Article							MOLECULAR-IONS	Rate coefficients for dissociative recombination of HD+ in selected vibrational states have been measured by a combination of two molecular fragment imaging methods by using the heavy-ion storage ring technique. Recombination fragment imaging yields state-to-state reaction rates. These rates are converted to rate coefficients by using vibrational level populations of the stored ion beam, derived from nuclear coordinate distributions measured on extracted ions. The results show strongly increasing rate coefficients for high vibrational excitation, where additional dissociation routes open up, in agreement with a theoretical calculation. Very low rate coefficients are found for certain, isolated vibrational states.	Weizmann Inst Sci, Dept Particle Phys, IL-76100 Rehovot, Israel; Heidelberg Univ, Max Planck Inst Kernphys, D-69029 Heidelberg, Germany; Heidelberg Univ, Inst Phys, D-69029 Heidelberg, Germany; Univ Paris 11, Photophys Mol Lab, F-91405 Orsay, France; Natl Inst Lasers Plasma & Radiat Phys, Bucharest 76900, Romania	Weizmann Institute of Science; Max Planck Society; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; UDICE-French Research Universities; Universite Paris Saclay; National Institute for Laser, Plasma & Radiation Physics - Romania	Zajfman, D (corresponding author), Weizmann Inst Sci, Dept Particle Phys, IL-76100 Rehovot, Israel.	fndaniel@wicc.weizmann.ac.il	Wolf, Andreas/O-4440-2017; Wester, Roland/J-6293-2012	Wolf, Andreas/0000-0003-1198-9013; Wester, Roland/0000-0001-7935-6066				AMITAY Z, 1994, PHYS REV A, V50, P2304, DOI 10.1103/PhysRevA.50.2304; Amitay Z, 1996, PHYS REV A, V54, P4032, DOI 10.1103/PhysRevA.54.4032; Dunn Alison M., NATURAL HIST HOST PA, P161, DOI [10.1016/S0065-308X(08)00607-6, DOI 10.1016/S0065-2199(08)60202-X, DOI 10.1016/S0065-308X(08)00607-6]; FORCK P, 1994, PHYS REV LETT, V72, P2002, DOI 10.1103/PhysRevLett.72.2002; GIUSTI A, 1980, J PHYS B ATOM MOL PH, V13, P3687; Guberman SL, 1997, SCIENCE, V278, P1276, DOI 10.1126/science.278.5341.1276; GUBERMAN SL, 1991, J CHEM PHYS, V95, P2602, DOI 10.1063/1.460913; HABS D, 1989, NUCL INSTRUM METH B, V43, P390, DOI 10.1016/0168-583X(89)90383-2; Kella D, 1997, SCIENCE, V276, P1530, DOI 10.1126/science.276.5318.1530; Larsson M, 1997, ANNU REV PHYS CHEM, V48, P151, DOI 10.1146/annurev.physchem.48.1.151; MITCHELL JBA, 1990, PHYS REP, V186, P215, DOI 10.1016/0370-1573(90)90159-Y; MOWAT JR, 1995, PHYS REV LETT, V74, P50, DOI 10.1103/PhysRevLett.74.50; NAKASHIMA K, 1987, J CHEM PHYS, V86, P726, DOI 10.1063/1.452275; Scoles G., 1988, ATOMIC MOL BEAM METH; SLANGER TG, 1988, SCIENCE, V241, P945, DOI 10.1126/science.241.4868.945; STROMHOLM C, 1995, PHYS REV A, V52, pR4320, DOI 10.1103/PhysRevA.52.R4320; TADJEDDINE M, 1977, MOL PHYS, V33, P1797, DOI 10.1080/00268977700101461; TAKAGI H, 1996, P 1995 WORKSH DISS R, V3, P174; VAGER Z, 1989, SCIENCE, V244, P426, DOI 10.1126/science.244.4903.426; ZAIFMAN D, 1992, PHYS REV A, V46, P194, DOI 10.1103/PhysRevA.46.194; ZAJFMAN D, 1995, PHYS REV A, V52, P839, DOI 10.1103/PhysRevA.52.839	21	48	48	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1998	281	5373					75	78		10.1126/science.281.5373.75	http://dx.doi.org/10.1126/science.281.5373.75			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651247				2022-12-28	WOS:000074685800039
J	Ezekowitz, M				Ezekowitz, M			Antithrombotics for left-ventricular impairment?	LANCET			English	Editorial Material									Yale Univ, Sch Med, Yale Clin Trials Off, New Haven, CT 06510 USA	Yale University	Ezekowitz, M (corresponding author), Yale Univ, Sch Med, Yale Clin Trials Off, New Haven, CT 06510 USA.		Ezekowitz, Michael/AAJ-2543-2021					Al-Khadra AS, 1998, J AM COLL CARDIOL, V31, P749, DOI 10.1016/S0735-1097(98)00006-0; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; Loh E, 1997, NEW ENGL J MED, V336, P251, DOI 10.1056/NEJM199701233360403	3	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1904	1904		10.1016/S0140-6736(05)78610-4	http://dx.doi.org/10.1016/S0140-6736(05)78610-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654255	hybrid			2022-12-28	WOS:000074464700005
J	Radcliffe-Richards, J; Daar, AS; Guttmann, RD; Hoffenberg, R; Kennedy, I; Lock, M; Sells, RA; Tilney, N				Radcliffe-Richards, J; Daar, AS; Guttmann, RD; Hoffenberg, R; Kennedy, I; Lock, M; Sells, RA; Tilney, N		Int Forum Transplant Eth	The case for allowing kidney sales	LANCET			English	Article							ORGAN		Royal Liverpool Univ Hosp, Renal Transplant Unit, Int Forum Transplant Clin, Liverpool L7 8XP, Merseyside, England; Kings Coll London, Fac Law, London WC2R 2LS, England; Sultan Qaboos Univ, Coll Med, Dept Surg, Muscat, Oman; Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; Dept Social Studies Med, Montreal, PQ, Canada; Open Univ, Dept Philosophy, Milton Keynes MK7 6AA, Bucks, England; Brigham & Womens Hosp, Boston, MA 02115 USA	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of London; King's College London; Sultan Qaboos University; McGill University; Royal Victoria Hospital; Open University - UK; Harvard University; Brigham & Women's Hospital	Sells, RA (corresponding author), Royal Liverpool Univ Hosp, Renal Transplant Unit, Int Forum Transplant Clin, Liverpool L7 8XP, Merseyside, England.							ALTSHULER JS, 1992, JAMA-J AM MED ASSOC, V267, P2037, DOI 10.1001/jama.1992.03480150043029; BARSOUM RS, 1992, ETHICAL PROBLEMS DIA, P169; Council o f The Transplantation Society, 1985, LANCET, V2, P715; DAAR AD, 1997, INPRESS T REV; Dossetor John B., 1992, ETHICAL PROBLEMS DIA, P61; GUTTMANN RD, 1992, TRANSPLANT P, V24, P2179; Hauptman PJ, 1997, NEW ENGL J MED, V336, P422, DOI 10.1056/NEJM199702063360607; MANI MK, 1992, ETHICAL PROBLEMS DIA, P164; Radcliffe-Richards J., 1996, J MED PHILOS, V21, P375; RADCLIFFERICHAR.J, 1992, ETHICAL PROBLEMS DIA, P53; SELLS RA, 1992, TRANSPLANT P, V24, P2401; SELLS RA, 1986, BRIT MED J, V293, P257; SELLS RA, 1992, TRANSPLANT P, V24, P2198; SHEIL R, 1995, TRANSPLANT SOC B, V3, P3; World Health Organization (WHO), 1992, REP DEV AUSP WHO 198, P12	15	207	209	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 27	1998	351	9120					1950	1952		10.1016/S0140-6736(97)08211-1	http://dx.doi.org/10.1016/S0140-6736(97)08211-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654279				2022-12-28	WOS:000074464700045
J	Tanaka, Y; Kanai, Y; Okada, Y; Nonaka, S; Takeda, S; Harada, A; Hirokawa, N				Tanaka, Y; Kanai, Y; Okada, Y; Nonaka, S; Takeda, S; Harada, A; Hirokawa, N			Targeted disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal perinuclear clustering of mitochondria	CELL			English	Article							ANTEROGRADE AXONAL-TRANSPORT; INTRACELLULAR-DISTRIBUTION; MICROTUBULE ORGANIZATION; ENDOPLASMIC-RETICULUM; ORGANELLE TRANSPORT; SUPERFAMILY PROTEIN; GOLGI-APPARATUS; NERVOUS-SYSTEM; RAT-BRAIN; IN-VIVO	Mouse kif5B gene was disrupted by homologous recombination. kif5B(-/-) mice were embryonic lethal with a severe growth retardation at 9.5-11.5 days postcoitum. To analyze the significance of this conventional kinesin heavy chain in organelle transport, we studied the distribution of major organelles in the extraembryonic cells. The null mutant cells impaired lysosomal dispersion, while brefeldin A could normally induce the breakdown of their Golgi apparatus. More prominently, their mitochondria abnormally clustered in the perinuclear region. This mitochondrial phenotype was reversed by an exogeneous expression of KIF5B, and a subcellular fractionation revealed that KIF5B is associated with mitochondria. These data collectively indicate that kinesin is essential for mitochondrial and lysosomal dispersion rather than for the Golgi-to-ER traffic in these cells.	Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Tokyo 1130033, Japan	University of Tokyo	Hirokawa, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Tokyo 1130033, Japan.		Nonaka, Shigenori/I-2132-2013; Kanai, Yoshimitsu/W-3486-2019; Okada, Yasushi/N-5067-2015; Takeda, Sen/I-8462-2012	Nonaka, Shigenori/0000-0002-8093-0325; Okada, Yasushi/0000-0003-2601-3689; Takeda, Sen/0000-0001-7090-2139; Tanaka, Yosuke/0000-0001-5376-5726; Kanai, Yoshimitsu/0000-0002-0375-6853				AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; AMARATUNGA A, 1993, J BIOL CHEM, V268, P17427; BostUsinger L, 1997, EXP EYE RES, V64, P781, DOI 10.1006/exer.1996.0271; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Brown NA, 1990, POSTIMPLANTATION MAM, P93; BURKHARDT JK, 1993, J CELL SCI, V104, P151; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; ELLURU RG, 1995, MOL BIOL CELL, V6, P21, DOI 10.1091/mbc.6.1.21; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; Funakoshi T, 1996, J CELL BIOL, V133, P1347, DOI 10.1083/jcb.133.6.1347; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GRAESSMANN M, 1994, CELL BIOL LAB HDB, V3, P3; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HammAlvarez SF, 1997, EXP EYE RES, V64, P141, DOI 10.1006/exer.1996.0198; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HENSON JH, 1992, J CELL SCI, V103, P309; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; Hogan B, 1994, MANIPULATING MOUSE E; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; Hurd DD, 1996, GENETICS, V142, P195; Hurd DD, 1996, GENETICS, V144, P1075; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; JELLALI A, 1994, CELL MOTIL CYTOSKEL, V28, P79, DOI 10.1002/cm.970280108; Johnson KJ, 1996, EUR J CELL BIOL, V69, P276; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEOPOLD PL, 1992, CELL MOTIL CYTOSKEL, V23, P19, DOI 10.1002/cm.970230104; Lin SXH, 1996, CELL MOTIL CYTOSKEL, V34, P299; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; MALEKZADEHHEMMAT K, 1993, CELL MOL BIOL, V39, P279; MARKS DL, 1994, J CELL SCI, V107, P2417; Meng YX, 1997, ENDOCRINOLOGY, V138, P1979, DOI 10.1210/en.138.5.1979; Morfini G, 1997, J CELL BIOL, V138, P657, DOI 10.1083/jcb.138.3.657; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OKABE S, 1991, J NEUROSCI, V11, P1918; OKADA Y, 1995, J NEUROSCI, V15, P3053; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; Pereira AJ, 1997, J CELL BIOL, V136, P1081, DOI 10.1083/jcb.136.5.1081; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; Rodriguez A, 1996, J CELL BIOL, V134, P349, DOI 10.1083/jcb.134.2.349; Saito N, 1997, NEURON, V18, P425, DOI 10.1016/S0896-6273(00)81243-X; Sambrook J., 2002, MOL CLONING LAB MANU; SATO K, 1986, MOL CELL BIOL, V6, P1032, DOI 10.1128/MCB.6.4.1032; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SCHMITZ F, 1994, EUR J CELL BIOL, V63, P77; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; Spector D. L., 1998, CELLS LAB MANUAL; Stearns T, 1997, J CELL BIOL, V138, P957, DOI 10.1083/jcb.138.5.957; Sturmer K, 1996, CELL TISSUE RES, V286, P547, DOI 10.1007/s004410050725; Takei Y, 1995, J CELL BIOL, V131, P1789, DOI 10.1083/jcb.131.6.1789; TANAHASHI S, 1992, FUSION ENG DES, V19, P269, DOI 10.1016/0920-3796(92)90035-3; TANAKA Y, 1995, J CELL SCI, V108, P1883; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vignali G, 1996, EUR J NEUROSCI, V8, P536, DOI 10.1111/j.1460-9568.1996.tb01238.x; WATANABE A, 1993, GENE DEV, V7, P403; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; WRIGHT BD, 1993, J CELL BIOL, V123, P681, DOI 10.1083/jcb.123.3.681; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864; Yang ZH, 1997, GENOMICS, V45, P123, DOI 10.1006/geno.1997.4901; YOKOI H, 1993, BIOCHEM BIOPH RES CO, V195, P769, DOI 10.1006/bbrc.1993.2112	81	483	492	1	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1147	1158		10.1016/S0092-8674(00)81459-2	http://dx.doi.org/10.1016/S0092-8674(00)81459-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657148	Bronze			2022-12-28	WOS:000074491100010
J	Gravil, JH; Al-Rawas, OA; Cotton, MM; Flanigan, U; Irwin, A; Stevenson, RD				Gravil, JH; Al-Rawas, OA; Cotton, MM; Flanigan, U; Irwin, A; Stevenson, RD			Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service	LANCET			English	Article							AIR-FLOW LIMITATION; CONTROLLED TRIAL; HEALTH WORKER; DISABILITY; IMPAIRMENT; DEPRESSION; COPD	Background Exacerbations of chronic obstructive pulmonary disease are a major cause of hospital admissions, but do not require intensive investigation or complex therapy. We investigated the suitability of home care for severe uncomplicated exacerbations. Methods Over 3.5 years we assessed 962 patients with exacerbations of chronic obstructive pulmonary disease after referral to a hospital respiratory department by their family physicians. All patients had chest radiographs, oxygen-saturation or arterial-gas analysis, spirometry, and physical assessment. Unless admission was thought to be essential, patients were allowed home with a customised treatment package. Each patient was visited daily by a respiratory nurse who monitored progress and treatment compliance and provided education and reassurance. Findings 145 (15%) of 962 required admission at initial referral and 115 (12%) were admitted later. 653 (68%) patients were managed entirely at home and 49 (5%) were referred inappropriately. One patient died at home. All patients had severe disease with a mean forced expiratory volume in 1 s of 1.02 L and 395 (41%) had required hospital admission in the previous year. Interpretation After formal assessment in a hospital respiratory unit, many patients with exacerbations of chronic obstructive pulmonary disease can be treated at home by respiratory nurses.	Royal Infirm, Dept Resp Med, Glasgow G31 2ER, Lanark, Scotland; Royal Alexandra Hosp, Palsley, England; Sultan Qaboos Univ, Coll Med, Muscat, Oman	Royal Infirmary of Edinburgh; Sultan Qaboos University	Stevenson, RD (corresponding author), Royal Infirm, Dept Resp Med, Alexandra Parade, Glasgow G31 2ER, Lanark, Scotland.							COCKCROFT A, 1987, BRIT MED J, V294, P225, DOI 10.1136/bmj.294.6566.225; GIFT AG, 1993, HEART LUNG, V22, P289; HAGGERTY MC, 1991, CHEST, V100, P607, DOI 10.1378/chest.100.3.607; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; KELLNER R, 1992, GEN HOSP PSYCHIAT, V14, P20, DOI 10.1016/0163-8343(92)90022-3; LITTLEJOHNS P, 1991, THORAX, V46, P559, DOI 10.1136/thx.46.8.559; *LUNG ASTHM INF AG, 1992, SICK ABS RESP DIS; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; SMALL SP, 1992, HEART LUNG, V21, P568	9	90	91	3	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1853	1855		10.1016/S0140-6736(97)11048-0	http://dx.doi.org/10.1016/S0140-6736(97)11048-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652670				2022-12-28	WOS:000074347100013
J	Jessop, DS				Jessop, DS			beta-endorphin in the immune system - mediator of pain and stress?	LANCET			English	Editorial Material									Univ Bristol, Div Med, Bristol BS2 8HW, Avon, England	University of Bristol	Jessop, DS (corresponding author), Univ Bristol, Div Med, Bristol BS2 8HW, Avon, England.							BLALOCK JE, 1994, IMMUNOL TODAY, V15, P504, DOI 10.1016/0167-5699(94)90205-4; Cabot PJ, 1997, J CLIN INVEST, V100, P142, DOI 10.1172/JCI119506; Carr DJJ, 1996, P SOC EXP BIOL MED, V213, P248; JESSOP DS, 1995, J NEUROIMMUNOL, V60, P29, DOI 10.1016/0165-5728(95)00049-8; JESSOP DS, 1998, CURR OPIN ENDOCRINOL, V5, P52; Karalis K, 1997, J NEUROIMMUNOL, V72, P131, DOI 10.1016/S0165-5728(96)00178-6; Lyons PD, 1997, J NEUROIMMUNOL, V78, P47, DOI 10.1016/S0165-5728(97)00081-7; PRZEWLOCKI R, 1992, NEUROSCIENCE, V48, P491, DOI 10.1016/0306-4522(92)90509-Z; Schafer M, 1997, EUR J PHARMACOL, V323, P1, DOI 10.1016/S0014-2999(97)00057-5	9	23	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1828	1829		10.1016/S0140-6736(05)78799-7	http://dx.doi.org/10.1016/S0140-6736(05)78799-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652661				2022-12-28	WOS:000074347100004
J	Falk, D				Falk, D			Paleontology - Hominid brain evolution: Looks can be deceiving	SCIENCE			English	Editorial Material									SUNY Albany, Dept Anthropol, Albany, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany	Falk, D (corresponding author), SUNY Albany, Dept Anthropol, Albany, NY 12222 USA.		Falk, Dean/C-6400-2019	Falk, Dean/0000-0003-1654-0469				Conroy GC, 1998, SCIENCE, V280, P1730, DOI 10.1126/science.280.5370.1730; FALK D, 1987, ANNU REV ANTHROPOL, V16, P13; FALK D, 1985, NATURE, V313, P45, DOI 10.1038/313045a0; FALK D, 1992, EVOLUTION BRAIN COGN; Holloway Ralph L., 1995, P42; Kappelman J, 1996, J HUM EVOL, V30, P243, DOI 10.1006/jhev.1996.0021; Leakey R., 1985, National Geographic Magazine, V168, P624; LEIGH SR, 1992, AM J PHYS ANTHROPOL, V87, P1, DOI 10.1002/ajpa.1330870102; Seidler H, 1997, J HUM EVOL, V33, P691, DOI 10.1006/jhev.1997.0163; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; WALKER A, 1986, NATURE, V322, P517, DOI 10.1038/322517a0	11	16	18	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1714	1714		10.1126/science.280.5370.1714	http://dx.doi.org/10.1126/science.280.5370.1714			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZU446	9660712				2022-12-28	WOS:000074197800030
J	Rubin, P				Rubin, P			Put out the fire or risk an inferno	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham Hosp, Queens Med Ctr, Fac Med & Hlth Sci, Nottingham NG7 2UH, England	University of Nottingham	Rubin, P (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Fac Med & Hlth Sci, Nottingham NG7 2UH, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1739	1739						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9652927				2022-12-28	WOS:000074129500040
J	Dunlap, J				Dunlap, J			An end in the beginning	SCIENCE			English	Article							CIRCADIAN CLOCK; PERIOD PROTEIN		Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Dunlap, J (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.							Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Cheng YZ, 1998, J NEUROSCI, V18, P741; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DUNLAP JC, 1995, CIBA F SYMP, V183, P3; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Heintzen C, 1997, P NATL ACAD SCI USA, V94, P8515, DOI 10.1073/pnas.94.16.8515; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; HUANG J, 1993, NATURE, V364, P269; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Liu Y, 1997, CELL, V89, P477, DOI 10.1016/S0092-8674(00)80228-7; Rosato E, 1997, NUCLEIC ACIDS RES, V25, P455, DOI 10.1093/nar/25.3.455; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sauman I, 1996, NEURON, V17, P889, DOI 10.1016/S0896-6273(00)80220-2; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Young MW, 1996, COLD SPRING HARB SYM, V61, P279	21	76	78	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1548	1549		10.1126/science.280.5369.1548	http://dx.doi.org/10.1126/science.280.5369.1548			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9644021				2022-12-28	WOS:000074061200027
J	Mayaud, P; Hawkes, S; Mabey, D				Mayaud, P; Hawkes, S; Mabey, D			Advances in control of sexually transmitted diseases in developing countries	LANCET			English	Article							RISK ASSESSMENT; HIV-INFECTION; KENYA; TRANSMISSION; HEALTH; WOMEN; MEN; GONORRHEA; THAILAND; DECLINE		Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Mabey, D (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.		Hawkes, Sarah/AAK-7375-2020	Mabey, David/0000-0002-0031-8276; MAYAUD, Philippe/0000-0001-5730-947X; Hawkes, Sarah/0000-0003-1062-3538				BarbosaCesnik CT, 1997, GENITOURIN MED, V73, P336; BRABIN L, 1994, LANCET, V344, P300; CAMERON DW, 1989, LANCET, V2, P403; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; GHYS PD, 1997, AIDS, V11, P85; Gichangi PB, 1997, AM J OBSTET GYNECOL, V177, P680, DOI 10.1016/S0002-9378(97)70164-9; Gilson L, 1997, LANCET, V350, P1805, DOI 10.1016/S0140-6736(97)08222-6; Grosskurth H, 1996, BRIT MED J, V312, P277, DOI 10.1136/bmj.312.7026.277; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HAWKES S, IN PRESS HLTH POLICY; Hayes R, 1997, GENITOURIN MED, V73, P432; Jackson DJ, 1997, AIDS, V11, P903, DOI 10.1097/00002030-199707000-00010; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LAGA M, 1994, AIDS S1, V8, pS119; LAMPTEY PR, 1996, HDB DESIGN MANAGEMEN, P73; Mayaud P, 1995, B WORLD HEALTH ORGAN, V73, P621; Mayaud P, 1997, AIDS, V11, P1873, DOI 10.1097/00002030-199715000-00013; MAYAUD P, IN PRESS SEX TRANSM; Mostad SB, 1997, LANCET, V350, P922, DOI 10.1016/S0140-6736(97)04240-2; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; Ngugi EN, 1996, J INFECT DIS, V174, pS240, DOI 10.1093/infdis/174.Supplement_2.S240; NJERU EK, 1995, SEX TRANSM DIS, V22, P231, DOI 10.1097/00007435-199507000-00006; OAKLEY A, 1995, BRIT MED J, V310, P158, DOI 10.1136/bmj.310.6973.158; Over M, 1993, DIS CONTROL PRIORITI, P455; TEMMERMAN M, 1993, HEALTH POLICY PLANN, V8, P122, DOI 10.1093/heapol/8.2.113; Thomas T, 1996, GENITOURIN MED, V72, P334; *UN, 1994, UN INT C POP DEV NEW; VUYLSTEKE B, 1993, CLIN INFECT DIS, V17, P82, DOI 10.1093/clinids/17.1.82; WALT G, 1996, HLTH POLICY INTRO PR, P178; WASSERHEIT JN, 1989, INT J GYNECOL OBST S, V3, P145; WAWER MJ, 1997, INT C SEX TRANSM DIS	32	32	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN	1998	351			3			29	32						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV844	9652719				2022-12-28	WOS:000074347300010
J	Jonas, P; Bischofberger, J; Sandkuhler, J				Jonas, P; Bischofberger, J; Sandkuhler, J			Corelease of two fast neurotransmitters at a central synapse	SCIENCE			English	Article							GAMMA-AMINOBUTYRIC ACID; RAT SPINAL-CORD; GLYCINE-RECEPTOR; HIPPOCAMPAL SLICES; GUINEA-PIG; GABA; TERMINALS; NEURONS; COLOCALIZATION; RECORDINGS	It is widely accepted that individual neurons in the central nervous system release only a single fast transmitter. The possibility of corelease of fast neurotransmitters was examined by making paired recordings from synaptically connected neurons in spinal cord slices. Unitary inhibitory postsynaptic currents generated at interneuron-motoneuron synapses consisted of a strychnine-sensitive, glycine receptor-mediated component and a bicuculline-sensitive gamma-aminobutyric acid (GABA)(A) receptor-mediated component. These results indicate that spinal interneurons release both glycine and GABA to activate functionally distinct receptors in their postsynaptic target cells. A subset of miniature synaptic currents also showed both components, consistent with corelease from individual synaptic vesicles.	Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany	University of Freiburg	Jonas, P (corresponding author), Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany.	jonasp@ruf.uni-freiburg.de	Jansen, Heiko T./A-5770-2008; Sandkühler, Jürgen/B-6648-2012; Oka, Yoshitaka/C-9670-2010	Jansen, Heiko T./0000-0003-0178-396X; Sandkühler, Jürgen/0000-0002-5209-485X; Oka, Yoshitaka/0000-0002-3482-3051; Jonas, Peter/0000-0001-5001-4804; Bischofberger, Josef/0000-0002-4006-1663				Becker C.-M., 1992, HDB EXPT PHARM, V102, P539; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BOHLHALTER S, 1994, BRAIN RES, V642, P59, DOI 10.1016/0006-8993(94)90905-9; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; Brune W, 1996, AM J HUM GENET, V58, P989; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; BURNSTOCK G, 1976, NEUROSCIENCE, V1, P239, DOI 10.1016/0306-4522(76)90054-3; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; CURTIS DR, 1968, EXP BRAIN RES, V6, P1; Eccles, 2013, PHYSL SYNAPSES; Geiger JRP, 1997, NEURON, V18, P1009, DOI 10.1016/S0896-6273(00)80339-6; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; JANKOWSKA E, 1972, J PHYSIOL-LONDON, V222, P623, DOI 10.1113/jphysiol.1972.sp009818; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Juiz JM, 1996, J COMP NEUROL, V373, P11, DOI 10.1002/(SICI)1096-9861(19960909)373:1<11::AID-CNE2>3.0.CO;2-G; Katz B., 1969, RELEASE NEURAL TRANS; LAUBE B, 1995, NEUROREPORT, V6, P897, DOI 10.1097/00001756-199504190-00018; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; Mellor JR, 1997, J PHYSIOL-LONDON, V503, P353, DOI 10.1111/j.1469-7793.1997.353bh.x; MILES R, 1984, J PHYSIOL-LONDON, V356, P97, DOI 10.1113/jphysiol.1984.sp015455; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; Ornung G, 1996, J COMP NEUROL, V365, P413; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TAKAHASHI T, 1992, J PHYSIOL-LONDON, V450, P593, DOI 10.1113/jphysiol.1992.sp019145; TEGNER J, 1993, J NEUROPHYSIOL, V69, P647, DOI 10.1152/jn.1993.69.3.647; Todd AJ, 1996, J NEUROSCI, V16, P974; TODD AJ, 1990, J COMP NEUROL, V296, P496, DOI 10.1002/cne.902960312; TRILLER A, 1987, J CELL BIOL, V104, P947, DOI 10.1083/jcb.104.4.947; Zhu WJ, 1997, J NEUROSCI, V17, P4022	31	644	667	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					419	424		10.1126/science.281.5375.419	http://dx.doi.org/10.1126/science.281.5375.419			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665886				2022-12-28	WOS:000074918800049
J	Rockey, DC; Koch, J; Cello, JP; Sanders, LL; McQuaid, K				Rockey, DC; Koch, J; Cello, JP; Sanders, LL; McQuaid, K			Relative frequency of upper gastrointestinal and colonic lesions in patients with positive fecal occult-blood tests	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLORECTAL-CANCER; CHEMICAL-TESTS; NEGATIVE COLONOSCOPY; RECTAL EXAMINATION; UPPER ENDOSCOPY; CR-51 METHOD; SENSITIVITY; MORTALITY; DISEASE; POLYPS	Background Although bleeding lesions anywhere in the gastrointestinal tract can cause a positive reaction on guaiac-based fecal occult-blood tests, the relative frequency of upper gastrointestinal and colonic lesions is unknown. Methods During a period of 30 months, we prospectively studied all patients with at least one stool specimen containing fecal occult blood who were referred for further evaluation. Fecal occult blood was detected by standard guaiac-based tests of stool specimens obtained as part of routine screening or of stool obtained by digital rectal examination. Patients with documented iron-deficiency anemia or active gastrointestinal bleeding were excluded from the study. All participants had a detailed history taken and underwent colonoscopy, followed by esophagogastroduodenoscopy. Results Of the 409 patients with fecal occult blood who were referred, 310 were potentially eligible to participate, and 248 (mean age, 61 years; range, 40 to 89) were studied; 40 percent were women. We identified lesions consistent with occult bleeding in 119 patients (48 percent); in 71 bleeding lesions were found in the upper gastrointestinal tract, and in 54 they were identified in the colon. Six patients had abnormalities in both areas. The most common upper gastrointestinal lesions were esophagitis (23 patients), gastric ulcer (14), gastritis (12), and duodenal ulcer (10). Thirty patients with lesions in the upper gastrointestinal tract were long-term users of aspirin, ethanol, nonsteroidal antiinflammatory drugs, or a combination of these substances. The most com mon colonic lesions were adenomas more than 1.0 cm in diameter (29 patients), carcinoma (13), colitis (5), and vascular ectasia (5). Although the overall sensitivity of symptoms for the detection of gastrointestinal lesions was low, logistic-regression analysis demonstrated that the presence of symptoms in the upper gastrointestinal tract was associated with the detection of lesions in the upper gastrointestinal tract (odds ratio, 2.6; 95 percent confidence interval, 1.4 to 4.7). In both patients with symptoms and those without symptoms, the prevalence of lesions in the upper gastrointestinal tract was greater than or equal to that of colonic lesions. Conclusions In a group of patients with positive fecal occult-blood tests who were referred for further evaluation, from which those with iron-deficiency anemia and active bleeding had been excluded, up per gastrointestinal lesions were identified more frequently than colonic lesions. (N Engl J Med 1998; 339:153-9.) (C)1998, Massachusetts Medical Society.	Duke Univ, Med Ctr, Div Gastroenterol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	Duke University; Duke University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rockey, DC (corresponding author), Duke Univ, Med Ctr, Liver Res Lab, Sands Bldg,Rm 334,Res Dr,Box 3038, Durham, NC 27710 USA.							AHLQUIST DA, 1985, NEW ENGL J MED, V312, P1422, DOI 10.1056/NEJM198505303122204; AKDAMAR K, 1986, GASTROINTEST ENDOSC, V32, P78, DOI 10.1016/S0016-5107(86)71760-4; ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; Allison JE, 1996, NEW ENGL J MED, V334, P155, DOI 10.1056/NEJM199601183340304; BRINT SL, 1993, SOUTHERN MED J, V86, P601, DOI 10.1097/00007611-199306000-00001; CHEN YK, 1993, AM J GASTROENTEROL, V88, P2026; DYBDAHL JH, 1984, SCAND J GASTROENTERO, V19, P245, DOI 10.1080/00365521.1984.12005716; DYBDAHL JH, 1984, SCAND J GASTROENTERO, V19, P235, DOI 10.1080/00365521.1984.12005715; EISNER MS, 1991, ARCH INTERN MED, V151, P2180, DOI 10.1001/archinte.151.11.2180; Ferguson A, 1996, GUT, V38, P120, DOI 10.1136/gut.38.1.120; GELLER AJ, 1993, AM J GASTROENTEROL, V88, P1184; Greenberg PD, 1996, AM J MED, V100, P598, DOI 10.1016/S0002-9343(96)00009-5; HERZOG P, 1982, GASTROENTEROLOGY, V83, P957; HSIA PC, 1992, AM J GASTROENTEROL, V87, P1571; JOHNSEN R, 1991, BRIT MED J, V302, P749, DOI 10.1136/bmj.302.6779.749; Kleinbaum D, 1988, APPL REGRESSION ANAL; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; LANCE P, 1993, GASTROENTEROLOGY, V104, P1852, DOI 10.1016/0016-5085(93)90669-4; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; Lieberman D, 1996, LANCET, V348, P1463, DOI 10.1016/S0140-6736(05)65886-2; LIEBERMAN DA, 1990, ARCH INTERN MED, V150, P740; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; Marks RD, 1997, GASTROENTEROLOGY, V112, pA29; MORRIS DW, 1976, AM J DIG DIS, V21, P845, DOI 10.1007/BF01072075; OSTROW JD, 1973, AM J DIG DIS, V18, P930, DOI 10.1007/BF01072436; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; Rockey D, 1997, GASTROENTEROLOGY, V112, pA40; SAS Institute, 1990, SAS STAT US GUID, V2; SONTAG SJ, 1992, GASTROENTEROLOGY, V102, P109, DOI 10.1016/0016-5085(92)91790-B; STJOHN DJB, 1993, GASTROENTEROLOGY, V104, P1661, DOI 10.1016/0016-5085(93)90643-Q; STROEHLEIN JR, 1976, AM J DIG DIS, V21, P841, DOI 10.1007/BF01072074; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038; YOUNG GP, 1993, JAMA-J AM MED ASSOC, V270, P451, DOI 10.1001/jama.1993.03510040055022; ZUCKERMAN G, 1992, AM J GASTROENTEROL, V87, P62	37	138	141	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					153	159		10.1056/NEJM199807163390303	http://dx.doi.org/10.1056/NEJM199807163390303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ922	9664091				2022-12-28	WOS:000074782900003
J	Wijns, W; Vatner, SF; Camici, PG				Wijns, W; Vatner, SF; Camici, PG			Hibernating myocardium	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POSITRON EMISSION TOMOGRAPHY; CORONARY-ARTERY DISEASE; LEFT-VENTRICULAR FUNCTION; WALL-MOTION ABNORMALITIES; DOSE DOBUTAMINE ECHOCARDIOGRAPHY; ISCHEMIC-HEART-DISEASE; BLOOD-FLOW; VIABLE MYOCARDIUM; COMPUTED-TOMOGRAPHY; PREDICTING RECOVERY		Allegheny Univ Hlth Sci, Cardiovasc & Pulm Res Inst, Pittsburgh, PA 15212 USA; Onze Lieve Vrouw Hosp, Ctr Cardiovasc, Aalst, Belgium; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, MRC,Cyclotron Unit, London, England	Cardiovascular Center Aalst; Imperial College London	Vatner, SF (corresponding author), Allegheny Univ Hlth Sci, Cardiovasc & Pulm Res Inst, 320 E North Ave, Pittsburgh, PA 15212 USA.		Camici, Paolo/AAN-1959-2020; Schulz, Rainer/ABD-5069-2021	Camici, Paolo/0000-0001-5584-0750; Schulz, Rainer/0000-0003-3017-0476; Wijns, William/0000-0002-7267-4376				AFRIDI I, 1995, CIRCULATION, V91, P663, DOI 10.1161/01.CIR.91.3.663; ALDERMAN EL, 1983, CIRCULATION, V68, P785, DOI 10.1161/01.CIR.68.4.785; Ambrosio G, 1996, CIRCULATION, V94, P2455, DOI 10.1161/01.CIR.94.10.2455; ARNESE M, 1995, CIRCULATION, V91, P2748, DOI 10.1161/01.CIR.91.11.2748; AUSMA J, 1995, CARDIOVASC PATHOL, V4, P29, DOI 10.1016/1054-8807(94)00028-P; BAER FM, 1995, CIRCULATION, V91, P1006, DOI 10.1161/01.CIR.91.4.1006; Baer FM, 1996, J AM COLL CARDIOL, V28, P60, DOI 10.1016/0735-1097(96)00106-4; Bax JJ, 1997, J AM COLL CARDIOL, V30, P1451, DOI 10.1016/S0735-1097(97)00352-5; Bax JJ, 1996, J AM COLL CARDIOL, V28, P558, DOI 10.1016/0735-1097(96)00222-7; BORGERS M, 1993, CARDIOVASC PATHOL, V2, P237, DOI 10.1016/1054-8807(93)90030-6; BRAUNWALD E, 1982, CIRCULATION, V66, P1146, DOI 10.1161/01.CIR.66.6.1146; BRUNKEN R, 1986, CIRCULATION, V73, P951, DOI 10.1161/01.CIR.73.5.951; CAMICI P, 1989, PROG CARDIOVASC DIS, V32, P217, DOI 10.1016/0033-0620(89)90027-3; Camici PG, 1996, EUR HEART J, V17, P25; Camici PG, 1997, CIRCULATION, V96, P3205, DOI 10.1161/01.CIR.96.9.3205; CHATTERJEE K, 1973, CIRCULATION, V47, P276, DOI 10.1161/01.CIR.47.2.276; COHEN M, 1988, J AM COLL CARDIOL, V12, P1193, DOI 10.1016/0735-1097(88)92599-5; Conversano A, 1996, AM HEART J, V131, P440, DOI 10.1016/S0002-8703(96)90521-9; DECOSTER PM, 1990, CIRCULATION, V82, P2152, DOI 10.1161/01.CIR.82.6.2152; DEFILIPPI CR, 1995, CIRCULATION, V92, P2863, DOI 10.1161/01.CIR.92.10.2863; DEPRE C, 1995, AM J PHYSIOL-HEART C, V268, pH1265, DOI 10.1152/ajpheart.1995.268.3.H1265; DESILVA R, 1992, CIRCULATION, V86, P1738, DOI 10.1161/01.CIR.86.6.1738; DIAMOND GA, 1978, AM HEART J, V95, P204, DOI 10.1016/0002-8703(78)90464-7; DICARLI MF, 1995, CIRCULATION, V92, P3436, DOI 10.1161/01.CIR.92.12.3436; DICARLI MF, 1994, AM J CARDIOL, V73, P527, DOI 10.1016/0002-9149(94)90327-1; DILSIZIAN, 1993, CIRCULATION, V87, P2070; DILSIZIAN V, 1993, CIRCULATION, V87, P1; DREYFUS GD, 1994, ANN THORAC SURG, V57, P1402, DOI 10.1016/0003-4975(94)90091-4; DYKE SH, 1974, CIRCULATION, V50, P694, DOI 10.1161/01.CIR.50.4.694; EITZMAN D, 1992, J AM COLL CARDIOL, V20, P559, DOI 10.1016/0735-1097(92)90008-B; FEDELE FA, 1988, CIRCULATION, V78, P729, DOI 10.1161/01.CIR.78.3.729; FLAMENG W, 1981, AM HEART J, V102, P846, DOI 10.1016/0002-8703(81)90035-1; Gerber BL, 1996, CIRCULATION, V94, P651, DOI 10.1161/01.CIR.94.4.651; GIOIA G, 1995, AM J CARDIOL, V75, P759, DOI 10.1016/S0002-9149(99)80406-8; GRANDIN C, 1995, J NUCL MED, V36, P1543; GROPLER RJ, 1992, J AM COLL CARDIOL, V20, P569, DOI 10.1016/0735-1097(92)90010-K; GROPLER RJ, 1993, J AM COLL CARDIOL, V22, P1587, DOI 10.1016/0735-1097(93)90582-L; GUTH BD, 1993, CIRCULATION, V87, P35; HAMER AW, 1994, CIRCULATION, V90, P2899, DOI 10.1161/01.CIR.90.6.2899; HELFANT RH, 1974, CIRCULATION, V50, P108, DOI 10.1161/01.CIR.50.1.108; Heusch G, 1996, CIRCULATION, V93, P1556, DOI 10.1161/01.CIR.93.8.1556; HEYNDRICKX GR, 1975, J CLIN INVEST, V56, P978, DOI 10.1172/JCI108178; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; HOFFMAN JIE, 1995, BASIC RES CARDIOL, V90, P103, DOI 10.1007/BF00789440; HORN HR, 1974, CIRCULATION, V49, P1063, DOI 10.1161/01.CIR.49.6.1063; Kudej RK, 1998, CIRC RES, V82, P1199, DOI 10.1161/01.RES.82.11.1199; LACANNA G, 1994, J AM COLL CARDIOL, V23, P617, DOI 10.1016/0735-1097(94)90745-5; LEE KS, 1994, CIRCULATION, V90, P2687, DOI 10.1161/01.CIR.90.6.2687; LEWIS SJ, 1991, AM HEART J, V121, P1088, DOI 10.1016/0002-8703(91)90666-6; LOUIE HW, 1991, CIRCULATION, V84, P290; Maki M, 1996, CIRCULATION, V93, P1658, DOI 10.1161/01.CIR.93.9.1658; Marinho NVS, 1996, CIRCULATION, V93, P737, DOI 10.1161/01.CIR.93.4.737; MARWICK TH, 1992, AM J CARDIOL, V69, P854, DOI 10.1016/0002-9149(92)90782-T; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Pagano D, 1998, HEART, V79, P281, DOI 10.1136/hrt.79.3.281; Pagano D, 1998, J THORAC CARDIOV SUR, V115, P791, DOI 10.1016/S0022-5223(98)70357-5; Pagano D, 1996, CIRCULATION, V94, P1354; PARODI O, 1984, J COMPUT ASSIST TOMO, V8, P1083, DOI 10.1097/00004728-198412000-00008; PIGOTT JD, 1985, J AM COLL CARDIOL, V5, P1036, DOI 10.1016/S0735-1097(85)80003-6; POPIO KA, 1977, AM J CARDIOL, V39, P944, DOI 10.1016/S0002-9149(77)80206-3; RAGOSTA M, 1993, CIRCULATION, V87, P1630, DOI 10.1161/01.CIR.87.5.1630; RAHIMTOOLA SH, 1989, AM HEART J, V117, P211, DOI 10.1016/0002-8703(89)90685-6; RAHIMTOOLA SH, 1985, CIRCULATION S, P72; REES G, 1971, NEW ENGL J MED, V284, P1116, DOI 10.1056/NEJM197105202842002; SAMBUCETI G, 1993, AM J CARDIOL, V72, P538, DOI 10.1016/0002-9149(93)90348-G; SCHULZ R, 1993, CIRCULATION, V88, P684, DOI 10.1161/01.CIR.88.2.684; Schwarz ER, 1996, J AM COLL CARDIOL, V27, P1577, DOI 10.1016/0735-1097(96)00059-9; SEVERI S, 1995, J AM COLL CARDIOL, V26, P1187, DOI 10.1016/0735-1097(95)00319-3; SHEN YT, 1995, CIRC RES, V76, P479, DOI 10.1161/01.RES.76.3.479; Shen YT, 1996, BASIC RES CARDIOL, V91, P479, DOI 10.1007/BF00788729; Sun KT, 1996, CIRCULATION, V94, P3146, DOI 10.1161/01.CIR.94.12.3146; TILLISCH J, 1986, NEW ENGL J MED, V314, P884, DOI 10.1056/NEJM198604033141405; TOPOL EJ, 1984, J AM COLL CARDIOL, V4, P1123, DOI 10.1016/S0735-1097(84)80131-X; UDELSON JE, 1994, CIRCULATION, V89, P2552, DOI 10.1161/01.CIR.89.6.2552; VANOVERSCHELDE JL, 1994, CIRCULATION, V90, P378; VANOVERSCHELDE JLJ, 1993, CIRCULATION, V87, P1513, DOI 10.1161/01.CIR.87.5.1513; VANOVERSCHELDE JLJ, 1995, CIRCULATION, V92, P37, DOI 10.1161/01.CIR.92.9.37; Vanoverschelde JLJ, 1996, J AM COLL CARDIOL, V28, P432, DOI 10.1016/0735-1097(96)00167-2; Williams MJ, 1996, J AM COLL CARDIOL, V27, P132, DOI 10.1016/0735-1097(95)00393-2; YOSHIDA K, 1993, J AM COLL CARDIOL, V22, P984, DOI 10.1016/0735-1097(93)90407-R; ZARET BL, 1993, NEW ENGL J MED, V329, P775, DOI 10.1056/NEJM199309093291107; ZIMMERMANN R, 1995, CIRCULATION, V91, P1016, DOI 10.1161/01.CIR.91.4.1016	82	346	369	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					173	181		10.1056/NEJM199807163390307	http://dx.doi.org/10.1056/NEJM199807163390307			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ922	9664095				2022-12-28	WOS:000074782900007
J	Carne, C				Carne, C			Recent advances - Sexually transmitted infections	BRITISH MEDICAL JOURNAL			English	Review							SIMPLEX VIRUS TYPE-1; HERPES-SIMPLEX; AZITHROMYCIN; TRACHOMATIS; GONORRHEA; WOMEN		Addenbrookes Hosp, Dept Genitourinary Med, Cambridge CB2 2QQ, England	Addenbrooke's Hospital; University of Cambridge	Carne, C (corresponding author), Addenbrookes Hosp, Dept Genitourinary Med, Hills Rd, Cambridge CB2 2QQ, England.							Adler MW, 1997, BRIT MED J, V314, P1743, DOI 10.1136/bmj.314.7096.1743; Ahmed A., 1996, P EUR C HERP VIR GEN; Ashley RL, 1997, GENITOURIN MED, V73, P235; Battu VR, 1997, LANCET, V350, P1100, DOI 10.1016/S0140-6736(05)70460-8; Bodsworth NJ, 1997, GENITOURIN MED, V73, P110; Buimer M, 1996, J CLIN MICROBIOL, V34, P2395, DOI 10.1128/JCM.34.10.2395-2400.1996; Caul EO, 1997, LANCET, V349, P1070, DOI 10.1016/S0140-6736(05)62293-3; Coker DM, 1997, GENITOURIN MED, V73, P580; Cowan FM, 1996, J INFECT DIS, V174, P470, DOI 10.1093/infdis/174.3.470; *DEP HLTH, 1998, CEMCMO983 DEP HLTH; EDWARDS S, 1994, GENITOURIN MED, V70, P426; Fairley I, 1997, GENITOURIN MED, V73, P259; FIELD HJ, 1995, ANTIMICROB AGENTS CH, V39, P1114, DOI 10.1128/AAC.39.5.1114; Fitzgerald M, 1997, GENITOURIN MED, V73, P149; FitzGerald MR, 1998, INT J STD AIDS, V9, P253, DOI 10.1258/0956462981922179; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hillis SD, 1998, SEX TRANSM DIS, V25, P5, DOI 10.1097/00007435-199801000-00002; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Ison CA, 1996, GENITOURIN MED, V72, P253; LAUHARANTA J, 1993, J ANTIMICROB CHEMOTH, V31, P177, DOI 10.1093/jac/31.suppl_E.177; Lewis DA, 1997, GENITOURIN MED, V73, P325; Londesborough P, 1996, INT J CANCER, V69, P364; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Patel R, 1997, GENITOURIN MED, V73, P105; ROSS JDC, 1993, GENITOURIN MED, V69, P381; Rozendaal L, 1996, INT J CANCER, V68, P766, DOI 10.1002/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z; Simmons A, 1998, SEX TRANSM INFECT, V74, P1; Simms I., 1998, CDR Weekly, V8, pS1; Stary A, 1997, GENITOURIN MED, V73, P99; STEINGRIMSSON O, 1994, SEX TRANSM DIS, V21, P43, DOI 10.1097/00007435-199401000-00009; TAYAL SC, 1994, INT J STD AIDS, V5, P359, DOI 10.1177/095646249400500514; TAYLORROBINSON D, 1997, SEXUALLY TRANSMITTED, V1, P37; Tichonova L, 1997, LANCET, V350, P210, DOI 10.1016/S0140-6736(97)01382-2; van de Laar MJW, 1997, GENITOURIN MED, V73, P510; VANDELAAR MJW, 1997, GENITOURIN MED, V73, P512; VOLBERDING PA, 1997, LANCET S111, V350, P10; Waugh MA, 1997, LANCET, V350, P595, DOI 10.1016/S0140-6736(05)63189-3	37	1	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					129	132		10.1136/bmj.317.7151.129	http://dx.doi.org/10.1136/bmj.317.7151.129			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657793	Green Published			2022-12-28	WOS:000075081700027
J	Martin, RM; Kapoor, KV; Wilton, LV; Mann, RD				Martin, RM; Kapoor, KV; Wilton, LV; Mann, RD			Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study	BRITISH MEDICAL JOURNAL			English	Article									Drug Safety Res Unit, Southampton SO31 1AA, Hants, England; Univ Southampton, Fac Med Hlth & Biol Sci, Sch Med, Southampton SO16 7PX, Hants, England	University of Southampton	Martin, RM (corresponding author), Drug Safety Res Unit, Southampton SO31 1AA, Hants, England.							BELTON KJ, 1995, BRIT J CLIN PHARMACO, V39, P223, DOI 10.1111/j.1365-2125.1995.tb04440.x; BEM JL, 1988, BRIT MED J, V296, P1319, DOI 10.1136/bmj.296.6632.1319; *JOINT FORM COMM, 1997, BRIT NATL FORMULARY, P10; LUMLEY C E, 1986, Pharmaceutical Medicine (London), V1, P205; RAWLINS MD, 1993, BR J CLIN PHARM, V35, P590	5	129	136	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					119	120		10.1136/bmj.317.7151.119	http://dx.doi.org/10.1136/bmj.317.7151.119			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657787	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000075081700022
J	Lai, CL; Chien, RN; Leung, NWY; Chang, TT; Guan, R; Tai, DI; Ng, KY; Wu, PC; Dent, JC; Barber, J; Stephenson, SL; Gray, DF				Lai, CL; Chien, RN; Leung, NWY; Chang, TT; Guan, R; Tai, DI; Ng, KY; Wu, PC; Dent, JC; Barber, J; Stephenson, SL; Gray, DF		Asia Hepatitis Lamivudine Study Grp	A one-year trial of lamivudine for chronic hepatitis B	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIAL; ALPHA-INTERFERON TREATMENT; HBSAG-CARRIER CHILDREN; TERM FOLLOW-UP; RECOMBINANT ALPHA-2-INTERFERON; POSITIVE PATIENTS; CHINESE PATIENTS; VIRUS-INFECTION; PREDNISONE; PREVENTION	Background and Methods In preliminary trials, lamivudine, an oral nucleoside analogue, has shown promise for the treatment of chronic hepatitis B. We conducted a one-year, double-blind trial of lamivudine in 358 Chinese patients with chronic hepatitis B. The patients were randomly assigned to receive 25 mg of lamivudine (142 patients), 100 mg of lamivudine (143), or placebo (73) orally once daily. The pa tients underwent liver biopsies before entering the study and after completing the assigned treatment regimen. The primary end point was a reduction of at least two points in the Knodell necroinflammatory score. Results Hepatic necroinflammatory activity improved by two points or more in 56 percent of the patients receiving 100 mg of lamivudine, 49 percent of those receiving 25 mg of lamivudine, and 25 percent of those receiving placebo (P<0.001 and P=0.001, respectively, for the comparisons of lamivudine treatment with placebo). Necroinflammatory activity worsened in 7 percent of the patients receiving 100 mg of lamivudine, 8 percent of those receiving 25 mg, and 26 percent of those receiving placebo. The 100-mg dose of lamivudine was associated with a reduced progression of fibrosis (P=0.01 for the com parison with placebo) and with the highest rate of hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg, development of antibody to HBeAg, and undetectable HBV DNA) (16 percent), the greatest suppression of HBV DNA (98 percent reduction at week 52 as compared with the base-line value), and the highest rate of sustained normalization of alanine aminotransferase levels (72 percent). Ninety-six percent of the patients completed the study. The incidence of adverse events was similar in all groups, and there were few serious events. Conclusions In a one-year study, lamivudine was associated with substantial histologic improvement in many patients with chronic hepatitis B. A daily dose of 100 mg was more effective than a daily dose of 25 mg. (N Engl J Med 1998;339:61-8.) (C)1998, Massachusetts Medical Society.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China; Queen Mary Hosp, Dept Pathol, Hong Kong, Peoples R China; Chang Gung Mem Hosp, Liver Unit, Taipei 10591, Taiwan; Prince Wales Hosp, Dept Med, Hong Kong, Peoples R China; Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan; Natl Univ Singapore Hosp, Dept Med, Singapore 117548, Singapore; Chang Gung Mem Hosp, Liver Unit, Kaohsiung, Taiwan; Singapore Gen Hosp, Dept Gastroenterol, Singapore 0316, Singapore; Glaxo Wellcome China, Med Affairs Dept, Hong Kong, Peoples R China; Glaxo Wellcome Res & Dev Ltd, Dept European Clin Stat, Greenford, Middx, England; Glaxo Wellcome Res & Dev Ltd, Dept Infect Dis & Rheumatol, Greenford, Middx, England	University of Hong Kong; University of Hong Kong; Chang Gung Memorial Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National University of Singapore; Chang Gung Memorial Hospital; Singapore General Hospital; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Lai, CL (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China.		Lai, Ching Lung/C-4298-2009; ting, huang/V-6326-2017; Chang, Ting-Tsung/B-4306-2009	Lai, Ching-Lung/0000-0002-5927-2436				Armitage P., 1987, STAT METHODS MED RES; Bartholomew MM, 1997, LANCET, V349, P20, DOI 10.1016/S0140-6736(96)02266-0; BEASLEY RP, 1983, J INFECT DIS, V147, P185, DOI 10.1093/infdis/147.2.185; BEASLEY RP, 1981, LANCET, V2, P1129; CHUNG HT, 1993, J HEPATOL, V17, P208, DOI 10.1016/S0168-8278(05)80040-6; DEJONGH FE, 1992, GASTROENTEROLOGY, V103, P1630, DOI 10.1016/0016-5085(92)91188-A; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; DUSHEIKO GM, 1995, PHARMACOL THERAPEUT, V65, P47, DOI 10.1016/0163-7258(94)00056-9; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Fleiss J. L., 1981, STAT METHODS RATES P, V2; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; LAI CL, 1991, Q J MED, V78, P155; Lai CL, 1997, HEPATOLOGY, V25, P241, DOI 10.1002/hep.510250144; LAI CL, 1987, LANCET, V2, P877; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; LIAW YF, 1994, J HEPATOL, V20, P175, DOI 10.1016/S0168-8278(05)80055-8; Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347; LOK ASF, 1988, LANCET, V2, P298; LOK ASF, 1992, GASTROENTEROLOGY, V102, P2091, DOI 10.1016/0016-5085(92)90337-X; MAYNARD JE, 1990, VACCINE, V8, pS18, DOI 10.1016/0264-410X(90)90209-5; Nevens F, 1997, GASTROENTEROLOGY, V113, P1258, DOI 10.1053/gast.1997.v113.pm9322520; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; STEVENS CE, 1979, J MED VIROL, V3, P237, DOI 10.1002/jmv.1890030310; STOKES M, 1995, CATEGORICAL DATA ANA; TYRELL DLJ, 1993, HEPATOLOGY, V18, pA112; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; WU PC, 1993, AM J CLIN PATHOL, V100, P648, DOI 10.1093/ajcp/100.6.648; Wu PC, 1996, AM J CLIN PATHOL, V105, P87; XU ZY, 1985, PEDIATRICS, V76, P713	30	1514	1632	0	80	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1998	339	2					61	68		10.1056/NEJM199807093390201	http://dx.doi.org/10.1056/NEJM199807093390201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY828	9654535	Green Published			2022-12-28	WOS:000074665300001
J	Husband, DJ				Husband, DJ			Malignant spinal cord compression: prospective study of delays in referral and treatment	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; DIAGNOSIS	Objectives: To examine the delay in presentation diagnosis, and treatment of malignant spinal cord compression and to define the effect of this delay on motor and bladder function at the time of treatment Design: Prospective study of all new patients presenting to a regional cancer centre with this condition. Setting: Regional cancer centre. Subjects: 301 consecutive patients. Main outcome measures: Interval from onset of symptoms to presentation and treatment, delay at each stage of referral, and functional deterioration. Results: The median (range) delay from onset of symptoms of spinal cord compression to treatment was 14 (0-840) days. Of the total delay 3 (0-300) days were accounted for by patients, 3 (0-330) days by general practitioners, 4 (0-794) days by the district general hospital, and 0 (0-114) days by the treatment unit Initial presentation to the regional cancer centre with symptoms of malignant spinal cord compression led to a significant reduction in delay to treatment and improved functional status at the time of treatment Deterioration of motor or bladder function greater than or equal to 1 grade occurred at the general practice stage in 28% (57) and 18% (36) of patients, the general hospital stage in 36% (83) and 29% (66), and the treatment unit stage in 6% (19) and 5% (15), respectively. Conclusions: Unacceptable delay in diagnosis, investigation, and referral occurs in most patients with malignant spinal cord compression and results in preventable loss of function before treatment Improvement in the outcome of such patients requires earlier diagnosis and treatment.	Clatterbridge Ctr Oncol, Wirral L63 4JY, Merseyside, England	Clatterbridge Cancer Centre	Husband, DJ (corresponding author), Clatterbridge Ctr Oncol, Wirral L63 4JY, Merseyside, England.							BACH F, 1990, ACTA NEUROCHIR, V107, P37, DOI 10.1007/BF01402610; BOOGERD W, 1993, CANCER TREAT REV, V19, P129, DOI 10.1016/0305-7372(93)90031-L; BYRNE TN, 1995, NEUROLOGICAL COMPLIC, P23; CAMPBELL MJ, 1989, STAT CONFIDENCE; Delaney TF, 1993, CANC PRINCIPLES PRAC, P2118; FINDLAY GFG, 1984, J NEUROL NEUROSUR PS, V47, P761, DOI 10.1136/jnnp.47.8.761; GILBERT RW, 1978, ANN NEUROL, V3, P40, DOI 10.1002/ana.410030107; JOHNSTON RA, 1993, J NEUROL NEUROSUR PS, V56, P1046, DOI 10.1136/jnnp.56.10.1046; Posner J.B., 1995, NEUROLOGICAL COMPLIC; SIEGEL S, 1988, NONPARAMETRIC STAT	10	112	116	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					18	21		10.1136/bmj.317.7150.18	http://dx.doi.org/10.1136/bmj.317.7150.18			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651261	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000075081600017
J	Schott, JJ; Benson, DW; Basson, CT; Pease, W; Silberbach, GM; Moak, JP; Maron, BJ; Seidman, CE; Seidman, JG				Schott, JJ; Benson, DW; Basson, CT; Pease, W; Silberbach, GM; Moak, JP; Maron, BJ; Seidman, CE; Seidman, JG			Congenital heart disease caused by mutations in the transcription factor NKX2-5	SCIENCE			English	Article							MOLECULAR-CLONING; TINMAN; GENES	Mutations in the gene encoding the homeobox transcription factor NKX2-5 were found to cause nonsyndromic, human congenital heart disease. A dominant disease locus associated with cardiac malformations and atrioventricular conduction abnormalities was mapped to chromosome 5q35, where NKX2-5, a Drosophila tinman homolog, is located. Three different NKX2-5 mutations were identified. Two are predicted to impair binding of NKX2-5 to target DNA, resulting in haploinsufficiency, and a third potentially augments target-DNA binding. These data indicate that NKX2-5 is important for regulation of septation during cardiac morphogenesis and for maturation and maintenance of atrioventricular node function throughout life.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harrisburg Hosp, Harrisburg, PA 17104 USA; Oregon Hlth Sci Univ, Div Pediat Cardiol, Portland, OR 97201 USA; Childrens Natl Med Ctr, Div Pediat Cardiol, Washington, DC 20010 USA; Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Oregon Health & Science University; Children's National Health System; Minneapolis Heart Institute Foundation	Seidman, JG (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.		Schott, jean-Jacques/F-8842-2013	Schott, jean-Jacques/0000-0002-9578-9475				Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; BASSON CT, 1995, CIRCULATION, V91, P1326, DOI 10.1161/01.CIR.91.5.1326; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; BODMER R, 1993, DEVELOPMENT, V118, P719; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Fishman MC, 1997, DEVELOPMENT, V124, P2099; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HOFFMAN JIE, 1990, PEDIATR CLIN N AM, V37, P25; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kostrzewa M, 1996, HUM GENET, V97, P399, DOI 10.1007/BF02185781; Li QY, 1997, NAT GENET, V15, P21; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MOORE KL, 1998, DEV HUMAN CLIN ORIEN, P349; MOORMAN AFM, 1994, TRENDS CARDIOVAS MED, V4, P257, DOI 10.1016/1050-1738(94)90029-9; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; PEASE WE, 1976, CIRCULATION, V53, P759, DOI 10.1161/01.CIR.53.5.759; Schott JJ, UNPUB; Shiojima I, 1996, CIRC RES, V79, P920, DOI 10.1161/01.RES.79.5.920; Turbay D, 1996, MOL MED, V2, P86, DOI 10.1007/BF03402205	19	958	997	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					108	111		10.1126/science.281.5373.108	http://dx.doi.org/10.1126/science.281.5373.108			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651244				2022-12-28	WOS:000074685800049
J	Levinson, W; Branch, WT; Kroenke, K				Levinson, W; Branch, WT; Kroenke, K			Clinician-educators in academic medical centers: A two-part challenge	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							FACULTY; CARE; PROMOTION; TEACHERS	As academic medical centers increasingly deliver care in primary care settings, a new category of faculty-clinician-educators- has emerged. Although the shift of education and patient care to outpatient settings makes the expanded role of clinician-educators necessary, it also presents challenges to clinician-educators themselves and to the institutions for which they work. This article examines these contemporary challenges (including financial constraints, undefined processes of promotion, and limited opportunities for professional development) and suggests strategies for meeting them. The number of clinician-educators joining the ranks of medical school faculties will probably continue to increase. As clinician-educators seek to provide the highest-quality education and patient care in the new medical marketplace, their success will be critical to the viability of the academic centers of the future.	Univ Chicago, Chicago, IL 60637 USA; Emory Clin, Atlanta, GA 30322 USA; Indiana Univ, Sch Med, Indianapolis, IN USA	University of Chicago; Emory University; Indiana University System; Indiana University-Purdue University Indianapolis	Levinson, W (corresponding author), Univ Chicago, 5841 S Maryland,MC 6098, Chicago, IL 60637 USA.		anand, amit/A-7222-2009	Kroenke, Kurt/0000-0002-0114-4669				Adams M, 1997, J GEN INTERN MED, V12, pS104, DOI 10.1046/j.1525-1497.12.s2.15.x; *AM COLL PHYS, 1995, GOV CLASS 1996 LEARN; BALDWIN CD, 1995, ACAD MED, V70, pS97, DOI 10.1097/00001888-199501000-00032; BARDES CL, 1995, ACAD MED, V70, P111, DOI 10.1097/00001888-199502000-00013; Beasley BW, 1997, JAMA-J AM MED ASSOC, V278, P723, DOI 10.1001/jama.278.9.723; BICKEL J, 1991, ACAD MED, V66, P249, DOI 10.1097/00001888-199105000-00002; Block SD, 1996, JAMA-J AM MED ASSOC, V276, P677, DOI 10.1001/jama.276.9.677; Bowen JL, 1997, ACAD MED, V72, P506, DOI 10.1097/00001888-199706000-00014; Branch WT, 1997, J GEN INTERN MED, V12, pS1, DOI 10.1046/j.1525-1497.12.s2.16.x; Burke R, 1997, TEACH LEARN MED, V9, P204, DOI 10.1080/10401339709539842; Culbertson RA, 1996, ACAD MED, V71, P858, DOI 10.1097/00001888-199608000-00013; Davidoff F, 1997, J GEN INTERN MED, V12, pS15, DOI 10.1046/j.1525-1497.12.s2.2.x; ENDE J, 1995, ACAD MED, V70, P224, DOI 10.1097/00001888-199503000-00014; Ende J, 1997, J GEN INTERN MED, V12, pS41, DOI 10.1046/j.1525-1497.12.s2.6.x; EVANS CH, 1995, ACAD MED, V70, P14, DOI 10.1097/00001888-199501000-00007; Ferenchick G, 1997, ACAD MED, V72, P277, DOI 10.1097/00001888-199704000-00011; Fletcher RH, 1997, J GEN INTERN MED, V12, pS5, DOI 10.1046/j.1525-1497.12.s2.1.x; Henderson MC, 1996, AM J MED, V101, P648, DOI 10.1016/S0002-9343(96)00334-8; Hensel WA, 1996, ACAD MED, V71, P441, DOI 10.1097/00001888-199605000-00011; Humphrey HJ, 1997, J GEN INTERN MED, V12, pS79, DOI 10.1046/j.1525-1497.12.s2.11.x; INUI TS, 1994, J GEN INTERN MED, V9, pS1, DOI 10.1007/BF02598110; IRBY DM, 1995, ACAD MED, V70, P898, DOI 10.1097/00001888-199510000-00014; Johnston MAC, 1996, ACAD MED, V71, P138, DOI 10.1097/00001888-199602000-00015; Karp S, 1997, ACAD MED, V72, P341, DOI 10.1097/00001888-199705000-00010; KELLY JV, 1994, ACAD MED, V69, P931, DOI 10.1097/00001888-199412000-00001; Kernan WN, 1997, TEACH LEARN MED, V9, P96, DOI 10.1080/10401339709539822; Kroenke K, 1997, SOUTHERN MED J, V90, P1069, DOI 10.1097/00007611-199711000-00002; Kurth RJ, 1997, ACAD MED, V72, P601, DOI 10.1097/00001888-199707000-00012; LESKY LG, 1995, ARCH INTERN MED, V155, P897, DOI 10.1001/archinte.155.9.897; LEVINSON W, 1993, ANN INTERN MED, V119, P220, DOI 10.7326/0003-4819-119-3-199308010-00008; LEVINSON W, 1995, SGIM FORUM, V18, P3; Levy BT, 1997, ACAD MED, V72, P382, DOI 10.1097/00001888-199705000-00018; Libby DL, 1997, ACAD MED, V72, P301, DOI 10.1097/00001888-199704000-00016; Lovejoy FH, 1995, ACAD MED, V70, P1079, DOI 10.1097/00001888-199512000-00009; Lubitz RM, 1997, J GEN INTERN MED, V12, pS71, DOI 10.1046/j.1525-1497.12.s2.10.x; Lurie N, 1996, ACAD MED, V71, P1044, DOI 10.1097/00001888-199610000-00009; McGee SR, 1997, J GEN INTERN MED, V12, pS34, DOI 10.1046/j.1525-1497.12.s2.5.x; MURRAY E, 1995, MED EDUC, V29, P66, DOI 10.1111/j.1365-2923.1995.tb02804.x; Nieman LZ, 1997, ACAD MED, V72, P496, DOI 10.1097/00001888-199706000-00012; Norris TE, 1997, J GEN INTERN MED, V12, pS64, DOI 10.1046/j.1525-1497.12.s2.9.x; Olmesdahl PJ, 1997, MED EDUC, V31, P27, DOI 10.1111/j.1365-2923.1997.tb00039.x; Osborn LM, 1997, J GEN INTERN MED, V12, pS83, DOI 10.1046/j.1525-1497.12.s2.12.x; REISER SJ, 1995, ACAD MED, V70, P272, DOI 10.1097/00001888-199504000-00009; RIVO ML, 1995, ACAD MED S, V70, pS1; Shorey JM, 1997, J GEN INTERN MED, V12, pS98, DOI 10.1046/j.1525-1497.12.s2.14.x; SKEFF K M, 1988, Journal of General Internal Medicine, V3, pS26, DOI 10.1007/BF02600249; Skeff KM, 1997, J GEN INTERN MED, V12, pS56, DOI 10.1046/j.1525-1497.12.s2.8.x; WHITE LJ, 1991, ANN INTERN MED, V114, P63, DOI 10.7326/0003-4819-114-1-63; 1995, P E MED REG C AL AIN, V29, pS1; 1990, J GEN INTERN MED S, V5, pS1	50	51	51	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					59	64		10.7326/0003-4819-129-1-199807010-00013	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00013			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9653001				2022-12-28	WOS:000074513300009
J	Smeenk, FWJM; van Haastregt, JCM; de Witte, LP; Crebolder, FJM				Smeenk, FWJM; van Haastregt, JCM; de Witte, LP; Crebolder, FJM			Effectiveness of home care programmes for patients with incurable cancer on their quality of life and time spent in hospital: systematic review	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIAL; TERMINAL CANCER; COST-EFFECTIVENESS; NATIONAL HOSPICE; ILL; STRATEGIES; CONTINUITY; SERVICE; DEATH	Objective: To investigate whether for patients with incurable cancer comprehensive home care programmes are more effective than standard care in maintaining the patients' quality of life and reducing their "readmission time" (percentage of days spent in hospital from start of care till death). Design: Systematic review. Methods: A computer aided search was conducted using the databases of Medline, Embase, CancerLit, and PsychLit The search for studies and the assessment of the methodological quality of the relevant studies were performed by two investigators, blinded from each other. Prospective, controlled studies investigating the effects of a home care intervention programme on patients' quality of life or on readmission time were included in the analyses. Results: Only 9 prospective controlled studies were found; eight were performed in the United States and 1 in the United Kingdom. Their methodological quality was judged to be moderate (median rating 62 on a 100 point scale). None of the studies showed a negative influence of home care interventions on quality of life: A significantly positive influence on the outcome measures was seen in 2 out of the 5 studies measuring patients' satisfaction with care, in 3/7 studies measuring physical dimensions of quality of life, in 1/6 studies measuring psychosocial dimensions, and in 2/5 studies measuring readmission time. The incorporation of team members' visits to patients at home or regular multidisciplinary team meetings into the intervention programme seemed to be related to positive results. Conclusions: The effectiveness of comprehensive home care programmes remains unclear. Given the enormity of the problems faced by society in caring for patients with terminal cancer, further research is urgently needed.	Catharina Hosp, Dept Multidisciplinary Oncol, NL-5602 ZA Eindhoven, Netherlands; Catharina Hosp, Dept Pulmonol, NL-5602 ZA Eindhoven, Netherlands; Inst Rehabil Res, Hlth Care Intervent & Serv Dept, NL-6430 AD Hoensbroek, Netherlands; Maastricht Univ, Dept Gen Practice, NL-6200 MD Maastricht, Netherlands	Catharina Hospital; Catharina Hospital; Maastricht University	Smeenk, FWJM (corresponding author), Catharina Hosp, Dept Multidisciplinary Oncol, POB 1350, NL-5602 ZA Eindhoven, Netherlands.			de Witte, Luc/0000-0002-3013-2640				ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; AHMEDZAI S, 1991, EFFECT CANC QUALITY, P323; Beck-Friis Barbro, 1993, Palliative Medicine, V7, P93, DOI 10.1177/026921639300700202; CONKLING VK, 1989, CANCER, V64, P290, DOI 10.1002/1097-0142(19890701)64:1+<290::AID-CNCR2820641324>3.0.CO;2-K; CUMMINGS JE, 1990, ARCH INTERN MED, V150, P1274, DOI 10.1001/archinte.150.6.1274; DESSLOCH A, 1992, PSYCHOTHER PSYCH MED, V42, P424; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; DUNLOP RJ, 1989, PALLIAT MED, V0003, P00197, DOI DOI 10.1177/026921638900300305; FIELD D, 1993, FUTURE PALLIATIVE CA, P6; FRAUMENI JF, 1993, CANC PRINCIPLES PRAC, P196; Greenhalgh T, 1997, BRIT MED J, V315, P180, DOI 10.1136/bmj.315.7101.180; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; HUGHES SL, 1992, HEALTH SERV RES, V26, P801; JONES RVH, 1993, BRIT MED J, V306, P249, DOI 10.1136/bmj.306.6872.249; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; MACDONALD N, 1997, OXFORD TXB PALLIATIV, P11; MCCORKLE R, 1994, RES NURS HEALTH, V17, P243, DOI 10.1002/nur.4770170403; MCCORKLE R, 1989, CANCER, V64, P1375, DOI 10.1002/1097-0142(19890915)64:6<1375::AID-CNCR2820640634>3.0.CO;2-6; MEIER ML, 1995, SUPPORT CARE CANCER, V3, P389, DOI 10.1007/BF00364978; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; MOR V, 1985, HEALTH SERV RES, V20, P407; OHARE PA, 1993, CANCER INVEST, V11, P140, DOI 10.3109/07357909309024832; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PARKES CM, 1980, POSTGRAD MED J, V56, P685, DOI 10.1136/pgmj.56.660.685; SEALE C, 1991, SOC SCI MED, V32, P147, DOI 10.1016/0277-9536(91)90054-G; *STEER COMM FUT HL, 1988, CANC NETH SCEN CANC; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; TSAMANDOURAKI K, 1992, SCAND J SOC MED, V20, P51, DOI 10.1177/140349489202000110; VANDERAKKER PAM, 1994, LEVEN DOOD OVER TERM; VENTAFRIDDA V, 1989, TUMORI, V75, P619, DOI 10.1177/030089168907500622; VINCIGUERRA V, 1986, J CLIN ONCOL, V4, P1521, DOI 10.1200/JCO.1986.4.10.1521; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; WILKES E, 1984, LANCET, V1, P950; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	36	92	92	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1939	1944		10.1136/bmj.316.7149.1939	http://dx.doi.org/10.1136/bmj.316.7149.1939			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZY568	9641929	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000074636700024
J	Venter, JC; Adams, MD; Sutton, GG; Kerlavage, AR; Smith, HO; Hunkapiller, M				Venter, JC; Adams, MD; Sutton, GG; Kerlavage, AR; Smith, HO; Hunkapiller, M			Shotgun sequencing of the human genome	SCIENCE			English	Article							MAP; PROJECT; TAGS; DNA		TIGR, Rockville, MD 20850 USA; Perkin Elmer Appl Biosyst, Foster City, CA 94404 USA	J. Craig Venter Institute; Thermo Fisher Scientific; Applied Biosystems	Venter, JC (corresponding author), TIGR, Rockville, MD 20850 USA.			Kerlavage, Anthony/0000-0002-3954-9653				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ADAMS MD, 1995, NATURE S, V37, P3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; FRASER CM, IN PRESS SCIENCE; Goffeau A, 1997, NATURE, V387, P5, DOI DOI 10.1038/387005B0.PUBMED:9169864; GREEN E, 1997, GENOME RES, V7, P410; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Venter JC, 1996, NATURE, V381, P364, DOI 10.1038/381364a0; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401	22	222	244	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1540	1542		10.1126/science.280.5369.1540	http://dx.doi.org/10.1126/science.280.5369.1540			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9644018				2022-12-28	WOS:000074061200021
J	Aral, SO; Peterman, TA				Aral, SO; Peterman, TA			Do we know the effectiveness of behavioural interventions?	LANCET			English	Article							HIV-INFECTION; CONTROLLED TRIALS; AIDS-PREVENTION; RISK; ADOLESCENTS; BIAS		Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Aral, SO (corresponding author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA.							Aral SO, 1996, INT J STD AIDS, V7, P30, DOI 10.1258/0956462961917753; BEGG CB, 1998, STAT SOC, V151, P419; Boyer CB, 1997, AIDS, V11, P359, DOI 10.1097/00002030-199703110-00014; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1401, DOI 10.1001/jama.263.10.1401; DICKERSIN K, 1993, ANN NY ACAD SCI, V703, P135, DOI 10.1111/j.1749-6632.1993.tb26343.x; Eldridge GD, 1997, AIDS EDUC PREV, V9, P62; Green SB, 1997, AM J PUBLIC HEALTH, V87, P541, DOI 10.2105/AJPH.87.4.541; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Haddix A, 1996, PREVENTION EFFECTIVE; JEMMOTT JB, 1992, AM J PUBLIC HEALTH, V82, P372, DOI 10.2105/AJPH.82.3.372; KALICHMAN SC, 1995, PSYCHIATR SERV, V46, P275; KAMB ML, 1997, 12 M INT SOC STD RES; Kelly JA, 1997, LANCET, V350, P1500, DOI 10.1016/S0140-6736(97)07439-4; KELLY JA, 1994, AM J PUBLIC HEALTH, V84, P1918, DOI 10.2105/AJPH.84.12.1918; Koopman JS, 1996, AM J PUBLIC HEALTH, V86, P630, DOI 10.2105/AJPH.86.5.630; Leviton L C, 1990, AIDS Educ Prev, V2, P95; May RM, 1997, SCIENCE, V275, P793, DOI 10.1126/science.275.5301.793; OAKLEY A, 1995, AIDS, V9, P479, DOI 10.1097/00002030-199509050-00010; ODONNELL L, 1995, SEX TRANSM DIS, V22, P97, DOI 10.1097/00007435-199503000-00004; OLeary A, 1997, AIDS EDUC PREV, V9, P1; PETERMAN TA, 1993, JAMA-J AM MED ASSOC, V269, P2845, DOI 10.1001/jama.1993.03500220031011; PETERMAN TA, 1998, 1I WORLD AIDS C GEN; Peterson JL, 1996, AIDS, V10, P319, DOI 10.1097/00002030-199603000-00011; ROTHERAMBORUS MJ, 1991, JAMA-J AM MED ASSOC, V266, P1237, DOI 10.1001/jama.266.9.1237; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; STERLING TD, 1959, J AM STAT ASSOC, V54, P30, DOI 10.2307/2282137; STLAWRENCE JS, 1995, J CONSULT CLIN PSYCH, V63, P154, DOI 10.1037/0022-006X.63.1.154; STLAWRENCE JS, 1995, J CONSULT CLIN PSYCH, V63, P221, DOI 10.1037/0022-006X.63.2.221; Wasserheit JN, 1996, J INFECT DIS, V174, pS201, DOI 10.1093/infdis/174.Supplement_2.S201; 1997, AIDS S2, V11, pS1	30	38	39	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN	1998	351			3			33	36						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZV844	9652720				2022-12-28	WOS:000074347300011
J	Arner, P				Arner, P			Not all fat is alike	LANCET			English	Editorial Material							REGIONAL ADIPOSITY		Huddinge Hosp, Karolinska Inst, Dept Med, S-14186 Huddinge, Sweden	Karolinska Institutet	Arner, P (corresponding author), Huddinge Hosp, Karolinska Inst, Dept Med, S-14186 Huddinge, Sweden.			Arner, Peter/0000-0002-6208-6220				ABATE N, 1995, PROG LIPID RES, V34, P53, DOI 10.1016/0163-7827(94)00006-8; ARNER P, 1996, DIABETES REV, V4, P450; Bjorntorp P, 1998, HDB OBESITY, P573; BLUM WF, 1997, LEPTIN VOICE ADIPOSE, P1; Frayn KN, 1996, CLIN SCI, V90, P243, DOI 10.1042/cs0900243; KISSEBAH AH, 1994, PHYSIOL REV, V74, P761, DOI 10.1152/physrev.1994.74.4.761; Lefebvre AM, 1998, DIABETES, V47, P98, DOI 10.2337/diabetes.47.1.98; Montague CT, 1997, DIABETES, V46, P342, DOI 10.2337/diabetes.46.3.342; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; VANHARMELEN V, IN PRESS DIABETES	10	132	134	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1301	1302		10.1016/S0140-6736(05)79052-8	http://dx.doi.org/10.1016/S0140-6736(05)79052-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643790				2022-12-28	WOS:000073439400005
J	Coats, AJS				Coats, AJS			Teaching heart-failure patients how to breathe	LANCET			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England; Royal Brompton Hosp, London SW3 6LY, England	Imperial College London; Royal Brompton Hospital	Coats, AJS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.		Coats, Andrew J Stewart/E-4451-2012	Coats, Andrew J Stewart/0000-0002-2771-4260				CHUA TP, 1995, EUR HEART J, V16, P882, DOI 10.1093/oxfordjournals.eurheartj.a061019; Coats AJS, 1997, CARDIOVASC DRUG THER, V11, P265, DOI 10.1023/A:1007739830030; LIEBER C, 1992, YALE J BIOL MED, V65, P39; Mortara Andrea, 1996, Clinical Science (London), V91, P72; Ponikowski P, 1997, CIRCULATION, V96, P2586, DOI 10.1161/01.CIR.96.8.2586; STANESCU DC, 1981, J APPL PHYSIOL, V51, P1625, DOI 10.1152/jappl.1981.51.6.1625	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1299	1300		10.1016/S0140-6736(05)79050-4	http://dx.doi.org/10.1016/S0140-6736(05)79050-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643788				2022-12-28	WOS:000073439400003
J	Andersen, HR; Nielsen, JC; Thomsen, PEB; Thuesen, L; Mortensen, PT; Vesterlund, T; Pedersen, AK				Andersen, HR; Nielsen, JC; Thomsen, PEB; Thuesen, L; Mortensen, PT; Vesterlund, T; Pedersen, AK			Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome	LANCET			English	Article							ATRIOVENTRICULAR-BLOCK; ACTIVATION SEQUENCE; STIMULATION MODE; NATURAL-HISTORY; NODE DISEASE; FIBRILLATION; STROKE; ANTICOAGULATION	Background In a previous study of 225 patients with sick-sinus syndrome randomised to either single-chamber atrial pacing (n=110) or single-chamber ventricular pacing (n=115), we found that after a mean follow-up of 3.3 years, atrial pacing was associated with significantly less atrial fibrillation and thromboembolism whereas there was no significant difference in mortality and heart failure between the two groups. We aimed to find out whether this beneficial effect of atrial pacing is maintained during extended follow-up of up to 8 years. Methods Follow-up visits for all patients were at 3 months, 12 months, then once a year at which patients had a physical examination, ECG recording, and pacemaker check-up. Endpoints were mortality, cardiovascular death, atrial fibrillation, thromboembolic events, heart failure, and atrioventricular block. Data was analysed on Dec 31, 1996. Findings At long-term follow-up, 39 patients from the atrial group had died versus 57 from the ventricular group (relative risk 0.66 [95% CI 0.44-0.99]; p=0.045). 19 patients from the atrial group and 39 patients from the ventricular group died from a cardiovascular cause (0.47 [0.27-0.82]; p=0.0065). The cumulative incidences of atrial fibrillation and chronic atrial fibrillation were also significantly lower in the atrial group than in the ventricular group (0.54 [0.33-0.89], p=0.012 and 0.35 [0.16-0.76], p=0.004, respectively). Thromboembolic events occurred in 13 patients in the atrial group and 26 in the ventricular group (0.47 [0.24-0.92], p=0.023). Heart failure was less severe in the atrial group than in the ventricular group (p<0.05). In multivariate analysis, atrial pacing was significantly associated with freedom from thromboembolic events (0.47 [0.24-0.92], p=0.028) and survival from cardiovascular death (0.52 [0.30-0.91], p=0.022), but no longer with overall survival (0.71 [0.46-1.08], p=0.11) or chronic atrial fibrillation (0.45 [0.20-1.05], p=0.063). Atrioventricular block occurred in four patients in the atrial group (0.6% annual risk). Interpretation The beneficial effect of atrial pacing found in our previous study is enhanced substantially over time. Patients with sick-sinus syndrome should be treated with an atrial rather than ventricular-pacing system because after long-term follow-up, atrial pacing is associated with a significantly higher survival, less atrial fibrillation, fewer thromboembolic complications, less heart failure, and a low-risk of atrioventricular block.			Andersen, HR (corresponding author), AARHUS UNIV HOSP,SKEJBY SYGEHUS,DEPT CARDIOL,DK-8200 AARHUS N,DENMARK.			Nielsen, Jens Cosedis/0000-0001-9414-1653				AMITZUR G, 1995, PACE, V18, P697, DOI 10.1111/j.1540-8159.1995.tb04664.x; ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; Antani MR, 1996, J GEN INTERN MED, V11, P713, DOI 10.1007/BF02598984; BEDOTTO JB, 1990, J AM COLL CARDIOL, V15, P658, DOI 10.1016/0735-1097(90)90642-3; BERNSTEIN SB, 1988, AM J CARDIOL, V61, P13; BRANDT J, 1992, J AM COLL CARDIOL, V20, P633, DOI 10.1016/0735-1097(92)90018-I; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; ELSHOT SRE, 1993, INT J CARDIOL, V38, P303, DOI 10.1016/0167-5273(93)90249-G; HAYWOOD GA, 1990, PACE, V13, P2054, DOI 10.1111/j.1540-8159.1990.tb06941.x; KARPAWICH PP, 1990, AM HEART J, V119, P1077, DOI 10.1016/S0002-8703(05)80237-6; KERR CR, 1989, PACE, V12, P1049, DOI 10.1111/j.1540-8159.1989.tb01925.x; LECLERCQ C, 1995, AM HEART J, V129, P1133, DOI 10.1016/0002-8703(95)90394-1; LEE MA, 1994, J AM COLL CARDIOL, V24, P225, DOI 10.1016/0735-1097(94)90567-3; LIP GYH, 1994, BRIT HEART J, V71, P92; Morley J, 1996, AM J CARDIOL, V77, pA38, DOI 10.1016/S0002-9149(97)89116-3; Munschauer FE, 1997, STROKE, V28, P72, DOI 10.1161/01.STR.28.1.72; Nielsen JC, 1997, PACING CLIN ELECTROP, V20, P1574; Orsinelli DA, 1996, PROG CARDIOVASC DIS, V39, P1, DOI 10.1016/S0033-0620(96)80037-5; PETERSEN P, 1989, LANCET, V1, P175; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; ROSENQVIST M, 1991, AM J CARDIOL, V67, P148, DOI 10.1016/0002-9149(91)90437-P; ROSENQVIST M, 1989, PACE, V12, P97, DOI 10.1111/pace.1989.12.p1.97; Rosenqvist M, 1996, PACE, V19, P1279, DOI 10.1111/j.1540-8159.1996.tb04205.x; RUBENSTEIN JJ, 1972, CIRCULATION, V46, P5, DOI 10.1161/01.CIR.46.1.5; SANTINI M, 1990, AM J CARDIOL, V65, P729, DOI 10.1016/0002-9149(90)91379-K; SASAKI Y, 1988, PACE, V11, P1575, DOI 10.1111/j.1540-8159.1988.tb06277.x; SGARBOSSA EB, 1993, ANN INTERN MED, V119, P359, DOI 10.7326/0003-4819-119-5-199309010-00002; SGARBOSSA EB, 1993, CIRCULATION, V88, P1045, DOI 10.1161/01.CIR.88.3.1045; Sgarbossa EB, 1993, PACING CLIN ELECTROP, V16, P872; Stroke Prevention in Atrial Fibrillation Investigators, 1996, LANCET, V348, P633; SUTTON R, 1986, PACE, V9, P1110, DOI 10.1111/j.1540-8159.1986.tb06678.x; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	32	651	715	1	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1210	1216		10.1016/S0140-6736(97)03425-9	http://dx.doi.org/10.1016/S0140-6736(97)03425-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652562				2022-12-28	WOS:A1997YD23800011
J	Moxon, ER				Moxon, ER			Applications of molecular microbiology to vaccinology	LANCET			English	Article							IMMUNE-RESPONSES; SURFACE	Genetics, cell biology, and whole-genome sequencing of pathogens have changed dramatically the opportunities to investigate the epidemiology, pathogenesis, diagnosis, and control of microbial diseases. For example, recombinant DNA and PCR are powerful tools used to isolate genes whose role in pathogenicity can be investigated in biologically relevant virulence assays. Vaccines that target one or more of these genes can then be developed. Complete genome sequences of microbes provide an Inventory of the genes encoding every virulence factor and potential immunogen. Candidate vaccines can be selected and developed using various approaches, including the recent innovation of immunlsation with nucleic acids. Although many successful vaccines have been and will continue to be developed through empirical approaches, molecular microbiology provides a rational basis for discovery, development, and implementation of safer, more effective and, potentially cheaper vaccines.	UNIV OXFORD,JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND	University of Oxford	Moxon, ER (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOL MED,MOL INFECT DIS GRP,OXFORD OX3 9DU,ENGLAND.							ANDERSON RM, 1982, PARASITOLOGY, V85, P411, DOI 10.1017/S0031182000055360; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BORST P, 1994, SCIENCE, V264, P1872, DOI 10.1126/science.7516579; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; FALKOW S, 1988, REV INFECT DIS, V10, pS274; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HECKELS JE, 1989, CLIN MICROBIOL REV, V2, pS66, DOI 10.1128/CMR.2.Suppl.S66-S73.1989; Hoffman SL, 1995, ANN NY ACAD SCI, V772, P88, DOI 10.1111/j.1749-6632.1995.tb44734.x; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; JILG W, 1989, INFECTION, V17, P70, DOI 10.1007/BF01646879; KENDALL AP, 1987, AM J MED, V82, pS4; KENNEDY MJ, 1988, MYCOPATHOLOGIA, V102, P149, DOI 10.1007/BF00437397; Lipsitch M, 1997, TRENDS MICROBIOL, V5, P31, DOI 10.1016/S0966-842X(97)81772-6; Masoud H, 1997, BIOCHEMISTRY-US, V36, P2091, DOI 10.1021/bi961989y; Moxon ER, 1997, NATURE, V387, P659, DOI 10.1038/42607; MOXON ER, 1995, TRENDS MICROBIOL, V3, P335, DOI 10.1016/S0966-842X(00)88970-2; MURPHY BR, 1985, VIROLOGY, P1179; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; PIZZA M, 1989, SCIENCE, V246, P497, DOI 10.1126/science.2683073; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Tarr PI, 1996, NEW ENGL J MED, V335, P635, DOI 10.1056/NEJM199608293350905; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	24	17	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1240	1244		10.1016/S0140-6736(97)03259-5	http://dx.doi.org/10.1016/S0140-6736(97)03259-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652581				2022-12-28	WOS:A1997YD23800042
J	Dimitroulis, G				Dimitroulis, G			Fortnightly review - Temporomandibular disorders: a clinical update	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PAIN-DYSFUNCTION; COMPUTED-TOMOGRAPHY; JOINT; RELIABILITY; THERAPY; SIGNS		Univ Melbourne, Sch Dent Sci, Melbourne, Vic 3000, Australia	University of Melbourne	Dimitroulis, G (corresponding author), Suite 5,10th Floor,20 Collins St, Melbourne, Vic 3000, Australia.							BELL WE, 1989, OROFACIAL PAIN CLASS, P477; Bronstein S, 1989, ORAL MAXILLOFAC SURG, V1, P59; CARLSSON SG, 1977, BIOFEEDBACK SELF-REG, V2, P161, DOI 10.1007/BF00998666; CLARK G T, 1989, Journal of Craniomandibular Disorders, V3, P7; CLARK GT, 1990, J AM DENT ASSOC, V121, P151, DOI 10.14219/jada.archive.1990.0140; CLARK GT, 1985, J AM DENT ASSOC, V110, P743, DOI 10.14219/jada.archive.1985.0430; CLARK GT, 1984, J AM DENT ASSOC, V108, P359, DOI 10.14219/jada.archive.1984.0010; Dimitroulis G, 1996, AUST DENT J, V41, P16, DOI 10.1111/j.1834-7819.1996.tb05649.x; Dimitroulis G, 1995, AUST DENT J, V40, P372, DOI 10.1111/j.1834-7819.1995.tb04835.x; DIMITROULIS G, 1995, AUST DENT J, V40, P301, DOI 10.1111/j.1834-7819.1995.tb04817.x; DOLWICK MF, 1994, BRIT J ORAL MAX SURG, V32, P307, DOI 10.1016/0266-4356(94)90052-3; Dolwick MF, 1989, ORAL MAXILLOFAC SURG, V1, P1; DUINKERKE ASH, 1985, COMMUNITY DENT ORAL, V13, P185, DOI 10.1111/j.1600-0528.1985.tb00442.x; DWORKIN SF, 1990, J AM DENT ASSOC, V120, P273, DOI 10.14219/jada.archive.1990.0043; DWORKIN SF, 1990, J PROSTHET DENT, V63, P574, DOI 10.1016/0022-3913(90)90079-R; GANGAROSA LP, 1982, EAR NOSE THROAT J, V61, P670; GREENE CS, 1988, J AM DENT ASSOC, V117, P461, DOI 10.1016/S0002-8177(88)73018-4; GREENE CS, 1982, J PROSTHET DENT, V48, P184, DOI 10.1016/0022-3913(82)90110-X; HANSSON LG, 1983, J PROSTHET DENT, V50, P89, DOI 10.1016/0022-3913(83)90172-5; Hansson T, 1975, J Oral Rehabil, V2, P313, DOI 10.1111/j.1365-2842.1975.tb01532.x; HELMS CA, 1982, RADIOLOGY, V145, P719, DOI 10.1148/radiology.145.3.7146402; Keith DA, 1989, ORAL MAXILLOFAC SURG, V1, P7; KIRCOS LT, 1987, J ORAL MAXILLOFAC SU, V45, P397; McNeill C., 1993, TEMPOROMANDIBULAR DI, V2nd ed.; MEJERSJO C, 1983, J PROSTHET DENT, V49, P809, DOI 10.1016/0022-3913(83)90355-4; MOSS RA, 1984, J ORAL REHABIL, V11, P233, DOI 10.1111/j.1365-2842.1984.tb00572.x; Nickerson JW, 1989, ORAL MAXILLOFAC SURG, V1, P27; OHRBACH R, 1989, PAIN, V39, P157, DOI 10.1016/0304-3959(89)90003-1; OKERSON JP, 1989, MANAGEMENT TEMPOROMA; PULLINGER AG, 1988, J PROSTHET DENT, V59, P228, DOI 10.1016/0022-3913(88)90019-4; RAUSTIA AM, 1985, CLIN RADIOL, V36, P291, DOI 10.1016/S0009-9260(85)80067-2; Ready LB, 1979, ANESTHESIOLOGY REV, V6, P28; RUGH JD, 1987, DENT CLIN N AM, V31, P579; SALONEN L, 1990, Journal of Craniomandibular Disorders, V4, P241; Sanders B, 1987, J Craniomandib Disord, V1, P202; SCHELLHAS KP, 1989, ORAL MAXILLOFAC SURG, V1, P13; SCHIFFMAN EL, 1990, J AM DENT ASSOC, V120, P295, DOI 10.14219/jada.archive.1990.0059	37	86	96	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 18	1998	317	7152					190	194		10.1136/bmj.317.7152.190	http://dx.doi.org/10.1136/bmj.317.7152.190			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665905	Green Published			2022-12-28	WOS:000075047800031
J	Williams, CJ; Pieri, L; Sims, A				Williams, CJ; Pieri, L; Sims, A			We should strive to keep patients alive	BRITISH MEDICAL JOURNAL			English	Article							ANOREXIA-NERVOSA		St James Univ Hosp, Div Psychiat & Behav Sci Relat Med, Leeds LS9 7TF, W Yorkshire, England; Seacroft Hosp, Yorkshire Ctr Eating Disorder, Leeds LS14 6UH, W Yorkshire, England	Saint James's University Hospital	Williams, CJ (corresponding author), St James Univ Hosp, Div Psychiat & Behav Sci Relat Med, Clin Sci Bldg, Leeds LS9 7TF, W Yorkshire, England.							ECKERT ED, 1995, PSYCHOL MED, V25, P143, DOI 10.1017/S0033291700028166; Keyes A, 1950, BIOL HUMAN STARVATIO, V1; KEYES A, 1950, BIOL HUMAN STARVATIO, V2; LEE MA, 1992, J AM GERIATR SOC, V13, P21; OGILVIE AD, 1994, BRIT MED J, V309, P492, DOI 10.1136/bmj.309.6953.492; ONEILL J, 1994, AM J HOSPICE PAL NOV, P36; RATNASURIYA RH, 1991, BRIT J PSYCHIAT, V158, P495, DOI 10.1192/bjp.158.4.495; SLADE PD, 1973, PSYCHOL MED, V3, P188, DOI 10.1017/S0033291700048510; TILLER J, 1993, BRIT J PSYCHIAT, V162, P679, DOI 10.1192/bjp.162.5.679	9	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					195	196		10.1136/bmj.317.7152.195	http://dx.doi.org/10.1136/bmj.317.7152.195			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	103FZ	9665907	Green Published			2022-12-28	WOS:000075047800033
J	Ghosh, S; Drummond, HE; Ferguson, A				Ghosh, S; Drummond, HE; Ferguson, A			Neglect of growth and development in the clinical monitoring of children and teenagers with inflammatory bowel disease: review of case records	BRITISH MEDICAL JOURNAL			English	Article									Western Gen Hosp, Dept Med, Gastrointestinal Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Ferguson, A (corresponding author), Western Gen Hosp, Dept Med, Gastrointestinal Unit, Edinburgh EH4 2XU, Midlothian, Scotland.							BARTON JR, 1989, BRIT MED J, V298, P865, DOI 10.1136/bmj.298.6677.865; KURTZ Z, 1996, SERVICES YOUNG PEOPL, P141	2	14	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					120	121		10.1136/bmj.317.7151.120	http://dx.doi.org/10.1136/bmj.317.7151.120			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657788	Green Published, Green Submitted			2022-12-28	WOS:000075081700023
J	Douglas, C				Douglas, C			Soundings - Audit in Auchendreich	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					88	88		10.1136/bmj.317.7150.88	http://dx.doi.org/10.1136/bmj.317.7150.88			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651299	Green Published			2022-12-28	WOS:000075081600072
J	Iwata, S; Lee, JW; Okada, K; Lee, JK; Iwata, M; Rasmussen, B; Link, TA; Ramaswamy, S; Jap, BK				Iwata, S; Lee, JW; Okada, K; Lee, JK; Iwata, M; Rasmussen, B; Link, TA; Ramaswamy, S; Jap, BK			Complete structure of the 11-subunit bovine mitochondrial cytochrome bc(1) complex	SCIENCE			English	Article							IRON-SULFUR PROTEIN; C REDUCTASE; PROCESSING PEPTIDASE; BC1 COMPLEX; BEEF-HEART; UBIQUINOL; OXIDOREDUCTASE; OXIDATION; BINDING; SITE	Mitochondrial cytochrome bc(1) complex performs two functions: It is a respiratory multienzyme complex and it recognizes a mitochondrial targeting presequence. Refined crystal structures of the 11-subunit bc(1) complex from bovine heart reveal full views of this bifunctional enzyme. The "Rieske" iron-sulfur protein subunit shows significant conformational changes in different crystal forms, suggesting a new electron transport mechanism of the enzyme. The mitochondrial targeting presequence of the "Rieske" protein (subunit 9) is lodged between the two "core" subunits at the matrix side of the complex. These "core" subunits are related to the matrix processing peptidase, and the structure unveils how mitochondrial targeting presequences are recognized.	Uppsala Univ, Ctr Biomed, Dept Biochem, S-75123 Uppsala, Sweden; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biol, S-75124 Uppsala, Sweden; Univ Frankfurt Klinikum, ZBC, D-60590 Frankfurt, Germany; Inst Max Von Laue Paul Langevin, European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble, France	Uppsala University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Swedish University of Agricultural Sciences; Goethe University Frankfurt; Goethe University Frankfurt Hospital; European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL)	Iwata, S (corresponding author), Uppsala Univ, Ctr Biomed, Dept Biochem, Box 576, S-75123 Uppsala, Sweden.	iwata@xray.bmc.uu.se; BKJap@lbl.gov	Subramanian, Ramaswamy/Q-8671-2019	Subramanian, Ramaswamy/0000-0002-6709-190X				ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BERRY EA, 1992, J MOL BIOL, V224, P1161, DOI 10.1016/0022-2836(92)90476-Z; BRANDT U, 1993, J BIOL CHEM, V268, P8387; BRANDT U, 1991, J BIOL CHEM, V266, P19958; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; Brandt U, 1997, BIOCHEMISTRY-US, V36, P11234, DOI 10.1021/bi970968g; Brandt U, 1996, FEBS LETT, V387, P1, DOI 10.1016/0014-5793(96)00436-X; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; CROFTS AR, 1997, IN PRESS P 9 INT S P; DENG K, 1996, BIOPHYS J, V72, pA319; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM CH, 1983, J BIOL CHEM, V258, P3543; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lancaster CRD, 1997, STRUCTURE, V5, P1339, DOI 10.1016/S0969-2126(97)00285-2; LEE JW, 1995, J MOL BIOL, V252, P15, DOI 10.1006/jmbi.1994.0470; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; LINK TA, 1997, BIOINORG CHEM, P312; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MUKAI K, 1985, J BIOCHEM-TOKYO, V98, P1417, DOI 10.1093/oxfordjournals.jbchem.a135409; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PHILLIPS JD, 1993, J BIOL CHEM, V268, P11727; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; ROBERTSON DE, 1993, BIOCHEMISTRY-US, V32, P1310, DOI 10.1021/bi00056a016; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; Robinson, 1982, CYCLOTRONS CYTOCHROM, P263, DOI 10.1016/B978-0-12-397580-5.50026-0; Schagger H, 1995, METHOD ENZYMOL, V260, P82, DOI 10.1016/0076-6879(95)60132-5; SCHAGGER H, 1990, EUR J BIOCHEM, V190, P123, DOI 10.1111/j.1432-1033.1990.tb15554.x; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; STONEHUERNER J, 1985, J BIOL CHEM, V260, P5392; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1998, BIOCHIM BIOPHYS ACTA, V1365, P261; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; WAKABAYASHI S, 1982, J BIOCHEM, V91, P2077, DOI 10.1093/oxfordjournals.jbchem.a133901; WIKSTROM MK, 1972, BIOCHIM BIOPHYS ACTA, V283, P403, DOI 10.1016/0005-2728(72)90258-7; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG M, 1991, J BIOL CHEM, V266, P6416; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	50	1032	1068	2	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1998	281	5373					64	71		10.1126/science.281.5373.64	http://dx.doi.org/10.1126/science.281.5373.64			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651245				2022-12-28	WOS:000074685800037
J	Kahn, JO; Walker, BD				Kahn, JO; Walker, BD			Acute human immunodeficiency virus type 1 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PRIMARY HIV-1 INFECTION; T-LYMPHOCYTE ACTIVITY; ORAL INTERCOURSE; DISEASE; SEROCONVERSION; VIREMIA; PLASMA; RESPONSES; RECEPTOR; CELLS		San Francisco Gen Hosp, AIDS Program, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Walker, BD (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, 149 13th St, Charlestown, MA 02129 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763, R37AI028568] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI28568, P30 AI 27763] Funding Source: Medline; PHS HHS [UO1 41531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BALSLEV E, 1990, J CLIN PATHOL, V43, P201, DOI 10.1136/jcp.43.3.201; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Berrey MM, 1997, J ACQ IMMUN DEF SYND, V14, P475; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Bollinger RC, 1997, JAMA-J AM MED ASSOC, V278, P2085, DOI 10.1001/jama.278.23.2085; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Busch Michael P., 1997, American Journal of Medicine, V102, P117, DOI 10.1016/S0002-9343(97)00077-6; BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Cavert W, 1997, SCIENCE, V276, P1321; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Cossarizza A, 1997, AIDS, V11, P1075, DOI 10.1097/00002030-199709000-00001; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DORRUCCI M, 1995, AIDS, V9, P597, DOI 10.1097/00002030-199506000-00011; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; GOLDBERG DJ, 1988, LANCET, V2, P1363; Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; HECHT FM, 1998, 5 C RETR OPP INF CHI, P189; HENRARD DR, 1994, TRANSFUSION, V34, P376, DOI 10.1046/j.1537-2995.1994.34594249046.x; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; HO DD, 1985, NEW ENGL J MED, V313, P1493, DOI 10.1056/NEJM198512123132401; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P1367; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lafeuillade A, 1997, J INFECT DIS, V175, P1051, DOI 10.1086/516442; LANE HC, 1991, AM J PUBLIC HEALTH, V81, P658, DOI 10.2105/AJPH.81.5.658; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LOES SKD, 1993, CLIN INFECT DIS, V17, P59, DOI 10.1093/clinids/17.1.59; MACKEWICZ CE, 1994, LANCET, V344, P1671, DOI 10.1016/S0140-6736(94)90459-6; MEHENDALE SM, 1995, J INFECT DIS, V172, P1486, DOI 10.1093/infdis/172.6.1486; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, SCIENCE, V275, P14; Michael NL, 1997, J INFECT DIS, V175, P1352, DOI 10.1086/516467; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; NELSON KE, 1994, AIDS RES HUM RETROV, V10, pS201; NIU MT, 1993, J INFECT DIS, V168, P1490, DOI 10.1093/infdis/168.6.1490; NIU MT, 1993, AIDS RES HUM RETROV, V9, P913, DOI 10.1089/aid.1993.9.913; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; OSMOND DH, 1994, AM J PUBLIC HEALTH, V84, P1933, DOI 10.2105/AJPH.84.12.1933; Pantaleo G, 1997, P NATL ACAD SCI USA, V94, P254, DOI 10.1073/pnas.94.1.254; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PERRIN L, 1997, 4 C RETR OPP INF WAS, P108; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Quinn TC, 1997, JAMA-J AM MED ASSOC, V278, P58, DOI 10.1001/jama.278.1.58; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Schacker T, 1997, ANN INTERN MED, V126, P174, DOI 10.7326/0003-4819-126-2-199701150-00024; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; Tindall B, 1988, Infect Dis Clin North Am, V2, P329; *UNAIDS, 1908, REP GLOB HIV AIDS EP; VONSYDOW M, 1988, BRIT MED J, V296, P525; VONSYDOW M, 1988, BMJ-BRIT MED J, V296, P238, DOI 10.1136/bmj.296.6617.238; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yang OO, 1996, J VIROL, V70, P5799, DOI 10.1128/JVI.70.9.5799-5806.1996; Yang OO, 1997, J VIROL, V71, P3120, DOI 10.1128/JVI.71.4.3120-3128.1997; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993; Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996; 1997, MMWR MORB MORTAL WKL, V46, P861; 1997, MMWR MORB MORTAL WKL, V46, P889	81	444	461	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					33	39		10.1056/NEJM199807023390107	http://dx.doi.org/10.1056/NEJM199807023390107			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647878				2022-12-28	WOS:000074500000007
J	Ham, C				Ham, C			Retracing the Oregon trail: the experience of rationing and the Oregon health plan	BRITISH MEDICAL JOURNAL			English	Article							CARE		Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of Birmingham	Ham, C (corresponding author), Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England.							*AM MED ASS, 1993, PHYS CURR PROC TERM; Bodenheimer T, 1997, NEW ENGL J MED, V337, P651, DOI 10.1056/NEJM199708283370923; Bodenheimer T, 1997, NEW ENGL J MED, V337, P720, DOI 10.1056/NEJM199709043371021; BROWN LD, 1991, HEALTH AFFAIR, V10, P28, DOI 10.1377/hlthaff.10.2.28; DIXON J, 1991, LANCET, V337, P891, DOI 10.1016/0140-6736(91)90213-9; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2439, DOI 10.1001/jama.266.17.2439; FOX DM, 1991, HEALTH AFFAIR, V10, P7, DOI 10.1377/hlthaff.10.2.7; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; KLEIN R, 1991, BRIT MED J, V302, P1, DOI 10.1136/bmj.302.6767.1; KLEIN R, 1992, BRIT MED J, V309, P1457; SMITH R, 1991, BRIT MED J, V303, P1561, DOI 10.1136/bmj.303.6817.1561	11	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1965	1969		10.1136/bmj.316.7149.1965	http://dx.doi.org/10.1136/bmj.316.7149.1965			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641942	Green Published			2022-12-28	WOS:000074636700036
J	Rae, C; Lee, MA; Dixon, RM; Blamire, AM; Thompson, CH; Styles, P; Talcott, J; Richardson, AJ; Stein, JF				Rae, C; Lee, MA; Dixon, RM; Blamire, AM; Thompson, CH; Styles, P; Talcott, J; Richardson, AJ; Stein, JF			Metabolic abnormalities in developmental dyslexia detected by H-1 magnetic resonance spectroscopy	LANCET			English	Article							DEFICITS; CHILDREN	Background Neurological and physiological deficits have been reported in the brain in developmental dyslexia. The temporoparietal cortex has been directly implicated in dyslexic dysfunction, and substantial indirect evidence suggests that the cerebellum is also implicated. We wanted to find out whether the neurological and physiological deficits manifested as biochemical changes in the brain. Methods We obtained localised proton magnetic resonance spectra bilaterally from the temporo-parietal cortex and cerebellum of 14 well-defined dyslexic men and 15 control men of similar age. Findings We found biochemical differences between dyslexic men and controls in the left temporo-parietal lobe (ratio of choline-containing compounds [Cho] to N-acetylaspartate [NA] p less than or equal to 0.01) and right cerebellum (Cho/NA, p less than or equal to 0.01; creatine [Cre] to NA p less than or equal to 0.05; (not significant). We found lateral biochemical differences in dyslexic men in both these brain regions (Cho/NA in temporo-parietal lobe, left vs right, p less than or equal to 0.01; Cre/NA in cerebellum, left vs right, p less than or equal to 0.001). We found no such lateral differences in controls. There was no significant relation between the degree of contralateral chemical difference and handedness in dyslexic or control men. Interpretation We suggest that the observed differences reflect changes in cell density in the temporo-parietal lobe in developmental dyslexia and that the altered cerebral structural symmetry in dyslexia is associated with abnormal development of cells or intracellular connections or both. The cerebellum is biochemically asymmetric in dyslexic men, indicating altered development of this organ. These differences provide direct evidence of the involvement of the cerebellum in dyslexic dysfunction.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; John Radcliffe Hosp, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX3 9DU, England; Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	University of Sydney; University of Oxford; Radcliffe Infirmary; University of Oxford	Rae, C (corresponding author), Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia.	crae@biochem.usyd.edu.au	Thompson, Campbell/E-2885-2010; Blamire, Andrew/AAU-6100-2021; Rae, Caroline/B-7537-2008	Thompson, Campbell/0000-0002-5164-3327; Rae, Caroline/0000-0003-0673-8084; Richardson, Alex/0000-0001-5650-4409; Blamire, Andrew/0000-0002-8749-1257				ANNETT M, 1970, BRIT J PSYCHOL, V61, P303, DOI 10.1111/j.2044-8295.1970.tb01248.x; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; BRADLEY L, 1978, NATURE, V271, P746, DOI 10.1038/271746a0; CASTLES A, 1993, COGNITION, V47, P149, DOI 10.1016/0010-0277(93)90003-E; Eden GF, 1996, NATURE, V382, P66, DOI 10.1038/382066a0; FAWCETT AJ, 1992, PERCEPT MOTOR SKILL, V75, P507, DOI 10.2466/pms.1992.75.2.507; FRAHM J, 1987, J MAGN RESON, V72, P502, DOI 10.1016/0022-2364(87)90154-5; GALABURDA AM, 1985, ANN NEUROL, V18, P222, DOI 10.1002/ana.410180210; HIER DB, 1978, ARCH NEUROL-CHICAGO, V35, P90, DOI 10.1001/archneur.1978.00500260028005; LARSEN JP, 1990, BRAIN LANG, V39, P289, DOI 10.1016/0093-934X(90)90015-9; LIVINGSTONE MS, 1991, P NATL ACAD SCI USA, V88, P7943, DOI 10.1073/pnas.88.18.7943; LOVEGROVE WJ, 1980, NEUROPSYCHOLOGIA, V18, P111, DOI 10.1016/0028-3932(80)90093-7; Miller BL, 1996, LIFE SCI, V58, P1929, DOI 10.1016/0024-3205(96)00182-8; NICOLSON RI, 1995, P ROY SOC B-BIOL SCI, V259, P43, DOI 10.1098/rspb.1995.0007; Paulesu E, 1996, BRAIN, V119, P143, DOI 10.1093/brain/119.1.143; Rae C, 1996, P ROY SOC B-BIOL SCI, V263, P1061, DOI 10.1098/rspb.1996.0156; RAMSEY JM, 1992, ARCH NEUROL-CHICAGO, V49, P527; SNOWLING MJ, 1987, DYXLEXIA COGNITIVE D; Stein J, 1997, TRENDS NEUROSCI, V20, P147, DOI 10.1016/S0166-2236(96)01005-3; STEIN JF, 1992, PHYSIOL REV, V72, P967, DOI 10.1152/physrev.1992.72.4.967; TALLAL P, 1980, BRAIN LANG, V9, P182, DOI 10.1016/0093-934X(80)90139-X; TEDESCHI G, 1995, NEUROLOGY, V45, P1384, DOI 10.1212/WNL.45.7.1384; TRACEY I, 1995, LANCET, V345, P1260, DOI 10.1016/S0140-6736(95)90923-0; VAN IJZENDOORN MH, 1994, READ RES QUART, V29, P267; WILSHER CR, 1987, J CLIN PSYCHOPHARM, V7, P230	25	138	138	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1849	1852		10.1016/S0140-6736(97)99001-2	http://dx.doi.org/10.1016/S0140-6736(97)99001-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652669				2022-12-28	WOS:000074347100012
J	Yung, YL; Kass, DM				Yung, YL; Kass, DM			Deuteronomy? A puzzle of deuterium and oxygen on Mars	SCIENCE			English	Article							MARTIAN ATMOSPHERE; ABUNDANCE; WATER; HDO		CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	California Institute of Technology	Yung, YL (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.		Yung, Yuk/AAM-4850-2021	Yung, Yuk/0000-0002-4263-2562				BARTH CA, 1972, ICARUS, V17, P457, DOI 10.1016/0019-1035(72)90011-5; Farquhar J, 1998, SCIENCE, V280, P1580, DOI 10.1126/science.280.5369.1580; KASS DM, 1995, SCIENCE, V268, P697, DOI 10.1126/science.7732377; Krasnopolsky VA, 1998, SCIENCE, V280, P1576, DOI 10.1126/science.280.5369.1576; LECLUSE C, 1994, GEOCHIM COSMOCHIM AC, V58, P2927, DOI 10.1016/0016-7037(94)90126-0; Leshin LA, 1996, GEOCHIM COSMOCHIM AC, V60, P2635, DOI 10.1016/0016-7037(96)00122-6; MCELROY MB, 1970, J GEOPHYS RES, V75, P1188, DOI 10.1029/JA075i007p01188; MCELROY MB, 1976, PLANET SPACE SCI, V24, P1107, DOI 10.1016/0032-0633(76)90148-3; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; THIEMENS MH, 1995, SCIENCE, V270, P969, DOI 10.1126/science.270.5238.969; YUNG YL, 1988, ICARUS, V76, P146, DOI 10.1016/0019-1035(88)90147-9; [No title captured]; [No title captured]	13	17	17	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1545	1546		10.1126/science.280.5369.1545	http://dx.doi.org/10.1126/science.280.5369.1545			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9644019				2022-12-28	WOS:000074061200025
J	Cohen, MS				Cohen, MS			Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; AIDS; SECRETIONS; URETHRITIS; CLINICS; TYPE-1		Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Cohen, MS (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.							[Anonymous], 1997, CONFR AIDS PUBL PRIO; BERSOFFMATCHA SJ, 1997, INF DIS SOC AM 35 AN; Catchpole MA, 1996, BRIT MED J, V312, P539, DOI 10.1136/bmj.312.7030.539; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; COHEN MS, 1994, ANN INTERN MED, V120, P340, DOI 10.7326/0003-4819-120-4-199402150-00014; Coombs RW, 1998, J INFECT DIS, V177, P320, DOI 10.1086/514213; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Dickerson MC, 1996, SEX TRANSM DIS, V23, P429, DOI 10.1097/00007435-199609000-00015; Dyer JR, 1998, J INFECT DIS, V177, P224, DOI 10.1086/517359; Dyer JR, 1997, AIDS, V11, P543; Eron JJ, 1996, JAMA-J AM MED ASSOC, V275, P36, DOI 10.1001/jama.275.1.36; Fiore JR, 1997, AIDS, V11, P1089, DOI 10.1097/00002030-199709000-00002; Ghys PD, 1997, AIDS, V11, pF85, DOI 10.1097/00002030-199712000-00001; Gilson L, 1997, LANCET, V350, P1805, DOI 10.1016/S0140-6736(97)08222-6; Graziosi C, 1997, NAT MED, V3, P1318, DOI 10.1038/nm1297-1318; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HO JL, 1995, J EXP MED, V181, P1493, DOI 10.1084/jem.181.4.1493; John GC, 1997, J INFECT DIS, V175, P57, DOI 10.1093/infdis/175.1.57; KUNANUSONT C, 1995, LANCET, V345, P1078, DOI 10.1016/S0140-6736(95)90818-8; Levine WC, 1998, J INFECT DIS, V177, P167, DOI 10.1086/513820; Mayaud P, 1997, AIDS, V11, P1873, DOI 10.1097/00002030-199715000-00013; Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250; MOSS GB, 1995, J INFECT DIS, V172, P1469, DOI 10.1093/infdis/172.6.1469; Mostad SB, 1997, LANCET, V350, P922, DOI 10.1016/S0140-6736(97)04240-2; MUSICCO M, 1994, ARCH INTERN MED, V154, P1971, DOI 10.1001/archinte.154.17.1971; Operskalski EA, 1997, AM J EPIDEMIOL, V146, P655, DOI 10.1093/oxfordjournals.aje.a009331; Pope M, 1997, SCIENCE, V278, P786; POSS M, 1995, J VIROL, V69, P8118, DOI 10.1128/JVI.69.12.8118-8122.1995; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; Rasmussen SJ, 1997, J CLIN INVEST, V99, P77, DOI 10.1172/JCI119136; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Sewankambo N, 1997, LANCET, V350, P546, DOI 10.1016/S0140-6736(97)01063-5; Shearer GM, 1996, IMMUNOL TODAY, V17, P21, DOI 10.1016/0167-5699(96)80564-0; SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291; Spear GT, 1997, AIDS, V11, P1319, DOI 10.1097/00002030-199711000-00005; TAHA TE, 1997, 10 INT C AIDS STD AB; Theus SA, 1998, J INFECT DIS, V177, P941, DOI 10.1086/515240; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; VERNAZZA PL, 1997, AIDS, P11989; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WAWER MJ, 1995, SCIENCE, V270, P564; Xu C, 1997, J INFECT DIS, V176, P941, DOI 10.1086/516539; ZAITSEVA A, 1997, NAT MED, V3, P1369	43	363	372	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN	1998	351			3			5	7						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV844	9652712	Bronze			2022-12-28	WOS:000074347300003
J	Taylor-Robinson, D; Furr, PM				Taylor-Robinson, D; Furr, PM			Update on sexually transmitted mycoplasmas	LANCET			English	Article							ACUTE NONGONOCOCCAL URETHRITIS; NEWLY DISCOVERED MYCOPLASMA; HUMAN UROGENITAL TRACT; UREAPLASMA-UREALYTICUM; GENITALIUM; ARTHRITIS; SALPINGITIS; PROSTATITIS; ASSOCIATION; FERMENTANS		St Marys Hosp, Imperial Coll, Sch Med, Dept Genitourinary Med & Communicable Dis, London W2 1NY, England	Imperial College London	Taylor-Robinson, D (corresponding author), St Marys Hosp, Imperial Coll, Sch Med, Dept Genitourinary Med & Communicable Dis, Praed St, London W2 1NY, England.							DEGUCHI T, 1995, INT J STD AIDS, V6, P144, DOI 10.1177/095646249500600219; Deguchi T, 1996, EUR J CLIN MICROBIOL, V15, P169, DOI 10.1007/BF01591493; Dienes L, 1937, PROC SOC EXP BIOLMED, V36, P740; DOBLE A, 1989, BRIT J UROL, V64, P297, DOI 10.1111/j.1464-410X.1989.tb06017.x; FURR PM, 1994, ANN RHEUM DIS, V53, P183, DOI 10.1136/ard.53.3.183; GOULET M, 1995, J CLIN MICROBIOL, V33, P2823, DOI 10.1128/JCM.33.11.2823-2825.1995; HAY PE, 1994, BRIT J OBSTET GYNAEC, V101, P1048, DOI 10.1111/j.1471-0528.1994.tb13580.x; HORNER PJ, 1993, LANCET, V342, P582, DOI 10.1016/0140-6736(93)91411-E; HOROWITZ S, 1994, J RHEUMATOL, V21, P877; JALIL N, 1988, GENITOURIN MED, V64, P367; JANIER M, 1995, SEX TRANSM DIS, V22, P244, DOI 10.1097/00007435-199507000-00008; Jensen JS, 1996, J CLIN MICROBIOL, V34, P286, DOI 10.1128/JCM.34.2.286-291.1996; JENSEN JS, 1993, GENITOURIN MED, V69, P265; KATSENI VL, 1993, LANCET, V341, P271, DOI 10.1016/0140-6736(93)92617-3; Keane FEA, 1997, GENITOURIN MED, V73, P373; Krieger JN, 1996, J CLIN MICROBIOL, V34, P3120, DOI 10.1128/JCM.34.12.3120-3128.1996; LACKEY PC, 1995, CLIN INFECT DIS, V21, P759; LAMONT RF, 1987, J MED MICROBIOL, V24, P253, DOI 10.1099/00222615-24-3-253; Li F, 1996, ARTHRITIS RHEUM, V39, P950, DOI 10.1002/art.1780390612; LIND K, 1987, EUR J CLIN MICROBIOL, V6, P205, DOI 10.1007/BF02018216; LO SC, 1991, LANCET, V338, P1415, DOI 10.1016/0140-6736(91)92721-D; MARDH PA, 1970, BRIT J VENER DIS, V46, P390; MARDH PA, 1970, BRIT J VENER DIS, V46, P179; MOLLER BR, 1984, LANCET, V1, P1102; ROSENSTEIN IJ, 1996, J MED MICROBIOL, V44, P1; RUITER M, 1952, J INVEST DERMATOL, V18, P313, DOI 10.1038/jid.1952.36; SHEPARD M C, 1954, Am J Syph Gonorrhea Vener Dis, V38, P113; STAMM WE, 1995, JAMA-J AM MED ASSOC, V274, P545, DOI 10.1001/jama.274.7.545; Taylor-Robinson D, 1997, J ANTIMICROB CHEMOTH, V40, P622, DOI 10.1093/jac/40.5.622; Taylor-Robinson D, 1988, GENITAL TRACT INFECT, P228; TAYLORROBINSON D, 1995, GENITOURIN MED, V71, P1; TAYLORROBINSON D, 1994, EUR J CLIN MICROBIOL, V13, P1066, DOI 10.1007/BF02111830; TaylorRobinson D, 1996, SEX TRANSM DIS, V23, P86, DOI 10.1097/00007435-199601000-00020; TAYLORROBINSON D, 1993, CLIN INFECT DIS   S1, V17, P66; TAYLORROBINSON D, 1985, MYCOPLASMAS, V4, P27; TULLY JG, 1981, LANCET, V1, P1288; Uno M, 1997, SEX TRANSM DIS, V24, P284, DOI 10.1097/00007435-199705000-00009; WAITES KB, 1988, LANCET, V1, P17; WANG RYH, 1993, CLIN INFECT DIS, V17, P724, DOI 10.1093/clinids/17.4.724; Wang RYH, 1997, FEMS IMMUNOL MED MIC, V19, P237, DOI 10.1016/S0928-8244(97)00089-8	40	50	54	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN	1998	351			3			12	15						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV844	9652714				2022-12-28	WOS:000074347300005
J	Boysen, G; Truelsen, T				Boysen, G; Truelsen, T			Looking beyond first-ever stroke incidence	LANCET			English	Editorial Material							RISK-FACTORS; RACE		Bispebjerg Hosp, Dept Neurol, DK-1399 Copenhagen K, Denmark; Kommune Hosp, Inst Prevent Med, DK-1399 Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital	Boysen, G (corresponding author), Bispebjerg Hosp, Dept Neurol, DK-1399 Copenhagen K, Denmark.		Truelsen, Thomas/AAY-1549-2020					*AM HEART ASS, 1997, HEART STROK STAT UPD; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; Brown RD, 1996, STROKE, V27, P373; CAPLAN LR, 1986, STROKE, V17, P648, DOI 10.1161/01.STR.17.4.648; Heyman A, 1971, STROKE, V2, P509, DOI 10.1161/01.STR.2.6.509; HORNER RD, 1991, STROKE, V22, P1497, DOI 10.1161/01.STR.22.12.1497; KITTNER SJ, 1990, JAMA-J AM MED ASSOC, V264, P1267, DOI 10.1001/jama.264.10.1267; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; RESCH JA, 1970, ATHEROSCLEROSIS, V12, P401, DOI 10.1016/0021-9150(70)90044-4; SACCO RL, 1995, NEUROLOGY, V45, P659, DOI 10.1212/WNL.45.4.659; Smith GD, 1998, LANCET, V351, P934, DOI 10.1016/S0140-6736(05)60603-4	11	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1073	1074		10.1016/S0140-6736(05)79374-0	http://dx.doi.org/10.1016/S0140-6736(05)79374-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660571				2022-12-28	WOS:000073090200003
J	Kiviluoto, T; Siren, J; Luukkonen, P; Kivilaakso, E				Kiviluoto, T; Siren, J; Luukkonen, P; Kivilaakso, E			Randomised trial of laparoscopic versus open cholecystectomy for acute and gangrenous cholecystitis	LANCET			English	Article							PERCUTANEOUS CHOLECYSTOSTOMY; EXPERIENCE; COMPLICATIONS; MANAGEMENT; BILE; DIAGNOSIS; INJURY; CHOICE	Background Laparoscopic cholecystectomy (LC) has become the treatment of choice for elective cholecystectomy, but controversy persists over use of this approach in the treatment of acute cholecystitis. We undertook a randomised comparison of the safety and outcome of LC and open cholecystectomy (OC) in patients with acute cholecystitis. Methods 63 of 68 consecutive patients who met criteria for acute cholecystitis were randomly assigned OC (31 patients) or LC (32 patients). The primary endpoints were hospital mortality and morbidity, length of hospital stay, and length of sick leave from work. Analysis was by intention to treat. Suspected bile-duct stones were investigated by preoperative endoscopic retrograde cholangiography (LC group) or intraoperative cholangiography (OC group). Findings The two randomised groups were similar in demographic, physical, and clinical characteristics. 48% of the patients in the OC group and 59% in the LC group were older than 60 years. 13 patients in each group had gangrene or empyema, and one in each group had perforation of the gallbladder causing diffuse peritonitis. Five (16%) patients in the LC group required conversion to OC, in most because severe inflammation distorted the anatomy of Calot's triangle. There were no deaths or bile-duct lesions in either group, but the postoperative complication rate was significantly (p=0.0048) higher in the OC than in the LC group: seven (23%) patients had major and six (19%) major complications after OC, whereas only one (3%) minor complication occurred after LC. The postoperative hospital stay was significantly shorter in the LC than the OC group (median 4 [IQR 2-5] vs 6 [5-8] days; p=0.0063). Mean length of sick leave was shorter in the LC group (13.9 vs 30.1 days; 95% CI for difference 10.9-21.7). Interpretation Even though LC for acute and gangrenous cholecystitis is technically demanding, in experienced. hands it is safe and effective. It does not increase the mortality rate, and the morbidity rate seems to be even. lower than that in OC. However, a moderately high conversion rate must be accepted.	Univ Helsinki, Cent Hosp, Dept Surg 2, FIN-00290 Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital	Kiviluoto, T (corresponding author), Univ Helsinki, Cent Hosp, Dept Surg 2, Haartmaninkatu 4, FIN-00290 Helsinki, Finland.							Altaca G, 1996, SURG LAPAROSC ENDOSC, V6, P26, DOI 10.1097/00019509-199602000-00006; BAILEY RW, 1991, ANN SURG, V214, P531, DOI 10.1097/00000658-199110000-00017; BRANUM G, 1993, ANN SURG, V217, P532, DOI 10.1097/00000658-199305010-00014; Carroll BJ, 1996, SURG ENDOSC-ULTRAS, V10, P319, DOI 10.1007/BF00187380; Carroll BJ, 1996, SURG ENDOSC, V10, P1194, DOI 10.1007/s004649900277; CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; Fitzgibbons RJ, 1996, SURG ENDOSC-ULTRAS, V10, P1180, DOI 10.1007/s004649900274; FLOWERS JL, 1991, AM J SURG, V161, P388, DOI 10.1016/0002-9610(91)90604-C; Hamy A, 1997, SURGERY, V121, P398, DOI 10.1016/S0039-6060(97)90309-3; Jacobs M, 1991, J Laparoendosc Surg, V1, P175, DOI 10.1089/lps.1991.1.175; JATZKO GR, 1995, ANN SURG, V221, P381, DOI 10.1097/00000658-199504000-00008; KIVILUOTO T, 1992, ANN CHIR GYNAECOL FE, V81, P343; KUM CK, 1994, SURG LAPAROSC ENDOSC, V4, P22; LANDAU O, 1992, WORLD J SURG, V16, P962, DOI 10.1007/BF02067003; LARSON GM, 1992, AM J SURG, V163, P221, DOI 10.1016/0002-9610(92)90105-Z; Ovaska J, 1996, ANN CHIR GYNAECOL FE, V85, P208; Patterson EJ, 1996, SURG ENDOSC, V10, P1185, DOI 10.1007/s004649900275; PETERS JH, 1991, SURGERY, V110, P769; PETERS JH, 1994, SURG LAPAROSC ENDOSC, V4, P163; PHILLIPS EH, 1992, AM SURGEON, V58, P273; PICKLEMAN J, 1986, ARCH SURG-CHICAGO, V121, P930; RATTNER DW, 1993, ANN SURG, V217, P233, DOI 10.1097/00000658-199303000-00003; REDDICK EJ, 1991, AM J SURG, V161, P377, DOI 10.1016/0002-9610(91)90601-9; SCHIRMER BD, 1991, ANN SURG, V213, P665, DOI 10.1097/00000658-199106000-00018; SINGER JA, 1994, AM SURGEON, V60, P326; STRASBERG SM, 1995, J AM COLL SURGEONS, V180, P101; VANDERLINDEN W, 1981, BRIT J SURG, V68, P753; VAUTHEY JN, 1993, SURG GYNECOL OBSTET, V176, P49; WAY LW, 1992, ANN SURG, V215, P195, DOI 10.1097/00000658-199203000-00001; WIESEN SM, 1993, AM J GASTROENTEROL, V88, P334	30	284	297	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					321	325		10.1016/S0140-6736(97)08447-X	http://dx.doi.org/10.1016/S0140-6736(97)08447-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652612				2022-12-28	WOS:000071864000010
J	Joensuu, J; Koskenniemi, E; Pang, XL; Vesikari, T				Joensuu, J; Koskenniemi, E; Pang, XL; Vesikari, T			Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis	LANCET			English	Article							PROTECTIVE EFFICACY; WC3 VACCINE; FIELD TRIAL; INFANTS; DIARRHEA; CHILDREN; IMMUNOGENICITY; SEROTYPE-1; SPECIFICITY; EPIDEMIC	Background Rotavirus is the most common cause of acute childhood gastroenteritis. Vaccination with live oral heterologous rotavirus Vaccines may prevent rotavirus gastroenteritis. We assessed the efficacy of rhesus-human reassortant rotavirus tetravalent vaccine (RRV-TV) against severe rotavirus gastroenteritis in Finnish children in a randomised placebo-controlled double-blind trial. Methods Placebo or RRV-TV (titre 4x10(5) plaque-forming units) was given to infants at ages 2, 3, and 5 months. The children were followed up for one or two rotavirus epidemic seasons. The main outcome measure was protection against severe rotavirus gastroenteritis (score greater than or equal to 11 on a 20-point severity scale). 2398 children were enrolled and received at least one dose of RRV-TV (n=1191) or placebo (n=1207). The primary efficacy analysis was based on children who received three doses of RRV-TV (n=1128) or placebo (n=1145). Findings 256 episodes of rotavirus gastroenteritis occurred at any time during the study; 65 were among 1191 RRV-TV recipients, and 191 among 1207 placebo recipients (vaccine efficacy 66% [95% CI 55-74]; intention-to-treat analysis). 226 episodes were included in the primary efficacy analysis of fully vaccinated children (54 among 1128 RRV-TV recipients, 172 among 1145 placebo recipients; Vaccine efficacy 68% [57-76]). 100 episodes were severe, eight in RRV-TV recipients and 92 in placebo recipients (vaccine efficacy 91% [82-96]). Interpretation RRV-TV vaccine was highly effective against severe rotavirus gastroenteritis in young children. Incorporation of this vaccine into routine immunisation schedules of infants could reduce severe rotavirus gastroenteritis by 90% and severe gastroenteritis of all causes in young children by 60%.	UNIV TAMPERE,SCH MED,FIN-33101 TAMPERE,FINLAND; NATL PUBL HLTH INST,HELSINKI,FINLAND	Tampere University; Finland National Institute for Health & Welfare								BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; BERNSTEIN DI, 1995, JAMA-J AM MED ASSOC, V273, P1191, DOI 10.1001/jama.273.15.1191; CHRISTY C, 1988, PEDIATR INFECT DIS J, V7, P645, DOI 10.1097/00006454-198809000-00009; CLARK HF, 1988, J INFECT DIS, V158, P570, DOI 10.1093/infdis/158.3.570; FLORES J, 1987, LANCET, V1, P882; FLORES J, 1993, J CLIN MICROBIOL, V31, P2439, DOI 10.1128/JCM.31.9.2439-2445.1993; GEORGESCOURBOT MC, 1991, RES VIROLOGY, V142, P405, DOI 10.1016/0923-2516(91)90008-Q; Glass RI, 1996, J INFECT DIS, V174, pS5, DOI 10.1093/infdis/174.Supplement_1.S5; GOTHEFORS L, 1989, J INFECT DIS, V159, P753, DOI 10.1093/infdis/159.4.753; GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276, DOI 10.1128/JCM.28.2.276-282.1990; HANLON P, 1987, LANCET, V1, P1342; ISOLAURI E, 1995, VACCINE, V13, P310, DOI 10.1016/0264-410X(95)93319-5; KAPIKIAN AZ, 1986, J INFECT DIS, V153, P815, DOI 10.1093/infdis/153.5.815; Kapikian AZ, 1996, J INFECT DIS, V174, pS65, DOI 10.1093/infdis/174.Supplement_1.S65; Lanata CF, 1996, J INFECT DIS, V174, P268, DOI 10.1093/infdis/174.2.268; LANATA CF, 1989, J INFECT DIS, V159, P452, DOI 10.1093/infdis/159.3.452; Linhares AC, 1996, B WORLD HEALTH ORGAN, V74, P491; MADORE HP, 1992, J INFECT DIS, V166, P235, DOI 10.1093/infdis/166.2.235; MAUNULA L, 1995, ARCH VIROL, V140, P877, DOI 10.1007/BF01314964; MIDTHUN K, 1985, J VIROL, V53, P949, DOI 10.1128/JVI.53.3.949-954.1985; RENNELS MB, 1990, AM J DIS CHILD, V144, P601, DOI 10.1001/archpedi.1990.02150290095037; Rennels MB, 1996, PEDIATRICS, V97, P7; RUUSKA T, 1990, SCAND J INFECT DIS, V22, P259, DOI 10.3109/00365549009027046; RUUSKA T, 1990, SCAND J INFECT DIS, V22, P269, DOI 10.3109/00365549009027047; Ryan MJ, 1996, J INFECT DIS, V174, pS12, DOI 10.1093/infdis/174.Supplement_1.S12; VESIKARI T, 1984, LANCET, V1, P977; VESIKARI T, 1991, ACTA PAEDIATR SCAND, V80, P173, DOI 10.1111/j.1651-2227.1991.tb11830.x; VESIKARI T, 1990, AM J DIS CHILD, V144, P285, DOI 10.1001/archpedi.1990.02150270035021; VESIKARI T, 1992, PEDIATR INFECT DIS J, V11, P535, DOI 10.1097/00006454-199207000-00006; VESIKARI T, 1986, J INFECT DIS, V153, P832, DOI 10.1093/infdis/153.5.832; Vesikari T, 1996, J INFECT DIS, V174, pS81, DOI 10.1093/infdis/174.Supplement_1.S81; VESIKARI T, 1985, J PEDIATR-US, V107, P189, DOI 10.1016/S0022-3476(85)80123-2; Ward RL, 1996, J INFECT DIS, V174, pS51, DOI 10.1093/infdis/174.Supplement_1.S51; WARD RL, 1995, VACCINE, V13, P1226, DOI 10.1016/0264-410X(95)00060-E	34	233	243	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1205	1209		10.1016/S0140-6736(97)05118-0	http://dx.doi.org/10.1016/S0140-6736(97)05118-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652561				2022-12-28	WOS:A1997YD23800010
J	Nudler, E; Gusarov, I; Avetissova, E; Kozlov, M; Goldfarb, A				Nudler, E; Gusarov, I; Avetissova, E; Kozlov, M; Goldfarb, A			Spatial organization of transcription elongation complex in Escherichia coli	SCIENCE			English	Article							RNA-POLYMERASE; TERMINATION	During RNA synthesis in the ternary elongation complex, RNA polymerase enzyme holds nucleic acids in three contiguous sites: the double-stranded DNA-binding site (DBS) ahead of the transcription bubble, the RNA-DNA heteroduplex-binding site (HBS), and the RNA-binding site (RBS) upstream of HBS. Photochemical cross-linking allowed mapping of the DNA and RNA contacts to specific positions on the amino acid sequence. Unexpectedly, the same protein regions were found to participate in both DBS and RES. Thus, DNA entry and RNA exit occur close together in the RNA polymerase molecule, suggesting that the three sites constitute I single unit. The results explain how RNA in the integrated unit RBS-HBS-DBS may stabilize the ternary complex, whereas a hairpin in RNA result in its dissociation.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA; Publ Hlth Res Inst City New York Inc, New York, NY 10016 USA	New York University	Nudler, E (corresponding author), NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA.		Kozlov, Maxim/GLN-3047-2022; Gusarov, Ivan/AAJ-6282-2020	Kozlov, Maxim/0000-0002-5994-9099; Nudler, Evgeny/0000-0002-8811-3071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; KUMAR S A, 1975, Journal of Biological Chemistry, V250, P2878; KURIYAN J, 1994, J MOL BIOL, V234, P915; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; NUDLER E, UNPUB; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; Severinov K, 1997, J BIOL CHEM, V272, P24137, DOI 10.1074/jbc.272.39.24137; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793	16	71	73	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					424	428		10.1126/science.281.5375.424	http://dx.doi.org/10.1126/science.281.5375.424			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665887				2022-12-28	WOS:000074918800050
J	Schroder, FC; Farmer, JJ; Attygalle, AB; Smedley, SR; Eisner, T; Meinwald, J				Schroder, FC; Farmer, JJ; Attygalle, AB; Smedley, SR; Eisner, T; Meinwald, J			Combinatorial chemistry in insects: A library of defensive macrocyclic polyamines	SCIENCE			English	Article							EPILACHNA-BOREALIS; SQUASH-BEETLE; SECRETION	The pupal defensive secretion of the coccinellid beetle Epilachna borealis is composed principally of a combinatorial Library of macrocyclic polyamines. These compounds constitute a previously unrecognized family of natural products, characterized by extremely Large-ring lactonic structures derived from a small set of (2-hydroxyethylamino)alkanoic acids. The combinatorial assembly of these simple building blocks generates a high degree of structural diversity, which is further increased by slow. spontaneous intramolecular rearrangement of the macrocycles.	Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA; Trinity Coll, Dept Biol, Hartford, CT 06106 USA; Cornell Univ, Neurobiol & Behav Sect, Ithaca, NY 14853 USA	Cornell University; Trinity College; Cornell University	Schroder, FC (corresponding author), Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA.		Schroeder, Frank/H-5026-2012	Attygalle, Athula/0000-0002-5847-2794; Schroeder, Frank/0000-0002-4420-0237	NIAID NIH HHS [AI2908] Funding Source: Medline; NIGMS NIH HHS [GM53830] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI002908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053830] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Attygalle AB, 1996, EXPERIENTIA, V52, P616, DOI 10.1007/BF01969741; Attygalle AB, 1996, NATURWISSENSCHAFTEN, V83, P277; ATTYGALLE AB, 1993, P NATL ACAD SCI USA, V90, P5204, DOI 10.1073/pnas.90.11.5204; Daloze Desire, 1995, Chemoecology, V5-6, P173, DOI 10.1007/BF01240602; Eisner Thomas, 1992, Psyche (Cambridge), V99, P265, DOI 10.1155/1992/54859; GIANNIS A, 1989, ANGEW CHEM INT EDIT, V28, P218, DOI 10.1002/anie.198902181; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; HINTON H. E., 1955, TRANS SOC BRIT ENT, V12, P49; King AG, 1996, CHEM REV, V96, P1105; MUKAIYAMA T, 1977, CHEM LETT, P441, DOI 10.1246/cl.1977.441; OLIYAI R, 1995, BIOORG MED CHEM LETT, V5, P2735, DOI 10.1016/0960-894X(95)00454-2; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; SCHRODER FR, UNPUB	13	57	61	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					428	431		10.1126/science.281.5375.428	http://dx.doi.org/10.1126/science.281.5375.428			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665888				2022-12-28	WOS:000074918800051
J	Dunea, G				Dunea, G			Soundings - Catastrophic cat care	BRITISH MEDICAL JOURNAL			English	Editorial Material									Cook Cty Hosp, Chicago, IL 60612 USA	John H Stroger Junior Hospital Cook County	Dunea, G (corresponding author), Cook Cty Hosp, Chicago, IL 60612 USA.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					152	152		10.1136/bmj.317.7151.152	http://dx.doi.org/10.1136/bmj.317.7151.152			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657814	Green Published			2022-12-28	WOS:000075081700065
J	Tian, SS; Lamb, P; King, AG; Miller, SG; Kessler, L; Luengo, JI; Averill, L; Johnson, RK; Gleason, JG; Pelus, LM; Dillon, SB; Rosen, J				Tian, SS; Lamb, P; King, AG; Miller, SG; Kessler, L; Luengo, JI; Averill, L; Johnson, RK; Gleason, JG; Pelus, LM; Dillon, SB; Rosen, J			A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor	SCIENCE			English	Article							FACTOR-RECEPTOR; TYROSINE PHOSPHORYLATION; CELL-LINE; STAT3; ERYTHROPOIETIN; INTERLEUKIN-6; DIMERIZATION; BINDING; CSF	A nonpeptidyl small molecule SB 247464, capable of activating granulocyte-colony-stimulating factor (G-CSF) signal transduction pathways, was identified in a high-throughput assay in cultured cells. Like G-CSF, SE 247464 induced tyrosine phosphorylation of multiple signaling proteins and stimulated primary murine bone marrow cells to form granulocytic colonies in vitro. It also elevated peripheral blood neutrophil counts in mice. The extracellular domain of the murine G-CSF receptor was required for the activity of SE 247464, suggesting that the compound acts by oligomerizing receptor chains. The results indicate that a small molecule can activate a receptor that normally binds a relatively Large protein Ligand.	Ligand Pharmaceut Inc, Dept Transcript Res, San Diego, CA 92121 USA; SmithKline Beecham Pharmaceut, Dept Mol Virol & Host Def US, Collegeville, PA 19426 USA; Ligand Pharmaceut Inc, Dept New Leads Discovery, San Diego, CA 92121 USA; SmithKline Beecham Pharmaceut, Dept Med Chem US, Collegeville, PA 19426 USA; SmithKline Beecham Pharmaceut, Dept Oncol, King Of Prussia, PA 19406 USA	Ligand Pharmaceuticals; GlaxoSmithKline; Ligand Pharmaceuticals; GlaxoSmithKline; GlaxoSmithKline	Lamb, P (corresponding author), Ligand Pharmaceut Inc, Dept Transcript Res, San Diego, CA 92121 USA.							ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; DEMETRI GD, 1991, BLOOD, V78, P2791; Fourcin M, 1996, J BIOL CHEM, V271, P11756, DOI 10.1074/jbc.271.20.11756; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KOMATSU N, 1993, BLOOD, V82, P456; METCALF D, 1983, J CELL PHYSIOL, V116, P198, DOI 10.1002/jcp.1041160211; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TIAN SS, 1994, BLOOD, V84, P1760; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	19	149	165	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					257	259		10.1126/science.281.5374.257	http://dx.doi.org/10.1126/science.281.5374.257			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657720				2022-12-28	WOS:000074714200049
J	Scally, G; Donaldson, LJ				Scally, G; Donaldson, LJ			Clinical governance and the drive for quality improvement in the new NHS in England	BRITISH MEDICAL JOURNAL			English	Article							TRIALS		NHS Execut South & West, Bristol BS34 8SR, Avon, England; Univ Durham, Durham DH1 3YG, England	Durham University	Scally, G (corresponding author), NHS Execut South & West, Westwoo House,Lime Kiln Close, Bristol BS34 8SR, Avon, England.	gscally@doh.gov.uk						BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BROTHERSTON HHF, 1962, MEASURE MED CARE OPE; Code C., 1992, FINANCIAL ASPECTS CO; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DONALDSON LJ, 1994, BRIT MED J, V308, P1277, DOI 10.1136/bmj.308.6939.1277; GALLIMORE SC, 1997, 19941995 NAT CONF EN; *GEN MED COUNC, 1995, GOOD MED PRACT GUID; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; Kanter R. M., 1984, CHANGE MASTERS; McGregor D., 1960, HUMAN SIDE ENTERPRIS; *NAT AUD OFF, 1995, CLIN AUD ENGL HC 27; *NHS EX, 1997, ACC KNOW BAS REV LIB; *NHS EX, 1996, GUID IMPL NHS COMPL; *NHS EX, 1998, CLIN EFF IND CONS DO; *NHS EX, 1997, REV CERV CANC SCREEN; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; *SECR STAT HLTH, 1997, CMND3807; Wood T J, 1995, Physician Exec, V21, P26; World Health Organization, 1983, PRINC QUAL ASS	19	489	497	1	60	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					61	65		10.1136/bmj.317.7150.61	http://dx.doi.org/10.1136/bmj.317.7150.61			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651278	Green Published			2022-12-28	WOS:000075081600034
J	Cordner, S; McKelvie, H				Cordner, S; McKelvie, H			Forensic medicine: International criminal tribunals and an international criminal court	LANCET			English	Editorial Material									Monash Univ, Victoria Inst Forens Pathol, Clayton, Vic 3006, Australia	Monash University	Cordner, S (corresponding author), Monash Univ, Victoria Inst Forens Pathol, Clayton, Vic 3006, Australia.								0	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1956	1957		10.1016/S0140-6736(05)78642-6	http://dx.doi.org/10.1016/S0140-6736(05)78642-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654283				2022-12-28	WOS:000074464700049
J	Cyna, AM; Hovenden, JL; Lehmann, A; Rajaseker, K; Kalia, P				Cyna, AM; Hovenden, JL; Lehmann, A; Rajaseker, K; Kalia, P			Routine replacement of central venous catheters: telephone survey of intensive care units in mainland Britain	BRITISH MEDICAL JOURNAL			English	Article									Hartlepool Dist Gen Hosp, Dept Pathol, Hartlepool TS24 9AH, Cleveland, England; Hartlepool Dist Gen Hosp, Dept Anaesthesia, Hartlepool TS24 9AH, Cleveland, England		Hovenden, JL (corresponding author), Hartlepool Dist Gen Hosp, Dept Pathol, Hartlepool TS24 9AH, Cleveland, England.		Cyna, Allan/AAN-5201-2021	Cyna, Allan/0000-0002-3138-1091				COBB DK, 1992, NEW ENGL J MED, V327, P1062, DOI 10.1056/NEJM199210083271505; EYER S, 1990, CRIT CARE MED, V18, P1073, DOI 10.1097/00003246-199010000-00005; Hospital Infection Control Practices Advisory Committee, 1990, AM J INFECT CONTROL, V24, P277; Ryan DW, 1997, ANAESTHESIA, V52, P286; ULLMAN RF, 1990, AM J INFECT CONTROL, V18, P201, DOI 10.1016/0196-6553(90)90185-U	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1944	1945		10.1136/bmj.316.7149.1944	http://dx.doi.org/10.1136/bmj.316.7149.1944			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641930	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000074636700025
J	Dahl, M; Tybjaerg-Hansen, A; Lange, P; Nordestgaard, BG				Dahl, M; Tybjaerg-Hansen, A; Lange, P; Nordestgaard, BG			Delta F508 heterozygosity in cystic fibrosis and susceptibility to asthma	LANCET			English	Article							OBLIGATE HETEROZYGOTES; BRONCHIAL-ASTHMA; REACTIVITY; AIRWAY	Background Cystic fibrosis is a recessive disorder mainly characterised by lung disease. We tested the hypothesis that individuals heterozygous for the common cystic fibrosis Delta F508 mutation are at risk of obstructive pulmonary disease. Methods We studied a cross-sectional sample from the general population of Copenhagen, Denmark, aged 20 years and older, We did spirometry to measure forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), and did genotyping on blood samples of 9141 individuals. We asked all participants whether they had asthma, and asked for information on smoking and other factors that could have contributed to obstructive pulmonary disease. Findings We identified 250 carriers of the Delta F508 mutation (2.7% [95% CI 2.5-3.1]). 9% of carriers reported having asthma compared with 6% of non-carriers (p=0.04). The odds ratio for asthma in participants heterozygous for Delta F508 mutation was 2.0 (1.2-3.5, p=0.02). Furthermore, among individuals with airway obstruction, the percentage predicted FEV1 and FVC were significantly lower in participants heterozygous for Delta F508 than in non-carriers (49 vs 58%, p=0.004; and 70 vs 82%, p<0.001, respectively), mainly due to an effect in those with self-reported asthma. Interpretation Cystic fibrosis Delta F508 heterozygosity may be over-represented among people with asthma and seems to be associated with decreased pulmonary function in people with airway obstruction who also have asthma.	Herlev Univ Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark; Bispebjerg Univ Hosp, Copenhagen City Heart Study, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital	Nordestgaard, BG (corresponding author), Glostrup Univ Hosp, Dept Clin Biochem, Nordre Ringvej, DK-2600 Glostrup, Denmark.		Dahl, Morten/F-4219-2014; Nordestgaard, Borge Gronne/ABF-1310-2020	Dahl, Morten/0000-0002-6686-312X; 				Appleyard M., 1989, SCAND J SOC MED, V41, P1; BATTEN J, 1963, LANCET, V1, P1348; BYARD PJ, 1988, AM REV RESPIR DIS, V138, P312, DOI 10.1164/ajrccm/138.2.312; COUNAHAN R, 1975, ARCH DIS CHILD, V50, P477, DOI 10.1136/adc.50.6.477; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DAVIS PB, 1989, J APPL PHYSIOL, V66, P2124, DOI 10.1152/jappl.1989.66.5.2124; DAVIS PB, 1984, AM REV RESPIR DIS, V129, P911; DAVIS PB, 1987, THORAX, V42, P120, DOI 10.1136/thx.42.2.120; GOLD WM, 1994, TXB RESP MED, P870; HALLETT WY, 1965, AM REV RESPIR DIS, V90, P714; KHOURY MJ, 1993, FUNDAMENTALS GENETIC, P77; LANGE P, 1991, EUR RESPIR J, V4, P1080; Leupold W, 1979, Monogr Paediatr, V10, P119; MENNIE M, 1995, NAT MED, V1, P978, DOI 10.1038/nm1095-978b; MITCHELL I, 1978, J PEDIATR-US, V93, P744, DOI 10.1016/S0022-3476(78)81070-1; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; ORZALESI MM, 1963, ACTA PAEDIATR, V52, P267, DOI 10.1111/j.1651-2227.1963.tb03779.x; Sandford AJ, 1997, EUR RESPIR J, V10, P1380, DOI 10.1183/09031936.97.10061380; SCHROEDER SA, 1995, NAT MED, V1, P703, DOI 10.1038/nm0795-703; SCHWARTZ M, 1992, ACTA PAEDIATR, V81, P522, DOI 10.1111/j.1651-2227.1992.tb12287.x; TybjaergHansen A, 1997, J CLIN INVEST, V99, P3034, DOI 10.1172/JCI119499; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; Wittrup HH, 1997, J CLIN INVEST, V99, P1606, DOI 10.1172/JCI119323; WOOD JA, 1959, NEW ENGL J MED, V260, P951, DOI 10.1056/NEJM195905072601901; WOOLCOCK AJ, 1994, TXB RESP MED, P1288	25	89	90	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1911	1913		10.1016/S0140-6736(97)11419-2	http://dx.doi.org/10.1016/S0140-6736(97)11419-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654257				2022-12-28	WOS:000074464700007
J	Summerfield, D				Summerfield, D			If children's lives are precious, which children?	LANCET			English	Editorial Material									Med Fdn Care Victims Torture, London NW5 3EJ, England		Summerfield, D (corresponding author), Med Fdn Care Victims Torture, London NW5 3EJ, England.							FERNANDES E, 1994, NETH Q HUM RIGHTS, V12, P117; Logie DE, 1997, BRIT MED J, V315, P1444, DOI 10.1136/bmj.315.7120.1444; UNICEF, 1996, STAT WORLDS CHILDR; World Health Organization, 1995, BRIDG GAPS	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1955	1955		10.1016/S0140-6736(98)06056-5	http://dx.doi.org/10.1016/S0140-6736(98)06056-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654281				2022-12-28	WOS:000074464700048
J	Trewby, PN; Rutter, MD; Earl, UM; Sattar, MA				Trewby, PN; Rutter, MD; Earl, UM; Sattar, MA			Teapot myositis	LANCET			English	Article									Darlington Mem Hosp, Dept Med, Darlington DL3 6HX, Durham, England; Darlington Mem Hosp, Dept Histol, Darlington DL3 6HX, Durham, England; Darlington Mem Hosp, Dept Rheumatol, Darlington DL3 6HX, Durham, England		Trewby, PN (corresponding author), Darlington Mem Hosp, Dept Med, Darlington DL3 6HX, Durham, England.							AGARWAL R, 1994, GASTROENTEROLOGY, V107, P548, DOI 10.1016/0016-5085(94)90184-8; BENOWITZ NL, 1982, JAMA-J AM MED ASSOC, V248, P1097, DOI 10.1001/jama.248.9.1097; BUCKLEY BM, 1982, LANCET, V2, P618; MICHL H, 1954, MONATSH CHEM, V85, P779; ZANTVOORT FA, 1996, ANN INTERN MED, V104, P134	5	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1248	1248		10.1016/S0140-6736(98)01294-X	http://dx.doi.org/10.1016/S0140-6736(98)01294-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643746				2022-12-28	WOS:000073283600012
J	Lopez-Jaramillo, P; Ruano, C; Rivera, J; Teran, E; Salazar-Irigoyen, R; Esplugues, JV; Moncada, S				Lopez-Jaramillo, P; Ruano, C; Rivera, J; Teran, E; Salazar-Irigoyen, R; Esplugues, JV; Moncada, S			Treatment of cutaneous leishmaniasis with nitric-oxide donor	LANCET			English	Article									Cent Univ, Fac Med, Mineral Metab Unit, Quito, Ecuador; IIDES, MSP, Quito, Ecuador; Univ Valencia, Dept Pharmacol, E-46003 Valencia, Spain; Univ Coll, Cruciform Project, London, England	Universidad Central del Ecuador; University of Valencia; University of London; University College London	Lopez-Jaramillo, P (corresponding author), Cent Univ, Fac Med, Mineral Metab Unit, Quito, Ecuador.		Terán, Enrique/L-6000-2016; Esplugues, Juan/ABC-1488-2021	Terán, Enrique/0000-0001-6979-5655; Esplugues Mota, Juan Vicente/0000-0001-8205-021X				Arevalo Jorge, 1993, P456; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MONCADA S, 1988, BIOCHEM PHARMACOL, V37, P2495, DOI 10.1016/0006-2952(88)90236-5; YAMASAKI K, IN PRESS J CLIN INVE	4	60	62	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1176	1177		10.1016/S0140-6736(05)79119-4	http://dx.doi.org/10.1016/S0140-6736(05)79119-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643692				2022-12-28	WOS:000073220200014
J	Melberg, A; Mattsson, P; Westerberg, CE				Melberg, A; Mattsson, P; Westerberg, CE			Loss of control after a cup of coffee	LANCET			English	Article							CHANNEL GENE; ATAXIA; MUTATIONS				Melberg, A (corresponding author), UNIV UPPSALA HOSP,DEPT NEUROL,S-75185 UPPSALA,SWEDEN.							Baloh RW, 1997, ANN NEUROL, V41, P8, DOI 10.1002/ana.410410105; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; GRIGGS RC, 1978, NEUROLOGY, V28, P1259, DOI 10.1212/WNL.28.12.1259; GRIGGS RC, 1995, ANN NEUROL, V37, P285, DOI 10.1002/ana.410370302; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1220	1220		10.1016/S0140-6736(97)07090-6	http://dx.doi.org/10.1016/S0140-6736(97)07090-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652564				2022-12-28	WOS:A1997YD23800013
J	Nashan, B; Moore, R; Amlot, P; Schmidt, AG; Abeywickrama, K; Soulillou, JP				Nashan, B; Moore, R; Amlot, P; Schmidt, AG; Abeywickrama, K; Soulillou, JP			Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients	LANCET			English	Article							MONOCLONAL-ANTIBODY; TRANSPLANT PATIENTS; KIDNEY-TRANSPLANTS; IL-2 RECEPTOR; T-CELLS; INTERLEUKIN-2; TACROLIMUS; THERAPY; IMPACT; PREVENTION	Background Currently available immunosuppressive regimens for cadaver-kidney recipients are far from ideal because acute-rejection episodes occur in about 30% to 50% of these patients. In the phase III study described here we assessed the ability of basiliximab, a chimeric interleukin (IL)-2 receptor monoclonal antibody, to prevent acute rejection episodes in renal allograft recipients. Methods 380 adult recipients of a primary cadaveric kidney transplant were randomly allocated, in this doubleblind trial, to receive a 20 mg infusion of basiliximab on day 0 (day of surgery) and on day 4, to provide IL-2-receptor suppression for 4-6 weeks (n=193), or to receive placebo (n=187). Both groups received baseline dual immunosuppressive therapy with cyclosporin and steroids throughout the study. The primary outcome measure was incidence of acute-rejection episodes during the 6 months after transplantation. Safety and tolerability were monitored over the 12 months of the study. Findings 376 patients were eligible for intention-to-treat analysis (basiliximab, n=190; placebo, n=186). No significant differences in patient characteristics were apparent. The incidence of biopsy-confirmed acute rejection 6 months after transplantation was 51 (29.8%) of 171 in the basiliximab group compared with 73 (44.0%) of 166 in the placebo group (32% reduction; 14.2% difference [95% Kaplan-Meier Cls 3% to 24%], p=0.012). The incidence of steroid-resistant first rejection episodes that required antibody therapy was significantly lower in the basiliximab group (10% vs 23.1%, 13.1% difference [5.4% to 20.8%], p<0.001). At weeks 2 and 4 post-transplantation, the mean daily dose of steroids was significantly higher in the placebo group (p<0.001 with one-way analysis of variance). The incidence of graft loss at 12 months post-transplantation was 23 (12.1%) of 190 in the basiliximab group and 25 (13.4%) of 186 in the placebo group (1.3% difference [-5% to 9%], p=0.591). The incidence of infection and other adverse events was similar in the two treatment groups. The acute tolerability of basiliximab was excellent, with no evidence-of cytokine-release syndrome, 14 deaths (basiliximab n=9; placebo n=5; -2.0% difference [-6% to 2%], p=0.293) occurred during the 12-month study and a further three deaths n=1; placebo n=2) occurred within the 380-day cut-off period. One post transplantation lymphoproliferative disorder was recorded in each group. Interpretation Prophylaxis with 40 mg basiliximab reduces the incidence of acute rejection episodes significantly, with no clinically relevant safety or tolerability concerns.	ROYAL FREE HOSP,SCH MED,LONDON,ENGLAND; CARDIFF ROYAL INFIRM,CARDIFF,S GLAM,WALES; NOVARTIS PHARMA,BASEL,SWITZERLAND; INST TRANSPLANTAT & RECH TRANSPLANTAT,NANTES,FRANCE	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Cardiff Royal Infirmary; Novartis	Nashan, B (corresponding author), HANNOVER MED SCH,ABDOMINAL & TRANSPLANTAT CHIRURG KLIN,CARL NEUBERG STR 1,D-30625 HANNOVER,GERMANY.		Nashan, Björn/H-9087-2019	Nashan, Björn/0000-0001-7587-9935				AMLOT PL, 1995, TRANSPLANTATION, V60, P748, DOI 10.1097/00007890-199510150-00023; Amlot PL, 1996, CLIN EXP IMMUNOL, V105, P176, DOI 10.1046/j.1365-2249.1996.d01-722.x; AMLOT PL, 1995, MED INTELL UNIT, P53; BASADONNA GP, 1993, TRANSPLANTATION, V55, P993, DOI 10.1097/00007890-199305000-00007; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DESCHLER DG, 1995, ARCH OTOLARYNGOL, V121, P1037; *EUR MYC MOF COOP, 1995, LANCET, V345, P1321; Furth S, 1996, PEDIATR NEPHROL, V10, P64, DOI 10.1007/BF00863448; GULANIKAR AC, 1992, TRANSPLANTATION, V53, P323, DOI 10.1097/00007890-199202010-00013; HARDIE IR, 1997, NEPHROLOGY, V3, pS71; ISHII N, 1994, INT IMMUNOL, V6, P1273, DOI 10.1093/intimm/6.8.1273; KELLY PA, 1995, AM J HEALTH-SYST PH, V52, P1521, DOI 10.1093/ajhp/52.14.1521; KHAZAELI MB, 1992, J CLIN IMMUNOL, V12, P116, DOI 10.1007/BF00918141; KIRKMAN RL, 1991, TRANSPLANTATION, V51, P107, DOI 10.1097/00007890-199101000-00016; KIRKMAN RL, 1985, J EXP MED, V162, P358, DOI 10.1084/jem.162.1.358; Kovarik JM, 1996, TRANSPLANT P, V28, P913; KUPIECWEGLINSKI JW, 1988, TRANSPLANTATION, V46, P785, DOI 10.1097/00007890-198812000-00001; KUPIECWEGLINSKI JW, 1986, P NATL ACAD SCI USA, V83, P2624, DOI 10.1073/pnas.83.8.2624; MATAS AJ, 1994, TRANSPLANTATION, V57, P857, DOI 10.1097/00007890-199403270-00015; MEREDITH RF, 1992, ANTIBODY IMMUNOCONJ, V5, P75; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; NALESNIK MA, 1988, CURR PROB SURG, V25, P367; NALESNIK MA, 1991, SPRINGER SEMIN IMMUN, V13, P199; Nashan B, 1996, TRANSPLANTATION, V61, P546, DOI 10.1097/00007890-199602270-00006; Nashan B, 1995, Transpl Immunol, V3, P203, DOI 10.1016/0966-3274(95)80026-3; NELSON PW, 1983, TRANSPLANTATION, V36, P587; *ORTH MULT TRANSPL, 1985, NEW ENGL J MED, V313, P337; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; SOLEZ K, 1993, KIDNEY INT, V44, P411, DOI 10.1038/ki.1993.259; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; SOULILLOU JP, 1990, NEW ENGL J MED, V322, P1175, DOI 10.1056/NEJM199004263221702; SOULILLOU JP, 1987, LANCET, V1, P1339; SOULILLOU JP, 1994, KIDNEY INT, V46, P540, DOI 10.1038/ki.1994.306; *TRIC MYC MOF REN, 1996, TRANSPLANTATION, V61, P1029; 1964, RECOMMENDATIONS GUID; 1990, GOOD CLIN PRACTICE T	36	553	573	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1193	1198		10.1016/S0140-6736(97)09278-7	http://dx.doi.org/10.1016/S0140-6736(97)09278-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652559				2022-12-28	WOS:A1997YD23800008
J	Roberts, J				Roberts, J			Primary care: core values - Primary care in an imperfect market	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY; COST		Madrona Med Grp, Bellingham, WA 98226 USA		Roberts, J (corresponding author), Madrona Med Grp, 4465 Cordata Pkwy, Bellingham, WA 98226 USA.							FELDSTEIN R, 1994, HLTH CARE EC; FRY J, 1995, REVIVING PRIMARY CAR; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; Light D. W., 1994, OXFORD MED COMPANION; Light DW, 1996, MED CARE, V34, P985, DOI 10.1097/00005650-199609000-00009; *MED LEAD COUNC, 1997, REP FRONT 1997; Miller RS, 1996, JAMA-J AM MED ASSOC, V275, P708, DOI 10.1001/jama.275.9.708; OGRADY KF, 1985, NEW ENGL J MED, V313, P484, DOI 10.1056/NEJM198508223130806; Selby JV, 1996, NEW ENGL J MED, V334, P635, DOI 10.1056/NEJM199603073341006; STOLINE AM, 1993, NEW MED MARKETPLACE	10	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					186	189		10.1136/bmj.317.7152.186	http://dx.doi.org/10.1136/bmj.317.7152.186			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665903	Green Published			2022-12-28	WOS:000075047800029
J	Clark, AA				Clark, AA			George Hebbington Field - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					83	83		10.1136/bmj.317.7150.83	http://dx.doi.org/10.1136/bmj.317.7150.83			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651297	Green Published			2022-12-28	WOS:000075081600060
J	McDonald, PJ				McDonald, PJ			A social experiment that keeps adapting	BRITISH MEDICAL JOURNAL			English	Article									SA HealthPlus, Adelaide, SA 5000, Australia		McDonald, PJ (corresponding author), SA HealthPlus, POB 65, Adelaide, SA 5000, Australia.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					55	56		10.1136/bmj.317.7150.55	http://dx.doi.org/10.1136/bmj.317.7150.55			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651276	Green Published			2022-12-28	WOS:000075081600031
J	Bellaiche, Y; The, I; Perrimon, N				Bellaiche, Y; The, I; Perrimon, N			Tout-velu is a Drosophila homologue of the putative tumour suppressor EXT-1 and is needed for Hh diffusion	NATURE			English	Article							HEREDITARY MULTIPLE EXOSTOSES; INDIAN HEDGEHOG; PROTEIN; GENE; FAMILY	Hedgehog (Hh) proteins act through both short-range and long-range signalling to pattern tissues during invertebrate and vertebrate development(1). The mechanisms allowing Hedgehog to diffuse over a long distance and to exert its long-range effects are not understood. Here we identify a new Drosophila gene, named tout-velu, that is required for diffusion of Hedgehog. Characterization of tout-velu shows that it encodes an integral membrane protein that belongs to the EXT gene family. Members of this family are involved in the human multiple exostoses syndrome, which affects bone morphogenesis(2-4). Our results, together with the previous characterization of the role of Indian Hedgehog in bone morphogenesis(5-7), lead us to propose that the multiple exostoses syndrome is associated with abnormal diffusion of Hedgehog proteins. These results show the existence of a new conserved mechanism required for diffusion of Hedgehog.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.	perrimon@rascal.med.harvard.edu	The, Inge/B-8884-2011	Perrimon, Norbert/0000-0001-7542-472X				AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; Chen CH, 1996, LAB ROBOTICS AUTOMAT, V8, P87; Clines GA, 1997, GENOME RES, V7, P359, DOI 10.1101/gr.7.4.359; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Mullor JL, 1997, DEVELOPMENT, V124, P1227; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; Perrimon N, 1996, GENETICS, V144, P1681; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; RIEMER D, 1995, J CELL SCI, V108, P3189; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; STICKENS D, BIOCH MOL MED, V16, P97; Strigini M, 1997, DEVELOPMENT, V124, P4697; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WICKLUND CL, 1995, AM J MED GENET, V55, P43, DOI 10.1002/ajmg.1320550113; XU T, 1993, DEVELOPMENT, V117, P1223	28	417	427	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 2	1998	394	6688					85	88		10.1038/27932	http://dx.doi.org/10.1038/27932			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665133				2022-12-28	WOS:000074579600054
J	Johnston, LA; Edgar, BA				Johnston, LA; Edgar, BA			Wingless and Notch regulate cell-cycle arrest in the developing Drosophila wing	NATURE			English	Article							GENE-EXPRESSION; LINEAGE RESTRICTION; S-PHASE; ACHAETE; EMBRYOGENESIS; MELANOGASTER; RECEPTION; BOUNDARY; TISSUES; SIGNAL	In developing organs, the regulation of cell proliferation and patterning of cell fates is coordinated. How this coordination is achieved, however, is unknown. In the developing Drosophila wing, both cell proliferation and patterning require the secreted morphogen Wingless (Wg) at the dorsoventral compartment boundary (reviewed in ref. 1). Late in wing development, Wg also induces a zone of non-proliferating cells at the dorsoventral boundary. This zone gives rise to sensory bristles of the adult wing margin(2,3). Here we investigate how Wg coordinates the cell cycle with patterning by studying the regulation of this growth arrest. We show that Wg, in conjunction with Notch, induces arrest in both the G1 and G2 phases of the cell cycle in separate subdomains of the zone of non-proliferating cells. Wg induces G2 arrest in two subdomains by inducing the proneural genes achaete and scute, which downregulate the mitosis-inducing phosphatase String (Cdc25)(4), Notch activity creates a third domain by preventing arrest at G2 in wg-expressing cells, resulting in their arrest in G1.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Johnston, LA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Johnston, Laura A/ABC-1945-2021	JOHNSTON, LAURA A/0000-0001-9477-7897	NIGMS NIH HHS [F32 GM017373-03, F32 GM017373, F32 GM017373-04, R01 GM051186] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017373, R01GM051186] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; deCelis JF, 1996, DEVELOPMENT, V122, P359; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; Gustafson K, 1996, GENOME, V39, P174, DOI 10.1139/g96-023; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; Johnston LA, 1996, DEVELOPMENT, V122, P3519; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; OBROCHTA DA, 1985, NATURE, V313, P138, DOI 10.1038/313138a0; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SCHWEISGUTH F, 1995, DEVELOPMENT, V121, P1875; SERRANO N, 1997, CURR BIOL, V7, P186; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; USUI K, 1992, DEVELOPMENT, V116, P601; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; XU T, 1993, DEVELOPMENT, V117, P1223; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	30	222	227	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					82	84		10.1038/27925	http://dx.doi.org/10.1038/27925			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665132				2022-12-28	WOS:000074579600053
J	Nightingale, SL				Nightingale, SL			Video program on guidelines for the use of antiretroviral agents in pediatric HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					12	12		10.1001/jama.280.1.12	http://dx.doi.org/10.1001/jama.280.1.12			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660348				2022-12-28	WOS:000074379400007
J	Jackman, RJ; Brittain, ST; Adams, A; Prentiss, MG; Whitesides, GM				Jackman, RJ; Brittain, ST; Adams, A; Prentiss, MG; Whitesides, GM			Design and fabrication of topologically complex, three-dimensional microstructures	SCIENCE			English	Article							SILICON; MICROFABRICATION; LASER; MEMS	Two concepts for use in the fabrication of three-dimensional (3D) microstructures with complex topologies are described. Both routes begin with a two-dimensional (2D) pattern and transform it into a 3D microstructure, The concepts are illustrated by use of soft lithographic techniques to transfer 2D patterns to cylindrical (pseudo-3D) substrates. Subsequent steps-application of uniaxial strain, connection of patterns on intersecting surfaces-transform these patterns into free-standing, 3D, noncylindrically symmetrical microstructures. Microelectrodeposition provides an additive method that strengthens thin metal designs produced by patterning, welds nonconnected structures, and enables the high-strain deformations required in one method to be carried out successfully.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA	Harvard University; Harvard University	Whitesides, GM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.		Prentiss, Mara/AAU-2940-2021					Becker E. W., 1986, Microelectronic Engineering, V4, P35, DOI 10.1016/0167-9317(86)90004-3; FRAZIER AB, 1993, J MICROELECTRON SYST, V2, P2; Gobet J., 1993, Journal of Micromechanics and Microengineering, V3, P123, DOI 10.1088/0960-1317/3/3/007; Harvey EC, 1995, P SOC PHOTO-OPT INS, V2639, P266, DOI 10.1117/12.221283; Ikuta K., 1994, Proceedings IEEE Micro Electro Mechanical Systems. An Investigation of Micro Structures, Sensors, Actuators, Machines and Robotic Systems (Cat. No.94CH3404-1), P1, DOI 10.1109/MEMSYS.1994.555588; JACKMAN RJ, 1995, SCIENCE, V269, P664, DOI 10.1126/science.7624795; KAUFFMAN LH, 1967, KNOTS; Kovacs GTA, 1996, ANAL CHEM, V68, pA407, DOI 10.1021/ac961977i; LAKES R, 1993, ADV MATER, V5, P293, DOI 10.1002/adma.19930050416; LEHMANN O, 1995, SCIENCE, V270, P1644, DOI 10.1126/science.270.5242.1644; Lochel B, 1996, SENSOR ACTUAT A-PHYS, V54, P663, DOI 10.1016/S0924-4247(97)80034-9; Madden JD, 1996, J MICROELECTROMECH S, V5, P24, DOI 10.1109/84.485212; Menz W, 1996, SENSOR ACTUAT A-PHYS, V54, P785, DOI 10.1016/S0924-4247(97)80056-8; Miyajima H, 1995, J MICROELECTROMECH S, V4, P220, DOI 10.1109/84.475549; PETERSEN KE, 1982, P IEEE, V70, P420, DOI 10.1109/PROC.1982.12331; Porter T., 1994, KNOTS SURFACES; Qin D, 1996, ADV MATER, V8, P917, DOI 10.1002/adma.19960081110; Rogers JA, 1997, J MICROELECTROMECH S, V6, P184, DOI 10.1109/84.623106; Rogers JA, 1997, ADV MATER, V9, P475, DOI 10.1002/adma.19970090603; ROMANKIW LT, 1996, ECS P S MAG MAT PROC, V4, P253; Sachs E., 1992, Manufacturing Review, V5, P117; SANDER D, 1995, J MICROELECTROMECH S, V4, P81, DOI 10.1109/84.388116; Varadan VK, 1996, P SOC PHOTO-OPT INS, V2722, P156, DOI 10.1117/12.240440; Xia YN, 1996, J ELECTROCHEM SOC, V143, P1070, DOI 10.1149/1.1836585; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G	25	146	162	2	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2089	2091		10.1126/science.280.5372.2089	http://dx.doi.org/10.1126/science.280.5372.2089			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641907				2022-12-28	WOS:000074435900035
J	Pierre, P; Mellman, I				Pierre, P; Mellman, I			Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells	CELL			English	Article							HUMAN CYSTATIN-C; CYSTEINE PROTEINASE-INHIBITORS; COLONY-STIMULATING FACTOR; CATHEPSIN-S; LANGERHANS CELLS; ENDOPLASMIC-RETICULUM; SURFACE EXPRESSION; CYTOPLASMIC TAIL; DOWN-REGULATION; HLA-DM	Dendritic cells (DCs) developmentally regulate their capacity for antigen presentation by controlling the transport and surface expression of MHC class II molecules. These events reflect a developmental regulation of invariant (li) chain cleavage, most likely by the cysteine protease cathepsin S. In immature DCs, inefficient Il chain cleavage due to low cathepsin S activity leads to the transport of class II-ii chain complexes to lysosomes, while in mature DCs, elevated cathepsin S activity results in efficient delivery of class II alpha beta dimers to.the plasma membrane. Cathepsin S is not controlled transcriptionally but by a novel mechanism involving alterations in the expression and localization of an endogenous cathepsin S inhibitor cystatin C. Thus, the ratio of cystatin C to cathepsin S in developing DCs helps to determine the fate of newly synthesized MHC class II molecules.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA	Yale University; Yale University	Mellman, I (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.		Mellman, Ira/ABG-5896-2020	pierre, philippe/0000-0003-0863-8255	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034098, R01AI034098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033904] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-34098] Funding Source: Medline; NIGMS NIH HHS [GM-33904] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON M, 1991, BIOCHEM J, V273, P621, DOI 10.1042/bj2730621; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ABRAHAMSON M, 1991, BIOMED BIOCHIM ACTA, V50, P587; AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; Brachet V, 1997, J CELL BIOL, V137, P51, DOI 10.1083/jcb.137.1.51; BROMME D, 1991, BIOMED BIOCHIM ACTA, V50, P631; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Chapman HA, 1998, CURR OPIN IMMUNOL, V10, P93, DOI 10.1016/S0952-7915(98)80038-1; Cresswell P, 1998, SCIENCE, V280, P394, DOI 10.1126/science.280.5362.394; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; Drake JR, 1997, J EXP MED, V186, P1299, DOI 10.1084/jem.186.8.1299; Ekiel I, 1996, J BIOL CHEM, V271, P1314, DOI 10.1074/jbc.271.3.1314; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; Hall A, 1998, BIOCHEMISTRY-US, V37, P4071, DOI 10.1021/bi971197j; Henskens YMC, 1996, BIOL CHEM H-S, V377, P71; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; KIRSCHKE H, 1994, METHOD ENZYMOL, V244, P500; KLEIJMEER MJ, 1994, J INVEST DERMATOL, V103, P516, DOI 10.1111/1523-1747.ep12395666; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; KNOCH H, 1994, INT J ONCOL, V5, P77; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; LENARCIC B, 1991, FEBS LETT, V280, P211, DOI 10.1016/0014-5793(91)80295-E; Leonardi A, 1996, BIOL CHEM H-S, V377, P319; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mellman I, 1998, TRENDS CELL BIOL, V8, P231, DOI 10.1016/S0962-8924(98)01276-8; Merz GS, 1997, J CELL PHYSIOL, V173, P423; Miyake T, 1996, MOL BRAIN RES, V37, P273; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; Pierre P, 1996, IMMUNITY, V4, P229, DOI 10.1016/S1074-7613(00)80431-8; Pierre P, 1998, CURR OPIN IMMUNOL, V10, P145, DOI 10.1016/S0952-7915(98)80242-2; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; PIETERS J, 1993, J CELL SCI, V106, P831; Rider BJ, 1996, MOL IMMUNOL, V33, P625, DOI 10.1016/0161-5890(96)00022-3; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; SHI GP, 1994, J BIOL CHEM, V269, P11530; SOLEM M, 1990, BIOCHEM BIOPH RES CO, V172, P945, DOI 10.1016/0006-291X(90)90767-H; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; WARFEL AH, 1987, J EXP MED, V166, P1912, DOI 10.1084/jem.166.6.1912; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	62	318	326	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1135	1145		10.1016/S0092-8674(00)81458-0	http://dx.doi.org/10.1016/S0092-8674(00)81458-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657147	hybrid			2022-12-28	WOS:000074491100009
J	DiGabriele, AD; Lax, I; Chen, DI; Svahn, CM; Jaye, M; Schlessinger, J; Hendrickson, WA				DiGabriele, AD; Lax, I; Chen, DI; Svahn, CM; Jaye, M; Schlessinger, J; Hendrickson, WA			Structure of a heparin-linked biologically active dimer of fibroblast growth factor	NATURE			English	Article							SIGNAL TRANSDUCTION; BINDING DOMAIN; RECEPTOR; OLIGOMERIZATION; IDENTIFICATION; MITOGENESIS; ACTIVATION	The fibroblast growth factors (FGFs) form a large family of structurally related, multifunctional proteins that regulate various biological responses(1.) They mediate cellular functions by binding to transmembrane FGF receptors(2), which are protein tyrosine kinases. FGF receptors are activated by oligomerization(3), and both this activation and FGF-stimulated biological responses require heparin-like molecules as well as FGF(4), Heparins are linear anionic polysaccharide chains; they are typically heterogeneously sulphated on alternating L-iduronic and D-glucosamino sugars, and are nearly ubiquitous in animal tissues as heparan sulphate proteoglycans on cell surfaces and in the extracellular matrix. Although several crystal structures have been described for FGF molecules in complexes with heparin-like sugars(5-7), the nature of a biologically active complex has been unknown until now. Here we describe the X-ray crystal structure, at 2.9 Angstrom resolution, of a biologically active dimer of human acidic FGF in a complex with a fully sulphated, homogeneous heparin decassacharide. The dimerization of heparin-linked acidic FGF observed here is an elegant mechanism for the modulation of signalling through combinatorial homodimerization and heterodimerization of the 12 known members of the FGF family.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; NYU Med Ctr, Dept Pharmacol, New York, NY 10016 USA; Pharmacia & Upjohn Inc, S-11287 Stockholm, Sweden; Rhone Poulenc Rorer, Collegeville, PA 19426 USA	Columbia University; Columbia University; Howard Hughes Medical Institute; New York University; Pfizer; Pharmacia Corporation	Hendrickson, WA (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA.	hendw@convex.hhmi.columbia.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; HENDERSON IC, 1990, ANN ONCOL, V1, P9, DOI 10.1093/oxfordjournals.annonc.a057685; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; OTWINOWSKI Z, 1993, 15662 DENZO SERC DAR; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	29	318	332	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 25	1998	393	6687					812	817		10.1038/31741	http://dx.doi.org/10.1038/31741			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655399				2022-12-28	WOS:000074433100056
J	Delbanco, TL; Daley, J; Hartman, EE				Delbanco, TL; Daley, J; Hartman, EE			A 42-year-old man with hypertension, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Delbanco TL, 1997, JAMA-J AM MED ASSOC, V278, P1015	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1998	1998		10.1001/jama.279.24.1998	http://dx.doi.org/10.1001/jama.279.24.1998			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU945	9643865				2022-12-28	WOS:000074252100038
J	Bernardi, L; Spadacini, G; Bellwon, J; Hajric, R; Roskamm, H; Frey, AW				Bernardi, L; Spadacini, G; Bellwon, J; Hajric, R; Roskamm, H; Frey, AW			Effect of breathing rate on oxygen saturation and exercise performance in chronic heart failure	LANCET			English	Article								Background In chronic heart failure (CHF), impaired pulmonary function can independently contribute to oxygen desaturation and reduced physical activity. We investigated the effect of breathing rate on oxygen saturation and other respiratory indices. Methods Arterial oxygen saturation (SaO(2)) and respiratory indices were recorded during spontaneous breathing (baseline) and during controlled breathing at 15, six, and three breaths per min in 50 patients with CHF and in 11 healthy volunteers (controls). 15 patients with CHF were randomly allocated 1 month of respiratory training to decrease their respiratory rate to six breaths per min. Respiratory indices were recorded before training, at the end of training, and 1 month after training. Findings During spontaneous breathing, mean SaO(2) was lower in CHF patients than in controls (91.4% [SD 0.4] vs 95.4% [0.2], p<0.001). Controlled breathing increased SaO(2) at all breathing rates in patients with CHF. Compared with baseline, minute ventilation increased at 15 breaths per min (+45.9% [9.8], p<0.01), did not change at six breaths per min, and decreased at three breaths per min (-40.3% [4.8], p<0.001). In the nine CHF patients who had 1 month of respiratory training, resting SaO(2) increased from 92.5% (0.3) at baseline to 93.2% (0.4) (p<0.05), their breathing rate per min decreased from 13.4 (1.5) to 7.6 (1.9) (p<0.001), peak oxygen consumption increased from 1157 (83) to 1368 (110) L/min (p<0.05), exercise time increased from 583 (29) to 615 (23) min/s (p<0.05), and perception of dyspnoea reduced from a score of 19.0 (0.4) to 17.3 (0.9) on the Borg scale (p<0.05). There were no changes in the respiratory indices in the patients who did not have respiratory training. Interpretation Slowing respiratory rate reduces dyspnoea and improves both resting pulmonary gas exchange and exercise performance in patients with CHF.	Univ Pavia, IRCCS S Matteo, Dept Internal Med, I-27100 Pavia, Italy; Herz Zentrum, Bad Krozingen, Germany; Med Univ Gdansk, Cardiol Dept 1, Gdansk, Poland	IRCCS Fondazione San Matteo; University of Pavia; Fahrenheit Universities; Medical University Gdansk	Bernardi, L (corresponding author), Univ Pavia, IRCCS S Matteo, Dept Internal Med, Via Palestro 3, I-27100 Pavia, Italy.							ALLISON J, 1970, LANCET, V1, P833; ASKANAZI J, 1980, J APPL PHYSIOL, V48, P577, DOI 10.1152/jappl.1980.48.4.577; BEAVER WL, 1986, J APPL PHYSIOL, V60, P2020, DOI 10.1152/jappl.1986.60.6.2020; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; CLARK A, 1992, EUR HEART J, V13, P1698, DOI 10.1093/oxfordjournals.eurheartj.a060127; COATS AJS, 1990, LANCET, V335, P63, DOI 10.1016/0140-6736(90)90536-E; COTES JE, 1979, LUNG FUNCTION ASSESS, P160; HEWITT J, 1983, YOGA BREATHING POSTU, P89; Itoh H, 1990, CIRCULATION, V81, pII31; Mancini D, 1997, J AM COLL CARDIOL, V29, P590, DOI 10.1016/S0735-1097(96)00556-6; MANCINI DM, 1992, CIRCULATION, V86, P909, DOI 10.1161/01.CIR.86.3.909; MANCINI DM, 1995, CIRCULATION, V91, P320, DOI 10.1161/01.CIR.91.2.320; Mortara Andrea, 1996, Clinical Science (London), V91, P72; MUNGER MA, 1994, AM J CARDIOL, V73, P180, DOI 10.1016/0002-9149(94)90211-9; Piepoli M, 1997, CIRCULATION, V95, P1813; Sanderson JE, 1996, CLIN SCI, V91, P35, DOI 10.1042/cs0910035; STANESCU DC, 1981, J APPL PHYSIOL, V51, P1625, DOI 10.1152/jappl.1981.51.6.1625; SULLIVAN MJ, 1988, CIRCULATION, V77, P552, DOI 10.1161/01.CIR.77.3.552; TATTERSFIELD AE, 1972, CLIN SCI, V42, P751, DOI 10.1042/cs0420751	19	152	167	2	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1308	1311		10.1016/S0140-6736(97)10341-5	http://dx.doi.org/10.1016/S0140-6736(97)10341-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643792				2022-12-28	WOS:000073439400007
J	Davies, CH; Ormerod, OJM				Davies, CH; Ormerod, OJM			Failed coronary thrombolysis	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; RANDOMIZED TRIAL; ARTERY PATENCY; INTRAVENOUS STREPTOKINASE; AORTIC COUNTERPULSATION; VASCULAR REOCCLUSION; RESCUE ANGIOPLASTY; STRONG PREDICTOR; EARLY FAILURE		Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Dept Cardiol, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Davies, CH (corresponding author), Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England.	Crispin.Davies@cardiov.ox.ac.uk						ABE S, 1994, J AM COLL CARDIOL, V23, P1382, DOI 10.1016/0735-1097(94)90381-6; Agnelli G, 1996, CARDIOVASC RES, V31, P232, DOI 10.1016/S0008-6363(96)00004-1; Anderson JL, 1996, AM J CARDIOL, V78, P1, DOI 10.1016/S0002-9149(96)00217-2; Apple FS, 1996, AM J CLIN PATHOL, V105, P6; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BELENKIE I, 1992, CAN J CARDIOL, V8, P357; Berger PB, 1997, CIRCULATION, V96, P122; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Boersma E, 1997, EUR HEART J, V18, P1703; BRUGEMANN J, 1990, BRIT HEART J, V64, P355; CALIFF RM, 1988, ANN INTERN MED, V108, P658, DOI 10.7326/0003-4819-108-5-658; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; Christenson RH, 1997, CIRCULATION, V96, P1776, DOI 10.1161/01.CIR.96.6.1776; CLEMMENSEN P, 1990, AM J CARDIOL, V66, P1407, DOI 10.1016/0002-9149(90)90524-5; DEFRANCO AC, 1996, HANDBOOK; ElGaylani N, 1996, INT J CARDIOL, V57, P45, DOI 10.1016/S0167-5273(96)02780-5; ELLIS SG, 1994, CIRCULATION, V90, P2280, DOI 10.1161/01.CIR.90.5.2280; FEARS R, 1992, AM HEART J, V124, P305, DOI 10.1016/0002-8703(92)90591-I; GULBA DC, 1991, CIRCULATION, V83, P937, DOI 10.1161/01.CIR.83.3.937; HACKETT D, 1987, NEW ENGL J MED, V317, P1055, DOI 10.1056/NEJM198710223171704; HO CH, 1990, THROMB RES, V58, P331, DOI 10.1016/0049-3848(90)90102-I; HOCHMAN JS, 1995, CIRCULATION, V91, P873, DOI 10.1161/01.CIR.91.3.873; Iliceto S, 1996, EUR HEART J, V17, P344; Iliceto S, 1997, EUR HEART J, V18, P618; ISHIHARA M, 1995, AM J CARDIOL, V76, P73, DOI 10.1016/S0002-9149(99)80805-4; ISHII J, 1994, AM HEART J, V128, P641, DOI 10.1016/0002-8703(94)90259-3; Ishii J, 1997, CLIN CHIM ACTA, V262, P13, DOI 10.1016/S0009-8981(97)06547-9; Ito H, 1996, CIRCULATION, V93, P1993, DOI 10.1161/01.CIR.93.11.1993; JEREMY RW, 1990, J AM COLL CARDIOL, V16, P695, DOI 10.1016/0735-1097(90)90362-S; Julian DG, 1996, EUR HEART J, V17, P43; Kern MJ, 1996, CIRCULATION, V94, P1545, DOI 10.1161/01.CIR.94.7.1545; KIRCHER BJ, 1987, AM J CARDIOL, V59, P513, DOI 10.1016/0002-9149(87)91158-1; Kleiman NS, 1993, J AM COLL CARDIOL, V22, P381, DOI 10.1016/0735-1097(93)90041-X; Klootwijk P, 1996, EUR HEART J, V17, P689; Kono T, 1996, J AM COLL CARDIOL, V28, P876, DOI 10.1016/S0735-1097(96)00240-9; KRUCOFF MW, 1997, J AM COLL CARDIOL, V29, P131; Kusniec J, 1997, EUR HEART J, V18, P420; LAPERCHE T, 1995, CIRCULATION, V92, P2079, DOI 10.1161/01.CIR.92.8.2079; LAPERCHE T, 1992, AM J CARDIOL, V70, P1129, DOI 10.1016/0002-9149(92)90042-W; LAVIN F, 1995, BRIT HEART J, V73, P422; LeBreton H, 1996, CARDIOVASC RES, V31, P235, DOI 10.1016/0008-6363(96)00005-3; Lefkovits J, 1996, AM J CARDIOL, V77, P1045, DOI 10.1016/S0002-9149(96)00128-2; MAES A, 1995, CIRCULATION, V92, P2072, DOI 10.1161/01.CIR.92.8.2072; MATTFELDT T, 1984, AM J CARDIOL, V54, P530, DOI 10.1016/0002-9149(84)90243-1; MAURI F, 1989, AM J CARDIOL, V63, P1291, DOI 10.1016/0002-9149(89)91037-0; MAURI F, 1994, J AM COLL CARDIOL, V24, P600, DOI 10.1016/0735-1097(94)90003-5; MAURI F, 1995, J AM COLL CARDIOL, V25, P805; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; MOLITERNO DJ, 1993, CIRCULATION, V88, P935, DOI 10.1161/01.CIR.88.3.935; MOUNSEY JP, 1995, BRIT HEART J, V74, P348; NEUHAUS KL, 1994, CIRCULATION, V90, P1638, DOI 10.1161/01.CIR.90.4.1638; NICOLAU JC, 1989, INT J CARDIOL, V25, P313, DOI 10.1016/0167-5273(89)90221-0; Ohman EM, 1997, CIRCULATION, V95, P846; OHMAN EM, 1994, CIRCULATION, V90, P792, DOI 10.1161/01.CIR.90.2.792; ONODERA T, 1989, BRIT HEART J, V61, P385; OSTERMANN H, 1992, EUR HEART J, V13, P1225, DOI 10.1093/oxfordjournals.eurheartj.a060341; PARISE P, 1991, BLOOD COAGUL FIBRIN, V2, P749, DOI 10.1097/00001721-199112000-00009; Prendergast BD, 1997, INT J CARDIOL, V61, P39, DOI 10.1016/S0167-5273(97)00116-2; Purcell IF, 1997, HEART, V78, P465, DOI 10.1136/hrt.78.5.465; RICHARDSON SG, 1989, BRIT HEART J, V61, P390; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; SARAN RK, 1990, BRIT HEART J, V64, P113; Scharfstein JS, 1996, AM J CARDIOL, V78, P503, DOI 10.1016/S0002-9149(96)00353-0; SCHRODER R, 1995, J AM COLL CARDIOL, V26, P1657, DOI 10.1016/0735-1097(95)00372-X; SCHRODER R, 1994, J AM COLL CARDIOL, V24, P384, DOI 10.1016/0735-1097(94)90292-5; SHAH PK, 1993, J AM COLL CARDIOL, V21, P55, DOI 10.1016/0735-1097(93)90716-E; SIMES RJ, 1995, CIRCULATION, V91, P1923, DOI 10.1161/01.CIR.91.7.1923; SIMOONS ML, 1993, CIRCULATION, V88, P2556, DOI 10.1161/01.CIR.88.6.2556; Stauffer JC, 1997, CIRCULATION, V96, P1141; Steinhubl SR, 1997, LANCET, V350, P532, DOI 10.1016/S0140-6736(05)63135-2; Strasberg B, 1996, EUR HEART J, V17, P333; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; vandeWerf F, 1996, EUR HEART J, V17, P325; vantHof AWJ, 1997, LANCET, V350, P615, DOI 10.1016/S0140-6736(96)07120-6; VELDKAMP RF, 1994, AM J CARDIOL, V73, P1069, DOI 10.1016/0002-9149(94)90285-2; WILLEMS JL, 1990, CIRCULATION, V82, P1147, DOI 10.1161/01.CIR.82.4.1147	76	43	43	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 18	1998	351	9110					1191	1196		10.1016/S0140-6736(97)11198-9	http://dx.doi.org/10.1016/S0140-6736(97)11198-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643708				2022-12-28	WOS:000073220200046
J	King, M				King, M			Misled by moonshine	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1218	1218		10.1016/S0140-6736(05)79179-0	http://dx.doi.org/10.1016/S0140-6736(05)79179-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643734				2022-12-28	WOS:000073220200076
J	de Craen, AJM; Vickers, AJ; Tijssen, JGP; Kleijnen, J				de Craen, AJM; Vickers, AJ; Tijssen, JGP; Kleijnen, J			Number-needed-to-treat and placebo-controlled trials	LANCET			English	Editorial Material									Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DE Amsterdam, Netherlands; Res Council Complementary Med, London, England	University of Amsterdam; Academic Medical Center Amsterdam	de Craen, AJM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DE Amsterdam, Netherlands.							Bienenfeld L, 1996, AM HEART J, V132, P1207, DOI 10.1016/S0002-8703(96)90465-2; COLLINS R, 1995, LANCET, V345, P669; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; DEVITA C, 1994, LANCET, V343, P1115; DUNDEE JW, 1988, J ROY SOC MED, V81, P456, DOI 10.1177/014107688808100813; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; PETTINGALE KW, 1985, LANCET, V1, P750; Sackett D. L., 1997, EVIDENCE BASED MED P	9	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					310	310		10.1016/S0140-6736(05)78341-0	http://dx.doi.org/10.1016/S0140-6736(05)78341-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652609				2022-12-28	WOS:000071864000007
J	Gangarosa, EJ; Galazka, AM; Wolfe, CR; Phillips, LM; Gangarosa, RE; Miller, E; Chen, RT				Gangarosa, EJ; Galazka, AM; Wolfe, CR; Phillips, LM; Gangarosa, RE; Miller, E; Chen, RT			Impact of anti-vaccine movements on pertussis control: the untold story	LANCET			English	Review							UNITED-STATES; CHILDREN; IMMUNIZATION; EPIDEMIOLOGY; EXPERIENCE; EFFICACY; SAFETY	To assess the impact of anti-vaccine movements that targeted pertussis whole-cell vaccines, we compared pertussis incidence in countries where high coverage with diphtheria-tetanus-pertussis vaccines (DTP) was maintained (Hungary, the former East Germany, Poland, and the USA) with countries where immunisation was disrupted by anti-vaccine movements (Sweden, Japan, Uh, The Russian Federation, Ireland, Italy, the former West Germany, and Australia). Pertussis incidence was 10 to 100 times lower in countries where high vaccine coverage was maintained than in countries where immunisation programs were compromised by anti-vaccine movements. Comparisons of neighbouring countries with high and low vaccine coverage further underscore the efficacy of these vaccines. Given the safety and cost-effectiveness of whole-cell pertussis vaccines, our study shows that, far from being obsolete, these vaccines continue to have an important role in global immunisation.	Emory Univ, Gangarosa Int Hlth Fdn, Atlanta, GA 30322 USA; Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; WHO, CH-1211 Geneva, Switzerland; Ctr Dis Control & Prevent, Georgia, GA 30333 USA; Publ Hlth Lab Serv, London, England	Emory University; Emory University; Rollins School Public Health; World Health Organization; Centers for Disease Control & Prevention - USA; Public Health England	Gangarosa, EJ (corresponding author), 5305 Greencastle Way, Stone Mt, GA 30087 USA.		Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367				Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; [Anonymous], 1982, BRIT MED J, V285, P357; BINKIN NJ, 1992, PEDIATR INFECT DIS J, V11, P653; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P22; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; COULTER HL, 1991, DTP SHOT DARK WHY P; Evans G, 1996, PEDIATR INFECT DIS J, V15, P477, DOI 10.1097/00006454-199606000-00002; FINE PEM, 1986, AM J EPIDEMIOL, V124, P1012, DOI 10.1093/oxfordjournals.aje.a114471; FINGER H, 1991, DEV BIOLOGICALS, V73, P343; Freed GL, 1996, JAMA-J AM MED ASSOC, V276, P1869, DOI 10.1001/jama.276.23.1869; Galazka Artur, 1992, World Health Statistics Quarterly, V45, P238; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; GRIFFITH AH, 1989, VACCINE, V7, P199, DOI 10.1016/0264-410X(89)90229-6; HALPERIN SA, 1989, J PEDIATR-US, V115, P686, DOI 10.1016/S0022-3476(89)80643-2; Halsey NA, 1996, PEDIATRICS, V97, P279; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Howell F, 1992, Commun Dis Rep CDR Rev, V2, pR31; JOO I, 1991, DEV BIOLOGICALS, V73, P357; KANAI K, 1980, JPN J MED SCI BIOL, V33, P107, DOI 10.7883/yoken1952.33.107; KIMURA M, 1990, LANCET, V336, P30, DOI 10.1016/0140-6736(90)91530-N; KIMURA M, 1988, Acta Paediatrica Japonica, V30, P109; KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46; LESTER R, 1993, MED J AUSTRALIA, V159, P631, DOI 10.5694/j.1326-5377.1993.tb138057.x; Lindgren C, 1997, EUR J PEDIATR, V156, P405, DOI 10.1007/s004310050626; MACINTYRE CR, 1994, MED J AUSTRALIA, V161, P295; MALLESON PN, 1977, LANCET, V1, P237; MENDELSOHN R, 1988, IMMUNICATIONS TERRIB; MILLER E, 1996, DEV BIOL STAND, V89, P301; NICOLL A, 1988, ARCH DIS CHILD, V63, P41, DOI 10.1136/adc.63.1.41; ONORATO IM, 1992, JAMA-J AM MED ASSOC, V267, P2745, DOI 10.1001/jama.267.20.2745; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; Plotkin SA, 1997, PEDIATR INFECT DIS J, V16, P508, DOI 10.1097/00006454-199705000-00011; ROMANUS V, 1987, PEDIATR INFECT DIS J, V6, P364, DOI 10.1097/00006454-198704000-00005; SALISBURY D, 1992, 25 NAT IMM C P 1991, P49; SCHEIBNER V, 1996, VACCINATION 100 YEAR; STEWART GT, 1977, LANCET, V1, P234; STROFFOLINI T, 1989, INFECTION, V17, P280, DOI 10.1007/BF01650708; STROM J, 1960, BRIT MED J, V2, P1184, DOI 10.1136/bmj.2.5207.1184; SUTTER RW, 1992, JAMA-J AM MED ASSOC, V267, P386, DOI 10.1001/jama.267.3.386; Taylor CE, 1997, AM J PUBLIC HEALTH, V87, P922, DOI 10.2105/AJPH.87.6.922; VELIMIROVIC B, 1991, WHO M NAT PROGR MAN	42	427	447	4	85	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	1998	351	9099					356	361		10.1016/S0140-6736(97)04334-1	http://dx.doi.org/10.1016/S0140-6736(97)04334-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652634				2022-12-28	WOS:000071864000044
J	Acerini, CL; Patton, CM; Savage, MO; Kernell, A; Westphal, O; Dunger, DB				Acerini, CL; Patton, CM; Savage, MO; Kernell, A; Westphal, O; Dunger, DB			Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus	LANCET			English	Article							HORMONE; BINDING; RETINOPATHY; INFUSION	Background Good glycaemic control in insulin-dependent diabetes mellitus (IDDM) to prevent complications may be difficult to achieve during adolescence, because abnormalities in production of growth hormone or insulinlike growth-factor-I (IGF-I) can lead to lower insulin sensitivity. Recombinant human IGF-I (rhIGF-I) given as an adjunct to insulin therapy in IDDM, might improve glycaemic control in adolescents; we investigated the effects of the addition of IGF-I in a randomised, double-blind, placebo-controlled trial. Methods 53 patients with IDDM (26 male, 27 female) with a median age of 16.1 years (range 10.8-20.6) and diabetes of more than 2 years' duration were randomly assigned subcutaneous rhIGF-1 (20 or 40 mu g/kg daily [n=18, n=18, respectively]) or placebo (n=17), both in addition to multiple-injection insulin therapy for 24 weeks. The primary endpoint, glycated haemoglobin (HbA(1c)) and routine biochemistry were measured every 4 weeks. Retinal photographs and glomerular-filtration rates were assessed at base line and at the end of the study. Data were analysed by intention to treat. Findings With a dose of 40 mu g/kg rhIGF-1 daily, we found significant reductions in HbA(1c) compared with placebo (p=0.03), without changes in body-mass index, rate of hypoglycaemia, insulin dose, or circulating concentrations of IGF-binding proteins 1 and 3. The greatest median change in HbA(1c) of -0.6% (range -2.8 to -1.5%) was seen with rhIGF-I 40 mu g/kg at week 12, but was not sustained at week 24. The greatest reductions in HbA(1c) at week 24 were seen among patients with the greatest changes in IGF-I concentrations (r=0.442, p=0.002]. Retinal photographs, renal function (glomerular filtration rate and urinary albumin excretion), and routine biochemistry showed no adverse events. Interpretation Our data confirm that rhIGF-I as an adjunct to insulin therapy can improve HbA(1c) values in adolescents with IDDM without overt toxic effects, but they raise questions about whether these effects can be sustained in cases of poor compliance or reduced bioefficacy.	UNIV OXFORD,JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND; ST BARTHOLOMEWS HOSP,LONDON,ENGLAND; LINKOPING UNIV HOSP,LINKOPING,SWEDEN; SAHLGRENS UNIV HOSP,S-41345 GOTHENBURG,SWEDEN	University of Oxford; University of London; Queen Mary University London; Linkoping University; Sahlgrenska University Hospital				Acerini, Carlo/0000-0003-2121-5871; Dunger, Professor David/0000-0002-2566-9304				BACH MA, 1994, J CLIN ENDOCR METAB, V79, P1040, DOI 10.1210/jc.79.4.1040; BOULWARE SD, 1994, J CLIN INVEST, V93, P1131, DOI 10.1172/JCI117065; CHEETHAM TD, 1994, J ENDOCRINOL, V142, P367, DOI 10.1677/joe.0.1420367; CHEETHAM TD, 1994, CLIN ENDOCRINOL, V40, P515, DOI 10.1111/j.1365-2265.1994.tb02492.x; CHEETHAM TD, 1995, DIABETIC MED, V12, P885, DOI 10.1111/j.1464-5491.1995.tb00391.x; CHEETHAM TD, 1993, DIABETOLOGIA, V36, P678, DOI 10.1007/BF00404081; CROWNE EC, IN PRESS METABOLISM; DCCT Res Grp, 1994, J PEDIATR-US, V125, P177, DOI 10.1016/S0022-3476(94)70190-3; *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401; Diabet Control Complications Trial Res Grp, 1995, DIABETES CARE, V18, P1415; DUNGER DB, 1995, ARCH DIS CHILD, V72, P469, DOI 10.1136/adc.72.6.469; DUNGER DB, 1991, ACTA PEDIAT SCAND S, V337, P69; Edge J A, 1990, Diabetes Res, V15, P109; EDGE JA, 1990, J CLIN ENDOCR METAB, V71, P1356, DOI 10.1210/jcem-71-5-1356; GERICH JE, 1984, NEW ENGL J MED, V310, P848, DOI 10.1056/NEJM198403293101310; GRANT MB, 1993, DIABETOLOGIA, V36, P282, DOI 10.1007/BF00400229; JABRI N, 1994, DIABETES, V43, P369, DOI 10.2337/diabetes.43.3.369; Jeppsson JO, 1996, DIABETES CARE, V19, P142, DOI 10.2337/diacare.19.2.142; Kernell A, 1997, DIABETOLOGIA, V40, P307, DOI 10.1007/s001250050679; *KROC COLL STUD GR, 1984, NEW ENGL J MED, V311, P365; MANN NP, 1982, ARCH DIS CHILD, V57, P434, DOI 10.1136/adc.57.6.434; MERIMEE TJ, 1983, NEW ENGL J MED, V309, P527, DOI 10.1056/NEJM198309013090904; Moses AC, 1996, DIABETES, V45, P91, DOI 10.2337/diabetes.45.1.91; Quattrin T, 1997, DIABETES CARE, V20, P374, DOI 10.2337/diacare.20.3.374; SHISHKO PI, 1992, DIABETES, V41, P1042, DOI 10.2337/diabetes.41.9.1042; TAYLOR AM, 1990, CLIN ENDOCRINOL, V32, P229, DOI 10.1111/j.1365-2265.1990.tb00859.x; Thrailkill K, 1997, J CLIN ENDOCR METAB, V82, P1181, DOI 10.1210/jc.82.4.1181; WANG Q, 1995, DIABETES, V44, P161, DOI 10.2337/diabetes.44.2.161; ZAPF J, 1981, EUR J BIOCHEM, V113, P605, DOI 10.1111/j.1432-1033.1981.tb05105.x; ZENOBI PD, 1994, EUR J ENDOCRINOL, V131, P251, DOI 10.1530/eje.0.1310251	30	75	80	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1199	1204		10.1016/S0140-6736(97)06467-2	http://dx.doi.org/10.1016/S0140-6736(97)06467-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652560				2022-12-28	WOS:A1997YD23800009
J	Baecklund, E; Ekbom, A; Sparen, P; Feltelius, N; Klareskog, L				Baecklund, E; Ekbom, A; Sparen, P; Feltelius, N; Klareskog, L			Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study	BRITISH MEDICAL JOURNAL			English	Article							CANCER		Univ Uppsala Hosp, Dept Med, S-75185 Uppsala, Sweden; Karolinska Inst, Dept Med Epidemiol, S-17111 Stockholm, Sweden; Karolinska Inst, Dept Med, S-17111 Stockholm, Sweden	Uppsala University; Uppsala University Hospital; Karolinska Institutet; Karolinska Institutet	Baecklund, E (corresponding author), Univ Uppsala Hosp, Dept Med, S-75185 Uppsala, Sweden.			Sparen, Par/0000-0002-5184-8971; Klareskog, Lars/0000-0001-9601-6186				GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; MYLLYKANGASLUOSUJARVI R, 1995, SCAND J RHEUMATOL, V24, P76, DOI 10.3109/03009749509099288; PRIOR P, 1984, ANN RHEUM DIS, V43, P128, DOI 10.1136/ard.43.2.128; SILMAN AJ, 1988, ANN RHEUM DIS, V47, P988, DOI 10.1136/ard.47.12.988; SYMMONS DPM, 1985, AM J MED, V78, P22, DOI 10.1016/0002-9343(85)90241-4	5	303	308	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					180	181		10.1136/bmj.317.7152.180	http://dx.doi.org/10.1136/bmj.317.7152.180			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665898	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000075047800025
J	Colman, JJ; Blake, DR; Rowland, FS				Colman, JJ; Blake, DR; Rowland, FS			Atmospheric residence time of CH3Br estimated from the Junge spatial variability relation	SCIENCE			English	Article							OH	The atmospheric residence time for methyl bromide (CH,Br) has been estimated as 0.8 +/- 0.1 years from its empirical spatial variability relative to C2H6. C2Cl4, CHCl3, and CH3Cl. This evaluation of the atmospheric residence time, based on Junge's 1963 general proposal, provides an estimate for CH3Br that is independent of source and sink estimates. Methyl bromide from combined natural and anthropogenic sources furnishes about half of the bromine that enters the stratosphere, where it plays an important role in ozone destruction. This residence time is consistent with the 0.7-year value recently calculated for CH3Br from the combined strength estimates for its known significant sinks.	Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Colman, JJ (corresponding author), Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA.			Blake, Donald/0000-0002-8283-5014				BAKER MB, 1979, TELLUS, V31, P39, DOI 10.1111/j.2153-3490.1979.tb00880.x; CICERONE RJ, 1997, 1997 METH BROM STAT; DeMore W.B., 1997, CHEM KINETICS PHOTOC; ELLIOTT S, 1993, GEOPHYS RES LETT, V20, P1043, DOI 10.1029/93GL01081; GIBBS AG, 1973, J GEOPHYS RES, V78, P574, DOI 10.1029/JC078i003p00574; HAMRUD M, 1983, TELLUS, V358, P295; JAESCHKE R, 1982, CHEM UNPOLLUTED POLL, P341; Junge C. E., 1963, AIR CHEM RADIOACTIVI, DOI 10.1002/ange.19650770328; JUNGE CE, 1974, TELLUS, V26, P477, DOI 10.1111/j.2153-3490.1974.tb01625.x; King DB, 1997, J GEOPHYS RES-OCEANS, V102, P18715, DOI 10.1029/97JC01214; PRATHER M, 1990, J GEOPHYS RES-ATMOS, V95, P18723, DOI 10.1029/JD095iD11p18723; PRINN RG, 1995, SCIENCE, V269, P187, DOI 10.1126/science.269.5221.187; SHORTER JH, 1995, NATURE, V377, P717, DOI 10.1038/377717a0; Slinn W. G. N., 1988, Tellus, Series B (Chemical and Physical Meteorology), V40B, P229, DOI 10.1111/j.1600-0889.1988.tb00292.x; WANG CJL, 1995, GEOPHYS RES LETT, V22, P1097, DOI 10.1029/95GL01069; YvonLewis SA, 1997, GEOPHYS RES LETT, V24, P1227, DOI 10.1029/97GL01090	16	22	22	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					392	396		10.1126/science.281.5375.392	http://dx.doi.org/10.1126/science.281.5375.392			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665878	Green Submitted			2022-12-28	WOS:000074918800041
J	Monsma, DJ; Vlutters, R; Lodder, JC				Monsma, DJ; Vlutters, R; Lodder, JC			Room temperature - Operating spin-valve transistors formed by vacuum bonding	SCIENCE			English	Article								Functional integration between semiconductors and ferromagnets was demonstrated with the spin-valve transistor. A ferromagnetic multilayer was sandwiched between two device-quality silicon substrates by means of vacuum bonding. The emitter Schottky barrier injected hot electrons into the spin-valve base. The collector Schottky barrier accepts only ballistic electrons, which makes the collector current very sensitive to magnetic fields. Room temperature operation was accomplished by preparing Si-Pt-Co-Cu-Co-Si devices. The vacuum bonding technique allows the realization of many ideas for vertical transport devices and forms a permanent link that is useful in demanding adhesion applications.	Univ Twente, MESA Res Inst, NL-7500 AE Enschede, Netherlands	University of Twente	Monsma, DJ (corresponding author), IBM Corp, Almaden Res, 650 Harry Rd, San Jose, CA 95120 USA.		monsma, douwe/ABH-1609-2020					BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; BELL LD, 1988, PHYS REV LETT, V61, P2368, DOI 10.1103/PhysRevLett.61.2368; Brug JA, 1996, J APPL PHYS, V79, P4491, DOI 10.1063/1.361763; COWLEY AM, 1968, IEEE T ELECTRON DEV, VED15, P761, DOI 10.1109/T-ED.1968.16512; CROWELL CR, 1967, PHYSICS THIN FILMS, V4; Gijs MAM, 1997, ADV PHYS, V46, P285, DOI 10.1080/00018739700101518; Kools JCS, 1996, IEEE T MAGN, V32, P3165, DOI 10.1109/20.508381; Mizushima K, 1997, IEEE T MAGN, V33, P3500, DOI 10.1109/20.619479; MONSMA DJ, 1995, PHYS REV LETT, V74, P5260, DOI 10.1103/PhysRevLett.74.5260; Monsma DJ, 1997, IEEE T MAGN, V33, P3495, DOI 10.1109/20.619478; SHIMATSU T, IN PRESS J VAC SCI A; SZE SM, 1969, PHYSICS SEMICONDUCTO, pCH11	12	193	199	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					407	409		10.1126/science.281.5375.407	http://dx.doi.org/10.1126/science.281.5375.407			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665882	Green Submitted			2022-12-28	WOS:000074918800045
J	Sheldon, TA; Guyatt, GH; Haines, A				Sheldon, TA; Guyatt, GH; Haines, A			Getting-research findings into practice - When to act on the evidence	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL LITERATURE; CLINICAL-TRIALS; USERS GUIDES; ARTICLE; RECOMMENDATIONS; INTERVENTIONS; PREVENTION; POLITICS; POLICY		Univ York, NHS Ctr Reviews & Disseminat, York YO1 5DD, N Yorkshire, England; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biostat, Hamilton, ON L8N 3Z5, Canada; Royal Free Hosp, Sch Med, Dept Primary Care & Populat, London NW3 2PF, England; UCL, Sch Med, London NW3 2PF, England	University of York - UK; McMaster University; McMaster University; McMaster University; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School	Sheldon, TA (corresponding author), Univ York, NHS Ctr Reviews & Disseminat, York YO1 5DD, N Yorkshire, England.	tas5@york.ac.uk	Sheldon, Trevor/AAK-7088-2021	Sheldon, Trevor/0000-0002-7479-5913; Haines, Andy/0000-0002-8053-4605				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BAILEY KR, 1994, CONTROL CLIN TRIALS, V15, P15, DOI 10.1016/0197-2456(94)90024-8; Bauman KE, 1997, AM J PUBLIC HEALTH, V87, P666, DOI 10.2105/AJPH.87.4.666; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; COWAN CD, 1994, CONTROL CLIN TRIALS, V15, P24, DOI 10.1016/0197-2456(94)90025-6; DAVEYSMITH G, 1993, BRIT MED J, V306, P1367; DAVIDOFF F, 1995, BRIT MED J, V310, P1122; DAVIS CE, 1994, CONTROL CLIN TRIALS, V15, P11, DOI 10.1016/0197-2456(94)90023-X; *DEP HLTH, 1996, NHS EX GUID PURCH IM; DIAMOND GA, 1993, ANN INTERN MED, V118, P455, DOI 10.7326/0003-4819-118-6-199303150-00010; Dowie J, 1996, J Health Serv Res Policy, V1, P104; ENTWISTLE V, 1998, IN PRESS INT J TECHN; GLASZIOU PP, 1995, BRIT MED J, V311, P356; Gotzsche PC, 1996, INT J TECHNOL ASSESS, V12, P238, DOI 10.1017/S0266462300009594; Green SB, 1997, AM J PUBLIC HEALTH, V87, P541, DOI 10.2105/AJPH.87.4.541; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; HAMMOND KR, 1983, TECHNOL FORECAST SOC, V24, P287, DOI 10.1016/0040-1625(83)90001-X; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615; Liddle J., 1996, METHOD EVALUATING RE; Mahon J, 1996, BRIT MED J, V312, P1069; Marchioli R, 1996, ARCH INTERN MED, V156, P1158, DOI 10.1001/archinte.156.11.1158; MATERSON BJ, 1982, JAMA-J AM MED ASSOC, V248, P1996; Mays N, 1996, QUALITATIVE RES HLTH; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; *NHS, 1995, EFF HLTH CAR B, V9; *NHS, 1996, 4 NHS CRD U YORK; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; Pearson TA, 1997, JAMA-J AM MED ASSOC, V277, P1320, DOI 10.1001/jama.277.16.1320; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SMITH GD, 1994, BMJ-BRIT MED J, V308, P72, DOI 10.1136/bmj.308.6921.72; Tanenbaum SJ, 1996, HEALTH SERV RES, V31, P517; TANENBAUM SJ, 1994, J HEALTH POLIT POLIC, V19, P27, DOI 10.1215/03616878-19-1-27; THORNTON JG, 1995, BRIT MED J, V310, P791, DOI 10.1136/bmj.310.6982.791; WALLEY T, 1995, BRIT MED J, V311, P796, DOI 10.1136/bmj.311.7008.796; WARLOW C, 1997, STROKE MODULE COCHRA; WITTES RE, 1987, STAT MED, V6, P269, DOI 10.1002/sim.4780060312	40	48	49	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					139	142		10.1136/bmj.317.7151.139	http://dx.doi.org/10.1136/bmj.317.7151.139			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105PE	9657797	Green Published, Green Accepted			2022-12-28	WOS:000075081700031
J	Duarte, CM; Agusti, S				Duarte, CM; Agusti, S			The CO2 balance of unproductive aquatic ecosystems	SCIENCE			English	Article							ORGANIC-CARBON; WATERS; LAKES	Community respiration (R) rates are scaled as the two-thirds power of the gross primary production (P) rates of aquatic ecosystems, indicating that the role of aquatic biota as carbon dioxide sources or sinks depends on its productivity. Unproductive aquatic ecosystems support a disproportionately higher respiration rate than that. of productive aquatic ecosystems, tend ro be heterotrophic (R > P), and act as carbon dioxide sources. The average P required for aquatic ecosystems to become autotrophic (P > R) is over an order of magnitude greater For marshes than for the open sea. Although four-fifths of the upper ocean is expected to be nee heterotrophic, this carbon demand can be balanced by the excess production over the remaining one-fifth of the ocean.	CSIC, Ctr Estudios Avanzados Blanes, Blanes 17300, Girona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centre d'Estudis Avancats de Blanes (CEAB)	Duarte, CM (corresponding author), CSIC, Ctr Estudios Avanzados Blanes, Cami Santa Barbara S-N, Blanes 17300, Girona, Spain.		Agusti, Susana/H-8421-2012; Duarte Quesada, Carlos Manuel/ABD-6208-2021; Duarte, Carlos M/A-7670-2013; Agusti, Susana/G-2864-2017	Duarte, Carlos M/0000-0002-1213-1361; Agusti, Susana/0000-0003-0536-7293				Bauer JE, 1998, NATURE, V392, P482, DOI 10.1038/33122; BERHENFELD MJ, 1997, LIMNOL OCEANOGR, V42, P1; Broecker WS, 1991, GLOBAL BIOGEOCHEM CY, V5, P191, DOI 10.1029/91GB01421; COLE JJ, 1994, SCIENCE, V265, P1568, DOI 10.1126/science.265.5178.1568; CORNELL S, 1995, LIMNOL OCEANOGR, V40, P243; Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; DELGIORGIO PA, 1994, LIMNOL OCEANOGR, V39, P772, DOI 10.4319/lo.1994.39.4.0772; delGiorgio PA, 1997, NATURE, V385, P148, DOI 10.1038/385148a0; DELGIORGIO PA, 1997, NATURE, V388, P133; GELDER RJ, 1997, NATURE, V388, P132; HEIKES B, 1996, J GEOPHYS RES, V101, P15741; Heip CHR, 1995, OCEANOGR MAR BIOL, V33, P1; JORGENSEN BB, 1977, LIMNOL OCEANOGR, V22, P814; Kemp WM, 1997, MAR ECOL PROG SER, V150, P229, DOI 10.3354/meps150229; Kirchman DL, 1997, NATURE, V385, P121, DOI 10.1038/385121a0; LEGENDRE L, 1995, OPHELIA, V41, P153, DOI 10.1080/00785236.1995.10422042; LONGHURST A, 1995, J PLANKTON RES, V17, P1245, DOI 10.1093/plankt/17.6.1245; Schlesinger WH., 1998, BIOGEOCHEMISTRY ANAL, V73, P353, DOI 10.1016/0016-7037(92)90106-s; SLEGENTHALER U, 1993, NATURE, V365, P119; SMITH SV, 1993, REV GEOPHYS, V31, P75, DOI 10.1029/92RG02584; Watson RT, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P1	21	276	285	0	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					234	236		10.1126/science.281.5374.234	http://dx.doi.org/10.1126/science.281.5374.234			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657712				2022-12-28	WOS:000074714200041
J	Goldhaber, SZ				Goldhaber, SZ			Medical progress - Pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; TOTAL HIP-REPLACEMENT; ACTIVATED PROTEIN-C; FACTOR-V LEIDEN; IDIOPATHIC VENOUS THROMBOEMBOLISM; EXTERNAL PNEUMATIC COMPRESSION; PROBABILITY LUNG-SCAN; COAGULATION-FACTOR-V; CASE-FATALITY RATES		Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Goldhaber, SZ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.							ALLENBY F, 1973, LANCET, V2, P1412; ALVING BM, 1992, AM J OBSTET GYNECOL, V167, P1184, DOI 10.1016/S0002-9378(12)90409-3; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; BARRITT DW, 1960, LANCET, V1, P1309; Bergqvist D, 1997, BRIT J SURG, V84, P1099; Bergqvist D, 1996, NEW ENGL J MED, V335, P696, DOI 10.1056/NEJM199609053351002; BERGQVIST D, 1985, BRIT J SURG, V72, P105, DOI 10.1002/bjs.1800720211; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; BONE RC, 1993, ARCH INTERN MED, V153, P2621; Bounameaux H, 1997, QJM-INT J MED, V90, P437, DOI 10.1093/qjmed/90.7.437; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; Bussey HI, 1996, J THROMB THROMBOLYS, V2, P315, DOI [10.1007/BF01061919, DOI 10.1007/BF01061919]; CALLANDER N, 1993, WESTERN J MED, V158, P364; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P235; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; COME PC, 1992, CHEST, V101, pS151, DOI 10.1378/chest.101.4_Supplement.151S; COMEROTA AJ, 1992, AM J SURG, V164, P265, DOI 10.1016/S0002-9610(05)81083-9; COMP PC, 1986, BLOOD, V68, P881; Dahl OE, 1997, THROMB HAEMOSTASIS, V77, P26; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DAngelo A, 1997, BLOOD, V90, P1; Daniels LB, 1997, AM J CARDIOL, V80, P184, DOI 10.1016/S0002-9149(97)00315-9; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; DEMOERLOOSE P, 1994, THROMB HAEMOSTASIS, V72, P89; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; ELLIOTT CG, 1992, CHEST, V101, pS163, DOI 10.1378/chest.101.4.163S; FARLEY TMM, 1995, LANCET, V346, P1582; Farmer RDT, 1997, LANCET, V349, P83, DOI 10.1016/S0140-6736(96)07496-X; Fava M, 1997, J VASC INTERV RADIOL, V8, P261, DOI 10.1016/S1051-0443(97)70552-9; FEDULLO PF, 1995, CURRENT MED, V3; Ferrari E, 1997, CHEST, V111, P537, DOI 10.1378/chest.111.3.537; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; GOLDHABER SZ, 1993, PREVENTION VENOUS TH; Goodman LR, 1996, RADIOLOGY, V199, P25, DOI 10.1148/radiology.199.1.8633154; GOTTSCHALK A, 1993, J NUCL MED, V34, P1119; GREENFIELD LJ, 1993, J VASC SURG, V18, P450, DOI 10.1016/0741-5214(93)90263-L; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; GULBA DC, 1994, LANCET, V343, P576, DOI 10.1016/S0140-6736(94)91523-7; GUYTON DP, 1988, SURG GYNECOL OBSTET, V166, P338; HALKIN H, 1982, ANN INTERN MED, V96, P561, DOI 10.7326/0003-4819-96-5-561; Harrison L, 1997, ANN INTERN MED, V126, P133, DOI 10.7326/0003-4819-126-2-199701150-00006; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; Heit JA, 1997, THROMB HAEMOSTASIS, V77, P32; HIRSCH DR, 1995, JAMA-J AM MED ASSOC, V274, P335, DOI 10.1001/jama.274.4.335; Hirsch DR, 1996, AM HEART J, V131, P1145, DOI 10.1016/S0002-8703(96)90089-7; Hirsh J, 1997, ARCH INTERN MED, V157, P2174, DOI 10.1001/archinte.157.19.2174; HOEK JA, 1992, THROMB HAEMOSTASIS, V67, P28; HUBER O, 1992, ARCH SURG-CHICAGO, V127, P310; HUGHES GRV, 1993, LANCET, V342, P341, DOI 10.1016/0140-6736(93)91477-4; HULL RD, 1990, JAMA-J AM MED ASSOC, V263, P2313, DOI 10.1001/jama.263.17.2313; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; HULL RD, 1995, ARCH INTERN MED, V155, P1845; Hunt BJ, 1997, THROMB HAEMOSTASIS, V77, P39; Jardin F, 1997, CHEST, V111, P209, DOI 10.1378/chest.111.1.209; Jerjes-Sanchez, 1995, J Thromb Thrombolysis, V2, P227; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; KAKKAR VV, 1975, LANCET, V2, P674; Kasper W, 1997, J AM COLL CARDIOL, V30, P1165, DOI 10.1016/S0735-1097(97)00319-7; Kasper W, 1997, HEART, V77, P346, DOI 10.1136/hrt.77.4.346; Kessler CM, 1996, BLOOD COAGUL FIBRIN, V7, P437, DOI 10.1097/00001721-199606000-00002; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; Koning R, 1997, CIRCULATION, V96, P2498, DOI 10.1161/01.CIR.96.8.2498; Konstantinides S, 1997, CIRCULATION, V96, P882; Koonin L M, 1991, MMWR CDC Surveill Summ, V40, P1; Layish DT, 1997, CHEST, V111, P218, DOI 10.1378/chest.111.1.218; Leclerc JR, 1998, ARCH INTERN MED, V158, P873, DOI 10.1001/archinte.158.8.873; Leclerc JR, 1996, ANN INTERN MED, V124, P619, DOI 10.7326/0003-4819-124-7-199604010-00001; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LEVINE MN, 1994, ARCH INTERN MED, V154, P49, DOI 10.1001/archinte.154.1.49; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; Levine MN, 1996, ARCH INTERN MED, V156, P851, DOI 10.1001/archinte.156.8.851; MAGNANI HN, 1993, THROMB HAEMOSTASIS, V70, P1072; MAGNANI HN, 1993, THROMB HAEMOSTASIS, V70, P554; McConnell MV, 1996, AM J CARDIOL, V78, P469, DOI 10.1016/S0002-9149(96)00339-6; Meaney JFM, 1997, NEW ENGL J MED, V336, P1422, DOI 10.1056/NEJM199705153362004; Mikkola KM, 1997, AM HEART J, V134, P69, DOI 10.1016/S0002-8703(97)70108-X; Moll S, 1997, ANN INTERN MED, V127, P177, DOI 10.7326/0003-4819-127-3-199708010-00001; MOSER KM, 1994, JAMA-J AM MED ASSOC, V271, P1908; MOSER KM, 1994, JAMA-J AM MED ASSOC, V271, P223, DOI 10.1001/jama.271.3.223; Nass N, 1997, CIRCULATION, V96, P136; Nicolaides AN, 1997, INT ANGIOL, V16, P3; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; OLIVIERI O, 1995, BRIT J HAEMATOL, V91, P465, DOI 10.1111/j.1365-2141.1995.tb05323.x; Pacouret G, 1997, ARCH INTERN MED, V157, P305, DOI 10.1001/archinte.157.3.305; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; PALLA A, 1983, AM J ROENTGENOL, V141, P513, DOI 10.2214/ajr.141.3.513; PARMET JL, 1993, LANCET, V341, P1057, DOI 10.1016/0140-6736(93)92414-O; Piccioli A, 1996, AM HEART J, V132, P850, DOI 10.1016/S0002-8703(96)90321-X; Planes A, 1996, LANCET, V348, P224, DOI 10.1016/S0140-6736(96)01453-5; POULTER NR, 1995, LANCET, V346, P1575; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; Price DT, 1997, ANN INTERN MED, V127, P895, DOI 10.7326/0003-4819-127-10-199711150-00007; RASCHKE RA, 1993, ANN INTERN MED, V119, P874, DOI 10.7326/0003-4819-119-9-199311010-00002; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RemyJardin M, 1996, RADIOLOGY, V200, P699, DOI 10.1148/radiology.200.3.8756918; Ribeiro A, 1997, AM HEART J, V134, P479, DOI 10.1016/S0002-8703(97)70085-1; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Ridker PM, 1997, CIRCULATION, V95, P1777; Robinson KS, 1997, ANN INTERN MED, V127, P439, DOI 10.7326/0003-4819-127-6-199709150-00004; Rosing J, 1997, BRIT J HAEMATOL, V97, P233, DOI 10.1046/j.1365-2141.1997.192707.x; Schulman S, 1997, NEW ENGL J MED, V336, P393, DOI 10.1056/NEJM199702063360601; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Schwarz RP, 1997, CLIN APPL THROMB-HEM, V3, P1, DOI 10.1177/107602969700300101; Siddique RM, 1996, ARCH INTERN MED, V156, P2343, DOI 10.1001/archinte.156.20.2343; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; Simioni P, 1996, THROMB HAEMOSTASIS, V76, P187; Simioni P, 1996, THROMB HAEMOSTASIS, V76, P883; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; SKIBO L, 1995, CARDIOPULMONARY DIS, V3; Stannard J P, 1996, Am J Orthop (Belle Mead NJ), V25, P127; Stein PD, 1996, CHEST, V109, P78, DOI 10.1378/chest.109.1.78; STEIN PD, 1991, CHEST, V100, P598, DOI 10.1378/chest.100.3.598; STEIN PD, 1992, CIRCULATION, V85, P462, DOI 10.1161/01.CIR.85.2.462; STEIN PD, 1995, CHEST, V107, P139, DOI 10.1378/chest.107.1.139; STEIN PD, 1992, AM J CARDIOL, V69, P1239, DOI 10.1016/0002-9149(92)90944-T; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; tenCate JW, 1997, NEW ENGL J MED, V337, P657; Toglia MR, 1996, NEW ENGL J MED, V335, P108, DOI 10.1056/NEJM199607113350207; Turkstra F, 1997, ANN INTERN MED, V126, P775, DOI 10.7326/0003-4819-126-10-199705150-00005; vandenBelt AGM, 1997, ARCH INTERN MED, V157, P2227, DOI 10.1001/archinte.157.19.2227; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; Vandenbroucke JP, 1996, LANCET, V348, P972, DOI 10.1016/S0140-6736(05)64918-5; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Warkentin TE, 1997, ANN INTERN MED, V127, P804, DOI 10.7326/0003-4819-127-9-199711010-00005; Warkentin TE, 1996, TRANSFUS MED REV, V10, P249, DOI 10.1016/S0887-7963(96)80001-0; Warkentin TE, 1996, AM J MED, V101, P502, DOI 10.1016/S0002-9343(96)00258-6; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; Weitz JI, 1997, NEW ENGL J MED, V337, P1567; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008; WHITE RH, 1989, ANN INTERN MED, V111, P730, DOI 10.7326/0003-4819-111-9-730; Whitehill T A, 1996, Semin Vasc Surg, V9, P59; ZOLLER B, 1994, J CLIN INVEST, V94, P2521, DOI 10.1172/JCI117623	142	381	399	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1998	339	2					93	104		10.1056/NEJM199807093390207	http://dx.doi.org/10.1056/NEJM199807093390207			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY828	9654541				2022-12-28	WOS:000074665300007
J	Gillett, G				Gillett, G			Justice and health care in a caring society	BRITISH MEDICAL JOURNAL			English	Article									Univ Otago, Otago Med Sch, Dept Neurosurg, Dunedin, New Zealand	University of Otago	Gillett, G (corresponding author), Univ Otago, Otago Med Sch, Dept Neurosurg, POB 913, Dunedin, New Zealand.							*HLTH DIS COMM OFF, 1998, CANT HLTH LTD; Rawls John, 1971, THEORY JUSTICE, P78	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					53	54		10.1136/bmj.317.7150.53	http://dx.doi.org/10.1136/bmj.317.7150.53			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105PD	9651275	Green Published			2022-12-28	WOS:000075081600030
J	Plamping, D				Plamping, D			Change and resistance to change in the NHS	BRITISH MEDICAL JOURNAL			English	Article									Kings Fund, Urban Hlth Partnership, Primary Care Grp, London W1M 0AN, England		Plamping, D (corresponding author), Kings Fund, Urban Hlth Partnership, Primary Care Grp, London W1M 0AN, England.							AMBROSE P, 1996, REA COST POOR HOMES; [Anonymous], HIGH TECHNOLOGY MED; Beck Ulrich., 1992, RISK SOC NEW MODERNI; Bunker BB., 1997, LARGE GROUP INTERVEN; COCHRANE AL, 1991, EFFECTIVENESS EFFICI; *DEP HLTH, 1998, OUR HLTH NAT CONTR H; *DHSS WORK GROUP, 1980, BLACK REP; Popay J, 1996, SOC SCI MED, V42, P759, DOI 10.1016/0277-9536(95)00341-X; PRATT J, IN PRESS BR J HLTH C; PRATT J, IN PRESS WORKING WHO; *SECR STAT HLTH, 1997, CMND3807	11	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					69	71		10.1136/bmj.317.7150.69	http://dx.doi.org/10.1136/bmj.317.7150.69			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651280	Green Published			2022-12-28	WOS:000075081600036
J	Grinspoon, S; Corcoran, C; Askari, H; Schoenfeld, D; Wolf, L; Burrows, B; Walsh, M; Hayden, D; Parlman, K; Anderson, E; Basgoz, N; Klibanski, A				Grinspoon, S; Corcoran, C; Askari, H; Schoenfeld, D; Wolf, L; Burrows, B; Walsh, M; Hayden, D; Parlman, K; Anderson, E; Basgoz, N; Klibanski, A			Effects of androgen administration in men with the AIDS wasting syndrome - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						HIV wasting syndrome; acquired immunodeficiency syndrome; hypergonadism; testosterone; body composition	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MEGESTROL-ACETATE; BODY-COMPOSITION; HYPOGONADAL MEN; MUSCLE MASS; LEAN BODY; TESTOSTERONE; DISORDERS; CACHEXIA; HORMONE	Background: Development of successful anabolic strategies to reverse the loss of lean body mass is of critical importance to increase survival in men with the AIDS wasting syndrome. Hypogonadism, an acquired endocrine deficiency state characterized by loss of testosterone, occurs in more than half of all men with advanced HIV disease. It is unknown whether testosterone deficiency contributes to the profound catabolic state and loss of lean body mass associated with the AIDS wasting syndrome. Objective: To investigate the effects of physiologic testosterone administration on body composition, exercise functional capacity, and quality of life in androgen-deficient men with the AIDS wasting syndrome. Design: Randomized, double-blind, placebo-controlled study. Setting: University medical center. Patients: 51 HIV-positive men (age 42 +/- 8 years) with wasting (body weight < 90% of ideal body weight or weight loss > 10% of baseline weight) and a free testosterone level less than 42 pmol/L (normal range for men 18 to 49 years of age, 42 to 121 pmol/L [12.0 to 35.0 pg/mL]). Intervention: Patients were randomly assigned to receive testosterone enanthate, 300 mg, or placebo intramuscularly every 3 weeks for 6 months. Measurements: Change in fat-free mass was the primary end point. Secondary clinical end points were weight, lean body mass, muscle mass, exercise functional capacity, and change in perceived quality of life. Virologic variables were assessed by CD4 count and viral load. Results: Compared with patients who received placebo, testosterone-treated patients gained fat-free mass (-0.6 kg and 2.0 kg; P = 0.036), lean body mass (0.0 kg and 1.9 kg; P = 0.041), and muscle mass (-0.8 kg and 2.4 kg; P = 0.005). The changes in weight, fat mass, total-body water content, and exercise functional capacity did not significantly differ between the groups. Patients who received testosterone reported benefit from the treatment (P = 0.036), feeling better (P = 0.033), improved quality of life (P = 0.040), and improved appearance (P = 0.021). Testosterone was well tolerated in all patients. Conclusions: Physiologic testosterone administration increases lean body mass and improves quality of life among androgen-deficient men with the AIDS wasting syndrome.	Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA; Boston Vet Affairs Med Ctr, Boston, MA USA; Boston Univ, Med Ctr, Boston, MA USA; Harvard Med Sch, Boston, MA USA; Massachusetts Gen Hosp, Gen Clin Res Ctr, Ctr Biostat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Gen Clin Res Ctr, Nutr Ctr, Boston, MA 02114 USA; Massachusetts Gen Hosp, Wang Ambulatory Care Ctr 128, Phys Therapy Dept, Boston, MA 02114 USA; Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Boston University; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Grinspoon, S (corresponding author), Massachusetts Gen Hosp, Neuroendocrine Unit, Bulfinch 457B,55 Fruit St, Boston, MA 02114 USA.				NCRR NIH HHS [MO1-RR01066] Funding Source: Medline; NIDDK NIH HHS [P32-DK07028, R01-DK49302] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049302, T32DK007028] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXIEVAFIGUSCH J, 1984, EUR J CANCER CLIN ON, V20, P1135, DOI 10.1016/0277-5379(84)90121-4; Bhasin S, 1997, J CLIN ENDOCR METAB, V82, P407, DOI 10.1210/jc.82.2.407; Brodsky IG, 1996, J CLIN ENDOCR METAB, V81, P3469, DOI 10.1210/jc.81.10.3469; CSUKA M, 1985, AM J MED, V78, P77, DOI 10.1016/0002-9343(85)90465-6; DOBS AS, 1988, AM J MED, V84, P611, DOI 10.1016/0002-9343(88)90144-1; Engelson ES, 1996, J ACQ IMMUN DEF SYND, V11, P510, DOI 10.1097/00042560-199604150-00012; FORBES GB, 1956, J CLIN INVEST, V35, P596, DOI 10.1172/JCI103313; Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P4051, DOI 10.1210/jc.81.11.4051; Grinspoon S, 1997, J CLIN ENDOCR METAB, V82, P1332, DOI 10.1210/jc.82.5.1332; GUYATT GH, 1985, J CHRON DIS, V38, P517, DOI 10.1016/0021-9681(85)90035-9; Harris JA., 1919, BIOMETRIC STUDY BASA; HEYMSFIELD SB, 1983, AM J CLIN NUTR, V37, P478, DOI 10.1093/ajcn/37.3.478; Katznelson L, 1996, J CLIN ENDOCR METAB, V81, P4358, DOI 10.1210/jc.81.12.4358; KOHL HW, 1988, AM J EPIDEMIOL, V127, P1228, DOI 10.1093/oxfordjournals.aje.a114915; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; KUSHNER RF, 1986, AM J CLIN NUTR, V44, P417, DOI 10.1093/ajcn/44.3.417; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; MENDEZ J, 1971, AM J CLIN NUTR, V24, P385; Metropolitan Life Insurance Company, 1983, STAT B, V64, P3; MILLER K, 1998, IN PRESS J CLIN ENDO; MORLEY JE, 1979, METABOLISM, V28, P1051, DOI 10.1016/0026-0495(79)90010-6; OSTER MH, 1994, ANN INTERN MED, V121, P400, DOI 10.7326/0003-4819-121-6-199409150-00002; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; RABKIN JG, 1995, AIDS READER      JUL, P136; Schambelan M, 1996, ANN INTERN MED, V125, P873, DOI 10.7326/0003-4819-125-11-199612010-00002; SHILS ME, 1994, MODERN NUTR HLTH DIS, P829; SNYDER PJ, 1980, J CLIN ENDOCR METAB, V51, P1335, DOI 10.1210/jcem-51-6-1335; SPIEKERMAN AM, 1993, CLIN LAB MED, V13, P353, DOI 10.1016/S0272-2712(18)30443-8; SUTTMANN U, 1995, J ACQ IMMUN DEF SYND, V8, P239, DOI 10.1097/00042560-199503010-00004; TENOVER JS, 1992, J CLIN ENDOCR METAB, V75, P1092, DOI 10.1210/jc.75.4.1092; URBAN RJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE820, DOI 10.1152/ajpendo.1995.269.5.E820; VELDHUIS JD, 1993, J CLIN ENDOCR METAB, V76, P587, DOI 10.1210/jcem.76.3.8445014; VONROENN JH, 1994, ANN INTERN MED, V121, P393, DOI 10.7326/0003-4819-121-6-199409150-00001; WACHTEL T, 1992, ANN INTERN MED, V116, P129, DOI 10.7326/0003-4819-116-2-129; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911; 1987, MMWR MORB MORTAL S1, V36, pS3	39	161	168	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					18	+		10.7326/0003-4819-129-1-199807010-00005	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9652995				2022-12-28	WOS:000074513300003
J	Neuschwander-Tetri, BA; Isley, WL; Oki, JC; Ramrakhiani, S; Quiason, SG; Phillips, NJ; Brunt, EM				Neuschwander-Tetri, BA; Isley, WL; Oki, JC; Ramrakhiani, S; Quiason, SG; Phillips, NJ; Brunt, EM			Troglitazone-induced hepatic failure leading to liver transplantation - A case report	ANNALS OF INTERNAL MEDICINE			English	Article								Background: Troglitazone is a new drug for the treatment of type 2 diabetes. Although mild liver injury occurred in 1.9% of participants in controlled trials, the U.S. Food and Drug Administration has received reports of five postmarketing cases of severe liver disease that resulted in death or liver transplantation. Objective: To report the clinical and histopathologic characteristics of a patient with troglitazone-associated severe liver injury leading to transplantation. Design: Case report. Setting: Two university hospitals. Patient: A 55-year-old woman taking troglitazone, 400 mg/d, and insulin, 120 U/d. Intervention: Discontinuation of troglitazone therapy, pretransplantation liver biopsy, and liver transplantation. Results: Early nonspecific symptoms were attributed to other causes and were not evaluated. After the patient had used troglitazone for 3.5 months, massive loss of liver parenchyma and symptoms of liver failure developed, necessitating liver transplantation. Conclusion: Troglitazone may cause subfulminant liver failure.	St Louis Univ, Sch Med, Dept Gastroenterol & Hepatol, St Louis, MO 63110 USA; Univ Missouri, Sch Med, Kansas City, MO 64108 USA; St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Saint Louis University; University of Missouri System; University of Missouri Kansas City; Saint Louis University	Neuschwander-Tetri, BA (corresponding author), St Louis Univ, Sch Med, Dept Gastroenterol & Hepatol, 3635 Vista Ave, St Louis, MO 63110 USA.							Cominacini L, 1997, DIABETOLOGIA, V40, P165, DOI 10.1007/s001250050658; Henry RR, 1997, ENDOCRIN METAB CLIN, V26, P553, DOI 10.1016/S0889-8529(05)70267-X; Imura H, 1998, NEW ENGL J MED, V338, P908, DOI 10.1056/NEJM199803263381311; Inoue I, 1997, BIOCHEM BIOPH RES CO, V235, P113, DOI 10.1006/bbrc.1997.6512; Kumar S, 1996, DIABETOLOGIA, V39, P701; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MISBIN RI, 1998, M FOOD DRUG ADM CARD; *PARK, 1997, PRESCR INF REZ; Spencer CM, 1997, DRUGS, V54, P89, DOI 10.2165/00003495-199754010-00010; Watkins PB, 1998, NEW ENGL J MED, V338, P916, DOI 10.1056/NEJM199803263381314	10	171	173	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					38	41		10.7326/0003-4819-129-1-199807010-00009	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9652998				2022-12-28	WOS:000074513300006
J	Beecham, L				Beecham, L			Tax funded health service works well	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1988	1988						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641962				2022-12-28	WOS:000074636700083
J	Goy, JJ; Eeckhout, E				Goy, JJ; Eeckhout, E			Intracoronary stenting	LANCET			English	Article							SINGLE-CENTER EXPERIENCE; ANGIOGRAPHIC FOLLOW-UP; SAPHENOUS-VEIN GRAFTS; CORONARY-ARTERY STENOSIS; BALLOON-EXPANDABLE-STENT; DIRECTIONAL ATHERECTOMY; ANGIOPLASTY; IMPLANTATION; RESTENOSIS; IMMEDIATE				Goy, JJ (corresponding author), Univ Lausanne Hosp, Div Cardiol, CH-1011 Lausanne, Switzerland.							Antoniucci D, 1998, J AM COLL CARDIOL, V31, P1234, DOI 10.1016/S0735-1097(98)00097-7; BAIM DS, 1997, CIRCULATION, V96, P593; Balcon R, 1997, EUR HEART J, V18, P1536; BARRIGAN P, 1994, CATHET CARDIOVASC DI, V32, P132; BEERTRAND OF, 1997, EUR HEART J, V18, P1385; Berland G, 1997, CATHETER CARDIO DIAG, V40, P337; CARROZZA JP, 1992, J AM COLL CARDIOL, V20, P328, DOI 10.1016/0735-1097(92)90098-8; Cohen EA, 1996, PROG CARDIOVASC DIS, V39, P83, DOI 10.1016/S0033-0620(96)80020-X; Colombo A, 1996, J AM COLL CARDIOL, V28, P830, DOI 10.1016/S0735-1097(96)00266-5; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; COURIER D, 1995, CIRCULATION S, V92, P1; de Jaegere P P, 1996, Semin Interv Cardiol, V1, P233; Debbas NMG, 1996, J INVASIVE CARDIOL, V8, P241; DEBBAS NMG, 1996, ENDOLUMINAL STENTING, V415; deJaegere PP, 1996, J AM COLL CARDIOL, V28, P89, DOI 10.1016/0735-1097(96)00104-0; Edelman ER, 1996, CIRCULATION, V94, P1199, DOI 10.1161/01.CIR.94.6.1199; EECKHOUT E, 1994, AM HEART J, V127, P262, DOI 10.1016/0002-8703(94)90112-0; EECKHOUT E, 1994, CATHETER CARDIO DIAG, V32, P139, DOI 10.1002/ccd.1810320209; EEKHOUT E, 1996, J AM COLL CARDIOL, V27, P757; FENTON SH, 1994, AM J CARDIOL, V74, P1187, DOI 10.1016/0002-9149(94)90545-2; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Garcia E., 1997, European Heart Journal, V18, P350; GOY JJ, 1992, J AM COLL CARDIOL, V19, P1593, DOI 10.1016/0735-1097(92)90623-U; GRUNTZIG A, 1978, LANCET, V1, P263, DOI 10.1016/s0140-6736(78)90500-7; HANEKAMP CEE, 1997, AM J CARDIOL, V80, pS30; Hermiller JB, 1996, AM J CARDIOL, V77, P247, DOI 10.1016/S0002-9149(97)89387-3; Heuser R., 1997, European Heart Journal, V18, P348; Kimura T, 1996, NEW ENGL J MED, V334, P561, DOI 10.1056/NEJM199602293340903; Klugherz BD, 1996, J AM COLL CARDIOL, V27, P1185, DOI 10.1016/0735-1097(95)00574-9; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; Laham RJ, 1996, J AM COLL CARDIOL, V28, P820, DOI 10.1016/S0735-1097(96)00244-6; Macaya C, 1996, J AM COLL CARDIOL, V27, P255, DOI 10.1016/0735-1097(95)00473-4; Mak KH, 1996, J AM COLL CARDIOL, V27, P494, DOI 10.1016/0735-1097(95)00466-1; Moussa I, 1997, J AM COLL CARDIOL, V29, P6, DOI 10.1016/S0735-1097(96)00452-4; Pepine CJ, 1996, J AM COLL CARDIOL, V28, P782; PIANA RN, 1994, J AM COLL CARDIOL, V23, P1296, DOI 10.1016/0735-1097(94)90370-0; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; POMERANTZ RM, 1992, AM J CARDIOL, V70, P161, DOI 10.1016/0002-9149(92)91269-A; POPMA JJ, 1991, CIRCULATION, V84, P1426, DOI 10.1161/01.CIR.84.3.1426; Saito S, 1996, J AM COLL CARDIOL, V28, P74, DOI 10.1016/0735-1097(96)00125-8; SAITO S, 1997, CIRCULATION, V96, P595; Savage MP, 1997, NEW ENGL J MED, V337, P740, DOI 10.1056/NEJM199709113371103; SAVAGE MP, 1994, J AM COLL CARDIOL, V24, P1207, DOI 10.1016/0735-1097(94)90099-X; SCHOMIG A, 1994, CIRCULATION, V90, P2716, DOI 10.1161/01.CIR.90.6.2716; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; Serruys PW, 1996, CIRCULATION, V93, P412, DOI 10.1161/01.CIR.93.3.412; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P70; Sirnes PA, 1996, J AM COLL CARDIOL, V28, P1444, DOI 10.1016/S0735-1097(96)00349-X; Teirstein PS, 1997, NEW ENGL J MED, V336, P1697, DOI 10.1056/NEJM199706123362402; Van Hout B A, 1996, Semin Interv Cardiol, V1, P263; Vrolix M. C., 1997, European Heart Journal, V18, P155; WONG SC, 1995, J AM COLL CARDIOL, V26, P704, DOI 10.1016/0735-1097(95)00217-R	53	24	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1943	1949		10.1016/S0140-6736(98)03084-0	http://dx.doi.org/10.1016/S0140-6736(98)03084-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654278				2022-12-28	WOS:000074464700044
J	Parry, GJ; Gould, CR; McCabe, CJ; Tarnow-Mordi, WO				Parry, GJ; Gould, CR; McCabe, CJ; Tarnow-Mordi, WO		Int Neonatal Network; Scottish Neonatal Consultants Nurses Collabora	Annual league tables of mortality in neonatal intensive care units: longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							LOW-BIRTH-WEIGHT; INSTITUTIONAL PERFORMANCE; STATISTICAL ISSUES; LIMITATIONS; INFANTS; QUALITY; CRIB	Objective: To assess whether crude league tables of mortality and league tables of risk adjusted mortality accurately reflect the performance of hospitals. Design: Longitudinal study of mortality occurring in hospital. Setting: 9 neonatal intensive care units in the United Kingdom. Subjects: 2671 very low birth weight or preterm infants admitted to neonatal intensive care units between 1988 and 1994. Main outcome measures: Crude hospital mortality and hospital mortality adjusted using the clinical risk index for babies (CRIB) score. Results: Hospitals had wide and overlapping confidence intervals when ranked by mortality in annual league tables; this made it impossible to discriminate between hospitals reliably. In most years there was no significant difference between hospitals, only random variation. The apparent performance of individual hospitals fluctuated substantially from year to year. Conclusions: Annual league tables are not reliable indicators of performance or best practice; they do not reflect consistent differences between hospitals. Any action prompted by the annual league tables would have been equally likely to have been beneficial, detrimental, or irrelevant Mortality should be compared between groups of hospitals using specific criteria-such as differences in the volume of patients, staffing policy, training of staff, or aspects of clinical practice-after adjusting for risk. This will produce more reliable estimates with narrower confidence intervals, and more reliable and rapid conclusions.	Univ Sheffield, Sch Hlth & Related Res, Med Care Res Unit, Sheffield S3 7XL, S Yorkshire, England; Sch Hlth & Related Res, Sheffield Hlth Econ Grp, Sheffield, S Yorkshire, England; Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Dundee DD1 9SY, Scotland	University of Sheffield; University of Sheffield; University of Dundee	Parry, GJ (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Med Care Res Unit, Sheffield S3 7XL, S Yorkshire, England.	g.parry@sheffield.ac.uk	Parry, Gareth/CAF-6975-2022		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMITAE P, 1994, STAT METHODS MED RES; Butler R, 1996, J R STAT SOC A STAT, V159, P409; *CLIN OUTC WORK GR, 1994, CLIN OUTC IND; Department of Health, 1991, PAT CHART; Fowlie PW, 1996, ARCH DIS CHILD-FETAL, V75, pF49, DOI 10.1136/fn.75.1.F49; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; Gould C, 1996, BRIT J OBSTET GYNAEC, V103, P534; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HOSMER DW, 1989, APPL LOGISTIC REGRES; *INT NEON NETW, 1993, LANCET, V342, P192; KENDRICK S, 1996, J R STAT SOC A, V159, P433; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; McKee M, 1997, BRIT MED J, V315, P142, DOI 10.1136/bmj.315.7101.142; Pearson G, 1997, LANCET, V349, P1213, DOI 10.1016/S0140-6736(96)12396-5; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X; TarnowMordi W, 1996, ARCH DIS CHILD-FETAL, V74, pF79, DOI 10.1136/fn.74.1.F79-b; TARNOWMORDI W, 1990, BRIT MED J, V300, P1611, DOI 10.1136/bmj.300.6740.1611; TARNOWMORDI W, 1996, J R STAT SOC A, V159, P436; TARNOWMORDI WO, 1997, SEMIN NEONATOL, V2, P171; WHEELER RHB, 1995, ARCH DIS CHILD, V73, pF32; Wise J, 1997, BRIT MED J, V315, P76; YATES DW, 1992, BRIT MED J, V305, P737, DOI 10.1136/bmj.305.6856.737	24	77	78	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1931	1935		10.1136/bmj.316.7149.1931	http://dx.doi.org/10.1136/bmj.316.7149.1931			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641927	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000074636700022
J	Skolbekken, JA				Skolbekken, JA			Communicating the risk reduction achieved by cholesterol reducing drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVENTION; DECISIONS; DISEASE		Univ Tromso, Dept Psychol, N-9037 Tromso, Norway	UiT The Arctic University of Tromso	Skolbekken, JA (corresponding author), Univ Tromso, Dept Psychol, N-9037 Tromso, Norway.	johns@psyk.uit.no						BUCHER HC, 1994, BRIT MED J, V309, P761, DOI 10.1136/bmj.309.6957.761; Calman KC, 1996, BRIT MED J, V313, P799; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; Cranney M, 1996, BRIT J GEN PRACT, V46, P661; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; HEDEVIK I, 1994, TIDSSKR NOR LAERGERF, V114, P1709; HOLLNAGEL H, 1996, PRACTICUS, V116, P237; KJEKSHUS J, 1995, AM J CARDIOL, V76, pC64, DOI 10.1016/S0002-9149(99)80473-1; Lip GYH, 1997, LANCET, V350, P378, DOI 10.1016/S0140-6736(97)22032-5; LUPTON D, 1994, AUST NZ J SOCIOL, V30, P334; MALENKA DJ, 1993, J GEN INTERN MED, V8, P543, DOI 10.1007/BF02599636; Maseri A, 1997, NEW ENGL J MED, V336, P1014, DOI 10.1056/NEJM199704033361409; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; OLIVER M, 1995, BMJ-BRIT MED J, V310, P1280, DOI 10.1136/bmj.310.6990.1280; OLIVER MF, 1992, BMJ-BRIT MED J, V304, P303; PEDERSEN TR, 1994, LANCET, V344, P1383; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Roberts WC, 1996, AM J CARDIOL, V78, P377; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SLOVIC P, 1982, JUDGMENT UNCERTAINTY, P463, DOI DOI 10.1017/CBO9780511809477; *W SCOTL COR PREV, 1996, LANCET, V336, P1339	23	68	68	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 27	1998	316	7149					1956	1958		10.1136/bmj.316.7149.1956	http://dx.doi.org/10.1136/bmj.316.7149.1956			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641937	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000074636700033
J	Bowen, D; Rocheleau, TA; Blackburn, M; Andreev, O; Golubeva, E; Bhartia, R; ffrench-Constant, RH				Bowen, D; Rocheleau, TA; Blackburn, M; Andreev, O; Golubeva, E; Bhartia, R; ffrench-Constant, RH			Insecticidal toxins from the bacterium Photorhabdus luminescens	SCIENCE			English	Article							BACILLUS-THURINGIENSIS; XENORHABDUS; LARVAE; LEPIDOPTERA; HETERORHABDITIDAE; RESISTANCE; NEMATODES; MOTH	Transgenic plants expressing Bacillus thuringiensis (Bt) toxins are currently being deployed for insect control. In response to concerns about Bt resistance, we investigated a toxin secreted by a different bacterium Photorhabdus luminescens, which lives in the gut of entomophagous nematodes. In insects infected by the nematode, the bacteria are released into the insect hemocoel; the insect dies and the nematodes and bacteria replicate in the cadaver. The toxin consists of a series of four native complexes encoded by toxin complex loci tca, tcb, tcc, and tcd. Both tca and tcd encode complexes with high oral toxicity to Manduca sexta and therefore they represent potential alternatives to Bt for transgenic deployment.	Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	ffrench-Constant, RH (corresponding author), Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA.			Bhartia, Rohit/0000-0002-1434-7481; ffrench-Constant, Richard/0000-0001-5385-9888; Blackburn, Michael/0000-0001-5541-4831				AKHURST RJ, 1982, J GEN MICROBIOL, V128, P3061; BANNO Y, 1984, REV INFECT DIS S1, V6, P11; BOWEN D, 1995, THESIS U WISCONSIN M; BOWEN D, IN PRESS APPL ENV MI; CLARKE DJ, 1995, J INVERTEBR PATHOL, V66, P149, DOI 10.1006/jipa.1995.1078; DUNPHY GB, 1988, J GEN MICROBIOL, V134, P1017; DUNPHY GB, 1988, INT J PARASITOL, V18, P729, DOI 10.1016/0020-7519(88)90112-9; ENDO Y, 1980, J INVERTEBR PATHOL, V36, P90, DOI 10.1016/0022-2011(80)90140-8; ENSIGN JC, 1997, Patent No. 17432; GOTZ P, 1981, P R SOC LONDON B, V211, P330; GUINEY D, COMMUNICATION; HOFTE H, 1989, MICROBIOL REV, V53, P242; JOHNSON JL, 1990, CURR MICROBIOL, V20, P397, DOI 10.1007/BF02095867; KHAN A, 1977, J INVERTEBR PATHOL, V29, P253, DOI 10.1016/S0022-2011(77)80030-X; KINSINGER RA, 1979, ANN ENTOMOL SOC AM, V72, P787, DOI 10.1093/aesa/72.6.787; Libby SJ, 1997, INFECT IMMUN, V65, P1786, DOI 10.1128/IAI.65.5.1786-1792.1997; MCGAUGHEY WH, 1985, SCIENCE, V229, P193, DOI 10.1126/science.229.4709.193; McGaughey WH, 1998, NAT BIOTECHNOL, V16, P144, DOI 10.1038/nbt0298-144; PAUL VJ, 1981, J CHEM ECOL, V7, P589, DOI 10.1007/BF00987707; POINAR GO, 1977, NEMATOLOGICA, V23, P97, DOI 10.1163/187529277X00273; PURCELL JP, 1993, BIOCHEM BIOPH RES CO, V196, P1406, DOI 10.1006/bbrc.1993.2409; SCHMIDT TM, 1988, APPL ENVIRON MICROB, V54, P2793, DOI 10.1128/AEM.54.11.2793-2797.1988; SUTTER GR, 1967, J INVERTEBR PATHOL, V9, P90, DOI 10.1016/0022-2011(67)90048-1; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593; YAMANAKA S, 1992, ARCH MICROBIOL, V158, P387; Yu CG, 1997, APPL ENVIRON MICROB, V63, P532, DOI 10.1128/AEM.63.2.532-536.1997	26	335	397	3	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2129	2132		10.1126/science.280.5372.2129	http://dx.doi.org/10.1126/science.280.5372.2129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641921				2022-12-28	WOS:000074435900049
J	Hart, MJ; Jiang, XJ; Kozasa, T; Roscoe, W; Singer, WD; Gilman, AG; Sternweis, PC; Bollag, G				Hart, MJ; Jiang, XJ; Kozasa, T; Roscoe, W; Singer, WD; Gilman, AG; Sternweis, PC; Bollag, G			Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by G alpha(13)	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPASE C-BETA-1; RAS; STATE; IDENTIFICATION; DEACTIVATION; SITE	Signaling pathways that link extracellular factors to activation of the monomeric guanosine triphosphatase (GTPase) Rho control cytoskeletal rearrangements and cell growth. Heterotrimeric guanine nucleotide-binding proteins (G proteins) participate in several of these pathways, although their mechanisms are unclear. The GTPase activities of two G protein alpha subunits, G alpha(12 )and G alpha(13), are stimulated by the Rho guanine nucleotide exchange factor p115 RhoGEF. Activated G alpha(13) bound tightly to p115 RhoGEF and stimulated its capacity to catalyze nucleotide exchange on Rho, In contrast, activated G alpha(12) inhibited stimulation by G alpha(13). Thus, p115 RhoGEF can directly link heterotrimeric G protein a subunits to regulation of Rho.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sternweis, PC (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.	sternwei@utsw.swmed.edu; bollag@onyx-pharm.com		Hart, Matthew/0000-0002-2683-480X	NIGMS NIH HHS [GM 31954, GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM031954, R01GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANEY SA, 1994, J BIOL CHEM, V269, P16541; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HART MJ, UNPUB; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Singer WD, 1996, J BIOL CHEM, V271, P4504; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	30	648	658	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2112	2114		10.1126/science.280.5372.2112	http://dx.doi.org/10.1126/science.280.5372.2112			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641916				2022-12-28	WOS:000074435900044
J	Priscu, JC; Fritsen, CH; Adams, EE; Giovannoni, SJ; Paerl, HW; McKay, CP; Doran, PT; Gordon, DA; Lanoil, BD; Pinckney, JL				Priscu, JC; Fritsen, CH; Adams, EE; Giovannoni, SJ; Paerl, HW; McKay, CP; Doran, PT; Gordon, DA; Lanoil, BD; Pinckney, JL			Perennial Antarctic lake ice: An oasis for life in a polar desert	SCIENCE			English	Article								The permanent ice covers of Antarctic lakes in the McMurdo Dry Valleys develop liquid water inclusions in response to solar heating of internal aeolian-derived sediments. The ice sediment particles serve as nutrient (inorganic and organic)-enriched microzones for the establishment of a physiologically and ecologically complex microbial consortium capable of contemporaneous photosynthesis,.nitrogen fixation, and decomposition. The consortium is capable of physically and chemically establishing and modifying a relatively nutrient- and organic matter-enriched microbial "oasis" embedded in the lake ice cover.	Montana State Univ, Dept Biol Sci, Bozeman, MT 59717 USA; Montana State Univ, Dept Civil Engn, Bozeman, MT 59717 USA; Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA; Univ N Carolina, Inst Marine Sci, Morehead City, NC 28557 USA; NASA, Ames Res Ctr, Div Space Sci, Moffett Field, CA 94035 USA; Univ Illinois, Chicago, IL 60607 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Oregon State University; University of North Carolina; University of North Carolina Chapel Hill; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Priscu, JC (corresponding author), Montana State Univ, Dept Biol Sci, Bozeman, MT 59717 USA.			Lanoil, Brian/0000-0001-8603-8330; Pinckney, James/0000-0002-6056-6511				Adams EE, 1998, ANTARCT RES SER, V72, P281; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; Clow GD, 1988, J CLIMATE, V1, P715, DOI 10.1175/1520-0442(1988)001<0715:COAPSR>2.0.CO;2; FELIP M, 1995, APPL ENVIRON MICROB, V61, P2394, DOI 10.1128/AEM.61.6.2394-2401.1995; FELSENSTEIN J, 1991, PHYLIP; FLETT RJ, 1976, CAN J MICROBIOL, V22, P43, DOI 10.1139/m76-006; FRITSEN CH, 1994, SCIENCE, V266, P782, DOI 10.1126/science.266.5186.782; Fritsen CH, 1998, J PHYCOL, V34, P587, DOI 10.1046/j.1529-8817.1998.340587.x; Fritsen CH, 1998, ANTARCT RES SER, V72, P269; Lane DJ, 1991, NUCL ACID TECHNIQUES, P115, DOI DOI 10.1007/S00227-012-2133-0; MCKAY CP, 1989, REV GEOPHYS, V27, P189, DOI 10.1029/RG027i002p00189; MCKAY CP, 1992, ADV SPACE RES-SERIES, V12, P231, DOI 10.1016/0273-1177(92)90177-Y; MCKAY CP, 1985, NATURE, V313, P561, DOI 10.1038/313561a0; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; PAERL HW, 1979, LIMNOL OCEANOGR, V24, P1166, DOI 10.4319/lo.1979.24.6.1166; Parsons T.R., 1984, MANUAL BIOL CHEM MET; PITCHER DG, 1989, LETT APPL MICROBIOL, V8, P151, DOI 10.1111/j.1472-765X.1989.tb00262.x; Priscu JC, 1997, GLOBAL CHANGE BIOL, V3, P301, DOI 10.1046/j.1365-2486.1997.00147.x; PRISCU JC, UNPUB; REDFIELD AC, 1958, AM SCI, V46, P205; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALKI RK, 1988, SCIENCE, V239, P487; Wing K., 1993, ANTARCT J US, V28, P246	24	282	304	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2095	2098		10.1126/science.280.5372.2095	http://dx.doi.org/10.1126/science.280.5372.2095			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641910				2022-12-28	WOS:000074435900038
J	Stone, EC; Lindsley, DH; Pigott, V; Harbottle, G; Ford, MT				Stone, EC; Lindsley, DH; Pigott, V; Harbottle, G; Ford, MT			From shifting silt to solid stone: The manufacture of synthetic basalt in ancient Mesopotamia	SCIENCE			English	Article								Slabs and fragments of gray-black vesicular "rock," superficially resembling natural basalt but distinctive in chemistry and mineralogy, were excavated at the second-millennium B.C. Mesopotamian city of Mashkan-shapir, about 80 kilometers south of Baghdad, iraq. Most of this material appears to have been deliberately manufactured by the melting and slow cooling of local alluvial silts. The high temperatures (about 1200 degrees C) required and the large volume of material processed indicate an industry in which lithic materials were manufactured ("synthetic basalt") for grinding grain and construction.	SUNY Stony Brook, Dept Anthropol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA; Univ Penn, Museum Archaeol & Anthropol, Museum Appl Sci Ctr Archaeol, Philadelphia, PA 19104 USA; Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA; Alfred Univ, Dept Geol, Alfred, NY 14802 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Pennsylvania; United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; Alfred University	Stone, EC (corresponding author), SUNY Stony Brook, Dept Anthropol, Stony Brook, NY 11794 USA.							Basaltic Volcanism Study Project, 1981, BAS VOLC TERR PLAN; CARTER E, 1993, SUMER, V46, P60; LINDSLEY DH, 1992, AM MINERAL, V77, P987; LOFGREN GE, 1983, J PETROL, V24, P229, DOI 10.1093/petrology/24.3.229; STONE EC, 1990, J FIELD ARCHAEOL, V17, P141, DOI 10.1179/009346990791548376	5	8	11	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2091	2093		10.1126/science.280.5372.2091	http://dx.doi.org/10.1126/science.280.5372.2091			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641908				2022-12-28	WOS:000074435900036
J	Grant, MD; Rudberg, MA; Brody, JA				Grant, MD; Rudberg, MA; Brody, JA			Gastrostomy placement and mortality among hospitalized Medicare beneficiaries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	50th Annual Scientific Meeting of the Gerontological-Society-of-America	NOV 07-18, 1997	CINCINNATI, OHIO	Gerontol Soc Amer			PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; ELDERLY PATIENTS; POPULATION; OUTCOMES; TUBES	Context.-Although the use of feeding tubes among older individuals stirs considerable controversy, population-based descriptive data regarding patient outcomes are scarce. Objective.-To describe hospitalized Medicare beneficiaries having gastrostomies placed and their associated mortality rates. Design.-Retrospective cohort study. Setting and Patients.-Hospitalized Medicare beneficiaries aged 65 years or older discharged in 1991 following gastrostomy placement (excluding individuals in health maintenance organizations). Main Outcome Measures.-Mortality at 30 days, 1 year, and 3 years following gastrostomy and characteristics of individuals undergoing gastrostomy placement. Results.-In 1991, claims reflecting gastrostomy insertion were submitted for 81 105 older Medicare beneficiaries following hospital discharge. The in-hospital mortality rate was 15.3%. Cerebrovascular disease, neoplasms, fluid and electrolyte disorders, and aspiration pneumonia were the most common primary diagnoses, The overall mortality rate at 30 days was 23.9% (95% confidence interval [CI], 23.65%-24.2%), reaching 63.0% (95% CI, 62.7%-63.4%) at 1 year and 81.3% (95% CI, 81.0%-81.5%) by 3 years. One in 131 white and 1 in 58 black Medicare beneficiaries aged 85 years or older was discharged alive or deceased from a hospital in 1991 following gastrostomy placement. Conclusions.-Gastrostomies are frequently placed in older individuals and more often in blacks; mortality rates following placement are substantial.	W Suburban Hosp Family Practice Residency, Oak Pk, IL USA; Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Grant, MD (corresponding author), W Suburban Ctr Primary Care, 7411 W Lake St, River Forest, IL 60305 USA.							AGARWAL N, 1988, AM J CLIN NUTR, V48, P1173, DOI 10.1093/ajcn/48.5.1173; Allison P. D., 1995, SURVIVAL ANAL USING; BERGSTROM LR, 1995, MAYO CLIN PROC, V70, P829; CAMPBELLTAYLOR I, 1987, J AM GERIATR SOC, V35, P1100, DOI 10.1111/j.1532-5415.1987.tb04927.x; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; ELIXHAUSER A, 1994, AHCPR PUBLICATION; Elixhauser A., 1993, AHCPR PUBLICATION; FINUCANE TE, 1995, J AM GERIATR SOC, V43, P447, DOI 10.1111/j.1532-5415.1995.tb05822.x; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; GAINES K, 1995, NEUROEPIDEMIOLOGY, V14, P209, DOI 10.1159/000109798; GAUDERER MWL, 1980, J PEDIATR SURG, V15, P872, DOI 10.1016/S0022-3468(80)80296-X; GRAVES EJ, 1997, VITAL HLTH STAT 13, V130, P124; *HLTH CAR FIN ADM, 1996, HLTH CARE FINANCIN S, P126; IEZZONI LI, 1997, RISK ADJUSTMENT MEAS, P169; KLBFLEISCH JD, 1980, STAT ANAL FAILURE TI; LAUDERDALE DS, 1993, EPIDEMIOL REV, V15, P319, DOI 10.1093/oxfordjournals.epirev.a036123; *NAT HOSP DISCH SU, 1991, VIT HLTH STAT 13, V107, P116; QUILL TE, 1989, ARCH INTERN MED, V149, P1937, DOI 10.1001/archinte.149.9.1937; Rabeneck L, 1996, J GEN INTERN MED, V11, P287, DOI 10.1007/BF02598270; RAHA SK, 1994, AGE AGEING, V23, P162, DOI 10.1093/ageing/23.2.162; *SAS I INC, 1991, SAS STAT SOFTW PHREG; STEINBROOK R, 1988, NEW ENGL J MED, V318, P286, DOI 10.1056/NEJM198802043180505; SULLIVAN DH, 1990, AM J CLIN NUTR, V51, P749, DOI 10.1093/ajcn/51.5.749	23	191	191	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1973	1976		10.1001/jama.279.24.1973	http://dx.doi.org/10.1001/jama.279.24.1973			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU945	9643861				2022-12-28	WOS:000074252100034
J	Carr, A; Samaras, K; Chisholm, DJ; Cooper, DA				Carr, A; Samaras, K; Chisholm, DJ; Cooper, DA			Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance	LANCET			English	Article							RECEPTOR-RELATED PROTEIN; RETINOIC ACID; BINDING PROTEIN; METABOLISM	HIV-1 protease-inhibitor treatments are associated with a syndrome of peripheral lipodystrophy, central adiposity, breast hypertrophy in women, hyperlipidaemia, and insulin resistance. The catalytic region of HIV-1 protease, to which protease inhibitors bind, has approximately 60% homology to regions within two proteins that regulate lipid metabolism: cytoplasmic retinoic-acid binding protein type 1 (CRABP-1) and low density lipoprotein-receptor-related protein (LRP). We hypothesise that protease inhibitors inhibit CRABP-1-modified, and cytochrome P450 3A-mediated synthesis of cis-9-retinoic acid, a key activator of the retinoid X receptor; and peroxisome proliferator activated receptor type gamma (PPAR-gamma) heterodimer, an adipocyte receptor that regulates peripheral adipocyte differentiation and apoptosis. Protease-inhibitor binding to LRP would Impair hepatic chylomicron uptake and triglyceride clearance by the endothelial LRP-lipoprotein lipase complex. The resulting hyperlipidaemia contributes to central fat deposition (and in the breasts in the presence of oestrogen), insulin resistance, and, in susceptible individuals, type 2 diabetes. Understanding the syndrome's pathogenesis should lead to treatment strategies and to the design of protease inhibitors that do not cause this syndrome.	St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia; Garvan Inst Med Res, Div Metab, Sydney, NSW, Australia; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia	St Vincents Hospital Sydney; Garvan Institute of Medical Research; University of New South Wales Sydney; Kirby Institute	Carr, A (corresponding author), St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia.	acarr@stvincents.com.au	Chisholm, Donald J/J-9332-2013	Chisholm, Donald J/0000-0002-5349-5735				Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DESPRES JP, 1995, INT J OBESITY, V19, pS76; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Herry I, 1997, CLIN INFECT DIS, V25, P937, DOI 10.1086/597649; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; JENKINS AB, 1988, J CLIN INVEST, V82, P293, DOI 10.1172/JCI113586; KPRINS JB, 1997, CLIN SCI, V92, P3; Kraegen Edward W., 1997, P305; Li E, 1996, ANNU REV NUTR, V16, P205, DOI 10.1146/annurev.nu.16.070196.001225; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; Pfahl M, 1996, ANNU REV NUTR, V16, P257, DOI 10.1146/annurev.nu.16.070196.001353; RANDLE PJ, 1963, LANCET, V1, P785; Samaras K, 1997, INT J OBESITY, V21, P839, DOI 10.1038/sj.ijo.0800502; THOMPSON JR, 1995, J MOL BIOL, V252, P433, DOI 10.1006/jmbi.1995.0509; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Viraben R, 1998, AIDS, V12, pF37, DOI 10.1097/00002030-199806000-00001; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194	25	853	876	1	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 20	1998	351	9119					1881	1883		10.1016/S0140-6736(98)03391-1	http://dx.doi.org/10.1016/S0140-6736(98)03391-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652687				2022-12-28	WOS:000074347100044
J	Chantler, C; Chantler, S				Chantler, C; Chantler, S			Deception: difficulties and initiatives	BRITISH MEDICAL JOURNAL			English	Article									United Med & Dent Sch Guys & St Thomas Hosp, Guys Hosp, London SE1 9RT, England; Fdn Study Infant Deaths, London SW1X 7DP, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Chantler, S (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Guys Hosp, London SE1 9RT, England.	C.Chantler@kci.ac.uk						DALTON R, 1996, NATURE, V383, pS107; Dyer C, 1998, BRIT MED J, V316, P647; *GEN MED COUNC, 1995, GOOD MED PRACT GUID; Lock S, 1997, J ROY COLL PHYS LOND, V31, P90; LOCK S, 1996, FRAUD MISCONDUCT MED; *ROYAL COLL PHYS, 1991, FRAUD MISC MED RES; Smith R, 1996, BRIT MED J, V312, P789; 1996, LANCET, V347, P843	8	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1731	1732						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9652923				2022-12-28	WOS:000074129500032
J	Dandona, L; Dandona, R; Naduvilath, TJ; McCarty, CA; Nanda, A; Srinivas, M; Mandal, P; Rao, GN				Dandona, L; Dandona, R; Naduvilath, TJ; McCarty, CA; Nanda, A; Srinivas, M; Mandal, P; Rao, GN			Is current eye-care-policy focus almost exclusively on cataract adequate to deal with blindness in India?	LANCET			English	Article							VISUAL-ACUITY; BALTIMORE	Background India's National Programme for Control of Blindness focuses almost exclusively on cataract, based on a national survey done in the 1980s which reported that cataract caused 80% of the blindness in India, No current population-based data on the causes of blindness in India are available, We assessed the rate and causes of blindness in an urban population in southern India. Methods We selected 2954 participants by stratified, random, cluster, systematic sampling from Hyderabad city. Eligible participants were interviewed and given a detailed ocular assessment, including visual acuity, refraction, slitlamp biomicroscopy, applanation intraocular pressure, gonioscopy, dilatation, grading of cataract, stereoscopic fundus assessment, and automated-threshold visual fields. Findings 2522 participants, including 1399 aged 30 years or more, were assessed. 49 participants tall aged greater than or equal to 30 years) were blind (presenting distance visual acuity <6/60 or central visual field <20 degrees in the better eye). The rate of blindness among those aged 30 years or more, adjusted for age and sex, was 3.08% ([95% CI 1.95-4.21]), Causes included cataract (29.7%), retinal disease (17.1%), corneal disease (15.4%), refractive error (12.5%), glaucoma (12.1%), and optic atrophy (11.0%). 15.7% of the blindness caused by visual-field constriction would have been missed without visual-field examination. Also without visual-field and detailed dilated-fundus assessments, blindness attributed to cataract would have been overestimated by up to 75.8%. If the use of cataract surgery in this urban population was half that found in this study, which simulates the situation in rural India, cataract would have caused 51.8% (39.4-64.2) of blindness, significantly less than the 80% accepted by current policy. Interpretation Much of the blindness in this Indian population was due to non-cataract causes. The previous national survey did not include detailed dilated-fundus assessment and visual-field examination which could have led to overestimation of cataract as a cause of blindness in India. Policy-makers in India should encourage well-designed population-based epidemiological studies from which to develop a comprehensive long-term policy on blindness in addition to dealing with cataract.	LV Prasad Eye Inst, Publ Hlth Ophthalmol Serv, Hyderabad 500034, Andhra Pradesh, India; Univ Melbourne, Dept Ophthalmol, Epidemiol Res Unit, Melbourne, Vic, Australia	L. V. Prasad Eye Institute; University of Melbourne	Dandona, L (corresponding author), LV Prasad Eye Inst, Publ Hlth Ophthalmol Serv, Rd 2 Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.			Dandona, Rakhi/0000-0003-0926-788X; McCarty, Catherine/0000-0003-1089-0142; Naduvilath, Thomas/0000-0001-8813-2048				Attebo K, 1996, OPHTHALMOLOGY, V103, P357; BENNETT S, 1991, World Health Statistics Quarterly, V44, P98; CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035; *DAN ASS NAT PROGR, 1997, RAP ASS CAT BLINDN P, P10; Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514; Dandona Lalit, 1998, Indian Journal of Ophthalmology, V46, P93; Dandona Rakhi, 1997, Indian Journal of Ophthalmology, V45, P251; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; *GOV IND DIR GEN H, 1993, PRES STAT NAT PROGR; *HUMPHR INSTR INC, 1974, HUMPHR FIELD AN 2 US; *INT ARM EP STUD G, 1995, OLK, V39, P367; KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310; MOHAN M, 1992, PRESENT STATUS NATL, P79; OLK RJ, 1993, DIABETIC RETINOPATHY, P3; PRADESH A, 1995, CENSUS INDIA 1991; *REG GEN CENS COMM, 1992, CENS IND 1991 FIN PO; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P302; SCHEIE HG, 1957, ARCH OPHTHALMOL-CHIC, V58, P510, DOI 10.1001/archopht.1957.00940010526005; SHAFFER R N, 1960, Trans Am Acad Ophthalmol Otolaryngol, V64, P112; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; Taylor H, 1988, LENS RES, V5, P175; Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; VANHERICK W, 1969, AM J OPHTHALMOL, V68, P626, DOI 10.1016/0002-9394(69)91241-0; *WHO, 1973, INT STAT CLASS DIS R, V518, P10; 1994, HDB STAT HYDERABAD D	27	115	119	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1312	1316		10.1016/S0140-6736(97)09509-3	http://dx.doi.org/10.1016/S0140-6736(97)09509-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643793				2022-12-28	WOS:000073439400008
J	Moschos, M; Droutsas, D				Moschos, M; Droutsas, D			A man who lost weight and his sight	LANCET			English	Article									Univ Athens, Eye Dept, Athens, Greece	National & Kapodistrian University of Athens	Moschos, M (corresponding author), 144 Kauntouriotou, Piraeus 18535, Greece.							Cohen H, 1936, LANCET, V2, P1202; DALLMAN PR, 1960, J PEDIATR-US, V57, P689, DOI 10.1016/S0022-3476(60)80162-X; FOULDS SW, 1969, ARCH OPHTHALMOL-CHIC, V82, P427; STAMBOLIAN D, 1977, AM J OPHTHALMOL, V83, P465, DOI 10.1016/0002-9394(77)90549-9; VALMAN HB, 1974, ARCH DIS CHILD, V49, P932, DOI 10.1136/adc.49.12.932	5	16	16	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1174	1174		10.1016/S0140-6736(97)11074-1	http://dx.doi.org/10.1016/S0140-6736(97)11074-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643689				2022-12-28	WOS:000073220200011
J	Burn, J; Brennan, P; Little, J; Holloway, S; Coffey, R; Somerville, J; Dennis, NR; Allan, L; Arnold, R; Deanfield, JE; Godman, M; Houston, A; Keeton, B; Oakley, C; Scott, O; Silove, E; Wilkinson, J; Pembrey, M; Hunter, AS				Burn, J; Brennan, P; Little, J; Holloway, S; Coffey, R; Somerville, J; Dennis, NR; Allan, L; Arnold, R; Deanfield, JE; Godman, M; Houston, A; Keeton, B; Oakley, C; Scott, O; Silove, E; Wilkinson, J; Pembrey, M; Hunter, AS			Recurrence risks in offspring of adults with major heart defects: results from first cohort of British collaborative study	LANCET			English	Article							SEPTAL-DEFECT; PARENTS; TETRALOGY; CHILDREN; DISEASE	Background Congenital heart defects are generally assumed to have a multifactorial aetiology. We have tested this hypothesis by studying adults with heart defects and their families. Methods We identified 1094 patients who survived surgery for major cardiac defects before 1970. We chose individuals with disturbance of situs or segmental connection, with atrioventricular septal defect or with tetralogy of Fallot. After exclusion and non-participation, 727 individuals were traced. Each was visited by an investigator and completed a detailed questionnaire. If possible, all "normal" offspring were examined by a paediatric cardiologist. Findings The 727 individuals had 393 live offspring. There were 71 miscarriages and five terminated pregnancies. Overall, we found recurrent heart defects in 16 liveborn offspring-a recurrence risk of 4.1%. This result differed significantly from sibling risk (2,1%; p=0.021). More congenital heart defects occurred in the offspring of affected women than in those of affected men (p=0.047); when all malformations (cardiac and non-cardiac) in the offspring were taken into account the excess was more significant (p=0.032). We found an excess of miscarriages in the offspring of affected women (p=0.001). In tetralogy of Fallot, heart defects occured in seven (3.1%) of 223 offspring, 12 (2.2%) of 539 siblings, five (0.3%) of 1575 second-degree relatives, and eight (0.3%) of 2728 third-degree relatives. Interpretation Our findings do not support a polygenic basis for all heart defects. Atrioventricular septal defect seems to be a single-gene defect and tetralogy of Fallot a polygenic disorder with a small number of interacting genes. Our data suggest that isolated transposition of the great arteries is a sporadic defect.	Univ Newcastle Upon Tyne, Dept Human Genet, Newcastle Upon Tyne NE2 4AH, Tyne & Wear, England; Univ Aberdeen, Dept Med & Therapeut, Aberdeen AB9 1FX, Scotland; Western Gen Hosp, Clin Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Inst Child Hlth, Mothercare Unit Clin Genet, London, England; Royal Brompton Hosp, GUCH Unit, London SW3 6LY, England; Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England; Guys Hosp, London SE1 9RT, England; Royal Liverpool Childrens Hosp, Dept Cardiol, Liverpool L7 7DG, Merseyside, England; Great Ormond St Hosp Children, Dept Cardiol, London WC1N 3JH, England; Royal Hosp Sick Children, Dept Cardiol, Edinburgh EH9 1LF, Midlothian, Scotland; Royal Hosp Sick Children, Dept Paediat Cardiol, Glasgow G3 8SJ, Lanark, Scotland; Southampton Gen Hosp, Dept Paediat Cardiol, Southampton SO9 4XY, Hants, England; Hammersmith Hosp, Dept Clin Cardiol, London, England; Killingbeck Hosp, Leeds LS14 6UQ, W Yorkshire, England; Birmingham Childrens Hosp, Dept Paediat Cardiol, Birmingham, W Midlands, England; Royal Childrens Hosp, Dept Cardiol, Melbourne, Vic, Australia; Freeman Rd Hosp, Dept Paediat Cardiol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England	Newcastle University - UK; University of Aberdeen; University of Edinburgh; University of London; University College London; Royal Brompton Hospital; Guy's & St Thomas' NHS Foundation Trust; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Glasgow; University of Southampton; Imperial College London; University of Birmingham; Royal Children's Hospital Melbourne; Newcastle Freeman Hospital; Newcastle University - UK	Burn, J (corresponding author), Univ Newcastle Upon Tyne, Dept Human Genet, Newcastle Upon Tyne NE2 4AH, Tyne & Wear, England.		Deanfield, John E/C-5178-2008; Little, Julian/AAR-6117-2020	Little, Julian/0000-0001-5026-5531; Burn, John/0000-0002-9823-2322; Deanfield, John/0000-0001-8806-6052	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barker DJP, 1992, FETAL INFANT ORIGINS; BURN J, 1979, J MED GENET, V16, P210, DOI 10.1136/jmg.16.3.210; BURN J, 1987, PAEDIAT CARDIOLOGY, P15; CONNOLLY HM, 1994, J AM COLL CARDIOL, V23, P1194, DOI 10.1016/0735-1097(94)90610-6; CZIEZEL A, 1982, BRIT HEART J, V47, P290; DENNIS NR, 1981, J MED GENET, V18, P8, DOI 10.1136/jmg.18.1.8; DRISCOLL DJ, 1993, CIRCULATION, V87, P114; EMANUEL R, 1983, BRIT HEART J, V49, P144; FARRALL M, 1992, AM J HUM GENET, V50, P270; NANCE W E, 1971, Birth Defects Original Article Series, V7, P97; NewburyEcob RA, 1996, J MED GENET, V33, P300, DOI 10.1136/jmg.33.4.300; NORA JJ, 1968, CIRCULATION, V38, P604, DOI 10.1161/01.CIR.38.3.604; NORA JJ, 1987, AM J CARDIOL, V59, P459, DOI 10.1016/0002-9149(87)90956-8; PIERPONT MEM, 1988, AM J CARDIOL, V61, P423, DOI 10.1016/0002-9149(88)90298-6; RISCH N, 1990, AM J HUM GENET, V46, P222; ROSE V, 1985, J AM COLL CARDIOL, V6, P376, DOI 10.1016/S0735-1097(85)80175-3; Ryan AK, 1997, J MED GENET, V34, P798, DOI 10.1136/jmg.34.10.798; Sheffield VC, 1997, HUM MOL GENET, V6, P117, DOI 10.1093/hmg/6.1.117; SUMNER RG, 1967, AM J MED SCI, V254, P266, DOI 10.1097/00000441-196709000-00002; Trainer AH, 1996, ARCH DIS CHILD, V74, P62, DOI 10.1136/adc.74.1.62; WHITTEMORE R, 1994, J AM COLL CARDIOL, V23, P1459, DOI 10.1016/0735-1097(94)90392-1; WHITTEMORE R, 1982, AM J CARDIOL, V50, P361; WILLIAMSON E M, 1969, Journal of Medical Genetics, V6, P255, DOI 10.1136/jmg.6.3.255; WILSON DI, 1992, LANCET, V340, P573, DOI 10.1016/0140-6736(92)92107-Q; WILSON L, 1993, AM J HUM GENET, V53, P1262; WILSON L, 1996, THESIS U NEWCASTLE U; ZELLERS TM, 1990, AM J CARDIOL, V65, P523, DOI 10.1016/0002-9149(90)90825-L; ZETTERQVIST P, 1972, CLIN GENETIC STUDY C	28	236	239	1	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					311	316		10.1016/S0140-6736(97)06486-6	http://dx.doi.org/10.1016/S0140-6736(97)06486-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652610				2022-12-28	WOS:000071864000008
J	Grant, RM; Abrams, DI				Grant, RM; Abrams, DI			Not all is dead in HIV-1 graveyard	LANCET			English	Editorial Material							LYMPHOCYTES		Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA; Univ Calif San Francisco, AIDS Program, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Grant, RM (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA.			Grant, Robert/0000-0002-0851-7085				Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; MCCUNE JM, 1995, CELL, V82, P183, DOI 10.1016/0092-8674(95)90305-4; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	11	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					308	309		10.1016/S0140-6736(05)78343-4	http://dx.doi.org/10.1016/S0140-6736(05)78343-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652607				2022-12-28	WOS:000071864000005
J	Neuberger, J; Adams, D; MacMaster, P; Maidment, A; Speed, M				Neuberger, J; Adams, D; MacMaster, P; Maidment, A; Speed, M			Assessing priorities for allocation of donor liver grafts: survey of public and clinicians	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives: To compare the priorities of the general public, family doctors, and gastroenterologists in allocating donor livers to potential recipients of liver allograft. Design: Representative quota sampling of 1000 members of the general public and 200 family doctors, and a postal questionnaire of 100 gastroenterologists. Subjects: Respondents were given eight hypothetical case histories (based on real patients) and asked to select recipients for four donor livers. Cases were selected to identify controversial areas such as extremes of age, misuse of alcohol, and intravenous drugs. Respondents were also asked to select the least deserving case and which of seven possible factors (time on waiting list, outcome, age, value to society, return to work, precious use of illicit drugs, and involvement of alcohol in the liver damage) should be used to select patients already listed for transplantation. Focus groups were also held to explore farther the reasons for the choices given. Results: There were considerable differences between the three groups in the choice of the recipients. although alcohol use and antisocial behaviour always rated low For selection of recipients the general public thought that, in decreasing order of importance, age, outcome, aid time on the waiting list were the most important factors in selecting recipients; family doctors rated outcome, age, and likely work status after transplantation and the gastroenterologists outcome, work status, and non-involvement of alcohol in the cause of the liver disease as the most important factors. Conclusions: The views of the public are at variance with those of clinicians. Further debate is required to ensure an equitable and appropriate distribution of a scarce resource.	Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, W Midlands, England; MORI, London SE1 0HX, England	University of Birmingham	Neuberger, J (corresponding author), Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, W Midlands, England.	james.neuberger@university-b.umsds.nhs.uk	Neuberger, James/ABG-3010-2020; MAIDMENT, ANDREW/AAH-4946-2019					Ahn JH, 1996, MANAGE SCI, V42, P629, DOI 10.1287/mnsc.42.5.629; ALTMAN LK, 1995, NY TIMES        0815; [Anonymous], 1991, LANCET, V337, P1470; BENJAMIN M, LIVER TRANSPLANT SUR, V3, P337; DIXON J, 1991, LANCET, V337, P891, DOI 10.1016/0140-6736(91)90213-9; EGHTESAD B, 1994, HEPATOLOGY, V20, pS56, DOI 10.1016/0270-9139(94)90274-7; Evans JG, 1997, BRIT MED J, V314, P822, DOI 10.1136/bmj.314.7083.822; FERGUSON M, 1995, ANN INTERN MED, V155, P29; Ferguson ME, 1997, CLIN TRANSPLANT, V11, P49; Harrison S, 1997, BRIT MED J, V314, P970, DOI 10.1136/bmj.314.7085.970; Hauptman PJ, 1997, NEW ENGL J MED, V336, P422, DOI 10.1056/NEJM199702063360607; Lenaghan J, 1997, BRIT MED J, V314, P967, DOI 10.1136/bmj.314.7085.967; Light DW, 1997, BRIT MED J, V315, P112, DOI 10.1136/bmj.315.7100.112; Mullen MA, 1996, CAN MED ASSOC J, V154, P337; Neuberger J, 1997, Liver Transpl Surg, V3, P275, DOI 10.1053/jlts.1997.v3.ajlts0030275; Neuberger J, 1997, BRIT MED J, V314, P1140, DOI 10.1136/bmj.314.7088.1140; Peters TG, 1996, ARCH INTERN MED, V156, P2419, DOI 10.1001/archinte.156.21.2419; Smith R, 1996, BRIT MED J, V312, P1553, DOI 10.1136/bmj.312.7046.1553; Steinbrook R, 1997, NEW ENGL J MED, V336, P436, DOI 10.1056/NEJM199702063360610; Stewart J., 1994, CITIZENS JURIES; Ubel P A, 1997, Liver Transpl Surg, V3, P343; Ubel PA, 1996, MED DECIS MAKING, V16, P234, DOI 10.1177/0272989X9601600307; *UKTSSA, 1996, TRANSPL ACT 1996; *UN NETW ORG SHAR, 1998, ANN REP 1997; Wiesner R H, 1997, Liver Transpl Surg, V3, P231, DOI 10.1053/jlts.1997.v3.ajlts0030231; Williams A, 1997, BRIT MED J, V314, P820, DOI 10.1136/bmj.314.7083.820	26	201	202	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 18	1998	317	7152					172	175		10.1136/bmj.317.7152.172	http://dx.doi.org/10.1136/bmj.317.7152.172			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665895	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000075047800022
J	Aronson, J				Aronson, J			Words - Protean elephants	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					89	89		10.1136/bmj.317.7150.89	http://dx.doi.org/10.1136/bmj.317.7150.89			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651302	Green Published			2022-12-28	WOS:000075081600074
J	Nightingale, SL				Nightingale, SL			Advisory on need for caution with use of vacuum-assisted delivery devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					12	12		10.1001/jama.280.1.12	http://dx.doi.org/10.1001/jama.280.1.12			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660348				2022-12-28	WOS:000074379400006
J	Tabenkin, H; Gross, R; Brammli, S; Shvartzman, P				Tabenkin, H; Gross, R; Brammli, S; Shvartzman, P			Patients' views of direct access to specialists - An Israeli experience	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE; HEALTH-SERVICES; UNITED-STATES; GATEKEEPER; SYSTEMS; SATISFACTION; MEDICINE; COSTS	Context.-Surveys carried out among users of medical services can be a useful tool for health care organizations in designing proper services. Specifically, patients' views of direct access to specialists can be useful to health organizations considering the gatekeeper model. Objective.-To assess patients' opinions about direct access to specialists and referral to specialists through their primary care physician. Design.-An intercept survey, in which patients were interviewed at the randomly selected service provision sites, was carried out in 3 districts in Israel during 1995. A total of 1445 and 1289 patients were interviewed in primary care and specialty clinics, respectively. Setting.-Primary care and specialty clinics in 3 regions in Israel serving 750 000 members of Kupat Holim Clalit, Israel's largest sick fund, Participants.-Hebrew-speaking members of Kupat Holim Clalit who visited the primary care or specialty clinics in the 3 regions during the study period. Main Outcome Measures.-Rate of preferences for direct access to specialists and preferences for referral through primary care physician. Results.-Fifty-two percent of the respondents preferred direct access to specialists, while 48% preferred a referral from their primary care physician, Multivariate logistic regression analysis indicated that the preference for direct access was significantly lower among patients older than 45 years (odds ratio [OR], 0.75; 95% confidence interval [CI], 0.62-0.91); patients whose primary care physician was a specialist in family medicine (OR, 0.80; 95% CI, 0.67-0.97); and patients who were satisfied with their primary care physician (OR, 0.34; 95% CI, 0.27-0.44), Preference for direct access was significantly higher among more highly educated patients (OR, 1.38; 95% CI, 1.16-1.65) and patients residing in Jerusalem (OR, 2.46; 95% CI, 2.05-2.95) and those younger than 45 years who were dissatisfied with their family physician or a primary care physician who was not board certified. If direct access was not available, 33% of respondents would leave the sick fund and 48% would remain; 19% did not know, Conclusions.-Informing sick fund members, particularly the younger and more educated among them, about the advantages of consulting with the primary care physician, as well as providing specialty training in family medicine to primary care physicians, may reduce patients' preference for direct access to specialists.	Haemek Hosp, Dept Family Med, Kupat Holim Clalit No Dist, Afula, Israel; Ben Gurion Univ Negev, Dept Family Med, IL-84105 Beer Sheva, Israel; JDC Brookdale Inst, Jerusalem, Israel	Emek Medical Center; Ben Gurion University	Tabenkin, H (corresponding author), Haemek Med Ctr, Dept Family Med, IL-18101 Afula, Israel.		SHVARTZMAN, PESACH/F-2134-2012					Backstrom C. H., 1981, SURVEY RES; BERTAKIS KD, 1987, J FAM PRACTICE, V24, P305; Bishop CE, 1996, MILBANK Q, V74, P361, DOI 10.2307/3350305; Black F, 1994, Aust Fam Physician, V23, P722; BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; BOERMA GW, 1993, HLTH CARE GEN PRACTI, P9; BUETOW SA, 1995, SOC SCI MED, V40, P21; CALMAN M, 1994, J FAM PRACTICE, V11, P468; CLANCY CM, 1989, ARCH INTERN MED, V149, P917, DOI 10.1001/archinte.149.4.917; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GINSBERG E, 1985, INQUIRY, V22, P272; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRUMBACH K, 1993, NEW ENGL J MED, V328, P940, DOI 10.1056/NEJM199304013281308; KASIRER JP, 1994, NEW ENGL J MED, V331, P151; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; MARTIN DP, 1989, AM J PUBLIC HEALTH, V79, P1628, DOI 10.2105/AJPH.79.12.1628; MOORE SH, 1983, NEW ENGL J MED, V309, P1400, DOI 10.1056/NEJM198312013092239; NEWMAN P, 1995, BRIT MED J, V310, P1652, DOI 10.1136/bmj.310.6995.1652; REAGAN MD, 1987, NEW ENGL J MED, V317, P1173; ROBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835; Rosenthal TC, 1996, J FAM PRACTICE, V42, P362; *ROYAL COLL GEN PR, 1996, NAT GEN PRACT REP WO; SIPS F, 1995, J FAM PRACTICE, V41, P24; SPIEGEL JS, 1983, NEW ENGL J MED, V308, P1208, DOI 10.1056/NEJM198305193082007; STARFIELD B, 1994, JAMA-J AM MED ASSOC, V272, P1903, DOI 10.1001/jama.272.24.1903; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; STARFIELD B, 1992, PRIMARY CONCEPT; STARFIELD B, 1991, JAMA-J AM MED ASSOC, V266, P268; STEIN SR, 1989, SOUTHERN MED J, V82, P3, DOI 10.1097/00007611-198901000-00003; TAYLOR TR, 1989, BRIT MED J, V299, P1323, DOI 10.1136/bmj.299.6711.1323; WACHTER RM, 1995, SOUTHERN MED J, V88, P25, DOI 10.1097/00007611-199501000-00003; WARE J, 1988, QUALITY MED CARE INF; *WORLD BANK, 1993, WORLD DEV REP 1993 I; Yodfat Y, 1994, Harefuah, V126, P361	34	24	25	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1943	1948		10.1001/jama.279.24.1943	http://dx.doi.org/10.1001/jama.279.24.1943			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZU945	9643847				2022-12-28	WOS:000074252100014
J	Mindel, A				Mindel, A			Genital herpes - how much of a public-health problem?	LANCET			English	Article							SIMPLEX VIRUS TYPE-2; RISK-FACTORS; INFECTION; PREVALENCE; TRANSMISSION; VALACICLOVIR; EPIDEMIOLOGY; FAMCICLOVIR; FREQUENCY; ANTIBODY		Sydney Hosp, Acad Unit Sexual Hlth Med, Sydney, NSW 2001, Australia		Mindel, A (corresponding author), Sydney Hosp, Acad Unit Sexual Hlth Med, GPO Box 1614, Sydney, NSW 2001, Australia.	amindel@mail.usyd.edu.au		Mindel, Adrian/0000-0002-8780-9982				Ashley RL, 1997, GENITOURIN MED, V73, P235; BASSETT I, 1994, MED J AUSTRALIA, V160, P697, DOI 10.5694/j.1326-5377.1994.tb125907.x; Brown ZA, 1997, NEW ENGL J MED, V337, P509, DOI 10.1056/NEJM199708213370801; CAMERON DW, 1989, LANCET, V2, P403; CARNEY O, 1993, GENITOURIN MED, V69, P457; *CDCP, 1982, MMWR-MORBID MORTAL W, V31, P137; COREY L, 1994, SEX TRANSM DIS, V21, pS38; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1997, 37 INT C ANT AG CHEM; COWAN FM, 1994, BRIT MED J, V309, P1325, DOI 10.1136/bmj.309.6965.1325; Fairley I, 1997, GENITOURIN MED, V73, P259; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; FORSGREN M, 1994, INT J STD AIDS, V5, P113, DOI 10.1177/095646249400500207; GIBSON JJ, 1990, J INFECT DIS, V162, P306, DOI 10.1093/infdis/162.2.306; *GOV STAT SERV, 1996, SEX TRANSM DIS ENGL, P1; Huerta K, 1996, J ADOLESCENT HEALTH, V18, P384, DOI 10.1016/1054-139X(96)00019-5; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; Langeland N, 1998, INT J STD AIDS, V9, P104, DOI 10.1258/0956462981921765; MEHEUS A, 1983, SEX TRANSM DIS, V10, P33, DOI 10.1097/00007435-198301000-00007; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; MINDEL A, 1995, ANTIVIRAL CHEMOTHERA; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; PERSSON K, 1995, SCAND J INFECT DIS, V27, P195, DOI 10.3109/00365549509019008; Rosenthal SL, 1997, CLIN INFECT DIS, V24, P135, DOI 10.1093/clinids/24.2.135; Sacks SL, 1996, JAMA-J AM MED ASSOC, V276, P44, DOI 10.1001/jama.276.1.44; SMITH J, 1997, HERPES, V4, P55; Spruance SL, 1996, ARCH INTERN MED, V156, P1729, DOI 10.1001/archinte.156.15.1729; TAYAL SC, 1994, INT J STD AIDS, V5, P359, DOI 10.1177/095646249400500514; Thackray AM, 1996, ANTIMICROB AGENTS CH, V40, P846, DOI 10.1128/AAC.40.4.846; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; WHITLEY RJ, 1993, J MED VIROL, P13	34	39	39	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN	1998	351			3			16	18						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV844	9652715				2022-12-28	WOS:000074347300006
J	Burnham, G				Burnham, G			Onchocerciasis	LANCET			English	Article							IVERMECTIN TREATMENT; OCULAR ONCHOCERCIASIS; WEST-AFRICA; IMMUNE RESPONSIVENESS; VOLVULUS ANTIGENS; VISUAL IMPAIRMENT; FOCUS; PATHOGENESIS; PREVALENCE; RESPONSES		Johns Hopkins Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA	Johns Hopkins University	Burnham, G (corresponding author), Johns Hopkins Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	gburnham@jhs.ph.edu						ABIOSE A, 1994, BRIT J OPHTHALMOL, V78, P8, DOI 10.1136/bjo.78.1.8; ABIOSE A, 1993, LANCET, V341, P153; ACKERMAN SJ, 1990, J IMMUNOL, V144, P3961; ALBIEZ EJ, 1985, TROPENMED PARASITOL, V36, P17; ALLEY ES, 1994, T ROY SOC TROP MED H, V88, P581, DOI 10.1016/0035-9203(94)90172-4; AMAZIGO UO, 1994, TROP GEOGR MED, V46, P322; Anderson J, 1977, Trop Dis Bull, V74, P257; AOKI Y, 1983, AM J TROP MED HYG, V32, P741, DOI 10.4269/ajtmh.1983.32.741; ARENA JP, 1994, PARASITOL TODAY, V10, P35, DOI 10.1016/0169-4758(94)90357-3; BLACKLOCK D. B., 1926, ANN TROP MED & PARASITOL, V20, P1; Bradley JE, 1996, ADV PARASIT, V37, P57, DOI 10.1016/S0065-308X(08)60219-5; BRATTIG NW, 1994, J INFECT DIS, V170, P995; BURNHAM G, 1995, AM J TROP MED HYG, V52, P270, DOI 10.4269/ajtmh.52-270; BURNHAM GM, 1991, T ROY SOC TROP MED H, V85, P497, DOI 10.1016/0035-9203(91)90234-P; CHAN CC, 1989, CLIN EXP IMMUNOL, V77, P367; CHAN CC, 1987, OPHTHALMOLOGY, V94, P439; Chandrashekar R, 1996, TROP MED INT HEALTH, V1, P575; COPEMAN DB, 1993, ACTA TROP, V53, P307, DOI 10.1016/0001-706X(93)90036-B; Cousens SN, 1997, B WORLD HEALTH ORGAN, V75, P229; Cupp EW, 1997, J MED ENTOMOL, V34, P87, DOI 10.1093/jmedent/34.2.87; CUPP EW, 1992, AM J TROP MED HYG, V47, P170, DOI 10.4269/ajtmh.1992.47.170; DADZIE KY, 1991, T ROY SOC TROP MED H, V85, P267, DOI 10.1016/0035-9203(91)90051-Y; DUKE BOL, 1993, TROP MED PARASITOL, V44, P61; DUKE BOL, 1992, AM J TROP MED HYG, V46, P189, DOI 10.4269/ajtmh.1992.46.189; DUKE BOL, 1981, ANN SOC BELG MED TR, V61, P179; DUKE BOL, 1966, ANN TROP MED PARASIT, V60, P318, DOI 10.1080/00034983.1966.11686422; DUKE BOL, 1970, T ROY SOC TROP MED H, V64, P791, DOI 10.1016/0035-9203(70)90030-1; DUKE BOL, 1964, ANN TROP MED PARASIT, V58, P83, DOI 10.1080/00034983.1964.11686217; DUKE BOL, 1990, TROP MED PARASITOL, V42, P25; DUKE BOL, 1986, B WORLD HEALTH ORGAN, V39, P137; ELKHALIFA MY, 1991, CLIN EXP IMMUNOL, V86, P433, DOI 10.1111/j.1365-2249.1991.tb02949.x; ERTTMANN KD, 1987, NATURE, V327, P415, DOI 10.1038/327415a0; EVANS TG, 1995, B WORLD HEALTH ORGAN, V73, P495; GREENE BM, 1985, NEW ENGL J MED, V313, P133, DOI 10.1056/NEJM198507183130301; Guderian RH, 1997, T ROY SOC TROP MED H, V91, P315, DOI 10.1016/S0035-9203(97)90089-4; GUILLET P, 1995, B WORLD HEALTH ORGAN, V73, P199; HABBEMA JDF, 1992, PARASITOL TODAY, V8, P99, DOI 10.1016/0169-4758(92)90248-Z; HISSETTE J, 1938, AM J TROP MED HYG, V8, P58; HOWELLS RE, 1987, CIBA F SYMP, V127, P94; Kabore JK, 1996, LANCET, V347, P836, DOI 10.1016/S0140-6736(96)90917-4; Kaiser C, 1996, B WORLD HEALTH ORGAN, V74, P361; Kipp W, 1996, AM J TROP MED HYG, V54, P80, DOI 10.4269/ajtmh.1996.54.80; KIRKWOOD B, 1983, T ROY SOC TROP MED H, V77, P862, DOI 10.1016/0035-9203(83)90308-5; Klager SL, 1996, TROP MED INT HEALTH, V1, P581; LAW PA, IN PRESS AM J TROP M; MACKENZIE CD, 1985, REV INFECT DIS, V7, P802; MARSHALL TFD, 1986, T ROY SOC TROP MED H, V80, P426, DOI 10.1016/0035-9203(86)90333-0; MCCARTHY J, 1994, J INFECT DIS, V170, P734; *MECT DON PROGR, 1997, DON PROGR STAT REP M; Molyneux DH, 1997, PARASITOL TODAY, V13, P418, DOI 10.1016/S0169-4758(97)00142-7; Murdoch IE, 1997, B WORLD HEALTH ORGAN, V75, P141; MURDOCH ME, 1993, BRIT J DERMATOL, V129, P260, DOI 10.1111/j.1365-2133.1993.tb11844.x; NELSON G. S., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P272, DOI 10.1016/0035-9203(58)90087-7; NGOUMOU P, 1994, ANN TROP MED PARASIT, V88, P463, DOI 10.1080/00034983.1994.11812893; O'Neil J., 1875, LANCET, Vi, P265; OTTESEN EA, 1995, J INFECT DIS, V171, P659, DOI 10.1093/infdis/171.3.659; PATTERSON DK, 1978, DIS AFRICAN HIST, P88; Plaisier AP, 1997, B WORLD HEALTH ORGAN, V75, P237; PROST A, 1986, T ROY SOC TROP MED H, V80, P525, DOI 10.1016/0035-9203(86)90129-X; Richards F, 1996, ACTA TROP, V61, P137, DOI 10.1016/0001-706X(95)00116-V; RIDLEY H, 1945, BR J OPHTHALMOL, P5; RODGER F. C., 1959, TRANS ROY SOC TROP MED AND HYG, V53, P138, DOI 10.1016/0035-9203(59)90062-8; Samba E.M., 1994, ONCHOCERCIASIS CONTR; SCHULZ-KEY H, 1986, Parasitology Today, V2, P284, DOI 10.1016/0169-4758(86)90138-9; SHOOP WL, 1993, PARASITOL TODAY, V9, P154, DOI 10.1016/0169-4758(93)90136-4; SMITH RJ, 1988, TROP MED PARASITOL, V39, P634; SOUTHGATE BA, 1987, CIBA F SYMP, V127, P32; STEEL C, 1994, LANCET, V343, P890, DOI 10.1016/S0140-6736(94)90009-4; Strong R. P., 1938, American Journal of Tropical Medicine Baltimore 1 Suppl, V18, P1; Tawill SA, 1996, T ROY SOC TROP MED H, V90, P85, DOI 10.1016/S0035-9203(96)90488-5; TOE L, 1994, AM J TROP MED HYG, V51, P676, DOI 10.4269/ajtmh.1994.51.676; Toe L, 1997, LANCET, V349, P163, DOI 10.1016/S0140-6736(96)05265-8; TSALIKIS G, 1993, HEALTH POLICY PLANN, V8, P349, DOI 10.1093/heapol/8.4.349; VUONG PN, 1988, TROP MED PARASITOL, V39, P235; WADDY BB, 1969, B WORLD HEALTH ORGAN, V40, P843; Whitworth JAG, 1996, TROP MED INT HEALTH, V1, P786; *WHO, 1976, TECH REP SER WHO, V597; *WHO, 1974, ONCH SYMPT PATH DIAG; WHO, 1995, TDRONCHO951 WHO; *WHO, 1995, TECH REP SER WHO, V852; WORKNEH W, 1993, ACTA TROP, V54, P89, DOI 10.1016/0001-706X(93)90054-F; ZIMMERMAN PA, 1994, J INFECT DIS, V169, P686, DOI 10.1093/infdis/169.3.686	82	80	80	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1341	1346		10.1016/S0140-6736(97)12450-3	http://dx.doi.org/10.1016/S0140-6736(97)12450-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643811	hybrid			2022-12-28	WOS:000073439400040
J	Gaston, B; Sears, S; Woods, J; Hunt, J; Ponaman, M; McMahon, T; Stamler, JS				Gaston, B; Sears, S; Woods, J; Hunt, J; Ponaman, M; McMahon, T; Stamler, JS			Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure	LANCET			English	Article							NITRIC-OXIDE; NITROSOGLUTATHIONE	Background Nitric oxide (NO) gas concentrations are high in the expired air of individuals with asthma, but not consistently so in the expired air of people with pneumonia. S-nitrosothiols are naturally occurring bronchodilators, the concentrations of which are raised in the airways of patients with pneumonia. Airway S-nitrosothiols have not been studied in asthma. Methods Tracheal S-nitrosothiol concentrations from eight asthmatic children in respiratory failure were compared with those of 21 children undergoing elective surgery. Results Mean S-nitrosothiol concentrations in asthmatic children were lower than in normal children (65 [SD 45] nmol/L vs 502 [SD 429] nmol/L) and did not vary with inspired oxygen concentration or airway thiol concentration. Interpretation Severe asthma is associated with low concentrations of airway S-nitrosothiols. This is the first reported deficiency of an endogenous bronchodilator in the human asthmatic airway lining fluid, We suggest that S-nitrosothiol metabolism may be a target for the development of new asthma therapies.	Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA; USN, Med Ctr, Dept Pediat, Div Pulm, San Diego, CA 92152 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC USA; Duke Univ, Med Ctr, Dept Med, Durham, NC USA	University of Virginia; United States Department of Defense; United States Navy; Duke University; Howard Hughes Medical Institute; Duke University	Gaston, B (corresponding author), Univ Virginia Hlth Syst, Box 386, Charlottesville, VA 22908 USA.	bmg3g@virginia.edu	McMahon, Tim/K-3986-2012	McMahon, Tim/0000-0002-3404-3223; Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HL52529, HLO2582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052529, K08HL002582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akaike T, 1997, J BIOCHEM-TOKYO, V122, P459; BANNENBERG G, 1995, J PHARMACOL EXP THER, V272, P1238; CLANCY RM, 1992, ANAL BIOCHEM, V204, P365, DOI 10.1016/0003-2697(92)90253-4; FANG K, 1998, IN PRESS AM J RESP C; GASTON B, 1994, J PHARMACOL EXP THER, V268, P978; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gordge MP, 1996, BRIT J PHARMACOL, V119, P533, DOI 10.1111/j.1476-5381.1996.tb15704.x; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; JIA L, 1996, NATURE, V380, P21; Lewis SJ, 1996, EUR J PHARMACOL, V312, pR3, DOI 10.1016/0014-2999(96)00607-3; LEWIS SJ, 1993, AM REV RESPIR DIS, V147, P1461; MASSARO AF, 1995, AM J RESP CRIT CARE, V151, P832; MCANINLY J, 1993, J CHEM SOC CHEM COMM, P1758, DOI 10.1039/c39930001758; MEHTA S, 1997, AM J PHYSIOL, V272, P124; Nelson BV, 1997, J PEDIATR-US, V130, P423, DOI 10.1016/S0022-3476(97)70204-X; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Raghavender B, 1997, J PEDIATR-US, V130, P944, DOI 10.1016/S0022-3476(97)70281-6; RICCIARDOLO F, 1998, IN PRESS LANCET; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; RUTGERS S, 1992, AM J RESP CRIT CARE, V155; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; VANIN AF, 1997, BIOL CHEM, V1, P191; ZEHR BB, 1989, CHEST, V95, P1059, DOI 10.1378/chest.95.5.1059	27	181	187	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 2	1998	351	9112					1317	1319		10.1016/S0140-6736(97)07485-0	http://dx.doi.org/10.1016/S0140-6736(97)07485-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643794				2022-12-28	WOS:000073439400009
J	Nath, I; Reddy, KS; Dinshaw, KA; Bhisey, AN; Krishnaswami, K; Bhan, MK; Ganguly, NK; Kaur, S; Panda, SK; Jameel, S; Srinivasan, K; Thankappan, KR; Valiathan, MS				Nath, I; Reddy, KS; Dinshaw, KA; Bhisey, AN; Krishnaswami, K; Bhan, MK; Ganguly, NK; Kaur, S; Panda, SK; Jameel, S; Srinivasan, K; Thankappan, KR; Valiathan, MS			India	LANCET			English	Article								In the past decade the largest democracy in the world had ended its long love affair with Soviet-style planning and embraced the free market. The returning visitor sees much that has changed-though also much that has not. What has been happening to healthcare and medical research? The Lancet's able and energetic guide in this profile was Indira Nath, immunologist and professor of Biotechnology at the All India Institute of Medical Sciences.	All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, India; All India Inst Med Sci, Dept Cardiol, New Delhi 110029, India; Tata Mem Ctr, Mumbai 400012, Maharashtra, India; Natl Inst Nutr, Hyderabad 500007, Andhra Pradesh, India; All India Inst Med Sci, Dept Paediat, New Delhi 110029, India; Indian Council Med Res, New Delhi 110029, India; Postgrad Inst Med Educ & Res, Chandigarh 160012, India; All India Inst Med Sci, Dept Pathol, New Delhi 110029, India; All India Inst Med Sci, Int Ctr Genet Engn & Biotechnol, New Delhi 110067, India; Populat Fdn India, New Delhi 110016, India; Sree Chitra Tirunal Inst, Trivandrum 695011, Kerala, India; Manipal Acad Higer Educ, Manipal 576119, India; Canc Res Inst, Mumbai 400012, Maharashtra, India	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; Tata Memorial Centre (TMC); Indian Council of Medical Research (ICMR); ICMR - National Institute of Nutrition (NIN); All India Institute of Medical Sciences (AIIMS) New Delhi; Indian Council of Medical Research (ICMR); Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; Department of Science & Technology (India); Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST); Manipal Academy of Higher Education (MAHE)	Nath, I (corresponding author), All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, India.		Thankappan, Kr/ABC-9551-2021	, KR/0000-0002-4536-2684					0	42	42	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1265	1275		10.1016/S0140-6736(98)03010-4	http://dx.doi.org/10.1016/S0140-6736(98)03010-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643763				2022-12-28	WOS:000073283600042
J	Kaski, JC				Kaski, JC			Chest pain and normal coronary arteriograms: role of "microvascular spasm"	LANCET			English	Editorial Material							SYNDROME-X; MYOCARDIAL-ISCHEMIA; ANGINA-PECTORIS; VIEW		St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England	St Georges University London	Kaski, JC (corresponding author), St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England.							CANNON RO, 1992, CIRCULATION, V85, P883, DOI 10.1161/01.CIR.85.3.883; CLARKE JG, 1987, LANCET, V1, P1057; FACTOR SM, 1982, CIRCULATION, V66, P342, DOI 10.1161/01.CIR.66.2.342; HUTCHISON SJ, 1992, QJM, V268, P677; KASKI JC, 1990, CORONARY ARTERY DIS, V1, P660, DOI 10.1097/00019501-199011000-00005; KASKI JC, 1995, J AM COLL CARDIOL, V25, P807, DOI 10.1016/0735-1097(94)00507-M; KASKI JC, 1986, AM J CARDIOL, V58, P1242, DOI 10.1016/0002-9149(86)90390-5; KASKI JC, 1994, ANGINA PECTORIS NORM; KASKI JC, 1981, CIRCULATION, V63, P817; KESSLER KM, 1992, J AM COLL CARDIOL, V19, P32, DOI 10.1016/0735-1097(92)90047-Q; OPHERK D, 1981, CIRCULATION, V63, P817, DOI 10.1161/01.CIR.63.4.817; Panza JA, 1997, J AM COLL CARDIOL, V29, P293, DOI 10.1016/S0735-1097(96)00481-0; Rosano GMC, 1996, EUR HEART J, V17, P1175; WALDENSTROM A, 1992, J INTERN MED, V231, P327, DOI 10.1111/j.1365-2796.1992.tb00940.x; ZEIHER AM, 1995, CIRCULATION, V91, P2345, DOI 10.1161/01.CIR.91.9.2345	15	15	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1144	1145		10.1016/S0140-6736(98)22016-2	http://dx.doi.org/10.1016/S0140-6736(98)22016-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643680				2022-12-28	WOS:000073220200002
J	Parkin, DE				Parkin, DE			Prognostic factors for success of endometrial ablation and resection	LANCET			English	Editorial Material							HYSTERECTOMY; MENORRHAGIA; TRIAL; WOMEN		Aberdeen Royal Infirm, Dept Obstet & Gynaecol, Aberdeen AB25 2ZN, Scotland	University of Aberdeen	Parkin, DE (corresponding author), Aberdeen Royal Infirm, Dept Obstet & Gynaecol, Aberdeen AB25 2ZN, Scotland.							ABRAMOVICH DR, 1995, BRIT J OBSTET GYNAEC, V102, P249; Bhattacharya S, 1997, BRIT J OBSTET GYNAEC, V104, P601, DOI 10.1111/j.1471-0528.1997.tb11540.x; Chullapram T, 1996, OBSTET GYNECOL, V88, P71, DOI 10.1016/0029-7844(96)00085-3; Cooper KG, 1997, BRIT J OBSTET GYNAEC, V104, P1360, DOI 10.1111/j.1471-0528.1997.tb11004.x; Davis JR, 1998, AM J CLIN PATHOL, V109, P96; DWYER N, 1993, BRIT J OBSTET GYNAEC, V100, P237, DOI 10.1111/j.1471-0528.1993.tb15237.x; Gannon MJ, 1996, BRIT J OBSTET GYNAEC, V103, P1029, DOI 10.1111/j.1471-0528.1996.tb09556.x; PINION SB, 1994, BRIT MED J, V309, P979, DOI 10.1136/bmj.309.6960.979	8	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1147	1148		10.1016/S0140-6736(05)79116-9	http://dx.doi.org/10.1016/S0140-6736(05)79116-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643682				2022-12-28	WOS:000073220200004
J	Suhara, T; Sudo, Y; Yoshida, K; Okubo, Y; Fukuda, H; Obata, T; Yoshikawa, K; Suzuki, K; Sasaki, Y				Suhara, T; Sudo, Y; Yoshida, K; Okubo, Y; Fukuda, H; Obata, T; Yoshikawa, K; Suzuki, K; Sasaki, Y			Lung as reservoir for antidepressants in pharmacokinetic drug interactions	LANCET			English	Article							BINDING-SITES; TRICYCLIC ANTIDEPRESSANTS; SEROTONIN TRANSPORTER; H-3 IMIPRAMINE; AMINES; BRAIN; ACCUMULATION; FLUOXETINE; INHIBITION; COCAINE	Background Although high-affinity imipramine binding sites have been reported in both rat and human lung, the role of the lungs in the pharmacokinetics of antidepressants has not received much attention. Substantial accumulation of selective serotonin-reuptake inhibitors (SSRIs) in the lungs has been reported. We have investigated the role of the lungs in pharmacokinetic drug interactions between tricyclic antidepressants and SSRIs. Methods We used a carbon-11-labelled form of the imipramine derivative cyanoimipramine to measure uptake in the lungs and brain of healthy volunteers by positron emission tomography. Clomipramine (50 mg) was administered to measure the effect of antidepressants with high affinity for the serotonin transporter on lung and brain uptake. Findings A large proportion of the injected C-11-cyanoimipramine (68-86% in the four volunteers) was extracted by the lungs. Clomipramine decreased the lung uptake from 68% to 35% and from 81% to 54% in the two volunteers studied. By contrast, whole-brain uptake was low in control studies (1.7-2.0% in three volunteers) and increased after clomipramine administration (to 4.5-4.9%). Plasma radioactivity was also higher after clomipramine than in control studies. Interpretation The lungs may function as a reservoir for antidepressants with high affinity to the serotonin transporter. The accumulated antidepressants may be displaced by other antidepressants, and this displacement would substantially increase plasma concentrations and thus cause toxic effects.	Natl Inst Radiol Sci, Div Adv Technol Med Imaging, Inage Ku, Chiba 263, Japan; Japan Sci & Technol Corp, CREST, Chiba, Japan	National Institutes for Quantum Science & Technology; Japan Science & Technology Agency (JST)	Suhara, T (corresponding author), Natl Inst Radiol Sci, Div Adv Technol Med Imaging, Inage Ku, 9-1 Anagawa 4 Chome, Chiba 263, Japan.	suhara@nirs.go.jp	Obata, Takayuki/AAR-9820-2020	Obata, Takayuki/0000-0001-7678-5033				ANDERSON MW, 1974, J PHARMACOL EXP THER, V189, P456; CATRAVAS JD, 1980, J PHARMACOL EXP THER, V213, P120; DOWNS JM, 1989, AM J PSYCHIAT, V146, P814; HASHIMOTO K, 1987, NUCL MED BIOL, V14, P587; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; IWASAWA Y, 1973, J PHARMACOL EXP THER, V186, P498; JUNOD AF, 1972, J PHARMACOL EXP THER, V183, P182; JUNOD AF, 1975, LUNG METABOLISM, P219; LEMBERGER L, 1985, J CLIN PSYCHIAT, V46, P14; MORIN D, 1984, BIOCHEM BIOPH RES CO, V120, P926, DOI 10.1016/S0006-291X(84)80195-3; PAUL SM, 1980, LIFE SCI, V26, P953, DOI 10.1016/0024-3205(80)90116-2; PISTOLESI M, 1988, AM REV RESPIR DIS, V138, P1429, DOI 10.1164/ajrccm/138.6.1429; RAISMAN R, 1983, EUR J PHARMACOL, V94, P345, DOI 10.1016/0014-2999(83)90426-0; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; SCHLYER DJ, 1992, SYNAPSE, V11, P10, DOI 10.1002/syn.890110103; SHIUE CY, 1995, NUCL MED BIOL, V22, P613, DOI 10.1016/0969-8051(94)00146-B; Suhara T, 1996, Ann Nucl Med, V10, P85; TAYLOR D, 1995, BRIT J PSYCHIAT, V167, P575, DOI 10.1192/bjp.167.5.575; VESTAL RE, 1980, J PHARMACOL EXP THER, V214, P106; WILSON AGE, 1982, DRUG METAB DISPOS, V10, P281; WOLFE J, 1987, J PHARMACOL EXP THER, V241, P196	21	74	76	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					332	335		10.1016/S0140-6736(97)07336-4	http://dx.doi.org/10.1016/S0140-6736(97)07336-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652614				2022-12-28	WOS:000071864000014
J	Horton, R				Horton, R			Vaccines 1997	LANCET			English	Editorial Material																		1990, LANCET REV	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1192	1192		10.1016/S0140-6736(05)63451-4	http://dx.doi.org/10.1016/S0140-6736(05)63451-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652558				2022-12-28	WOS:A1997YD23800007
J	Skuse, D; Bentovim, A; Hodges, J; Stevenson, J; Andreou, C; Lanyado, M; New, M; Williams, B; McMillan, D				Skuse, D; Bentovim, A; Hodges, J; Stevenson, J; Andreou, C; Lanyado, M; New, M; Williams, B; McMillan, D			Risk factors for development of sexually abusive behaviour in sexually victimised adolescent boys: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN	Objective: To identify factors that may increase the risk of a sexually victimised adolescent boy developing sexually abusive behaviour. Design: Sexually victimised boys who had sexually abused other children were compared with sexually victimised boys who had not done so. Setting: Social services departments in south east England were incited to refer sexually abused and sexually abusing boys to a London postgraduate teaching hospital. Subjects: 25 adolescent boys aged between 11 years and 15 years and 11 months. Main outcome measures: Adjusted odds ratios estimated from unconditional logistic regression. Results: Unadjusted odds rations for witnessing (8.1) as well as experiencing (18.0) intrafamilial violence and discontinuity of care (7.2) discriminated boys who had sexually abused from others who were solely victims of sexual abuse. Only the adjusted odds ratios for witnessing intrafamilial violence (39.7) discriminated the two groups. Conclusions: The risk of adolescent boys who have been victims of sexual abuse engaging in sexually abusive behaviour towards other children is increased by life circumstances which may be unrelated directly to the original abusive experience, in particular exposure to a climate of intrafamilial violence. Our findings have implications for the management of boys found to have been sexually abused and raise important questions about the possibility of secondary prevention of subsequent abusive behaviour in those at greatest risk.	Inst Child Hlth, Behav Sci Unit, London WC1N 1EH, England; Great Ormond St Hosp Children NHS Trust, Dept Psychol Med, London WC1N 3JH, England; Univ Southampton, Dept Psychol, Southampton SO17 1RJ, Hants, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Southampton	Skuse, D (corresponding author), Inst Child Hlth, Behav Sci Unit, 30 Guilford St, London WC1N 1EH, England.	dskuse@ich.ucl.ac.uk						ASHER SR, 1986, DEV PSYCHOL, V22, P444, DOI 10.1037/0012-1649.22.4.444; BECK AT, 1987, BECK HOPELESSNESS SC; BEITCHMAN JH, 1992, CHILD ABUSE NEGLECT, V16, P101, DOI 10.1016/0145-2134(92)90011-F; BUSS AH, 1957, J CONSULT PSYCHOL, V21, P343, DOI 10.1037/h0046900; Dhaliwal GK, 1996, CLIN PSYCHOL REV, V16, P619, DOI 10.1016/S0272-7358(96)00018-9; FREEMANLONGO RE, 1986, CHILD ABUSE NEGLECT, V10, P411, DOI 10.1016/0145-2134(86)90017-7; FURMAN W, 1985, DEV PSYCHOL, V21, P1016, DOI 10.1037/0012-1649.21.6.1016; George C., 1985, ADULT ATTACHMENT INT; Glaser B.G., 1965, AWARENESS DYING; GROTH AN, 1982, CRIME DELINQUENCY, V28, P450, DOI 10.1177/001112878202800305; LANYADO M., 1994, J CHILD PSYCHOTHERAP, V20, P283; LANYADO M., 1995, PSYCHOANAL PSYCHOL, V9, P231; OSBORN AF, 1987, SOCIOLOGY, V21, P429, DOI 10.1177/0038038587021003008; PARKHURST JT, 1992, DEV PSYCHOL, V28, P231, DOI 10.1037/0012-1649.28.2.231; Peters S.D., 1986, SOURCEBOOK CHILD SEX, P15; Rutter M, 1994, CHILD ADOL PSYCH CL, P230, DOI 10.1136/bmj.312.7042.1326; Ryan G, 1996, J AM ACAD CHILD PSY, V35, P17, DOI 10.1097/00004583-199601000-00008; RYAN G, 1997, JUVENILE SEXUAL OFFE, P433; TANNER JM, 1989, FOETUS MAN PHYSICAL; WATKINS B, 1992, J CHILD PSYCHOL PSYC, V33, P197, DOI 10.1111/j.1469-7610.1992.tb00862.x; Wechsler D., 1992, WECHSLER INTELLIGENC	21	40	41	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					175	179		10.1136/bmj.317.7152.175	http://dx.doi.org/10.1136/bmj.317.7152.175			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	103FZ	9665896	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000075047800023
J	Berwick, DM				Berwick, DM			Looking forward - The NHS: Feeling well and thriving at 75	BRITISH MEDICAL JOURNAL			English	Article							OUTCOMES		Inst Healthcare Improvement, Boston, MA 02215 USA	Institute for Healthcare Improvement	Berwick, DM (corresponding author), Inst Healthcare Improvement, 135 Francis St, Boston, MA 02215 USA.							BATALDEN PB, 1998, QUAL MANAGE HLTH CAR, V5, P41; Berwick DM, 1998, ANN INTERN MED, V128, P289, DOI 10.7326/0003-4819-128-4-199802150-00008; DEVINE EC, 1992, PATIENT EDUC COUNS, V19, P129, DOI 10.1016/0738-3991(92)90193-M; Gerteis M., 1993, PATIENTS EYES; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Lahdensuo A, 1996, BRIT MED J, V312, P748; MULLEY A, 1996, QUALITY CONNECTION, V5, P5; Nelson EC, 1998, ANN INTERN MED, V128, P460, DOI 10.7326/0003-4819-128-6-199803150-00007; Nolan T.W., 1996, REDUCING DELAYS WAIT; Rogers E., 2003, DIFFUSION INNOVATION, VFifth; *SECR STAT HLTH, 1997, CMND3807; SOBEL DS, 1995, PSYCHOSOM MED, V57, P234, DOI 10.1097/00006842-199505000-00005; Womack J., 1996, LEAN THINKING BANISH	13	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					57	61		10.1136/bmj.317.7150.57	http://dx.doi.org/10.1136/bmj.317.7150.57			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651277	Green Published			2022-12-28	WOS:000075081600033
J	Henry, GL; Melton, DA				Henry, GL; Melton, DA			Mixer, a homeobox gene required for endoderm development	SCIENCE			English	Article							MESSENGER-RNA; XENOPUS EMBRYOS; TGF-BETA; SPEMANNS-ORGANIZER; EXPRESSION; INDUCTION; LAEVIS; MESODERM; SEQUENCE; PROTEINS	An expression cloning strategy in Xenopus laevis was used to isolate a homeobox-containing gene, Mixer, that can cause embryonic cells to form endoderm. Mixer transcripts are found specifically in the prospective endoderm of gastrula, which coincides with the time and place that endodermal cells become histologically distinct and irreversibly determined. Loss-of-function studies with a dominant inhibitory mutant demonstrate that Mixer activity is required for endoderm development. In particular, the expression of Sox17 alpha and Sox17 beta, two previously identified endodermal determinants, require Mixer function. Together, these data suggest that Mixer is an embryonic transcription factor involved in specifying the endodermal germ layer.	Harvard Univ, Dept Mol & Cellular Biol, Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute	Melton, DA (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Howard Hughes Med Inst, 7 Divin Ave, Cambridge, MA 02138 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				BANVILLE D, 1985, NUCLEIC ACIDS RES, V13, P5407, DOI 10.1093/nar/13.15.5407; BAUER DV, 1994, DEVELOPMENT, V120, P1179; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; GAMER LW, 1995, DEV BIOL, V171, P240, DOI 10.1006/dbio.1995.1275; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; GORDON JI, 1983, J BIOL CHEM, V258, P3356; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; HEASMAN J, 1984, CELL, V37, P185, DOI 10.1016/0092-8674(84)90314-3; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; HENRY G, UNPUB; Henry GL, 1996, DEVELOPMENT, V122, P1007; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; Hudson C, 1997, CELL, V91, P397, DOI 10.1016/S0092-8674(00)80423-7; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; KESSLER DA, UNPUB; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KINTNER CR, 1987, DEVELOPMENT, V99, P311; Mead PE, 1996, NATURE, V382, P357, DOI 10.1038/382357a0; Okada T. S., 1954, Memoirs of the College of Science Kyoto, V20B, P157; Okada T. S., 1954, Memoirs of the College of Science Kyoto, V21B, P1; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; Sasai Y, 1996, EMBO J, V15, P4547, DOI 10.1002/j.1460-2075.1996.tb00832.x; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; SMITH JC, 1991, CELL, V71, P731; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; STUTZ F, 1986, J MOL BIOL, V187, P349, DOI 10.1016/0022-2836(86)90438-9; TAKATA CHINAKI, 1960, EMBRYOLOGIA, V5, P38, DOI 10.1111/j.1440-169X.1960.tb00265.x; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WRIGHT CVE, 1988, DEVELOPMENT, V105, P787	35	167	179	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					91	96		10.1126/science.281.5373.91	http://dx.doi.org/10.1126/science.281.5373.91			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651252				2022-12-28	WOS:000074685800044
J	Seidemann, E; Zohary, E; Newsome, WT				Seidemann, E; Zohary, E; Newsome, WT			Temporal gating of neural signals during performance of a visual discrimination task	NATURE			English	Article							AREA MT; FUNCTIONAL-PROPERTIES; RESPONSE PROPERTIES; ATTENTION; MACAQUE; DIRECTION; NEURONS; MONKEY; MICROSTIMULATION; ORGANIZATION	The flow of neural signals within the cerebral cortex must be subject to multiple controls as behaviour unfolds in time. In a visual discrimination task that includes a delay period, the transmission of sensory signals to circuitry that mediates memory, decision-making and motor-planning must be governed closely by 'filtering' or 'gating' mechanisms so that extraneous events occurring before, during or after presentation of the critical visual stimulus have little or no effect on the subject's behavioural responses. Here we study one such mechanism physiologically by applying electrical microstimulation(1-3) to columns of directionally selective neurons in the middle temporal visual area(4-9) at varying times during single trials of a direction-discrimination task. The behavioural effects of microstimulation varied strikingly according to the timing of delivery within the trial, indicating that signals produced by microstimulation may be subject to active 'gating'. Our results show several important features of this gating process: first, signal flow is modulated upwards on onset of the visual stimulus and downwards, typically with a slower time course, after stimulus offset; second, gating efficacy can be modified by behavioural training; and third, gating is implemented primarily downstream of the middle temporal visual area.	Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA; Hebrew Univ Jerusalem, Inst Life Sci, Dept Neurobiol, IL-91904 Jerusalem, Israel	Howard Hughes Medical Institute; Stanford University; Stanford University; Hebrew University of Jerusalem	Seidemann, E (corresponding author), Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA.		Newsome, William T./W-7171-2019	Seidemann, Eyal/0000-0003-2841-5948				ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V51, P16, DOI 10.1152/jn.1984.51.1.16; BAKER JF, 1981, J NEUROPHYSIOL, V45, P397, DOI 10.1152/jn.1981.45.3.397; CORBETTA M, 1991, J NEUROSCI, V11, P2383; CORBETTA M, 1993, J NEUROSCI, V13, P1202; Cox DR., 1970, ANAL BINARY DATA; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DUBNER R, 1971, BRAIN RES, V35, P528, DOI 10.1016/0006-8993(71)90494-X; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1994, J NEUROSCI, V14, P2190; MOUNTCASTLE VB, 1984, DYNAMIC ASPECTS NEOC, P159; MURASUGI CM, 1993, J NEUROSCI, V13, P1719; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; SALZMAN CD, 1994, SCIENCE, V264, P231, DOI 10.1126/science.8146653; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; VANESSEN DC, 1981, J COMP NEUROL, V199, P293, DOI 10.1002/cne.901990302	19	60	60	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					72	75		10.1038/27906	http://dx.doi.org/10.1038/27906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665129				2022-12-28	WOS:000074579600050
J	Beecham, L				Beecham, L			NHS could run out of doctors	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1988	1988						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641962				2022-12-28	WOS:000074636700082
J	Skegg, DCG				Skegg, DCG			Mission-oriented research: A case study	LANCET			English	Editorial Material							RISK; CANCER		Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand	University of Otago	Skegg, DCG (corresponding author), Univ Otago, Dept Prevent & Social Med, POB 913, Dunedin, New Zealand.							Bailar JC, 1997, NEW ENGL J MED, V336, P1569, DOI 10.1056/NEJM199705293362206; BERRY G, 1993, INT J CANCER, V55, P228; Comroe J., 1977, RETROSPECTROSCOPE; FARLEY TMM, 1992, LANCET, V339, P785, DOI 10.1016/0140-6736(92)91904-M; FARLEY TMM, 1995, LANCET, V346, P1582; Lumbiganon P, 1996, BRIT J OBSTET GYNAEC, V103, P909, DOI 10.1111/j.1471-0528.1996.tb09911.x; Mari JD, 1997, BMJ-BRIT MED J, V314, P390, DOI 10.1136/bmj.314.7078.390; MEIRIK O, 1997, HRP ANN TECHN REP 19, P125; MOLLER H, 1994, BRIT MED J, V309, P295, DOI 10.1136/bmj.309.6950.295; PAUL C, 1989, BRIT MED J, V299, P759, DOI 10.1136/bmj.299.6702.759; Poulter NR, 1996, LANCET, V348, P505; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1996, LANCET, V348, P498; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; Rowe PJ, 1997, CONTRACEPTION, V56, P341; SHAABAN M, 1994, CONTRACEPTION, V50, P35; Skegg DCG, 1996, NATURE, V382, P755, DOI 10.1038/382755a0; THOMAS DB, 1991, INT J CANCER, V49, P191; THOMAS DB, 1991, LANCET, V338, P833; THOMAS DB, 1991, INT J CANCER, V49, P186; THOMAS DB, 1991, CONTRACEPTION, V43, P695, DOI 10.1016/0010-7824(91)90010-D; THOMAS DB, 1992, CONTRACEPTION, V45, P299; THOMAS DB, 1991, INT J CANCER, V49, P182	23	0	0	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1952	1954		10.1016/S0140-6736(97)11306-X	http://dx.doi.org/10.1016/S0140-6736(97)11306-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654280				2022-12-28	WOS:000074464700046
J	Woodroffe, R; Ginsberg, JR				Woodroffe, R; Ginsberg, JR			Edge effects and the extinction of populations inside protected areas	SCIENCE			English	Article							YELLOWSTONE GRIZZLY BEARS; SOCIAL-ORGANIZATION; PREY RELATIONSHIPS; SPOTTED HYENA; BLACK BEARS; HOME RANGE; MOVEMENTS; DYNAMICS; ECOLOGY; ALBERTA	Theory predicts that small populations may be driven to extinction by random fluctuations in demography and loss of genetic diversity through drift, However, population size is a poor predictor of extinction in large carnivores inhabiting protected areas. Conflict with people on reserve borders is the major cause of mortality in such populations, so that border areas represent population sinks. The species most likely to disappear from small reserves are those that range widely-and are therefore most exposed to threats on reserve borders-irrespective of population size. Conservation efforts that combat only stochastic processes are therefore unlikely to avert extinction.	Dept Zool, Cambridge CB2 3EJ, England; Wildlife Conservat Soc, Bronx, NY 10460 USA	Wildlife Conservation Society	Woodroffe, R (corresponding author), Dept Zool, Downing St, Cambridge CB2 3EJ, England.	rbw20@cam.ac.uk						Ballard Warren B., 1997, Wildlife Monographs, V135, P1; BALLARD WB, 1987, WILDLIFE MONOGR, P1; BERGER J, 1990, CONSERV BIOL, V4, P91, DOI 10.1111/j.1523-1739.1990.tb00271.x; BININDAEMONDS ORP, UNPUB; BJORGE RR, 1989, CAN FIELD NAT, V103, P327; BLANCHARD BM, 1991, BIOL CONSERV, V58, P41, DOI 10.1016/0006-3207(91)90044-A; Boyd DK, 1995, ECOLOGY CONSERVATION; BRODY AJ, 1989, WILDLIFE SOC B, V17, P5; CAUGHLEY G, 1994, J ANIM ECOL, V63, P215, DOI 10.2307/5542; COX DR, 1990, ANAL BINARY DATA; Creel S, 1997, AFR J ECOL, V35, P83, DOI 10.1111/j.1365-2028.1997.062-89062.x; CREEL SR, 1996, CONS BIOL, V101, P1; DoanCrider DL, 1996, J WILDLIFE MANAGE, V60, P398, DOI 10.2307/3802242; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FERRERAS P, 1992, BIOL CONSERV, V61, P197, DOI 10.1016/0006-3207(92)91116-A; FORBES GJ, 1995, ECOLOGY CONSERVATION; FRANK LG, 1986, ANIM BEHAV, V34, P1500, DOI 10.1016/S0003-3472(86)80220-2; FULLER TK, 1989, WILDLIFE MONOGR, P1; FULLER TK, 1980, J WILDLIFE MANAGE, V44, P583, DOI 10.2307/3808006; GARSHELIS DL, 1981, J WILDLIFE MANAGE, V45, P912, DOI 10.2307/3808099; GARSHELLS DL, 1981, J WILDLIFE MANAGE, V41, P912; Ginsberg J., 1990, FOXES WOLVES JACKALS; GRANT JWA, 1992, BEHAV ECOL SOCIOBIOL, V31, P149; HELLGREN EC, 1989, J WILDLIFE MANAGE, V53, P969, DOI 10.2307/3809597; HOFER H, 1993, ANIM BEHAV, V46, P547, DOI 10.1006/anbe.1993.1222; Hofer Heribert, 1993, Symposia of the Zoological Society of London, V65, P347; IUCN, 1992, PROT AR WORLD REV NA; Jackson P., 1996, BIOL CONSERVATION; JACKSON R, 1989, NATL GEOGR RES, V5, P161; KNICK ST, 1989, WILDLIFE SOC B, V17, P11; KNIGHT RR, 1985, ECOLOGY, V66, P323, DOI 10.2307/1940382; Kruuk H., 1972, SPOTTED HYAENA; KRUUK H, 1972, SPOTTED HAYAENA; LANDE R, 1988, SCIENCE, V241, P1455, DOI 10.1126/science.3420403; MCLELLAN BN, 1989, CAN J ZOOL, V67, P1856, DOI 10.1139/z89-264; NEWMARK WD, 1995, CONSERV BIOL, V9, P512, DOI 10.1046/j.1523-1739.1995.09030512.x; NOVICK HJ, 1982, CALIF FISH GAME, V68, P21; Ontario Trappers Association, 1987, WILD FURBEARER MANAG; Packer C, 1988, REPROD SUCCESS; PEEK JM, 1987, WILDLIFE SOC B, V15, P160; Powell RA, 1996, CONSERV BIOL, V10, P224, DOI 10.1046/j.1523-1739.1996.10010224.x; PURVIS A, 1994, COMP ANAL INDEPENDEN, V2; RABINOWITZ AR, 1986, J ZOOL, V210, P149, DOI 10.1111/j.1469-7998.1986.tb03627.x; RUDNAI J, 1979, AFR J ECOL, V17, P85, DOI 10.1111/j.1365-2028.1979.tb00460.x; SCHALLER GB, 1972, SERGENTEI LION STUDY; SERVHEEN C, 1983, J WILDLIFE MANAGE, V47, P1026, DOI 10.2307/3808161; SILLEROZUBIRI C, 1992, AFR J ECOL, V30, P292, DOI 10.1111/j.1365-2028.1992.tb00505.x; STANDER PE, 1901, MADOUQA, V18, P1; Sunquist ME., 1981, SMITHSON CONTRIB ZOO, DOI DOI 10.5479/SI.00810282.336; Tewes M. E., 1987, WILD FURBEARER MANAG, P697; VANORSDOL KG, 1985, J ZOOL, V206, P97; Venkataraman AB, 1995, J ZOOL, V237, P543, DOI 10.1111/j.1469-7998.1995.tb05014.x; WIELGUS RB, 1994, J WILDLIFE MANAGE, V58, P266, DOI 10.2307/3809390; WIELGUS RB, 1994, BIOL CONSERV, V67, P161, DOI 10.1016/0006-3207(94)90362-X; Woodroffe R., 2013, AFRICAN WILD DOG STA, P7; [No title captured]	56	1108	1165	9	504	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2126	2128		10.1126/science.280.5372.2126	http://dx.doi.org/10.1126/science.280.5372.2126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641920				2022-12-28	WOS:000074435900048
J	Riis, P				Riis, P			Honest advice from Denmark	BRITISH MEDICAL JOURNAL			English	Article									Minist Sci, DK-2900 Hellerup, Denmark		Riis, P (corresponding author), Minist Sci, DK-2900 Hellerup, Denmark.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1733	1733						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9652924				2022-12-28	WOS:000074129500034
J	Moller, N; Orskov, H				Moller, N; Orskov, H			Does IGF-I therapy in insulin-dependent diabetes mellitus limit complications?	LANCET			English	Editorial Material							GROWTH-FACTOR-I; RETINOPATHY; HORMONE				Moller, N (corresponding author), AARHUS UNIV HOSP,INST EXPT CLIN RES,DK-8000 AARHUS C,DENMARK.		Moller, Niels/E-5091-2011	Moller, Niels/0000-0001-5627-7322				AMIEL SA, 1984, DIABETES, V33, P1175, DOI 10.2337/diabetes.33.12.1175; BROWN M, 1994, DIABETIC MED, V11, P182, DOI 10.1111/j.1464-5491.1994.tb02017.x; Flyvbjerg Allan, 1993, P271; Froesch ER, 1996, DIABETES METAB REV, V12, P195, DOI 10.1002/(SICI)1099-0895(199610)12:3<195::AID-DMR164>3.3.CO;2-7; Frystyk J, 1997, J CLIN ENDOCR METAB, V82, P3124, DOI 10.1210/jc.82.9.3124; GRANT MB, 1993, DIABETOLOGIA, V36, P282, DOI 10.1007/BF00400229; HANSEN AP, 1970, DIABETOLOGIA, V6, P27, DOI 10.1007/BF00425888; JABRI N, 1994, DIABETES, V43, P369, DOI 10.2337/diabetes.43.3.369; Janssen JAMJL, 1997, J CLIN ENDOCR METAB, V82, P2809, DOI 10.1210/jc.82.9.2809; LUNDBAEK K, 1976, DIABETES, V25, P845; MERIMEE TJ, 1983, NEW ENGL J MED, V309, P527, DOI 10.1056/NEJM198309013090904; MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877; MOLLER N, 1995, METABOLISM, V44, P33, DOI 10.1016/0026-0495(95)90218-X; SHARP PS, 1987, DIABETOLOGIA, V30, P199, DOI 10.1007/BF00270416; Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706	15	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1188	1189		10.1016/S0140-6736(97)22043-X	http://dx.doi.org/10.1016/S0140-6736(97)22043-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652553				2022-12-28	WOS:A1997YD23800002
J	Westin, S				Westin, S			A great leap for humankind?	BRITISH MEDICAL JOURNAL			English	Article									Norwegian Univ Sci & Technol, Dept Community Med & Gen Practice, Med Tekn Forskningssenter, N-7005 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Westin, S (corresponding author), Norwegian Univ Sci & Technol, Dept Community Med & Gen Practice, Med Tekn Forskningssenter, N-7005 Trondheim, Norway.							Beecham L, 1997, BRIT MED J, V314, P1852; Christie W, 1998, Tidsskr Nor Laegeforen, V118, P1023; Fairfield G, 1997, BRIT MED J, V314, P1895, DOI 10.1136/bmj.314.7098.1895; FRY J, 1995, REVIVING PRIMARY CAR; GoldbeckWood S, 1997, BRIT MED J, V314, P771; Hornblow A, 1997, BRIT MED J, V314, P1892, DOI 10.1136/bmj.314.7098.1892; OLESEN F, 1998, EUR J GEN PRACT, V4, P81; Tudor Hart J, 1994, FEASIBLE SOCIALISM N; Westin S, 1995, FAM PRACT, V12, P394, DOI 10.1093/fampra/12.4.394; WESTIN S, 1998, EUR J GEN PRACT, V4, P53; WHITEHEAD M, 1994, BRIT MED J, V308, P1284, DOI 10.1136/bmj.308.6939.1284	11	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					49	51		10.1136/bmj.317.7150.49	http://dx.doi.org/10.1136/bmj.317.7150.49			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651273	Green Published			2022-12-28	WOS:000075081600028
J	Mandelbrot, L; Le Chenadec, J; Berrebi, A; Bongain, M; Benifla, JL; Delfraissy, JF; Blanche, S; Mayaux, MJ				Mandelbrot, L; Le Chenadec, J; Berrebi, A; Bongain, M; Benifla, JL; Delfraissy, JF; Blanche, S; Mayaux, MJ		French Perinatal Cohort	Perinatal HIV-1 transmission - Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MOTHER-TO-CHILD; CESAREAN-SECTION; INFECTED WOMEN; INFANT; COMPLICATIONS; PREGNANCY; RISK	Context.-It is unclear whether elective cesarean delivery may have a protective effect against the transmission of human immunodeficiency virus 1 (HIV-1). Objective.-To investigate whether mode of delivery has an impact on perinatal HIV-1 transmission in the presence of zidovudine prophylaxis. Design.-A prospective cohort study. Setting.-The 85 perinatal centers in the French Perinatal Cohort, from 1985 to 1996. Patients.-A total of 2834 singleton children born to mothers with HIV-1 infection. Main Outcome Measure.-Human immunodeficiency virus 1 infection of the infant. Results.-No zidovudine was used in 1917 pregnancies and zidovudine prophylaxis was used in 902 pregnancies. Cesarean deliveries were performed in 10.9% on an emergent basis and in 8.3% electively, prior to labor or membrane rupture. In 1917 mothers who did not receive zidovudine, of 1877 with information on mode of delivery, 17.2% transmitted HIV-1 to their child. Risk factors statistically significantly associated with transmission were maternal p24 antigenemia, cervicovaginal infections during pregnancy, amniotic fluid color, and rupture of membranes 4 hours or more before delivery. Mode of delivery was not related to transmission. in 902 mothers receiving zidovudine, transmission was 6.4% in 872 with information on mode of delivery, and elective cesarean delivery (n = 133) was associated with a lower transmission rate than emergent cesarean or vaginal delivery (0.8%, 11.4%, and 6.6%, respectively; P=.002). In a multivariate analysis of all mother-child pairs, including obstetrical risk factors, maternal p24 antigenemia, and zidovudine prophylaxis, interaction between mode of delivery and zidovudine prophylaxis was significant (P=.007). In the multivariate analysis of pregnancies with zidovudine prophylaxis, factors related to transmission rate were maternal p24 antigenemia, amniotic fluid color, and mode of delivery. Adjusted odds ratios (95% confidence intervals) were 1.6 (0.7-3.6) for emergent cesarean delivery and 0.2 (0.0-0.9) for elective cesarean delivery (P =.04) in comparison with vaginal delivery. Conclusions.-We observed an interaction between zidovudine prophylaxis and elective cesarean delivery in decreasing transmission of HIV-1 from mother to child. This observation may have clinical implications for prevention.	Hop Cochin Port Royal, Serv Gynecol Obstet 1, F-75014 Paris, France; INSERM, U149, Paris, France; INSERM, U292, Le Kremlin Bicetre, France; Hop La Grave, Serv Gynecol Obstet, Toulouse, France; Hop Archet 2, Serv Gynecol Obstet, Nice, France; Hop Bichat Claude Bernard, Serv Gynecol Obstet, F-75877 Paris, France; Hop Kremlin Bicetre, Serv Med Interne, Le Kremlin Bicetre, France; Hop Necker Enfants Malad, Serv Pediat, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Mandelbrot, L (corresponding author), Hop Cochin Port Royal, Serv Gynecol Obstet 1, 123 Blvd Port Royal, F-75014 Paris, France.	laurent.mandelbrot@cch.ap-hop-paris.fr	Mandelbrot, Laurent/AAD-3554-2019	Mandelbrot, Laurent/0000-0002-5883-7597				[Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; Biggar RJ, 1997, AIDS, V11, P1375, DOI 10.1097/00002030-199711000-00012; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; BROSSARD Y, 1995, AIDS, V9, P359, DOI 10.1097/00002030-199509040-00007; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; Bulterys M, 1996, AIDS, V10, P923, DOI 10.1097/00002030-199607000-00019; BWAYO J, 1995, AM J OBSTET GYNECOL, V172, P700, DOI 10.1016/0002-9378(95)90597-9; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DUNN DT, 1994, J ACQ IMMUN DEF SYND, V7, P1064; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; HOGBERG U, 1994, OBSTET GYNECOL, V84, P240; Kind C, 1998, AIDS, V12, P205, DOI 10.1097/00002030-199802000-00011; KIND C, 1995, EUR J PEDIATR, V154, P542, DOI 10.1007/s004310050339; Kuhn L, 1997, AIDS, V11, P429, DOI 10.1097/00002030-199704000-00005; KUHN L, 1994, AM J PUBLIC HEALTH, V84, P1110, DOI 10.2105/AJPH.84.7.1110; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; Lin HH, 1996, OBSTET GYNECOL, V87, P244, DOI 10.1016/0029-7844(95)00385-1; LoussertAjaka I, 1997, AIDS, V11, P1575, DOI 10.1097/00002030-199713000-00005; Mandelbrot L, 1996, AM J OBSTET GYNECOL, V175, P661; Mandelbrot L, 1997, AIDS PATIENT CARE ST, V11, P139, DOI 10.1089/apc.1997.11.139; MANDELBROT L, 1997, 1 SEM ANN RECH CLIN, pA42; MAYAUX MJ, 1995, J ACQ IMMUN DEF SYND, V8, P188; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; Mayaux MJ, 1997, J INFECT DIS, V175, P172, DOI 10.1093/infdis/175.1.172; Minkoff H, 1997, AM J OBSTET GYNECOL, V176, P478, DOI 10.1016/S0002-9378(97)70519-2; NAIR P, 1993, J ACQ IMMUN DEF SYND, V6, P298; NEWELL ML, 1994, LANCET, V343, P1464; Newell ML, 1996, AIDS, V10, P1675; Newell ML, 1998, BRIT J OBSTET GYNAEC, V105, P281, DOI 10.1111/j.1471-0528.1998.tb10087.x; ROMERO R, 1988, CLIN OBSTET GYNECOL, V31, P553, DOI 10.1097/00003081-198809000-00006; ROSSI P, 1992, J ACQ IMMUN DEF SYND, V5, P1169; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; SCARAVELLI G, 1995, EUR J OBSTET GYN R B, V62, P7, DOI 10.1016/0301-2115(95)02143-U; SEMPRINI AE, 1995, AIDS, V9, P913, DOI 10.1097/00002030-199508000-00013; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; THOMAS PA, 1994, PEDIATR INFECT DIS J, V13, P489, DOI 10.1097/00006454-199406000-00005; VANDEPERRE P, 1995, AM J OBSTET GYNECOL, V173, P483, DOI 10.1016/0002-9378(95)90270-8	40	202	208	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					55	60		10.1001/jama.280.1.55	http://dx.doi.org/10.1001/jama.280.1.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660364	Bronze			2022-12-28	WOS:000074379400024
J	Coulter, A				Coulter, A			Managing demand - Managing demand at the interface between primary and secondary care	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; REFERRAL PATTERNS; RATES; ADMISSION; DECISION; SURGERY; IMPACT		Kings Fund, Policy & Dev, London WC1M 0AN, England		Coulter, A (corresponding author), Kings Fund, Policy & Dev, London WC1M 0AN, England.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				COULTER A, 1990, BMJ-BRIT MED J, V301, P273, DOI 10.1136/bmj.301.6746.273; Coulter A, 1997, J Health Serv Res Policy, V2, P112; COULTER A, 1994, FAM PRACT, V11, P67, DOI 10.1093/fampra/11.1.67; Coulter A, 1992, HOSP REFERRALS; DEMARCO P, 1993, BRIT MED J, V307, P1465, DOI 10.1136/bmj.307.6917.1465; FERTIG A, 1993, BRIT MED J, V307, P1467, DOI 10.1136/bmj.307.6917.1467; Flood AB, 1996, J GEN INTERN MED, V11, P342, DOI 10.1007/BF02600045; GRACE JF, 1987, FAM PRACT, V4, P170, DOI 10.1093/fampra/4.3.170; KNOTTNERUS JA, 1990, BRIT J GEN PRACT, V40, P178; KUH D, 1995, BRIT MED J, V311, P840, DOI 10.1136/bmj.311.7009.840; LOWY A, 1993, BRIT MED J, V307, P413, DOI 10.1136/bmj.307.6901.413; *NHS CTR REV DISS, 1994, EFF HLTH CAR B NHS, V8; *OFF POP CENS SURV, 1997, LIV BRIT RES 1995 GE; OSWALD N, 1992, HOPS REFERRALS; RINK E, 1993, BRIT MED J, V307, P775, DOI 10.1136/bmj.307.6907.775; Roland M, 1992, HOSP REFERRALS; *ROYAL COLL GEN PR, 1979, MORB STAT GEN PRACT; *SECR STAT HLTH, 1998, CM3807; *SECR STAT HLTH SO, 1987, PROM BETT HLTH GOV P; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; SURENDER R, 1995, BRIT MED J, V311, P1205, DOI 10.1136/bmj.311.7014.1205; WAGNER EH, 1995, MED CARE, V33, P765, DOI 10.1097/00005650-199508000-00002; WILKIN D, 1992, HOSP REFERRALS; Wolf AMD, 1996, ARCH INTERN MED, V156, P1333, DOI 10.1001/archinte.156.12.1333	24	41	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1974	1976		10.1136/bmj.316.7149.1974	http://dx.doi.org/10.1136/bmj.316.7149.1974			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641944	Green Published			2022-12-28	WOS:000074636700039
J	Greenhalgh, T				Greenhalgh, T			The long march	BRITISH MEDICAL JOURNAL			English	Editorial Material													Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088					0	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1989	1989		10.1136/bmj.316.7149.1989	http://dx.doi.org/10.1136/bmj.316.7149.1989			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641963	Green Published			2022-12-28	WOS:000074636700085
J	Braune, S; Wrocklage, C; Raczek, J; Gailus, T; Lucking, CH				Braune, S; Wrocklage, C; Raczek, J; Gailus, T; Lucking, CH			Resting blood pressure increase during exposure to a radio-frequency electromagnetic field	LANCET			English	Article							CARDIOVASCULAR PARAMETERS		Univ Freiburg, Neurol Klin, D-79106 Freiburg, Germany; Deutsch Telekom AG, Technol Zentrum, Darmstadt, Germany	University of Freiburg; Deutsche Telekom AG	Braune, S (corresponding author), Univ Freiburg, Neurol Klin, Hugstetter Str 55, D-79106 Freiburg, Germany.							BENNARROCH EE, 1991, MUSCLE NERVE, V14, P1165; Braune S, 1996, CLIN AUTON RES, V6, P3, DOI 10.1007/BF02291400; Braune S, 1996, J AUTONOM NERV SYST, V60, P103, DOI 10.1016/0165-1838(96)00018-5	3	135	138	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1857	1858		10.1016/S0140-6736(98)24025-6	http://dx.doi.org/10.1016/S0140-6736(98)24025-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652672				2022-12-28	WOS:000074347100015
J	Osterziel, KJ; Strohm, O; Schuler, J; Friedrich, M; Hanlein, D; Willenbrock, R; Anker, SD; Poole-Wilson, PA; Ranke, MB; Dietz, R				Osterziel, KJ; Strohm, O; Schuler, J; Friedrich, M; Hanlein, D; Willenbrock, R; Anker, SD; Poole-Wilson, PA; Ranke, MB; Dietz, R			Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy	LANCET			English	Article							BODY-MASS INDEX; FACTOR-I; SERUM LEVELS; DEFICIENT ADULTS; IGF-I; AGE; VARIABILITY; REPERFUSION; PERFORMANCE; SECRETION	Background Some studies have suggested that treatment with recombinant human growth hormone (rhGH) increases left-ventricular mass and improves haemodynamic and functional status in patients with heart failure due to dilated cardiomyopathy. We did a double-blind, randomised, placebo-controlled study of rhGH in patients with chronic heart failure due to dilated cardiomyopathy. Methods 50 patients (43 men) were randomly allocated treatment with subcutaneous rhGH (2 IU daily) or placebo for a minimum of 12 weeks. The primary endpoints were the effects on left-ventricular mass and systolic wall stress. The secondary endpoints were the effects on left-ventricular size and function. Data were analysed by intention to treat. Findings Patients in the rhGH group had an increase in left-ventricular mass compared with those in the placebo group (27%, p=0.0001). There was no significant difference in left-ventricular systolic wall stress, mean blood pressure, or systemic vascular resistance between the two groups. New York Heart Association functional class, left-ventricular ejection fraction, and distance on the 6 min walking test were unchanged. The change in serum insulin-like growth factor (IGF)-I concentrations (rhGH 77 ng/mL; placebo -19 ng/mL, GH vs placebo p=0.0001) was significantly related to the change in left-ventricular mass (r=0.55, p=0.0001). One patient in the rhGH group was withdrawn at 6 weeks because of worsening heart failure. Interpretation There is a significant increase in left-ventricular mass in patients with dilated cardiomyopathy given rhGH but this is not accompanied by an improvement in clinical status. Changes in left-ventricular mass are related to changes in serum IGF-I concentrations. Whether a longer treatment period would provide clinical benefits and decrease mortality is unknown.	Humboldt Univ, Charite, Max Delbruck Ctr Mol Med, Franz Volhard Klin, D-13122 Berlin, Germany; Humbolt Krankenhaus, Berlin, Germany; Natl Heart & Lung Inst, London, England; Univ Tubingen, Kinderklin, Sekt Padiat Endokrinol, D-72074 Tubingen, Germany	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Imperial College London; Eberhard Karls University of Tubingen	Osterziel, KJ (corresponding author), Humboldt Univ, Charite, Max Delbruck Ctr Mol Med, Franz Volhard Klin, Wiltbergstr 50,Campus Berlin Buch, D-13122 Berlin, Germany.		Schuler, Jochen/J-7892-2012; Friedrich, Matthias/H-8474-2015	Friedrich, Matthias/0000-0003-1204-5647				Anker SD, 1997, CIRCULATION, V96, P526; ARTS T, 1982, AM J PHYSIOL, V243, pH379, DOI 10.1152/ajpheart.1982.243.3.H379; Batista RJV, 1996, J CARDIAC SURG, V11, P96, DOI 10.1111/j.1540-8191.1996.tb00019.x; BESHYAH SA, 1994, EUR J ENDOCRINOL, V130, P451, DOI 10.1530/eje.0.1300451; Blum W., 1996, DIAGNOSTICS ENDOCRIN, P190; BLUM WF, 1993, J CLIN ENDOCR METAB, V76, P1610, DOI 10.1210/jc.76.6.1610; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; BUSER PT, 1989, J AM COLL CARDIOL, V13, P1294, DOI 10.1016/0735-1097(89)90304-5; CELNIKER AC, 1989, J CLIN ENDOCR METAB, V68, P469, DOI 10.1210/jcem-68-2-469; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Cittadini A, 1996, CIRCULATION, V93, P800, DOI 10.1161/01.CIR.93.4.800; Cittadini A, 1997, J AM COLL CARDIOL, V29, P1109, DOI 10.1016/S0735-1097(97)00010-7; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; DONALDSON DL, 1989, J PEDIATR-US, V115, P51, DOI 10.1016/S0022-3476(89)80328-2; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; Fazio S, 1996, NEW ENGL J MED, V334, P809, DOI 10.1056/NEJM199603283341301; FRUSTACI A, 1992, AM J CLIN PATHOL, V97, P503, DOI 10.1093/ajcp/97.4.503; GERMAIN P, 1992, EUR HEART J, V13, P1011, DOI 10.1093/oxfordjournals.eurheartj.a060307; Giustina A, 1996, AM HEART J, V131, P620, DOI 10.1016/S0002-8703(96)90552-9; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Johannsson G, 1996, J CLIN ENDOCR METAB, V81, P1575, DOI 10.1210/jc.81.4.1575; JUUL A, 1994, CLIN ENDOCRINOL, V41, P85, DOI 10.1111/j.1365-2265.1994.tb03788.x; JUUL A, 1995, J CLIN ENDOCR METAB, V80, P2534, DOI 10.1210/jc.80.8.2534; KATZ J, 1988, RADIOLOGY, V169, P495, DOI 10.1148/radiology.169.2.2971985; LEVIN HR, 1995, CIRCULATION, V91, P2717, DOI 10.1161/01.CIR.91.11.2717; POULEUR HG, 1993, J AM COLL CARDIOL, V22, pA43, DOI 10.1016/0735-1097(93)90462-A; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; THUESEN L, 1988, DAN MED BULL, V35, P193; VALCAVI R, 1995, J CLIN ENDOCR METAB, V80, P659, DOI 10.1210/jc.80.2.659	30	284	299	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1233	1237		10.1016/S0140-6736(97)11329-0	http://dx.doi.org/10.1016/S0140-6736(97)11329-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643742				2022-12-28	WOS:000073283600008
J	Sinei, SK; Morrison, CS; Sekadde-Kigondu, C; Allen, M; Kokonya, D				Sinei, SK; Morrison, CS; Sekadde-Kigondu, C; Allen, M; Kokonya, D			Complications of use of intrauterine devices among HIV-1-infected women	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PELVIC INFLAMMATORY DISEASE; SEXUALLY-TRANSMITTED DISEASES; INFECTION; TRANSMISSION; KENYA; RISK; CRITERIA; NAIROBI	Background A WHO expert group and the International Planned Parenthood Federation recommend against use of intrauterine devices (IUDs) in HIV-1-infected women based on theoretical concerns about pelvic infection and increased blood loss, We investigated whether the risk of complications after IUD insertion is higher in HIV-1-infected women than in non-infected women. Methods 649 (156 HIV-1 infected 493 non-infected) women in Nairobi, Kenya, who requested and met local eligibility criteria for insertion of an IUD were enrolled, We gathered information on IUD-related complications, including pelvic inflammatory disease, removals due to infection, pain, or bleeding, expulsions, and pregnancies at 1 and 4 months after insertion. Patients' HIV-1 status was masked from physicians. Findings Complications were identified in 48 of 615 women (11 [7.6%] HIV-1-infected women, 37 [7.9%] non-infected), Incident pelvic inflammatory disease (two [1.4%] HIV-1 infected, one [0.2%] non-infected) and infection-related complications (any tenderness, removal of IUD for infection or pain; ten [6.9%] HIV-1 infected, 27 [5.7%] non-infected) were also rare and similar in the two groups. Complication rates were similar by CD4 (immune) status. Multivariate analyses suggested no association between HIV-1 infection and increased risks for overall complications (odds ratio 0.8 [95% CI 0.4-1.7]) or infection-related complications (1.0 [0.5-2.3]), adjusted for marital status, study site, previous IUD use, ethnic origin, and frequency of sexual intercourse, but a slight increase cannot be ruled out. Interpretation Our data suggest that IUDs may be a safe contraceptive method for appropriately selected HIV-1-infected women with continuing access to medical services.	Family Hlth Int, Res Triangle Pk, NC 27709 USA; Univ Nairobi, Dept Obstet & Gynaecol, Nairobi, Kenya	University of Nairobi	Morrison, CS (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.	cmorrison@fhi.org	Kokonya, Donald/GLR-2492-2022	Kokonya, Donald/0000-0002-4206-9933				BRBOSA C, 1997, OBSTET GYNECOL, V89, P65; BUKUSI E, 1996, 11 INT C AIDS JUL; CARAEL M, 1988, AIDS, V2, P201; CLEMETSON DBA, 1993, JAMA-J AM MED ASSOC, V269, P2860, DOI 10.1001/jama.269.22.2860; COHEN C, 1996, 11 INT C AIDS JUL; DEVINCENZI I, 1992, BRIT MED J, V304, P809; DEVINCENZI I, 1989, BRIT MED J, V298, P411; FARLEY TMM, 1992, LANCET, V339, P785, DOI 10.1016/0140-6736(92)91904-M; HAGER WD, 1983, OBSTET GYNECOL, V61, P113; HOEGSBERG B, 1990, AM J OBSTET GYNECOL, V163, P1135, DOI 10.1016/0002-9378(90)90671-S; HOSMER DW, 1989, APPL LOGISTIC REGRES; *IPPF INT MED ADV, 1991, IPPF MED B, V25, P1; Kapiga SH, 1998, AIDS, V12, P75, DOI 10.1097/00002030-199801000-00009; KELSEY JL, 1986, METHODS OBSERVATIONA; KORN AP, 1993, OBSTET GYNECOL, V82, P765; LADIPO O A, 1991, Advances in Contraception, V7, P43, DOI 10.1007/BF01850718; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; MATI JKG, 1995, INT J GYNECOL OBSTET, V48, P61; MAULDIN WP, 1994, P 4 INT C IUDS, P1; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Mostad SB, 1997, LANCET, V350, P922, DOI 10.1016/S0140-6736(97)04240-2; MUSICCO M, 1994, P 4 INT C IUDS, P179; PLOURDE PJ, 1992, J INFECT DIS, V166, P86, DOI 10.1093/infdis/166.1.86; SINEI SKA, 1990, BRIT J OBSTET GYNAEC, V97, P412, DOI 10.1111/j.1471-0528.1990.tb01828.x; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; Sweet RL, 1997, LANCET, V349, P1265, DOI 10.1016/S0140-6736(05)62501-9; *UNAIDS WHO, 1997, REP GLOB HIV AIDS EP; *WHO, 1992, WKLY EPIDEMIOL REC, V67, P145; *WHO SCI WORK GROU, 1996, MED EL CRIT IN CONT	29	73	74	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1238	1241		10.1016/S0140-6736(97)10319-1	http://dx.doi.org/10.1016/S0140-6736(97)10319-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643743				2022-12-28	WOS:000073283600009
J	Godward, S; Dezateux, C				Godward, S; Dezateux, C		MRC Working Paryt Congenital Dislocation Hip	Surgery for congenital dislocation of the hip in the UK as a measure of outcome of screening	LANCET			English	Article							LATE DIAGNOSIS; MANAGEMENT; INFANTS	Background Universal clinical screening for congenital dislocation of the hip to detect hip instability in neonates was introduced in the UK as a national policy in 1969, but its effectiveness is not known. We aimed to assess the extent to which surgery for congenital dislocation of the hip is the result of a failure of detection through screening or follows non-surgical treatment after detection by screening. Methods We established a national orthopaedic surveillance scheme and used routine hospital data for inpatients for 20% of births in the UK (Scotland and the Northern and Wessex regions) to ascertain the number of children aged under 5 years per 1000 livebirths who had received at lease one operative procedure for congenital dislocation of the hip from April, 1993, to April, 1994. Estimates of the incidence of operative procedures were adjusted for under-ascertainment by capture-recapture techniques. Findings The ascertainment-adjusted incidence of a first operative procedure for congenital dislocation of the hip in the UK was 0.78 per 1000 livebirths (95% CI 0.72-0.84). Congenital dislocation of the hip had not been detected by routine screening in 222 (70%) of 318 children reported to the national orthopaedic surveillance scheme. In 112 (35%) children the diagnosis was made primarily as a result of parental concern. 67 (21%) children had previously received non-surgical treatment. In Scotland and the Northern and Wessex regions, 81 cases were notified to the national orthopaedic surveillance scheme, 62 cases were identified only through routine hospital data on inpatients, and an estimated 20 cases were not identified by either source, making a total of 163 cases. Thus, 81 (50%) of these 163 cases were identified by surveillance, 125 (77%) by routine data, and 143 (88%) by both sources. Interpretation The incidence of a first operative procedure for congenital dislocation of the hip in the UK was similar to that reported before screening was introduced. In most children who received surgery, congenital dislocation of the hip was not detected by screening, Formal evaluation of current and alternative screening policies, including universal primary ultrasound imaging, is needed.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England	University of London; University College London	Dezateux, C (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.	c.dezateux@ich.ucl.ac.uk	Dezateux, Carol/A-3416-2009	Dezateux, Carol/0000-0001-9787-6276				BENNET GC, 1992, J BONE JOINT SURG BR, V74, P643, DOI 10.1302/0301-620X.74B5.1527106; CATFORD JC, 1982, BMJ-BRIT MED J, V285, P1527, DOI 10.1136/bmj.285.6354.1527; CATTERALL A, 1994, J BONE JOINT SURG BR, V76B, P515, DOI 10.1302/0301-620X.76B4.8027129; DAVID TJ, 1983, LANCET, V2, P147; Dezateux C, 1996, ARCH DIS CHILD, V74, P445, DOI 10.1136/adc.74.5.445; Dezateux C, 1995, J Med Screen, V2, P200; DUNN PM, 1985, ARCH DIS CHILD, V60, P407, DOI 10.1136/adc.60.5.407; GODWARD S, 1996, ARCH DIS CHILD, V75, P1; Hall S M, 1988, Arch Dis Child, V63, P344; HEY K, 1994, ARCH DIS CHILD-FETAL, V71, pF198, DOI 10.1136/fn.71.3.F198; Hook EB, 1995, EPIDEMIOL REV, V17, P243, DOI 10.1093/oxfordjournals.epirev.a036192; KNOX EG, 1987, J EPIDEMIOL COMMUN H, V41, P283, DOI 10.1136/jech.41.4.283; LECK I, 1986, J ROY COLL PHYS LOND, V20, P56; LECK I, 1968, TERATOLOGY, V1, P263, DOI 10.1002/tera.1420010305; LENNOX IAC, 1993, J BONE JOINT SURG BR, V75, P72, DOI 10.1302/0301-620X.75B1.8421040; MacFarlane A, 1980, J MATERN CHILD HLTH, V5, P13; MACKENZIE IG, 1981, J BONE JOINT SURG BR, V63, P38, DOI 10.1302/0301-620X.63B1.7204472; MITCHELL G P, 1972, Journal of Bone and Joint Surgery British Volume, V54, P4; *OFF NAT STAT, 1996, POP TRENDS, P84; *OFF POP CENS SURV, 1993, CLASS SURG OP PROC; PATTERSON CC, 1995, PAEDIATR PERINAT EP, V9, P90, DOI 10.1111/j.1365-3016.1995.tb00121.x; PLACE MJ, 1978, LANCET, V2, P249; RAO S, 1986, NEW ZEAL MED J, V99, P752; RECORD R G, 1958, Br J Prev Soc Med, V12, P8; RICHARDS ID, 1971, BRIT J PREV SOC MED, V25, P59; SANFRIDSON J, 1991, ACTA ORTHOP SCAND, V62, P87, DOI 10.3109/17453679108999228; SMITHELLS RW, 1968, BRIT J PREV SOC MED, V22, P36; *STAND MED ADV COM, 1969, SCREEN DET CONG DISL; Standing Medical Advisory Committee and the Standing Nursing and Midwifery Advisory Committee, 1986, SCREEN DET CONG DISL; STONE DH, 1992, AM J EPIDEMIOL, V136, P498, DOI 10.1093/oxfordjournals.aje.a116523; TREDWELL SJ, 1992, CLIN ORTHOP RELAT R, P63; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; YIP PSF, 1995, AM J EPIDEMIOL, V142, P1047; YNGVE D, 1990, J PEDIATR ORTHOPED, V10, P777, DOI 10.1097/01241398-199011000-00013; 1991, LANCET, V337, P947	35	92	93	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1149	1152		10.1016/S0140-6736(97)10466-4	http://dx.doi.org/10.1016/S0140-6736(97)10466-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643684				2022-12-28	WOS:000073220200006
J	Glendinning, C; Rummery, K; Clarke, R				Glendinning, C; Rummery, K; Clarke, R			From collaboration to commissioning: developing relationships between primary health and social services	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Natl Primary Care Res & Dev, Manchester M13 9PL, Lancs, England	University of Manchester	Glendinning, C (corresponding author), Univ Manchester, Natl Primary Care Res & Dev, Manchester M13 9PL, Lancs, England.		Rummery, Kirstein/AAC-4807-2019	Rummery, Kirstein/0000-0003-4413-7394				BOOTH T, 1981, POLICY POLIT, V19, P23; CUMELLA S, 1996, SOCIAL WORK PRACTICE; Department of Health, 1989, CAR PEOPL; EDWARDS P, 1997, COMMUNITY CARE TREND; GARLICK C, 1996, NURS TIMES, V92, P28; GLENNERSTER H, 1996, WRP126 STICERD LOND; GLENNERSTER H, 1994, EVALUATING NHS REFOR; HIGGINS R, 1994, HEALTH SOC CARE COMM, V2, P269; JONES R, 1995, PRIMARY CARE MANAGE, V5, P3; MACALISTERSMITH E, 1995, PRIMARY CARE MANAGE, V5, P6; MASON P, 1992, COMMUNITY CARE, V917, P17; MCINTOSH J, 1992, HEALTH SOC CARE COMM, V1, P91; McNally D, 1996, SOCIAL WORKERS ATTAC; *NAT HLTH SERV EX, 1997, HLTH ACT ZON IN BID; NOCON A, 1994, COLLABORATION COMMUN; PITHOUSE A, 1994, RES POLICY PLANN, V12, P16; Poxton R., 1996, JOINT APPROACHES BET; ROYSTON S, 1991, CARING PEOPLE, V3, P1; RUMMERY K, 1997, WORKING TOGETHER PRI; *SECR STAT HLTH, 1997, NEW NHS; SHEPPARD M, 1992, BRIT J SOC WORK, V22, P419; SMITH R, 1993, SCH ADV URBAN STUDIE; STANNARD J, 1996, HLTH SOCIAL CARE ALL; WISTOW G, 1988, JOINT PLANNING JOINT	24	17	18	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					122	125		10.1136/bmj.317.7151.122	http://dx.doi.org/10.1136/bmj.317.7151.122			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105PE	9657791	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000075081700025
J	Beecham, L				Beecham, L			Labour party starts discussion on health	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1988	1988						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641962				2022-12-28	WOS:000074636700084
J	Bhopal, R				Bhopal, R			Spectre of racism in health and health care: Lessons from history and the United States	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OF-VETERANS-AFFAIRS; EPIDEMIOLOGIC RESEARCH; CARDIAC PROCEDURES; ETHNIC-MINORITIES; MEDICAL-RESEARCH; BLOOD-PRESSURE; HEART-DISEASE; SOCIAL-CLASS; RACE; DISCRIMINATION		Newcastle Univ, Sch Med, Div Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Bhopal, R (corresponding author), Newcastle Univ, Sch Med, Div Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	r.s.phopal@ncl.ac.uk						Ahmad W, 1993, RACE HLTH CONT BRITA; AHMAD WIU, 1989, LANCET, V1, P148; Ahmad WIU, 1992, POLITICS RACE HLTH; [Anonymous], 1989, RACIAL ETHNIC DIFFER; ARMSTEAD CA, 1989, HEALTH PSYCHOL, V8, P541, DOI 10.1037/0278-6133.8.5.541; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; Banton Michael, 1987, RACIAL THEORIES; Barkan Elazar., 1992, RETREAT SCI RACISM; Bhopal R, 1997, BRIT MED J, V314, P1751, DOI 10.1136/bmj.314.7096.1751; Biddiss M, 1979, IMAGES RACE; Bolt Christine, 1971, VICTORIAN ATTITUDES; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; Chadwick J., 1950, MED WORKS HIPPOCRATE; Chavkin W, 1997, NEW ENGL J MED, V336, P1321; COOPER R, 1984, AM HEART J, V108, P715, DOI 10.1016/0002-8703(84)90662-8; Down JL., 1995, MENT RETARD, V3, P54; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; ESMAIL A, 1993, BRIT MED J, V306, P691, DOI 10.1136/bmj.306.6879.691; GAMBLE VN, 1993, AM J PREV MED, V9, P35, DOI 10.1016/S0749-3797(18)30664-0; Geiger HJ, 1996, NEW ENGL J MED, V335, P815, DOI 10.1056/NEJM199609123351110; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GORNICK ME, 1986, NEW ENGL J MED, V335, P791; Gould Stephen Jay, 1984, MISMEASURE MAN; Guinan M E, 1993, Ann Epidemiol, V3, P193; HANNAN EL, 1991, MED CARE, V29, P430, DOI 10.1097/00005650-199105000-00004; Hernstein R. J., 1994, BELL CURVE; Jones JH, 1993, TUSKEGEE SYPHILIS EX; Kaufman JS, 1995, PUBLIC HEALTH REP, V110, P662; Kiple K. F, 2003, ANOTHER DIMENSION BL; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; Krieger N, 1996, AM J PUBLIC HEALTH, V86, P1370, DOI 10.2105/AJPH.86.10.1370; Krieger N, 1992, J Public Health Policy, V13, P412; KRIEGER N, 1993, AM J PREV MED, V9, P82, DOI 10.1016/S0749-3797(18)30666-4; Kuper Leo, 1975, RACE SCI SOC; KUSHNICK L, 1988, INT J HEALTH SERV, V18, P457, DOI 10.2190/LEUW-X7VW-Q2KD-UML9; LAVEIST TA, 1995, HUMBOLDT J SOCIAL RE, V21, P119; LESLIE C, 1990, SOC SCI MED, V31, P891, DOI 10.1016/0277-9536(90)90025-N; LOWRY S, 1988, BRIT MED J, V296, P657, DOI 10.1136/bmj.296.6623.657; MAYER WJ, 1989, AM J PUBLIC HEALTH, V79, P772, DOI 10.2105/AJPH.79.6.772; MCKEIGUE PM, 1990, BRIT MED J, V301, P961, DOI 10.1136/bmj.301.6758.961; McNeilly MD, 1995, INT J BEHAV MED, V2, P321, DOI 10.1207/s15327558ijbm0204_3; Modood T., 1997, ETHNIC MINORITIES BR; Muntaner C, 1996, AM J EPIDEMIOL, V144, P531; OBERMAN A, 1984, AM HEART J, V108, P688, DOI 10.1016/0002-8703(84)90656-2; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2344; OSBORNE NG, 1992, JAMA-J AM MED ASSOC, V267, P275, DOI 10.1001/jama.267.2.275; Parker H, 1997, J Health Serv Res Policy, V2, P256; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Reynolds G., 1993, ANN EPIDEMIOL, V3, P119; SENIOR PA, 1994, BRIT MED J, V309, P327, DOI 10.1136/bmj.309.6950.327; Shuster E, 1998, LANCET, V351, P974; SMAJE C, 1995, HLTH RACE ETHNICITY; SORLIE P, 1992, LANCET, V340, P346, DOI 10.1016/0140-6736(92)91413-3; Stepan N., 1982, IDEA RACE SCI; TURSHEN M, 1996, CURR ISSUES PUBLIC H, V2, P61; Varma J K, 1996, JAMA, V275, P737, DOI 10.1001/jama.275.9.734; Warren R C, 1993, Ann Epidemiol, V3, P127; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WHITRIDGE WJ, 1926, TXB USE STUDENTS PRA; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; WISE PH, 1993, AM J PREV MED, V9, P7, DOI 10.1016/S0749-3797(18)30660-3; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003	62	65	67	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 27	1998	316	7149					1970	1973		10.1136/bmj.316.7149.1970	http://dx.doi.org/10.1136/bmj.316.7149.1970			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZY568	9641943	Green Published			2022-12-28	WOS:000074636700038
J	Yasuda, R; Noji, H; Kinosita, K; Yoshida, M				Yasuda, R; Noji, H; Kinosita, K; Yoshida, M			F-1-ATPase is a highly efficient molecular motor that rotates with discrete 120 degrees steps	CELL			English	Article							ESCHERICHIA-COLI F1-ATPASE; CATALYTIC SITE; MITOCHONDRIAL ATPASE; COOPERATIVITY; HYDROLYSIS	A single molecule of F-1-ATPase, a portion of ATP synthase, is by itself a rotary motor in which a central gamma subunit rotates against a surrounding cylinder made of alpha(3)beta(3) subunits. Driven by three catalytic beta s, each fueled with ATP, gamma makes discrete 120 degrees steps, occasionally stepping backward. The work done in each step is constant over a broad range of imposed load and is close to the free energy of hydrolysis of one ATP molecule.	Keio Univ, Fac Sci & Technol, Dept Phys, Yokohama, Kanagawa 2238522, Japan; Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 2268503, Japan; Teikyo Univ, Biotechnol Res Ctr 3F, CREST Genet Programming Team 13, Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan	Keio University; Tokyo Institute of Technology; Japan Science & Technology Agency (JST); Teikyo University	Kinosita, K (corresponding author), Keio Univ, Fac Sci & Technol, Dept Phys, Yokohama, Kanagawa 2238522, Japan.		Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER B, 1997, J BIOL CHEM, V272, P19621; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DeLuca M., 1978, METHOD ENZYMOL, V57, P3, DOI DOI 10.1016/0076-6879(78)57003-1; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; Higuchi H, 1997, P NATL ACAD SCI USA, V94, P4395, DOI 10.1073/pnas.94.9.4395; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kagawa Y, 1997, BIOCHEM BIOPH RES CO, V240, P247, DOI 10.1006/bbrc.1997.7574; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; Kinosita K, 1998, CELL, V93, P21, DOI 10.1016/S0092-8674(00)81142-3; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; MEISTER M, 1987, CELL, V49, P643, DOI 10.1016/0092-8674(87)90540-X; Milgrom YM, 1998, BIOCHEM J, V330, P1037; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MUNEYUKI E, 1988, FEBS LETT, V234, P455, DOI 10.1016/0014-5793(88)80137-6; Muneyuki E, 1997, FEBS LETT, V413, P55, DOI 10.1016/S0014-5793(97)00878-8; MUNEYUKI E, 1989, J BIOL CHEM, V264, P6092; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Oosawa F, 1986, Adv Biophys, V22, P151, DOI 10.1016/0065-227X(86)90005-5; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sase I, 1997, P NATL ACAD SCI USA, V94, P5646, DOI 10.1073/pnas.94.11.5646; SASE I, 1995, BIOPHYS J, V69, P323, DOI 10.1016/S0006-3495(95)79937-4; SOUID AK, 1995, J BIOL CHEM, V270, P9074, DOI 10.1074/jbc.270.16.9074; STRYER L, 1995, BIOCHEMISTRY-US, P443; XIAO R, 1994, J BIOL CHEM, V269, P19232; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	37	669	681	4	76	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1117	1124		10.1016/S0092-8674(00)81456-7	http://dx.doi.org/10.1016/S0092-8674(00)81456-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657145	Bronze			2022-12-28	WOS:000074491100007
J	Arber, S; Barbayannis, FA; Hanser, H; Schneider, C; Stanyon, CA; Bernard, O; Caroni, P				Arber, S; Barbayannis, FA; Hanser, H; Schneider, C; Stanyon, CA; Bernard, O; Caroni, P			Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase	NATURE			English	Article							DEPOLYMERIZING FACTOR; ZINC-FINGER; IDENTIFICATION; PROTEIN; MOTIFS	Cell division, cell motility and the formation and maintenance of specialized structures in differentiated cells depend directly on the regulated dynamics of the actin cytoskeleton(1,2). To understand the mechanisms of these basic cellular processes, the signalling pathways that link external signals to the regulation of the actin cytoskeleton need to be characterized(2,3). Here we identify a pathway for the regulation of cofilin, a ubiquitous actin-binding protein that is essential for effective depolymerization of actin filaments(4-8). LIM-kinase 1, also known as KIZ, is a protein kinase with two amino-terminal LIM motifs(9-11) that induces stabilization of F-actin structures in transfected cells. Dominant-negative LIM-kinase1 inhibits the accumulation of the F-actin. Phosphorylation experiments in vivo and in vitro provide evidence that cofilin is a physiological substrate of LIM-kinase 1. Phosphorylation by LIM-kinase 1 inactivates cofilin, leading to accumulation of actin filaments. Constitutively active Rac augmented cofilin phosphorylation and LIM-kinase 1 autophosphorylation whereas phorbol ester inhibited these processes. Our results define a mechanism for the regulation of cofilin and hence of actin dynamics in vivo. By modulating the stability of actin cytoskeletal structures, this pathway should play a central role in regulating cell motility and morphogenesis.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Friedrich Miescher Institute for Biomedical Research; Walter & Eliza Hall Institute	Caroni, P (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Stanyon, Clem/AAM-5040-2020	Arber, Silvia/0000-0002-6261-250X; Stanyon, Clement/0000-0001-5030-6823				Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; CALIER MF, 1997, J CELL BIOL, V136, P1307; DAVID IB, 1995, CR HEBD ACAD SCI, V318, P295; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; MICHISON TJ, 1996, CELL, V84, P371; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; NAGOAKA R, 1995, J CELL SCI, V108, P581; Nebl G, 1996, J BIOL CHEM, V271, P26276, DOI 10.1074/jbc.271.42.26276; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Theriot JA, 1997, J CELL BIOL, V136, P1165, DOI 10.1083/jcb.136.6.1165; vonArx P, 1995, J CELL BIOL, V131, P1759, DOI 10.1083/jcb.131.6.1759; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4	22	1125	1144	2	66	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1998	393	6687					805	809		10.1038/31729	http://dx.doi.org/10.1038/31729			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655397				2022-12-28	WOS:000074433100054
J	Berwick, DM				Berwick, DM			You cannot expect people to be heroes	BRITISH MEDICAL JOURNAL			English	Article									Inst Healthcare Improvement, Boston, MA 02215 USA	Institute for Healthcare Improvement	Berwick, DM (corresponding author), Inst Healthcare Improvement, 135 Francis St, Boston, MA 02215 USA.								0	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1738	1738						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9652926				2022-12-28	WOS:000074129500038
J	Treasure, T				Treasure, T			Present system of whistleblowing is unsatisfactory	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, London SW17 0QT, England	St Georges University London	Treasure, T (corresponding author), Univ London St Georges Hosp, London SW17 0QT, England.							Dyer C, 1998, BRIT MED J, V316, P646; *GEN MED COUNC, 1995, DUT DOCT GOOD MED PR; *HLTH POL EC RES U, 1996, 1 BMA HLTH POL EC RE; *SEN SURG GREAT BR, 1997, 2 SEN SURG GREAT BRI; 1998, BMJ, V316, P1756	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1739	1740						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9652928				2022-12-28	WOS:000074129500039
J	Vanderpool, HY				Vanderpool, HY			Critical ethical issues in clinical trials with xenotransplants	LANCET			English	Article									Univ Texas, Med Branch, Inst Med Humanities, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Vanderpool, HY (corresponding author), Univ Texas, Med Branch, Inst Med Humanities, Galveston, TX 77555 USA.							[Anonymous], 1979, FED REG, V44, P23192; Bach FH, 1998, NAT MED, V4, P141, DOI 10.1038/nm0298-141; Bach FH, 1997, NAT MED, V3, P944, DOI 10.1038/nm0997-944; Beauchamp T L, 1992, Law Med Health Care, V20, P7; Bulger R.E., 1995, SOC CHOICES SOCIAL E, P560; CAPLAN AL, 1992, TRANSPLANT P, V24, P722; CHAPMAN LE, 1995, NEW ENGL J MED, V333, P1498, DOI 10.1056/NEJM199511303332211; CRAVEN JL, 1991, PSYCHOSOMATICS, V32, P94, DOI 10.1016/S0033-3182(91)72117-8; CZAPLICKI J, 1992, J HEART LUNG TRANSPL, V11, P393; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; DEGROEN P, 1992, PSYCHIAT ASPECTS ORG, P67; EBERT JW, 1996, CURRENT ISSUES PUBLI, V2, P215; FOX RC, 1992, HASTINGS CENT REP, V22, P9, DOI 10.2307/3562136; FREEDMAN B, 1996, ETHICS RES INVOLVING, P327; HASTILLO A, 1993, J HEART LUNG TRANSPL, V12, P3; Lanza RP, 1996, NAT BIOTECHNOL, V14, P1107, DOI 10.1038/nbt0996-1107; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; McCarthy Charles R., 1995, ILAR J, V37, P3; Michler RE, 1996, EMERG INFECT DIS, V2, P64, DOI 10.3201/eid0201.960111; NELSON JL, 1993, BIOETHICS, V7, P314; *NUFF COUNC BIOETH, 1966, AN HUM TRANSPL; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; PIERSON RN, 1993, J HEART LUNG TRANSPL, V12, P876; Platt Jeffrey L., 1995, ILAR J, V37, P22; POST SG, 1993, ARCH SURG-CHICAGO, V128, P131; REEMTSMA K, 1990, TRANSPLANT P, V22, P1042; Soos J, 1992, PSYCHIAT ASPECTS ORG, P89; Steele David J., 1995, ILAR J, V37, P13; *UK ADV GROUP ETH, 1997, GOV RESP AN TISS HUM; *US I MED COMM XEN, 1996, XEN SCI ETH PUBL POL; Vanderpool HY, 1996, ETHICS RES INVOLVING, P1; VEATCH RM, 1986, TRANSPLANT P, V18, P93; 1996, FED REG, V61, P49920	33	20	20	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1347	1350		10.1016/S0140-6736(97)10354-3	http://dx.doi.org/10.1016/S0140-6736(97)10354-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643812				2022-12-28	WOS:000073439400041
J	Solomon, T; Kneen, R; Dung, NM; Khanh, VG; Thuy, TTN; Ha, DQ; Day, NPJ; Nisalak, A; Vaughn, DW; White, NJ				Solomon, T; Kneen, R; Dung, NM; Khanh, VG; Thuy, TTN; Ha, DQ; Day, NPJ; Nisalak, A; Vaughn, DW; White, NJ			Poliomyelitis-like illness due to Japanese encephalitis virus	LANCET			English	Article							GUILLAIN-BARRE-SYNDROME; NORTHERN CHINA; ANTIBODIES	Background Acute flaccid paralysis remains common among Vietnamese children despite a pronounced fall in the incidence of poliomyelitis. Methods During 1995, all 22 children presenting with acute flaccid paralysis to a referral centre in Ho Chi Mlnh City, Vietnam, had virological cultures and antibody measurements done on serum, cerebrospinal fluid, and faeces. A year later the children were reassessed and electrophysiological studies were done. Findings Wild poliovirus type 1 was isolated from the faeces of only one patient, and non-polio enteroviruses from three patients. 12 (55%) of the 22 children with acute flaccid paralysis had evidence of acute Japanese encephalitis virus (JEV) infection, compared with only one (1%) of 88 age-matched hospital controls (children with diphtheria; p<0.0001). Compared with JEV-negative patients, weakness in JEV-infected children was more rapid in onset, tended to be asymmetrical, but was less likely to involve the arms. All 12 children with JEV infection were febrile at the onset of weakness, seven had acute retention of urine, and ten had CSF pleiocytosis. Seven of eight JEV-negative patients met the case-definition of Guillain-Barre syndrome, compared with only one of 12 JEV-positive children. At follow-up, patients with JEV infection had greater disability and were more likely to have muscle wasting than were JEV-negative children. Nerve conduction and electromyographic studies indicated damage to the anterior horn cells. Interpretation JEV causes an acute flaccid paralysis in children that has similar clinical and pathological features to poliomyelitis. In endemic areas, children with acute flaccid paralysis should be investigated for evidence of JEV infection.	Cho Quan Hosp, Ctr Trop Dis, Wellcome Trust Clin Res Unit, Ho Chi Minh City, Vietnam; John Radcliffe Hosp, Ctr Trop Med & Infect Dis, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Inst Pasteur, Ho Chi Minh City, Vietnam; USA, Dept Virol, Med Component, Armed Forces Res Inst Med Sci, Bangkok, Thailand	University of Oxford; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)	White, NJ (corresponding author), Cho Quan Hosp, Ctr Trop Dis, Wellcome Trust Clin Res Unit, Ho Chi Minh City, Vietnam.		White, Nicholas J/I-4629-2012; White, Nick/AAC-6527-2019	White, Nick/0000-0002-1897-1978; Solomon, Tom/0000-0001-7266-6547	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASBURY AK, 1981, ANN NEUROL, V9, P1, DOI 10.1002/ana.410090703; Breinl A., 1918, MED J AUSTRALIA, V1, P209; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P169; BURKE DS, 1982, J CLIN MICROBIOL, V16, P1034, DOI 10.1128/JCM.16.6.1034-1042.1982; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P412; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HO TW, 1995, BRAIN, V118, P597, DOI 10.1093/brain/118.3.597; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; KUMAR R, 1991, INDIAN PEDIATR, V23, P1525; MCKHANN GM, 1991, LANCET, V338, P593, DOI 10.1016/0140-6736(91)90606-P; MISRA UK, 1994, J NEUROL NEUROSUR PS, V57, P1484, DOI 10.1136/jnnp.57.12.1484; PREVOT M., 1954, BULLL SOC PATHOL EXOT, V47, P490; Read SJ, 1997, J CLIN MICROBIOL, V35, P691, DOI 10.1128/JCM.35.3.691-696.1997; Solomon T, 1997, NEUROL INFECT EPIDEM, V2, P191; Tangermann RH, 1997, J INFECT DIS, V175, pS97, DOI 10.1093/infdis/175.Supplement_1.S97; *WHO, 1997, WEEKLY EPIDEMIOL REC, V5, P27; *WHO, 1993, AC ONS FLACC PAR; World Health Organization, 1992, MAN VIR INV POL; ZIMMERMAN HM, 1946, AM J PATHOL, V22, P965; 1993, MORBID MORTAL WEEKLY, V42, P1	20	186	191	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1094	1097		10.1016/S0140-6736(97)07509-0	http://dx.doi.org/10.1016/S0140-6736(97)07509-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660579				2022-12-28	WOS:000073090200011
J	Arant, BS				Arant, BS			Screening for urinary abnormalities: worth doing and worth doing well	LANCET			English	Editorial Material									Univ Tennessee, Coll Med, Dept Pediat, Chattanooga Unit, Chattanooga, TN 37403 USA	University of Tennessee System; University of Tennessee Health Science Center	Arant, BS (corresponding author), Univ Tennessee, Coll Med, Dept Pediat, Chattanooga Unit, Chattanooga, TN 37403 USA.							*AM AC PED, 1993, POL REF GUID COMPR G; DODGE WF, 1976, J PEDIATR-US, V88, P327, DOI 10.1016/S0022-3476(76)81012-8; Graff L, 1983, HDB ROUTINE URINALYS; Kaplan RE, 1997, PEDIATRICS, V100, P919, DOI 10.1542/peds.100.6.919; KUNIN CM, 1970, J INFECT DIS, V122, P382, DOI 10.1093/infdis/122.5.382; Linshaw MA, 1997, PEDIATRICS, V100, P1031, DOI 10.1542/peds.100.6.1031; LIPPMAN RW, 1957, URINE URINARY SEDIME	7	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					307	308		10.1016/S0140-6736(05)78344-6	http://dx.doi.org/10.1016/S0140-6736(05)78344-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652606				2022-12-28	WOS:000071864000004
J	Jack, D				Jack, D			The name of the dose	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					380	380		10.1016/S0140-6736(05)78346-X	http://dx.doi.org/10.1016/S0140-6736(05)78346-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652657				2022-12-28	WOS:000071864000075
J	Sattar, N; Hopkinson, ZEC; Greer, IA				Sattar, N; Hopkinson, ZEC; Greer, IA			Insulin-sensitising agents in polycystic-ovary syndrome	LANCET			English	Editorial Material							RESISTANCE		Univ Glasgow, Dept Clin Biochem, Glasgow G31 2ER, Lanark, Scotland; Univ Glasgow, Glasgow Royal Infirm, Univ NHS Trust, Glasgow G31 2ER, Lanark, Scotland	University of Glasgow; University of Glasgow	Sattar, N (corresponding author), Univ Glasgow, Dept Clin Biochem, Glasgow G31 2ER, Lanark, Scotland.			Sattar, Naveed/0000-0002-1604-2593				Acbay O, 1996, FERTIL STERIL, V65, P946, DOI 10.1016/S0015-0282(16)58266-1; CASIMIRRI F, 1997, INT J OBESITY S2, V21, pS61; CRAVE JC, 1995, J CLIN ENDOCR METAB, V80, P2057, DOI 10.1210/jc.80.7.2057; Dunaif A, 1997, ENDOCR REV, V18, P774, DOI 10.1210/er.18.6.774; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P3299, DOI 10.1210/jc.81.9.3299; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P524, DOI 10.1210/jc.82.2.524; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P2108, DOI 10.1210/jc.82.7.2108; Nestler JE, 1996, NEW ENGL J MED, V335, P617, DOI 10.1056/NEJM199608293350902; VANDERSPUY ZM, 1996, HUM REPROD, V11, P167; Velazquez E, 1997, OBSTET GYNECOL, V90, P392; Velazquez EM, 1997, METABOLISM, V46, P454, DOI 10.1016/S0026-0495(97)90066-4; VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7	12	39	39	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					305	307		10.1016/S0140-6736(05)78345-8	http://dx.doi.org/10.1016/S0140-6736(05)78345-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652605				2022-12-28	WOS:000071864000003
J	Beddows, R				Beddows, R			Loaded, but no place to go	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1260	1260		10.1016/S0140-6736(05)63505-2	http://dx.doi.org/10.1016/S0140-6736(05)63505-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652602				2022-12-28	WOS:A1997YD23800068
J	Nelson, JA; Strauss, L; Skowronski, M; Ciufo, R; Novak, R; McFadden, ER				Nelson, JA; Strauss, L; Skowronski, M; Ciufo, R; Novak, R; McFadden, ER			Effect of long-term salmeterol treatment on exercise-induced asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDUCED BRONCHOCONSTRICTION; INHALED SALMETEROL; MILD ASTHMA; PROTECTION; ALBUTEROL; DURATION; AGONIST; RESPONSIVENESS; SALBUTAMOL; THERAPY	Background With long-term administration of salmeterol, the extent of protection afforded by the drug against experimental precipitants of asthma such as methacholine and adenosine may decrease. Whether this effect extends to a clinically relevant stimulus such as exercise is unknown. Methods We performed a random-order, double-blind, crossover trial in 20 patients with exercise-induced asthma. Each patient received inhaled salmeterol or placebo twice daily for a month, with a one-week washout period between treatments. The patients performed cycle ergometry while breathing frigid air 30 minutes after the morning dose and 9 hours later on the 1st, 14th, and 29th study days. The primary end point was the extent of the decrease in forced expiratory volume in 1 second (FEV1) 10 minutes after exertion. Results With placebo, significant airway narrowing developed at all times (mean [+/-SE] decrease from base line in FEV1, 19+/-2 percent in the morning and 18+/-2 percent in the evening). The morning dose of salmeterol attenuated the degree of bronchoconstriction at all times (decrease in FEV1 on day 1, 5+/-2 percent; on day 14, 10+/-3 percent; and on day 29, 9+/-3 percent; P = 0.10). Its ability to act throughout the day, however, decreased with long-term administration (decrease in FEV1 from morning to evening on day 1, 6+/-2 percent; on day 14, 15+/-3 percent; and on day 29, 14+/-3 percent; P = 0.003). Conclusions Protection against exercise-induced asthma is maintained with long-term administration of salmeterol, but the length of time that the drug remains active after a single dose decreases. (N Engl J Med 1998;339:141-6.) (C)1998, Massachusetts Medical Society.	Univ Hosp Cleveland, Div Pulm & Crit Care Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA	University Hospitals of Cleveland; Case Western Reserve University	McFadden, ER (corresponding author), Univ Hosp Cleveland, Div Pulm & Crit Care Med, 11100 Euclid Ave, Cleveland, OH 44106 USA.				NCRR NIH HHS [MO 1 RR-00080] Funding Source: Medline; NHLBI NIH HHS [HL-07288, HL-33791] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033791] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON SD, 1991, CHEST, V100, P1254, DOI 10.1378/chest.100.5.1254; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; FITZPATRICK MF, 1990, BRIT MED J, V301, P1365, DOI 10.1136/bmj.301.6765.1365; GILBERT IA, 1988, J APPL PHYSIOL, V64, P2167, DOI 10.1152/jappl.1988.64.5.2167; GREEN CP, 1992, ARCH DIS CHILD, V67, P1014, DOI 10.1136/adc.67.8.1014; HETZEL MR, 1977, BRIT J DIS CHEST, V71, P109, DOI 10.1016/0007-0971(77)90091-2; HIGGS CMB, 1983, BRIT J DIS CHEST, V77, P262; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65, DOI 10.1164/ajrccm.153.1.8542164; KEMP JP, 1994, AM J RESP CRIT CARE, V150, P1612, DOI 10.1164/ajrccm.150.6.7952623; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V95, P641, DOI 10.1016/S0091-6749(95)70166-4; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; NEWNHAM DM, 1993, RESP MED, V87, P439, DOI 10.1016/0954-6111(93)90070-G; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; REPSHER LH, 1984, CHEST, V85, P34, DOI 10.1378/chest.85.1.34; SCHOEFFEL RE, 1981, ANN ALLERGY, V46, P273; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; VATHENEN AS, 1988, LANCET, V1, P554; Zar J.H., 1999, ZAR KUHR 5 2019, V4th	25	119	119	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					141	146		10.1056/NEJM199807163390301	http://dx.doi.org/10.1056/NEJM199807163390301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ922	9664089				2022-12-28	WOS:000074782900001
J	Berkenkamp, S; Kirpekar, F; Hillenkamp, F				Berkenkamp, S; Kirpekar, F; Hillenkamp, F			Infrared MALDI mass spectrometry of large nucleic acids	SCIENCE			English	Article							IONS; RNA; PCR	Mass spectrometry has become an increasingly important tool of high accuracy, efficiency, and speed for the routine analysis of nucleic acids. To make it useful for large-scale sequencing of genomic material as required for example in genotyping and clinical diagnosis, it is necessary to find approaches that allow the analysis of sequences much larger than the 100 nucleotides currently possible. Matrix-assisted laser desorption/ionization (MALDI) mass spectra of synthetic DNA, restriction enzyme fragments of plasmid DNA, and RNA transcripts up to a size of 2180 nucleotides are reported. The demonstrated mass accuracy of 1 percent or better and the sample requirement of a few femtomoles or Less surpass all currently available techniques for the analysis of large nucleic acids. DNA and RNA can be analyzed with only a limited investment in sample purification.	Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany; Odense Univ, Dept Mol Biol, DK-5230 Odense M, Denmark	University of Munster; University of Southern Denmark	Hillenkamp, F (corresponding author), Univ Munster, Inst Med Phys & Biophys, Robert Koch Str 31, D-48149 Munster, Germany.	hillenk@uni-muenster.de		Kirpekar, Finn/0000-0003-1901-2266				Berkenkamp S, 1997, RAPID COMMUN MASS SP, V11, P1399; CHEN RD, 1995, ANAL CHEM, V67, P1159, DOI 10.1021/ac00103a004; Fuerstenau SD, 1995, RAPID COMMUN MASS SP, V9, P1528, DOI 10.1002/rcm.1290091513; HOPERT A, 1993, J IMMUNOL METHODS, V164, P91, DOI 10.1016/0022-1759(93)90279-G; KIRPEKAR F, 1994, NUCLEIC ACIDS RES, V22, P3866, DOI 10.1093/nar/22.19.3866; Kussmann M, 1997, J MASS SPECTROM, V32, P593; LIMBACH PA, 1995, J AM SOC MASS SPECTR, V6, P27, DOI 10.1016/1044-0305(94)00086-F; Little DP, 1997, ANAL CHEM, V69, P4540, DOI 10.1021/ac970758+; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Muddiman DC, 1996, ANAL CHEM, V68, P3705, DOI 10.1021/ac960689j; Naito Y, 1997, J AM SOC MASS SPECTR, V8, P737, DOI 10.1016/S1044-0305(97)00083-4; Nordhoff E, 1996, MASS SPECTROM REV, V15, P67, DOI 10.1002/(SICI)1098-2787(1996)15:2<67::AID-MAS1>3.0.CO;2-8; NORDHOFF E, 1993, NUCLEIC ACIDS RES, V21, P3347, DOI 10.1093/nar/21.15.3347; NUI S, 1998, J AM SOC MASS SPECTR, V9, P1; Ross PL, 1997, ANAL CHEM, V69, P3966, DOI 10.1021/ac970312t	15	182	206	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					260	262		10.1126/science.281.5374.260	http://dx.doi.org/10.1126/science.281.5374.260			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657721				2022-12-28	WOS:000074714200050
J	Jickells, TD				Jickells, TD			Nutrient biogeochemistry of the coastal zone	SCIENCE			English	Review							NORTH-ATLANTIC OCEAN; ATMOSPHERIC NITROGEN DEPOSITION; SEA; EUTROPHICATION; PHOSPHORUS; RIVERS; DENITRIFICATION; ESTUARIES; FIXATION; BUDGETS	The coastal seas are one of the most valuable and vulnerable of Earth's habitats. Significant inputs of nutrients to the coastal zone arrive via rivers, groundwater, and the atmosphere. Nutrient fluxes through these routes have been increased by human activity. In addition, the N:P:Si ratios of these inputs have been perturbed, and many coastal management practices exacerbate these perturbations. There is evidence of impacts arising from these changes tin phytoplankton numbers and relative species abundance, and deepwater oxygen declines) in areas of restricted water exchange. Elsewhere, the nutrient fluxes through the coastal zone appear to be still dominated by Large inputs from the open ocean, and there is Little evidence of anthropogenic perturbations.	Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Jickells, TD (corresponding author), Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England.	t.jickells@uea.ac.uk						ANDERSON DM, 1994, SCI AM, V271, P62, DOI 10.1038/scientificamerican0894-62; Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; ASMAN WAH, 1996, EUTROPHICATION COAST, P21; Atkinson LP, 1985, OCEANOGRAPHY SE US C; BALLS PW, 1994, ESTUAR COAST SHELF S, V39, P329, DOI 10.1006/ecss.1994.1068; BARTH H, 1990, 16 EUR COMM WAT POLL; BILLEN G, 1991, PHYS CH EAR, P19; BLANTON JO, 1991, PHYS CH EAR, P145; Botsford LW, 1997, SCIENCE, V277, P509, DOI 10.1126/science.277.5325.509; BRIMBLECOMBE P, 1980, TELLUS, V32, P261, DOI 10.1111/j.2153-3490.1980.tb00953.x; BROCKMAN U, 1990, BIOGEOCHEMICAL CYCLE; CADEE GC, 1986, NETH J SEA RES, V20, P29, DOI 10.1016/0077-7579(86)90058-X; Church TM, 1996, NATURE, V380, P579, DOI 10.1038/380579a0; Constanza R., NATURE, V387, P253; DeJonge VN, 1997, MAR POLLUT BULL, V34, P427, DOI 10.1016/S0025-326X(96)00143-9; DEMORA S, 1996, TRIBUTYL TIN CASE ST; DICKSON RR, 1988, J PLANKTON RES, V10, P151, DOI 10.1093/plankt/10.1.151; Duce RA, 1991, GLOBAL BIOGEOCHEM CY, V5, P193, DOI 10.1029/91GB01778; DYBERN B, 1981, BALTIC SEA, P353; Dyer K.R., 1997, ESTUARIES, V2nd; FONSELIUS S, 1982, MAR POLLUT B, V12, P187; FROELICH PN, 1988, LIMNOL OCEANOGR, V33, P649, DOI 10.4319/lo.1988.33.4_part_2.0649; GALLOWAY JN, 1995, GLOBAL BIOGEOCHEM CY, V9, P235, DOI 10.1029/95GB00158; Galloway JN, 1996, BIOGEOCHEMISTRY, V35, P3, DOI 10.1007/BF02179823; Gard EE, 1998, SCIENCE, V279, P1184, DOI 10.1126/science.279.5354.1184; GESAMP (Group of Experts on the Scientific Aspects of Marine Environmental Protection), 1990, STAT MAR ENV; Goldberg ED, 1995, MAR POLLUT BULL, V31, P152, DOI 10.1016/0025-326X(95)00102-S; HALIM Y, 1991, PHYS CH EAR, P301; Harding LW, 1997, MAR ECOL PROG SER, V157, P39, DOI 10.3354/meps157039; Hinrichsen D, 1994, People Planet, V3, P6; Holligan P.M., 1993, LAND OCEAN INTERACTI; Howarth R., 1995, SCOPE, V54, P323; Howarth RW, 1996, BIOGEOCHEMISTRY, V35, P75, DOI 10.1007/BF02179825; Humborg C, 1997, NATURE, V386, P385, DOI 10.1038/386385a0; Jickells T. D., 1997, BIOGEOCHEMISTRY INTE; JICKELLS TD, 1991, PHYS CH EAR, P211; Jonas RB, 1997, AM ZOOL, V37, P612; JORGENSEN B, 1996, EUTROPHICATION COAST, P1; JUSTIC D, 1995, MAR POLLUT BULL, V30, P41, DOI 10.1016/0025-326X(94)00105-I; JUSTIC D, 1987, ESTUAR COAST SHELF S, V25, P435, DOI 10.1016/0272-7714(87)90035-7; KANE MM, 1994, ATMOS ENVIRON, V28, P2523, DOI 10.1016/1352-2310(94)90402-2; LANCELOT C, 1987, AMBIO, V16, P38; LANCELOT C, 1991, 23 EUR COMM WAT POLL; LANCELOT C, 1989, 12 EUR COMM WAT POLL; Lipschultz F, 1996, BIOGEOCHEMISTRY, V35, P261, DOI 10.1007/BF02179830; LISS P, 1991, OCEAN MARGIN PROCESS; LONGHURST A, 1995, J PLANKTON RES, V17, P1245, DOI 10.1093/plankt/17.6.1245; MAGNIEN RE, 1992, ESTUARIES, V15, P497, DOI 10.2307/1352393; MATHEWS E, 1994, GLOBAL BIOGEOCHEM CY, V8, P411; McIntyre AD, 1995, MAR POLLUT BULL, V31, P147, DOI 10.1016/0025-326X(95)00099-9; MEYBECK M, 1982, AM J SCI, V282, P401, DOI 10.2475/ajs.282.4.401; MILLIMAN JD, 1991, PHYS CH EAR, P69; Moore WS, 1996, NATURE, V380, P612, DOI 10.1038/380612a0; *N SEA TASK FORC, 1993, N SEA STAT REP; Nixon SW, 1996, BIOGEOCHEMISTRY, V35, P141, DOI 10.1007/BF02179826; NIXON SW, 1995, OPHELIA, V41, P199, DOI 10.1080/00785236.1995.10422044; OTTLEY C, 1992, ATMOS ENVIRON, V27, P1689; OWENS NJP, 1992, NATURE, V357, P397, DOI 10.1038/357397a0; PAERL HW, 1995, OPHELIA, V41, P237, DOI 10.1080/00785236.1995.10422046; Pernetta J.C., 1995, 33 IGBP; PRASTKA K, IN PRESS MAR POLLUT; Reid PC, 1998, NATURE, V391, P546, DOI 10.1038/35290; RENDELL A, 1997, J SEA RES, V45, P653; RENDELL AR, 1993, TELLUS B, V45, P53, DOI 10.1034/j.1600-0889.1993.00005.x; RICHARDSON K, 1996, EUTROPHICATION COAST, P95; Sander R, 1996, J GEOPHYS RES-ATMOS, V101, P9121, DOI 10.1029/95JD03793; Sanders R, 1997, ESTUAR COAST SHELF S, V44, P543, DOI 10.1006/ecss.1996.0170; Sanders RJ, 1997, J SEA RES, V37, P3, DOI 10.1016/S1385-1101(96)00002-0; SEITZINGER S, 1990, MAR ECOL-PROG SER, V159, P1; SEITZINGER SP, 1988, LIMNOL OCEANOGR, V33, P702, DOI 10.4319/lo.1988.33.4_part_2.0702; Seitzinger SP, 1996, BIOGEOCHEMISTRY, V35, P235, DOI 10.1007/BF02179829; SMETACEK V, 1991, PHYS CH EAR, P251; SMITH SV, 1993, REV GEOPHYS, V31, P75, DOI 10.1029/92RG02584; Summerhayes C. P., 1996, OCEANOGRAPHY ILLUSTR, P314; Tett P.B., 1994, UNDERSTANDING N SEA, P115; Trimmer M, 1998, MAR ECOL PROG SER, V163, P109, DOI 10.3354/meps163109; TURNER RE, 1994, NATURE, V368, P619, DOI 10.1038/368619a0; Turner RK, 1998, ECOL ECON, V25, P61, DOI 10.1016/S0921-8009(98)00018-4; [No title captured]	80	402	441	11	209	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					217	222		10.1126/science.281.5374.217	http://dx.doi.org/10.1126/science.281.5374.217			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9660744				2022-12-28	WOS:000074714200038
J	Miller, TP; Dahlberg, S; Cassady, JR; Adelstein, DJ; Spier, CM; Grogan, TM; LeBlanc, M; Carlin, S; Chase, E; Fisher, RI				Miller, TP; Dahlberg, S; Cassady, JR; Adelstein, DJ; Spier, CM; Grogan, TM; LeBlanc, M; Carlin, S; Chase, E; Fisher, RI			Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIFFUSE HISTIOCYTIC LYMPHOMA; FIELD RADIATION-THERAPY; STAGE-I; FOLLOW-UP; INITIAL CHEMOTHERAPY; LIMITED-STAGE; DISEASE; SURVIVAL	Background Patients with clinically localized, intermediate- or high-grade non-Hodgkin's lymphoma usually receive initial treatment with a doxorubicin-containing regimen such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Pilot studies suggest that eight cycles of CHOP alone or three cycles of CHOP followed by involved-field radiotherapy are effective in such patients. Methods We compared these two approaches in a prospective, randomized, multi-institutional study. The end points were progression-free survival, overall survival, and life-threatening or fatal toxic effects. Two hundred eligible patients were randomly assigned to receive CHOP plus radiotherapy, and 201 received CHOP alone. Results Patients treated with three cycles of CHOP plus radiotherapy had significantly better progression-free survival (P=0.03) and overall survival (P=0.02) than patients treated with CHOP alone. The five-year estimates of progression-free survival for patients receiving CHOP plus radiotherapy and for patients receiving CHOP alone were 77 percent and 64 percent, respectively. The five-year estimates of overall survival for patients receiving CHOP plus radiotherapy and for patients receiving CHOP alone were 82 percent and 72 percent, respectively. The adverse effects included one death in each treatment group. Life-threatening toxic effects of any type were seen in 61 of 200 patients treated with CHOP plus radiotherapy and in 80 of 201 patients treated with CHOP alone (P=0.06). The left ventricular function was decreased in seven patients who received CHOP alone, whereas no cardiac events were recorded in the group receiving CHOP plus radiotherapy (P=0.02). Conclusions Three cycles of CHOP followed by involved-field radiotherapy are superior to eight cycles of CHOP alone for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma. (N Engl J Med 1998;339:21-6.) (C) 1998, Massachusetts Medical Society.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA; SW Oncol Grp, Ctr Stat, Seattle, WA USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA	Arizona Center Cancer Care; University of Arizona; Southwest Oncology Group; Cleveland Clinic Foundation; Loyola University Chicago	Miller, TP (corresponding author), SW Oncol Grp, Operat Off, 14980 Omicron Dr, San Antonio, TX 78245 USA.				NCI NIH HHS [CA32102, CA387926, CA13612] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA032102, U10CA013612] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSEN JF, 1993, J CLIN ONCOL, V11, P255, DOI 10.1200/JCO.1993.11.2.255; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BONADONNA G, 1984, ADJUVANT THERAPY CAN, V4, P661; CABANILLAS F, 1980, CANCER, V46, P2356, DOI 10.1002/1097-0142(19801201)46:11<2356::AID-CNCR2820461107>3.0.CO;2-X; CARBONE PP, 1971, CANCER RES, V31, P1860; CONNORS JM, 1987, ANN INTERN MED, V107, P25, DOI 10.7326/0003-4819-107-1-25; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; GLICK JH, 1995, P AN M AM SOC CLIN, V14, P391; JONES SE, 1989, J CLIN ONCOL, V7, P1186, DOI 10.1200/JCO.1989.7.9.1186; KAMINSKI MS, 1986, ANN INTERN MED, V104, P747, DOI 10.7326/0003-4819-104-6-747; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LANDBERG TG, 1979, CANCER, V44, P831, DOI 10.1002/1097-0142(197909)44:3<831::AID-CNCR2820440307>3.0.CO;2-S; LEVITT SH, 1980, CANCER TREAT REP, V64, P175; LONGO DL, 1989, J CLIN ONCOL, V7, P1295, DOI 10.1200/JCO.1989.7.9.1295; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MILLER TP, 1983, BLOOD, V62, P413; MILLER TP, 1980, CANCER CHEMOTH PHARM, V4, P67; MILLER TP, 1979, LANCET, V1, P358; NISSEN NI, 1983, CANCER, V52, P1, DOI 10.1002/1097-0142(19830701)52:1<1::AID-CNCR2820520102>3.0.CO;2-M; ROSENBERG SA, 1982, CANCER, V49, P2112; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SWEET DL, 1981, BLOOD, V58, P1218; TRAVIS LB, 1993, JNCI-J NATL CANCER I, V85, P1932, DOI 10.1093/jnci/85.23.1932; VANLEEUWEN FE, 1994, J CLIN ONCOL, V12, P312, DOI 10.1200/JCO.1994.12.2.312	25	693	735	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					21	26		10.1056/NEJM199807023390104	http://dx.doi.org/10.1056/NEJM199807023390104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647875				2022-12-28	WOS:000074500000004
J	Uemura, T				Uemura, T			The cadherin superfamily at the synapse: More members, more missions	CELL			English	Review							STRUCTURAL BASIS; CELL-ADHESION; MOLECULES		Kyoto Univ, Fac Sci, Dept Biophys, Sakyo Ku, Kyoto 60601, Japan; Japan Sci & Technol Corp, PRESTO, Tokyo, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Uemura, T (corresponding author), Kyoto Univ, Fac Sci, Dept Biophys, Sakyo Ku, Kyoto 60601, Japan.			UEMURA, Tadashi/0000-0001-7204-3606				Arndt K, 1998, MOL CELL NEUROSCI, V10, P211, DOI 10.1006/mcne.1998.0665; Bradley RS, 1998, CURR BIOL, V8, P325, DOI 10.1016/S0960-9822(98)70132-0; Colman DR, 1997, MOL CELL NEUROSCI, V10, P1, DOI 10.1006/mcne.1997.0648; Inoue A, 1997, SCIENCE, V276, P1428, DOI 10.1126/science.276.5317.1428; Inoue T, 1998, DEV DYNAM, V211, P338, DOI 10.1002/(SICI)1097-0177(199804)211:4<338::AID-AJA5>3.3.CO;2-R; Iwai Y, 1997, NEURON, V19, P77, DOI 10.1016/S0896-6273(00)80349-9; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Riehl R, 1996, NEURON, V17, P837, DOI 10.1016/S0896-6273(00)80216-0; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	19	83	85	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1095	1098		10.1016/S0092-8674(00)81452-X	http://dx.doi.org/10.1016/S0092-8674(00)81452-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657141	Bronze			2022-12-28	WOS:000074491100003
J	Henry, TD				Henry, TD			Can we really grow new blood vessels?	LANCET			English	Editorial Material							THERAPEUTIC ANGIOGENESIS		Hennepin Cty Med Ctr, Div Cardiol, Minneapolis, MN 55415 USA	Hennepin County Medical Center	Henry, TD (corresponding author), Hennepin Cty Med Ctr, Div Cardiol, Minneapolis, MN 55415 USA.							AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; CHARNEY R, 1993, AM HEART J, V126, P937, DOI 10.1016/0002-8703(93)90710-Q; Engler DA, 1996, CIRCULATION, V94, P1496, DOI 10.1161/01.CIR.94.7.1496; Ferrara N, 1997, ENDOCR REV, V18, P1; Folkman J, 1998, CIRCULATION, V97, P1108, DOI 10.1161/01.CIR.97.12.1108; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Harada K, 1996, AM J PHYSIOL-HEART C, V270, pH1791, DOI 10.1152/ajpheart.1996.270.5.H1791; Henry TD, 1998, J AM COLL CARDIOL, V31, p65A, DOI 10.1016/S0735-1097(97)83989-7; Pepper MS, 1992, BIOCHEM BIOPH RES CO, V3, P211; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schaper W, 1996, CIRC RES, V79, P911, DOI 10.1161/01.RES.79.5.911; Schumacher B, 1998, CIRCULATION, V97, P645, DOI 10.1161/01.CIR.97.7.645; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Tsurumi Y, 1996, CIRCULATION, V94, P3281, DOI 10.1161/01.CIR.94.12.3281	15	16	20	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1826	1827		10.1016/S0140-6736(98)22025-3	http://dx.doi.org/10.1016/S0140-6736(98)22025-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652659				2022-12-28	WOS:000074347100002
J	Baldari, M; Tamburro, A; Sabatinelli, G; Romi, R; Severini, C; Cuccagna, G; Fiorilli, G; Allegri, MP; Buriani, C; Toti, M				Baldari, M; Tamburro, A; Sabatinelli, G; Romi, R; Severini, C; Cuccagna, G; Fiorilli, G; Allegri, MP; Buriani, C; Toti, M			Malaria in Maremma, Italy	LANCET			English	Article								Background In August, 1997, a woman with no history of travel to malarious regions developed Plasmodium vivax malaria. She lived in a rural area of Italy where indigenous Anophyles labranchiae mosquitoes were present. Methods and findings An environmental investigation was done within a 3 km radius of the patient's house. Adult mosquitoes and larvae were collected and examined by PCR with the gene for plasmodium circumsporozoite protein as target. About 200 people living in the area were interviewed to detect possible carriers of P vivax. Findings None of the mosquitoes captured were carrying any malarial organisms. The house-to-house investigation identified a 7-year-old girl who had had a feverish illness a few days after her arrival in Italy from India, and who, 3 months later, still had P vivax in her blood; she and her mother had antimalarial antibodies. Interpretation These investigations suggest that the index case of malaria was caused by local anopheline mosquitoes infected with exogenous P vivax.	USL 9 Grosseto, Dipartimento Prevenz, I-58100 Grosseto, Italy; Ist Super Sanita, Dept Parasitol, I-00161 Rome, Italy; Osped Grosseto, Internal Med Unit, Grosseto, Italy; Osped Grosseto, Haematol Lab, Grosseto, Italy; Osped Grosseto, Infect Dis Unit, Grosseto, Italy	Istituto Superiore di Sanita (ISS)	Baldari, M (corresponding author), USL 9 Grosseto, Dipartimento Prevenz, Via Manetti 31, I-58100 Grosseto, Italy.		SEVERINI, CARLO/C-4977-2016	SEVERINI, CARLO/0000-0002-6545-0278				BETTINI S, WHO VBC SERIES; DEZOLUETA J, 1975, B WORLD HEALTH ORGAN, V52, P109; HACKETT L. W., 1935, RIV MALANOL, V14, P45; RAMSDALE C D, 1975, Parassitologia (Rome), V17, P39; Romi R, 1997, J MED ENTOMOL, V34, P263, DOI 10.1093/jmedent/34.3.263; ROSENBERG R, 1989, SCIENCE, V245, P973, DOI 10.1126/science.2672336; Sabatinelli G., 1996, Giornale Italiano di Medicina Tropicale, V1, P23; SABATINELLI G, 1994, EUR J EPIDEMIOL, V10, P309; SAUTET J, 1971, PRESSE MED, V79, P524; WHITE GB, 1996, MANSONS TROPICAL DIS, P1674; ZAHAR AR, WHOVBC SERIES	11	89	96	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1246	1247		10.1016/S0140-6736(97)10312-9	http://dx.doi.org/10.1016/S0140-6736(97)10312-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643745				2022-12-28	WOS:000073283600011
J	Horton, R				Horton, R			Lancet fellowships 1998/99	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Horton, R (corresponding author), The Lancet, London WC1B 3SL, England.								0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1076	1076		10.1016/S0140-6736(05)79377-6	http://dx.doi.org/10.1016/S0140-6736(05)79377-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660574				2022-12-28	WOS:000073090200006
J	Yablonski, D; Kuhne, MR; Kadlecek, T; Weiss, A				Yablonski, D; Kuhne, MR; Kadlecek, T; Weiss, A			Uncoupling of nonreceptor tyrosine kinases from PLC-gamma 1 in an SLP-76-deficient T cell	SCIENCE			English	Article							ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; GENE-EXPRESSION; ACTIVATION; PHOSPHORYLATION; SLP-76; PROTEIN; PHOSPHOPROTEIN; GRB2	Activation of nonreceptor protein tyrosine kinases (PTKs) is essential for T cell receptor (TCR) responsiveness; however, the function of individual PTK substrates is often uncertain. A mutant T cell Line was isolated that Lacked expression of SLP-76 (SH2 domain-containing Leukocyte protein of 76 kilodaltons), a hematopoietically expressed adaptor protein and PTK substrate. SLP-76 was not required for TCR-induced tyrosine phosphorylation of most proteins, but was required for optimal tyrosine phosphorylation and activation of phospholipase C-gamma l (PLC-gamma l), as well as Ras pathway activation. TCR-inducible gene expression was dependent on SLP-76. Thus, coupling of TCR-regulated PTKs to downstream signaling pathways requires SLP-76.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weiss, A (corresponding author), Univ Calif San Francisco, Dept Med, Box 0795, San Francisco, CA 94143 USA.			Kadlecek, Theresa/0000-0002-1020-8169; Yablonski, Deborah/0000-0003-2979-0440	NATIONAL CANCER INSTITUTE [R01CA072531] Funding Source: NIH RePORTER; NCI NIH HHS [CA72531] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUDAY L, 1994, J BIOL CHEM, V269, P9019; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Fang N, 1996, J IMMUNOL, V157, P3769; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZHANG R, 1995, NATURE, V374, P471; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	32	358	364	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					413	416		10.1126/science.281.5375.413	http://dx.doi.org/10.1126/science.281.5375.413			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665884				2022-12-28	WOS:000074918800047
J	Ostergaard, L; Andersen, B; Olesen, F; Moller, JK				Ostergaard, L; Andersen, B; Olesen, F; Moller, JK			Efficacy of home sampling for screening of Chlamydia trachomatis: randomised study	BRITISH MEDICAL JOURNAL			English	Article							INFECTION; WOMEN		Aarhus Univ Hosp, Dept Infect Dis, DK-8000 Aarhus C, Denmark; Aarhus Univ, Res Unit Gen Practice, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Clin Microbiol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University; Aarhus University	Ostergaard, L (corresponding author), Aarhus Univ Hosp, Dept Infect Dis, PP Orumsgade 11, DK-8000 Aarhus C, Denmark.		Andersen, Berit/J-3402-2017; Ostergaard, Lars/AAA-3020-2020	Andersen, Berit/0000-0003-4074-6504; Ostergaard, Lars/0000-0003-2459-0511; Moller, Jens Kjolseth/0000-0002-5547-5498; Ostergaard, Lars/0000-0002-7619-605X				Andersen B, 1998, BMJ-BRIT MED J, V316, P350, DOI 10.1136/bmj.316.7128.350; OSTERGAARD L, 1995, J CLIN MICROBIOL, V33, P2620, DOI 10.1128/JCM.33.10.2620-2623.1995; Ostergaard L, 1996, BRIT MED J, V313, P1186, DOI 10.1136/bmj.313.7066.1186; Ronsmans C, 1996, GENITOURIN MED, V72, P182; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103	5	83	83	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					26	27		10.1136/bmj.317.7150.26	http://dx.doi.org/10.1136/bmj.317.7150.26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651263	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000075081600019
J	Scherer, RP; Aldahan, A; Tulaczyk, S; Possnert, G; Engelhardt, H; Kamb, B				Scherer, RP; Aldahan, A; Tulaczyk, S; Possnert, G; Engelhardt, H; Kamb, B			Pleistocene collapse of the West Antarctic ice sheet	SCIENCE			English	Article							STREAM-B; BENEATH; DEPOSITS; ISLAND; EVENTS; SHELF; SEA	Some glacial sediment samples recovered from beneath the West Antarctic ice sheet at ice stream B contain Quaternary diatoms and up to 10(8) atoms of beryllium-10 per gram. Other samples contain no Quaternary diatoms and only background levels of beryllium-10 (less than 10(6) atoms per gram). The occurrence of young diatoms and high concentrations of beryllium-10 beneath grounded ice indicates that the Ross Embayment was an open marine environment after a late Pleistocene collapse of the marine ice sheet.	Uppsala Univ, Dept Earth Sci, S-75236 Uppsala, Sweden; CALTECH, Dept Geol & Planetary Sci, Pasadena, CA 91125 USA; Uppsala Univ, Angstrom Lab, Tandem Lab, Uppsala, Sweden	Uppsala University; California Institute of Technology; Uppsala University	Scherer, RP (corresponding author), Uppsala Univ, Dept Earth Sci, Villavagen 16, S-75236 Uppsala, Sweden.	reed.scherer@natgeog.uu.se	Tulaczyk, Slawek/O-7375-2018	Tulaczyk, Slawek/0000-0002-9711-4332				ALDAHAN A, IN PRESS Q SCI REV; Aldahan AA, 1997, MAR GEOL, V144, P147, DOI 10.1016/S0025-3227(97)00084-4; ALLEY RB, 1986, NATURE, V322, P57, DOI 10.1038/322057a0; ALLEY RB, 1991, SCIENCE, V254, P959, DOI 10.1126/science.254.5034.959; BARRON J, 1996, 96173 US GEOL SURV O; Bentley CR, 1997, SCIENCE, V275, P1077, DOI 10.1126/science.275.5303.1077; Bindschadler R, 1998, SCIENCE, V279, P689, DOI 10.1126/science.279.5351.689; BINDSHADLER R, 1997, SCIENCE, V276, P5313; BLANKENSHIP DD, 1986, NATURE, V322, P54, DOI 10.1038/322054a0; BRANCOLINI G, 1995, GEOLOGY SEISMIC STRA, V68, P209; *CAP ROB SCI TEAM, 1998, TERRA ANTARTICA, V5, P1; COOPER AK, 1991, MAR GEOL, V102, P175, DOI 10.1016/0025-3227(91)90008-R; Doake CSM, 1998, NATURE, V391, P778, DOI 10.1038/35832; EISENHAUER A, 1994, EARTH PLANET SC LETT, V124, P171, DOI 10.1016/0012-821X(94)00069-7; Engelhardt H, 1997, J GLACIOL, V43, P207, DOI 10.3189/S0022143000003166; ENGELHARDT H, 1990, SCIENCE, V248, P57, DOI 10.1126/science.248.4951.57; Gersonde R, 1998, MICROPALEONTOLOGY, V44, P84, DOI 10.2307/1486086; HARWOOD DM, 1989, MAR MICROPALEONTOL, V15, P91, DOI 10.1016/0377-8398(89)90006-6; HAYES DE, 1975, INIT REPTS DEEP SEA, V28, P912; HODELL DA, 1993, PALEOCEANOGRAPHY, V8, P47, DOI 10.1029/92PA02774; Howard WR, 1997, NATURE, V388, P418, DOI 10.1038/41201; Jackson M, 1997, J GLACIOL, V43, P415, DOI 10.3189/S0022143000035000; Kellogg DE, 1996, GEOLOGY, V24, P115, DOI 10.1130/0091-7613(1996)024<0115:DISPII>2.3.CO;2; Kindler P, 1997, GEOLOGY, V25, P1147, DOI 10.1130/0091-7613(1997)025<1147:RSLCAT>2.3.CO;2; MACAYEAL DR, 1992, NATURE, V359, P29, DOI 10.1038/359029a0; MERCER JH, 1978, NATURE, V271, P321, DOI 10.1038/271321a0; Neumann AC, 1996, GEOLOGY, V24, P775; ROONEY ST, 1987, J GEOPHYS RES-SOLID, V92, P8913, DOI 10.1029/JB092iB09p08913; Rott H, 1996, SCIENCE, V271, P788, DOI 10.1126/science.271.5250.788; SCHERER R, 1993, J GLACIOL, V39, P716, DOI 10.3189/S0022143000016671; Scherer Reed P., 1994, Journal of Paleolimnology, V12, P171, DOI 10.1007/BF00678093; SCHERER RP, 1994, ANTARCT J US, V29, P11; SCHERER RP, 1992, THESIS OHIO STATE U; SHERMAN CE, 1993, GEOLOGY, V21, P1079, DOI 10.1130/0091-7613(1993)021<1079:NEFTHO>2.3.CO;2; Spielhagen RF, 1997, GEOLOGY, V25, P783, DOI 10.1130/0091-7613(1997)025<0783:AOEFLQ>2.3.CO;2; Tulaczyk S, 1998, J SEDIMENT RES, V68, P487, DOI 10.2110/jsr.68.487; WARD BL, 1986, J FORAMIN RES, V16, P176, DOI 10.2113/gsjfr.16.3.176; WARRICK RA, 1996, 2 ASSESSMENT REPORT; YOU CF, 1994, GEOCHIM COSMOCHIM AC, V58, P4887, DOI 10.1016/0016-7037(94)90219-4	39	204	211	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					82	85		10.1126/science.281.5373.82	http://dx.doi.org/10.1126/science.281.5373.82			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651249				2022-12-28	WOS:000074685800041
J	Welch, MD; Rosenblatt, J; Skoble, J; Portnoy, DA; Mitchison, TJ				Welch, MD; Rosenblatt, J; Skoble, J; Portnoy, DA; Mitchison, TJ			Interaction of human Arp2/3 complex and the Listeria monocytogenes ActA protein in actin filament nucleation	SCIENCE			English	Article							HOST-CELL ACTIN; PROLINE-RICH REGION; SACCHAROMYCES-CEREVISIAE; OWN CYTOSKELETON; FOCAL ADHESION; MOTILITY; GENE; POLYMERIZATION; MOVEMENT; PROFILIN	Actin filament assembly at the cell surface of the pathogenic bacterium Listeria monocytogenes requires the bacterial ActA surface protein and the host cell Arp2/3 complex. Purified Arp2/3 complex accelerated the nucleation of actin polymerization in vitro, but pure ActA had no effect. However, when combined, the Arp2/3 complex and ActA synergistically stimulated the nucleation of actin filaments. This mechanism of activating the host Arp2/3 complex at the L. monocytogenes surface may be similar to the strategy used by cells to control Arp2/3 complex activity and hence the spatial and temporal distribution of actin polymerization.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; University of California System; University of California Berkeley	Welch, MD (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.		Rosenblatt, Jody/AAD-4260-2019	Rosenblatt, Jody/0000-0001-9460-5868	NIAID NIH HHS [AI26919] Funding Source: Medline; NIGMS NIH HHS [GM48027] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balasubramanian MK, 1996, EMBO J, V15, P6426, DOI 10.1002/j.1460-2075.1996.tb01034.x; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Huang ME, 1996, YEAST, V12, P839, DOI 10.1002/(SICI)1097-0061(199607)12:9<839::AID-YEA982>3.0.CO;2-8; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; LEESMILLER JP, 1992, P NATL ACAD SCI USA, V89, P80, DOI 10.1073/pnas.89.1.80; Machesky LM, 1997, BIOCHEM J, V328, P105; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; McCollum D, 1996, EMBO J, V15, P6438, DOI 10.1002/j.1460-2075.1996.tb01035.x; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; Moreau V, 1996, J CELL BIOL, V134, P117, DOI 10.1083/jcb.134.1.117; Mourrain P, 1997, P NATL ACAD SCI USA, V94, P10034, DOI 10.1073/pnas.94.19.10034; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; SMITH GA, 1995, MOL MICROBIOL, V17, P945, DOI 10.1111/j.1365-2958.1995.mmi_17050945.x; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TILNEY LG, 1992, J CELL BIOL, V118, P71, DOI 10.1083/jcb.118.1.71; TILNEY LG, 1992, J CELL BIOL, V118, P83, DOI 10.1083/jcb.118.1.83; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; Walczak CE, 1997, J CELL BIOL, V136, P859, DOI 10.1083/jcb.136.4.859; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; WELCH MD, 1998, METHODS ENZYMOL, V298; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5	41	411	439	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					105	108		10.1126/science.281.5373.105	http://dx.doi.org/10.1126/science.281.5373.105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651243				2022-12-28	WOS:000074685800048
J	Rainey, PB; Travisano, M				Rainey, PB; Travisano, M			Adaptive radiation in a heterogeneous environment	NATURE			English	Article							EVOLUTION; ADAPTATION; BACTERIA; DIVERSIFICATION; POLYMORPHISM; POPULATIONS; DIVERGENCE; TESTS	Successive adaptive radiations have played a pivotal role in the evolution of biological diversity(1-3). The effects of adaptive radiation are often seen(4-6), but the underlying causes are difficult to disentangle and remain unclear(7-9). Here we examine directly the role of ecological opportunity and competition in driving genetic diversification. We use the common aerobic bacterium Pseudomonas fluorescens(10), which evolves rapidly under novel environmental conditions to generate a large repertoire of mutants(11-13). When provided with ecological opportunity (afforded by spatial structure), identical populations diversify morphologically, but when ecological opportunity is restricted there is no such divergence. In spatially structured environments, the evolution of variant morphs follows a predictable sequence and we show that competition among the newly evolved niche-specialists maintains this variation. These results demonstrate that the elementary processes of mutation and selection alone are suifficient to promote rapid proliferation of new designs and support the theory that trade-offs in competitive ability drive adaptive radiation(14,15).	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England	University of Oxford	Rainey, PB (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.	prainey@worf.molbiol.ox.ac.uk	Rainey, Paul/A-3207-2008; Travisano, Michael/AAI-4809-2020	Rainey, Paul/0000-0003-0879-5795; 				ABRAHAM DJ, 1987, PROTEINS, V2, P130, DOI 10.1002/prot.340020207; ATWOOD KC, 1951, P NATL ACAD SCI USA, V37, P146, DOI 10.1073/pnas.37.3.146; Bell G, 1997, HEREDITY, V78, P498, DOI 10.1038/hdy.1997.78; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; CHARLESWORTH B, 1982, EVOLUTION, V46, P16; CONNELL JH, 1961, ECOLOGY, V42, P710, DOI 10.2307/1933500; DOBZHANSKY T, 1972, SCIENCE, V177, P664, DOI 10.1126/science.177.4050.664; Elena SF, 1996, SCIENCE, V272, P1802, DOI 10.1126/science.272.5269.1802; Gould S. J., 1989, WONDERFUL LIFE BURGE; Grant P. R., 1986, ECOLOGY EVOLUTION DA; Haldane JB., 1990, CAUSES EVOLUTION; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; HEDRICK PW, 1986, ANNU REV ECOL SYST, V17, P535; HOPF FA, 1993, EVOL ECOL, V7, P142, DOI 10.1007/BF01239385; KLEIN D, 1993, NATURE, V364, P330, DOI 10.1038/364330a0; KORONA R, 1994, P NATL ACAD SCI USA, V91, P9037, DOI 10.1073/pnas.91.19.9037; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; MORRIS SC, 1979, SCI AM, V241, P122, DOI 10.1038/scientificamerican0779-122; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Otte D., 1989, SPECIATION ITS CONSE; Rainey PB, 1996, MOL MICROBIOL, V19, P521, DOI 10.1046/j.1365-2958.1996.391926.x; Rainey PB, 1993, ADV MICROB ECOL, P263; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; ROSENZWEIG RF, 1994, GENETICS, V137, P903; SCHLUTER D, 1994, SCIENCE, V266, P798, DOI 10.1126/science.266.5186.798; SHAPRIO JA, 1986, BACTERIA BIOL PSEUDO, P27; TAPER MT, 1994, OXFORD SURVEYS EVOLU, V8, P63; TRAVISANO M, 1995, SCIENCE, V267, P87, DOI 10.1126/science.7809610; Turner PE, 1996, ECOLOGY, V77, P2119, DOI 10.2307/2265706	30	860	878	3	425	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 2	1998	394	6688					69	72		10.1038/27900	http://dx.doi.org/10.1038/27900			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665128				2022-12-28	WOS:000074579600049
J	Roingeard, P; Brand, D				Roingeard, P; Brand, D			Budding of human immunodeficiency virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									CHU Tours, F-37044 Tours, France	CHU Tours	Roingeard, P (corresponding author), CHU Tours, F-37044 Tours, France.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					32	32		10.1056/NEJM199807023390106	http://dx.doi.org/10.1056/NEJM199807023390106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647877				2022-12-28	WOS:000074500000006
J	Tzivion, G; Luo, ZJ; Avruch, J				Tzivion, G; Luo, ZJ; Avruch, J			A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity	NATURE			English	Article							14-3-3-PROTEINS; ACTIVATION; C-RAF-1; IDENTIFICATION; PATHWAY; BINDING	cRaf-1 is a mitogen-activated protein kinase that is the main effector recruited by GTP-bound Ras in order to activate the MAP kinase pathway(1). Inactive Raf is found in the cytosol in a complex with Hsp90, Hsp50 (Cdc37)(2,3) and the 14-3-3 proteins(4). GTP-bound Ras binds Raf and is necessary but not sufficient for the stable activation of Raf that occurs in response to serum, epidermal growth factor, platelet-derived growth factor or insulin(5-8). These agents cause a two- to threefold increase in overall phosphorylation of Raf on serine/threonine residues(8,9), and treatment of cRaf-1 with protein (serine/threonine) phosphatases can deactivate it, at least partially(10). The role of 14-3-3 proteins in the regulation of Raf's kinase activity is uncertain(4,11) and is investigated here. Active Raf can be almost completely deactivated in vitro by displacement of 14-3-3 using synthetic phosphopeptides. Deactivation can be substantially reversed by addition of purified recombinant bacterial 14-3-3; however, Raf must have been previously activated in vivo to be reactivated by 14-3-3 in vitro. The ability of 14-3-3 to support Raf activity is dependent on phosphorylation of serine residues on Raf and on the integrity of the 14-3-3 dimer; mutant monomeric forms of 14-3-3, although able to bind Raf in vivo, do not enable Raf to be activated in vivo or restore Raf activity after displacement of 14-3-3 in vitro. The 14-3-3 protein is not required to induce dimerization of Raf, We propose that dimeric 14-3-3 is needed both to maintain Raf in an inactive state in the absence of GTP-bound Ras and to stabilize an active conformation of Raf produced during activation in vivo.	Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Avruch, J (corresponding author), Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu	Luo, Zhijun/AAE-9302-2019; Tzivion, Guri/D-8954-2011	Luo, Zhijun/0000-0001-8105-5289; 				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KNOCKEL L, 1997, GENE DEV, V11, P1140; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; STANCATO LE, 1995, J BIOL CHEM, V268, P21711; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUEN KL, 1995, ONCOGENE, V11, P825; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	28	383	391	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					88	92		10.1038/27938	http://dx.doi.org/10.1038/27938			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665134				2022-12-28	WOS:000074579600055
J	Grunewald, T; Lampe, J; Weissbrich, B; Reichmann, H				Grunewald, T; Lampe, J; Weissbrich, B; Reichmann, H			A 35-year-old bricklayer with hemimyoclonic jerks	LANCET			English	Article							SCLEROSING PANENCEPHALITIS		Tech Univ Dresden, Dept Neurol, D-01307 Dresden, Germany; Univ Wurzburg, Inst Immunol & Virol, Wurzburg, Germany	Technische Universitat Dresden; University of Wurzburg	Grunewald, T (corresponding author), Tech Univ Dresden, Dept Neurol, Fetscherstasse 74, D-01307 Dresden, Germany.							BILLETER MA, 1994, ANN NY ACAD SCI, V724, P367, DOI 10.1111/j.1749-6632.1994.tb38934.x; Dawson JR, 1933, AM J PATHOL, V9, P7; RADERMECKER J, 1949, ACTA NEUROL PSYCHIAT, V49, P222; RISK WS, 1979, ARCH NEUROL-CHICAGO, V36, P610, DOI 10.1001/archneur.1979.00500460044004; Singer C, 1997, MOVEMENT DISORD, V12, P342, DOI 10.1002/mds.870120313	5	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 27	1998	351	9120					1926	1926		10.1016/S0140-6736(98)04091-4	http://dx.doi.org/10.1016/S0140-6736(98)04091-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654261				2022-12-28	WOS:000074464700011
J	Heathfield, H; Pitty, D; Hanka, R				Heathfield, H; Pitty, D; Hanka, R			Evaluating information technology in health care: barriers and challenges	BRITISH MEDICAL JOURNAL			English	Article							DECISION-SUPPORT SYSTEMS; IMPLEMENTATION; NHS; MANAGEMENT; QUALITY		Univ Cambridge, Inst Publ Hlth, Med Informat Unit, Cambridge CB2 2SR, England; Manchester Metropolitan Univ, Dept Comp & Math, Manchester M15 6BH, Lancs, England; Royal Brompton Hosp, Healthcare Informat Team, London SW3 6LY, England	University of Cambridge; Manchester Metropolitan University; Royal Brompton Hospital	Heathfield, H (corresponding author), Univ Cambridge, Inst Publ Hlth, Med Informat Unit, Cambridge CB2 2SR, England.							ANDESEN JG, 1994, EVALUATING HEALTHCAR; BRENNAN S, 1997, BRIT J HEALTHC COMP, V14, P16; Dick R.S., 1991, COMPUTER BASED PATIE; Donaldson LJ, 1996, BRIT MED J, V312, P1371; Friedman C.P., 1997, EVALUATION METHODS M, P41; Heatherfield H A, 1995, Yearb Med Inform, P455; HEATHFIELD HA, 1993, METHOD INFORM MED, V32, P1; HEATHFIELD HA, IN PRESS J IT PEOPLE; IGBARIA M, 1995, INFORM MANAGE, V29, P227, DOI 10.1016/0378-7206(95)00031-0; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KAPLAN B, 1995, P 2 EUR C INF TECHN, P174; KAPLAN B, 1995, ACM SIGBIO NEWSLETTE, V15, P2; LEANING MS, 1993, BRIT MED J, V307, P217, DOI 10.1136/bmj.307.6898.217; Lee F, 1996, J AM MED INFORM ASSN, V3, P42, DOI 10.1136/jamia.1996.96342648; Lock C, 1996, BRIT MED J, V312, P1407; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; McManus C, 1996, QUAL HEALTH CARE, V5, P127, DOI 10.1136/qshc.5.3.127; MONGERSON P, 1995, J AM MED INFORM ASSN, V2, P79, DOI 10.1136/jamia.1995.95261909; Rotman BL, 1996, J AM MED INFORM ASSN, V3, P340, DOI 10.1136/jamia.1996.97035025; SULLIVAN F, 1995, BMJ-BRIT MED J, V311, P848, DOI 10.1136/bmj.311.7009.848; van Gennip E, 1995, ASSESSMENT EVALUATIO; VANDERLOO JA, 1995, ASSESSMENT EVALUATIO, P64; WALTON RT, 1997, BRIT MED J, V315, P37; Wise J, 1996, BRIT MED J, V313, P250, DOI 10.1136/bmj.313.7052.250a; WYATT J, 1990, MED INFORM, V15, P205, DOI 10.3109/14639239009025268; WYATT JC, 1995, BRIT MED J, V311, P175, DOI 10.1136/bmj.311.6998.175; WYATT JC, 1994, LANCET, V344, P1543, DOI 10.1016/S0140-6736(94)90353-0	27	128	129	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1959	1961		10.1136/bmj.316.7149.1959	http://dx.doi.org/10.1136/bmj.316.7149.1959			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641938	Green Published			2022-12-28	WOS:000074636700034
J	Pocovi, M; Cenarro, A; Civeira, F; Torralba, MA; Perez-Calvo, JI; Mozas, P; Giraldo, P; Giralt, M; Myers, RH; Cupples, LA; Ordovas, JM				Pocovi, M; Cenarro, A; Civeira, F; Torralba, MA; Perez-Calvo, JI; Mozas, P; Giraldo, P; Giralt, M; Myers, RH; Cupples, LA; Ordovas, JM			beta-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-alpha-lipoproteinaemia	LANCET			English	Article							HIGH-DENSITY-LIPOPROTEIN; ASHKENAZI JEWS; CHOLESTEROL; MUTATION; POPULATION; IDENTIFICATION; FREQUENCIES; GENOTYPE; DNA	Background Gaucher's disease is the most common lysosomal storage disorder, caused by deficiency of glucocerebrosidase resulting from homozygosity for any of several mutations of the glucocerebrosidase gene locus. Affected people have decreased concentrations of LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C). We assessed the association between mutations in the glucocerebrosidase locus and hypo-alpha-lipoproteinaemia. Methods We studied 258 people from 43 unrelated Spanish families. 57 participants were affected, 137 were nonaffected carriers, and 64 were non-carriers. We determined glucocerebrosidase genotypes and measured plasmid lipids, apolipoproteins A-I, B, and E, and leucocyte glucocerebrosidase activity. Findings The most common glucocerebrosidase mutations were N37OS (45%), L444P (23%), and G377S (5%). Deletions and recombinants accounted for another 5%, and point mutations in exons 5, 6, 9, and 10 were present in 12%, Affected participants had lower LDL-C and HDL-C concentrations than non-affected carriers (p<0.001) and non-carriers (p<0 001). HDL-C values were also significantly different between the non-affected carriers and non-carriers. Mutations at this locus may account for as much as 19.5% of the genetic variability in HDL-C in the population studied. Interpretation Heterozygosity for these mutations at the glucocerebrosidase locus does not result in clinical expression of Gaucher's disease but can decrease HDLC concentrations, Given the high frequency of these mutations, the glucocerebrosidase locus might lead to familial low alpha-lipoproteinaemia in up to 2% of the general population and be one of the most common known genetic causes of HDL-C.	Univ Zaragoza, Fac Sci, Dept Biochem Mol & Cellular Biol, E-50009 Zaragoza, Spain; Univ Hosp, Dept Internal Med, Zaragoza, Spain; Hosp Miguel Servet, Dept Internal Med, Zaragoza, Spain; Hosp Miguel Servet, Dept Haematol, Zaragoza, Spain; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Publ Hlth, Boston, MA 02118 USA; Tufts Univ, Lipid Metab Lab JM HNRCA, Boston, MA 02111 USA	University of Zaragoza; Miguel Servet University Hospital; Miguel Servet University Hospital; Miguel Servet University Hospital; Boston University; Boston University; Tufts University; United States Department of Agriculture (USDA)	Ordovas, JM (corresponding author), Tufts Univ, JM USDA Human Nutr Res Ctr, 711 Washington St, Boston, MA 02111 USA.	ordovas_li@hnrc.tufts.edu	Calvo, Juan Ignacio Pérez/I-4194-2019; MOZAS, PILAR/AAR-8624-2021; Ordovas, Jose/B-8727-2013	Calvo, Juan Ignacio Pérez/0000-0003-2361-9941; Ordovas, Jose/0000-0002-7581-5680; Myers, Richard/0000-0002-8365-2674	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054776] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54776] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AMARAL O, 1993, BIOCHEM MED METAB B, V49, P97, DOI 10.1006/bmmb.1993.1011; BEUTLER E, 1990, CLIN CHIM ACTA, V194, P161, DOI 10.1016/0009-8981(90)90130-K; BEUTLER E, 1994, HUM MUTAT, V4, P212, DOI 10.1002/humu.1380040307; BEUTLER E, 1991, NEW ENGL J MED, V325, P1354; BEUTLER E, 1994, MOL MED, V1, P82, DOI 10.1007/bf03403534; BEUTLER E, 1993, AM J HUM GENET, V52, P85; Beutler E., 1995, METABOLIC MOL BASES, P2641; BOERWINKLE E, 1987, ANN HUM GENET, V51, P211, DOI 10.1111/j.1469-1809.1987.tb00874.x; Cormand B, 1997, HUM GENET, V100, P75, DOI 10.1007/s004390050468; DeMarchi JM, 1996, HUM MUTAT, V8, P116; FRANCESCHINI G, 1980, J CLIN INVEST, V66, P892, DOI 10.1172/JCI109956; GINSBERG H, 1984, CLIN GENET, V26, P109; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GRABOWSKI GA, 1993, ADV HUM GENET, V21, P377; LACERDA L, 1994, CLIN GENET, V45, P298; LAUBSCHER KH, 1994, HUM MUTAT, V3, P411, DOI 10.1002/humu.1380030418; LE NA, 1988, METABOLISM, V37, P240, DOI 10.1016/0026-0495(88)90102-3; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MIDDLETONPRICE HR, 1988, HUM GENET, V79, P283, DOI 10.1007/BF00366253; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MISTRY PK, 1995, LANCET, V346, P982, DOI 10.1016/S0140-6736(95)91680-6; *NIH, 1995, GAUCH DIS CURR ISS D; RAGHAVAN SS, 1980, AM J HUM GENET, V32, P158; UCHIYAMA A, 1994, HUM MOL GENET, V3, P1183, DOI 10.1093/hmg/3.7.1183; ZIMRAN A, 1989, LANCET, V2, P349; ZIMRAN A, 1991, AM J HUM GENET, V49, P855	27	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1919	1923		10.1016/S0140-6736(97)09490-7	http://dx.doi.org/10.1016/S0140-6736(97)09490-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654259	hybrid			2022-12-28	WOS:000074464700009
J	Poldrack, RA; Gabrieli, JDE				Poldrack, RA; Gabrieli, JDE			Memory and the brain: What's right and what's left?	CELL			English	Review									Stanford Univ, Dept Psychol, Stanford, CA 94305 USA	Stanford University	Poldrack, RA (corresponding author), Stanford Univ, Dept Psychol, Stanford, CA 94305 USA.		Gabrieli, John/AAJ-2869-2020					Buckner RL, 1996, P NATL ACAD SCI USA, V93, P1249, DOI 10.1073/pnas.93.3.1249; Cohen N. J., 1993, MEMORY AMNESIA HIPPO; Dolan RJ, 1997, NATURE, V388, P582, DOI 10.1038/41561; Gabrieli JDE, 1998, P NATL ACAD SCI USA, V95, P906, DOI 10.1073/pnas.95.3.906; Haxby JV, 1995, HUM BRAIN MAPP, V3, P68, DOI 10.1002/hbm.460030204; Kelley WM, 1998, NEURON, V20, P927, DOI 10.1016/S0896-6273(00)80474-2; Klingberg T, 1998, CEREB CORTEX, V8, P73, DOI 10.1093/cercor/8.1.73; MILNER B, 1982, PHILOS T R SOC B, V298, P211, DOI 10.1098/rstb.1982.0083; MILNER B, 1970, BIOL MEMORY; Nyberg L, 1996, PSYCHON B REV, V3, P135, DOI 10.3758/BF03212412; Poldrack RA, 1997, J CLIN NEUROPHYSIOL, V14, P294, DOI 10.1097/00004691-199707000-00003; RAICHLE ME, 1994, ANNU REV PSYCHOL, V45, P333, DOI 10.1146/annurev.psych.45.1.333; SHIMAMURA AP, 1995, COGNITIVE NEUROSCIEN; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; WAGNER AD, 1998, IN PRESS BRAIN	16	14	14	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1091	1093		10.1016/S0092-8674(00)81451-8	http://dx.doi.org/10.1016/S0092-8674(00)81451-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657140	Bronze			2022-12-28	WOS:000074491100002
J	Benke, TA; Luthi, A; Isaac, JTR; Collingridge, GL				Benke, TA; Luthi, A; Isaac, JTR; Collingridge, GL			Modulation of AMPA receptor unitary conductance by synaptic activity	NATURE			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; EXCITATORY AMINO-ACIDS; HIPPOCAMPAL-NEURONS; PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; SILENT SYNAPSES; BRAIN-SLICES; GLUTAMATE; CHANNELS	Activity-dependent alteration in synaptic strength is a fundamental property of the vertebrate central nervous system and is thought to underlie learning and memory. The most extensively studied model of activity-dependent synaptic plasticity is longterm potentiation (LTP) of glutamate-responsive (glutamatergic) synapses, a widespread phenomenon involving multiple mechanisms(1). The best characterized form of LTP occurs in the CA1 region of the hippocampus, in which LTP is initiated by transient activation of NMDA (N-methyl-D-aspartate) receptors and is expressed as a persistent increase in synaptic transmission through AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole pionate) receptors(2). This increase is due, at least in part, to a postsynaptic modification of AMPA-receptor function(3); this modification could be caused by an increase in the number of receptors, their open probability, their kinetics or their single-channel conductance. Here we show that the induction of LTP in the CA1 region of the hippocampus is often associated with an increase in single-channel conductance of AMPA receptors. This shows that elementary channel properties can be rapidly modified by synaptic activity and provides an insight into one molecular mechanism by which glutamatergic synapses can alter their strength.	Univ Bristol, Sch Med Sci, Dept Anat, Bristol BS8 1TD, Avon, England	University of Bristol	Collingridge, GL (corresponding author), Univ Bristol, Sch Med Sci, Dept Anat, Univ Walk, Bristol BS8 1TD, Avon, England.		collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015	Collingridge, Graham L/0000-0002-9572-5359	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CLAY JR, 1983, BIOPHYS J, V42, P151, DOI 10.1016/S0006-3495(83)84381-1; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DE KONINCK Y, 1994, J NEUROPHYSIOL, V71, P1318, DOI 10.1152/jn.1994.71.4.1318; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HINES M, 1984, INT J BIOMED COMPUT, V15, P69, DOI 10.1016/0020-7101(84)90008-4; HOMES WR, 1990, J NEUROPHYSIOL, V63, P1148; Isaac JTR, 1996, P NATL ACAD SCI USA, V93, P8710, DOI 10.1073/pnas.93.16.8710; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MAJOR G, 1994, J NEUROSCI, V14, P4613; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; SHRIKE AM, 1997, J NEUROPHYSIOL, V78, P2682; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325, DOI 10.1113/jphysiol.1995.sp020521; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Traynelis SF, 1997, J PHYSIOL-LONDON, V503, P513, DOI 10.1111/j.1469-7793.1997.513bg.x; TRAYNELIS SF, 1993, NEURON, V11, P279, DOI 10.1016/0896-6273(93)90184-S; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455	30	397	411	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1998	393	6687					793	797		10.1038/31709	http://dx.doi.org/10.1038/31709			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655394				2022-12-28	WOS:000074433100051
J	Choo, V				Choo, V			Outlook for sexually transmitted diseases	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Choo, V (corresponding author), Lancet, London WC1B 3SL, England.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1832	1832		10.1016/S0140-6736(05)78803-6	http://dx.doi.org/10.1016/S0140-6736(05)78803-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652665				2022-12-28	WOS:000074347100008
J	Marshall, SJ				Marshall, SJ			On being a ginseng connoisseur	LANCET			English	Editorial Material																			0	1	1	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1898	1898		10.1016/S0140-6736(05)78859-0	http://dx.doi.org/10.1016/S0140-6736(05)78859-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652710				2022-12-28	WOS:000074347100072
J	Gerbase, AC; Rowley, JT; Mertens, TE				Gerbase, AC; Rowley, JT; Mertens, TE			Global epidemiology of sexually transmitted diseases	LANCET			English	Article							HIV-INFECTION; IMPACT; WOMEN		WHO, CH-1211 Geneva 27, Switzerland; MRC Labs, Banjul, Gambia	World Health Organization; MRC Laboratory Molecular Biology	Gerbase, AC (corresponding author), WHO, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	gerbasea@who.ch		Mertens, Thierry Eric/0000-0002-1593-6608				ANDERSON R M, 1991; [Anonymous], 1995, Bull World Health Organ, V73 Suppl, P1; [Anonymous], 1993, WORLD DEV REPORT 199; BEHETS FMT, 1995, J INFECT DIS, V172, P764, DOI 10.1093/infdis/172.3.764; BRANDT A, 1987, NO MAGIC BULLET; GERBASE AC, 1998, IN PRESS GENITOURIN; Gilson L, 1997, LANCET, V350, P1805, DOI 10.1016/S0140-6736(97)08222-6; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; MERTENS TE, 1997, AIDS BIOL DIAGNOSIS; *MIN HLTH CHILD WE, 1995, NAT AIDS COORD PROGR; *NAT I PUBL HLTH, 1993, MSIS REP; *PAHO WHO, 1992, AIDS HIV STD ANN SUR; ROWLEY J, 1998, HLTH DIMENSIONS SEX; Ward H, 1997, HEALTH POLICY PLANN, V12, P19, DOI 10.1093/heapol/12.1.19; WASSERHEIT JN, 1989, INT J GYNECOL OBSTET, P145; *WHO UNAIDS, 1997, SEX TRANSM DIS POL P	19	227	240	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN	1998	351			3			2	4						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV844	9652711				2022-12-28	WOS:000074347300002
J	Vaidya, JS				Vaidya, JS			Interpretation of thrombosis prevention trial	LANCET			English	Letter									UCL, Dept Surg, London W1P 7LD, England	University of London; University College London	Vaidya, JS (corresponding author), UCL, Dept Surg, London W1P 7LD, England.		Iacoviello, Licia/AGX-7071-2022; Vaidya, Jayant S/A-7218-2008; Fahey, Tom/C-9367-2012; Donati, Maria Benedetta/K-6606-2016	Iacoviello, Licia/0000-0003-0514-5885; Vaidya, Jayant S/0000-0003-1760-1278; Fahey, Tom/0000-0002-5896-5783; Donati, Maria Benedetta/0000-0003-1747-5443				Howard G, 1998, JAMA-J AM MED ASSOC, V279, P119, DOI 10.1001/jama.279.2.119; JOSEFSON D, 1998, BRIT MED J, V316, P329; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; Verheugt FWA, 1998, LANCET, V351, P227, DOI 10.1016/S0140-6736(05)78280-5	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1204	1204		10.1016/S0140-6736(98)26016-8	http://dx.doi.org/10.1016/S0140-6736(98)26016-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643712				2022-12-28	WOS:000073220200050
J	Sliwa, K; Skudicky, D; Candy, G; Wisenbaugh, T; Sareli, P				Sliwa, K; Skudicky, D; Candy, G; Wisenbaugh, T; Sareli, P			Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy	LANCET			English	Article							NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; CHRONIC HEART-FAILURE; CIRCULATING LEVELS; CARDIAC MYOCYTES; OXPENTIFYLLINE; CYTOKINES; DISEASE	Background There is accumulating evidence that inflammatory cytokines have an important role in the pathogenesis of heart failure, Plasma concentrations of tumour necrosis factor a (TNF-alpha) are high in heart failure and have been correlated with the severity of symptoms. Pentoxifylline suppresses the production of TNF-alpha. This study aimed to assess the effects of pentoxifylline on left-ventricular function and functional class in patients with idiopathic dilated cardiomyopathy. Methods We undertook a single-centre, prospective, double-blind, randomised, placebo-controlled trial, in which 28 patients with idiopathic dilated cardiomyopathy were assigned pentoxifylline 400 mg three times daily or matching placebo. Clinical, echocardiographic, and radionuclide assessments were done at baseline and after 6 months of treatment, Primary endpoints were New York Heart Association (NYHA) functional class and left-ventricular function. Findings Baseline characteristics were similar in the two groups. Four patients died during the study period, all in the placebo group. After 6 months of treatment, the proportion of patients in NYHA functional class I or II was higher in the pentoxifylline group than in the placebo group (14/14 vs 10/14; p=0.01), and ejection fraction was higher in the pentoxifylline group than in the placebo group (mean 38.7% [SD 15.0] vs 26.8% [11.0], p=0.04). At 6 months, TNF-alpha plasma concentrations were significantly lower in the pentoxifylline-treated group than in the placebo group (2.1 [1.0] vs 6.5 [5.0] pg/mL, p=0.001). Interpretation Our results suggest that pentoxifylline improves symptoms and left-ventricular systolic function in patients with idiopathic dilated cardiomyopathy. These results must be confirmed in larger-scale trials.	Univ Witwatersrand, Dept Cardiol, Baragwanath Hosp, ZA-2013 Johannesburg, South Africa; Univ Witwatersrand, Baragwanath Hosp, Dept Nucl Med, ZA-2013 Johannesburg, South Africa	University of Witwatersrand; University of Witwatersrand	Skudicky, D (corresponding author), Univ Witwatersrand, Dept Cardiol, Baragwanath Hosp, PO Bertsham, ZA-2013 Johannesburg, South Africa.			Sliwa, Karen/0000-0002-8272-0911				ANTIN JH, 1992, BLOOD, V80, P2964; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BORROW KM, 1982, AM HEART J, V103, P879; CALDERON MJ, 1993, BRIT J DERMATOL, V128, P706, DOI 10.1111/j.1365-2133.1993.tb00276.x; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; Habib FM, 1996, LANCET, V347, P1151, DOI 10.1016/S0140-6736(96)90610-8; HEGEWISCH S, 1990, LANCET, V335, P294, DOI 10.1016/0140-6736(90)90115-L; KAPADIA S, 1995, AM J PHYSIOL-HEART C, V268, pH517, DOI 10.1152/ajpheart.1995.268.2.H517; Kelly RA, 1997, CIRCULATION, V95, P778; KREMSNER PG, 1991, J INFECT DIS, V164, P605, DOI 10.1093/infdis/164.3.605; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; MACDONALD MJ, 1994, JAMA-J AM MED ASSOC, V271, P27, DOI 10.1001/jama.271.1.27; MAKSYMOWYCH WP, 1995, J RHEUMATOL, V22, P625; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PINSKY DJ, 1995, J CLIN INVEST, V95, P677, DOI 10.1172/JCI117713; QUINONES MA, 1980, AM J CARDIOL, V45, P782, DOI 10.1016/0002-9149(80)90122-8; REIBER JHC, 1985, EUR J NUCL MED, V10, P97, DOI 10.1007/BF00252715; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; Testa M, 1996, J AM COLL CARDIOL, V28, P964, DOI 10.1016/S0735-1097(96)00268-9; TorreAmione G, 1996, J AM COLL CARDIOL, V27, P1201, DOI 10.1016/0735-1097(95)00589-7; WAAGE A, 1990, LANCET, V335, P543, DOI 10.1016/0140-6736(90)90779-5; WARD A, 1987, DRUGS, V34, P50, DOI 10.2165/00003495-198734010-00003; ZABEL P, 1989, LANCET, V2, P1474	24	168	180	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1091	1093		10.1016/S0140-6736(97)09338-0	http://dx.doi.org/10.1016/S0140-6736(97)09338-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660578				2022-12-28	WOS:000073090200010
J	Ferro, D; Basili, S; Alessandri, C; Mantovani, B; Cordova, C; Violi, F				Ferro, D; Basili, S; Alessandri, C; Mantovani, B; Cordova, C; Violi, F			Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia	LANCET			English	Article							CHOLESTEROL; INDUCTION		UNIV ROMA LA SAPIENZA, IST CLIN MED 1, I-00185 ROME, ITALY; UNIV ROMA LA SAPIENZA, IST TERAPIA MED SISTEMAT, I-00185 ROME, ITALY; UNIV ROMA LA SAPIENZA, IST TERAPIA MED, I-00185 ROME, ITALY	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome			Basili, Stefania/K-4024-2016; Violi, Francesco/K-1509-2016; ferro, domenico/AAT-5861-2020	Basili, Stefania/0000-0002-6987-1926; Violi, Francesco/0000-0002-6610-7068; 				KORNBERG A, 1994, J IMMUNOL, V153, P1328; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SEMERARO N, 1983, IMMUNOLOGY, V50, P529; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2	5	60	62	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 25	1997	350	9086					1222	1222		10.1016/S0140-6736(05)63452-6	http://dx.doi.org/10.1016/S0140-6736(05)63452-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652566				2022-12-28	WOS:A1997YD23800015
J	Wellwood, J; Sculpher, MJ; Stoker, D; Nicholls, GJ; Geddes, C; Whitehead, A; Singh, R; Spiegelhalter, D				Wellwood, J; Sculpher, MJ; Stoker, D; Nicholls, GJ; Geddes, C; Whitehead, A; Singh, R; Spiegelhalter, D			Randomised controlled trial of laparoscopic versus open mesh repair for inguinal hernia: outcome and cost	BRITISH MEDICAL JOURNAL			English	Article							TENSION-FREE HERNIOPLASTY; HEALTH SURVEY QUESTIONNAIRE; HERNIORRHAPHY; SF-36; SURGERY	Objective: To compare tension-free open mesh hernioplasty under local anaesthetic with transabdominal preperitoneal laparoscopic hernia repair under general anaesthetic. Design: A randomised controlled trial of 403 patients with inguinal hernias. Setting: Two acute general hospitals in London between May 1995 and December 1996. Subjects: 400 patients with a diagnosis of groin hernia, 200 in each group. Main outcome measures: Time until discharge, postoperative pain, and complications; patients' perceived health (SF-36), duration of convalescence, and patients' satisfaction with surgery; and health service costs. Results: More patients in the open group (96%) than in the laparoscopic group (89%) were discharged on the same day as the operation (chi(2) = 6.7; 1 df; P = 0.01). Although pain scores were lower in the open group while the effect of the local anaesthetic persisted (proportional odds ratio at 2 hours 3.5 (2.3 to 5.1)), scores after open repair were significantly higher for each day of the first week (0.5 (0.3 to 0.7) on day 7) and during the second week (0.? (0.5 to 0.9)). At 1 month there was a greater improvement (or less deterioration) in mean SF-36 scores over baseline in the laparoscopic group compared with the open group on seven of eight dimensions, reaching significance on five. For every activity considered the median time until return to normal was significantly shorter for the laparoscopic group. Patients randomised to laparoscopic repair were more satisfied with surgery at 1 month and 3 months after surgery. The mean cost per patient of laparoscopic repair was pound 335 (95% confidence interval pound 228 to pound 441) more than the cost of open repair: Conclusion: This study confirms that laparoscopic hernia repair has considerable short term clinical advantages after discharge compared with open mesh hernioplasty, although it was more expensive.	Whipps Cross Hosp, London E11 1NR, England; Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England	Brunel University	Wellwood, J (corresponding author), Whipps Cross Hosp, London E11 1NR, England.			Sculpher, Mark/0000-0003-3746-9913				AMID PK, 1993, AM J SURG, V165, P369, DOI 10.1016/S0002-9610(05)80847-5; BAILEY IS, 1992, BRIT MED J, V304, P469, DOI 10.1136/bmj.304.6825.469; BARKUN JS, 1995, SURGERY, V118, P703, DOI 10.1016/S0039-6060(05)80038-8; *BRIT MED ASS, 1996, BRIT NAT FORM; CORBITT JD, 1993, SURG LAPAROSC ENDOSC, V3, P328; COX DR, 1972, J R STAT SOC B, V34, P187; DEVLIN HB, 1986, BRIT J SURG, V73, P123, DOI 10.1002/bjs.1800730217; Drummond MF, 2015, METHODS EC EVALUATIO; Fenn P, 1996, J HEALTH ECON, V15, P115, DOI 10.1016/0167-6296(95)00016-X; Garratt A M, 1994, Qual Health Care, V3, P186, DOI 10.1136/qshc.3.4.186; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Hauters P, 1996, ANN CHIR, V50, P776; *HM TREAS, 1991, EV APPR CENTR GOV TE; JENKINSON C, 1994, QUAL LIFE RES, V3, P7, DOI 10.1007/BF00647843; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAWRENCE K, 1995, BRIT MED J, V311, P981; LEIBL B, 1995, CHIRURG, V66, P895; LICHTENSTEIN IL, 1989, AM J SURG, V157, P188, DOI 10.1016/0002-9610(89)90526-6; MADDERN GJ, 1994, SURG ENDOSC-ULTRAS, V8, P1404; MALONEY GE, 1948, LANCET, V2, P45; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; NETTEN A, 1996, UNIT COSTS HLTH SOCI; *NHS EX, 1996, HLTH SERV COST IND; Ruta D A, 1994, Qual Health Care, V3, P180, DOI 10.1136/qshc.3.4.180; SAS, 1989, SAS STAT US GUID; STOKER D, 1994, LANCET, V343, P1243, DOI 10.1016/S0140-6736(94)92148-2; TEASDALE C, 1982, ANN ROY COLL SURG, V64, P238; VOGT DM, 1995, AM J SURG, V169, P84, DOI 10.1016/S0002-9610(99)80114-7; Wright DM, 1996, SURGERY, V119, P552, DOI 10.1016/S0039-6060(96)80266-2	30	193	196	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					103	110		10.1136/bmj.317.7151.103	http://dx.doi.org/10.1136/bmj.317.7151.103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657784	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000075081700019
J	Agnelli, G; Piovella, F; Buoncristiani, P; Severi, P; Pini, M; D'Angelo, A; Beltrametti, C; Damiani, M; Andrioli, GC; Pugliese, R; Iorio, A; Brambilla, G				Agnelli, G; Piovella, F; Buoncristiani, P; Severi, P; Pini, M; D'Angelo, A; Beltrametti, C; Damiani, M; Andrioli, GC; Pugliese, R; Iorio, A; Brambilla, G			Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; INTERMITTENT PNEUMATIC COMPRESSION; LOW-DOSE HEPARIN; RANDOMIZED TRIAL; INTRACRANIAL DISEASE; HIP-SURGERY; PROPHYLAXIS; DIAGNOSIS; CALF	Background Compression stockings are recommended for prophylaxis against venous thromboembolism in patients undergoing neurosurgery, but anticoagulant agents have not gained wide acceptance because of concern about intracranial bleeding. Methods In a multicenter, randomized, double-blind trial, we assessed the efficacy and safety of enoxaparin in conjunction with the use of compression stockings in the prevention of venous thromboembolism in patients undergoing elective neurosurgery. Enoxaparin (40 mg once daily) or placebo was given subcutaneously for not less than seven days beginning within 24 hours after surgery. The primary end point was symptomatic, objectively confirmed venous thromboembolism or deep-vein thrombosis assessed by bilateral venography, which was performed in all patients on day 8+/-1. Bleeding side effects were carefully assessed. Results Among the 307 patients assigned to treatment groups, 129 of the 154 patients receiving placebo (84 percent) and 130 of the 153 patients receiving enoxaparin (85 percent) had venographic studies adequate for analysis. An additional patient in the placebo group died before venography of autopsy-confirmed pulmonary embolism. In this analysis, 42 patients given placebo (32 percent) and 22 patients given enoxaparin (17 percent) had deep-vein thrombosis (relative risk in the enoxaparin group, 0.52; 95 percent confidence interval, 0.33 to 0.82; P=0.004). The rates of proximal deep-vein thrombosis were 13 percent in patients receiving placebo and 5 percent in patients receiving enoxaparin (relative risk in the enoxaparin group, 0.41; 95 percent confidence interval, 0.17 to 0.95; P=0.04). Two patients in the placebo group died of autopsy-confirmed pulmonary embolism on days 9 and 16. Major bleeding occurred in four patients receiving placebo (intracranial bleeding in all four) and four patients (intracranial bleeding in three) receiving enoxaparin (3 percent of each group). Conclusions Enoxaparin combined with compression stockings is more effective than compression stockings alone for the prevention of venous thromboembolism after elective neurosurgery and does not cause excessive bleeding. (N Engl J Med 1998; 339:80-5.) (C)1998, Massachusetts Medical Society.	Univ Perugia, Ist Med Interna & Med Vasc, I-06123 Perugia, Italy; Osped Silvestrini, Div Neurochirurg, Perugia, Italy; Univ Pavia, Med Clin 2, I-27100 Pavia, Italy; Osped Galliera, Div Neurochirurg, Genoa, Italy; Azienda Osped, Div Med 5, Parma, Italy; Osped S Raffaele, Serv Coagulaz, Milan, Italy; Osped S Raffaele, Div Neurochirurg, Milan, Italy; Univ Pavia, Clin Neurochirurg, I-27100 Pavia, Italy	University of Perugia; University of Pavia; Ente Ospedaliero Ospedali Galliera; University of Parma; University Hospital of Parma; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Pavia	Agnelli, G (corresponding author), Univ Perugia, Ist Med Interna & Med Vasc, Via Enrico dal Pozzo, I-06123 Perugia, Italy.		Iorio, Alfonso/B-9478-2013; D'Angelo, Armando/K-2583-2018; Piovella, Franco/AAM-8305-2020	Iorio, Alfonso/0000-0002-3331-8766; D'Angelo, Armando/0000-0002-9857-4509; 				AGNELLI G, 1995, THROMB HAEMOSTASIS, V74, P1042; AGNELLI G, 1995, HAEMOSTASIS, V25, P40; BUCCI MN, 1989, SURG NEUROL, V32, P285, DOI 10.1016/0090-3019(89)90231-0; CERRATO D, 1978, J NEUROSURG, V49, P378, DOI 10.3171/jns.1978.49.3.0378; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; COLLINS R, 1977, THROMB HAEMOSTASIS, V38, P196; COOK DJ, 1995, CHEST, V108, P227; Fleiss JL, 1981, STATISTICAL METHODS, P19; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; Ricotta S, 1996, THROMB HAEMOSTASIS, V76, P887; SKILLMAN JJ, 1978, SURGERY, V83, P354; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; TURPIE AGG, 1989, ARCH INTERN MED, V149, P679, DOI 10.1001/archinte.149.3.679; TURPIE AGG, 1977, NEUROLOGY, V27, P435, DOI 10.1212/WNL.27.5.435; TURPIE AGG, 1979, THROMB RES, V15, P611, DOI 10.1016/0049-3848(79)90171-3; TURPIE AGG, 1985, THROMB RES, V39, P173, DOI 10.1016/0049-3848(85)90105-7; ZELIKOVSKI A, 1981, J NEUROSURG, V54, P652, DOI 10.3171/jns.1981.54.5.0652	22	383	392	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1998	339	2					80	85		10.1056/NEJM199807093390204	http://dx.doi.org/10.1056/NEJM199807093390204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY828	9654538	Bronze			2022-12-28	WOS:000074665300004
J	Snowdon, C; Garcia, J; Elbourne, D				Snowdon, C; Garcia, J; Elbourne, D			Reactions of participants to the results of a randomised controlled trial: exploratory study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives: To assess views of parents of babies who participated in a neonatal trial, about feedback of trial results. Design: Qualitative analysis of interviews. Setting: Parents' homes. Subjects: Parents of 24 surviving babies enrolled in a UK randomised controlled trial comparing ventilatory support by extracorporeal membrane oxygenation with conventional management Main outcome measures: Views about contents of results, reactions to results, effect of hindsight, and importance of feedback, Results: Information about mortality was well understood by the parents but morbidity was less clearly reported. Even when the content was emotionally exacting, the information was still wanted as it removed uncertainty; provided an endpoint to difficult events; promoted further discussion within couples; and acknowledged their contribution to answering an important clinical question. Conclusions: Feedback of trial results to participants should be a consideration of researchers, but a careful approach is required. This study was based on a highly selective group of parents within a particularly sensitive trial. More research is needed to assess the extent to which these results can be generalised to other trials or to groups such as bereaved parents.	Univ London London Sch Hyg & Trop Med, Med Stat Unit, London WC1E 7HT, England; Univ Oxford, Radcliffe Infirm, Natl Perinatal Epidemiol Unit, Oxford OX2 6HE, England	University of London; London School of Hygiene & Tropical Medicine; Radcliffe Infirmary; University of Oxford	Snowdon, C (corresponding author), Univ Cambridge, Ctr Family Res, Cambridge CB2 3RF, England.	CMS1000@cam.ac.uk		Snowdon, Claire/0000-0002-9133-5476	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*ASS IMPR MAT SERV, 1997, CHART ETH RES MAT CA; BUCHWALD H, 1993, CONTROL CLIN TRIALS, V14, P500, DOI 10.1016/0197-2456(93)90030-H; Bunin GR, 1996, PEDIATRICS, V97, P486; Douglas C, 1997, BRIT MED J, V314, P1134, DOI 10.1136/bmj.314.7087.1134; Field D, 1996, LANCET, V348, P75; GOODARE H, 1995, BMJ-BRIT MED J, V310, P1277, DOI 10.1136/bmj.310.6990.1277; Marshall S, 1996, BRIT MED J, V312, P186; MUHR T, 1991, QUALITATIVE SOCIOLOG; *ROYAL COLL PHYS, 1990, RES INV PATIENTS; SCHULTE PA, 1991, J CLIN EPIDEMIOL, V44, pS57; Snowdon C, 1997, SOC SCI MED, V45, P1337, DOI 10.1016/S0277-9536(97)00063-4; UK Collaborative ECMO Group, 1998, PEDIATRICS, V101, P690	12	68	68	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 4	1998	317	7150					21	26		10.1136/bmj.317.7150.21	http://dx.doi.org/10.1136/bmj.317.7150.21			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651262	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000075081600018
J	Fiorillo, CD; Williams, JT				Fiorillo, CD; Williams, JT			Glutamate mediates an inhibitory postsynaptic potential in dopamine neurons	NATURE			English	Article							CEREBELLAR GRANULE CELLS; VENTRAL TEGMENTAL AREA; EXCITATORY AMINO-ACID; SYNAPTIC POTENTIALS; RAT; RECEPTORS; CONDUCTANCE; BRAIN; CA-2+-ATPASE; ACTIVATION	Rapid information transfer within the brain depends on chemical signalling between neurons that is mediated primarily by glutamate and GABA (gamma-aminobutyric acid), acting at ionotropic receptors to cause excitatory or inhibitory postsynaptic potentials (EPSPs or IPSPs), respectively. In addition, synaptically released glutamate acts on metabotropic receptors to excite neurons on a slower timescale through second-messenger cascades, including phosphoinositide hydrolysis'. We now report a unique IPSP mediated by the activation of metabotropic glutamate receptors. Tn ventral midbrain dopamine neurons, activation of metabotropic glutamate receptors (mGluR1) mobilized calcium from caffeine/ryanodine-sensitive stores and increased an apamin-sensitive potassium conductance. The underlying potassium conductance and dependence on calcium stores set this IPSP apart from the slow IPSPs described so far(2-4). The mGluR-induced hyperpolarization was dependent on brief exposure to agonist, because prolonged application of exogenous agonist desensitized the hyperpolarization and caused the more commonly reported depolarization(1,5,6). The rapid rise and brief duration of synaptically released glutamate in the extracellular space can therefore mediate a rapid excitation through activation of ionotropic receptors, followed by inhibition through the mGluR1 receptor. Thus the idea that glutamate is solely an excitatory neurotransmitter must be replaced with a more complex view of its dual function in synaptic transmission.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University	Williams, JT (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Fiorillo, Christopher Dante/C-1718-2011	Fiorillo, Christopher/0000-0002-7232-9505				BRABET I, 1995, NEUROPHARMACOLOGY, V34, P895, DOI 10.1016/0028-3908(95)00079-L; CAMERON DL, 1993, NATURE, V366, P344, DOI 10.1038/366344a0; CHARPAK S, 1990, NATURE, V347, P765, DOI 10.1038/347765a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FAGNI L, 1991, EUR J NEUROSCI, V3, P778, DOI 10.1111/j.1460-9568.1991.tb01674.x; IRVING AJ, 1992, J PHYSIOL-LONDON, V456, P667, DOI 10.1113/jphysiol.1992.sp019360; Johnson SW, 1997, NEUROSCI LETT, V231, P13, DOI 10.1016/S0304-3940(97)00508-9; JOHNSON SW, 1992, J NEUROSCI, V12, P2000; JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136; KALIVAS PW, 1995, J NEUROSCI, V15, P5379, DOI 10.1523/jneurosci.15-07-05379.1995; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; KOLINSKI CM, INPRESS NEUROSCIENCE; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MERCURI NB, 1993, NEUROSCIENCE, V56, P399, DOI 10.1016/0306-4522(93)90341-C; Moroni F, 1997, J PHARMACOL EXP THER, V281, P721; OTIS TS, 1993, J PHYSIOL-LONDON, V463, P391, DOI 10.1113/jphysiol.1993.sp019600; PAN ZZ, 1989, J NEUROPHYSIOL, V62, P481, DOI 10.1152/jn.1989.62.2.481; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; ROUSSEAU E, 1987, AM J PHYSIOL, V253, P364; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Shen KZ, 1997, EUR J NEUROSCI, V9, P48, DOI 10.1111/j.1460-9568.1997.tb01352.x; SHEPARD PD, 1991, EXP BRAIN RES, V86, P141, DOI 10.1007/BF00231048; SHIRASAKI T, 1994, J PHYSIOL-LONDON, V475, P439, DOI 10.1113/jphysiol.1994.sp020084; SURPRENANT A, 1987, J PHYSIOL-LONDON, V382, P87, DOI 10.1113/jphysiol.1987.sp016357; TESTA CM, 1994, J NEUROSCI, V14, P3005; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466	30	226	232	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					78	82		10.1038/27919	http://dx.doi.org/10.1038/27919			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665131				2022-12-28	WOS:000074579600052
J	Flick, KE; Jurica, MS; Monnat, RJ; Stoddard, BL				Flick, KE; Jurica, MS; Monnat, RJ; Stoddard, BL			DNA binding and cleavage by the nuclear intron-encoded homing endonuclease I-PpoI	NATURE			English	Article							CRYSTAL-STRUCTURE; FINGER DOMAIN; MINOR-GROOVE; ZINC-FINGER; PROTEIN; RECOGNITION; COMPLEX; FAMILY; MOTIF	Homing endonucleases are a diverse collection of proteins that are encoded by genes with mobile, self-splicing introns(1-3). They have also been identified in self-splicing inteins (protein introns)(4). These enzymes promote the movement of the DNA sequences that encode them from one chromosome location to another; they do this by making a site-specific double-strand break at a target site in an allele that lacks the corresponding mobile intron(3). The target sites recognized by these small endonucleases are generally long (14-44 base pairs). Four families of homing endonucleases have been identified, including the LAGLIDADG, the His-Cys box, the GIY-YIG and the H-N-H endonucleases(1). The first identified His-Cys box homing endonuclease was I-PpoI from the slime mould Physarum polycephalum(5,6). Its gene resides in one of only a few nuclear introns known to exhibit genetic mobility(7). Here we report the structure of the I-PpoI homing endonuclease bound to homing-site DNA determined to 1.8 Angstrom resolution. I-PpoI displays an elongated fold of dimensions 25 x 35 x 80 Angstrom, with mixed (alpha/beta topology. Each I-PpoI monomer contains three antiparallel beta-sheets flanked by two long ol-helices and a long carboxy-terminal tail, and is stabilized by two bound zinc ions 15 Angstrom apart. The enzyme possesses a new zinc-bound fold and endonuclease active site. The structure has been determined in both uncleaved substrate and cleaved product complexes.	Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stoddard, BL (corresponding author), Univ Washington, Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	bstoddar@fred.fhcrc.org						BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BELFORT M, 1995, J BACTERIOL, V177, P3897, DOI 10.1128/jb.177.14.3897-3903.1995; Belfort M, 1995, J BIOL CHEM, V270, P30237, DOI 10.1074/jbc.270.51.30237; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; *DAR LAB, 1979, 4 CCP4 SERC UK COLL; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; ELLISON EL, 1993, MOL CELL BIOL, V13, P7531, DOI 10.1128/MCB.13.12.7531; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EVERETT RD, 1993, J MOL BIOL, V234, P1038, DOI 10.1006/jmbi.1993.1657; FLICK KE, 1997, PROTEIN SCI, V6, P1; Heath PJ, 1997, NAT STRUCT BIOL, V4, P468, DOI 10.1038/nsb0697-468; JOHANSEN S, 1993, NUCLEIC ACIDS RES, V21, P4405, DOI 10.1093/nar/21.18.4405; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LASKOWSKI RJ, 1993, J APPL CRYSTALLOGR, V26, P383; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PHILLIPS SEV, 1994, ANNU REV BIOPH BIOM, V23, P671, DOI 10.1146/annurev.bb.23.060194.003323; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; 1996, QUANTA96 XRAY STRUCT	27	187	197	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					96	101		10.1038/27952	http://dx.doi.org/10.1038/27952			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665136				2022-12-28	WOS:000074579600057
J	Kurokawa, M; Mitani, K; Irie, K; Matsuyama, T; Takahashi, T; Chiba, S; Yazaki, Y; Matsumoto, K; Hirai, H				Kurokawa, M; Mitani, K; Irie, K; Matsuyama, T; Takahashi, T; Chiba, S; Yazaki, Y; Matsumoto, K; Hirai, H			The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3	NATURE			English	Article							CHRONIC MYELOCYTIC-LEUKEMIA; TRANSFORMING ACTIVITY; MYELOID-LEUKEMIA; BLASTIC CRISIS; EXPRESSION; PROTEIN; GENE; ACTIVATION; RECEPTOR; DOMAIN	Evi-1 encodes a zinc-finger protein that may be involved in leukaemic transformation of haematopoietic cells(1-5). Evi-1 has two zinc-finger domains, one with seven repeats of a zinc-finger motif and one with three repeats(6), and it has characteristics of a transcriptional regulator(7,8). Although Evi-1 is thought to be able to promote growth and to block differentiation in some cell types(9-11), its biological functions are poorly understood. Here we study the mechanisms that underlie oncogenesis induced by Evi-1 by investigating whether Evi-1 perturbs signalling through transforming growth factor-beta (TGF-beta), one of the most studied growth-regulatory factors, which inhibits proliferation of a wide range of cell types(12). We show that Evi-1 represses TGF-beta signalling and antagonizes the growth-inhibitory effects of TGF-beta. Two separate regions of Evi-1 are responsible for this repression; one of these regions is the first zinc-finger domain. Through this domain, Evi-1 interacts with Smad3, an intracellular mediator of TGF-beta signalling(13), thereby suppressing the transcriptional activity of Smad3, These results define a new function of Evi-1 as a repressor of signalling through TGF-beta.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 1138655, Japan; Nagoya Univ, Fac Sci, Dept Biol Mol, Chikusa Ku, Nagoya, Aichi 46401, Japan	University of Tokyo; Nagoya University	Hirai, H (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.			Takahashi, Tokiharu/0000-0002-5785-8660				Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kurokawa M, 1996, J BIOL CHEM, V271, P16870, DOI 10.1074/jbc.271.28.16870; KUROKAWA M, 1995, ONCOGENE, V11, P833; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lopingco MC, 1996, CURR TOP MICROBIOL, V211, P211; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Ogawa S, 1996, LEUKEMIA, V10, P788; Ogawa S, 1996, ONCOGENE, V13, P183; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	29	298	312	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					92	96		10.1038/27945	http://dx.doi.org/10.1038/27945			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665135				2022-12-28	WOS:000074579600056
J	Betteridge, DJ; Kahn, M				Betteridge, DJ; Kahn, M			Genetic influence on HDL cholesterol	LANCET			English	Editorial Material							METABOLISM		UCL, Sch Med, Middlesex Hosp, Dept Med, London W1N 8AA, England; Univ Warwick, Dept Med, Coventry CV4 7AL, W Midlands, England	University of London; University College London; UCL Medical School; University of Warwick	Betteridge, DJ (corresponding author), UCL, Sch Med, Middlesex Hosp, Dept Med, Mortimer St, London W1N 8AA, England.			Khan, Michael/0000-0002-8591-384X				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BRESLOW JL, 1995, METABOLIC MOL BASES, P2031; Calabresi L, 1997, CURR OPIN LIPIDOL, V8, P219, DOI 10.1097/00041433-199708000-00005; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; MACKNESS MI, 1995, ATHEROSCLEROSIS, V115, P243, DOI 10.1016/0021-9150(94)05524-M; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; *NAT CHOL ED PROGR, 1993, CIRCULATION, V89, P1329; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; ROMA P, 1993, J CLIN INVEST, V91, P1445, DOI 10.1172/JCI116349; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722	11	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 27	1998	351	9120					1903	1904						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654254				2022-12-28	WOS:000074464700004
J	Bieber, D; Ramer, SW; Wu, CY; Murray, WJ; Tobe, T; Fernandez, R; Schoolnik, GK				Bieber, D; Ramer, SW; Wu, CY; Murray, WJ; Tobe, T; Fernandez, R; Schoolnik, GK			Type IV pili, transient bacterial aggregates, and virulence of enteropathogenic Escherichia coli	SCIENCE			English	Article							OUTER-MEMBRANE PROTEINS; BUNDLE-FORMING PILUS; TISSUE-CULTURE CELLS; LOCALIZED ADHERENCE; TWITCHING MOTILITY; BINDING PROTEINS; GENETIC-LOCUS; PLASMID; SEROTYPES; PATHOGENESIS	Type IV bundle-forming pill of enteropathogenic Escherichia coli are required for the localized adherence and autoaggregation phenotypes, Whether these pill are also required for virulence was tested in volunteers by inactivating bfpA or bfpT (perA) encoding, respectively, the pilus subunit and the bfp operon transcriptional activator. Both mutants caused significantly less diarrhea. Mutation of the bfpF nucleotide-binding domain Caused increased piliation, enhanced localized adherence, and abolished the twitching motility-dispersal phase of the autoaggregation phenotype. The bfpF mutant colonized the human intestine but was about 200-fold less virulent. Thus, BfpF is required for dispersal from the bacterial aggregate and for full virulence.	Stanford Univ, Med Ctr, Sch Med, Dept Med,Div Infect Dis & Geog Med, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Sch Med,Stanford Program Vaccine Res, Dept Microbiol & Immunol, Stanford, CA 94305 USA; San Jose State Univ, Dept Biol Sci, San Jose, CA 95912 USA; Univ Tokyo, Inst Med Sci, Dept Bacteriol, Tokyo, Japan	Stanford University; Stanford University; California State University System; San Jose State University; University of Tokyo	Schoolnik, GK (corresponding author), Stanford Univ, Med Ctr, Sch Med, Dept Med,Div Infect Dis & Geog Med, Stanford, CA 94305 USA.	ml.gks@forsythe.stanford.edu			NCRR NIH HHS [MO1-RR00070] Funding Source: Medline; NIAID NIH HHS [1RO1-AI39521] Funding Source: Medline; NIDDK NIH HHS [1RO3-DK52038] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK052038] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANATHA RP, 1998, INFECT IMMUN, V66, P122; BALDINI MM, 1983, J PEDIATR GASTR NUTR, V2, P534, DOI 10.1097/00005176-198302030-00023; BALDINI MM, 1986, INFECT IMMUN, V52, P334, DOI 10.1128/IAI.52.1.334-336.1986; BIEBER D, UNPUB; CRAVIOTO A, 1979, CURR MICROBIOL, V3, P95, DOI 10.1007/BF02602439; Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295; Donnenberg Michael S., 1995, P709; DONNENBERG MS, 1993, J CLIN INVEST, V92, P1412, DOI 10.1172/JCI116717; Donnenberg MS, 1997, TRENDS MICROBIOL, V5, P109, DOI 10.1016/S0966-842X(97)01000-7; DONNENBERG MS, 1992, MOL MICROBIOL, V6, P3427, DOI 10.1111/j.1365-2958.1992.tb02210.x; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; GOMEZDUARTE OG, 1995, INFECT IMMUN, V63, P1767; HENRICHSEN J, 1983, ANNU REV MICROBIOL, V37, P81, DOI 10.1146/annurev.mi.37.100183.000501; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; Hicks S, 1998, INFECT IMMUN, V66, P1570, DOI 10.1128/IAI.66.4.1570-1578.1998; HILL SM, 1991, GUT, V32, P154, DOI 10.1136/gut.32.2.154; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; JERSE AE, 1991, INFECT IMMUN, V59, P3869, DOI 10.1128/IAI.59.11.3869-3875.1991; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; LAUER P, 1993, MOL MICROBIOL, V8, P357, DOI 10.1111/j.1365-2958.1993.tb01579.x; LEVINE MM, 1985, J INFECT DIS, V152, P550, DOI 10.1093/infdis/152.3.550; Manning PA, 1997, GENE, V192, P1; McDaniel TK, 1997, MOL MICROBIOL, V23, P399, DOI 10.1046/j.1365-2958.1997.2311591.x; MCDANIEL TK, 1995, P NATL ACAD SCI USA, V92, P1664, DOI 10.1073/pnas.92.5.1664; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; NATARO JP, 1985, INFECT IMMUN, V48, P378, DOI 10.1128/IAI.48.2.378-383.1985; NATARO JP, 1987, INFECT IMMUN, V55, P2370, DOI 10.1128/IAI.55.10.2370-2377.1987; Puente JL, 1996, MOL MICROBIOL, V20, P87, DOI 10.1111/j.1365-2958.1996.tb02491.x; Ramer SW, 1996, J BACTERIOL, V178, P6555, DOI 10.1128/jb.178.22.6555-6563.1996; ROTHBAUM R, 1982, GASTROENTEROLOGY, V83, P441; SCALETSKY ICA, 1984, INFECT IMMUN, V45, P534, DOI 10.1128/IAI.45.2.534-536.1984; SOHEL I, 1993, MOL MICROBIOL, V7, P563, DOI 10.1111/j.1365-2958.1993.tb01147.x; Sohel I, 1996, J BACTERIOL, V178, P2613, DOI 10.1128/jb.178.9.2613-2628.1996; Stone KD, 1996, MOL MICROBIOL, V20, P325, DOI 10.1111/j.1365-2958.1996.tb02620.x; Swanson J., 1989, MOBILE DNA, P743; Swift S, 1996, TRENDS BIOCHEM SCI, V21, P214; TAYLOR CJ, 1986, J PEDIATR GASTR NUTR, V5, P70, DOI 10.1097/00005176-198601000-00013; Tobe T, 1996, MOL MICROBIOL, V21, P963, DOI 10.1046/j.1365-2958.1996.531415.x; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x; VUOPIOVARKILA J, 1991, J EXP MED, V174, P1167, DOI 10.1084/jem.174.5.1167; WHITCHURCH CB, 1991, GENE, V101, P33, DOI 10.1016/0378-1119(91)90221-V	45	363	368	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2114	2118		10.1126/science.280.5372.2114	http://dx.doi.org/10.1126/science.280.5372.2114			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641917				2022-12-28	WOS:000074435900045
J	Cleaver, JE				Cleaver, JE			Hair today, gone tomorrow: Transgenic mice with human repair deficient hair disease	CELL			English	Review							XERODERMA-PIGMENTOSUM; GENE; TRICHOTHIODYSTROPHY		Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Radiobiol Lab, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Cleaver, JE (corresponding author), Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.							Ahrens C, 1997, P NATL ACAD SCI USA, V94, P6837, DOI 10.1073/pnas.94.13.6837; Bohr VA, 1995, CARCINOGENESIS, V16, P2885, DOI 10.1093/carcin/16.12.2885; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; CLEAVER JE, 1984, MECH AGEING DEV, V27, P189, DOI 10.1016/0047-6374(84)90044-7; de Boer J, 1998, MOL CELL, V1, P981, DOI 10.1016/S1097-2765(00)80098-2; de Boer J, 1998, CANCER RES, V58, P89; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; EVENO E, 1995, CANCER RES, V55, P4325; Friedberg EC, 1997, MUTAT RES-DNA REPAIR, V383, P183, DOI 10.1016/S0921-8777(96)00057-2; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; KIM J, 1995, J BIOL CHEM, V270, P13620, DOI 10.1074/jbc.270.23.13620; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; Quilliet X, 1997, MUTAT RES-DNA REPAIR, V385, P235, DOI 10.1016/S0921-8777(97)00049-9; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VUILLAUME M, 1992, CARCINOGENESIS, V13, P321, DOI 10.1093/carcin/13.3.321; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEICHSELBAUM RR, 1980, CANCER RES, V40, P920	20	6	6	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1099	1102		10.1016/S0092-8674(00)81453-1	http://dx.doi.org/10.1016/S0092-8674(00)81453-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657142	Bronze			2022-12-28	WOS:000074491100004
J	Xu, ZY; Sato, K; Wickner, W				Xu, ZY; Sato, K; Wickner, W			LMA1 binds to vacuoles at Sec18p (NSF), transfers upon ATP hydrolysis to a t-SNARE (Vam3p) complex, and is released during fusion	CELL			English	Article							PROTEIN DISULFIDE-ISOMERASE; SACCHAROMYCES-CEREVISIAE; ALPHA-SNAP; ESCHERICHIA-COLI; IN-VITRO; YEAST; INHERITANCE; SEGREGATION; THIOREDOXIN; MEMBRANE	Vacuole fusion requires Sec18p (NSF), Sec17p (alpha-SNAP), Ypt7p (GTP binding protein), Vam3p (t-SNARE), Nyv1p (V-SNARE), and LMA1 (low M-r activity 1, a heterodimer of thioredoxin and I-2(B)). LMA1 requires Sec18p for saturable, high-affinity binding to vacuoles, and Sec18p "priming" ATPase requires both Sec17p and LMA1. Either the sec18-1 mutation and deletion of I-2(B), or deletion of both I-2(B), and p13 (an I-2(B) homolog) causes a striking synthetic vacuole fragmentation phenotype. Upon Sec18p ATP hydrolysis, LMA1 transfers to (and stabilizes) a Vam3p complex. LMA1 is released from vacuoles in a phosphatase-regulated reaction. This LMA1 cycle explains how priming by Sec18p is coupled to t-SNARE stabilization and to fusion.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.				NIAMS NIH HHS [T32AR07576] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007576] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ausubel F, 1997, SHORT PROTOCOLS MOL; Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; DEMESQUITA DSG, 1991, J GEN MICROBIOL, V137, P2447, DOI 10.1099/00221287-137-10-2447; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HUBER HE, 1986, J BIOL CHEM, V261, P5006; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MAIER K, 1979, J BIOL CHEM, V254, P8491; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MULLER EGD, 1995, ARCH BIOCHEM BIOPHYS, V318, P356, DOI 10.1006/abbi.1995.1240; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NICOLSON TA, 1995, J CELL BIOL, V130, P835, DOI 10.1083/jcb.130.4.835; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHU P, 1991, EUR J BIOCHEM, V197, P1, DOI 10.1111/j.1432-1033.1991.tb15874.x; SHAW JM, 1991, EMBO J, V10, P1741, DOI 10.1002/j.1460-2075.1991.tb07698.x; Slusarewicz P, 1997, P NATL ACAD SCI USA, V94, P5582, DOI 10.1073/pnas.94.11.5582; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang YX, 1996, MOL BIOL CELL, V7, P1375, DOI 10.1091/mbc.7.9.1375; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; WEISMAN LS, 1988, SCIENCE, V241, P589, DOI 10.1126/science.3041591; WEISMAN LS, 1990, P NATL ACAD SCI USA, V87, P1076, DOI 10.1073/pnas.87.3.1076; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651	44	75	80	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1998	93	7					1125	1134		10.1016/S0092-8674(00)81457-9	http://dx.doi.org/10.1016/S0092-8674(00)81457-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657146	Bronze			2022-12-28	WOS:000074491100008
J	Halmi, KA				Halmi, KA			A 24-year-old woman with anorexia nervosa	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BULIMIA-NERVOSA; LONG-TERM; FOLLOW-UP; PREVALENCE; DISORDERS; POPULATION; FEATURES; WOMEN		Cornell Univ, Coll Med, White Plains, NY 10605 USA	Cornell University	Halmi, KA (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Bell Rudolph, 1985, HOLY ANOREXIA; BLUNDELL JE, 1986, PHARM EATING DISORDE, P54; BRAUN DL, 1994, PSYCHOL MED, V24, P859, DOI 10.1017/S0033291700028956; BREWERTON TD, 1995, J CLIN PSYCHIAT, V56, P777; BRUCH H, 1993, EATING DISORDERS; CASPER RC, 1990, PSYCHOSOM MED, V52, P156, DOI 10.1097/00006842-199003000-00004; CASPER RC, 1980, ARCH GEN PSYCHIAT, V37, P1030, DOI 10.1001/archpsyc.1980.01780220068007; Commerford M. C., 1997, EAT DISORD, V5, P69; CRISP AH, 1987, BRIT J PSYCHIAT, V150, P355, DOI 10.1192/bjp.150.3.355; DARE C, 1995, EATING DISORDERS, P333; DEMITRACK MA, 1990, AM J PSYCHIAT, V147, P882; Di Nicola, 1990, TRANSCULT PSYCHIATRY, V27, P165, DOI [DOI 10.1177/136346159002700301, 10.1177/136346159002700301]; EAGLES JM, 1995, AM J PSYCHIAT, V152, P1266; ECKERT ED, 1995, PSYCHOL MED, V25, P143, DOI 10.1017/S0033291700028166; FICHTER MM, 1988, EUR ARCH PSY CLIN N, V237, P200, DOI 10.1007/BF00449908; FOX C, 1997, LIFE, V12, P78; GARFINKEL PE, 1995, AM J PSYCHIAT, V152, P1052; GARFINKEL PE, 1982, ANOREXIA NERVOSA MUL, P235; GERSHON E, 1984, AM J PSYCHIAT, V149, P1419; GOLD P, 1986, NEW ENGL J MED, V314, P335; HALMI KA, 1986, ARCH GEN PSYCHIAT, V43, P177; HALMI KA, 1979, PSYCHIAT RES, V1, P209, DOI 10.1016/0165-1781(79)90063-5; HALMI KA, 1994, AM J PSYCHIAT, V151, P8; HALMI KA, 1991, ARCH GEN PSYCHIAT, V489, P7129; Halmi Katherine A., 1994, P857; Hoek Hans Wijbrand, 1993, International Review of Psychiatry, V5, P61, DOI 10.3109/09540269309028295; HOEK HW, 1991, PSYCHOL MED, V21, P455, DOI 10.1017/S0033291700020560; HOTTA M, 1986, J CLIN ENDOCR METAB, V62, P319, DOI 10.1210/jcem-62-2-319; KAYE WH, 1991, J CLIN PSYCHIAT, V52, P464; KAYE WH, 1991, ARCH GEN PSYCHIAT, V48, P556; Keys A, 1950, BIOL HUMAN STARVATIO; Kleifield EI, 1996, PSYCHIAT CLIN N AM, V19, P715, DOI 10.1016/S0193-953X(05)70377-4; KURTH CL, 1995, J PSYCHIAT RES, V29, P211, DOI 10.1016/0022-3956(95)00002-M; LEE S, 1991, PSYCHOL MED, V21, P703, DOI 10.1017/S0033291700022340; LUCAS AR, 1991, AM J PSYCHIAT, V148, P917; Metropolitan Life Foundation New weight standards for men and women, 1959, STAT B, V40, P1; MORTON R, 1720, PHTHISIOLOGIA TREATU; ROONEY B, 1995, INT J EAT DISORDER, V18, P299, DOI 10.1002/1098-108X(199512)18:4&lt;299::AID-EAT2260180402&gt;3.0.CO;2-K; STROBER M, 1990, INT J EAT DISORDER, V9, P239, DOI 10.1002/1098-108X(199005)9:3&lt;239::AID-EAT2260090302&gt;3.0.CO;2-7; STROBER M, 1980, J PSYCHOSOM RES, V24, P353, DOI 10.1016/0022-3999(80)90027-6; THEANDER S, 1985, J PSYCHIATR RES, V19, P493, DOI 10.1016/0022-3956(85)90059-7; TONER BB, 1988, INT J PSYCHIAT MED, V18, P357; Treasure J., 1989, CHILD YOUTH PSYCHIAT, P59	44	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1992	1998		10.1001/jama.279.24.1992	http://dx.doi.org/10.1001/jama.279.24.1992			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZU945	9643864				2022-12-28	WOS:000074252100037
J	Macknin, ML; Piedmonte, M; Calendine, C; Janosky, J; Wald, E				Macknin, ML; Piedmonte, M; Calendine, C; Janosky, J; Wald, E			Zinc gluconate lozenges for treating the common cold in children - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-TRACT INFECTIONS; DOUBLE-BLIND; ZN-2+; FAILURE; MODELS	Context.-The common cold is one of the most frequently occurring illnesses and is responsible for substantial morbidity and economic loss. Biochemical evidence suggests that zinc may be an effective treatment, and zinc gluconate glycine (ZGG) lozenges have been shown to reduce the duration of cold symptoms in adults. Objective.-To determine the efficacy of ZGG treatment of colds in children and adolescents. Design.-A randomized, double-masked, placebo-controlled study. Setting.-Two suburban school districts in Cleveland, Ohio. Patients.-A total of 249 students in grades 1 through 12 were enrolled within the first 24 hours of experiencing at least 2 of 9 symptoms of the common cold. Intervention.-Zinc lozenges, 10 mg, orally dissolved, 5 times a day (in grades 1-6) or 6 times a day (in grades 7-12), Main Outcome Measures.-Time to resolution of cold symptoms based on subjective daily symptom scores for cough, headache, hoarseness, muscle ache, nasal congestion, nasal drainage, scratchy throat, sore throat, and sneezing. Results.-Time to resolution of all cold symptoms did not differ significantly between students receiving zinc (n = 124) and those receiving placebo (n = 125) (median, 9 days; 95% confidence interval [CI], 8-9 days; median, 9 days, 95% CI, 7-10 days, respectively; P=.71). There were no significant differences in the time to resolution of any of the 9 symptoms studied. Compared with controls, more students in the zinc group reported adverse effects (88.6% vs 79.8%; P=.06); bad taste (60.2% vs 37.9%; P=.001); nausea (29.3% vs 16.1%; P=.01); mouth, tongue, or throat discomfort (36.6% vs 24.2%; P=.03); and diarrhea (10.6% vs 4.0%; P=.05). Conclusions.-In this community-based, randomized controlled trial, ZGG lozenges were not effective in treating cold symptoms in children and adolescents. Further studies with virologic testing are needed to clarify what role, if any, zinc may play in treating cold symptoms.	Cleveland Clin Fdn, Dept Pediat & Adolescent Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Family Med & Clin Epidemiol, Pittsburgh, PA 15261 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Macknin, ML (corresponding author), Cleveland Clin Fdn, Dept Pediat & Adolescent Med, 9500 Euclid Ave,A120, Cleveland, OH 44195 USA.							ALNAKIB W, 1987, J ANTIMICROB CHEMOTH, V20, P893, DOI 10.1093/jac/20.6.893; BASHFORD CL, 1986, J BIOL CHEM, V261, P9300; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; COUCH RB, 1984, J INFECT DIS, V150, P167, DOI 10.1093/infdis/150.2.167; COX DR, 1972, J R STAT SOC B, V34, P187; Dingle JH., 1964, STUDY 25000 ILLNESSE; DOUGLAS RM, 1987, ANTIMICROB AGENTS CH, V31, P1263, DOI 10.1128/AAC.31.8.1263; EBY GA, 1984, ANTIMICROB AGENTS CH, V25, P20, DOI 10.1128/AAC.25.1.20; EFRON B, 1977, J AM STAT ASSOC, V72, P557, DOI 10.2307/2286217; FARR BM, 1987, ANTIMICROB AGENTS CH, V31, P1183, DOI 10.1128/AAC.31.8.1183; FIRPO EJ, 1979, ARCH VIROL, V61, P175, DOI 10.1007/BF01320603; GEIST FC, 1987, ANTIMICROB AGENTS CH, V31, P622, DOI 10.1128/AAC.31.4.622; GODFREY JC, 1992, J INT MED RES, V20, P234, DOI 10.1177/030006059202000305; GORDON YJ, 1975, ANTIMICROB AGENTS CH, V8, P377, DOI 10.1128/AAC.8.3.377; GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301; HARISCH G, 1987, RES COMMUN CHEM PATH, V55, P39; Jackson JL, 1997, ARCH INTERN MED, V157, P2373, DOI 10.1001/archinte.157.20.2373; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLY RW, 1983, BIOL REPROD, V28, P883, DOI 10.1095/biolreprod28.4.883; KORANT BD, 1976, J VIROL, V18, P298, DOI 10.1128/JVI.18.1.298-306.1976; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MARONE G, 1979, J ALLERGY CLIN IMMUN, V65, P171; MOFFAT AS, 1993, SCIENCE, V260, P910, DOI 10.1126/science.8493525; Mossad SB, 1996, ANN INTERN MED, V125, P81, DOI 10.7326/0003-4819-125-2-199607150-00001; Novick SG, 1996, MED HYPOTHESES, V46, P295, DOI 10.1016/S0306-9877(96)90259-5; PASTERNAK CA, 1987, BIOSCIENCE REP, V7, P81, DOI 10.1007/BF01121871; Prasad AS, 1996, ANN INTERN MED, V125, P142, DOI 10.7326/0003-4819-125-2-199607150-00012; RATKA M, 1989, J VIROL, V63, P3954, DOI 10.1128/JVI.63.9.3954-3960.1989; SALAS M, 1987, CLIN IMMUNOL IMMUNOP, V45, P139, DOI 10.1016/0090-1229(87)90120-6; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; SIMON G, 1995, J CLIN EPIDEMIOL, V48, P363, DOI 10.1016/0895-4356(94)00141-C; SMITH DS, 1989, ANTIMICROB AGENTS CH, V33, P646, DOI 10.1128/AAC.33.5.646; WEISMANN K, 1990, DAN MED BULL, V37, P279	33	82	83	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1962	1967		10.1001/jama.279.24.1962	http://dx.doi.org/10.1001/jama.279.24.1962			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU945	9643859	Bronze			2022-12-28	WOS:000074252100032
J	de Costa, C				de Costa, C			A sort of progress	LANCET			English	Article									Alloa, Epping, NSW 2121, Australia		de Costa, C (corresponding author), Alloa, 40 Pembroke St, Epping, NSW 2121, Australia.								0	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1202	1203		10.1016/S0140-6736(97)12035-9	http://dx.doi.org/10.1016/S0140-6736(97)12035-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643711				2022-12-28	WOS:000073220200049
J	Moutel, G; Leroux, N; Herve, C				Moutel, G; Leroux, N; Herve, C			Analysis of a survey of 36 French research committees on intracytoplasmic sperm injection	LANCET			English	Article							FERTILIZATION	Background In France, when a new medical technology is to be applied experimentally to human beings, it must adhere to the principles stipulated by the Huriet-Serusclat law on biomedical research. This law requires that the validation of a protocol applicable to human beings, with its corollary protection and information dimensions, is first submitted to a research committee, known as a Consultative Committee Protecting Persons in Biomedical Research (CCPPRB). We aimed to survey the competence of these committees in biotechnology, and whether or not intracytoplasmic sperm injection (ICSI) had been considered by the committees as being an innovative treatment. Methods We presented each of France's 48 CCPPRBs with a questionnaire to assess the choices and criteria for making decisions that arose at the time ICSI was implemented in the different centres in each region. Findings 36 committees look part. We found that ICSI had been largely introduced in settings outside the scope of the CCPPRBs and of the framework fixed by the law on biomedical research. Only three centres for medically assisted reproduction had submitted applications to a CCPPRB, although ICSI has been implemented in over 20 centres. 21 (58%) committees were of the opinion that the implementation of ICSI could have come under their supervision. 24 (67%) committees believed that, independently of their own involvement, evaluation procedures for ICSI should have been specified before centres decided to introduce it. Interpretation We observed important differences in the way CCPPRBs handled ICSI as being within or outside the medical research field. The status of the research committees is legally and identically defined. However, committees did not agree on the definition of the limits of their action, and, therefore, their handling of the same issue differed. An inquiry is needed to define how, now that ICSI is done in many centres, it should adhere to principles of evaluation and safety already in existence for other medical technologies.	Ctr Hosp Univ Reims, CECOS, F-51100 Reims, France; Fac Med Necker, Lab Ethique Med & Sante Publ, Paris, France	CHU de Reims; Universite de Reims Champagne-Ardenne; UDICE-French Research Universities; Universite Paris Cite	Moutel, G (corresponding author), Ctr Hosp Univ Reims, CECOS, Rue Cognacq Jay, F-51100 Reims, France.		MOUTEL, Grégoire/N-8777-2015; Moutel, Pr Grégoire/ABD-8926-2020	Moutel, Pr Grégoire/0000-0002-5585-106X				David G, 1995, B ACAD NAT MED PARIS, V179, P1751; *FRENCH NAT CONS E, 1994, DICT PERMANENT BIOET, V9, P9793; GOVAERTS I, 1995, LANCET, V346, P1095; HERVE C, 1995, LANCET, V346, P1096; LAPLANE R, 1996, B ACAD NATL MED, V180, P11; LIEBAERS I, 1995, LANCET, V346, P1095, DOI 10.1016/S0140-6736(95)91768-3; LIEBAERS I, 1995, P 15 WORLD C FERT ST, P409; MARTEI JF, 1993, BILAN APPL LOI HURIE, P49; Moutel G, 1996, PRESSE MED, V25, P989; Moutel G, 1997, FERTIL STERIL, V67, P583, DOI 10.1016/S0015-0282(97)80093-3; MOUTEL G, 1995, REV EUR BIOTECH MED, V17, P101; Palermo GD, 1996, FERTIL STERIL, V65, P899; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192	13	15	15	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1121	1123		10.1016/S0140-6736(97)07394-7	http://dx.doi.org/10.1016/S0140-6736(97)07394-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660598	Green Submitted			2022-12-28	WOS:000073090200045
J	Ryan, EA				Ryan, EA			Pancreas transplants: for whom?	LANCET			English	Editorial Material							QUALITY-OF-LIFE; KIDNEY-TRANSPLANTATION; DIABETES-MELLITUS; MORTALITY		Univ Alberta, Dept Med, Div Endocrinol, Edmonton, AB T6G 2S2, Canada	University of Alberta	Ryan, EA (corresponding author), Univ Alberta, Dept Med, Div Endocrinol, Edmonton, AB T6G 2S2, Canada.							Alejandro R, 1997, DIABETES, V46, P1983, DOI 10.2337/diabetes.46.12.1983; Bloom RD, 1997, TRANSPLANTATION, V64, P1689, DOI 10.1097/00007890-199712270-00010; Busing M, 1997, EXP CLIN ENDOCR DIAB, V105, P92; Gruessner RWG, 1997, TRANSPLANTATION, V64, P1572, DOI 10.1097/00007890-199712150-00011; Kendall DM, 1997, DIABETES, V46, P249, DOI 10.2337/diabetes.46.2.249; Kinkhabwala M, 1996, AM J SURG, V171, P516, DOI 10.1016/S0002-9610(97)89613-4; Korbutt GS, 1996, J CLIN INVEST, V97, P2119, DOI 10.1172/JCI118649; Landgraf R, 1996, DIABETOLOGIA, V39, P1415, DOI 10.1007/s001250050593; LARSEN JL, 1992, DIABETES CARE, V15, P35, DOI 10.2337/diacare.15.1.35; Manske CL, 1995, LANCET, V346, P1658, DOI 10.1016/S0140-6736(95)92838-3; Martinenghi S, 1997, DIABETES CARE, V20, P272, DOI 10.2337/diacare.20.3.272; NAVARRO X, 1990, DIABETES, V39, P802, DOI 10.2337/diabetes.39.7.802; Piehlmeier W, 1996, EUR J SURG, V162, P933; Stratta RJ, 1997, DIABETES CARE, V20, P362, DOI 10.2337/diacare.20.3.362; SUTHERLAND DER, 1997, CURRENT THERAPY ENDO, P496	15	22	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1072	1073		10.1016/S0140-6736(98)22015-0	http://dx.doi.org/10.1016/S0140-6736(98)22015-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660570				2022-12-28	WOS:000073090200002
J	Fleming, O				Fleming, O			A personal recollection - The wicked do not always prosper	BRITISH MEDICAL JOURNAL			English	Article																		ERNST E, 1995, ANN INTERN MED, V122, P789, DOI 10.7326/0003-4819-122-10-199505150-00009	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					203	203		10.1136/bmj.317.7152.203	http://dx.doi.org/10.1136/bmj.317.7152.203			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665911	Green Published			2022-12-28	WOS:000075047800039
J	Jordinson, H; Haskayne, L				Jordinson, H; Haskayne, L			Terence Kay - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					213	213		10.1136/bmj.317.7152.213	http://dx.doi.org/10.1136/bmj.317.7152.213			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665931	Green Published			2022-12-28	WOS:000075047800072
J	Emanuel, EJ; Battin, MP				Emanuel, EJ; Battin, MP			What are the potential cost savings from legalizing physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERMINAL CANCER-PATIENTS; ACTIVE EUTHANASIA; MEDICAL DECISIONS; MANAGED DEATH; DATA SHOW; LAST YEAR; CARE; LIFE; END; ATTITUDES		Dana Farber Canc Inst, Div Canc Epidemiol & Control, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Med Eth, Boston, MA USA; Univ Utah, Dept Philosophy, Salt Lake City, UT USA; Univ Utah, Sch Med, Dept Internal Med, Div Med Eth, Salt Lake City, UT USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Emanuel, EJ (corresponding author), Dana Farber Canc Inst, Div Canc Epidemiol & Control, Ctr Outcomes & Policy Res, 44 Binney St, Boston, MA 02115 USA.							Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BATTIN MP, 1994, LEAST WORST DEATH ES, P130; BAYER R, 1983, NEW ENGL J MED, V309, P1490, DOI 10.1056/NEJM198312153092405; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; DORONZIO JC, 1993, NY TIMES        0608, pA25; Emanuel EJ, 1998, MINN LAW REV, V82, P983; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Fireman BH, 1997, HEALTH CARE FINANC R, V18, P51; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; FRYE A, 1994, WASHINGTON POST 0102, pC3; Ginzberg E, 1980, Inquiry, V17, P293; GODEC MS, 1993, WASHINGTON POST 0502, pC3; KASS LR, 1989, PUBLIC INTEREST, V94, P25; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; LAPUMA J, 1995, ARCH INTERN MED, V155, P1553, DOI 10.1001/archinte.1995.00430140133014; LEAF A, 1977, NEW ENGL J MED, V297, P887, DOI 10.1056/NEJM197710202971612; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; LONG SH, 1984, INQUIRY-J HEALTH CAR, V21, P315; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V269, P2554, DOI 10.1001/jama.269.19.2554; MURPHY DJ, 1993, ARCH INTERN MED, V153, P1641, DOI 10.1001/archinte.153.14.1641; *NAT HOSP ORG, 1995, AN COST SAV MED HOSP; PETERSON PG, 1996, AM GROW UP IT GROWS, P176; RILEY G, 1987, INQUIRY-J HEALTH CAR, V24, P233; Riley G F, 1989, Health Care Financ Rev, V11, P1; SCHNEIDERMAN LJ, 1993, ARCH INTERN MED, V153, P437, DOI 10.1001/archinte.153.4.437; SCHROEDER SA, 1981, JAMA-J AM MED ASSOC, V245, P1446, DOI 10.1001/jama.245.14.1446; SCITOVSKY AA, 1984, MILBANK Q, V62, P591, DOI 10.2307/3349838; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; SPECTOR WD, 1984, INQUIRY-J HEALTH CAR, V21, P328; SULMASY DP, 1995, ARCH INTERN MED, V155, P133, DOI 10.1001/archinte.155.2.133; TAPLIN SH, 1995, J NATL CANCER I, V87, P417, DOI 10.1093/jnci/87.6.417; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; van der Maas PJ, 1992, HEALTH POLICY, V22, P1	42	53	53	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					167	172		10.1056/NEJM199807163390306	http://dx.doi.org/10.1056/NEJM199807163390306			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZZ922	9664094				2022-12-28	WOS:000074782900006
J	Iiri, T; Farfel, Z; Bourne, HR				Iiri, T; Farfel, Z; Bourne, HR			G-protein diseases furnish a model for the turn-on switch	NATURE			English	Article							HETEROTRIMERIC G-PROTEIN; CRYSTAL-STRUCTURE; BETA-GAMMA; GTP HYDROLYSIS; ALPHA-SUBUNIT; TRANSDUCIN; RHODOPSIN; MECHANISM; ACTIVATION; G(I-ALPHA-1)	How does a trimeric a protein on the inside of a cell membrane respond to activation by a transmembrane receptor? G-protein mutations in patients with hypertension and inherited endocrine disorders enhance or block signals from stimulated receptors. In combination with three-dimensional crystal structures and results from biochemical experiments, the phenotypes produced by these mutations suggest a model for the molecular activation mechanism that relays hormonal and sensory signals transmitted by many transmembrane receptors.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Tel Aviv Univ, Biochem Pharmacol Lab, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Med E, IL-52621 Tel Hashomer, Israel	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University	Bourne, HR (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	h_bourne@quickmail.ucsf.edu						Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; Bohm A, 1997, CURR OPIN BIOTECH, V8, P480, DOI 10.1016/S0958-1669(97)80072-9; Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DENKER BM, 1992, J BIOL CHEM, V267, P9998; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; Farfel Z, 1996, J BIOL CHEM, V271, P19653, DOI 10.1074/jbc.271.33.19653; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; IIRI T, 1998, NAT GENET, V18, P45; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHWINDINGER WF, 1994, J BIOL CHEM, V269, P25387; Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Stratton HF, 1996, MOL CELL BIOL, V16, P6325; SUNAHARA RK, 1997, GSA SCI, V278, P1943; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; WEST RE, 1985, J BIOL CHEM, V260, P4428	45	161	170	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 2	1998	394	6688					35	38		10.1038/27831	http://dx.doi.org/10.1038/27831			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665125				2022-12-28	WOS:000074579600039
J	Stefanick, ML; Mackey, S; Sheehan, M; Ellsworth, N; Haskell, WL; Wood, PD				Stefanick, ML; Mackey, S; Sheehan, M; Ellsworth, N; Haskell, WL; Wood, PD			Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY HEART-DISEASE; WEIGHT-LOSS; OVERWEIGHT MEN; PLASMA-LIPIDS; RISK-FACTORS; EFFICACY; TRIAL	Background Guidelines established by the National Cholesterol Education Program (NCEP) promote exercise and weight loss for the treatment of abnormal lipoprotein levels. Little is known, however, about the effects of exercise or the NCEP diet, which is moderately low in fat and cholesterol, in persons with lipoprotein levels that place them at high risk for coronary heart disease. Methods We studied plasma lipoprotein levels in 180 postmenopausal women, 45 through 64 years of age, and 197 men, 30 through 64 years of age, who had low high-density lipoprotein (HDL) cholesterol levels (less than or equal to 59 mg per deciliter in women and less than or equal to 44 mg per deciliter in men) and moderately elevated levels of low-density lipoprotein (LDL) cholesterol (>125 mg per deciliter but <210 mg per deciliter in women and >125 mg per deciliter but <190 mg per deciliter in men). The subjects were randomly assigned to aerobic exercise, the NCEP Step 2 diet, or diet plus exercise, or to a control group, which received no intervention. Results Dietary intake of fat and cholesterol decreased during the one-year study (P<0.001), as did body weight, in women and men in either the diet group or the diet-plus-exercise group, as compared with the controls (P<0.001) and the exercise group (P<0.05), in which dietary intake and body weight were unchanged. Changes in HDL cholesterol and triglyceride levels and the ratio of total to HDL cholesterol did not differ significantly among the treatment groups, for subjects of either sex. The serum level of LDL cholesterol was significantly reduced among women (a decrease of 14.5 +/- 22.2 mg per deciliter) and men (a decrease of 20.0 +/- 17.3 mg per deciliter) in the diet-plus-exercise group, as compared with the control group (women had a decrease of 2.5 +/- 16.6 mg per deciliter, P<0.05; men had a decrease of 4.6 +/- 21.1 mg per deciliter, P<0.001). The reduction in LDL cholesterol in men in the diet-plus-exercise group was also significant as compared with that among the men in the exercise group (3.6 +/- 18.8 mg per deciliter, P<0.001). In contrast, changes in LDL cholesterol levels were not significant among the women (a decrease of 7.3 +/- 18.9 mg per deciliter) or the men (10.8 +/- 18.8 mg per deciliter) in the diet group, as compared with the controls. Conclusions The NCEP Step 2 diet failed to lower LDL cholesterol levels in men or women with highrisk lipoprotein levels who did not engage in aerobic exercise. This finding highlights the importance of physical activity in the treatment of elevated LDL cholesterol levels. (N Engl J Med 1998;339:12-20.) (C) 1998, Massachusetts Medical Society.	Stanford Univ, Sch Med, Ctr Res Dis Prevent, Palo Alto, CA 94304 USA	Stanford University	Stefanick, ML (corresponding author), 730 Welch Rd,Suite B, Palo Alto, CA 94304 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045733] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45733] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; [Anonymous], 1996, JAMA, V276, P241; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; Connor WE, 1997, NEW ENGL J MED, V337, P562; Connor WE, 1997, NEW ENGL J MED, V337, P566; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.2307/2334377; FORTMANN SP, 1988, AM J CARDIOL, V62, P89, DOI 10.1016/0002-9149(88)91370-7; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAINLINE A, 1982, DHEW PUBLICATION; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; Katan MB, 1997, NEW ENGL J MED, V337, P563; Katan MB, 1997, NEW ENGL J MED, V337, P567; KATZEL LI, 1995, JAMA-J AM MED ASSOC, V274, P1915, DOI 10.1001/jama.274.24.1915; Knopp RH, 1997, JAMA-J AM MED ASSOC, V278, P1509, DOI 10.1001/jama.278.18.1509; KRISETHERTON PM, 1988, J AM DIET ASSOC, V88, P1373; MACIEJKO JJ, 1987, CLIN CHEM, V33, P2065; *OFF MED APPL RES, 1992, NIH CONS STAT, V10; PEDERSEN TR, 1994, LANCET, V344, P1383; POSNER BM, 1982, AM J CLIN NUTR, V36, P546, DOI 10.1093/ajcn/36.3.546; REAVEN GM, 1986, J NUTR, V116, P1143, DOI 10.1093/jn/116.7.1143; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RIFKIND BM, 1979, CIRCULATION, V60, P427; SAMPSON EJ, 1975, CLIN CHEM, V21, P1983; SAVIN WM, 1980, CIRCULATION, V62, P55, DOI 10.1161/01.CIR.62.1.55; SCHAEFER EJ, 1995, ARTERIOSCL THROM VAS, V15, P1079, DOI 10.1161/01.ATV.15.8.1079; SCHAKEL SF, 1988, J AM DIET ASSOC, V88, P1268; Stefanick M L, 1993, Exerc Sport Sci Rev, V21, P363; Stefanovic-Racic M., 1994, P417; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WILLIAMS PT, 1983, ATHEROSCLEROSIS, V47, P173, DOI 10.1016/0021-9150(83)90153-3; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; WOOD PD, 1991, NEW ENGL J MED, V325, P461, DOI 10.1056/NEJM199108153250703	36	384	400	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					12	20		10.1056/NEJM199807023390103	http://dx.doi.org/10.1056/NEJM199807023390103			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647874	Bronze			2022-12-28	WOS:000074500000003
J	Carpenter, CCJ; Fischl, MA; Hammer, SM; Hirsch, MS; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Saag, MS; Schooley, RT; Thompson, MA; Vella, S; Yeni, PG; Volberding, PA				Carpenter, CCJ; Fischl, MA; Hammer, SM; Hirsch, MS; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Saag, MS; Schooley, RT; Thompson, MA; Vella, S; Yeni, PG; Volberding, PA			Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CUBIC MILLIMETER; ADULTS	Objective.-To provide recommendations for antiretroviral therapy based on information available in mid-1998. Participants.-An international panel of physicians with expertise in antiretroviral research and care of patients with human immunodeficiency virus (HIV) infection, first convened by the International AIDS Society-USA in December 1995. Evidence.-The panel reviewed available clinical and basic science study results (including phase 3 controlled trials; clinical, virologic, and immunologic end point data; data presented at research conferences; and studies of HIV pathophysiology); opinions of panel members were also considered. Recommendations were limited to drugs available in mid-1998. Consensus Process.-Panel members monitor new clinical research reports and interim results. The full panel meets regularly to discuss how the new information may change treatment recommendations. Updated recommendations are developed through consensus of the entire panel at each stage of development. Conclusions.-Accumulating data from clinical and pathogenesis studies continue to support early institution of potent antiretroviral therapy in patients with HIV infection. A variety of combination regimens show potency, expanding choices for initial regimens for individual patients. Plasma HIV RNA assays with increased sensitivity are important in monitoring therapeutic response; however, more data are needed to determine precisely the HIV RNA levels that define treatment failure. Long-term adverse drug effects are beginning to emerge, requiring ongoing attention. Some issues regarding optimal long-term approaches to antiretroviral management are unresolved. The increased complexity in HIV management requires ongoing monitoring of new data for optimal treatment of HIV infection.	Int AIDS Soc USA, San Francisco, CA 94129 USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Univ Miami, Sch Med, Miami, FL USA; Harvard Univ, Sch Med, Boston, MA USA; Stanford Univ, Med Ctr, Stanford, CA 94305 USA; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; Univ Calif San Diego, San Diego, CA 92103 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Colorado, Sch Med, Denver, CO USA; AIDS Res Consortium, Atlanta, GA USA; Ist Super Sanita, I-00161 Rome, Italy; X Bichat Med Sch, Hop Bichat Claude Bernard, Paris, France; Univ Calif San Francisco, San Francisco, CA 94143 USA	Brown University; University of Miami; Harvard University; Harvard Medical School; Stanford University; St. Paul's Hospital; University of Saskatchewan; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Alabama System; University of Alabama Birmingham; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Istituto Superiore di Sanita (ISS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Francisco	Carpenter, CCJ (corresponding author), Int AIDS Soc USA, 1001 B OReilly Ave,Box 29916, San Francisco, CA 94129 USA.	Charles_Carpenter@brown.edu	VELLA, STEFANO/ABI-3368-2020; VELLA, STEFANO/V-8440-2019; Vella, Stefano/GZM-0519-2022	VELLA, STEFANO/0000-0003-2347-5984; katzenstein, david/0000-0002-8593-4560				Anis AH, 1998, PHARMACOECONOMICS, V13, P327, DOI 10.2165/00019053-199813030-00007; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1996, Lancet, V348, P283; BORLEFFS JC, 1998, 5 C RETR OPP INF FEB; BUSS N, 1998, 5 C RETR OPP INF FEB; CAMERON DW, 1998, 5 C RETR OPP INF FEB; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CARR A, 1998, 5 C RETR OPP INF FEB; Chesney M, 1997, ANN M AIDS CLIN TRIA; CHIASSON MA, 1998, 5 C RETR OPP INF FEB; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; CLENDENINN N, 1998, 5 C RETR OPP INF FEB; CLUMECK N, 1998, 5 C RETR OPP INF FEB; CONNICK E, 1998, 5 C RETR OPP INF FEB; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; COX SR, 1997, 4 C RETR OPP INF JAN; COX SR, 1998, 5 C RETR OPP INF FEB; DEWOLF F, 1998, 5 C RETR OPP INF FEB; FERRY JJ, 1997, 4 C RETR OPP INF JAN; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FISCUS SA, 1997, 4 C RETR OPP INF JAN; FISKE WD, 1998, 5 C RETR OPP INF FEB; FISKE WD, 1997, 37 INT C ANT AG CHEM; GALLANT JE, 1998, 5 C RETR OPP INF FEB; GISOLF E, 1998, 5 C RETR OPP INF FEB; GOEBEL F, 1997, 6 EUR C CLIN ASP TRE; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; GULICK RM, 1997, 37 INT C ANT AG CHEM; Gunthard HF, 1998, J VIROL, V72, P2422; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HAVLIR DV, 1998, 5 C RETR OPP INF FEB; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; HIRSCH MS, 1998, 5 C RETR OPP INF FEB; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; HSU A, 1997, 37 INT C ANT AG CHEM; JOHNSON M, 1998, 5 C RETR OPP INF FEB; KAHN J, 1998, 5 C RETR OPP INF FEB; KASPAR R, 1998, 5 C RETR OPP INF FEB; KATLAMA C, 1998, 5 C RETR OPP INF FEB; Katz MH, 1998, ANN INTERN MED, V128, P306, DOI 10.7326/0003-4819-128-4-199802150-00012; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; KRAVCIK S, 1997, 4 C RETR OPP INF JAN; KRAVCIK S, 1998, 5 C RETR OPP INF FEB; Lafeuillade A, 1997, Antivir Ther, V2, P219; Lipsky JJ, 1998, LANCET, V351, P847, DOI 10.1016/S0140-6736(05)70281-6; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; LORI F, 1998, 5 C RETR OPP INF FEB; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; MCCOLLUM M, 1998, 5 C RETR OPP INF FEB; MCCREA J, 1997, 4 C RETR OPP INF JAN; MEDURI GU, 1991, CHEST, V100, P1272, DOI 10.1378/chest.100.5.1272; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; MONTANER J, 1998, 5 C RETR OPP INF FEB; MONTANER J, 1997, 6 EUR C CLIN ASP TRE; Montaner JSG, 1997, J INFECT DIS, V175, P801, DOI 10.1086/513974; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; MONTANER JSG, IN PRESS AIDS; MURPHY R, 1997, 4 C RETR OPP INF JAN; OPRAVIL M, 1998, 5 C RETR OPP INF FEB; OPRAVIL M, 1998, 37 INT C ANT AG CHEM; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PEDNEAULT L, 1998, 4 C RETR OPP INF JAN; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PHILIPS P, 1997, 4 C RETR OPP INF JAN; POLIS MA, 1998, 5 C RETR OPP INF FEB; POSNIAK A, 1997, 6 EUR C CLIN ASP TRE; RABOUD JM, 1997, 3M INT C ANT AG CHEM; RACE E, 1997, 4 C RETR OPP INF JAN; RAFFI F, 1998, 5 C RETR OPP INF FEB; REGGY A, 1998, 5 C RETR OPP INF FEB; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SADLER BM, 1997, 37 INT C ANT AG CHEM; SAHAI J, 1997, 4 C RETR OPP INF JAN; SARGENT S, 1998, 5 C RETR OPP INF FEB; SENSION M, 1998, 5 C RETR OPP INF FEB; SHELTON M, 1997, 87 INT C ANT AG CHEM; Simpson BJ, 1997, J ACQ IMMUN DEF SYND, V14, P145, DOI 10.1097/00042560-199702010-00007; SKOWRON G, 1998, 37 INT C ANT AG CHEM; SKOWRON G, 1998, 5 C RETR OPP INF FEB; SLATER L, 1998, 5 C RETR OPP INF FEB; SOMMADOSSI JP, 1998, 5 C RETR OPP INF FEB; SQUIRES K, 1997, 6 EUR C CLIN ASP TRE; START I, 1998, 5 C RETR OPP INF FEB; STASZEWSKI S, 1998, 5 C RETR OPP INF FEB; TEBAS P, 1998, 5 C RETR OPP INF FEB; *US DEP HHS, 1998, MMWR-MORBID MORTAL W, V47, P43; VELLA S, 1997, 37 INT C ANT AG CHEM; VILLALBA N, 1998, 5 C RETR OPP INF FEB; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Welles SL, 1996, J INFECT DIS, V174, P696, DOI 10.1093/infdis/174.4.696; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; YUEN G, 1997, 4 C RETR OPP INF JAN; ZORRILLA C, 1998, 5 C RETR OPP INF FEB	102	644	650	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					78	86		10.1001/jama.280.1.78	http://dx.doi.org/10.1001/jama.280.1.78			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660368				2022-12-28	WOS:000074379400028
J	Luzuriaga, K; Sullivan, JL				Luzuriaga, K; Sullivan, JL			Prevention and treatment of pediatric HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; ZIDOVUDINE TREATMENT; TRANSMISSION; TYPE-1; INFANT		Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Sullivan, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Pediat, Suite 318,Biotech II,373 Plantat St, Worcester, MA 01605 USA.	John.Sullivan@banyan.ummed.edu						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P151; *CDCP, 1998, MMWR MORB MORTAL WKL, V47; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1086; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; Ho DD, 1997, J CLIN INVEST, V99, P2565, DOI 10.1172/JCI119443; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; LIDINJANSSON G, 1994, PEDIATRICS, V94, P815; LUZURIAGA K, 1993, J INFECT DIS, V167, P1008, DOI 10.1093/infdis/167.5.1008; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; Luzuriaga K, 1996, JAMA-J AM MED ASSOC, V275, P1360; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; MIROCHNICK M, IN PRESS J INFECT DI; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; ROSSI P, 1992, J ACQ IMMUN DEF SYND, V5, P1019; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; *UNAIDS WHO WORK G, 1998, GLOB HIV AIDS EP EST; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911	22	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					17	18		10.1001/jama.280.1.17	http://dx.doi.org/10.1001/jama.280.1.17			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660351				2022-12-28	WOS:000074379400010
J	Shishido, E; Takeichi, M; Nose, A				Shishido, E; Takeichi, M; Nose, A			Drosophila synapse formation: Regulation by transmembrane protein with leu-rich repeats, CAPRICIOUS	SCIENCE			English	Article							ADHESION MOLECULE; NERVOUS-SYSTEM; MOTOR AXONS; MOTONEURONS; EMBRYO; SUBSET; GENES	Upon reaching the target region, neuronal growth cones transiently search through potential targets and form synaptic connections with only a subset of these. The capricious (caps) gene may regulate these processes in Drosophila. caps encodes a transmembrane protein with leucine-rich repeats (LRRs). During the formation of neuromuscular synapses, caps is expressed in a small number of synaptic partners, including muscle 12 and the motorneurons that innervate it. Loss-of-function and ectopic expression of caps alter the target specificity of muscle 12 motorneurons, indicating a role for caps in selective synapse formation.	Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Kyoto 6068502, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kyoto University	Nose, A (corresponding author), Univ Tokyo, Sch Sci, Dept Phys, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138654, Japan.	nose@bio.phys.s.u-tokyo.ac.jp	Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378; Shishido, Emiko/0000-0002-2474-1343				BATE M, 1995, NEURON, V15, P513, DOI 10.1016/0896-6273(95)90141-8; CHANG Z, 1993, DEV BIOL, V160, P315, DOI 10.1006/dbio.1993.1310; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; Davis GW, 1998, NATURE, V392, P82, DOI 10.1038/32176; Davis GW, 1997, NEURON, V19, P561, DOI 10.1016/S0896-6273(00)80372-4; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GARRITY PA, 1995, CELL, V83, P177, DOI 10.1016/0092-8674(95)90159-0; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HARTENSTEIN V, 1992, ROUX ARCH DEV BIOL, V201, P194, DOI 10.1007/BF00188752; JIA XX, 1993, J NEUROBIOL, V24, P1025, DOI 10.1002/neu.480240804; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; Keshishian H, 1996, ANNU REV NEUROSCI, V19, P545, DOI 10.1146/annurev.ne.19.030196.002553; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kose H, 1997, DEVELOPMENT, V124, P4143; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; Landgraf M, 1997, J NEUROSCI, V17, P9642; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; Nose A, 1997, DEVELOPMENT, V124, P1433; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; Raghavan S, 1997, NEURON, V18, P873, DOI 10.1016/S0896-6273(00)80327-X; Rose D, 1997, DEVELOPMENT, V124, P1561; SHISHIDO E, UNPUB; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SINK H, 1991, DEVELOPMENT, V112, P307; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Yoshihara M, 1997, J NEUROSCI, V17, P8408; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	30	97	99	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2118	2121		10.1126/science.280.5372.2118	http://dx.doi.org/10.1126/science.280.5372.2118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641918				2022-12-28	WOS:000074435900046
J	Zhang, QM; Bharti, V; Zhao, X				Zhang, QM; Bharti, V; Zhao, X			Giant electrostriction and relaxor ferroelectric behavior in electron-irradiated poly(vinylidene fluoride-trifluoroethylene) copolymer	SCIENCE			English	Article							PHASE-TRANSITION; POLYMERS; FIELD	An exceptionally high electrostrictive response (similar to 4 percent) was observed in electron-irradiated poly(vinylidene fluoride-trifluoroethylene) [P(VDF-TrFE)] copolymer. The material exhibits typical relaxer ferroelectric behavior, suggesting that the electron irradiation breaks up the coherent polarization domain (all-trans chains) in normal ferroelectric P(VDF-TrFE) copolymer into nanopolar regions (nanometer-size, all-trans chains interrupted by trans and gauche bonds) that transform the material into a relaxer ferroelectric. The expanding and contracting of these polar regions under external fields, coupled with a large difference in the lattice strain between the polar and nonpolar phases, generate an ultrahigh strain response.	Penn State Univ, Mat Res Lab, University Pk, PA 16802 USA; Penn State Univ, Dept Elect Engn, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Zhang, QM (corresponding author), Penn State Univ, Mat Res Lab, University Pk, PA 16802 USA.							CROSS LE, 1987, FERROELECTRICS, V76, P241, DOI 10.2109/jcersj.99.829; Cross LE, 1996, CERAM T, V68, P15; DAUDIN B, 1987, J APPL PHYS, V62, P994, DOI 10.1063/1.339685; FURUKAWA T, 1990, JPN J APPL PHYS 1, V29, P675, DOI 10.1143/JJAP.29.675; FURUKAWA T, 1989, PHASE TRANSIT, V18, P143, DOI 10.1080/01411598908206863; GLURGIUTIU V, 1996, J INTELL MAT SYST ST, V7, P656; HAERTLING GH, 1987, FERROELECTRICS, V75, P25, DOI 10.1080/00150198708008208; HATHAWAY KB, 1993, MRS BULL, V18, P34, DOI 10.1557/S0883769400037337; LOVINGER AJ, 1985, MACROMOLECULES, V18, P910, DOI 10.1021/ma00147a016; LOVINGER AJ, 1987, POLYMER, V28, P617, DOI 10.1016/0032-3861(87)90478-2; LOVINGER AJ, 1983, SCIENCE, V220, P1115, DOI 10.1126/science.220.4602.1115; MATTSSON J, 1995, PHYS REV LETT, V74, P4305, DOI 10.1103/PhysRevLett.74.4305; Odajima A., 1985, JPN J APPL PHYS, V24, P881; Park SE, 1997, J APPL PHYS, V82, P1804, DOI 10.1063/1.365983; PELRINE R, 1998, ACTUATORS, V64, P77; Service RF, 1997, SCIENCE, V275, P1878, DOI 10.1126/science.275.5308.1878; SINHA JK, 1965, REV SCI INSTRUM, V42, P696; SOMMER R, 1993, PHYS REV B, V48, P13230, DOI 10.1103/PhysRevB.48.13230; SU J, IN PRESS REV SCI INS; SUNDAR V, 1992, FERROELECTRICS, V135, P431, DOI 10.1080/00150199208230043; TAGANTSEV AK, 1994, PHYS REV LETT, V72, P1100, DOI 10.1103/PhysRevLett.72.1100; TASHIRO K, 1984, FERROELECTRICS, V57, P297, DOI 10.1080/00150198408012770; TASHIRO K, 1995, PLAST ENG-CRC, V28, P63; Vogel H, 1921, PHYS Z, V22, P645; WAYMAN CM, 1993, MRS BULL, V18, P49, DOI 10.1557/S0883769400037350; Zhang QM, 1997, J APPL PHYS, V81, P2770, DOI 10.1063/1.363981; ZHENYL M, 1994, J POLYM SCI POL PHYS, V32, P2721, DOI 10.1002/polb.1994.090321618	27	1266	1338	17	500	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2101	2104		10.1126/science.280.5372.2101	http://dx.doi.org/10.1126/science.280.5372.2101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641912				2022-12-28	WOS:000074435900040
J	Postma, DS				Postma, DS			When can an exacerbation of COPD be treated at home?	LANCET			English	Editorial Material							DISEASE		Univ Groningen Hosp, Dept Pulm, NL-9713 EZ Groningen, Netherlands	University of Groningen	Postma, DS (corresponding author), Univ Groningen Hosp, Dept Pulm, NL-9713 EZ Groningen, Netherlands.							*AM HOSP ASS, 1992, HOSP STAT; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; HAGEDORN SD, 1992, POSTGRAD MED, V91, P105; *NAT CTR HLTH STAT, 1994, VITAL HLTH STAT, V12, P115; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398	6	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 20	1998	351	9119					1827	1828		10.1016/S0140-6736(05)78798-5	http://dx.doi.org/10.1016/S0140-6736(05)78798-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652660				2022-12-28	WOS:000074347100003
J	Ip, NY; Shahi, G				Ip, NY; Shahi, G			Policy: Science in Asia - A molecular biology network for Asia and the Pacific Rim	SCIENCE			English	Editorial Material									Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay, Hong Kong; Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Clear Water Bay, Hong Kong; IMBN Secretariat, Singapore, Singapore	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Ip, NY (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay, Hong Kong.			Ip, Nancy Yuk-Yu/0000-0002-2763-8907					0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1708	1708		10.1126/science.280.5370.1708	http://dx.doi.org/10.1126/science.280.5370.1708			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9660709				2022-12-28	WOS:000074197800025
J	Fahey, T; Peters, TJ				Fahey, T; Peters, TJ			Interpretation of thrombosis prevention trial	LANCET			English	Letter									Univ Bristol, Div Primary Care, Bristol BS8 2PR, Avon, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol; University of Bristol	Fahey, T (corresponding author), Univ Bristol, Div Primary Care, Canynge Hall, Bristol BS8 2PR, Avon, England.		Vaidya, Jayant S/A-7218-2008; Iacoviello, Licia/K-4676-2016; Fahey, Tom/C-9367-2012; Iacoviello, Licia/AGX-7071-2022; Vaidya, Jayant S/F-7717-2010; Donati, Maria Benedetta/K-6606-2016; Siani, Alfonso/B-7925-2015	Vaidya, Jayant S/0000-0003-1760-1278; Iacoviello, Licia/0000-0003-0514-5885; Fahey, Tom/0000-0002-5896-5783; Iacoviello, Licia/0000-0003-0514-5885; Vaidya, Jayant S/0000-0003-1760-1278; Donati, Maria Benedetta/0000-0003-1747-5443; Peters, Tim/0000-0003-2881-4180				Meade TW, 1998, LANCET, V351, P233; PEDERSEN TR, 1995, LANCET, V345, P1274; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; Vandenbroucke JP, 1996, LANCET, V347, P1267, DOI 10.1016/S0140-6736(96)90790-4	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1204	1205		10.1016/S0140-6736(05)79150-9	http://dx.doi.org/10.1016/S0140-6736(05)79150-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643713	Bronze			2022-12-28	WOS:000073220200051
J	Jolobe, OMP				Jolobe, OMP			Interpretation of thrombosis prevention trial	LANCET			English	Letter									Tameside Gen Hosp, Dept Med Elderly, Ashton upon Lyne OL6 9RW, Lancs, England		Jolobe, OMP (corresponding author), Tameside Gen Hosp, Dept Med Elderly, Ashton upon Lyne OL6 9RW, Lancs, England.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; JONKER JJC, 1994, LANCET, V343, P499; Meade TW, 1998, LANCET, V351, P233; Miller DB, 1997, ARCH INTERN MED, V157, P2045, DOI 10.1001/archinte.157.18.2045; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 18	1998	351	9110					1205	1205		10.1016/S0140-6736(05)79152-2	http://dx.doi.org/10.1016/S0140-6736(05)79152-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643715				2022-12-28	WOS:000073220200053
J	Kernick, DP				Kernick, DP			Personal paper - Has health economics lost its way?	BRITISH MEDICAL JOURNAL			English	Article							CARE; COST		St Thomas Hlth Ctr, Exeter EX4 1HJ, Devon, England		Kernick, DP (corresponding author), St Thomas Hlth Ctr, Exeter EX4 1HJ, Devon, England.							BAYER JM, 1982, ADM SCI Q, V27, P591; Blumenschein K, 1996, PHARMACOECONOMICS, V10, P114, DOI 10.2165/00019053-199610020-00003; Cho MK, 1996, ANN INTERN MED, V124, P485, DOI 10.7326/0003-4819-124-5-199603010-00004; Coyle D., 1993, INCREASING IMPACT EC; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; *DEP HLTH, 1994, REG COST EFF STUD; Department of Health Housing and Community Services, 1992, GUID PHARM IND PREP; Drummond M, 1993, Int J Technol Assess Health Care, V9, P26; DRUMMOND M, 1996, EC EVALUATION HLTH C; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; FREEMANTLE N, 1994, HEALTH ECON, V3, P63, DOI 10.1002/hec.4730030202; Graham B, 1997, BRIT J GEN PRACT, V47, P170; HUTTON J, 1994, HEALTH ECON, V3, P1, DOI 10.1002/hec.4730030103; Mason J, 1995, Health Trends, V27, P50; Maynard A, 1997, PHARMACOECONOMICS, V11, P115, DOI 10.2165/00019053-199711020-00001; Maynard Alan, 1997, NONRANDOM REFLECTION; *MIN HLTH, 1994, ONT GUID EC AN PHARM; *NHS EX, 1996, PRIOR PLANN GUID NHS; Posnett J, 1996, HEALTH ECON, V5, P13, DOI 10.1002/(SICI)1099-1050(199601)5:1<13::AID-HEC182>3.0.CO;2-J; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; RYAN M, 1990, BRIT MED J, V300, P1316, DOI 10.1136/bmj.300.6735.1316; Ryan M, 1995, Qual Health Care, V4, P207, DOI 10.1136/qshc.4.3.207; Sacristan JA, 1997, PHARMACOECONOMICS, V11, P289	23	12	14	2	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					197	199		10.1136/bmj.317.7152.197	http://dx.doi.org/10.1136/bmj.317.7152.197			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	103FZ	9665908	Green Published			2022-12-28	WOS:000075047800036
J	Petka, WA; Harden, JL; McGrath, KP; Wirtz, D; Tirrell, DA				Petka, WA; Harden, JL; McGrath, KP; Wirtz, D; Tirrell, DA			Reversible hydrogels from self-assembling artificial proteins	SCIENCE			English	Article							GCN4 LEUCINE-ZIPPER; COILED-COILS; SEQUENCES; MODEL	Recombinant DNA methods were used to create artificial proteins that undergo reversible gelation in response to changes in pH or temperature. The proteins consist of terminal Leucine zipper domains flanking a central, flexible, water-soluble polyelectrolyte segment. Formation of coiled-coil aggregates of the terminal domains in near-neutral aqueous solutions triggers formation of a three-dimensional polymer network, with the polyelectrolyte segment retaining solvent and preventing precipitation of the chain. Dissociation of the coiled-coil aggregates through elevation of pH or temperature causes dissolution of the gel and a return to the viscous behavior that is characteristic of polymer solutions. The mild conditions under which gel formation can be controlled (near-neutral pH and near-ambient temperature) suggest that these materials have potential in bioengineering applications requiring encapsulation or controlled release of molecular and cellular species.	Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA; Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA; USA, Sci & Technol Directorate, Natick Res Dev & Engn Ctr, Natick, MA 01760 USA	University of Massachusetts System; University of Massachusetts Amherst; Johns Hopkins University	Tirrell, DA (corresponding author), Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA.		Wirtz, Denis/A-3257-2010					CLARK AH, 1987, ADV POLYM SCI, V83, P57; Guenet J.-M., 1992, THERMOREVERSIBLE GEL, DOI 10.1002/adma.19930050316; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; KREJCHI MT, 1994, SCIENCE, V265, P1427, DOI 10.1126/science.8073284; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mason TG, 1996, J MOL STRUCT, V383, P81, DOI 10.1016/S0022-2860(96)09272-1; MCBRIDE LJ, 1983, TETRAHEDRON LETT, V24, P245, DOI 10.1016/S0040-4039(00)81376-3; McGrath K., 1997, PROTEIN BASED MAT; MCGRATH KP, 1992, J AM CHEM SOC, V114, P727, DOI 10.1021/ja00028a048; MORRIS ER, 1980, J MOL BIOL, V138, P349, DOI 10.1016/0022-2836(80)90291-0; Nijenhuis K.T., 1997, THERMOREVERSIBLE NET, DOI 10.1007/BFb0008699; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Palmer A, 1998, RHEOL ACTA, V37, P97, DOI 10.1007/s003970050095; PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIDA R, 1995, NATURE, V374, P240, DOI 10.1038/374240a0; Yu SJM, 1997, NATURE, V389, P167, DOI 10.1038/38254; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	27	888	943	10	387	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					389	392		10.1126/science.281.5375.389	http://dx.doi.org/10.1126/science.281.5375.389			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665877				2022-12-28	WOS:000074918800040
J	Poinar, HN; Hofreiter, M; Spaulding, WG; Martin, PS; Stankiewicz, BA; Bland, H; Evershed, RP; Possnert, G; Paabo, S				Poinar, HN; Hofreiter, M; Spaulding, WG; Martin, PS; Stankiewicz, BA; Bland, H; Evershed, RP; Possnert, G; Paabo, S			Molecular coproscopy: Dung and diet of the extinct ground sloth Nothrotheriops shastensis	SCIENCE			English	Article							ANCIENT DNA; ENZYMATIC AMPLIFICATION; EXTRACTION; MECHANISM; RETRIEVAL; SEQUENCES; DAMAGE; PLANTS; FOOD; PCR	DNA from excrements can be amplified by means of the polymerase chain reaction. However, this has not been possible with ancient feces. Cross-Links between reducing sugars and amino groups were shown to exist in a Pleistocene coprolite from Gypsum Cave, Nevada. A chemical agent, N-phenacylthiazolium bromide,,that cleaves such cross-links made it possible to amplify DNA sequences. Analyses of these DNA sequences showed that the coprolite is derived from an extinct sloth, presumably the Shasta ground sloth Nothrotheriops shastensis. Plant DNA sequences from seven groups of plants were identified in the coprolite. The plant assemblage that formed part of the sloth's diet exists today at elevations about 800 meters higher than the cave.	Univ Munich, Max Planck Inst Evolutionary Anthropol, D-80333 Munich, Germany; Univ Munich, Inst Zool, D-80333 Munich, Germany; Dames & Moore, Las Vegas, NV 89119 USA; Univ Arizona, Dept Geosci, Desert Lab, Tucson, AZ 85721 USA; Univ Bristol, Dept Geol, Biogeochem Res Ctr, Bristol BS8 1RJ, Avon, England; Div Ion Phys, Angstrom Lab, S-75121 Uppsala, Sweden	Max Planck Society; University of Munich; University of Munich; University of Arizona; University of Bristol	Poinar, HN (corresponding author), Univ Munich, Max Planck Inst Evolutionary Anthropol, Luisenstr 14, D-80333 Munich, Germany.		Hofreiter, Michael/A-3996-2017	Hofreiter, Michael/0000-0003-0441-4705				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BUCALA R, 1984, P NATL ACAD SCI-BIOL, V81, P105, DOI 10.1073/pnas.81.1.105; Evershed RP, 1997, SCIENCE, V278, P432, DOI 10.1126/science.278.5337.432; HANDT O, 1994, EXPERIENTIA, V50, P524, DOI 10.1007/BF01921720; Handt O, 1996, AM J HUM GENET, V59, P368; HANDT O, 1994, SCIENCE, V264, P1775, DOI 10.1126/science.8209259; HANSEN RM, 1978, PALEOBIOLOGY, V4, P302, DOI 10.1017/S0094837300006011; HARRINGTON MR, 1933, GYPSUM CAVE, V8; Hickman JC., 1993, JEPSON MANUAL; HOSS M, 1993, NUCLEIC ACIDS RES, V21, P3913, DOI 10.1093/nar/21.16.3913; Hoss M, 1996, NUCLEIC ACIDS RES, V24, P1304, DOI 10.1093/nar/24.7.1304; Hoss M, 1996, P NATL ACAD SCI USA, V93, P181, DOI 10.1073/pnas.93.1.181; HOSS M, 1992, NATURE, V359, P199, DOI 10.1038/359199a0; HOSS M, 1995, THESIS LUDWIGMAXIMIL; KOHN M, 1995, MOL ECOL, V4, P95, DOI 10.1111/j.1365-294X.1995.tb00196.x; Kohn MH, 1997, TRENDS ECOL EVOL, V12, P223, DOI 10.1016/S0169-5347(97)01050-1; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; KRINGS M, 1997, CELL, V90; Laudermilk J.D., 1934, CARNEGIE I WASHINGTO, V453, P31; LEE AT, 1987, MUTAT RES, V179, P151, DOI 10.1016/0027-5107(87)90305-8; LONG A, 1974, SCIENCE, V186, P638, DOI 10.1126/science.186.4164.638; MARTIN PS, 1961, AM J SCI, V259, P102, DOI 10.2475/ajs.259.2.102; MAURON J, 1981, PROG FOOD NUTR SCI, V5, P5; MULDER MM, 1991, J ANAL APPL PYROL, V19, P175, DOI 10.1016/0165-2370(91)80042-7; PAABO S, 1989, J BIOL CHEM, V264, P9709; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; PAABO S, 1990, J BIOL CHEM, V265, P4718; PAABO S, 1993, SCI AM, V269, P86; Paabo S., 1990, PCR PROTOCOLS GUIDE, P159; PAPOULIS A, 1995, BIOCHEMISTRY-US, V34, P648, DOI 10.1021/bi00002a032; POINAR HN, UNPUB; SAIZJIMENEZ C, 1984, ORG GEOCHEM, V6, P417, DOI DOI 10.1016/0146-6380(84)90064-0; SPAULDING WG, 1990, PACKRAT MIDDENS LAST, pCH9; Stankiewicz BA, 1997, NEW PHYTOL, V135, P375, DOI 10.1046/j.1469-8137.1997.00638.x; Stankiewicz BA, 1997, SCIENCE, V276, P1541, DOI 10.1126/science.276.5318.1541; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; TAYLOR P, 1996, MOL BIOL EVOL, V13, P2839; THORNE RF, 1992, BOT REV, V58, P225, DOI 10.1007/BF02858611; VANBERGEN PF, 1994, GEOCHIM COSMOCHIM AC, V58, P3823, DOI 10.1016/0016-7037(94)90366-2; Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0; WEENEN H, 1994, ACS SYM SER, V543, P142	41	353	375	2	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					402	406		10.1126/science.281.5375.402	http://dx.doi.org/10.1126/science.281.5375.402			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665881				2022-12-28	WOS:000074918800044
J	Falkowski, PG; Barber, RT; Smetacek, V				Falkowski, PG; Barber, RT; Smetacek, V			Biogeochemical controls and feedbacks on ocean primary production	SCIENCE			English	Review							EQUATORIAL PACIFIC-OCEAN; PERMIAN MASS EXTINCTION; PARTICULATE MATTER; ATMOSPHERIC CO2; PHYTOPLANKTON PHOTOSYNTHESIS; IRON LIMITATION; SOUTHERN-OCEAN; GROWTH-RATE; CARBON; OXYGEN	Changes in oceanic primary production, Linked to changes in the network of global biogeochemical cycles, have profoundly influenced the geochemistry of Earth for over 3 billion years. In the contemporary ocean, photosynthetic carbon fixation by marine phytoplankton Leads to formation of similar to 45 gigatons of organic carbon per annum, of which 16 gigatons are exported to the ocean interior. Changes in the magnitude of total and export production can strongly influence atmospheric CO, levels land hence climate) on geological time scales, as well as set upper bounds for sustainable fisheries harvest. The two fluxes are critically dependent on geophysical processes that determine mixed-layer depth, nutrient fluxes to and within the ocean, and food-web structure. Because the average turnover time of phytoplankton carbon in the ocean is on the order of a week or less, total and export production are extremely sensitive to external forcing and consequently are seldom in steady state. Elucidating the biogeochemical controls and feedbacks on primary production is essential to understanding how oceanic biota responded to and affected natural climatic variability in the geological past, and will respond to anthropogenically influenced changes in coming decades. One of the most crucial feedbacks results from changes in radiative forcing on the hydrological cycle, which influences the aeolian iron flux and, in turn, affects nitrogen fixation and primary production in the oceans.	Rutgers State Univ, Inst Marine & Coastal Sci, New Brunswick, NJ 08901 USA; Alfred Wegener Inst Polar & Marine Res, D-27570 Bremerhaven, Germany; Duke Univ, Div Earth & Ocean Sci, Beaufort, NC 28516 USA	Rutgers State University New Brunswick; Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; Duke University	Falkowski, PG (corresponding author), Rutgers State Univ, Inst Marine & Coastal Sci, New Brunswick, NJ 08901 USA.	falko@IMCS.rutgers.edu						ANDERSON LA, 1994, GLOBAL BIOGEOCHEM CY, V8, P65, DOI 10.1029/93GB03318; ANTIA NJ, 1963, LIMNOL OCEANOGR, V8, P166, DOI 10.4319/lo.1963.8.2.0166; Antoine D, 1996, GLOBAL BIOGEOCHEM CY, V10, P57, DOI 10.1029/95GB02832; ARCHER D, 1994, NATURE, V367, P260, DOI 10.1038/367260a0; Azam F, 1998, SCIENCE, V280, P694, DOI 10.1126/science.280.5364.694; AZAM F, 1983, MAR ECOL PROG SER, V10, P257, DOI 10.3354/meps010257; BAKUN A, 1990, SCIENCE, V247, P198, DOI 10.1126/science.247.4939.198; BANSE K, 1992, ENVIR SCI R, V43, P409; BARBER RT, 1991, LIMNOL OCEANOGR, V36, P1803, DOI 10.4319/lo.1991.36.8.1803; Barber RT, 1996, DEEP-SEA RES PT II, V43, P933, DOI 10.1016/0967-0645(96)00035-5; BARNOLA JM, 1987, NATURE, V329, P408, DOI 10.1038/329408a0; Basile I, 1997, EARTH PLANET SC LETT, V146, P573, DOI 10.1016/S0012-821X(96)00255-5; BEHRENFELD M, UNPUB; Behrenfeld MJ, 1997, LIMNOL OCEANOGR, V42, P1, DOI 10.4319/lo.1997.42.1.0001; Behrenfeld MJ, 1996, NATURE, V383, P508, DOI 10.1038/383508a0; BERNER RA, 1989, AM J SCI, V289, P333, DOI 10.2475/ajs.289.4.333; BERRY JA, 1992, ENVIR SCI R, V43, P441; Bhattacharya D, 1998, PLANT PHYSIOL, V116, P9, DOI 10.1104/pp.116.1.9; BIENFANG PK, 1992, ENVIR SCI R, V43, P285; BROECKER W, IN PRESS PALEOCEANOG; Capone DG, 1997, SCIENCE, V276, P1221, DOI 10.1126/science.276.5316.1221; CARDER KL, 1986, LIMNOL OCEANOGR, V31, P403, DOI 10.4319/lo.1986.31.2.0403; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; CHISHOLM SW, 1991, LIMNOL OCEANOGR, V36; Christensen JP, 1987, GLOBAL BIOGEOCHEM CY, V1, P97, DOI 10.1029/GB001i002p00097; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; CODISPOTI LA, 1995, NATURE, V376, P724, DOI 10.1038/376724a0; COPINMONTEGUT C, 1983, DEEP-SEA RES, V30, P31, DOI 10.1016/0198-0149(83)90031-6; Crowley T. J., 1991, PALEOCLIMATOLOGY; Dai A, 1997, J CLIMATE, V10, P2943, DOI 10.1175/1520-0442(1997)010<2943:SOGLPV>2.0.CO;2; DUCE RA, 1991, LIMNOL OCEANOGR, V36, P1715, DOI 10.4319/lo.1991.36.8.1715; Dugdale RC, 1998, NATURE, V391, P270, DOI 10.1038/34630; DUGDALE RC, 1967, LIMNOL OCEANOGR, V12, P685, DOI 10.4319/lo.1967.12.4.0685; EPPLEY RW, 1979, LIMNOL OCEANOGR, V24, P495, DOI 10.4319/lo.1979.24.3.0495; EPPLEY RW, 1979, NATURE, V282, P677, DOI 10.1038/282677a0; Falkowski P.G., 1992, OCEANOGRAPHY, V5, P84, DOI [DOI 10.5670/OCEANOG.1992.14, 10.5670/oceanog.1992.14]; Falkowski P.G., 2013, AQUATIC PHOTOSYNTHES; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; FALKOWSKI PG, 1991, NATURE, V352, P55, DOI 10.1038/352055a0; FANNING KA, 1992, J GEOPHYS RES-OCEANS, V97, P5693, DOI 10.1029/92JC00007; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; Francois R, 1992, PALEOCEANOGRAPHY, V7, P589, DOI 10.1029/92PA01573; Fung I, 1997, GLOBAL BIOGEOCHEM CY, V11, P507, DOI 10.1029/97GB01751; Goldman J. C, 1988, THEORY BIOL PHYSICAL, P273, DOI [10.1007/978-94-009-3023-0_15, DOI 10.1007/978-94-009-3023-0_15]; GOLDMAN JC, 1979, NATURE, V279, P210, DOI 10.1038/279210a0; Gruber N, 1997, GLOBAL BIOGEOCHEM CY, V11, P235, DOI 10.1029/97GB00077; HECKY RE, 1993, LIMNOL OCEANOGR, V38, P709, DOI 10.4319/lo.1993.38.4.0709; Holland HD., 1984, CHEM EVOLUTION ATMOS; Johnson KS, 1997, MAR CHEM, V57, P137, DOI 10.1016/S0304-4203(97)00043-1; Joos F, 1997, J GEOPHYS RES-OCEANS, V102, P12367, DOI 10.1029/97JC00470; KANA TM, 1993, LIMNOL OCEANOGR, V38, P18, DOI 10.4319/lo.1993.38.1.0018; Karl D, 1997, NATURE, V388, P533, DOI 10.1038/41474; KASTING JF, 1993, SCIENCE, V259, P835; KEELING RF, 1992, NATURE, V358, P723, DOI 10.1038/358723a0; Knoll AH, 1996, SCIENCE, V273, P452, DOI 10.1126/science.273.5274.452; KOLBER ZS, 1994, NATURE, V371, P145, DOI 10.1038/371145a0; KUMAR N, 1995, NATURE, V378, P675, DOI 10.1038/378675a0; LaRoche J, 1996, P NATL ACAD SCI USA, V93, P15244; LaRoche J, 1996, NATURE, V382, P802; LEWIN RA, 1993, ORIGINS PLASTIDS; Lindeman RL, 1942, ECOLOGY, V23, P399, DOI 10.2307/1930126; LONGHURST A, 1995, J PLANKTON RES, V17, P1245, DOI 10.1093/plankt/17.6.1245; Mackensen A., 1994, NATO ASI SERIES 1, V17, P104; MaierReimer E, 1996, CLIM DYNAM, V12, P711, DOI 10.1007/s003820050138; Malmstrom CM, 1997, GLOBAL BIOGEOCHEM CY, V11, P367, DOI 10.1029/97GB01419; Malone TC, 1980, PRIMARY PRODUCTIVITY, P301; Margulis L., 1974, Taxon, V23, P225; MARTIN JH, 1992, ENVIR SCI R, V43, P123; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; MCCARTHY JJ, 1979, SCIENCE, V203, P670, DOI 10.1126/science.203.4381.670; MOREL A, 1977, LIMNOL OCEANOGR, V22, P709, DOI 10.4319/lo.1977.22.4.0709; OLAIZOLA M, 1993, MAR BIOL, V116, P533, DOI 10.1007/BF00355471; PLATT T, 1992, ENVIR SCI R, V43, P273; POSTGATE JR, 1971, CHEM BIOCH NITROGEN; PROSPERO JM, 1986, NATURE, V320, P735, DOI 10.1038/320735a0; RAVEN JA, 1988, NEW PHYTOL, V109, P279, DOI 10.1111/j.1469-8137.1988.tb04196.x; REDFIELD AC, 1958, AM SCI, V46, P205; RHEE GY, 1978, LIMNOL OCEANOGR, V23, P10, DOI 10.4319/lo.1978.23.1.0010; RIDING R, 1992, NATURE, V359, P13, DOI 10.1038/359013a0; Rivkin RB, 1997, SCIENCE, V275, P554, DOI 10.1126/science.275.5299.554; RYE R, IN PRESS PRECAMBRIAN; RYTHER JH, 1959, DEEP-SEA RES, V6, P65, DOI 10.1016/0146-6313(59)90057-7; RYTHER JH, 1969, SCIENCE, V166, P72, DOI 10.1126/science.166.3901.72; SAGAN C, 1993, NATURE, V365, P715, DOI 10.1038/365715a0; SARMIENTO JL, 1991, LIMNOL OCEANOGR, V36, P1928, DOI 10.4319/lo.1991.36.8.1928; SARMIENTO JL, 1992, NATURE, V356, P589, DOI 10.1038/356589a0; Sarmiento JL, 1998, NATURE, V393, P245, DOI 10.1038/30455; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; SMETACEK V, 1978, MAR BIOL, V47, P211, DOI 10.1007/BF00541000; Straus N.A., 1994, MOL BIOL CYANOBACTER, P731, DOI DOI 10.1007/978-94-011-0227-8_25; SUBRAMANLAM A, IN PRESS LIMNOL OCEA; TETT P, 1985, J MAR BIOL ASSOC UK, V65, P487, DOI 10.1017/S0025315400050566; TREGUER P, 1995, SCIENCE, V268, P375, DOI 10.1126/science.268.5209.375; Trenberth KE, 1995, CLIMATE CHANGE 1995: THE SCIENCE OF CLIMATE CHANGE, P51; Volk T., 1985, GEOPHYS MONOGR SER, V32, P99, DOI DOI 10.1029/GM032P0099; Walsh J.J., 1988, NATURE CONTINENTAL S; WALSH JJ, 1978, LIMNOL OCEANOGR, V23, P659, DOI 10.4319/lo.1978.23.4.0659; Wignall PB, 1996, SCIENCE, V272, P1155, DOI 10.1126/science.272.5265.1155; WUNSCH C, 1988, ANN REV EARTH PLANET, V26, P219; YODER JA, 1993, GLOBAL BIOGEOCHEM CY, V7, P181, DOI 10.1029/93GB02358; [No title captured]; [No title captured]	102	1728	1805	30	942	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1998	281	5374					200	206		10.1126/science.281.5374.200	http://dx.doi.org/10.1126/science.281.5374.200			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9660741				2022-12-28	WOS:000074714200035
J	Weiner, S; Xu, QQ; Goldberg, P; Liu, JY; Bar-Yosef, O				Weiner, S; Xu, QQ; Goldberg, P; Liu, JY; Bar-Yosef, O			Evidence for the use of fire at Zhoukoudian, China	SCIENCE			English	Article							TRACES; CAVE	Zhoukoudian is widely regarded as having the oldest reliable evidence for the controlled use of fire by humans. A reexamination of the evidence in Layer 10, the earliest archaeological horizon in the site, shows that burned and unburned bones are present in the same Layer with stone tools. However, no ash or charcoal remnants could be detected. Hence, although indirect evidence for burning is present, there is no direct evidence for in situ burning.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Acad Sinica, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China; Boston Univ, Dept Archaeol, Boston, MA 02215 USA; Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA	Weizmann Institute of Science; Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS; Boston University; Harvard University	Weiner, S (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.							BARBETTI M, 1986, J HUM EVOL, V15, P771, DOI 10.1016/S0047-2484(86)80009-4; BINFORD LR, 1985, CURR ANTHROPOL, V26, P413, DOI 10.1086/203303; BINFORD LR, 1986, CURR ANTHROPOL, V27, P453, DOI 10.1086/203469; Black D., 1933, MEM GEOL SURV CHIN A, V11, P1; BRAIN CK, 1988, NATURE, V336, P464, DOI 10.1038/336464a0; Bullock P., 1985, HDB SOIL THIN SECTIO; Courty M.A., 1989, SOILS MICROMORPHOLOG; GOWLETT JAJ, 1981, NATURE, V294, P125, DOI 10.1038/294125a0; GRUN R, 1997, HUM EVOL, V32, P83; GUO SL, 1991, NUCL TRACKS RAD MEAS, V19, P719; HUMPHREYS GS, 1987, AUST J SOIL RES, V25, P115, DOI 10.1071/SR9870115; JAMES SR, 1989, CURR ANTHROPOL, V30, P1, DOI 10.1086/203705; LIU Z, 1988, GEOARCHAEOLOGY, V3, P103; LIU ZC, 1985, QUATERNARY RES, V23, P139; OAKLEY K, 1955, PREHISTORIC SOC, V4, P36; PEI W, 1985, PALAEONTOLOGICA SINI, V12; Schiegl S, 1996, J ARCHAEOL SCI, V23, P763, DOI 10.1006/jasc.1996.0071; Schiegl Solveig, 1994, Israel Journal of Earth Sciences, V43, P267; SEPTH JD, UNPUB; Shahack-Gross R, 1997, J ARCHAEOL SCI, V24, P439, DOI 10.1006/jasc.1996.0128; STINER MC, 1995, J ARCHAEOL SCI, V22, P223, DOI 10.1006/jasc.1995.0024; STRINGER CB, 1985, CURR ANTHROPOL, V26, P655; YANG Z, 1985, MULTIDISCIPLINARY ST, P1; Zhang S., 1985, PALAEOANTHROPOLOGY P, P147	24	122	139	3	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					251	253		10.1126/science.281.5374.251	http://dx.doi.org/10.1126/science.281.5374.251			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZZ286	9657718				2022-12-28	WOS:000074714200047
J	Fioretto, P; Steffes, MW; Sutherland, DER; Goetz, FC; Mauer, M				Fioretto, P; Steffes, MW; Sutherland, DER; Goetz, FC; Mauer, M			Reversal of lesions of diabetic nephropathy after pancreas transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULAR STRUCTURE; NORMAL KIDNEYS; IDDM PATIENTS; LONG-TERM; PROGRESSION; RECIPIENTS; MESANGIUM; MELLITUS; MEMBRANE; GLUCOSE	Background In patients with type 1 diabetes mellitus who do not have uremia and have not received a kidney transplant, pancreas transplantation does not ameliorate established lesions of diabetic nephropathy within five years after transplantation, but the effects of longer periods of normoglycemia are un known. Methods We studied kidney function and performed renal biopsies before pancreas transplantation and 5 and 10 years thereafter in eight patients with type 1 diabetes but without uremia who had mild to advanced lesions of diabetic nephropathy at the time of transplantation. The biopsy samples were analyzed morphometrically. Results All patients had persistently normal glycosylated hemoglobin values after transplantation. The median urinary albumin excretion rate was 103 mg per day before transplantation, 30 mg per day 5 years after transplantation, and 20 mg per day 10 years after transplantation (P=0.07 for the comparison of values at base line and at 5 years; P=0.11 for the comparison between base line and 10 years). The mean (+/-SD) creatinine clearance rate declined from 108+/-20 ml per minute per 1.73 m(2) of body-surface area at base line to 74+/-16 ml per minute per 1.73 m(2) at 5 years (P<0.001) and 74+/-14 ml per minute per 1.73 m(2) at 10 years (P<0.001). The thickness of the glomerular and tubular basement membranes was similar at 5 years (570+/-64 and 928+/-173 nm, respectively) and at base line (594+/-81 and 911+/-133 nm, respectively) but had decreased by 10 years (to 404+/-38 and 690+/-111 nm, respectively; P<0.001 and P=0.004 for the comparisons with the base-line values). The mesangial fractional volume (the proportion of the glomerulus occupied by the mesangium) increased from base line (0.33+/-0.07) to 5 years (0.39+/-0.10, P=0.02) but had decreased at 10 years (0,27+/-0.02, P=0.05 for the comparison with the baseline value and P=0.006 for the comparison with the value at 5 years), mostly because of a reduction in mesangial matrix. Conclusions Pancreas transplantation can reverse the lesions of diabetic nephropathy, but reversal requires more than five years of normoglycemia, (N Engl J Med 1998;339:69-75.) (C)1998, Massachusetts Medical Society.	Univ Minnesota, Sch Med, Dept Pediat, UMHC, Minneapolis, MN 55455 USA; Univ Padua, Sch Med, Dept Internal Med, Padua, Italy; Univ Padua, Sch Med, Natl Res Council, Ctr Study Aging, Padua, Italy; Univ Minnesota, Sch Med, Dept Surg, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Padua; University of Padua; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Mauer, M (corresponding author), Univ Minnesota, Sch Med, Dept Pediat, UMHC, Box 491,420 Delaware St SE, Minneapolis, MN 55455 USA.		Mauer, Michael/ABD-5415-2020; fioretto, paola/AHD-4415-2022	FIORETTO, PAOLA/0000-0003-3445-0387	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043605, P01DK013083] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43605, DK13083] Funding Source: Medline; PHS HHS [MO1-KK00400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANGSTAD HJ, 1994, DIABETOLOGIA, V37, P483, DOI 10.1007/s001250050136; BARBOSA J, 1994, JAMA-J AM MED ASSOC, V272, P600, DOI 10.1001/jama.272.8.600; BILOUS RW, 1989, NEW ENGL J MED, V321, P80, DOI 10.1056/NEJM198907133210204; Brito PL, 1998, KIDNEY INT, V53, P754, DOI 10.1046/j.1523-1755.1998.00809.x; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; ELLIS EN, 1986, METHODS DIABETES RES, V2, P633; FEUTREN G, 1992, NEW ENGL J MED, V326, P1654, DOI 10.1056/NEJM199206183262502; FIORETTO P, 1993, LANCET, V342, P1193, DOI 10.1016/0140-6736(93)92183-T; FIORETTO P, 1995, KIDNEY INT, V48, P1929, DOI 10.1038/ki.1995.493; FIORETTO P, 1994, DIABETES, V43, P1358, DOI 10.2337/diabetes.43.11.1358; FIORETTO P, 1995, KIDNEY INT, V48, P489, DOI 10.1038/ki.1995.318; FIORETTO P, 1992, AM J KIDNEY DIS, V20, P549, DOI 10.1016/S0272-6386(12)70217-2; JENSEN EB, 1979, J MICROSC-OXFORD, V115, P19, DOI 10.1111/j.1365-2818.1979.tb00149.x; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LUBEC G, 1980, Renal Physiology, V3, P4; MAUER SM, 1989, DIABETES, V38, P516, DOI 10.2337/diabetes.38.4.516; MAUER SM, 1983, DIABETES, V32, P948, DOI 10.2337/diabetes.32.10.948; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MECHAM RP, 1987, SCIENCE, V237, P423, DOI 10.1126/science.3603030; Moriya Rika, 1996, Journal of the American Society of Nephrology, V7, P1362; MYERS BD, 1988, KIDNEY INT, V33, P590, DOI 10.1038/ki.1988.38; OSTERBY R, 1991, DIABETOLOGIA, V34, P668, DOI 10.1007/BF00400997; PIRART J, 1978, DIABETES CARE, V1, P252; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEFFES MW, 1992, DIABETES, V41, P679, DOI 10.2337/diabetes.41.6.679; STEFFES MW, 1989, DIABETES, V38, P1077, DOI 10.2337/diabetes.38.9.1077; STEFFES MW, 1985, NEW ENGL J MED, V312, P1282, DOI 10.1056/NEJM198505163122003; SUTHERLAND DER, 1993, AM J SURG, V166, P456, DOI 10.1016/S0002-9610(05)81142-0; SUTHERLAND DER, 1994, TRANSPL P, V26, P379; WEIBEL ER, 1962, J APPL PHYSIOL, V17, P343, DOI 10.1152/jappl.1962.17.2.343; 1994, AM J KIDNEY DIS S2, V24, pS48	33	823	849	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1998	339	2					69	75		10.1056/NEJM199807093390202	http://dx.doi.org/10.1056/NEJM199807093390202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY828	9654536	Bronze			2022-12-28	WOS:000074665300002
J	Robertson, JA				Robertson, JA			Human cloning and the challenge of regulation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Texas, Sch Law, Austin, TX 78705 USA	University of Texas System; University of Texas Austin	Robertson, JA (corresponding author), Univ Texas, Sch Law, 727 E 26th St, Austin, TX 78705 USA.							BEGLEY S, 1997, NEWSWEEK        0310, P53; BONNICKSEN AL, 1998, POLITICS LIFE SC MAR, P3; DAVIS DS, 1997, JURIMETRICS J, V38, P83; Gusfield Joseph, 1986, SYMBOLIC CRUSADE STA; Heyd D., 1992, GENETHICS MORAL ISSU; HOLTZMAN NA, 1989, PROCEED CAUTION PRED; Jonas Hans, 1974, PHILOS ESSAYS ANCIEN, P161; Kassirer JP, 1998, NEW ENGL J MED, V338, P905, DOI 10.1056/NEJM199803263381309; KEARNEY W, 1992, EMERGING ISSUES BIOM, V1, P262; National Bioethics Advisory Commission, 1997, CLON HUM BEINGS REP; Robertson JA, 1998, TEX LAW REV, V76, P1371; Robertson JA, 1996, BOSTON U LAW REV, V76, P421; Robertson JA., 1994, CHILDREN CHOICE FREE; Segal N.L., 1997, JURIMETRICS, V38, P57; Silver LeeM., 1997, REMAKING EDEN CLONIN; Stolberg Sheryl Gay, 1998, N Y Times Web, pA21; Walters L., 1997, ETHICS HUMAN GENE TH; WILSON JQ, 1997, WEEKLY STANDARD 0526, P23; WOLF SM, HASTINGS CTR REP, V2712, P97; ZHANG J, 1997, FERTIL STERIL S1, V68, pS1	20	21	22	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1998	339	2					119	122		10.1056/NEJM199807093390212	http://dx.doi.org/10.1056/NEJM199807093390212			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY828	9654547				2022-12-28	WOS:000074665300012
J	Portillo, M				Portillo, M			Something to celebrate - The Bevan legacy	BRITISH MEDICAL JOURNAL			English	Article											Portillo, M (corresponding author), 75 Davies St, London W1Y 1FA, England.							Rivett Geoffrey, 1998, CRADLE GRAVE 50 YEAR	1	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					37	40		10.1136/bmj.317.7150.37	http://dx.doi.org/10.1136/bmj.317.7150.37			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651269	Green Published			2022-12-28	WOS:000075081600024
J	Kuttruff, JT; DeHart, SG; O'Brien, MJ				Kuttruff, JT; DeHart, SG; O'Brien, MJ			7500 years of prehistoric footwear from Arnold Research Cave, Missouri	SCIENCE			English	Article								Accelerator mass spectrometer dating of an assemblage of fibrous and leather footwear from Arnold Research Cave in central Missouri documents a long sequence of shoe construction by prehistoric Midwestern peoples, beginning perhaps as early as 8300 calendar years before the present (cal years B.P.). An earlier fibrous sandal form dates from 8325 to 7675 cal years B.P., and later fibrous or leather slip-ons span the period from 5575 to 1070 cat years B.P. The assemblage adds to a growing picture of the highly varied nature of prehistoric footwear production in the United States throughout the Holocene.	Univ Missouri, Dept Anthropol, Columbia, MO 65211 USA; Louisiana State Univ, Sch Human Ecol, Baton Rouge, LA 70803 USA	University of Missouri System; University of Missouri Columbia; Louisiana State University System; Louisiana State University	O'Brien, MJ (corresponding author), Univ Missouri, Dept Anthropol, 200 Swallow Hall, Columbia, MO 65211 USA.							Bedwell SF, 1973, FORT ROCK BASIN PREH; COLLINS MB, 1969, 16 TEX ARCH SALV PRO; Cressman LS, 1951, SOUTHWEST J ANTHROP, V7, P289, DOI 10.1086/soutjanth.7.3.3628606; Cressman L.S., 1977, PREHISTORY FAR W HOM; Deegan Ann Cordy, 1993, KIVA, V59, P49; DEHART SG, 1998, THESIS LOUISIANA STA; Emery I., 1980, PRIMARY STRUCTURES F; GEIB PR, 1996, UTAH ARCHAEOL, V9, P35; GREMILLION KJ, 1997, KENT HER COUNC ANN M; Harrington M. R., 1960, OZARK BLUFF DWELLERS; HARVEY AE, 1974, P I EM ROUNDT MUS TE, P133; Henning Amy E., 1966, MO ARCHAEOL, V28, P41; HEWITT NJ, 1980, ANTHR PAPERS, V10, P49; KANKAINEN K, 1995, TREADING PAST SANDAL; KING ME, 1974, ARCHAEOLOGY MAMMOTH, P31; Kuttruff Jenna, 1988, THESIS OHIO STATE U; KUTTRUFF JT, 1993, AM ANTIQUITY, V58, P125, DOI 10.2307/281458; Miller Joan, 1988, SE ARCHAEOL, V7, P132; OBRIEN MJ, 1998, PRESHISTORY MISSOURI; ORCHARD W, 1920, INDIAN NOTES MONOGRA, V4; Scholtz Sandra C., 1975, ARKANSAS ARCHEOLOGIC, V9; SHIPPEE JM, 1966, MISSOURI ARCHAEOLOGI, V28, P1; SHIPPEE JM, 1957, MISSOURI ARCHAEOLOGI, V1; WATSON PJ, 1969, 16 ILL STAT MUS; WORD JA, 1970, EXCAVATIONS BAKER CA, V16	25	33	33	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					72	75		10.1126/science.281.5373.72	http://dx.doi.org/10.1126/science.281.5373.72			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651246				2022-12-28	WOS:000074685800038
J	Cowie, LL; Songaila, A				Cowie, LL; Songaila, A			Heavy-element enrichment in low-density regions of the intergalactic medium	NATURE			English	Article							LYMAN-ALPHA FOREST; GRAVITATIONAL COLLAPSE; CLOUDS; MODEL; ABUNDANCE	Models for the composition of the diffuse intergalactic medium(1,2) predict that low-density intergalactic gas at high redshift should be very poor in heavy elements. This is because locations of early star formation land thus of heavy-element synthesis) and of gas delivery from such stars are located preferentially within higher-density regions of the intergalactic gas. Here we present a method for analysing carbon and oxygen absorption lines in quasar spectra that allows us to probe the heavy-element abundances at a redshift of three within low-density regions of intergalactic gas. We find that the ratio of triply ionized carbon to neutral hydrogen is roughly constant over a wide range of densities, and that, even as the density approaches zero, the ratio remains high. This unexpected enrichment of low-density gas in heavy elements suggests that early generations of small galaxies might be much more efficient at ejecting heavy elements into the intergalactic medium than has previously been thought.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA	University of Hawaii System	Cowie, LL (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.			Cowie, Lennox/0000-0002-6319-1575; Cowie Songaila, Antoinette/0000-0001-9028-6978				Bi HG, 1997, ASTROPHYS J, V479, P523, DOI 10.1086/303908; CEN RY, 1994, ASTROPHYS J, V437, pL9, DOI 10.1086/187670; COWIE LL, 1995, ASTRON J, V109, P1522, DOI 10.1086/117381; Croft RAC, 1997, ASTROPHYS J, V488, P532, DOI 10.1086/304723; Dave R, 1997, ASTROPHYS J, V477, P21, DOI 10.1086/303712; Giroux ML, 1997, ASTRON J, V113, P1505, DOI 10.1086/118367; Gnedin NY, 1998, MON NOT R ASTRON SOC, V294, P407, DOI 10.1046/j.1365-8711.1998.01156.x; Gnedin NY, 1997, ASTROPHYS J, V486, P581, DOI 10.1086/304548; Haardt F, 1996, ASTROPHYS J, V461, P20, DOI 10.1086/177035; Haiman Z, 1997, ASTROPHYS J, V483, P21, DOI 10.1086/304238; Hellsten U, 1997, ASTROPHYS J, V487, P482, DOI 10.1086/304641; Hernquist L, 1996, ASTROPHYS J, V457, pL51, DOI 10.1086/309899; HU EM, 1995, ASTRON J, V110, P1526, DOI 10.1086/117625; Hui L, 1997, MON NOT R ASTRON SOC, V292, P27, DOI 10.1093/mnras/292.1.27; LU LM, 1991, ASTROPHYS J, V379, P99, DOI 10.1086/170487; MEYER D, 1987, ASTROPHYS J, V315, pL8; MiraldaEscude J, 1996, ASTROPHYS J, V471, P582, DOI 10.1086/177992; MiraldaEscude J, 1997, ASTROPHYS J, V478, pL57, DOI 10.1086/310550; NORRIS J, 1983, ASTROPHYS J, V273, P450, DOI 10.1086/161383; PETITJEAN P, 1995, ASTRON ASTROPHYS, V295, pL9; Petitjean P., 1995, Science with VLT. Proceedings of the ESO Workshop, P339; Rauch M, 1997, ASTROPHYS J, V481, P601, DOI 10.1086/304085; SARGENT LL, ASTROPH9802189; Songaila A, 1997, ASTROPHYS J, V490, pL1, DOI 10.1086/311006; Songaila A, 1996, ASTRON J, V112, P335, DOI 10.1086/118018; SONGALILA A, IN PRESS ASTRON J; TYTLER D, 1994, ASTROPHYS J, V424, pL87, DOI 10.1086/187281; ZHANG Y, 1995, ASTROPHYS J, V453, pL57	28	131	132	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					44	46		10.1038/27845	http://dx.doi.org/10.1038/27845			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665126				2022-12-28	WOS:000074579600041
J	Doricchi, F; Incoccia, C				Doricchi, F; Incoccia, C			Seeing only the right half of the forest but cutting down all the trees?	NATURE			English	Article							NEGLECT; LESIONS; BRAIN	Unilateral neglect following damage to the right hemisphere of the brain can be characterized by failure of the global attentional mechanisms of the right hemisphere to direct the local detail processors of the left hemisphere towards the contralesional left hemispace, This is suggested by patients who recognize the global form of the left side of shapes (the forest) but fail to cancel out its local details (the trees)(1). Here we report the opposite behavioural dissociation in a patient (Q,M,) with damage to the right hemisphere of the brain. Q.M, detected local details (such as the tail of a dog) on the left or right side of visual shapes, regardless of whether these details belonged to predefined target shapes (a dog in this case) or to distracter shapes differing on the opposite side (a dog with a swan's neck and head, for example). Psychological testing showed an abnormal tendency of this patient to respond to local features, but perfect accuracy in interpreting global features when the local features could not interfere in global processing. The results indicate that the left hemisphere can integrate multiple local features simultaneously but loses global awareness as soon as local features individually compete for response selection. However, awareness of the whole is not necessary for the sequential processing of the parts.	IRCCS, Ctr Ric Neuropsicol, I-00179 Roma, Italy; Univ Urbino, Ist Psicol Luigi Meschieri, I-61029 Urbino, Italy	University of Urbino	Doricchi, F (corresponding author), IRCCS, Ctr Ric Neuropsicol, Via Ardeatina 306, I-00179 Roma, Italy.	fdoricchi@uniromal.it		Incoccia, Chiara/0000-0003-4068-6548				DRIVER J, 1991, COGNITIVE NEUROPSYCH, V8, P475, DOI 10.1080/02643299108253384; Fink GR, 1996, NATURE, V382, P626, DOI 10.1038/382626a0; Fink GR, 1997, P ROY SOC B-BIOL SCI, V264, P487, DOI 10.1098/rspb.1997.0070; GAINOTTI G, 1972, J NEUROL NEUROSUR PS, V35, P545, DOI 10.1136/jnnp.35.4.545; HALLIGAN PW, 1994, NEUROPSYCHOLOGIA, V32, P13, DOI 10.1016/0028-3932(94)90065-5; Hillis AE, 1995, NEUROCASE, V1, P189, DOI 10.1080/13554799508402364; MARSHALL JC, 1995, NATURE, V373, P521, DOI 10.1038/373521a0; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; PIZZAMIGLIO L, 1992, J CLIN EXP NEUROPSYC, V14, P901, DOI 10.1080/01688639208402543; ROBERTSON LC, 1988, J NEUROSCI, V8, P3757; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Walker R, 1995, NEUROCASE, V1, P371	12	31	32	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					75	78		10.1038/27913	http://dx.doi.org/10.1038/27913			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZY030	9665130				2022-12-28	WOS:000074579600051
J	Schrager, LK; D'Souza, MP				Schrager, LK; D'Souza, MP			Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CD8(+) T-CELLS; IN-VIVO; CEREBROSPINAL-FLUID; LYMPHOID-TISSUE; NERVOUS-SYSTEM; TYPE-1 RNA; LIFE-SPAN; INFECTION; LYMPHOCYTES	The eradication of human immunodeficiency virus 1 (HIV-1) from infected persons is the ultimate goal of HIV therapeutic interventions. Great strides have been made in developing potent antiretroviral regimens that greatly suppress HIV-1 replication. Despite these therapeutic advances, major obstacles remain to eradicating HIV-1. Reservoirs of HIV-1 have been identified that represent major impediments to eradication. Conceptually, there are 2 types of Sanctuaries for HIV-1, cellular and anatomical. Cellular sanctuaries may include latent CD4(+) T cells containing integrated HIV-1 provirus; macrophages, which may express HIV-1 for prolonged periods; and follicular dendritic cells, which may hold infectious HIV-1 on their surfaces for indeterminate lengths of time. The key anatomical reservoir for HIV-1 appears to be the central nervous system. An understanding of the nature of HIV within these reservoirs is critical to devising strategies to hasten viral eradication.	NIAID, Div Aids, Epidemiol Branch, Bethesda, MD 20892 USA; NIAID, Div Aids, Pathogenesis & Basic Res Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Schrager, LK (corresponding author), NIAID, Div Aids, Epidemiol Branch, Solar Bldg 2C10, Bethesda, MD 20892 USA.	LS14M@nih.gov						BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; BURTON GF, 1997, I HUM VIR 2 ANN M SE; Cavert W, 1997, SCIENCE, V276, P1321; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; CLEMENTS J, 1998, 5 C RETR OPP INF FEB; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cohen OJ, 1996, J INFECT DIS, V173, P849, DOI 10.1093/infdis/173.4.849; CUNNINGHAM P, 1998, 5 C RETR OPP INF FEB; ELLIS RJ, 1998, 5 C RETR OPP INF FEB; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; FAUCI A, 1998, 5 C RETR OPP INF FEB; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FOLKS T, 1986, J IMMUNOL, V136, P4049; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; FOX CH, 1992, J INFECT DIS, V165, P1161, DOI 10.1093/infdis/165.6.1161a; GABUZDA DH, 1987, ANN INTERN MED, V107, P383, DOI 10.7326/0003-4819-107-2-383; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; HAASE A, 1998, 5 C RETR OPP INF FEB; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Haworth SJ, 1998, J ACQ IMMUN DEF SYND, V17, P235, DOI 10.1097/00042560-199803010-00008; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; HO D, 1998, 5 C RETR OPP INF FEB; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; Kaczorowski S, 1995, LEUKEMIA LYMPHOMA, V20, P143, DOI 10.3109/10428199509054766; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; KURE K, 1991, HUM PATHOL, V22, P700, DOI 10.1016/0046-8177(91)90293-X; Lee CGL, 1998, J CLIN INVEST, V101, P287, DOI 10.1172/JCI2575; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; Lewis LL, 1996, J INFECT DIS, V174, P16, DOI 10.1093/infdis/174.1.16; *MED EC CO, 1998, PHYS DESK REF, P1167; MELTZER MS, 1990, AIDS RES HUM RETROV, V6, P967, DOI 10.1089/aid.1990.6.967; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Moreno P, 1996, AIDS, V10, P682, DOI 10.1097/00002030-199606000-00019; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857; PANTALEO G, 1994, IMMUNOL REV, V140, P105, DOI 10.1111/j.1600-065X.1994.tb00867.x; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PERNO CF, 1998, 5 C RETR OPP INF FEB; PHIPPS RP, 1981, CELL IMMUNOL, V57, P505, DOI 10.1016/0008-8749(81)90108-8; Picker Louis J., 1993, P145; POMERANTZ RJ, 1987, NEW ENGL J MED, V317, P1643, DOI 10.1056/NEJM198712243172607; POMERANTZ RJ, 1998, 5 C RETR OPP INF FEB; Pratt RD, 1996, J INFECT DIS, V174, P288, DOI 10.1093/infdis/174.2.288; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; ROTH V, 1998, 5 C RETR OPP INF FEB; SCHLEGEL PN, 1998, CAMPBELLS UROLOGY, P1254; Sei S, 1996, J INFECT DIS, V174, P1200, DOI 10.1093/infdis/174.6.1200; SILICIANO RF, 1998, KEYST S HIV PATH TRE; Stahle L, 1997, LANCET, V350, P1823, DOI 10.1016/S0140-6736(05)63640-9; van Furth R, 1989, Curr Top Pathol, V79, P125; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	64	254	258	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					67	71		10.1001/jama.280.1.67	http://dx.doi.org/10.1001/jama.280.1.67			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660366				2022-12-28	WOS:000074379400026
J	Thakur, CP				Thakur, CP			Sodium antimony gluconate, amphotericin, and myocardial damage	LANCET			English	Article									Uma Complex, Patna 800001, Bihar, India		Thakur, CP (corresponding author), Uma Complex, Patna 800001, Bihar, India.							DEMONACO HJ, 1983, DRUG INTEL CLIN PHAR, V17, P547, DOI 10.1177/106002808301700711; JHA TK, 1995, AM J TROP MED HYG, V52, P536, DOI 10.4269/ajtmh.1995.52.536; Thakur C. P., 1995, National Medical Journal of India, V8, P13; THAKUR CP, 1996, INDIAN J MED RES, V103, P29; UTZ JP, 1994, ANN INTERN MED, V61, P335	5	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1928	1929		10.1016/S0140-6736(05)78612-8	http://dx.doi.org/10.1016/S0140-6736(05)78612-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654264				2022-12-28	WOS:000074464700014
J	Hicks, DA				Hicks, DA			What risk of infection with IUD use?	LANCET			English	Editorial Material									Royal Hallamshire Hosp, Dept Genitourinary Med, Sheffield S10 2SF, S Yorkshire, England	University of Sheffield	Hicks, DA (corresponding author), Royal Hallamshire Hosp, Dept Genitourinary Med, Sheffield S10 2SF, S Yorkshire, England.							Carlin EM, 1995, INT J STD AIDS, V6, P373, DOI 10.1177/095646249500600601; FARLEY TMM, 1992, LANCET, V339, P785, DOI 10.1016/0140-6736(92)91904-M; HAUKKAMAA M, 1986, AM J OBSTET GYNECOL, V154, P520, DOI 10.1016/0002-9378(86)90594-6; HUGGINS GR, 1990, FERTIL STERIL, V54, P599; LANDERS DV, 1985, AM J OBSTET GYNECOL, V151, P1098, DOI 10.1016/0002-9378(85)90392-8; MAUDLIN WP, 1992, CONTRACEPTION, V45, P278; STEVENSON MM, 1995, INT J STD AIDS, V6, P305, DOI 10.1177/095646249500600501; TRIEMAN K, 1995, POPULATION REPORTS B, V6; Walsh T, 1998, LANCET, V351, P1005, DOI 10.1016/S0140-6736(97)09086-7	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1222	1223		10.1016/S0140-6736(05)79312-0	http://dx.doi.org/10.1016/S0140-6736(05)79312-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643738				2022-12-28	WOS:000073283600004
J	FitzGerald, GA; Charman, WN				FitzGerald, GA; Charman, WN			Interpretation of thrombosis prevention trial	LANCET			English	Letter							CONTROLLED-RELEASE ASPIRIN		Univ Penn, Med Ctr, Ctr Expt Therapeut, Dept Pharmacol, Philadelphia, PA 19104 USA; Montash Univ, Victorian Coll Pharm, Parkville, Vic, Australia	University of Pennsylvania	FitzGerald, GA (corresponding author), Univ Penn, Med Ctr, Ctr Expt Therapeut, Dept Pharmacol, Philadelphia, PA 19104 USA.							CHARMAN WN, 1993, BRIT J CLIN PHARMACO, V36, P470, DOI 10.1111/j.1365-2125.1993.tb00399.x; CLARKE RJ, 1991, NEW ENGL J MED, V325, P1137, DOI 10.1056/NEJM199110173251605; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; Meade TW, 1998, LANCET, V351, P233; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780	5	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1206	1206		10.1016/S0140-6736(05)79155-8	http://dx.doi.org/10.1016/S0140-6736(05)79155-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643718				2022-12-28	WOS:000073220200056
J	Turney, JH				Turney, JH			Doctors who changed a patient's life - Today's dogma may be tomorrow's joke	BRITISH MEDICAL JOURNAL			English	Article																			0	1	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					142	142		10.1136/bmj.317.7151.142	http://dx.doi.org/10.1136/bmj.317.7151.142			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657798	Green Published			2022-12-28	WOS:000075081700032
J	Webster, C				Webster, C			The BMA and the NHS	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford All Souls Coll, Oxford OX1 4AL, England	University of Oxford	Webster, C (corresponding author), Univ Oxford All Souls Coll, Oxford OX1 4AL, England.							CASTLE B, 1980, CASTLE DIARIES 1974, P364; DAIN HG, 1948, TIMES           0116, pE; KLEIN R, 1995, NEW POLITICS NATL HL, P131; MORGAN K, 1984, LABOUR POWER, P154; RUSSELLSMITH E, 1948, COMMUNICATION   0129; 1981, PRIMARY CARE TEAM RE	6	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					45	47		10.1136/bmj.317.7150.45	http://dx.doi.org/10.1136/bmj.317.7150.45			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651271	Green Published			2022-12-28	WOS:000075081600026
J	McEwen, AS; Keszthelyi, L; Spencer, JR; Schubert, G; Matson, DL; Lopes-Gautier, R; Klassen, KP; Johnson, TV; Head, JW; Geissler, P; Fagents, S; Davies, AG; Carr, MH; Breneman, HH; Belton, MJS				McEwen, AS; Keszthelyi, L; Spencer, JR; Schubert, G; Matson, DL; Lopes-Gautier, R; Klassen, KP; Johnson, TV; Head, JW; Geissler, P; Fagents, S; Davies, AG; Carr, MH; Breneman, HH; Belton, MJS			High-temperature silicate volcanism on Jupiter's moon Io	SCIENCE			English	Article							GALILEAN SATELLITES; INTERNAL STRUCTURE; TOPOGRAPHY; SPECTRA; SYSTEM	Infrared wavelength observations of lo by the Galileo spacecraft show that at Least 12 different vents are erupting lavas that are probably hotter than the highest temperature basaltic eruptions on Earth today. In at least one case, the eruption near Pillan Patera, two independent instruments on Galileo show that the lava temperature must have exceeded 1700 kelvin and may have reached 2000 kelvin. The most likely explanation is that these lavas are ultramafic (magnesium-rich) silicates, and this idea-is supported by the tentative identification of magnesium-rich orthopyroxene in Lava flows associated with these high-temperature hot spots.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85711 USA; Lowell Observ, Flagstaff, AZ 86001 USA; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; US Geol Survey, Menlo Park, CA 94025 USA; Natl Opt Astron Observ, Tucson, AZ 85719 USA	University of Arizona; University of California System; University of California Los Angeles; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Brown University; Arizona State University; Arizona State University-Tempe; United States Department of the Interior; United States Geological Survey; National Optical Astronomy Observatory	McEwen, AS (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85711 USA.	mcewen@lplarizona.edu	Lopes, Rosaly M.C./D-1608-2016; Fagents, Sarah/B-3983-2014; Davies, Ashley/S-5588-2018	Lopes, Rosaly M.C./0000-0002-7928-3167; Davies, Ashley/0000-0003-1747-8142; Kestay, Laszlo/0000-0003-1879-4331				ADAMS JB, 1974, J GEOPHYS RES, V79, P4829, DOI 10.1029/JB079i032p04829; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; BELTON MJS, 1992, SPACE SCI REV, V60, P413, DOI 10.1007/BF00216864; Bevington P. R, 1969, DATA REDUCTION ERROR; CARLSON RW, 1992, SPACE SCI REV, V60, P457, DOI 10.1007/BF00216865; CARR MH, 1986, J GEOPHYS RES-SOLID, V91, P3521, DOI 10.1029/JB091iB03p03521; CARR MH, IN PRESS ICARUS; DAVIES AG, 1998, LUNAR PLANET SCI, V29; GARCIA MO, 1995, GEOPHYS MONOGR SER, V92, P219; GASKELL RW, 1988, GEOPHYS RES LETT, V15, P581, DOI 10.1029/GL015i006p00581; Hall A, 1987, IGNEOUS PETROLOGY; HEAD JW, 1992, GEOCHIM COSMOCHIM AC, V56, P2155, DOI 10.1016/0016-7037(92)90183-J; HEIKEN G, 1991, LUNAR SORUCEBOOK USE; HERZBERG C, 1992, J GEOPHYS RES-SOL EA, V97, P4521, DOI 10.1029/91JB03066; Hess PC., 1989, ORIGINS IGNEOUS ROCK; JOHNSON ML, 1990, GEOPHYS RES LETT, V17, P981, DOI 10.1029/GL017i007p00981; JOHNSON TV, 1988, SCIENCE, V242, P1280, DOI 10.1126/science.242.4883.1280; Keszthelyi L, 1997, GEOPHYS RES LETT, V24, P2463, DOI 10.1029/97GL01368; Keszthelyi L, 1997, ICARUS, V130, P437, DOI 10.1006/icar.1997.5837; KLAASEN KP, 1984, OPT ENG, V23, P334, DOI 10.1117/12.7973290; KLASSEN KP, 1997, OPT ENG, V36, P3001; LopesGautier R, 1997, GEOPHYS RES LETT, V24, P2439, DOI 10.1029/97GL02662; LUNINE JI, 1985, ICARUS, V64, P345, DOI 10.1016/0019-1035(85)90060-0; MATSON DL, 1998, LUNAR PLANET SCI, V29; McEwen AS, 1997, GEOPHYS RES LETT, V24, P2443, DOI 10.1029/97GL01956; MCEWEN AS, 1989, NASA SP494, P11; MCEWEN AS, IN PRESS ICARUS; Morse S.A., 1980, BASALTS PHASE DIAGRA; NASH DB, 1990, SATELLITES, P629; Pearl J.S., 1982, SATELLITES JUPITER, P724; POLLACK JB, 1978, ICARUS, V36, P271, DOI 10.1016/0019-1035(78)90110-0; ROSS MN, 1990, ICARUS, V85, P309, DOI 10.1016/0019-1035(90)90119-T; Rothery DA, 1996, J GEOPHYS RES-PLANET, V101, P26131, DOI 10.1029/96JE02864; SCHABER GG, 1982, SATELLITES JUPITER, P556; SEGATZ M, 1988, ICARUS, V75, P187, DOI 10.1016/0019-1035(88)90001-2; SMITH BA, 1979, SCIENCE, V204, P951, DOI 10.1126/science.204.4396.951; Spencer JR, 1997, GEOPHYS RES LETT, V24, P2451, DOI 10.1029/97GL02591; Stansberry JA, 1997, GEOPHYS RES LETT, V24, P2455, DOI 10.1029/97GL02593; THOMAS PE, IN PRESS; VEEDER GJ, 1994, J GEOPHYS RES-PLANET, V99, P17095, DOI 10.1029/94JE00637	40	159	161	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					87	90		10.1126/science.281.5373.87	http://dx.doi.org/10.1126/science.281.5373.87			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651251				2022-12-28	WOS:000074685800043
J	DePace, AH; Santoso, A; Hillner, P; Weissman, JS				DePace, AH; Santoso, A; Hillner, P; Weissman, JS			A critical role for amino-terminal glutamine/asparagine repeats in the formation and propagation of a yeast prion	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; SUP35 GENE; PROTEIN; PSI(+); URE3	The yeast [PSI+] factor propagates by a prion-like mechanism involving self-replicating Sup35p amyloids. We identified multiple Sup35p mutants that either are poorly recruited into, or cause curing of, wildtype amyloids in vivo. In vitro, these mutants showed markedly decreased rates of amyloid formation, strongly supporting the protein-only prion hypothesis. Kinetic analysis suggests that the prion state replicates by accelerating slow conformational changes rather than by providing stable nuclei. Strikingly, our mutations map exclusively within a short glutamine/asparagine-rich region of Sup35p, and all but one occur at polar residues. Even after replacement of this region with polyglutamine, Sup35p retains its ability to form amyloids. These and other considerations suggest similarities between the prion-like propagation of [PSI+] and polyglutamine-mediated pathogenesis of several neurodegenerative diseases.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.			Weissman, Jonathan/0000-0003-2445-670X				BRIEHL RW, 1980, NATURE, V288, P622, DOI 10.1038/288622a0; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; DOEL SM, 1994, GENETICS, V137, P659; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; JAHLEM P, 1998, MOL CELL, V1, P595; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; KUSHNIROV VV, 1990, YEAST, V6, P461, DOI 10.1002/yea.320060603; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; Lazo ND, 1998, BIOCHEMISTRY-US, V37, P1731, DOI 10.1021/bi971016d; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; Moore DD, 1995, GLOB MOB SURV; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; Wetzel R, 1997, ADV PROTEIN CHEM, V50, P183, DOI 10.1016/S0065-3233(08)60322-8; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1995, YEAST, V11, P1671, DOI 10.1002/yea.320111609	38	326	329	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1998	93	7					1241	1252		10.1016/S0092-8674(00)81467-1	http://dx.doi.org/10.1016/S0092-8674(00)81467-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657156	Bronze			2022-12-28	WOS:000074491100018
J	Ward, WR; Hahn, JM				Ward, WR; Hahn, JM			Neptune's eccentricity and the nature of the Kuiper belt	SCIENCE			English	Article							SHORT-PERIOD COMETS; OUTER SOLAR-SYSTEM; DENSITY WAVES; ORBITAL MIGRATION; SATURNS RINGS; ACCRETION; LINDBLAD; ORIGIN; URANUS	The small eccentricity of Neptune may be a direct consequence of apsidal wave interaction with the trans-Neptune population of debris called the Kuiper belt. The Kuiper belt is subject to resonant perturbations from Neptune, so that the transport of angular momentum by density waves can result in orbital evolution of Neptune as well as changes in the structure of the Kuiper belt. In particular, for a belt eroded out to the vicinity of Neptune's 2:1 resonance at about 48 astronomical units, Neptune's eccentricity can damp to its current value over the age of the solar system if the belt contains slightly more than an earth mass of material out to about 75 astronomical units.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Lunar & Planetary Inst, Houston, TX 77058 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Ward, WR (corresponding author), SW Res Inst, 1050 Walnut St,Suite 429, Boulder, CO 80302 USA.							Abramowitz M., 1964, HDB MATH FUNCTIONS; Anderson JD, 1998, ICARUS, V131, P167, DOI 10.1006/icar.1997.5867; APPLEGATE JH, 1986, ASTRON J, V92, P176, DOI 10.1086/114149; Brahic A., 1984, IAU C, V75, P513; Brouwer D., 1964, METHODS CELESTIAL ME; CUZZI JN, 1981, NATURE, V292, P703, DOI 10.1038/292703a0; DUNCAN M, 1988, ASTROPHYS J, V328, pL69, DOI 10.1086/185162; Duncan MJ, 1997, SCIENCE, V276, P1670, DOI 10.1126/science.276.5319.1670; Duncan MJ, 1995, ASTRON J, V110, P3073, DOI 10.1086/117748; FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5; Fernandez JA, 1996, PLANET SPACE SCI, V44, P431, DOI 10.1016/0032-0633(95)00142-5; GOLDREICH P, 1978, ICARUS, V34, P240, DOI 10.1016/0019-1035(78)90165-3; GRADSHTEYN IS, 1995, TABLE INTEGRALS SERI; HAHN J, 1998, LUNAR PLANET SCI C, V29, P1398; HAMID SE, 1968, ASTRON J, V73, P727, DOI 10.1086/110685; HOLMAN MJ, 1993, ASTRON J, V105, P1987, DOI 10.1086/116574; IP WH, 1989, ICARUS, V80, P167, DOI 10.1016/0019-1035(89)90165-6; JEWITT D, 1993, NATURE, V362, P730, DOI 10.1038/362730a0; JEWITT D, 1996, IN PRESS ASTRON J, V112; JEWITT DC, 1995, ASTRON J, V109, P1867, DOI 10.1086/117413; LEVISON HF, 1993, ASTROPHYS J, V406, pL35, DOI 10.1086/186780; Lin DNC, 1996, NATURE, V380, P606, DOI 10.1038/380606a0; Lunine J. I, 1993, PROTOSTARS PLANETS, P749; Luu J, 1997, NATURE, V387, P573, DOI 10.1038/42413; LYNDENBELL D, 1972, MON NOT R ASTRON SOC, V157, P1; MALHOTRA R, 1995, ASTRON J, V110, P420, DOI 10.1086/117532; Morbidelli A, 1997, ICARUS, V128, P464, DOI 10.1006/icar.1997.5745; WARD WR, 1986, ICARUS, V67, P164, DOI 10.1016/0019-1035(86)90182-X; WARD WR, IN PRESS ASTRON J	31	10	10	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2104	2106		10.1126/science.280.5372.2104	http://dx.doi.org/10.1126/science.280.5372.2104			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641913				2022-12-28	WOS:000074435900041
J	Nomura, M; Li, E				Nomura, M; Li, E			Smad2 role in mesoderm formation, left-right patterning and craniofacial development	NATURE			English	Article							SIGNALING PATHWAYS; NODAL EXPRESSION; GENE; MOUSE; GASTRULATION; PROTEINS; MUTATION; ACTIVIN	Signalling by the transforming growth factor-p (TGF-P) superfamily of proteins depends on the phosphorylation and activation of SMAD proteins by heteromeric complexes of ligand-specific type I and type II receptors with serine/threonine-kinase activity(1). The vertebrate SMAD family includes at least nine members, of which Smad2 has been shown to mediate signalling by activin and TGF-beta(2-5). In Xenopus, Smad2 can induce dorsal mesoderm, mimicking Vg-1, activin and nodal(2,4), Here we investigate the function of Smad2 in mammalian development by generating two independent Smad2 mutant alleles in mice by gene targeting, We show that homozygous mutant embryos fail to form an organized egg cylinder and lack mesoderm, like mutant mice lacking nodal(6,7) or ActRIB the gene encoding the activin type-I receptor(8). About 20 per cent of Smad2 heterozygous embryos have severe gastrulation defects and lack mandibles or eyes, indicating that the gene dosage of Smad2 is critical for signalling. Mice trans-heterozygous for both Smad2 and nodal mutations display a range of phenotypes, including gastrulation defects, complex craniofacial abnormalities such as cyclopia, and defects in left-right patterning, indicating that Smad2 may mediate nodal signalling in these developmental processes. Our results show that Smad2 function is essential for early development and for several patterning processes in mice.	Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp E,Cardiovasc Res Ctr, Charlestown, MA 02129 USA	Harvard University	Li, E (corresponding author), Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp E,Cardiovasc Res Ctr, Charlestown, MA 02129 USA.							Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOGAN B, 1994, MANIPULATING MOUSE E, P51; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; JONES CM, 1995, DEVELOPMENT, V121, P3651; Kaufman M.H., 1992, ATLAS MOUSE DEV; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Varlet I, 1997, DEVELOPMENT, V124, P1033; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1992, IN SITU HYBRIDIXATIO; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	29	497	521	4	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1998	393	6687					786	790		10.1038/31693	http://dx.doi.org/10.1038/31693			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655392				2022-12-28	WOS:000074433100049
J	Foege, WH				Foege, WH			Global public health: Targeting inequities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Emory Univ, Dept Int Hlth, Atlanta, GA 30322 USA	Emory University	Foege, WH (corresponding author), Emory Univ, Dept Int Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA.							FOEGE WH, IN PRESS ANN TROP ME; GRANT J, 1990, 4 INT CHILD SURV C M; HENDERSON RH, 1984, PROVIDING IMMUNIZATI; *HLTH CAR FIN ADM, 1998, 1996 HLTH CAR EXP; KHANDKER SR, 1998, POVERTY REDUCTION ST; Lucas AO, 1997, INT J GYNECOL OBSTET, V59, pS11, DOI 10.1016/S0020-7292(97)00142-2; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Peto R, 1994, MORTALITY SMOKING DE; *UN CHILDR FUND, 1993, STAT WORLDS CHILDR 1; *UN CHILDR FUND, 1997, UNICEF ANN REP; United Nations Children's Fund, 1998, STAT WORLDS CHILDR 1; United Nations Development Program, 1996, HUM DEV REP 1996; *WHO, 1998, WORLD HLTH REP 1995; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Health Organization, 1998, WORLD HLTH REP 1997; 1998, TIM 2 SIDED ATTACK M	16	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1931	1932		10.1001/jama.279.24.1931	http://dx.doi.org/10.1001/jama.279.24.1931			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU945	9643841				2022-12-28	WOS:000074252100001
J	Richardson, S; Grimwood, K; Gorrell, R; Palombo, E; Barnes, G; Bishop, R				Richardson, S; Grimwood, K; Gorrell, R; Palombo, E; Barnes, G; Bishop, R			Extended excretion of rotavirus after severe diarrhoea in young children	LANCET			English	Article							POLYMERASE CHAIN-REACTION; MONOCLONAL-ANTIBODIES; IMMUNE-RESPONSE; CELL-CULTURE; SERUM; INFECTION; GASTROENTERITIS; ENTERITIS	Background Rotaviruses are the major cause of severe childhood diarrhoea. Knowledge of the natural history of infection, including duration of intestinal virus shedding, is important in the understanding of transmission, sources of infection, and immune responses. Methods We carried out a study of rotavirus excretion in 37 children admitted to hospital with severe rotavirus diarrhoea. Sequential faecal specimens were collected from each child during 100 days of surveillance, and screened for rotavirus by EIA and by amplification of genome double-stranded RNA by reverse-transcription PCR. IgA coproantibody was estimated by EIA. Findings Duration of rotavirus excretion ranged from 4 to 57 days after onset of diarrhoea. Excretion ceased within 10 days in 16 (43%) children, and within 20 days in 26 (70%) children. Extended excretion was detected for 25-57 days in the remaining 11 (30%) children owing mainly to continued excretion of the primary infecting strain. Extended excretion was significantly associated with antirotavirus IgA coproantibody boosts during 100 days of surveillance (p=0.001, log-rank test), and with recurrence of mild diarrhoea symptoms during convalescence (p=0.006, Fisher's exact test). Interpretation Severe rotavirus disease in young children may be followed by extended excretion of rotavirus. The risk of transmission to others may be greater than previously believed. Extended excretion could also explain some cases of the postgastroenteritis syndrome.	Royal Childrens Hosp, Dept Gastroenterol & Clin Nutr, Melbourne, Vic, Australia; Wellington Sch Med, Dept Paediat & Child Hlth, Wellington S, New Zealand	Royal Children's Hospital Melbourne; University of Otago	Bishop, R (corresponding author), Royal Childrens Hosp, Dept Gastroenterol & Clin Nutr, Flemington Rd, Parkville, Vic 3052, Australia.	bishop@cryptic.rch.unimelb.edu.au	Palombo, Enzo/AAV-8632-2021; Grimwood, Keith/F-9334-2011; Gorrell, Rebecca/H-5259-2019; Gorrell, Rebecca/J-1454-2012	Palombo, Enzo/0000-0001-5889-1393; Gorrell, Rebecca/0000-0003-0728-3325; Grimwood, Keith/0000-0003-3174-9834				ALBERT MJ, 1984, J MED VIROL, V13, P377, DOI 10.1002/jmv.1890130409; BASS DM, 1991, DIARRHOEAL DIS, P139; BEARDS GM, 1984, J CLIN MICROBIOL, V19, P248, DOI 10.1128/JCM.19.2.248-254.1984; BISHOP R, 1990, MED VIROL, V9, P85; CHIARINI A, 1983, J GEN VIROL, V64, P1101, DOI 10.1099/0022-1317-64-5-1101; COULSON BS, 1990, J CLIN MICROBIOL, V28, P1367, DOI 10.1128/JCM.28.6.1367-1374.1990; COULSON BS, 1987, J CLIN MICROBIOL, V25, P509, DOI 10.1128/JCM.25.3.509-515.1987; COULSON BS, 1989, J VIROL METHODS, V26, P53, DOI 10.1016/0166-0934(89)90074-8; DAVIDSON GP, 1975, LANCET, V1, P242; DAVIDSON GP, 1983, INFECT IMMUN, V40, P447, DOI 10.1128/IAI.40.2.447-452.1983; EIDEN JJ, 1988, PEDIATR INFECT DIS J, V7, P564; ESTES MK, 1980, ARCH VIROL, V65, P187, DOI 10.1007/BF01317330; GENTSCH JR, 1992, J CLIN MICROBIOL, V30, P1365, DOI 10.1128/JCM.30.6.1365-1373.1992; GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276, DOI 10.1128/JCM.28.2.276-282.1990; GRIMWOOD K, 1988, J CLIN MICROBIOL, V26, P732, DOI 10.1128/JCM.26.4.732-738.1988; GUARINO A, 1995, J PEDIATR GASTR NUTR, V20, P173, DOI 10.1097/00005176-199502000-00006; HJELT K, 1985, J PEDIATR GASTR NUTR, V4, P60, DOI 10.1097/00005176-198502000-00012; Kapikian A.Z., 1996, FIELDS VIROLOGY, P1657; KILBOURNE ED, 1973, J INFECT DIS, V128, P668, DOI 10.1093/infdis/128.5.668; KRAFT LISBETH M., 1961, PROC ANIMAL CARE PANEL, V11, P125; MISRA V, 1980, ICN UCLA S MOL CELL, V18, P727; NAGAYOSHI S, 1980, EUR J PEDIATR, V134, P99, DOI 10.1007/BF01846024; PALOMBO EA, 1993, ARCH VIROL, V133, P323, DOI 10.1007/BF01313772; RIEPENHOFFTALTY M, 1981, J MED VIROL, V8, P215, DOI 10.1002/jmv.1890080309; STALS F, 1984, J MED VIROL, V4, P333; VESIKARI T, 1981, ACTA PAEDIATR SCAND, V70, P717, DOI 10.1111/j.1651-2227.1981.tb05774.x; WARD RL, 1986, J INFECT DIS, V154, P871, DOI 10.1093/infdis/154.5.871; WARD RL, 1984, J CLIN MICROBIOL, V19, P748, DOI 10.1128/JCM.19.6.748-753.1984; WILDE J, 1991, LANCET, V337, P323, DOI 10.1016/0140-6736(91)90945-L; WILDE J, 1992, J INFECT DIS, V166, P507, DOI 10.1093/infdis/166.3.507; XU L, 1990, J VIROL METHODS, V27, P29, DOI 10.1016/0166-0934(90)90143-4	31	95	100	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1844	1848		10.1016/S0140-6736(97)11257-0	http://dx.doi.org/10.1016/S0140-6736(97)11257-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652668				2022-12-28	WOS:000074347100011
J	Carpenter, C; Feinberg, M; Aubry, W; Averitt, D; Coffin, J; Cooper, D; Follansbee, S; Hamburg, P; Harrington, M; Hidalgo, J; Jaffe, H; Landers, D; Masur, H; Pizzo, P; Richman, D; Saag, M; Schooley, R; Stone, V; Thompson, M; Trono, D; Vella, S; Walker, B; Yeni, P				Carpenter, C; Feinberg, M; Aubry, W; Averitt, D; Coffin, J; Cooper, D; Follansbee, S; Hamburg, P; Harrington, M; Hidalgo, J; Jaffe, H; Landers, D; Masur, H; Pizzo, P; Richman, D; Saag, M; Schooley, R; Stone, V; Thompson, M; Trono, D; Vella, S; Walker, B; Yeni, P		NIH Panel Define Principles Therapy HIV Infect	Report of the NIH Panel to Define Principles of Therapy of HIV Infection	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; ZIDOVUDINE COMBINATION THERAPY; DYNAMICS IN-VIVO; TYPE-1 RNA LOAD; VIRAL LOAD; REVERSE-TRANSCRIPTASE; PROTEASE INHIBITOR; CUBIC MILLIMETER; CONTROLLED TRIAL; CLINICAL COURSE	Recent research advances have afforded substantially improved understanding of the biology of HIV infection and the pathogenesis of AIDS. With the advent of sensitive tools for monitoring HIV replication in infected persons, the risk for disease progression and death can be assessed accurately and the efficacy of anti-HIV therapies can be determined directly. Furthermore, when used appropriately, combinations of newly available, potent antiviral therapies can effect prolonged suppression of detectable levels of HIV replication and circumvent the inherent tendency of HIV to generate drug-resistant viral variants. However, as antiretroviral therapy for HIV infection has become increasingly effective, it has also become increasingly complex. Familiarity with recent research advances is needed to ensure that newly available therapies are used in ways that most effectively improve the health and prolong the lives of HIV-infected persons. To enable practitioners and HIV-infected persons to best use rapidly accumulating new information about HIV disease pathogenesis and treatment, the Off ice of AIDS Research of the National Institutes of Health (NIH) sponsored the NIH Panel To Define Principles of Therapy of HIV Infection. This Panel was asked to define essential scientific principles that should be used to guide the most effective use of antiretroviral therapies and viral load testing in clinical practice. On the basis of detailed consideration of the most current data, the Panel delineated 11 principles that address issues of fundamental importance for the treatment of HIV infection. These principles provide the scientific basis for the specific treatment recommendations made by the Panel on Clinical Practices for the Treatment of HIV Infection sponsored by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation. The reports of both of these panels are provided in this supplement. Together, they summarize new data and provide both the scientific basis and specific guidelines for the treatment of HIV-infected persons. This information will be of interest to health care providers, HIV-infected persons, HIV and AIDS educators, public health educators, public health authorities, and all organizations that fund medical care of HIV-infected persons.	Brown Univ, Providence, RI 02912 USA; Miriam Hosp, Providence, RI 02912 USA; NIH, Bethesda, MD 20892 USA; Blue Cross Blue Shield Assoc, San Francisco, CA USA; Womens Informat Serv & Exchange, Atlanta, GA USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Davies Med Ctr, San Francisco, CA USA; New York City Dept Hlth, New York, NY 10013 USA; Treatment Act Grp, New York, NY USA; Ctr AIDS Serv Planning & Dev, Baltimore, MD USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Magee Womens Hosp, Pittsburgh, PA USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Brown Univ, Sch Med, Providence, RI 02912 USA; AIDS Res Consortium Atlanta, Atlanta, GA USA; Salk Inst Biol Studies, La Jolla, CA USA; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; X Bichat Med Sch, Paris, France	Brown University; Lifespan Health Rhode Island; Miriam Hospital; National Institutes of Health (NIH) - USA; Tufts University; University of New South Wales Sydney; Kirby Institute; California Pacific Medical Center; New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Brown University; Salk Institute; Istituto Superiore di Sanita (ISS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Carpenter, C (corresponding author), Brown Univ, Providence, RI 02912 USA.		Vella, Stefano/GZM-0519-2022; VELLA, STEFANO/ABI-3368-2020; VELLA, STEFANO/V-8440-2019	VELLA, STEFANO/0000-0003-2347-5984				[Anonymous], 1998, MMWR MORB MORTAL WKL, V47; BENHAMOU Y, 1997, 4 C RETR OPP INF WAS; Brichacek B, 1996, J INFECT DIS, V174, P1191, DOI 10.1093/infdis/174.6.1191; Cao YZ, 1997, NAT MED, V3, P549, DOI 10.1038/nm0597-549; CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; Carr A, 1997, LANCET, V349, P995, DOI 10.1016/S0140-6736(05)62892-9; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9; Deeks SG, 1997, J INFECT DIS, V176, P514, DOI 10.1086/517278; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DEGRUTTOLA V, 1996, P PUBL M NIH PAN DEF; deJong MD, 1996, P NATL ACAD SCI USA, V93, P5501, DOI 10.1073/pnas.93.11.5501; DICKOVER RE, 1994, J INFECT DIS, V170, P1279, DOI 10.1093/infdis/170.5.1279; DICKOVER RE, 1998, IN PRESS J INFECT DI; ELSADR W, 1994, CLIN PRACTICE GUIDEL, V7; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; Hicks CB, 1997, CLIN INFECT DIS, V24, P1023, DOI 10.1093/clinids/24.5.1023; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; HOEN B, 1997, 4 C RETR OPP INF WAS; HOLODNIY M, 1995, J VIROL, V69, P3510, DOI 10.1128/JVI.69.6.3510-3516.1995; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; Katlama C, 1996, JAMA-J AM MED ASSOC, V276, P118, DOI 10.1001/jama.276.2.118; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KEMPF D, 1997, 4 C RETR OPP INF WAS; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; Koot M, 1996, J INFECT DIS, V173, P349, DOI 10.1093/infdis/173.2.349; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Lafeuillade A, 1997, J INFECT DIS, V175, P1051, DOI 10.1086/516442; LOES SKD, 1993, CLIN INFECT DIS, V17, P59, DOI 10.1093/clinids/17.1.59; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; MARKOWITZ M, 1997, 4 C RETR OPP INF WAS; McDonald CK, 1997, ARCH INTERN MED, V157, P951, DOI 10.1001/archinte.157.9.951; McIntosh K, 1996, PEDIATR INFECT DIS J, V15, P1087, DOI 10.1097/00006454-199612000-00006; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Minkoff H, 1997, AM J OBSTET GYNECOL, V176, P478, DOI 10.1016/S0002-9378(97)70519-2; Mofenson LM, 1997, J INFECT DIS, V175, P1029, DOI 10.1086/516441; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MONTANER J, 1996, P PUBL M NIH PAN DEF; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Moutouh L, 1996, P NATL ACAD SCI USA, V93, P6106, DOI 10.1073/pnas.93.12.6106; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBRIEN TR, 1998, IN PRESS J ACQUIR IM; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; PALUMBO PE, 1997, 4 C RETR OPP INF WAS; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PERRIN L, 1997, 4 C RETR OPP INF WAS; PHILLIPS P, 1997, 4 C RETR OPP INF WAS; PIATAK M, 1993, LANCET, V341, P1099, DOI 10.1016/0140-6736(93)92463-4; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PLUDA JM, 1995, J INFECT DIS, V171, P1438, DOI 10.1093/infdis/171.6.1438; Raboud JM, 1996, J INFECT DIS, V174, P191, DOI 10.1093/infdis/174.1.191; Raboud JM, 1997, J INFECT DIS, V175, P576, DOI 10.1093/infdis/175.3.576; Revets H, 1996, J CLIN MICROBIOL, V34, P1058, DOI 10.1128/JCM.34.5.1058-1064.1996; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SAKSELA K, 1995, ANN INTERN MED, V123, P641, DOI 10.7326/0003-4819-123-9-199511010-00001; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SCHACKER T, 1997, 4 C RETR OPP INF WAS; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; Schuurman R, 1996, J CLIN MICROBIOL, V34, P3016, DOI 10.1128/JCM.34.12.3016-3022.1996; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; SHEARER GM, 1991, AIDS, V5, P245, DOI 10.1097/00002030-199103000-00001; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903; STAPRANS SI, 1995, J EXP MED, V182, P1727, DOI 10.1084/jem.182.6.1727; Staszewski S, 1996, JAMA-J AM MED ASSOC, V276, P111, DOI 10.1001/jama.276.2.111; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; TAMALET C, 1997, 4 C RETR OPP INF WAS; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; *USPHS, 1997, MMWR MORB MORTAL WKL, V46; VANDAMME AM, 1995, J VIROL METHODS, V52, P121, DOI 10.1016/0166-0934(94)00151-6; VANLEEUWEN R, 1995, J INFECT DIS, V171, P1166, DOI 10.1093/infdis/171.5.1166; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Weiss RA, 1996, SCIENCE, V272, P1885, DOI 10.1126/science.272.5270.1885; Whitcup SM, 1997, JAMA-J AM MED ASSOC, V277, P1519, DOI 10.1001/jama.277.19.1519; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; YenLieberman B, 1996, J CLIN MICROBIOL, V34, P2695, DOI 10.1128/JCM.34.11.2695-2701.1996; 1995, MMWR MORB MORTAL WKL, V44	107	74	76	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	2	S			1057	1078		10.7326/0003-4819-128-12_Part_2-199806151-00002	http://dx.doi.org/10.7326/0003-4819-128-12_Part_2-199806151-00002			22	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU477	9652992				2022-12-28	WOS:000074201700002
J	Arnsten, AFT				Arnsten, AFT			Research: Neuroscience - The biology of being frazzled	SCIENCE			English	Editorial Material							PREFRONTAL CORTEX; DOPAMINE TURNOVER; AMYGDALA; MODULATION; STRESS; RAT		Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06520 USA	Yale University	Arnsten, AFT (corresponding author), Yale Univ, Sch Med, Neurobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.	amy_arnsten@qm.yale.edu						AGGLETON JP, 1992, AMYGDALA; Arnsten AFT, 1998, ARCH GEN PSYCHIAT, V55, P362, DOI 10.1001/archpsyc.55.4.362; Arnsten AFT, 1997, PHARMACOL BIOCHEM BE, V58, P55, DOI 10.1016/S0091-3057(96)00477-7; Cahill L, 1997, ANN NY ACAD SCI, V821, P238, DOI 10.1111/j.1749-6632.1997.tb48283.x; CAHILL L, IN PRESS TRENDS NEUR; CHARNEY DS, 1993, ARCH GEN PSYCHIAT, V50, P294; DAVIS M, 1994, BRAIN RES, V664, P207, DOI 10.1016/0006-8993(94)91972-0; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; Goldstein LE, 1996, J NEUROSCI, V16, P4787; LAMONT EW, IN PRESS BRAIN RES; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; MAZURE CM, 1995, DOES STRESS CUASE PS; Murphy BL, 1996, P NATL ACAD SCI USA, V93, P1325, DOI 10.1073/pnas.93.3.1325; PACKARD MG, 1994, P NATL ACAD SCI USA, V91, P8477, DOI 10.1073/pnas.91.18.8477; Stuss D.T., 1986, FRONTAL LOBES; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; Yang CR, 1996, J NEUROSCI, V16, P1922; Zahrt J, 1997, J NEUROSCI, V17, P8528	19	207	210	6	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1998	280	5370					1711	1712		10.1126/science.280.5370.1711	http://dx.doi.org/10.1126/science.280.5370.1711			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZU446	9660710				2022-12-28	WOS:000074197800028
J	Greenberg, DS				Greenberg, DS			Stumbling in science studies	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1142	1142		10.1016/S0140-6736(05)79437-X	http://dx.doi.org/10.1016/S0140-6736(05)79437-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660623				2022-12-28	WOS:000073090200073
J	Eddleston, M; Sheriff, MHR; Hawton, K				Eddleston, M; Sheriff, MHR; Hawton, K			Deliberate self harm in Sri Lanka: an overlooked tragedy in the developing world	BRITISH MEDICAL JOURNAL			English	Article									John Radcliffe Hosp, Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England; Univ Colombo, Fac Med, Dept Clin Med, Colombo, Sri Lanka; Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England	University of Oxford; University of Colombo; University of Oxford	Eddleston, M (corresponding author), John Radcliffe Hosp, Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England.							DESILVA HJ, 1992, LANCET, V339, P1136, DOI 10.1016/0140-6736(92)90733-J; DESILVA P, 1989, SUICIDE SRI LANKA; DESJARLAIS R, 1995, MENTAL HLTH PROBLEMS; EDDLESTON M, IN PRESS CEYLON COLL; ELLAWALA NS, 1989, SUICIDE SRI LANKA; Food and Agricultural Organization of the United Nations, 1996, REP WORLD FOOD SUMM; Hawton K, 1997, BRIT J PSYCHIAT, V171, P556, DOI 10.1192/bjp.171.6.556; Hawton K., 1987, ATTEMPTED SUICIDE PR; JEYARATNAM J, 1990, World Health Statistics Quarterly, V43, P139; KASTURIARATCHI ND, 1997, STUDY SUICIDE SRI LA; *MIN HLTH, 1997, ANN HLTH B; OSMANI SR, 1994, DEV CHANGE, V25, P387, DOI 10.1111/j.1467-7660.1994.tb00520.x; SINGH S, 1995, INT J CLIN PHARM TH, V33, P628; Sood A K, 1994, Indian J Med Sci, V48, P68; *WHO, 1996, BAS DOC INCL AM AD U; *WHO, 1996, TDRGEN961 WHO; *WHO, 1995, 1994 WORLD HLTH STAT; World Health Organization, 1995, WORLD HLTH REP 1995	18	120	120	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					133	135		10.1136/bmj.317.7151.133	http://dx.doi.org/10.1136/bmj.317.7151.133			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657795	Green Published			2022-12-28	WOS:000075081700029
J	Griffin, BA; Adams, SR; Tsien, RY				Griffin, BA; Adams, SR; Tsien, RY			Specific covalent labeling of recombinant protein molecules inside live cells	SCIENCE			English	Article								Recombinant proteins containing four cysteines at the i, i + 1, i + 4, and i + 5 positions of an alpha helix were fluorescently labeled in Living cells by extracellular administration of 4',5'-bis(1,3,2-dithioarsolan-2-yl)fluor This designed small Ligand is membrane-permeant and nonfluorescent until it binds with high affinity and specificity to the tetracysteine domain, Such in situ Labeling adds much Less mass than does green fluorescent protein and offers greater versatility in attachment sites as well as potential spectroscopic and chemical properties. This system provides a recipe for slightly modifying a target protein so that it can be singled out from the many other proteins inside Live cells and fluorescently stained by small nonfluorescent dye molecules added from outside the cells.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NCI NIH HHS [T32 CA09523] Funding Source: Medline; NINDS NIH HHS [NS27177] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHALFIE M, 1998, GFP GREEN FLUORESCEN; Crabtree GR, 1996, TRENDS BIOCHEM SCI, V21, P418, DOI 10.1016/S0968-0004(96)20027-1; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Ford C F, 1991, Protein Expr Purif, V2, P95, DOI 10.1016/1046-5928(91)90057-P; GRIFFIN BA, 1998, THESIS U CALIFORNIA; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ; KALEF E, 1994, METHOD ENZYMOL, V233, P395; Lowe WG, 1935, J AM CHEM SOC, V57, P1081, DOI 10.1021/ja01309a035; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P4245, DOI 10.1021/bi00231a020; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; SPANG C, 1989, CHEM BER, V122, P1247, DOI 10.1002/cber.19891220706; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; WEBB EC, 1947, BIOCHEM J, V41, P74, DOI 10.1042/bj0410074; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; WHITTAKER VP, 1947, BIOCHEM J, V41, P56, DOI 10.1042/bj0410056; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	18	1200	1331	9	247	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1998	281	5374					269	272		10.1126/science.281.5374.269	http://dx.doi.org/10.1126/science.281.5374.269			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657724				2022-12-28	WOS:000074714200053
J	Morrell, D				Morrell, D			As I recall	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Morrell, D (corresponding author), 14 Higher Green, Surrey KT17 3BA, England.							*CENTR HLTH SERV S, 1963, FEEL PULS SURV DISTR; COLLINGS JS, 1950, LANCET, V258, P555; FRY J, 1961, CATARRHAL CHILD; HICKS D, 1976, PRIMARY HLTH CARE; HOCKEY L, 1966, FEELING PULSE SURVEY; HODGKIN K, 1963, EARLIER DIAGNOSIS; LOGAN W, 1957, STUDIES MED POPULATI, V12; LOGAN WPD, 1958, STUDIES MED POPULATI, V14; MECHANIC D, 1968, MED SOCIOLOGY COMPRE; MORRELL D, 1991, BMJ-BRIT MED J, V309, P1313; MORRELL D, 1965, ART GEN PRACTICE; SWIFT G, 1964, BRIT MED J, V1, P1697, DOI 10.1136/bmj.1.5399.1697; TAYLOR S, 1954, GOOD GEN PRACTICE, P7	13	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 4	1998	317	7150					40	45		10.1136/bmj.317.7150.40	http://dx.doi.org/10.1136/bmj.317.7150.40			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651270	Green Published			2022-12-28	WOS:000075081600025
J	Goldberg, RM; Fleming, TR; Tangen, CM; Moertel, CG; Macdonald, JS; Haller, DG; Laurie, JA				Goldberg, RM; Fleming, TR; Tangen, CM; Moertel, CG; Macdonald, JS; Haller, DG; Laurie, JA		Eastern Cooperative Oncology Grp; N Cent Canc Treatment Grp; SW Oncology Grp	Surgery for recurrent colon cancer: Strategies for identifying resectable recurrence and success rates after resection	ANNALS OF INTERNAL MEDICINE			English	Article						surgical procedures, operative; colonic neoplasms; salvage therapy; outcome and process assessment (health care); disease-free survival	COLORECTAL-CARCINOMA; SURGICAL-TREATMENT; ADJUVANT THERAPY; POLYPS; FLUOROURACIL; LEVAMISOLE; METASTASES; LIVER	Background: Follow-up testing after surgery for colon cancer is recommended principally to identify resectable recurrences, but data on the efficacy of, outcomes of, and optimal strategies for this testing are limited. Objectives: To determine the relation between followup tests and salvage surgery, assess outcomes, and document surgical mortality. Design: Retrospective cohort study. Setting: A North American multi-institutional trial comparing postoperative chemotherapy plus follow-up with follow-up alone. Patients: 1247 patients with resected stage II and stage III colon cancer. Intervention: The protocol mandated follow-up testing that could be supplemented at the discretion of treating physicians. Indications of recurrent disease were documented. Measurements: Recurrence, resectable recurrence, surgical mortality, and survival were studied. Results: 548 patients had recurrence of colon cancer. Salvage surgery was attempted in 222 patients (41%). In 109 patients (20%), curative-intent surgery was done for hepatic recurrence (28 patients), pulmonary metastasis (20 patients), local recurrence (24 patients), or recurrence at other sites (37 patients). Most curative-intent surgical procedures were motivated by follow-up testing (36 patients), elevated carcinoembryonic antigen level (41 patients), or symptoms (27 patients). The median follow-up time after curative-intent surgery exceeded 5 years; the estimated 5-year disease-free survival rate was 23%. A solitary lesion was a favorable prognostic factor. The surgical mortality rate was 2%. Curative-intent resections were done in 15 patients with second primary colorectal cancer; 12 of these patients have survived disease-free. Conclusions: Second operations for colon cancer that are triggered by follow-up testing or symptoms are common and can result in long-term disease-free survival.	Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Temple Univ, Sch Med, Philadelphia, PA 19122 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Grand Forks Clin Ltd, Grand Forks, ND 58201 USA	Mayo Clinic; Fred Hutchinson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	Goldberg, RM (corresponding author), Mayo Clin, Div Med Oncol, 200 1st St SW, Rochester, MN 55905 USA.	goldberg.richard@mayo.edu	Goldberg, Richard/O-1871-2017; Goldberg, Richard M/M-1311-2013	Goldberg, Richard/0000-0003-3713-6895; 	NATIONAL CANCER INSTITUTE [U10CA025224, P01CA031224, U10CA037404] Funding Source: NIH RePORTER; NCI NIH HHS [CA-31224, CA-37404, CA-25224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; BALLANTYNE GH, 1993, CANCER, V71, P4252, DOI 10.1002/1097-0142(19930615)71:12+<4252::AID-CNCR2820711815>3.0.CO;2-6; ECKARDT VF, 1988, CANCER, V61, P2552, DOI 10.1002/1097-0142(19880615)61:12<2552::AID-CNCR2820611227>3.0.CO;2-6; Fong YM, 1997, J CLIN ONCOL, V15, P938, DOI 10.1200/JCO.1997.15.3.938; HUGHES KS, 1986, SURGERY, V100, P278; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MCAFEE MK, 1992, ANN THORAC SURG, V53, P780, DOI 10.1016/0003-4975(92)91435-C; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; NELSON RL, 1993, CANCER-AM CANCER SOC, V71, P4298, DOI 10.1002/1097-0142(19930615)71:12+<4298::AID-CNCR2820711819>3.0.CO;2-9; NORFLEET RG, 1991, GASTROINTEST ENDOSC, V37, P531, DOI 10.1016/S0016-5107(91)70822-5; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; *SAS I INC, 1990, SAS STAT US GUID VER, P1027; STEELE G, 1993, CANCER, V71, P4225, DOI 10.1002/1097-0142(19930615)71:12+<4225::AID-CNCR2820711811>3.0.CO;2-C; TURK PS, 1993, CANCER-AM CANCER SOC, V71, P4267, DOI 10.1002/1097-0142(19930615)71:12+<4267::AID-CNCR2820711816>3.0.CO;2-O; WERNECKE K, 1991, AM J ROENTGENOL, V157, P731, DOI 10.2214/ajr.157.4.1892027; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301	19	226	229	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					27	+		10.7326/0003-4819-129-1-199807010-00007	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9652996				2022-12-28	WOS:000074513300004
J	Zumla, A; Grange, J				Zumla, A; Grange, J			Science, medicine, and the future - Tuberculosis	BRITISH MEDICAL JOURNAL			English	Review							MYCOBACTERIUM-TUBERCULOSIS; DNA		UCL, Sch Med, Ctr Infect Dis, London W1P 6DB, England; Natl Heart & Lung Inst, Imperial Coll Sch Med, London SW3 6LY, England	University of London; University College London; UCL Medical School; Imperial College London	Zumla, A (corresponding author), UCL, Sch Med, Ctr Infect Dis, London W1P 6DB, England.	a.zumla@ucl.ac.uk	ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735				Butcher PD, 1996, J APPL BACTERIOL, V81, pS53, DOI 10.1111/j.1365-2672.1996.tb04599.x; *DEP HLTH, 1996, IMM INF DIS, P219; Department for International Development, 1997, EL WORLD POV CHALL 2; DoucetPopulaire F, 1996, TUBERCLE LUNG DIS, V77, P358, DOI 10.1016/S0962-8479(96)90102-1; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; Grange JM, 1997, LANCET, V350, P157, DOI 10.1016/S0140-6736(05)62344-6; Grange JM, 1996, J MED MICROBIOL, V45, P81, DOI 10.1099/00222615-45-2-81; HERNANDEZPANDO R, 1994, IMMUNOLOGY, V82, P591; Rastogi N, 1996, RES MICROBIOL, V147, P7, DOI 10.1016/0923-2508(96)80196-3; RAVIGLIONE MC, 1997, AIDS RESP MED, P117; ROOK GAW, 1987, EUR J RESPIR DIS, V71, P286; Rook GAW, 1998, T LYMPHOCYTE SUBPOPULATIONS IN IMMUNOTOXICOLOGY, P179; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; *WHO, 1997, ANT DRUG RES WORLD W; WHO (World Health Organization), 1998, WORLD HLTH REP 1998; World Health Organization, 1994, TB GLOB EM WHO REP T; YOUNG DB, 1997, TUBERCULOSIS PROSPEC, P35; ZUMLA A, 1999, INT J TUBERC LUNG D, V3, P1	18	24	33	1	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1962	1964		10.1136/bmj.316.7149.1962	http://dx.doi.org/10.1136/bmj.316.7149.1962			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641941	Green Published			2022-12-28	WOS:000074636700035
J	Lotan, T; Ohto, M; Yee, KM; West, MAL; Lo, R; Kwong, RW; Yamagishi, K; Fischer, RL; Goldberg, RB; Harada, JJ				Lotan, T; Ohto, M; Yee, KM; West, MAL; Lo, R; Kwong, RW; Yamagishi, K; Fischer, RL; Goldberg, RB; Harada, JJ			Arabidopsis LEAFY COTYLEDON1 is sufficient to induce embryo development in vegetative cells	CELL			English	Article							CCAAT-BINDING-FACTOR; MOSAIC VIRUS-35S PROMOTER; HAP3 TRANSCRIPTION FACTOR; GENE-EXPRESSION; NF-Y; LATE EMBRYOGENESIS; SEED DEVELOPMENT; ABSCISIC-ACID; DNA-BINDING; PROTEIN	The Arabidopsis LEAN COTYLEDON1 (LEC1) gene is required for the specification of cotyledon identity and the completion of embryo maturation. We isolated the LEC1 gene and showed that it functions at an early developmental stage to maintain embryonic cell fate. The LEC1 gene encodes a transcription factor homolog, the CCAAT box-binding factor HAP3 subunit. LEC1 RNA accumulates only during seed development in embryo cell types and in endosperm tissue. Ectopic postembryonic expression of the LEC I gene in vegetative cells induces the expression of embryo-specific genes and initiates formation of embryo-like structures. Our results suggest that LEC1 is an important regulator of embryo development that activates the transcription of genes required for both embryo morphogenesis and cellular differentiation.	Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90024 USA	University of California System; University of California Davis; University of California System; University of California Berkeley; University of California System; University of California Los Angeles	Harada, JJ (corresponding author), Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA.			Lotan, Tamar/0000-0002-1679-4904				Albani D, 1995, GENE, V167, P209, DOI 10.1016/0378-1119(95)00680-X; BAUMLEIN H, 1994, PLANT J, V6, P379, DOI 10.1046/j.1365-313X.1994.06030379.x; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BECKER D, 1990, NUCLEIC ACIDS RES, V18, P203, DOI 10.1093/nar/18.1.203; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; Devic M, 1996, PLANT J, V9, P205, DOI 10.1046/j.1365-313X.1996.09020205.x; DIETRICH RA, 1989, PLANT CELL, V1, P73, DOI 10.1105/tpc.1.1.73; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; FELDMANN KA, 1987, MOL GEN GENET, V208, P1, DOI 10.1007/BF00330414; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; GOLDBERG RB, 1994, SCIENCE, V266, P605, DOI 10.1126/science.266.5185.605; GUARENTE L, 1984, CELL, V32, P317; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; Harada JJ, 1997, ADV CELL MOL BIOL PL, V4, P545; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KEITH K, 1994, PLANT CELL, V6, P589, DOI 10.1105/tpc.6.5.589; KENG T, 1987, P NATL ACAD SCI USA, V84, P9113, DOI 10.1073/pnas.84.24.9113; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MEINKE DW, 1992, SCIENCE, V258, P1647, DOI 10.1126/science.258.5088.1647; MEINKE DW, 1994, PLANT CELL, V6, P1049, DOI 10.1105/tpc.6.8.1049; MULDER W, 1994, MOL GEN GENET, V245, P96, DOI 10.1007/BF00279755; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAMBARA E, 1992, PLANT J, V2, P435, DOI 10.1111/j.1365-313X.1992.00435.x; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; Ogas J, 1997, SCIENCE, V277, P91, DOI 10.1126/science.277.5322.91; OLSEN LJ, 1993, PLANT CELL, V5, P941, DOI 10.1105/tpc.5.8.941; Papagiannopoulos P, 1996, MOL GEN GENET, V251, P412, DOI 10.1007/s004380050184; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; Parcy F, 1997, PLANT CELL, V9, P1265, DOI 10.1105/tpc.9.8.1265; SCHNEIDER JC, 1991, MOL CELL BIOL, V11, P4934, DOI 10.1128/MCB.11.10.4934; SCHWARTZ BW, 1994, DEVELOPMENT, V120, P3235; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Stam M, 1997, ANN BOT-LONDON, V79, P3, DOI 10.1006/anbo.1996.0295; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STEEVES TA, 1983, CAN J BOT, V61, P3550, DOI 10.1139/b83-404; TRUEBLOOD CE, 1988, MOL CELL BIOL, V8, P4537, DOI 10.1128/MCB.8.10.4537; Tsugeki R, 1996, PLANT J, V10, P479, DOI 10.1046/j.1365-313X.1996.10030479.x; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WALBOT V, 1978, DORMANCY DEV ARREST, P113; WEST MAL, 1994, PLANT CELL, V6, P1731, DOI 10.1105/tpc.6.12.1731; WEST MAL, 1993, PLANT CELL, V5, P1361, DOI 10.1105/tpc.5.10.1361; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; YADEGARI R, 1994, PLANT CELL, V6, P1713, DOI 10.1105/tpc.6.12.1713	56	703	830	9	118	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1195	1205		10.1016/S0092-8674(00)81463-4	http://dx.doi.org/10.1016/S0092-8674(00)81463-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657152	Bronze			2022-12-28	WOS:000074491100014
J	Roberts, F; Roberts, CW; Johnson, JJ; Kyle, DE; Krell, T; Coggins, JR; Coombs, GH; Milhous, WK; Tzipori, S; Ferguson, DJP; Chakrabarti, D; McLeod, R				Roberts, F; Roberts, CW; Johnson, JJ; Kyle, DE; Krell, T; Coggins, JR; Coombs, GH; Milhous, WK; Tzipori, S; Ferguson, DJP; Chakrabarti, D; McLeod, R			Evidence for the shikimate pathway in apicomplexan parasites	NATURE			English	Article							CHORISMATE SYNTHASE; PLASMODIUM-FALCIPARUM; NEUROSPORA-CRASSA; CLONING; GENES; ACID; 3-PHOSPHATE; SULFADOXINE; GLYPHOSATE; MECHANISMS	Parasites of the phylum Apicomplexa cause substantial morbidity, mortality and economic losses, and new medicines to treat them are needed urgently(1,2). The shikimate pathway is an attractive target for herbicides and antimicrobial agents because it is essential in algae, higher plants, bacteria and fungi, but absent from mammals(3,4). Here we present biochemical, genetic and chemotherapeutic evidence for the presence of enzymes of the shikimate pathway in apicomplexan parasites. In vitro growth of Toxoplasma gondii, Plasmodium falciparum (malaria) and Cryptosporidium parvum was inhibited by the herbicide glyphosate, a well-characterized inhibitor(3) of the shikimate pathway enzyme 5-enolpyruvyl shikimate 3-phosphate synthase. This effect on T. gondii and P. falciparum was reversed by treatment with p-aminobenzoate, which suggests that the shikimate pathway supplies folate precursors for their growth. Glyphosate in combination with pyrimethamine limited T. gondii infection in mice. Four shikimate pathway enzymes were detected in extracts of I: gondii and glyphosate inhibited 5-enolpyruvyl shikimate 3-phosphate synthase activity. Genes encoding chorismate synthase, the final shikimate pathway enzyme, were cloned from T. gondii and P.falciparum This discovery of a functional shikimate pathway in apicomplexan parasites provides several targets for the development of new antiparasite agents.	Michael Reese Hosp & Med Ctr, Chicago, IL 60616 USA; Univ Chicago, Chicago, IL 60616 USA; Univ Strathclyde, Dept Immunol, Glasgow G4 0NR, Lanark, Scotland; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA; Univ Oxford, John Radcliffe Hosp, Oxford OX3 9DU, England; Univ Cent Florida, Orlando, FL 32816 USA	Michael Reese Hospital & Medical Center; University of Chicago; University of Strathclyde; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; University of Glasgow; Tufts University; University of Oxford; State University System of Florida; University of Central Florida	McLeod, R (corresponding author), Michael Reese Hosp & Med Ctr, Chicago, IL 60616 USA.	rmcleod@midway.uchicago.edu	Roberts, Craig William/B-8016-2008; Krell, Tino/G-7296-2015	Roberts, Craig William/0000-0002-0653-835X; Krell, Tino/0000-0002-9040-3166; Ferguson, David/0000-0001-5045-819X; Kyle, Dennis/0000-0002-0238-965X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANERJI S, 1995, J EUKARYOT MICROBIOL, V42, P675, DOI 10.1111/j.1550-7408.1995.tb01614.x; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; COGGINS JR, 1987, METHOD ENZYMOL, V142, P325; DAVIES GM, 1994, ANTIMICROB AGENTS CH, V38, P403, DOI 10.1128/AAC.38.2.403; DEKA RK, 1994, FEBS LETT, V349, P397, DOI 10.1016/0014-5793(94)00710-1; DIECKMANN A, 1986, MOL BIOCHEM PARASIT, V19, P143, DOI 10.1016/0166-6851(86)90119-2; DUGGAN PJ, 1995, BIOORG MED CHEM LETT, V5, P2347, DOI 10.1016/0960-894X(95)00405-I; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GARBE T, 1991, MOL GEN GENET, V228, P385, DOI 10.1007/BF00260631; GORLACH J, 1993, PLANT MOL BIOL, V23, P707, DOI 10.1007/BF00021526; HACKSTEIN JHP, 1995, PARASITOL RES, V81, P207; Haslam E., 1993, SHIKIMIC ACID METABO; HAUCKE V, 1997, CELL BIOL, V7, P103; HENSTRAND JM, 1995, J BIOL CHEM, V270, P20447, DOI 10.1074/jbc.270.35.20447; JONES DGL, 1991, MOL MICROBIOL, V5, P2143, DOI 10.1111/j.1365-2958.1991.tb02144.x; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; MACK DG, 1984, ANTIMICROB AGENTS CH, V26, P26, DOI 10.1128/AAC.26.1.26; Marzabadi MR, 1996, BIOCHEMISTRY-US, V35, P4199, DOI 10.1021/bi9521349; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; MILHOUS WK, 1985, ANTIMICROB AGENTS CH, V27, P525, DOI 10.1128/AAC.27.4.525; MOUSDALE DM, 1985, J CHROMATOGR, V329, P268, DOI 10.1016/S0021-9673(01)81929-4; ODUOLA AMJ, 1988, EXP PARASITOL, V66, P86, DOI 10.1016/0014-4894(88)90053-7; RAMJEE MK, 1994, ANAL BIOCHEM, V220, P137, DOI 10.1006/abio.1994.1309; SCHMIDT J, 1993, J BIOL CHEM, V268, P27447; STEINRUCKEN HC, 1980, BIOCHEM BIOPH RES CO, V94, P1207, DOI 10.1016/0006-291X(80)90547-1; Tzipori S, 1998, ADV PARASIT, V40, P187, DOI 10.1016/S0065-308X(08)60121-9; WHITFIELD W, 1988, J ROYAL SOC HLTH, V1, P1; WILLIAMSON DH, 1994, MOL GEN GENET, V243, P249, DOI 10.1007/BF00280323	30	412	440	3	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 25	1998	393	6687					801	805		10.1038/31723	http://dx.doi.org/10.1038/31723			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655396				2022-12-28	WOS:000074433100053
J	Staels, B; Koenig, W; Habib, A; Merval, R; Lebret, M; Torra, IP; Delerive, P; Fadel, A; Chinetti, G; Fruchart, JC; Najib, J; Maclouf, J; Tedgui, A				Staels, B; Koenig, W; Habib, A; Merval, R; Lebret, M; Torra, IP; Delerive, P; Fadel, A; Chinetti, G; Fruchart, JC; Najib, J; Maclouf, J; Tedgui, A			Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPAR gamma activators	NATURE			English	Article							FACTOR-KAPPA-B; PHARMACOKINETIC PROPERTIES; THERAPEUTIC USE; EXPRESSION; CYCLOOXYGENASE-2; DYSLIPIDEMIA; SYNTHASE-2; RECEPTOR; ANGINA; SERUM	Peroxisome proliferator-activated receptors (PPARs) are key players in lipid and glucose metabolism and are implicated in metabolic disorders predisposing to atherosclerosis, such as dyslipidaemia and diabetes(1). Whereas PPAR gamma promotes Lipid storage by regulating adipocyte differentiation, PPAR alpha stimulates the beta-oxidative degradation of fatty acids. PPAR alpha-deficient mice show a prolonged response to inflammatory stimuli, suggesting that PPAR alpha is also a modulator of inflammation(2). Hypolipidaemic fibrate drugs are PPAR alpha ligands that inhibit the progressive formation of atherosclerotic lesions, which involves chronic inflammatory processes: even in the absence of their atherogenic lipoprotein-lowering effect(4,5). Here we show that PPAR alpha is expressed in human aortic smooth-muscle cells, which participate in plaque formation and post-angioplasty re-stenosis(3). In these smooth-muscle cells, we find that PPAR alpha ligands, and not PPAR gamma ligands, inhibit interleukin-1-induced production of interleukin-6 and prostaglandin and expression of cyclooxygenase-2. This inhibition of cyclooxygenase-2 induction occurs transcriptionally as a result of PPAR alpha repression of NF-kappa B signalling, In hyperlipidaemic patients, fenofibrate treatment decreases the plasma concentrations of interleukin-6, fibrinogen and C-reactive protein. We conclude that activators of PPAR alpha inhibit the inflammatory response of aortic smooth-muscle cells and decrease the concentration of plasma acute-phase proteins, indicating that PPAR alpha in the vascular wall may influence the process of atherosclerosis and re-stenosis.	Inst Pasteur, Dept Atherosclerose, INSERM, U325, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France; Univ Ulm, Dept Internal Med Cardiol 2, D-89081 Ulm, Germany; INSERM, U348, F-75745 Paris 10, France; INSERM, U141, F-75745 Paris 10, France; IFR Circulat Lariboisiere, F-75745 Paris 10, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Ulm University; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Staels, B (corresponding author), Inst Pasteur, Dept Atherosclerose, INSERM, U325, 1 Rue Calmette, F-59019 Lille, France.	Bart.Staels@pasteur-lille.fr	chinetti, giulia/Q-6901-2016; Habib, Aida/H-8647-2019; Staels, Bart/N-9497-2016	chinetti, giulia/0000-0001-8048-8138; Habib, Aida/0000-0001-6027-0043; Staels, Bart/0000-0002-3784-1503				Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; BALFOUR JA, 1990, DRUGS, V40, P260, DOI 10.2165/00003495-199040020-00007; BELMIN J, 1995, AM J PHYSIOL-HEART C, V268, pH2288, DOI 10.1152/ajpheart.1995.268.6.H2288; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; HABIB A, 1993, J BIOL CHEM, V268, P23448; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Saitoh Kiyoshi, 1995, Folia Pharmacologica Japonica, V106, P41, DOI 10.1254/fpj.106.41; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; TODD PA, 1988, DRUGS, V36, P314, DOI 10.2165/00003495-198836030-00004; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	30	973	1009	3	40	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 25	1998	393	6687					790	793		10.1038/31701	http://dx.doi.org/10.1038/31701			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655393				2022-12-28	WOS:000074433100050
J	Britton, TC				Britton, TC			Torticollis - what is straight ahead?	LANCET			English	Editorial Material							SPASMODIC TORTICOLLIS		Univ London Kings Coll Hosp, Dept Neurol, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Britton, TC (corresponding author), Univ London Kings Coll Hosp, Dept Neurol, Denmark Hill, London SE5 9RS, England.							Anastasopoulos D, 1997, MOVEMENT DISORD, V12, P561, DOI 10.1002/mds.870120413; Anastasopoulos D, 1997, MOVEMENT DISORD, V12, P709, DOI 10.1002/mds.870120514; Anastasopoulos D, 1998, BRAIN, V121, P91, DOI 10.1093/brain/121.1.91; Couch J R, 1976, Adv Neurol, V14, P245; Lekhel H, 1997, BRAIN, V120, P583, DOI 10.1093/brain/120.4.583; LEPLOW B, 1994, PERCEPT MOTOR SKILL, V78, P1363, DOI 10.2466/pms.1994.78.3c.1363; STELL R, 1989, J NEUROL NEUROSUR PS, V52, P57, DOI 10.1136/jnnp.52.1.57	7	1	1	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1223	1224		10.1016/S0140-6736(05)79313-2	http://dx.doi.org/10.1016/S0140-6736(05)79313-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643739				2022-12-28	WOS:000073283600005
J	Iacoviello, L; Donati, MB				Iacoviello, L; Donati, MB			Interpretation of thrombosis prevention trial	LANCET			English	Letter									Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Vasc Med & Pharmacol, I-66030 Santa Maria Imbaro, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Donati, MB (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Vasc Med & Pharmacol, I-66030 Santa Maria Imbaro, Italy.		Donati, Maria Benedetta/K-6606-2016; Iacoviello, Licia/K-4676-2016	Donati, Maria Benedetta/0000-0003-1747-5443; Iacoviello, Licia/0000-0003-0514-5885				Bernardi F, 1997, ARTERIOSCL THROM VAS, V17, P2548, DOI 10.1161/01.ATV.17.11.2548; Iacoviello L, 1998, NEW ENGL J MED, V338, P79, DOI 10.1056/NEJM199801083380202; Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203; Meade TW, 1998, LANCET, V351, P233	4	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 18	1998	351	9110					1205	1205						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643714				2022-12-28	WOS:000073220200052
J	van Duijn, CM; Delasnerie-Laupretre, N; Masullo, C; Zerr, I; de Silva, R; Wientjens, DPWM; Brandel, JP; Weber, T; Bonavita, V; Zeidler, M; Alperovitch, A; Poser, S; Granieri, E; Hofman, A; Will, RG				van Duijn, CM; Delasnerie-Laupretre, N; Masullo, C; Zerr, I; de Silva, R; Wientjens, DPWM; Brandel, JP; Weber, T; Bonavita, V; Zeidler, M; Alperovitch, A; Poser, S; Granieri, E; Hofman, A; Will, RG		Eur Union Collaborat Study Grp CJD	Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95	LANCET			English	Article							HUMAN GROWTH-HORMONE; PERSON TRANSMISSION; PRION DISEASES; HUMAN-BLOOD; EPIDEMIOLOGY; RECIPIENT; FRANCE; GENE	Background Creutzfeldt-Jakob disease (CJD) is a transmissible spongiform encephalopathy. Genetic and iatrogenic forms have been recognised but most are sporadic and of unknown cause. We have studied risk factors for CJD as part of the 1993-95 European Union collaborative studies of CJD in Europe. Methods The 405 patients with definite or probable CJD who took part in our study had taken part in population-based studies done between 1993 and 1995 in Belgium, France, Germany, Italy, the Netherlands, and the UK. Data on putative risk factors from these patients were compared with data from 405 controls. Findings We found evidence for familiar aggregation of CJD with dementia due to causes other than CJD (relative risk [RR] 2.26, 95% CI 1.31-3.90). No significant increased risk of CJD in relation to a history of surgery and blood tranfusion was shown. There was no evidence for an association between the risk of CJD and the consumption of beef, veal, lamb, cheese, or milk. No association was found with occupational exposure to animals or leather. The few positive findings of the study include increased risk in relation to consumption of raw meat (RR 1.63 [95% CI 1.18-2.23]) and brain (1.68 [1.18-2.39]), frequent exposure to leather products (1.94 [1.13-3.33]), and exposure to fertiliser consisting of hoofs and horns (2.32 [138-2.91]). Additional analyses, for example stratification by country and of exposures pre-1985 and post-1985, suggest that these results should be interpreted with great caution. Interpretation Within the limits of the retrospective design of the study, our findings suggest that genetic factors other than the known CJD mutations may play an important part in CJD. latrogenic transmission of disease seems rare in this large population-based sample of patients with CJD. There is little evidence for an association between the risk of CJD and either animal exposure, or consumption of processed bovine meat or milk products for the period studied.	Erasmus Univ, Dept Epidemiol & Biostat, Sch Med, NL-3000 DR Rotterdam, Netherlands; Hop La Pitie Salpetriere, INSERM, U360, Paris, France; Univ Cattolica Sacro Cuore, Dept Neurol, I-00168 Rome, Italy; Univ Gottingen, Neurol Klin, D-3400 Gottingen, Germany; Western Gen Hosp, CJD Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Marien Hosp, Hamburg, Germany; Univ Naples Federico II, Dept Neurol, Naples, Italy; Univ Ferrara, Dept Neurol, I-44100 Ferrara, Italy	Erasmus University Rotterdam; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Gottingen; University of Edinburgh; St. Marien Hospital; University of Naples Federico II; University of Ferrara	van Duijn, CM (corresponding author), Erasmus Univ, Dept Epidemiol & Biostat, Sch Med, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Giese, Armin/F-3271-2010	Giese, Armin/0000-0002-8238-4102; Weber, Thomas/0000-0002-3833-6197; Granieri, Enrico/0000-0003-4038-3192				Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; BERNOULLI C, 1977, LANCET, V1, P478; BROWN P, 1985, NEW ENGL J MED, V313, P728, DOI 10.1056/NEJM198509193131205; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; COCHIUS JI, 1990, AUST NZ J MED, V20, P592, DOI 10.1111/j.1445-5994.1990.tb01322.x; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; *DEP EP POP SCI NA, 1995, 4 DEP EP POP SCI NAT; DUFFY P, 1974, NEW ENGL J MED, V290, P692; GIBBS CJ, 1985, NEW ENGL J MED, V313, P734, DOI 10.1056/NEJM198509193131207; LAPLANCHE JL, 1994, NEUROLOGY, V44, P2347, DOI 10.1212/WNL.44.12.2347; MANUELIDIS EE, 1985, LANCET, V2, P896; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASTERS CL, 1978, BRAIN, V101, P333, DOI 10.1093/brain/101.2.333; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; POWELLJACKSON J, 1985, LANCET, V2, P244; PRUSINER SB, 1994, ANN NEUROL, V35, P385, DOI 10.1002/ana.410350404; SALVATORE M, 1994, HUM GENET, V94, P375, DOI 10.1007/BF00201596; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SMITH PG, 1984, INT J EPIDEMIOL, V13, P356, DOI 10.1093/ije/13.3.356; TATEISHI J, 1985, LANCET, V2, P1074; THADANI V, 1988, J NEUROSURG, V69, P766, DOI 10.3171/jns.1988.69.5.0766; VANDUIJN CM, 1991, INT J EPIDEMIOL, V20, pS13, DOI 10.1093/ije/20.Supplement_2.S13; Wientjens DPWM, 1996, NEUROLOGY, V46, P1287, DOI 10.1212/WNL.46.5.1287; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1982, J NEUROL NEUROSUR PS, V45, P235, DOI 10.1136/jnnp.45.3.235; WILL RG, IN PRESS ANN NEUROL; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204	27	151	151	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 11	1998	351	9109					1081	1085		10.1016/S0140-6736(97)09468-3	http://dx.doi.org/10.1016/S0140-6736(97)09468-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660576				2022-12-28	WOS:000073090200008
J	Verhoog, LC; Brekelmans, CTM; Seynaeve, C; van den Bosch, LMC; Dahmen, G; van Geel, AN; Tilanus-Linthorst, MMA; Bartels, CCM; Wagner, A; van den Ouweland, A; Devilee, P; Meijers-Heijboer, EJ; Klijn, JGM				Verhoog, LC; Brekelmans, CTM; Seynaeve, C; van den Bosch, LMC; Dahmen, G; van Geel, AN; Tilanus-Linthorst, MMA; Bartels, CCM; Wagner, A; van den Ouweland, A; Devilee, P; Meijers-Heijboer, EJ; Klijn, JGM			Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1	LANCET			English	Article							HISTOPROGNOSTIC GRADE; CARCINOMA; CARRIERS; LINKAGE; AGE	Background Hereditary breast cancer has been associated with mutations in the BRCA1 and BRCA2 genes and has a natural history different from sporadic breast cancer. We investigated disease-free and overall survival for patients with a proven BRCA1 alteration. Methods We estimated disease-free adn overall survival for 49 Dutch patients from 19 consecutive families with a proven specific BRCA1 mutation and one family with strong evidence for linkage to the BRCA1 gene. We compared clinical outcome and data on tumour size, histology, axillary nodal status, contralateral breast cancer, and oestrogen-receptor and progesterone-receptor status with those of 196 patients with sporadic breast cancer, matched for age and year of diagnosis. Findings Disease-free survival for BRCA1 and sporadic patients at 5 years was 49% (95% CI 33-64) and 51% (43-59), respectively (p=0.98). Overall survival at 5 years was 63% (47-76) and 69% (62-76), respectively (p=0.88). Recurrence and death rates did not differ significantly between groups. Hazard ratios for recurrence and death among BRCA1 patients were 1.00 (0.65-1.55) and 1.04 (0.63-1.71) relative to sporadic patients (p=0.88), and these did not differ significantly after adjustment for prognostic factors. Patients with BRCA1-associated breast cancer had twice as many progesterone-receptor-negative tumours (p<0.005) and development of contralateral breast cancer was four to five times as frequent as in the sporadic group (p<0.001). Interpretation We showed that disease-free and overall survival were similar for sporadic and hereditary breast cancer in the presence of different tumour characteristics, which has implications for screening prophylactic therapy, and different treatments of hereditary breast cancer.	Dr Daniel Denhoed Clin, Dept Med Oncol, Family Canc Clin, NL-3075 EA Rotterdam, Netherlands; Rotterdam Canc Inst, Dept Patient Registrat, Rotterdam, Netherlands; Acad Hosp Rotterdam Dijkzigt, Rotterdam, Netherlands; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Leiden Univ, Dept Human Genet, Leiden, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Leiden University; Leiden University - Excl LUMC	Klijn, JGM (corresponding author), Dr Daniel Denhoed Clin, Dept Med Oncol, Family Canc Clin, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands.		DEVILEE, PETER/ABR-2140-2022					Coebergh JWW, 1995, CANC INCIDENCE SURVI; CORNELIS RS, 1995, HUM GENET, V95, P539, DOI 10.1007/BF00223866; DELAROCHEFORDIERE A, 1993, LANCET, V341, P1039, DOI 10.1016/0140-6736(93)92407-K; EASTON DF, 1995, AM J HUM GENET, V56, P265; Eisinger F, 1996, CANCER RES, V56, P471; FOEKENS JA, 1989, CANCER RES, V49, P5823; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Henderson IC, 1997, LANCET, V349, P1488, DOI 10.1016/S0140-6736(97)22021-0; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; JACQUEMIER J, 1995, LANCET, V345, P1503, DOI 10.1016/S0140-6736(95)91060-3; Jacquemier J, 1996, LANCET, V348, P1098, DOI 10.1016/S0140-6736(05)64441-8; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KLIJN JGM, 1993, CANCER SURV, V18, P165; Klijn JGM, 1997, EUR J CANCER, V33, P2149, DOI 10.1016/S0959-8049(97)00360-2; Lakhani SR, 1997, LANCET, V349, P1505; LEES AW, 1989, BREAST CANCER RES TR, V13, P143, DOI 10.1007/BF01806526; LYNCH HT, 1981, JAMA-J AM MED ASSOC, V246, P1197, DOI 10.1001/jama.246.11.1197; LYNCH HT, 1993, P ASCO, V12, P82; LYNCH HT, 1994, P ASCO, V13, P56; Malone KE, 1996, CANCER, V78, P1417, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1417::AID-CNCR7>3.3.CO;2-Q; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Peelen T, 1997, AM J HUM GENET, V60, P1041; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Sobol A, 1996, CANCER RES, V56, P3216; SOLIN LJ, 1996, J LIBBEY EUROTEXT, P351; WOBBES T, 1987, EUR J SURG ONCOL, V13, P119	30	367	374	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	1998	351	9099					316	321		10.1016/S0140-6736(97)07065-7	http://dx.doi.org/10.1016/S0140-6736(97)07065-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652611				2022-12-28	WOS:000071864000009
J	Koffman, J				Koffman, J			There must be a better way	BRITISH MEDICAL JOURNAL			English	Editorial Material														Koffman, Jonathan/0000-0001-8513-5681					0	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1989	1990		10.1136/bmj.316.7149.1989a	http://dx.doi.org/10.1136/bmj.316.7149.1989a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	11682719				2022-12-28	WOS:000074636700086
